<SEC-DOCUMENT>0001171843-23-001307.txt : 20241204
<SEC-HEADER>0001171843-23-001307.hdr.sgml : 20241204
<ACCEPTANCE-DATETIME>20230301163056
ACCESSION NUMBER:		0001171843-23-001307
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230301
DATE AS OF CHANGE:		20230301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PORTAGE BIOTECH INC.
		CENTRAL INDEX KEY:			0001095435
		STANDARD INDUSTRIAL CLASSIFICATION:	CRUDE PETROLEUM & NATURAL GAS [1311]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40086
		FILM NUMBER:		23694069

	BUSINESS ADDRESS:	
		STREET 1:		6 ADELAIDE ST. EAST
		STREET 2:		SUITE 300
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5C 1H6
		BUSINESS PHONE:		416-737-7600

	MAIL ADDRESS:	
		STREET 1:		6 ADELAIDE ST. EAST
		STREET 2:		SUITE 300
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5C 1H6

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BONTAN CORP INC
		DATE OF NAME CHANGE:	20030421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DEALCHECK COM INC
		DATE OF NAME CHANGE:	19990921
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_022823.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:ptgef="http://portagebiotech.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_IFRS%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_ptgef_portagebiotech.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20220401_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001095435 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wMy0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentType_6%2DK -->
<!-- Field: Set; Name: xdx; ID: xdx_077_XDX_extensions.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_07F_SO_C%2D%2D\Users\Dell\Desktop\Manoj Live File\27.2.2023\PORTAGE\exh__991.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:EntityCentralIndexKey">0001095435</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:CurrentFiscalYearEndDate">--03-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:DocumentType">6-K</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ptgef-20221231.xsd" xlink:type="simple" />
  </ix:references>
  </ix:header>
</div>


<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>UNITED STATES</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION<br />
Washington, D.C. 20549</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>FORM <span id="xdx_908_edei--DocumentType_c20220401__20221231_z6DWKNjL2BM2"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:DocumentType">6-K</ix:nonNumeric></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</b></p>

<p style="margin: 0pt 0; text-indent: 20pt; font-size: 10pt; text-align: center"><b>UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>For the month of March 2023</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b></b>&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><span id="xdx_906_edei--DocumentPeriodEndDate_c20220401__20221231_zP8p5xCoeenh" style="display: none"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2022</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">Commission File Number: <b><span id="xdx_901_edei--EntityFileNumber_c20220401__20221231_zVxHr4ZVhUGl"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:EntityFileNumber">001-40086</ix:nonNumeric></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_901_edei--EntityRegistrantName_c20220401__20221231_zy6jqZNzllBj"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:EntityRegistrantName">Portage Biotech Inc.</ix:nonNumeric></span></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">(Translation of registrant&#8217;s name into English)</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_908_edei--EntityAddressAddressLine1_c20220401__20221231_zCgwWDjfy3Qj"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:EntityAddressAddressLine1">Clarence Thomas Building</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20220401__20221231_zjEr2zNA8yL7"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:EntityAddressAddressLine2">P.O. Box 4649</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine3_c20220401__20221231_z3Pkcdz9sMz9"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:EntityAddressAddressLine3">Road Town</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20220401__20221231_zghnE3pvrG17"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:EntityAddressCityOrTown">Tortola</ix:nonNumeric></span>, British
Virgin Islands, <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20220401__20221231" title="Entity Address, Postal Zip Code"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:EntityAddressPostalZipCode">VG1110</ix:nonNumeric></span></span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">(Address of principal executive offices)</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">Form 20-F&#160;&#9746;&#160;Form 40-F &#9744;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>EXHIBITS</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 10%; font-size: 10pt; text-align: center"><b>Exhibit No.</b></td>
    <td style="padding-bottom: 1pt; vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 89%; font-size: 10pt"><b>Exhibit</b></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-size: 10pt; text-align: center"><a href="exh_991.htm">99.1</a></td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><a href="exh_991.htm">Unaudited Condensed Consolidated Interim Financial Statements for the three and nine months ended December 31, 2022. Unaudited - Prepared by Management as of March 1, 2023.</a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><a href="exh_992.htm">99.2</a></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><a href="exh_992.htm">Management&#8217;s Discussion and Analysis for the three and nine months ended December 31, 2022.</a></td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; background-color: white"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 100%; font-size: 10pt">Date:&#160;&#160;March 1, 2023</td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white"><b>PORTAGE BIOTECH INC.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 2%; font-size: 10pt">By: &#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 36%; font-size: 10pt">/s/ Allan Shaw</td>
    <td style="width: 62%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt">Allan Shaw</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt">Chief Financial Officer</td>
    <td>&#160;</td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:srt="http://fasb.org/srt/2022" xmlns:ptgef="http://portagebiotech.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_IFRS%2D2022_srt -->
<!-- Field: Set; Name: xdx; ID: xdx_036_ptgef_portagebiotech.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20220401_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001095435 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentType_6%2DK -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wMy0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_077_XDX_extensions.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_07F_SO_C%2D%2D\Users\Dell\Desktop\Manoj Live File\27.2.2023\PORTAGE\exh__991.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_07D_CP_C%2D%2D\Users\Dell\Desktop\Manoj Live File\27.2.2023\PORTAGE\f6k__022823.htm -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_060_EURPShares_0_iso4217%2D%2DEUR_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:EntityCentralIndexKey">0001095435</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:DocumentType">6-K</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:CurrentFiscalYearEndDate">--03-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonFraction name="ptgef:ConvertibleNoteReceivable" contextRef="AsOf2022-03-31" id="xdx2ixbrl0042" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredCommitmentFee" contextRef="AsOf2022-03-31" id="xdx2ixbrl0063" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantLiabilityCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0083" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredPurchasePricePayableTarus" contextRef="AsOf2022-03-31" id="xdx2ixbrl0096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredObligationIoxMilestone" contextRef="AsOf2022-03-31" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0158" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ForeignExchangeLoss" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ForeignExchangeLoss" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0175" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0178" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0180" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0183" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0185" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InterestExpense" contextRef="From2022-10-012022-12-31" id="xdx2ixbrl0187" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedInTarusAcquisition" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedInTarusAcquisition" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedInTarusAcquisition" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedInTarusAcquisition" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedInIoxExchange" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedInIoxExchange" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedInIoxExchange" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedInIoxExchange" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredObligationIoxMilestoneValue" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredObligationIoxMilestoneValue" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredObligationIoxMilestoneValue" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredObligationIoxMilestoneValue" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredObligationIoxMilestoneValue" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestmentsValue" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestmentsValue" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestmentsValue" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestmentsValue" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantsExercised" contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantsExercised" contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantsExercised" contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantsExercised" contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares" contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares" contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares" contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares" contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchaseOfConvertibleNoteReceivable" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RepaymentOfNotesPayableAssumedInTarusAcquisition" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:RepaymentOfMilestoneObligationAssumedInTarusAcquisition" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0575" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0578" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ProceedsFromExerciseOfStockPurchaseWarrants" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl0586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CashPaidForInterest" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IncreaseInAccountsPayableForStockIssuanceCosts" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl0607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueOfSharesIssuedForTarus" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0614" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0617" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueOfDeferredPurchasePricePayabletarus" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0620" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueOfDeferredObligationIoxMilestone" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LiabilitiesAssumedInTarusAcquisition" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl0631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentReceivablesFromSaleOfProperties" contextRef="AsOf2022-03-31" id="xdx2ixbrl0737" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TarusGoodwill" contextRef="From2021-04-012022-03-31" id="xdx2ixbrl0952" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-03-31_custom_TarusAdenosineReceptorsMember" id="xdx2ixbrl0999" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-03-31_custom_TarusAdenosineReceptors1Member" id="xdx2ixbrl1003" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-03-31_custom_TarusAdenosineReceptors2Member" id="xdx2ixbrl1007" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-03-31_custom_TarusMember" id="xdx2ixbrl1011" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2022-12-31_custom_IOXMember327150515" id="xdx2ixbrl1056" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2022-12-31" id="xdx2ixbrl1058" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2022-12-31_custom_IOXMember327150515" id="xdx2ixbrl1064" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2022-12-31" id="xdx2ixbrl1066" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CurrentFederalIncomeTaxBenefit" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl1086" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CurrentFederalIncomeTaxBenefit" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1087" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:CurrentStateAndLocalIncomeTaxBenefit" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredFederalIncomeTaxBenefit" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl1101" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredFederalIncomeTaxBenefit" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredStateAndLocalIncomeTaxBenefit" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl1104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredStateAndLocalIncomeTaxBenefit" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:IncomeTaxBenefitExpense" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ChangeIncreaseInDeferredIncomeTaxRate" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1163" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:TaxEffectOfRAndDCredit" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl1168" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossesUnrecognized" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl1171" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossForWhichNoBenefitWasTaken" contextRef="AsOf2022-12-31_custom_BVIMember" id="xdx2ixbrl1193" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossForWhichNoBenefitWasTaken" contextRef="AsOf2022-12-31_custom_ForeignMember" id="xdx2ixbrl1194" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossForWhichNoBenefitWasTaken" contextRef="AsOf2021-12-31_custom_UnitedStateMember" id="xdx2ixbrl1196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossForWhichNoBenefitWasTaken" contextRef="AsOf2021-12-31_custom_BVIMember" id="xdx2ixbrl1197" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossForWhichNoBenefitWasTaken" contextRef="AsOf2021-12-31_custom_ForeignMember" id="xdx2ixbrl1198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossForWhichNoBenefitWasTaken" contextRef="AsOf2021-12-31" id="xdx2ixbrl1199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossesNotSubjectToTax" contextRef="AsOf2022-12-31_custom_UnitedStateMember" id="xdx2ixbrl1201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossesNotSubjectToTax" contextRef="AsOf2022-12-31_custom_ForeignMember" id="xdx2ixbrl1203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossesNotSubjectToTax" contextRef="AsOf2021-12-31_custom_UnitedStateMember" id="xdx2ixbrl1205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:LossesNotSubjectToTax" contextRef="AsOf2021-12-31_custom_ForeignMember" id="xdx2ixbrl1207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UtilizationOfLossesNotPreviouslyBenefitted" contextRef="AsOf2022-12-31_custom_BVIMember" id="xdx2ixbrl1211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UtilizationOfLossesNotPreviouslyBenefitted" contextRef="AsOf2022-12-31_custom_ForeignMember" id="xdx2ixbrl1212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UtilizationOfLossesNotPreviouslyBenefitted" contextRef="AsOf2021-12-31_custom_UnitedStateMember" id="xdx2ixbrl1214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UtilizationOfLossesNotPreviouslyBenefitted" contextRef="AsOf2021-12-31_custom_BVIMember" id="xdx2ixbrl1215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UtilizationOfLossesNotPreviouslyBenefitted" contextRef="AsOf2021-12-31_custom_ForeignMember" id="xdx2ixbrl1216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:UtilizationOfLossesNotPreviouslyBenefitted" contextRef="AsOf2021-12-31" id="xdx2ixbrl1217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PretaxLossSubjectToTax" contextRef="AsOf2022-12-31_custom_BVIMember" id="xdx2ixbrl1220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PretaxLossSubjectToTax" contextRef="AsOf2021-12-31_custom_BVIMember" id="xdx2ixbrl1224" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:FairValueAdjustmentExercisePriceAtEnd" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl1295" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantsOutstandingExercisePrice" contextRef="AsOf2022-12-31" id="xdx2ixbrl1301" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantsOutstandingShares" contextRef="AsOf2022-12-31" id="xdx2ixbrl1303" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantsOutstandingAmount" contextRef="AsOf2022-12-31" id="xdx2ixbrl1305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1331" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedInIoxExchangesShares" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1339" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ShareIssuedInIoxExchange" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl1343" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1347" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedToLincolnParksCommittedPurchaseShares" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1355" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SharesIssuedToLincolnParksCommittedPurchase" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1371" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts" contextRef="From2021-04-012021-12-31" id="xdx2ixbrl1373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:WarrantsExercisedShares" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl1383" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="From2022-04-01to2022-12-31" id="xdx2ixbrl1385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl1461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SettledInIoxExchange" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl1471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SettledInIoxExchange" contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl1473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:SettledInIoxExchange" contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember" id="xdx2ixbrl1475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2022-12-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl1477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2021-04-012021-12-31_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl1574" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2022-04-012022-12-31_custom_StockOptionsTwoMember" id="xdx2ixbrl1576" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2021-04-012021-12-31_custom_StockOptionsTwoMember" id="xdx2ixbrl1578" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl1580" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2021-04-012021-12-31_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl1582" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2022-12-31_custom_StockOptionsTwoMember" id="xdx2ixbrl1592" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="AsOf2022-12-31_custom_StockOptionsTwoMember" id="xdx2ixbrl1600" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2022-04-012022-12-31_custom_StockOptionsTwoMember" id="xdx2ixbrl1619" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="From2022-04-012022-12-31_custom_WarrantsMember" id="xdx2ixbrl1697" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1806" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1811" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ConvertibleNoteReceivableIncludingAccruedInterest" contextRef="AsOf2022-12-31_custom_AmortizedCostMember" id="xdx2ixbrl1815" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ConvertibleNoteReceivableIncludingAccruedInterest" contextRef="AsOf2022-03-31_custom_AmortizedCostMember" id="xdx2ixbrl1817" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ConvertibleNoteReceivableIncludingAccruedInterest" contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1818" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentInvestments" contextRef="AsOf2022-12-31_custom_AmortizedCostMember" id="xdx2ixbrl1820" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentInvestments" contextRef="AsOf2022-03-31_custom_AmortizedCostMember" id="xdx2ixbrl1822" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1831" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1833" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2022-12-31_custom_AmortizedCostMember" id="xdx2ixbrl1835" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1836" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2022-03-31_custom_AmortizedCostMember" id="xdx2ixbrl1837" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredPurchasePricePayableTarus" contextRef="AsOf2022-12-31_custom_AmortizedCostMember" id="xdx2ixbrl1840" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredPurchasePricePayableTarus" contextRef="AsOf2022-03-31_custom_AmortizedCostMember" id="xdx2ixbrl1842" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredPurchasePricePayableTarus" contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1843" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredObligationIoxMilestone" contextRef="AsOf2022-12-31_custom_AmortizedCostMember" id="xdx2ixbrl1845" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredObligationIoxMilestone" contextRef="AsOf2022-03-31_custom_AmortizedCostMember" id="xdx2ixbrl1847" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:DeferredObligationIoxMilestone" contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1848" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" contextRef="From2022-04-012022-12-31_custom_SaugatuckMember" id="xdx2ixbrl1911" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2022-12-31_custom_IOXMember327150515" id="xdx2ixbrl1915" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2021-04-012021-12-31_custom_SaugatuckMember" id="xdx2ixbrl1929" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ptgef:ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" contextRef="From2021-04-012021-12-31_custom_SaugatuckMember" id="xdx2ixbrl1935" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ptgef-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-04-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-13_custom_SalvaRxGroupPlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxGroupPlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-01</xbrli:startDate>
        <xbrli:endDate>2021-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-302022-12-31_custom_ATMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ATMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-30</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-302022-12-31_custom_LincolnMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:LincolnMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-30</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-012015-02-10_custom_SubsidiariesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-01</xbrli:startDate>
        <xbrli:endDate>2015-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-31_custom_SubsidiariesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_SubsidiariesTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-01_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-292020-06-01_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-29</xbrli:startDate>
        <xbrli:endDate>2020-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-022022-07-13_custom_StimunityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:StimunityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-02</xbrli:startDate>
        <xbrli:endDate>2022-07-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_StimunitySAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfSalvaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">ptgef:IntensityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-11_custom_AcquisitionOfIntensityHoldingLimitedMember_custom_IntensityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfIntensityHoldingLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">ptgef:IntensityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfSalvaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">ptgef:IntensityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TarusAcquisitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:TarusAcquisitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_TarusAcquisitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:TarusAcquisitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_TarusAcquisitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:TarusAcquisitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-12-31_custom_TarusAcquisitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:TarusAcquisitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_TarusAcquisitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:TarusAcquisitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_IMM60IOXMelanomaLungCancersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM60IOXMelanomaLungCancersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_IMM60IOXMelanomaLungCancersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM60IOXMelanomaLungCancersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_IMM65IOXOvarianProstateCancersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM65IOXOvarianProstateCancersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_IMM65IOXOvarianProstateCancersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM65IOXOvarianProstateCancersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_IOXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_IOXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_OncomerSaugatuckDNAAptamersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:OncomerSaugatuckDNAAptamersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_OncomerSaugatuckDNAAptamersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:OncomerSaugatuckDNAAptamersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TarusAdenosineReceptorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TarusAdenosineReceptorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TarusAdenosineReceptors1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptors1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TarusAdenosineReceptors1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptors1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TarusAdenosineReceptors2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptors2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TarusAdenosineReceptors2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptors2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TarusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TarusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_IOXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_IOXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_IOXMember327150515">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_IOXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-032019-01-31_custom_SalvaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-03</xbrli:startDate>
        <xbrli:endDate>2019-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-08_custom_IOXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_IOXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_IOXMember327152796">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_UnitedStateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:UnitedStateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_BVIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:BVIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ForeignMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:ForeignMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_UnitedStateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:UnitedStateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_BVIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:BVIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ForeignMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:ForeignMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-022020-06-16_custom_AccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:AccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-02</xbrli:startDate>
        <xbrli:endDate>2020-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-022020-06-16_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-02</xbrli:startDate>
        <xbrli:endDate>2020-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-08-19_custom_LincolnMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:LincolnMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:N2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-13_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-19_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-19_custom_TwoMembersMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TwoMembersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-19_custom_EmployeesMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-19_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-15_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012022-06-08_custom_ExecutiveMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ExecutiveMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-27_custom_BoardOfDirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:BoardOfDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012022-07-27_custom_BoardOfDirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:BoardOfDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-07-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_IOxOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_IOxOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_IOxOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ptgef:UnvestedOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-27_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ptgef:UnvestedOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_StockOptionsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_StockOptionsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_StockOptionsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_StockOptionsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_StockOptionsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_StockOptionsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember327165015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-06_custom_LincolnMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:LincolnMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_LincolnMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:LincolnMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-15_custom_ChiefExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ChiefExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AmortizedCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_AmortizedCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-12-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_IOXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012023-02-28_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2023-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EURPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:EUR</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000921" toRefs="Footnote000940"></ix:relationship>
  <ix:relationship fromRefs="Fact000925" toRefs="Footnote000940"></ix:relationship>
  <ix:relationship fromRefs="Fact000929" toRefs="Footnote000940"></ix:relationship>
  <ix:relationship fromRefs="Fact000933" toRefs="Footnote000940"></ix:relationship>
  <ix:relationship fromRefs="Fact000937" toRefs="Footnote000940"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>






















































































































<p style="margin: 0pt 0; font-size: 10pt; text-align: right"><b>Exhibit 99.1</b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 14pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>Condensed Consolidated Interim Financial Statements</b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>For the Three and Nine Months Ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20220401__20221231_zuNYOUc6sGRb"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2022</ix:nonNumeric></span></b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>(Unaudited &#8211; Prepared by Management as of March 1, 2023)</b></p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0 0pt 1in; font-size: 10pt"><b>(U.S. Dollars)</b></p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 88%; text-align: center"><b>Index</b></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><b>Page</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Notice to Reader</td>
    <td>&#160;</td>
    <td style="text-align: center">F-1</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Condensed Consolidated Interim Statements of Financial Position</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">As of December 31, 2022 (Unaudited) and March 31, 2022</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">F-2</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Three and nine months ended December 31, 2022 and 2021</td>
    <td>&#160;</td>
    <td style="text-align: center">F-3</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Condensed Consolidated Interim Statements of Changes in Shareholders&#8217; Equity (Unaudited)</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>Nine months ended December 31, 2022 and 2021</td>
    <td>&#160;</td>
    <td style="text-align: center">F-4</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Nine months ended December 31, 2022 and 2021</td>
    <td>&#160;</td>
    <td style="text-align: center">F-5</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>Notes to Condensed Consolidated Interim Financial Statements</td>
    <td>&#160;</td>
    <td style="text-align: center">F-6 to F-37</td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>NOTICE TO READER OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS </b></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">The condensed consolidated interim financial statements of Portage Biotech Inc. are comprised
of the condensed consolidated statements of financial position as of December 31, 2022 and March 31, 2022, the condensed consolidated
interim statements of operations and other comprehensive income (loss) for the three and nine months ended December 31, 2022 and 2021
and the statements of equity and cash flows for each of the nine months ended December 31, 2022 and 2021 and are the responsibility of
Portage Biotech Inc.&#8217;s management.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">The condensed consolidated interim financial statements of Portage Biotech Inc. have been prepared
by Portage Biotech Inc.&#8217;s management and include the selection of appropriate accounting principles, judgments and estimates necessary
to prepare these condensed consolidated interim financial statements in accordance with International Financial Reporting Standards.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 42%; text-align: center">/s/ Allan Shaw</td>
    <td style="width: 58%; text-align: center">/s/ Ian Walters</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">Allan Shaw, CFO</td>
    <td style="text-align: center">Ian Walters, MD, Chairman of the Board and Chief Executive Officer</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">DATE: March 1, 2023</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>
<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>



<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Statements of Financial Position</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars in thousands)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; see Notice to Reader dated March 1, 2023)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_pn3n3_zSlYzfMLAps8" summary="xdx: Statement -  Condensed Consolidated Interim Statements of Financial Position (Unaudited)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_496_20221231" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_496_20220331" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">As of,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Note</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">December 31,<br /> 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31,<br /> 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Audited)</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--AssetsAbstract_iB_zbBp6QvMKgfc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CurrentAssetsAbstract_i01B_zWeUlBhLUvi4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CashAndCashEquivalents_i02I_maCAz4NG_zcoEDQuYgMye" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 55%; font-size: 10pt; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 14%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,104</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,352</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherCurrentReceivables_i02I_maCAz4NG_zTd0lgqGRUgi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">5</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,786</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,480</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ConvertibleNoteReceivable_i02I_maCAz4NG_zIfJfigY5zAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Convertible note receivable</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">6</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ConvertibleNoteReceivable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">642</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0042">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentAssets_i01TI_mtCAz4NG_maAzotH_zqQFJfxy80n" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,532</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,832</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--NoncurrentAssetsAbstract_i01B_zvaCefzpsaFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Long-term assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_i02I_maNAzBqT_zuBpAKoEsQFl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Investment in associate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">6</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,405</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,673</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--InvestmentProperty_i02I_maNAzBqT_z1z27iNGrUEj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Investment in private company</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">7</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentProperty" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,363</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentProperty" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,409</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--Goodwill_i02I_maNAzBqT_zIOetAXcTVxj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">Goodwill</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">8, 9</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,862</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,324</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--InprocessResearchAndDevelopment_i02I_maNAzBqT_zwqY6ihaA2v6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">In-process research and development</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">8, 10</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145,588</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,388</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredCommitmentFee_i02I_maNAzBqT_zJdQ7jSc9Sve" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Deferred commitment fee</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">17</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredCommitmentFee" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">894</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0063">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--OtherAssets_i02I_maNAzBqT_zG6M7eJww2Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other assets, including equipment, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherAssets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--NoncurrentAssets_i02TI_mtNAzBqT_maAzotH_zSiuJ3sPCYJk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total long-term assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">195,151</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169,830</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--Assets_i01TI_mtAzotH_zXrypPBFxoej" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">210,683</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194,662</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--EquityAndLiabilitiesAbstract_iB_zVK8QOcCKC" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Equity</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--CurrentLiabilitiesAbstract_i01B_zjCWEiUpIKS8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherCurrentPayables_i02I_maCLzk90_zF6cyYnKD28k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accounts payable and accrued liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,422</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--WarrantLiabilityCurrent_i02I_maCLzk90_zM9WnNPujcQd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">13</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0083">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentLiabilities_i02TI_mtCLzk90_maLzKwd_zwB6sHAXihWb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,422</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">783</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--NoncurrentLiabilitiesAbstract_i01B_z51eLtwnEmSa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-current liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--DeferredTaxLiabilities_i02I_maNLzBxN_zG52qPJmHXn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Deferred tax liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">10, 12</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,515</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,445</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredPurchasePricePayableTarus_i02I_maNLzBxN_zK60c1ADjBV9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Deferred purchase price payable - Tarus</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">8, 19</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredPurchasePricePayableTarus" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,876</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0096">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredObligationIoxMilestone_i02I_maNLzBxN_zRYKKWk1SYpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred obligation - iOx milestone</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">18, 19</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredObligationIoxMilestone" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,568</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--NoncurrentLiabilities_i02TI_mtNLzBxN_maLzKwd_zU1t0OQR7Iz8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total non-current liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,959</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,445</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--Liabilities_i01TI_maCzk2A_mtLzKwd_zAXfJ0tdt2Ze" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,381</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,228</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--EquityAbstract_i01B_zegXUBCrL3a2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Shareholders&#8217; Equity</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--IssuedCapital_i02I_maCzN5V_zhg7kzJXL6k8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Capital stock</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">14</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216,630</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158,324</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--OtherReserves_i02I_maCzN5V_zqEZZaMvjo37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Stock option reserve</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">15</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,542</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,928</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--AccumulatedOtherComprehensiveIncome_i02I_maCzN5V_zHbaviTpJz4k" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Accumulated other comprehensive (loss) income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,059</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AccumulatedOtherComprehensiveIncome" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">958</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--RetainedEarnings_i02I_maCzN5V_zNZT28vfVKid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">65,168</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,005</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eifrs-full--EquityAttributableToOwnersOfParent_i02TI_mtCzN5V_maCzO5z_z2MQ1981poW6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total equity attributable to owners of the Company</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168,945</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121,205</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--NoncontrollingInterests_i02I_maCzO5z_zETdnAACvpYi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">21</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">643</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,229</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--Equity_i02TI_mtCzO5z_maCzk2A_zrKgvnRpMG6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total equity</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168,302</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165,434</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--EquityAndLiabilities_i01TI_mtCzk2A_ze7ylWksCoCc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">210,683</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194,662</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--CommitmentAndContingencies_i01I_zSwVgHXBH0bk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Commitments and Contingent Liabilities (Note 17)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Statements of Operations and Other Comprehensive
Income (Loss)</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>(U.S. Dollars in thousands, except per share amounts)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; see Notice to Reader dated March 1, 2023)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_pn3n3_zcgm3oJSUjH5" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_490_20221001_20221231" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20211001_20211231" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_495_20220401_20221231" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_493_20210401_20211231" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Note</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three months ended<br /> December 31,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine months ended<br /> December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">In 000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">In 000&#8217;$</td></tr>
  <tr id="xdx_409_eifrs-full--ProfitLossAbstract_iB_zdDvIW0vXKJj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold">Expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ResearchAndDevelopmentExpense_i01_msCzYhn_zvF2Ta5utou6" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; width: 45%; font-size: 10pt; text-align: left">Research and development</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 10%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,535</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,928</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,976</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,804</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--GeneralAndAdministrativeExpense_i01_msCzYhn_zjHG16Ec5Ovf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,224</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,241</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,523</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,288</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--ProfitLossFromOperatingActivities_i01T_mtCzYhn_maCzZT2_z1FZor9QWyml" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,759</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,169</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,499</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,092</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_i01_maCzZT2_z0OTcq0CA7Ui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">8, 18</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">498</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0158">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">428</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0160">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_i01_maCzZT2_zFzaWA3xMxVd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Share of loss in associate accounted for using equity method</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">6</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">152</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">261</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">268</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">363</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--GainsLossesOnChangeInFairValueOfWarrants_i01_maCzZT2_zPTsMsezGEBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">13</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">342</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:GainsLossesOnChangeInFairValueOfWarrants" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">726</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ForeignExchangeLoss_i01N_di_msCzZT2_zFGYwYRMvz2b" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Foreign exchange transaction gain (loss)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">10, 12</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ForeignExchangeLoss" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">50</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0173">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ForeignExchangeLoss" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0175">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--DepreciationAndAmortisationExpense_i01N_di_msCzZT2_zggCdoDwBg1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Depreciation expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0178">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0180">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--RevenueFromInterest_i01_maCzZT2_zVRKcnlvrqR1" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Interest income</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0183">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0185">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--InterestExpense_i01N_di_msCzZT2_zhQHrWHDrmCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Interest expense</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0187">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpense" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eifrs-full--ProfitLossBeforeTax_i01T_mtCzZT2_maNzg4P_zWShBMTYnWKi" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Loss before provision for income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,302</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,089</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,117</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,771</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eifrs-full--IncomeTaxExpenseContinuingOperations_i01N_di_msNzg4P_zNzkPRalqGVe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Income tax (expense) benefit</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">12</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,199</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,906</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">465</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--Netloss_iT_mtNzg4P_maOCIzC7R_zfN4FTNLp9m" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Net loss</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:Netloss" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,501</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:Netloss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,206</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:Netloss" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,211</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:Netloss" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,306</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--OtherComprehensiveIncomeAbstract_iB_zP0dF0wdjUtg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Other comprehensive income (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NetUnrealizedLossOnInvestments_maOCIzC7R_zOmw3Cwifdhl" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net unrealized loss on investments</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">7</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,017</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0213">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestments" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,017</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0215">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--OtherComprehensiveIncome_iT_mtOCIzC7R_z6kvL0ufvPK2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,518</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,206</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,228</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncome" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,306</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--ProfitLossAttributableToAbstract_iB_zCcQbtpJxdi8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Net loss attributable to:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_maNzLAN_zj9P817mhWhe" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Owners of the Company</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,485</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,512</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,163</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,553</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--ProfitLossAttributableToNoncontrollingInterests_i01_maNzLAN_zwdxYWjH7f1g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">21</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">694</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">753</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--Netloss_iT_mtNzLAN_zoZwctNuOlP8" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:Netloss" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,501</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:Netloss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,206</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:Netloss" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,211</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:Netloss" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,306</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--ComprehensiveIncomeAttributableToAbstract_iB_zMG2BwXv29Jd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Comprehensive loss attributable to:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--ComprehensiveIncomeAttributableToOwnersOfParent_i01_maCIzxQk_znikOXHfGX13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; font-weight: bold; text-align: left">Owners of the Company</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,502</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,512</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,180</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,553</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--ComprehensiveIncomeAttributableToNoncontrollingInterests_i01_maCIzxQk_z6o269ekXSNg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">21</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">694</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">753</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--ComprehensiveIncome_iT_mtCIzxQk_zB4aeS1iLDCf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,518</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,206</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,228</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,306</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--EarningsPerShareAbstract_iB_zu9yPXACM4Ei" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold">Loss per share</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">16</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--BasicAndDilutedEarningsLossPerShare_i01_pid_z64tYAfNHi1k" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:BasicAndDilutedEarningsLossPerShare" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:BasicAndDilutedEarningsLossPerShare" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:BasicAndDilutedEarningsLossPerShare" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.65</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:BasicAndDilutedEarningsLossPerShare" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.74</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_iB_zywDjK68RWDj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold">Weighted average shares outstanding</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">16</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--WeightedAveragesSharesoutstandingBasicAndDiluted_i01_pid_zSdmqOgkT7e1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Basic and diluted</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17,039</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13,344</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15,719</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12,966</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Statements of Changes in Shareholders&#8217;
Equity</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>For the Nine Months Ended December 31, 2022 and 2021</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; see Notice to Reader dated March 1, 2023)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_114_pn3n3_ziOJwjMPbJd6" summary="xdx: Statement - Condensed Consolidated Interim Statements of Changes in Shareholder&apos;s Equity (Unaudited)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B0_ifrs-full--ComponentsOfEquityAxis_ifrs-full--IssuedCapitalMember_zcTBJPz4yDuc" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4BF_ifrs-full--ComponentsOfEquityAxis_custom--StockOptionReserveMember_ztd392p2hc9i" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B0_ifrs-full--ComponentsOfEquityAxis_ifrs-full--AccumulatedOtherComprehensiveIncomeMember_zpf5oBC3faE7" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B3_ifrs-full--ComponentsOfEquityAxis_ifrs-full--RetainedEarningsMember_zl4ECoYCBSPf" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B1_ifrs-full--ComponentsOfEquityAxis_ifrs-full--EquityAttributableToOwnersOfParentMember_zLBWKCv1VbKl" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4BF_ifrs-full--ComponentsOfEquityAxis_ifrs-full--NoncontrollingInterestsMember_zbE1AizNc6o5" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B1_zotfJsXdZva9" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Capital Stock</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Accumulated <br />Other Comprehensive (Loss) Income</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Retained Earnings<br /> (Accumulated Deficit)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Equity Attributable to Owners of Company</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Non-</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Controlling Interest</p></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Total Equity</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In &#8216;000&#8217;$</td></tr>
  <tr id="xdx_436_c20220401__20221231_eifrs-full--Equity_iS_z26uJiqpMG75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; width: 44%; font-size: 10pt; font-weight: bold">Balance, April 1, 2022</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfSharesOutstanding_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zMMqSIUj6wj3" title="Beginning balance, shares" style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,349</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158,324</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,928</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">958</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,005</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121,205</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,229</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165,434</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_zIb6ux6xyNa5" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,614</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,614</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,614</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--SharesIssuedInTarusAcquisition_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Shares issued in Tarus acquisition</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--SharesIssuedInTarusAcquisitionShares_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zgmoZghSW1U2" title="Shares issued in Tarus acquisition , shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedInTarusAcquisitionShares" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,426</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedInTarusAcquisition" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,200</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedInTarusAcquisition" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,200</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedInTarusAcquisition" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,200</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--SharesIssuedInIoxExchange_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Shares issued in iOx exchange</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--SharesIssuedInIoxExchangeShares_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zpeRdasFJ9je" title="Shares issued in iOx exchange , shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedInIoxExchangeShares" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,070</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedInIoxExchange" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,737</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedInIoxExchange" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,737</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:SharesIssuedInIoxExchange" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,737</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredObligationIoxMilestoneValue_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Deferred obligation - iOx milestone</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:DeferredObligationIoxMilestoneValue" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,478</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:DeferredObligationIoxMilestoneValue" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,478</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Excess of non-controlling interest acquired over consideration - iOx</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,609</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,609</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,609</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement_zV4Nr9279smg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Shares issued to Lincoln for commitment fee under Committed Purchase Agreement</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zLBqhpDCchkk" title="Shares issued to Lincoln for commitment fee under Committed Purchase Agreement , shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">94</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--SharesIssuedUnderAtm_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Shares issued under ATM</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuedUnderAtmShares_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z1ClvHMPx3v9" title="Shares issued under ATM, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtmShares" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">88</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">604</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">604</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">604</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement_zZC3bctBpfzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Purchase of shares issued under Committed Purchase Agreement</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zGQuVvG7lG8c" title="Purchase of shares issued under Committed Purchase Agreement , shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">30</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ShareIssuanceCosts_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold">Share issuance costs</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--SharesIssuedOrAccruedForServices_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Shares issued or accrued for services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--SharesIssuedOrAccruedForServicesShares_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zhMtXWAHGp4g" title="Shares issued or accrued for services, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServicesShares" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--NetUnrealizedLossOnInvestmentsValue_znf4q7fpn6Ac" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">Net unrealized loss on investments</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestmentsValue" contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,017</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestmentsValue" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,017</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetUnrealizedLossOnInvestmentsValue" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,017</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_408_eifrs-full--ProfitLoss_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss for period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,163</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,163</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,211</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_431_c20220401__20221231_eifrs-full--Equity_iE_zUfPtHVABrk6" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfSharesOutstanding_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zfvQMx9ex8qj" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">17,070</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216,630</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-12-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,542</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,059</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-12-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">65,168</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168,945</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">643</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168,302</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20210401__20211231_eifrs-full--Equity_iS_zPRbSoR6p3mc" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt">Balance, April 1, 2021</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfSharesOutstanding_iS_pn3n3_c20210401__20211230__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zdHOGqVeTRbl" title="Beginning balance, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">12,084</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130,649</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,977</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">958</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,135</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101,449</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,153</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147,602</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_zV8bMOeWXEfh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Share-based compensation expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,248</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,248</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">191</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,439</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SharesIssuedUnderAtm_z2J7cljzlwSg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Shares issued under ATM</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharesIssuedUnderAtmShares_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zMqsTtFmyYx3" title="Shares issued under ATM, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtmShares" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">91</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,643</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,643</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,643</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SharesIssuedUnderOffering_iP3custom--SharesIssuedUnderAtmShares_zB8P6PyHNSyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Shares issued under public offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesIssuedUnderOfferingShares_iP3custom--SharesIssuedUnderOffering_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zZtCvvJRP4Og" title="Shares issued under public offering , shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderOfferingShares" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,150</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,450</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,450</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderOffering" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,450</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ShareIssuanceCosts_zmDVCWE5yNxa" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt">Share issuance costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,877</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,877</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ShareIssuanceCosts" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,877</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--SharesIssuedOrAccruedForServices_zrBH21C0RIw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Shares issued or accrued for services</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharesIssuedOrAccruedForServicesShares_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zNRm9PuJwdpf" title="Shares issued or accrued for services, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServicesShares" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--WarrantsExercised_iP3custom--SharesIssuedOrAccruedForServicesShares_zV8LC5FcdiZ3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Warrants exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--WarrantsExercisedShares_iP3custom--WarrantsExercised_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z8Pb5QTlw7ai" title="Warrants exercised , shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantsExercisedShares" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">16</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantsExercised" contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">339</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantsExercised" contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">339</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantsExercised" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">339</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShares_iP3custom--WarrantsExercisedShares_zSFUmwgDTBb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left">Exchange of notes payable and accrued interest for iOx shares</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares" contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--ProfitLoss_zujF6UghbLne" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss for period</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8211;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,553</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,553</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">753</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,306</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_430_c20210401__20211231_eifrs-full--Equity_iE_zOGnWXIYBQgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; font-size: 10pt; padding-bottom: 2.5pt">Balance, December 31, 2021</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NumberOfSharesOutstanding_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zrMjbsgjlXm1" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,345</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-12-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158,294</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-12-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,225</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">958</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-12-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,688</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125,789</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,775</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">171,564</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Statements of Cash Flows</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>For the Nine Months Ended December 31, 2022 and 2021</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars in thousands)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; see Notice to Reader dated March 1, 2023)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_112_pn3n3_zNLEPljYx706" summary="xdx: Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49C_20220401__20221231_zAZPlVF9bnv4" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_498_20210401__20211231_zHigwBBZR8qb" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr id="xdx_40D_eifrs-full--CashFlowsFromUsedInOperatingActivitiesAbstract_iB_zmKi2W8HY20g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from operating activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--ProfitLossFromDiscontinuedOperations_i01_maCzUV7_zKmnTCf0uMHj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 70%; font-size: 10pt; text-align: left">Net loss for the period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperations" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,211</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromDiscontinuedOperations" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,306</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--AdjustmentsForReconcileProfitLossAbstract_i01B_zzwHDIVPO6e3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Adjustments for non-cash items:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--AdjustmentsForSharebasedPayments_i02_maCzUV7_zx5DMZeNW3Z2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,614</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,439</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--IncreaseDecreaseInDeferredTaxLiabilityAsset_i02N_di_msCzUV7_zrqvoWOriF6i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Decrease in deferred tax liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,930</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">444</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--IncomeOnFairValueOfWarrantLiability_i02_maCzUV7_zDzNRojlPes9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:IncomeOnFairValueOfWarrantLiability" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">33</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:IncomeOnFairValueOfWarrantLiability" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">726</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone_i02N_di_msCzUV7_zHZpNqoze5r6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">428</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--FairValueOfStockIssuedForServices_i02_maCzUV7_zmlLbSvo0153" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">Fair value of shares issued for services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfStockIssuedForServices" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FairValueOfStockIssuedForServices" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--GainLossOnHedgeIneffectiveness_i02N_di_msCzUV7_zne9IfDQQfv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt">Share of loss in associate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectiveness" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">268</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GainLossOnHedgeIneffectiveness" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">363</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_i02N_di_msCzUV7_zROkZvQyCZS4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Foreign exchange transaction gain</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--AdjustmentsForDepreciationAndAmortisationExpense_i02_maCzUV7_zEpJpjfutFXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt">Depreciation</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--NetChangeInWorkingCapitalComponentsAbstract_i01B_zkohdECv2em9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Changes in operating working capital:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncreasingDecreasingAccountsReceivable_i02N_di_msCzUV7_z7knSdoifzvi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accounts receivable</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:IncreasingDecreasingAccountsReceivable" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:IncreasingDecreasingAccountsReceivable" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">385</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--AdjustmentsForDecreaseIncreaseInPrepaidExpenses_i02_maCzUV7_zlimiDq1n2te" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">354</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,286</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--AdjustmentsForDecreaseIncreaseInOtherAssets_i02_maCzUV7_z9SCOdxB6gx9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Other assets</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">144</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAccountPayable_i02_maCzUV7_zlRCXT049ov" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Accounts payable and accrued liabilities</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,671</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,486</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eifrs-full--AdjustmentsForIncreaseDecreaseInOtherLiabilities_i02_maCzUV7_z1jJaUCxn0Lb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--CashFlowsFromUsedInOperatingActivities_i01T_mtCzUV7_maCzQCV_zGzTml2iO451" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,392</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,513</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--CashFlowsFromUsedInInvestingActivitiesAbstract_iB_zbxu5MOo2pSi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from investing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PurchaseOfConvertibleNoteReceivable_i01N_di_msCzZWB_zlynmQQIqCjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Purchase of convertible note receivable</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PurchaseOfConvertibleNoteReceivable" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">614</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_i01N_di_msCzZWB_zVh5i9v226f8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; padding-bottom: 1pt">Purchase of equipment</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CashFlowsFromUsedInInvestingActivities_i01T_mtCzZWB_maCzQCV_zIUIffoL6UXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">617</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--CashFlowsFromUsedInFinancingActivitiesAbstract_iB_zWANuRhkt9pi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from financing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--RepaymentOfNotesPayableAssumedInTarusAcquisition_i01N_di_msCz4sk_zr6qo2ma8rm" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Repayment of notes payable assumed in Tarus acquisition</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:RepaymentOfNotesPayableAssumedInTarusAcquisition" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0572">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--RepaymentOfMilestoneObligationAssumedInTarusAcquisition_i01N_di_msCz4sk_zXiEbkFOzdZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Repayment of milestone obligation assumed in Tarus acquisition</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:RepaymentOfMilestoneObligationAssumedInTarusAcquisition" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,009</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0575">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase_i01_maCz4sk_zbyCg42UndEj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Proceeds from shares issued under ATM and Committed Purchase</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">794</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0578">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromSharesIssuedUnderRegisteredOffering_i01_maCz4sk_zL8OcnXG53Jh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Proceeds from shares issued under registered offering</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,093</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--PaymentsForShareIssueCosts_i01N_di_msCz4sk_zkzyFcrHpzP6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt">Share issuance costs</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,852</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--ProceedsFromExerciseOfStockPurchaseWarrants_i01_maCz4sk_z5djnZKJbPwe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from exercise of stock purchase warrants</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromExerciseOfStockPurchaseWarrants" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--CashFlowsFromUsedInFinancingActivities_i01T_mtCz4sk_maCzQCV_z4Syk5Edf3y5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash (used in) provided by financing activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,239</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,346</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--IncreaseDecreaseInCashAndCashEquivalents_iT_mtCzQCV_zQsi3zMyMLG2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">(Decrease) increase in cash and cash equivalents during period</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,248</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,833</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--CashAndCashEquivalents_iS_zmX47SAJiAA8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,352</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,770</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CashAndCashEquivalents_iE_z5t5t1Z4k1ta" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,104</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,603</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--SupplementalCashFlowInformationsAbstract_iB_zqAkLczbKa5l" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--CashPaidForInterest_i01_zoEEI3tQnfL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0604">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CashPaidForInterest" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IncreaseInAccountsPayableForStockIssuanceCosts_i01_zybYXekU7CWj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Increase in accounts payable for stock issuance costs</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0607">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:IncreaseInAccountsPayableForStockIssuanceCosts" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NoncashInvestingItemsAbstract_iB_zTgHaPUtLkLh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--FairValueOfSharesIssuedForTarus_zYjlhj71JRod" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; padding-bottom: 2.5pt">Fair value of shares issued for Tarus</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfSharesIssuedForTarus" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,200</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0614">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox_zWaLCA91n0Z7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Fair value of shares issued for non-controlling interest purchase of iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,737</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0617">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FairValueOfDeferredPurchasePricePayabletarus_zDnkP2xm5ex" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; padding-bottom: 2.5pt">Fair value of deferred purchase price payable-Tarus</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfDeferredPurchasePricePayabletarus" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,538</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FairValueOfDeferredObligationIoxMilestone_zCXnlB3Qv3H5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Fair value of deferred obligation - iOx milestone</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfDeferredObligationIoxMilestone" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,478</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--LiabilitiesAssumedInTarusAcquisition_zr8acTOCPie7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Liabilities assumed in Tarus acquisition</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LiabilitiesAssumedInTarusAcquisition" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase_zMTxSDKSxifa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Fair value of shares issued for commitment fees - Committed Purchase</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants_zscwmyCHhSp9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Exchange of iOx shares for settlement of notes payable, accrued interest and warrants</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0631">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:NatureOfOperationsExplanatory"><p id="xdx_801_ecustom--NatureOfOperationsExplanatory_z6pMnldN2zCc" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 1. <span id="xdx_825_zX60qVGRiP8j">NATURE OF OPERATIONS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Portage Biotech Inc. (the &#8220;Company&#8221; or &#8220;Portage&#8221;)
is incorporated in the British Virgin Islands (&#8220;BVI&#8221;) with its registered office located at Clarence Thomas Building, P.O.
Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development Services Inc. (&#8220;PDS&#8221;), is located at 61 Wilton Road,
Westport, CT, 06880, USA.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company is a foreign private issuer under the Securities and Exchange
Commission (the &#8220;SEC&#8221;) rules. It is also a reporting issuer under the securities legislation of the provinces of Ontario and
British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (&#8220;CSE&#8221;) under the symbol &#8220;PBT.U&#8221;.
On February 25, 2021, the ordinary shares of the Company began trading on the NASDAQ Capital Market (&#8220;NASDAQ&#8221;) under the symbol
&#8220;PRTG&#8221;. As the principal market for the Company&#8217;s ordinary shares is NASDAQ, the Company voluntarily delisted from the
CSE on April 23, 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Portage is a clinical-stage immuno-oncology company advancing therapies
that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive
cancers. Portage&#8217;s access to next-generation technologies coupled with a deep understanding of biological mechanisms enable the
identification of clinical therapies and product development strategies that accelerate these medicines through the translational pipeline.
Portage&#8217;s portfolio consists of six diverse platforms, with lead programs including invariant natural killer T-cell (&#8220;iNKT&#8221;)
agonists and a suite of treatments targeting the adenosine pathway. Additional programs leverage delivery by intratumorals, nanoparticles,
liposomes, aptamers, and virus-like particles. Within these six platforms, Portage has 16 products currently in development with multiple
clinical readouts expected through the end of 2023.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On August 13, 2018, the Company reached a definitive agreement to acquire
<span id="xdx_906_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zLLowsn1Im5l" title="Percentage of acquire"><ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="AsOf2018-08-13_custom_SalvaRxGroupPlcMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of SalvaRx Limited (&#8220;SalvaRx&#8221;) in exchange for 8,050,701 ordinary shares of the Company (the &#8220;SalvaRx Acquisition&#8221;).
The SalvaRx Acquisition was completed on January 8, 2019 (the &#8220;Acquisition Date&#8221;) upon receiving shareholder and regulatory
approval. In connection with the SalvaRx Acquisition, the Company acquired interests in SalvaRx&#8217;s five research and development
invested entities and subsidiaries: iOx Therapeutics Ltd. (&#8220;iOx&#8221;), Nekonal Oncology Limited (&#8220;Nekonal&#8221;), Intensity
Therapeutics, Inc. (&#8220;Intensity&#8221;), Saugatuck Therapeutics, Ltd. (&#8220;Saugatuck&#8221;) and Rift Biotherapeutics Inc. (&#8220;Rift&#8221;).&#160;
The Company also acquired an option in Nekonal SARL, a Luxembourg-based company holding intellectual property rights for therapeutics
and diagnostics in the field of autoimmune disorders and oncology, to participate in the funding of its autoimmune programs. During fiscal
2021, the Company abandoned its interests in Nekonal and Nekonal SARL.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:LiquidityTextBlock"><p id="xdx_805_ecustom--LiquidityTextBlock_zy8ODAk1nwCb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 2. <span id="xdx_821_zRxtRqqKiaIh">LIQUIDITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022, the Company had cash and cash equivalents of
approximately $<span id="xdx_90D_eifrs-full--Cash_iI_pn3n3_dm_c20221231_znof1qtzSALe" title="Cash and cash equivalents"><ix:nonFraction name="ifrs-full:Cash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">13.1</ix:nonFraction></span> million and total current liabilities of approximately $<span id="xdx_90B_ecustom--TotalCurrentLiabilities_iI_pn3n3_dm_c20221231_ztUDFGjzDzlk" title="Total current liabilities"><ix:nonFraction name="ptgef:TotalCurrentLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million. For the nine months ended December 31, 2022,
the Company is reporting a net loss of approximately $<span id="xdx_908_ecustom--NetLossIncome_pn3n3_dm_c20220401__20221231_zfJF0K8rpYD6" title="Net (loss) income"><ix:nonFraction name="ptgef:NetLossIncome" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">10.2</ix:nonFraction></span> million and cash used in operating activities of approximately $<span id="xdx_902_ecustom--CashUsedInOperatingActivities_pn3n3_dm_c20220401__20221231_zgFoveIn5FPh" title="Cash used in operating activities"><ix:nonFraction name="ptgef:CashUsedInOperatingActivities" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">7.4</ix:nonFraction></span> million.
As of January 31, 2023, the Company had approximately $<span id="xdx_90D_eifrs-full--CashOnHand_iI_pn3n3_dm_c20220731_zZg6oGlyWLyd" title="Cash on hand"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">13.2</ix:nonFraction></span> million of cash and cash equivalents on hand. The Company believes its current
cash resources, including its access to the ATM and Committed Purchase (each as defined below, are sufficient to fund operations for at
least 13 months from March 1, 2023, the date when the Company&#8217;s management prepared the Company&#8217;s condensed consolidated
interim financial statements for the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Portage filed a shelf registration statement and prospectus with the SEC
under which it may sell shares, debt securities, warrants and units in one or more offerings from time to time, which became effective
on March 8, 2021 (&#8220;Registration Statement&#8221; or &#8220;Prospectus&#8221;). In connection with the Registration Statement, Portage
has filed with the SEC:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23B_zvfnWntL99E9" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div id="xdx_234_zkXKuHvW5ENa" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td id="xdx_237_z2ixVuDs1zn8" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zJKuswGLGWCg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zp54bbtdPW4h" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zYTHdetaHodi" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_z9wyKPYDT4Sa" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zFRU0oDZAJ4" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>


<ix:exclude><p id="xdx_230_zOiycQcYvYP2" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zljW7HWCEnrh" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 2. LIQUIDITY <span style="background-color: white"><i>(Cont&#8217;d)</i></span></b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zjEZxA0SG1Xc" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>a base prospectus, which covers the offering, issuance and sale by Portage of up to $<span id="xdx_904_ecustom--IssuanceAndSales_c20220401__20221231_pn3n3" title="Issuance and sales"><ix:nonFraction name="ptgef:IssuanceAndSales" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200,000,000</ix:nonFraction></span> in the aggregate of the securities
identified above from time to time in one or more offerings;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>a prospectus supplement covering the offer, issuance and sale by Portage in an &#8220;at the market&#8221; (the &#8220;ATM&#8221;)
offering of up to a maximum aggregate offering price of up to $<span id="xdx_905_ecustom--MaximumAggregateOfferingPrice_c20220401__20221231_pn3n3" title="Maximum aggregate offering price"><ix:nonFraction name="ptgef:MaximumAggregateOfferingPrice" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,000,000</ix:nonFraction></span> of Portage&#8217;s ordinary shares that may be issued and sold
from time to time under a Controlled Equity Offering Sales Agreement dated February 24, 2021 (the &#8220;Sales Agreement&#8221;), with
Cantor Fitzgerald &amp; Co., the sales agent (&#8220;Cantor Fitzgerald&#8221;);</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by Portage of 1,150,000 ordinary shares for gross proceeds
of approximately $26.5 million in a firm commitment underwriting with Cantor Fitzgerald; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>a prospectus supplement dated August 19, 2022, for the resale of up to $30,000,000 of Portage&#8217;s ordinary shares that Portage
may sell from time to time to Lincoln Park Capital Fund, LLC (&#8220;Lincoln&#8221;) and an additional 94,508 shares that were issued
to Lincoln.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span id="xdx_90F_ecustom--CashFundDescription_c20220401__20221231" title="Cash fund, description"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="ptgef:CashFundDescription">The Sales Agreement permits the Company to sell in an ATM offering up
to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered,
issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an &#8220;at
the market&#8221; offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;). Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is
not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus. See Note 14, &#8220;Capital
Stock,&#8221; and Note 22, &#8220;Event After the Balance Sheet Date,&#8221; for a further discussion.</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">During the quarter ended June 30, 2021, the Company commenced an &#8220;at
the market&#8221; offering, under which it sold <span id="xdx_907_ecustom--NumberOfStockSold_c20210401__20210630_pdd" title="Number of stock sold"><ix:nonFraction name="ptgef:NumberOfStockSold" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,888</ix:nonFraction></span> ordinary shares generating gross proceeds of approximately $<span id="xdx_903_ecustom--GrossProceedsFromStockSold_pn3n3_dm_c20210401__20210630_zhj8CbgEcpL2" title="Gross proceeds from stock sold"><ix:nonFraction name="ptgef:GrossProceedsFromStockSold" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million ($<span id="xdx_901_ecustom--NetProceedsFromStockSold_pn3n3_dm_c20210401__20210630_zHMJ1jsgGfQb" title="Net proceeds from stock sold"><ix:nonFraction name="ptgef:NetProceedsFromStockSold" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million,
net of commissions).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 24, 2021, <span id="xdx_906_ecustom--OfferingAndThroughThatProcessDescription_c20210601__20210624_zakxQr2tWLcc" title="Offering and through that process, description"><ix:nonNumeric contextRef="From2021-06-012021-06-24" name="ptgef:OfferingAndThroughThatProcessDescription">the Company completed a firm commitment underwritten
public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8
million, including approximately $1.6 million of management, underwriting and selling expenses.</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 6, 2022, the Company entered into a Purchase Agreement (the &#8220;Committed
Purchase Agreement&#8221;) with Lincoln, under which it may require Lincoln to purchase ordinary shares of the Company having an aggregate
value of up to $30 million (the &#8220;Purchase Shares&#8221;) over a period of 36 months. Pursuant to the Committed Purchase Agreement,
Lincoln will be obligated to purchase the Purchase Shares in three different scenarios that are based on various market criteria and share
amounts. The Company has the right to terminate the Committed Purchase Agreement for any reason, effective upon one business day prior
written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The requirement that Lincoln must make
a purchase will be suspended based on various criteria such as there not being an effective registration statement for Lincoln to be able
to resell the ordinary shares it is committed to purchase and market criteria such as the Company continuing to be Depository Trust Company
eligible, among other things. The Committed Purchase Agreement does not impose any financial or business covenants on the Company, and
there are no limitations on the use of proceeds. The Company may raise capital from other sources in its sole discretion; provided, however,
that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year
anniversary of the date of the Committed Purchase Agreement, excluding, however, an at-the-market transaction with a registered broker-dealer.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In October 2022, the Company restarted the ATM and commenced sales of
ordinary shares pursuant to the Sales Agreement. Through December 31, 2022, the Company sold <span id="xdx_90A_ecustom--NumberOfSharesSold_pid_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zGMvhkSMlFt6" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2022-12-302022-12-31_custom_ATMMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,072</ix:nonFraction></span> ordinary shares under the ATM, generating
net proceeds of approximately $<span id="xdx_904_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zAzoqx3bPCa9" title="Net proceeds from sale"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfBiologicalAssets" contextRef="From2022-12-302022-12-31_custom_ATMMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million and sold <span id="xdx_908_ecustom--NumberOfSharesSold_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zvfIIFT9hVsk" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2022-12-302022-12-31_custom_LincolnMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span> ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds
totaling approximately $<span id="xdx_901_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zIws2MS0r0ci" title="Net proceeds from sale"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfBiologicalAssets" contextRef="From2022-12-302022-12-31_custom_LincolnMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_237_zWpm5OI3CXi5" style="margin: 0pt 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div id="xdx_236_zZHLTAmxSOGc" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td id="xdx_23B_z41zxz1Nwjyb" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_z1k9eamPLqi9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_z3Axxu6XEn0e" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_z9fb8AMiWuPi" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zUA39X017Vtb" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_z8MIC9QPq444" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zpgUHXaIQ1ga" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><i>&#160;</i></p></ix:exclude>

<ix:exclude><p id="xdx_234_zYObq4Hh0SU9" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 2. LIQUIDITY <span style="background-color: white"><i>(Cont&#8217;d)</i></span></b></p></ix:exclude>

<ix:exclude><p id="xdx_237_z08of7G0Os58" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has incurred substantial operating losses since inception
and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result
primarily from its conduct of research and development activities.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company historically has funded its operations principally from proceeds
from issuances of equity and debt securities and would expect to enter the capital markets if additional funding is required.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>COVID-19 Effect</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Beginning in early March 2020, the COVID-19 pandemic and the measures
imposed to contain this pandemic have disrupted and are expected to continue to impact the Company&#8217;s business operations. The magnitude
of the impact of the COVID-19 pandemic on the Company&#8217;s productivity, results of operations and financial position, and its disruption
to the Company&#8217;s business and clinical programs and timelines, will depend, in part, on the length and severity of these restrictions
and on the Company&#8217;s ability to conduct business in the ordinary course. There was a slowdown and temporary lack of research and
development resources, principally due to the focus of third party research on the pandemic. The research and development environment has substantially normalized
in  calendar 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfBasisOfPresentationExplanatory"><p id="xdx_800_ecustom--DisclosureOfBasisOfPresentationExplanatory_zL5nVY97c0dd" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 3. <span id="xdx_82D_zNOInjuubg2f">BASIS OF PRESENTATION</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Statement of Compliance and Basis of Presentation</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These condensed consolidated interim financial statements have been prepared
in accordance with the International Financial Reporting Standards (&#8220;IFRS&#8221;) issued by the International Accounting Standards
Board (&#8220;IASB&#8221;), IAS 34 <i>Interim Financial Reporting</i> and interpretations of the International Financial Reporting Interpretations
Committee. These condensed consolidated interim financial statements do not include all of the information required for full annual financial
statements and should be read in conjunction with the audited consolidated financial statements of the Company for the year ended March
31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These condensed consolidated interim financial statements have been prepared
on an historical cost basis except for items disclosed herein at fair value (see Note 19, &#8220;Financial Instruments and Risk Management&#8221;).
In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except
for cash flow information.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has only one reportable operating segment.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These condensed consolidated interim financial statements were approved
and authorized for issuance by the Audit Committee and Board of Directors of the Company (the &#8220;Board&#8221;) on March 1, 2023.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Consolidation</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The condensed consolidated interim financial statements include the accounts
of the Company and:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td>SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23A_zP6fkpDCOgZb" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div id="xdx_23E_zI7VsLpbGmgk" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zWSOVgOTf5n7" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td id="xdx_23B_zqLIOrpHjKC7" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zClpH6QMdzBd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zoTeYjUQpJrd" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z8kMdeB92HE1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zmyTieFvblH9" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zvq4KxFDkj7d" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zkxrSbEUphTb" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zsR3XrPkcfYl" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 3. BASIS OF PRESENTATION <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zRhBd0xoaORi" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Consolidation (Cont&#8217;d)</i></b></p>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td>iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company, through SalvaRx, exchanged
certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing <span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20150201__20150210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesOneMember_zQxiaxfG6Slb" title="Proportion of ownership interest in subsidiary"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2015-02-012015-02-10_custom_SubsidiariesOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.49</ix:nonFraction></span>% of the outstanding shares
of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to <span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20211201__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesOneMember_zeCOhznC0y6" title="Proportion of ownership interest in subsidiary"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-12-012021-12-31_custom_SubsidiariesOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">78.32</ix:nonFraction></span>%. On July 18,
2022, the Company purchased the remaining non-controlling interest of iOx. <span style="background-color: white">See Note 18, &#8220;Related
Party Transactions &#8211; Share Exchange Agreement &#8211; iOx,&#8221; for a further discussion;</span></td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(c)</td><td>Saugatuck, a <span id="xdx_904_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_z0oi2gSXwMF3" title="Proportion of ownership interest in subsidiary"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2022-04-012022-12-31_custom_SubsidiariesTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% owned subsidiary incorporated in the British Virgin Islands. Saugatuck and subsidiary refers to Saugatuck and Saugatuck
Rx LLC;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(d)</td><td>PDS, a 100% owned subsidiary incorporated in Delaware, which provides human resources, and other services to each operating subsidiary
via a shared services agreement;</td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(e)</td><td>SalvaRx LLC, a wholly-owned subsidiary through SalvaRx;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(f)</td><td>Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck; and</td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(g)</td><td>Tarus Therapeutics, LLC (&#8220;Tarus&#8221;), a wholly-owned subsidiary of Portage.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">All inter-company balances and transactions have been eliminated in consolidation.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Non-controlling interest in the equity of a subsidiary
is accounted for and reported as a component of stockholders&#8217; equity. As of December 31, 2022, non-controlling interest represents
the <span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pid_dp_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_z0pwkgNrPylb" title="Non-controlling interest"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" contextRef="From2022-04-012022-12-31_custom_SubsidiariesTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span>% shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company. See Note 11, &#8220;Unsecured Notes Payable
&#8211; iOx Unsecured Notes Payable,&#8221; for a discussion of the Company&#8217;s settlement of loans with iOx and Note 18, &#8220;Related
Party Transactions &#8211; Share Exchange Agreement &#8211; iOx&#8221; for a discussion of the Company&#8217;s purchase of the balance
of the non-controlling interest in iOx.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Functional and Presentation Currency</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s functional and presentation currency is the U.S. Dollar.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Use of Estimates and Judgments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The preparation of the condensed consolidated interim financial statements
in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies
and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Estimates and underlying assumptions are reviewed on an ongoing basis.
Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Significant areas where estimates are made include valuation of financial
instruments (including the convertible note receivable), deferred tax assets, deferred tax liability, research and development costs,
fair value used for acquisition of intangible assets, contingent consideration assumed and measurement of share-based compensation. Significant
areas where critical judgments are applied include assessment of impairment of investments and goodwill and the determination of the accounting
acquirer and acquiree in the business combination accounting.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23C_zAjwlyVbW1h1" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div id="xdx_237_zu7uZTXChjt6" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td id="xdx_230_zKzhVPSm7iKe" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zPXJ8ndykG54" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zKqqDcaf5JR2" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zdL1OK2umATg" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zeKQl8Ax4D5h" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z9gg6loKiwd7" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zX9uMsQ3g7Ah" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"><p id="xdx_80C_eifrs-full--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zDYaOYLpbLo2" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4. <span id="xdx_82D_zWbEFd9RM9O">SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The accounting policies are set out in Note 4 to the fiscal 2022 audited
consolidated financial statements of the Company. These policies have been applied consistently to all periods presented in these condensed
consolidated interim financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory"><p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zWCyteK9gkH4" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86F_zboD0Nhcx4Bf">Recent Accounting Pronouncements</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>IFRS Pronouncements Issued</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Impact of Adoption of Significant New IFRS Standards in 2022</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 23.05pt"><b>(a)</b></td><td><b>Annual Improvements to IFRS Standards 2018-2020</b></td></tr></table>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The annual improvements process addresses issues in the 2018-2020 reporting
cycles including changes to IFRS 9, &#8220;Financial Instruments,&#8221; IFRS 1, &#8220;First Time Adoption of IFRS,&#8221; IFRS 16, &#8220;Leases,&#8221;
and IAS 41, &#8220;Biological Assets&#8221;.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right">i)</td><td style="width: 5pt"></td><td style="text-align: justify">The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition
of financial liabilities.</td>
</tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right">ii)</td><td style="width: 5pt"></td><td style="text-align: justify">The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent
to also measure cumulative translation differences using the amounts reported by the parent based on the parent&#8217;s date of transition
to IFRS.</td>
</tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right">iii)</td><td style="width: 5pt"></td><td style="text-align: justify">The amendment to IFRS 16&#8217;s illustrative example 13 removes the illustration of payments
from the lessor related to leasehold improvements.</td>
</tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These amendments were effective for annual periods beginning on or after
January 1, 2022. The adoption of these amendments did not have a material effect on the Company&#8217;s annual consolidated financial
statements or the condensed consolidated interim financial statements for the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23A_z8K4kU2z4KDb" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zBgHKcEbMUBk" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div id="xdx_234_zOmwNlf4OA5f" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td id="xdx_231_zgpjr8Qe6Ad9" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zgzLJEBuckul" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zUFR0tqrpi9a" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_z65gUHvuUx4" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zmlylKhldg11" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zRJZ6CG4sO3l" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zHOQRKRviqKh" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_z4MMqWvMybw1" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4. SIGNIFICANT ACCOUNTING POLICIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_z6XeZzcpwrkg" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 23.05pt"><b>(b)</b></td><td><b>IAS 37: Onerous Contracts &#8211; Cost of Fulfilling a Contract</b></td></tr></table>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 37 clarifies the meaning of costs to fulfil a contract
and that before a separate provision for an onerous contract is established, an entity recognizes any impairment loss that has occurred
on assets used in fulfilling the contract, rather than on assets dedicated to the contract. This amendment is effective for annual periods
beginning January 1, 2022. The Company&#8217;s adoption of IAS 37 did not have a material effect on its consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 23.05pt"><b>(c)</b></td><td><b>IAS 16: Proceeds Before Intended Use</b></td></tr></table>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 16 prohibits an entity from deducting from the cost
of an item of property, plant and equipment any proceeds received from selling items produced while the entity is preparing the assets
for its intended use (for example, the proceeds from selling samples produced when testing a machine to see if it is functioning properly).
It also clarifies that an entity is testing whether the asset is functioning properly when it assesses the technical and physical performance
of the asset. The amendment also requires certain related disclosures. This amendment is effective for annual periods beginning January
1, 2022. The Company&#8217;s adoption of IAS 16 did not have a material effect on its consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>New Accounting Standards, Interpretations and Amendments</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Standards issued but not yet effective up to the date of issuance of the
Company&#8217;s condensed consolidated interim financial statements are listed below. This listing is of standards and interpretations
issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they
become effective.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 23.05pt"><b>(a)</b></td><td><b>IAS 1: Presentation of Financial Statements</b></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 1 clarifies how to classify debt and other liabilities
as either current or non-current. The amendment is effective for annual periods beginning on or after January 1, 2023. The Company is
currently evaluating the new guidance and impacts on its consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 23.05pt"><b>(b)</b></td><td><b>Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture</b></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white">The amendment addresses the conflict between
IFRS 10, &#8220;Consolidated Financial Statements,&#8221; and IAS 28, &#8220;Investments in Associates and Joint Ventures,&#8221; in dealing
with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the
gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, &#8220;Business Combinations,&#8221;
between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution
of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors&#8217; interests in the
associate or joint venture. On September 11, 2014, the IASB issued narrow-scope amendments to IFRS 10&#160;and IAS 28. The amendments
were to be effective for annual periods commencing on or after January 1, 2016. In December 2015, the IASB decided to postpone the effective
date of these amendments indefinitely.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<ix:exclude><p id="xdx_232_zPjNjfpPifvc" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zeWSFtnnz4Pc" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div id="xdx_236_zSgPnKK4Yjmd" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td id="xdx_233_z5jJ0Qssy3c6" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zhvS0Rnp3FHd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zayxqVjapI3a" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zV7DEsmiLZv1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_z1NqdkF385bb" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zconmU0KEmYg" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zj65j74yfppa" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:DisclosureOfOtherAssetsExplanatory"><p id="xdx_80C_eifrs-full--DisclosureOfOtherAssetsExplanatory_zPZjeqptTUt8" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 5. <span id="xdx_820_zYL7W0Gr7FRk">PREPAID EXPENSES AND OTHER RECEIVABLES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z9FYDvDSJNyd" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B1_zeFC0uRP9RAd" style="display: none">Schedule of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49E_20221231_zLbLLnAjUTwa" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_495_20220331_zSSOlg8LFVxk" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of<br /> December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of<br /> March 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_pn3n3_z8Qszzkcd9Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Prepaid clinical research costs</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentReceivablesFromSaleOfProperties" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,286</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPzymm_z4uAeSWIsJm7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid insurance</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAdvancesToSuppliers" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">164</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAdvancesToSuppliers" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,084</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3_maCPzymm_zWNuB5Koc7ie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Research &amp; development tax credits</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ResearchAndDevelopmentCredit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ResearchAndDevelopmentCredit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TaxDeposits_iI_pn3n3_maCPzymm_zOtl5uuWIh23" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax deposits</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TaxDeposits" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:TaxDeposits" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">142</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPzymm_z4IwR0DtZmHj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other prepaid expenses</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPzymm_z6KVymZaNuxh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPzymm_zDi4bRBk7t6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepayments" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,786</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepayments" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,480</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:InvestmentInAssociateDisclosureTextBlock"><p id="xdx_80C_ecustom--InvestmentInAssociateDisclosureTextBlock_z3T0Wmxqobdb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 6. <span id="xdx_82F_zNiBqGMdyEbg">INVESTMENT IN ASSOCIATE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Details of the Company&#8217;s associate as of December 31, 2022 and March
31, 2022 are as follows:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfInvestmentAssociatetableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_pn3n3_zxPQaOlhb0Y8" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_8B6_zONU6GDdLls9" style="display: none">Schedule of investment associate</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Name</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Principal Activity</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Place of Incorporation and <br />Principal Place of Business</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Voting Rights Held as <br />of December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Voting Rights Held as <br />of March&#160;31, 2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-size: 10pt; text-align: center"><span id="xdx_906_eifrs-full--NameOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Name of associate"><ix:nonNumeric contextRef="From2022-04-012022-12-31_custom_StimunitySAMember" name="ifrs-full:NameOfAssociate">Associate: Stimunity S.A.</ix:nonNumeric></span></td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_907_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Principal place of business of associate"><ix:nonNumeric contextRef="From2022-04-012022-12-31_custom_StimunitySAMember" name="ifrs-full:PrincipalPlaceOfBusinessOfAssociate">Biotechnology</ix:nonNumeric></span></td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90E_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Country of incorporation of associate"><ix:nonNumeric contextRef="From2022-04-012022-12-31_custom_StimunitySAMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfAssociate">Paris, France</ix:nonNumeric></span></td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_908_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zs0v3uXnDvp" title="Proportion of voting rights held in associate"><ix:nonFraction name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" contextRef="From2022-04-012022-12-31_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">44.0</ix:nonFraction></span>%</td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_907_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20210401__20220331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zICLOKswsrxa" title="Proportion of voting rights held in associate"><ix:nonFraction name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" contextRef="From2021-04-012022-03-31_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">44.0</ix:nonFraction></span>%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_ztxSSjb86aB" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table is a roll-forward of the Company&#8217;s investment
in Stimunity S.A. (&#8220;Stimunity&#8221;) as of and for the nine months ended December 31, 2022 and 2021:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfInvestmentInStimunitySaTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_zMYY2OvtWdm6" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B9_z2HYPQOUacGg" style="display: none">Schedule of investment in Stimunity S.A.</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">As of and for the</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Nine Months Ended December 31,</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20220401__20221231_zRDqryHTVI5j" title="Beginning balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,673</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20210401__20211231_zTQ1g6GD1uJf" title="Beginning balance" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,735</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Share of (loss)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20220401__20221231_zDPvdJCnrqbd" title="Share of (loss)" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:UnrecognisedShareOfLossesOfAssociates" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">268</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20210401__20211231_zOSJCsuv8Ma3" title="Share of (loss)" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:UnrecognisedShareOfLossesOfAssociates" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">363</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20220401__20221231_zGJq8kXDNG3k" title="Ending  balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,405</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20210401__20211231_znG1sFoL91qi" title="Ending  balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,372</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z4His2IdycD3" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 1, 2020, the Company made an additional investment of &#8364;<span id="xdx_90B_ecustom--AdditionalInvestment_iI_pn3n3_dm_uEUR_c20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zHw1QvcpWG54" title="Additional investments"><ix:nonFraction name="ptgef:AdditionalInvestment" contextRef="AsOf2020-06-01_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="EUR">0.9</ix:nonFraction></span>
million ($<span id="xdx_908_ecustom--AdditionalInvestment_iI_pn3n3_dm_uUSD_c20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zlqhTDDfCL25" title="Additional investments"><ix:nonFraction name="ptgef:AdditionalInvestment" contextRef="AsOf2020-06-01_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million) by executing its subscription for <span id="xdx_905_ecustom--SubscribingClassShares_c20200529__20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pdd" title="Subscribing class A shares"><ix:nonFraction name="ptgef:SubscribingClassShares" contextRef="From2020-05-292020-06-01_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,479</ix:nonFraction></span> Class A shares upon the achievement of certain milestones, as provided
in the Shareholders&#8217; Agreement, increasing its equity share in Stimunity to <span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInAssociate_pid_dp_c20200529__20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zYfJTbuLdkNg" title="Proportion of ownership interest in associate"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInAssociate" contextRef="From2020-05-292020-06-01_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">44</ix:nonFraction></span>%.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 13, 2022, <span id="xdx_900_ecustom--ConvertibleNoteDescription_c20220702__20220713__ifrs-full--CounterpartiesAxis__custom--StimunityMember_zrnQmBs9a5Nc" title="Convertible Note description"><ix:nonNumeric contextRef="From2022-07-022022-07-13_custom_StimunityMember" name="ptgef:ConvertibleNoteDescription">the Company entered into a commitment with Stimunity
to provide &#8364;600,000 under a convertible note (the &#8220;Stimunity Convertible Note&#8221;) with a maturity date of September 1,
2023 (the &#8220;Maturity Date&#8221;). The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible
Note is automatically converted into Series A shares upon Stimunity completing a Series A round for at least &#8364;20 million. If such
subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into
Series A shares at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares
(other than Common Shares or Series A shares) for at least &#8364;5 million (the &#8220;Minimum Raise&#8221;), the Company will have the
right to convert the Stimunity Convertible Note and the historical Series A shares owned into the new category of shares. In the event
that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the
right to convert the Stimunity Convertible Note into Series A shares at &#8364;363.00 per share or the raise price less 15%, whichever
is lower. The Stimunity Convertible Note was funded on September 12, 2022. See Note 17, &#8220;Commitments and Contingent Liabilities
&#8211; Stimunity Convertible Note,&#8221; for a further discussion.</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_231_z0V492SwcqEc" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zlCA9GasL5V7" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div id="xdx_23D_zvpMzeswXe6h" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td id="xdx_233_zn1WUskIy8Xg" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zHvTKuTtTx86" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zJtmknRuVQn6" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zJinHXZcBXR9" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zeq2UKeD29el" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zGPmZLJ2y6Dd" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zWICRN63HIFi" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zEnP3SG1El05" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 6. INVESTMENT IN ASSOCIATE <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zyqjXH1BtSXe" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company accounts for its investment in Stimunity under the equity
method and, accordingly, records its share of Stimunity&#8217;s earnings or loss based on its ownership percentage. The Company recorded
equity in loss in Stimunity of $<span id="xdx_902_ecustom--EquityInLossIncome_c20221001__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income"><ix:nonFraction name="ptgef:EquityInLossIncome" contextRef="From2022-10-012022-12-31_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152,000</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--EquityInLossIncome_c20211001__20211231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income"><ix:nonFraction name="ptgef:EquityInLossIncome" contextRef="From2021-10-012021-12-31_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">261,000</ix:nonFraction></span> for the three months ended December 31, 2022 and 2021, respectively, and $<span id="xdx_901_ecustom--EquityInLossIncome_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income"><ix:nonFraction name="ptgef:EquityInLossIncome" contextRef="From2022-04-012022-12-31_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">268,000</ix:nonFraction></span>
and $<span id="xdx_903_ecustom--EquityInLossIncome_c20210401__20211231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income"><ix:nonFraction name="ptgef:EquityInLossIncome" contextRef="From2021-04-012021-12-31_custom_StimunitySAMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">363,000</ix:nonFraction></span> for the nine months ended December 31, 2022 and 2021, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Under the Shareholders&#8217; Agreement, Portage has (i) a preferential
subscription right to maintain its equity interest in Stimunity in the event of a capital increase from the issuance of new securities
by Stimunity, except for issuances of new securities for stock options under a merger plan or for an acquisition, and (ii) the right to
vote against any (a) issuances of additional securities that would call for Portage to waive its preferential subscription right, or (b)
any dilutive issuance.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock"><p id="xdx_80B_ecustom--DisclosureOfPrivateCompaniesExplanatoryTextBlock_zi7zMldnKqB2" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 7. <span id="xdx_82C_zSwib493zObd">INVESTMENT IN PRIVATE COMPANY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a discussion of the Company&#8217;s investment in private
company as of December 31, 2022 and March 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Intensity Therapeutics, Inc.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the SalvaRx Acquisition in fiscal 2019, the Company
acquired a $<span id="xdx_907_ecustom--PrivateInvestments_iI_pn3n3_dm_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zxnC2VC1AK8" title="Investment"><ix:nonFraction name="ptgef:PrivateInvestments" contextRef="AsOf2022-12-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million interest in Intensity, a private clinical stage biotechnology company, of <span id="xdx_904_ecustom--InvestmentOwnedShares_iI_dm_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zGyhj4jMXfph" title="Number of shares purchased"><ix:nonFraction name="ptgef:InvestmentOwnedShares" contextRef="AsOf2022-12-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember" format="ixt:numdotdecimal" decimals="INF" scale="3" unitRef="Shares">1.0</ix:nonFraction></span> million shares, which represented
a <span id="xdx_90D_ecustom--InvestmentOwnershipPercentage_iI_pid_dp_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zuMvIcYwCtX" title="Percentage of equity held"><ix:nonFraction name="ptgef:InvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% equity interest in Intensity. The investment was recorded at fair value (which approximates cost) at the acquisition date. The
investment in Intensity has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through
other comprehensive income (&#8220;OCI&#8221;). The fair value of the asset is determined by considering other comparable equity funding
transactions by Intensity with unrelated investors.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 11, 2019, the Company entered into an agreement with Fast Forward
Innovations Limited (&#8220;Fast Forward&#8221;) to purchase Intensity Holdings Limited (&#8220;IHL&#8221;), a wholly-owned subsidiary
of Fast Forward. The Company paid $1.3 million for IHL through the issuance of <span id="xdx_909_eifrs-full--NumberOfInstrumentsOrInterestsIssuedOrIssuable_iI_pid_uPure_c20190711__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_z534hUYPNpP2" title="Number of ordinary shares issued in acquisition"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" contextRef="AsOf2019-07-11_custom_AcquisitionOfIntensityHoldingLimitedMember_custom_IntensityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">129,806</ix:nonFraction></span> ordinary shares. The sole asset of IHL consists
of <span id="xdx_908_ecustom--NumberOfPrivateCompanyShareConsistsInSoleAsset_iI_pid_c20190711__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zsLT7iubhcA" title="Number of private company share consists in sole asset"><ix:nonFraction name="ptgef:NumberOfPrivateCompanyShareConsistsInSoleAsset" contextRef="AsOf2019-07-11_custom_AcquisitionOfIntensityHoldingLimitedMember_custom_IntensityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">288,458</ix:nonFraction></span> shares of Intensity. This transaction increased the Company&#8217;s ownership of Intensity to 1,288,458 shares.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">There was no unrealized gain or loss recognized during the three and nine
months ended December 31, 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022 and March 31, 2022, the Company owned approximately
<span id="xdx_901_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zpGEov3B10f8" title="Percentage of voting equity interests acquired"><ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="AsOf2022-12-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.00</ix:nonFraction></span>% and approximately <span id="xdx_90D_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20220331__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zOe7ynvONFKj" title="Percentage of voting equity interests acquired"><ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="AsOf2022-03-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.35</ix:nonFraction></span>%, respectively, of the outstanding shares of Intensity, on a fully diluted basis.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On October 28, 2021, Intensity filed a Form S-1 Registration Statement
with the SEC to register shares for an initial public offering, which was declared effective by the SEC, but subsequently withdrawn prior
to closing. Intensity is still evaluating market conditions to determine the timing of an initial public offering. As of March 31, 2022,
the Company had valued its investment in Intensity based on Intensity&#8217;s Series C Preferred Stock Offering completed in 2020. If
the initial public offering is successful, the Company will value its investment in Intensity based upon fair value (market price) and
will record periodic changes in carrying value through OCI.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In October and November of 2022, Intensity filed amendments to its
Form S-1 Registration Statement, which reflected a proposed offering price in the range of $<span id="xdx_900_ecustom--OfferingPrice_pid_c20221001__20221031__ifrs-full--RangeAxis__srt--MinimumMember_zsjy0CxMyG23" title="Offering price"><span id="xdx_907_ecustom--OfferingPrice_pid_c20221101__20221130__ifrs-full--RangeAxis__srt--MinimumMember_zv7YP90vslGe" title="Offering price"><ix:nonFraction name="ptgef:OfferingPrice" contextRef="From2022-10-012022-10-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="ptgef:OfferingPrice" contextRef="From2022-11-012022-11-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></ix:nonFraction></span></span>
- $<span id="xdx_903_ecustom--OfferingPrice_pid_c20221001__20221031__ifrs-full--RangeAxis__srt--MaximumMember_zhezDBoxcNv3" title="Offering price"><span id="xdx_902_ecustom--OfferingPrice_pid_c20221101__20221130__ifrs-full--RangeAxis__srt--MaximumMember_zTDIDHta0nX2" title="Offering price"><ix:nonFraction name="ptgef:OfferingPrice" contextRef="From2022-10-012022-10-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="ptgef:OfferingPrice" contextRef="From2022-11-012022-11-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></ix:nonFraction></span></span>
per share, which is less than the Company&#8217;s carrying value, which indicated impairment. Accordingly, the Company
performed a fair value analysis and determined a fair value of $<span id="xdx_900_eifrs-full--ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets_pn3n3_dm_c20221001__20221031_zXAbf0BvhQq9" title="Fair value"><span id="xdx_90D_eifrs-full--ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets_pn3n3_dm_c20221101__20221130_zCeOGHM5yy1l" title="Fair value"><ix:nonFraction name="ifrs-full:ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets" contextRef="From2022-10-012022-10-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD"><ix:nonFraction name="ifrs-full:ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets" contextRef="From2022-11-012022-11-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">3.363</ix:nonFraction></ix:nonFraction></span></span>
million, which was $<span id="xdx_908_eifrs-full--AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied_pn3n3_dm_c20221001__20221031_ztBj0DDWrGpg" title="Carrying value"><span id="xdx_90C_eifrs-full--AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied_pn3n3_dm_c20221101__20221130_zNgYsCvetUVe" title="Carrying value"><ix:nonFraction name="ifrs-full:AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied" contextRef="From2022-10-012022-10-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD"><ix:nonFraction name="ifrs-full:AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied" contextRef="From2022-11-012022-11-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">4.046</ix:nonFraction></ix:nonFraction></span></span>
million less than the then carrying value. The Company recognized an unrealized loss in value in Intensity of $<span id="xdx_907_ecustom--UnrealizedLoss_pn3n3_dm_c20220401__20221231_zHbzv0Tg3lvb" title="Unrealized loss"><ix:nonFraction name="ptgef:UnrealizedLoss" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">4.046</ix:nonFraction></span>
million through OCI in the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23F_z8126EwhPuRl" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zg9cIHbId3Ne" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div id="xdx_230_zZxESgUBG654" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td id="xdx_232_z9OXQIUkmsLa" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zvJiZ2dNvdIc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zL0OnAtSd8dj" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_z4bZHo7P2Jl9" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_z3Nfr3JaD6Kg" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zfDc7hl6UFd1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_z6PFg8U5vH42" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:AcquisitionsOfTarusExplanatory"><p id="xdx_801_ecustom--AcquisitionsOfTarusExplanatory_zkabzFvg5gbb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 8. <span id="xdx_82F_z4XxMRKdSZqh">ACQUISITION OF TARUS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 1, 2022, the Company, its wholly-owned subsidiary, Tarus Acquisition
Inc., and Tarus Therapeutics, Inc., a Delaware corporation advancing adenosine receptor agonists for the treatment of solid tumors, entered
into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;). Under the structure of the Merger Agreement,
Tarus Therapeutics, Inc. was ultimately merged into a wholly-owned subsidiary of the Company with the surviving entity renamed Tarus Therapeutics,
LLC. The Tarus merger entitles the Company to the rights, know-how and/or ownership related to the assets developed by Tarus (the &#8220;Adenosine
Compounds&#8221;), including:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">1.</td><td>All rights and obligations related to the License Agreement between Tarus and Impetis Biosciences Limited, dated October 29, 2019,
and the Call Option under the License Agreement, which was exercised on November 5, 2020;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">2.</td><td>All intellectual property and related documents owned or controlled by Tarus, including issued or pending patents, patent applications
and trade secrets. Additionally, any draft submissions and/or correspondence with patent authorities;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">3.</td><td>All documents and supplies related to Adenosine Compounds including inventory, reagents, data, assays, reports, vendor agreements
and other information related to the preclinical development;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">4.</td><td style="text-align: left">All clinical supplies, manufacturing know-how, batch records, regulatory documents pertaining to the Adenosine
Compounds, certain reservations for manufacturing campaigns and any related agreements;</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">5.</td><td style="text-align: left">All regulatory documents and correspondence pertaining to the Adenosine Compounds;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">6.</td><td style="text-align: left">All Contract Research Organization (&#8220;CRO&#8221;) agreements and protocol related documents for Adenosine
Compounds;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">7.</td><td style="text-align: left">All current documents related to market research, forecasting, budgets and competitive intelligence; and</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">8.</td><td style="text-align: left">Rights to the use of Tarus Therapeutics&#8217; name for regulatory purposes.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">As consideration for Tarus, the Company issued to Tarus
shareholders an aggregate of <span id="xdx_903_ecustom--NumberOfSharesSold_c20220401__20221231_pdd" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,425,999</ix:nonFraction></span> ordinary shares of Portage, calculated on the basis of $18 million divided by the 60-day Volume
Weighted Average Price per share. The shares have not been registered with the SEC and are subject to lock-up agreements for terms ranging
from six to twelve months. Additionally, milestone payments of up to $<span id="xdx_904_eifrs-full--ProceedsFromIssueOfOrdinaryShares_pn3n3_dm_c20220401__20221231_zrQSA4mhDjh2" title="Proceeds from offering"><ix:nonFraction name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">32</ix:nonFraction></span> million in cash or Portage ordinary shares would be triggered
upon achievement of future development and sales milestones. As a result of the transaction:</p>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">The Company also assumed $2 million in short-term debt held by Tarus and deferred license milestones obligations
($1 million plus interest). The short-term debt was repaid by the Company in July 2022.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">Upon enrolling the first patient in a Phase 2 clinical trial, the Company will pay an additional one-time
milestone payment of $15 million. Payment will be in the form of cash or Portage ordinary shares (at the discretion of the Company). The
remaining $<span id="xdx_90F_ecustom--MilestonePayment_pn3n3_dm_c20220401__20221231_z1qt4rFfy5Ed" title="Milestone payment"><ix:nonFraction name="ptgef:MilestonePayment" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">17</ix:nonFraction></span> million milestone is based on targeted commercial sales.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in">&#160;</p>

<ix:exclude><p id="xdx_234_zX9LAvJgp0w8" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zdLLUiRijqCe" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 1 -->
    <div id="xdx_235_zSEE9FKzkL5b" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td id="xdx_23F_zosjHrr0QNAf" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_z23MyeYCi9q1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zJgH3JecZ2ai" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zoW4ZQALAlGk" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zbE3McqQh0H9" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zJ7c6sbRpqG2" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zhJDF3DPD0c3" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zRQxGJvpxQib" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 8. ACQUISITION OF TARUS <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zYk49TdcMbg8" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the acquisition of Tarus, the Company performed a fair
value analysis of the assets acquired and liabilities assumed. The Company based the analysis on its clinical plan and timing of development
events, and the probabilities of success determined primarily based upon empirical third party data and Company experience as well as
the relevant cost of capital. In its fair value analysis, the Company used the Multi-Period Excess Earnings Method for PORT-6 and PORT-7
and the Replacement Cost Method for PORT-8 and PORT-9, determined based upon the maturity of the assets and the availability of sufficient
data to measure fair value. The Company recorded the shares issued at $17.2 million, which represented the aggregate market value of the
shares issued on July 1, 2022. The Company followed the guidance of IAS 3 and IAS 32 and recorded a deferred purchase price payable -
Tarus of $8.538 million, which reflected the estimated acquisition date fair value of contractual milestone obligations incurred. The
principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount
rate used. The Company recorded the obligation as a non-current liability, in accordance with the provisions IAS 32 with respect to the
classification of financial assets and financial liabilities.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company will determine the fair value of the earnout shares at each
balance sheet date. Any change to the fair value will be recorded in the Company&#8217;s statements of operations and other comprehensive
income (loss).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table summarizes the preliminary purchase price allocation
to the fair value of assets acquired and liabilities assumed for Tarus:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_pn3n3_zcgJpov2ptab" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold"><span id="xdx_8B6_zBnEjiGJsVLb" style="display: none">Schedule of fair value of assets acquired and liabilities assumed</span></td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" id="xdx_499_20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zRfIBNUBk5Xj" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--AssetsAbstract_iB" style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">Assets:</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">(In thousands)</td></tr>
  <tr id="xdx_40F_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Identifiable intangible assets</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,200</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--Goodwill_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Goodwill</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">538</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--OtherTangibleOrIntangibleAssetsTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherTangibleOrIntangibleAssetsTransferred" contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,738</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Consideration:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Fair value of shares issued</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,200</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities assumed</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred purchase consideration at fair value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,538</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ContingentLiabilitiesRecognisedInBusinessCombination_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,738</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zD9luswZEGm7" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Pro forma Information</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Summary unaudited pro forma condensed
results of operations for the nine months ended December 31, 2022 and 2021, assuming the Tarus acquisition had occurred at the beginning
of the earliest period presented, are as follows:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfProformaInformationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfProformaInformationTableTextBlock_pn3n3_z7CpBwzy6t86" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_zWRu7EqIHft5" style="display: none">Schedule of pro forma information</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eifrs-full--ProfitLossFromContinuingOperations_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" title="Loss from operations" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2022-04-012022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,200</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eifrs-full--ProfitLossFromContinuingOperations_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" title="Loss from operations" style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2021-04-012021-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,431</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss before provision for income taxes</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_983_eifrs-full--ProfitLossBeforeTax_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" title="Loss before provision for income taxes" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2022-04-012022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,833</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_985_eifrs-full--ProfitLossBeforeTax_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" title="Loss before provision for income taxes" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2021-04-012021-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,110</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_985_eifrs-full--ProfitLoss_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" title="Net loss and other comprehensive loss" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-04-012022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,927</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_983_eifrs-full--ProfitLoss_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" title="Net loss and other comprehensive loss" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012021-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,645</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total comprehensive loss for period</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--ComprehensiveIncome_pn3n3_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zmKaplj5POOe" title="Total comprehensive loss for period" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2022-04-012022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,945</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_981_eifrs-full--ComprehensiveIncome_pn3n3_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zaB8v3M1mJRf" title="Total comprehensive loss for period" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-012021-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,645</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Loss per share</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--EarningLossPerShare_pid_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zJqemgtaRjoh" title="Loss per share" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:EarningLossPerShare" contextRef="From2022-04-012022-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.60</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--EarningLossPerShare_pid_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zk2Ts7F4UjDc" title="Loss per share" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:EarningLossPerShare" contextRef="From2021-04-012021-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.77</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Summary unaudited pro forma condensed
results of operations for the three months ended December 31, 2022 and 2021, assuming the Tarus acquisition had occurred at the beginning
of the earliest period presented, are as follows:</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<ix:exclude><p id="xdx_238_zS8SDtzba9j9" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zpw499RQpERg" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 1 -->
    <div id="xdx_235_zLOcgi4AyDYi" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td id="xdx_23F_zB9uXVGTVXz8" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zBPRPhyT1rH4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zdIAfkffvNCf" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zsWkjgVp8yN2" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zi42QMcrtxAa" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zJe9j7tV67zf" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_z91oNsFje7Pj" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zmFnVTrUBfs2" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 8. ACQUISITION OF TARUS <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zmsBI6L1mE6b" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Three Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>2022 <sup>(1)</sup></b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eifrs-full--ProfitLossFromContinuingOperations_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zHdfLCzdC7T3" title="Loss from operations" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2022-10-012022-12-31_custom_TarusAcquisitionMember" id="Fact000921" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,759</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eifrs-full--ProfitLossFromContinuingOperations_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" title="Loss from operations" style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromContinuingOperations" contextRef="From2021-10-012021-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,362</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss before provision for income taxes</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--ProfitLossBeforeTax_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zRs6TI3yaLDl" title="Loss before provision for income taxes" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2022-10-012022-12-31_custom_TarusAcquisitionMember" id="Fact000925" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,302</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eifrs-full--ProfitLossBeforeTax_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" title="Loss before provision for income taxes" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2021-10-012021-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,281</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_eifrs-full--ProfitLoss_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zquh5ZicSRXe" title="Net loss and other comprehensive loss" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2022-10-012022-12-31_custom_TarusAcquisitionMember" id="Fact000929" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,501</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_980_eifrs-full--ProfitLoss_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" title="Net loss and other comprehensive loss" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-10-012021-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,398</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total comprehensive loss for year</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eifrs-full--ComprehensiveIncome_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zov2r2vGJ3K7" title="Total comprehensive loss for year" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2022-10-012022-12-31_custom_TarusAcquisitionMember" id="Fact000933" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,518</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eifrs-full--ComprehensiveIncome_pn3n3_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zfzxq4miensg" title="Total comprehensive loss for year" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-10-012021-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,398</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Loss per share</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--EarningLossPerShare_pid_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_z5cPInowNzre" title="Loss per share" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:EarningLossPerShare" contextRef="From2022-10-012022-12-31_custom_TarusAcquisitionMember" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--EarningLossPerShare_pid_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zqNUVTjSNvR5" title="Loss per share" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:EarningLossPerShare" contextRef="From2021-10-012021-12-31_custom_TarusAcquisitionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><b><sup id="xdx_F05_zcAeLhLmlou">(1)</sup></b></td><td><span id="xdx_F10_zVMEtrMNyV8a" style="background-color: white"><ix:footnote id="Footnote000940" xml:lang="en-US">Includes the results of operations of Tarus for the period and, accordingly, there are no pro
forma adjustments for the three months ended December 31, 2022.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8A5_z5JuqaAE1sId" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">These pro forma results are not
necessarily indicative of what would have occurred if the acquisition had been in effect for the period presented, and they may not be
indicative of results expected in the future.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:GoodwillExplanatory"><p id="xdx_80C_ecustom--GoodwillExplanatory_zQMqwFKrF9Ed" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 9. <span id="xdx_821_zZ5bdKYv259f">GOODWILL</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a roll-forward of goodwill:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_pn3n3_zLudUd1v9bSd" summary="xdx: Disclosure - GOODWILL (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B4_zbIemXnbfJ7d" style="display: none">Schedule of IPR&amp;D projects</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>As of</b></p> <p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>December 31, 2022</b></p></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of <br />March 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_eifrs-full--Goodwill_iS_pn3n3_c20220401__20221231_zKF2Isk5FSS7" title="Balance, beginning of period" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,324</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--Goodwill_iS_pn3n3_c20210401__20220331_znVRzPGwTWZi" title="Balance, beginning of period" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,324</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Tarus goodwill</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--TarusGoodwill_pn3n3_c20220401__20221231_zBDPxH24xyQ8" title="Tarus goodwill" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TarusGoodwill" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">538</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--TarusGoodwill_pn3n3_c20210401__20220331_znfWoPq6WaWl" title="Tarus goodwill" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_eifrs-full--Goodwill_iE_pn3n3_c20220401__20221231_zBDVkEbbyoea" title="Balance, ending of period" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,862</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--Goodwill_iE_pn3n3_c20210401__20220331_zU9JFoExOgSk" title="Balance, ending of period" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,324</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s goodwill arose primarily from the acquisition of SalvaRx
and its portfolio of several projects and investments.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As a result of the acquisition of Tarus in July 2022, the Company recorded
$<span id="xdx_906_eifrs-full--Goodwill_iI_pn3n3_dm_c20220731_zMGxVvItlQK" title="Goodwill"><ix:nonFraction name="ifrs-full:Goodwill" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.538</ix:nonFraction></span> million of goodwill, representing the difference between the consideration paid of $<span id="xdx_906_eifrs-full--ConsiderationPaidReceived_pn3n3_dm_c20220701__20220731_z50dkGllOPMe" title="Consideration paid"><ix:nonFraction name="ifrs-full:ConsiderationPaidReceived" contextRef="From2022-07-012022-07-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">28.738</ix:nonFraction></span> million and the fair value of identifiable
assets acquired of $<span id="xdx_907_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iI_pn3n3_dm_c20220731_zkw0GF8wYyO9" title="Fair value of identifiable assets acquired"><ix:nonFraction name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">28.2</ix:nonFraction></span> million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Under purchase accounting as of July 1, 2022 (the acquisition date), the
assets and liabilities of Tarus Therapeutics, Inc., was recorded at their respective fair values and the excess of the acquisition consideration
is goodwill. The purchase was in the form of a merger in which Tarus Therapeutics, Inc. was merged into Tarus Therapeutics, LLC., which
is a wholly-owned subsidiary of Portage. All of the consideration for Tarus Therapeutics, LLC was paid or assumed by Portage and Portage
will control the voting rights, the board of directors and the operations of Tarus Therapeutics, LLC.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022, the Company determined that it has only one cash-generating
unit (&#8220;CGU&#8221;), the consolidated Portage Biotech Inc.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Impairment Review</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font-weight: normal">On an annual basis,
pursuant to IAS 36, &#8220;Impairment of Assets,&#8221; the Company assesses its long-lived assets with definite lives, which are not
yet available for use, for potential indicators of impairment.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">If any such indication exists, the Company estimates the recoverable amount
of the asset or CGU and compares it to the carrying value.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company performed its annual impairment test in each of fiscal 2022
and fiscal 2021 and estimated the recoverable amount of the above-noted CGU based on its value in use, which was determined using a capitalized
cash flow methodology and categorized within level 3 of the fair market value hierarchy.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_239_zxyoCTDN6xU1" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_z0xFHe9hEuv2" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 1 -->
    <div id="xdx_230_zWZAGHcPRWX7" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td id="xdx_238_zRQTjSO6ECYh" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zMJLswEZxoIj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zlNfLhK3Gzqc" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zvg2sMjRQLb3" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zcEzZn2vB8I1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_z7wAo2Rgylp2" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zN98edAOTXL3" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zH0aoEHT1vg7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 9. GOODWILL <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zanKoBCzvsU9" style="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The recoverable amount of the CGU has been determined based on its value
in use. The recoverable amount considered assumptions based on probabilities of technical, regulatory and clinical acceptances and financial
support. Further, management uses risk-adjusted cash flow projections based on financial budgets. Management believes that any reasonably
possible change in the key assumptions on which the recoverable amount is based would not cause the carrying amount to exceed its recoverable
amount. The discount rate has been determined based on the Company&#8217;s best estimate of a risk adjusted discount rate.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The key assumptions used in the calculation of the recoverable amount
include forecasts of the following:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.3in"></td><td style="width: 0.25in">(a)</td><td>revenues;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.3in"></td><td style="width: 0.25in">(b)</td><td>normalized operating expenses;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.3in"></td><td style="width: 0.25in">(c)</td><td>income taxes; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.3in"></td><td style="width: 0.25in">(d)</td><td>capital expenditures.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Discounted cash flows are determined with reference to undiscounted risk
adjusted cash flows, and the discount rate approximated <span id="xdx_902_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_pid_dp_c20220331_zCwNScr0c5p8" title="Discount rate applied to cash flow projections"><ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.5</ix:nonFraction></span>% and <span id="xdx_90D_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_pid_dp_c20210331_zoiBrA98PB95" title="Discount rate applied to cash flow projections"><ix:nonFraction name="ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.0</ix:nonFraction></span>% as of March 31, 2022 and 2021, respectively, based on the individual
characteristics of the Company&#8217;s CGU, the risk-free rate of return and other economic and operating factors.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font-weight: normal">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022, management assessed whether any indications of
impairment existed for the Company&#8217;s CGU. As of December 31, 2022, the Company&#8217;s market capitalization was less than its net
assets, which is an external indicator of potential impairment. The Company evaluated this factor in conjunction with its assessment of
the overall market environment and the progress made in developing the Company&#8217;s assets. The Company determined that a test for
impairment was not required and no impairment was recorded for the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability"><p id="xdx_80A_ecustom--InProcessResearchAndDevelopmentAndDeferredTaxLiability_z0t3q4vCUoP7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 10. <span id="xdx_82F_zmF2B0HJBA6h">IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In-process research and development (&#8220;IPR&amp;D&#8221;) consists
of the following projects (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_pn3n3_zHScnRDnlYbb" summary="xdx: Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BD_zbI1Fmg1K1Zd" style="display: none">Schedule of In process research and development</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Project #</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Description</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Value as of <br />December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Value as of <br />March 31, 2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">iOx:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 25%; font-size: 10pt">PORT 2 (IMM60)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: left">Melanoma &amp; Lung Cancers</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_pn3n3" title="In-process research and development" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-12-31_custom_IMM60IOXMelanomaLungCancersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84,213</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_pn3n3" title="In-process research and development" style="width: 22%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-03-31_custom_IMM60IOXMelanomaLungCancersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84,213</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">PORT 3 (IMM65)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Ovarian/Prostate Cancers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_pn3n3" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-12-31_custom_IMM65IOXOvarianProstateCancersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,997</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_pn3n3" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-03-31_custom_IMM65IOXOvarianProstateCancersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,997</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IOXMember_pn3n3" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-12-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,210</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IOXMember_pn3n3" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-03-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,210</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Oncomer/Saugatuck</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">DNA Aptamers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_pn3n3" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-12-31_custom_OncomerSaugatuckDNAAptamersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_pn3n3" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-03-31_custom_OncomerSaugatuckDNAAptamersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Tarus:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">PORT 6 &amp; PORT 7</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_pn3n3" title="In-process research and development" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-12-31_custom_TarusAdenosineReceptorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,138</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_zxIggqMDOTqb" title="In-process research and development" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">PORT 8</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_pn3n3" title="In-process research and development" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-12-31_custom_TarusAdenosineReceptors1Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_z2UTe8vC2o1h" title="In-process research and development" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">PORT 9</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_pn3n3" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-12-31_custom_TarusAdenosineReceptors2Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">562</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_zc1SfRt7Efih" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusMember_pn3n3" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-12-31_custom_TarusMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,200</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusMember_zF69TNYjLoka" title="In-process research and development" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1011">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">In-process research and development</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20221231_pn3n3" title="In-process research and development" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145,588</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331_zXEtNRf72jZi" title="In-process research and development" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:InprocessResearchAndDevelopment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,388</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Deferred tax liability</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--DeferredTaxesLiability_c20221231_pn3n3" title="Deferred tax liability" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredTaxesLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,409</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_985_ecustom--DeferredTaxesLiability_iI_pn3n3_c20220331_zy2OYFg0dPOl" title="Deferred tax liability" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:DeferredTaxesLiability" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,198</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Additionally, at the end of each reporting period, the Company is required
to assess whether there is any indication that an asset may be impaired. As indicated above, the Company identified an external indicator
of potential impairment as of December 31, 2022. Pursuant to IAS 36, the Company completed its review of underlying fundamentals, execution,
advancement of assets and value creation activities and concluded that no provision for impairment was required during the three and nine
months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_236_zXbfXKDdolki" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zpFlNUPIJdZk" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 1 -->
    <div id="xdx_23D_zJfVR4e2Ym6f" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td id="xdx_234_zPawztK7nFSf" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zgyCH5GEa5C9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_z4JJrX7XFCT7" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zCnJuKpObedi" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zgpWK7mcZosc" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zdcYsnC9WqA1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zUudqL48Mjoa" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zkvw87cKOV07" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 10. IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zKkxLlfAiZPf" style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font-weight: normal">&#160;</span></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Deferred tax liability represents iOx&#8217;s estimated tax on the difference
between book and tax basis of the IPR&amp;D, which is taxable in the U.K, and the effect of usable net operating loss carryforwards.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022 and March 31, 2022, iOx had a net deferred tax
liability of approximately $<span id="xdx_908_ecustom--DeferredTaxLiability_iI_pn3n3_dm_c20221231_zDJge99TLoe" title="Deferred tax liability"><ix:nonFraction name="ptgef:DeferredTaxLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">25.5</ix:nonFraction></span> million and approximately $<span id="xdx_90B_ecustom--DeferredTaxLiability_iI_pn3n3_dm_c20220331_zwOLOdYSRosl" title="Deferred tax liability"><ix:nonFraction name="ptgef:DeferredTaxLiability" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">28.4</ix:nonFraction></span> million, respectively. On January 8, 2019, the Company originally recognized
a $<span id="xdx_905_ecustom--DeferredTaxLiability_iI_pn3n3_dm_c20190108_z1ULMKngf0jf" title="Deferred tax liability"><ix:nonFraction name="ptgef:DeferredTaxLiability" contextRef="AsOf2019-01-08" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">19.8</ix:nonFraction></span> million deferred tax liability for the difference between the book and income tax basis of IPR&amp;D acquired as part of the SalvaRx
Acquisition. As the iOx IPR&amp;D is in the U.K., the deferred tax was recorded at 17%, the prevailing tax rate applicable in the U.K.
at the time. In fiscal 2022, the Company recorded $<span id="xdx_908_ecustom--IncreaseInDeferredIncomeTaxes_pn3n3_dm_c20220401__20221231_zSnMRswCpnH8" title="Increase in deferred income taxes"><ix:nonFraction name="ptgef:IncreaseInDeferredIncomeTaxes" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">7.0</ix:nonFraction></span> million increase in deferred income taxes to reflect a future change in the U.K.
income tax rate and recognized $0.7 million of current year losses and $0.8 million of prior year losses. The Company also recognized
a $<span id="xdx_906_eifrs-full--IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_pn3n3_dm_c20210401__20220331_zdAI4qGBrvEe" title="Increase (Decrease) in deferred tax liability"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million decrease in deferred tax liability in fiscal 2022 to reflect the effect of the change in exchange rates on the liability
settleable in British pound sterling. For the nine months ended December 31, 2022, the Company recognized the reduction in deferred tax
liability of $<span id="xdx_904_ecustom--ReductionInDeferredTaxLiability_pn3n3_dm_c20220401__20221231_z54kYTYHrhX7" title="Reduction in deferred tax liability"><ix:nonFraction name="ptgef:ReductionInDeferredTaxLiability" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million to reflect the effect of the change in exchange rates on the liability in the period and recognized $0.8 million
of current period losses, as well as the tax rate change effect of $<span id="xdx_906_eifrs-full--TaxEffectFromChangeInTaxRate_pn3n3_dm_c20221001__20221231_zT3cMvasNGw5" title="Change in tax effect rate"><ix:nonFraction name="ifrs-full:TaxEffectFromChangeInTaxRate" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million on the current period losses.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:UnsecuredNotesPayableAndWarrantsTextBlock"><p id="xdx_806_ecustom--UnsecuredNotesPayableAndWarrantsTextBlock_zSsTtfMNdY1i" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 11. <span id="xdx_821_zPAGPseEZqk5">UNSECURED NOTES PAYABLE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a roll-forward of current notes payable:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfNotesPayableTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfNotesPayableTableTextBlock_pn3n3_zeWFs1sHNQe9" summary="xdx: Disclosure - UNSECURED NOTES PAYABLE (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B6_zA0fi5D1dvOj" style="display: none">Schedule of notes payable</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt">Balance, April 1, 2021</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--NotePayable_iS_pn3n3_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zestGKdqCeS9" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2021-03-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--NotePayable_iS_pn3n3_c20210401__20220331_zfs96051DQC9" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NotePayable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Exchange of notes payable and accrued interest for iOx shares</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zhbajFJGiK68" title="Exchange of notes payable and accrued interest for iOx shares" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare" contextRef="From2021-04-012022-03-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">150</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20210401__20220331_z5sKKS9dM8D" title="Exchange of notes payable and accrued interest for iOx shares" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">150</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, March 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_985_ecustom--NotePayable_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zotCZUI590z6" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--NotePayable_iE_pn3n3_c20220401__20221231_z3hA9dz5u2b5" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; font-weight: bold">Exchange of notes payable and accrued interest for iOx shares</td><td style="display: none; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="display: none; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td title="Exchange of notes payable and accrued interest for iOx shares" id="xdx_98B_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zOU9l9CUtJ2a" style="display: none; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare" contextRef="From2022-04-012022-12-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">150</ix:nonFraction>)</td><td style="display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="display: none; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td title="Exchange of notes payable and accrued interest for iOx shares" id="xdx_981_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20220401__20221231_z4iu4zFeibZ1" style="display: none; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">150</ix:nonFraction>)</td><td style="display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98D_ecustom--NotePayable_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zCQQK7FxQfHb" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--NotePayable_iE_pn3n3_c20220401__20221231_zlxI21CXaGN8" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>iOx Unsecured Notes Payable</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the SalvaRx Acquisition in January 2019, <span id="xdx_90B_ecustom--DescriptionOfBusinessCombination_c20190103__20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember" title="Description of business combination"><ix:nonNumeric contextRef="From2019-01-032019-01-31_custom_SalvaRxMember" name="ptgef:DescriptionOfBusinessCombination">the Company
assumed $2.0 million of 7% convertible notes issued by iOx, a wholly-owned subsidiary of SalvaRx (the &#8220;Convertible Notes&#8221;),
of which the Company holds $1.9 million. As a result of the SalvaRx Acquisition, iOx became a subsidiary of the Company during the year
ended March 31, 2019. In accordance with IFRS 3, the fair value, including interest receivable, of the Convertible Notes were effectively
settled against the note receivable upon the business combination.</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">On September 8, 2021, <span id="xdx_90B_ecustom--IssuanceOfUnsecuredNotesDescription_c20210901__20210908__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember" title="Description of business combination"><ix:nonNumeric contextRef="From2021-09-012021-09-08_custom_IOXMember" name="ptgef:IssuanceOfUnsecuredNotesDescription">the&#160;Company,
through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for
23,772 ordinary shares of iOx at a price of &#163;162. Simultaneously, the Company entered into an agreement with Oxford Sciences Innovation,
Plc (&#8220;OSI&#8221;), the holder of $0.15&#160;million notes plus accrued interest under which OSI exchanged the notes plus accrued
interest for&#160;820&#160;shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated
November 29, 2016, following the general tenets of IAS 39, &#8220;Financial Instruments: Recognition and Measurement,&#8221; and IFRIC
19, &#8220;Extinguishing Financial Liabilities with Equity Instruments,&#8221; and recorded the exchange at historical cost. Additionally,
no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased
its ownership of iOx from&#160;60.49% to&#160;78.32%.</ix:nonNumeric></span> See Note 18, &#8220;Related Party Transactions &#8211; Share Exchange Agreement
&#8211; iOx,&#8221; for a further discussion.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23D_zrW0tfF9lAQi" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zfIbPVyaEeTj" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 20; Value: 1 -->
    <div id="xdx_231_ziGi1c4yYk1f" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td id="xdx_23A_zv5jGiDeTfqc" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zNgA9QPzrHia" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zbgxrtsUbnyc" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zCndSzJDhO77" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zr36smUPxxu2" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zIoUb9AXVpTd" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zh7VItSAFhV2" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfIncomeTaxExplanatory_z2bbpo4LmRrf" style="margin: 0pt 0; font-size: 10pt"><span style="background-color: white"><b>NOTE 12. <span id="xdx_824_zYRUCl5i95jj">INCOME TAXES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company is a BVI business company. The BVI government does not, under
existing legislation, impose any income or corporate tax on corporations.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">PDS is a U.S. corporation and is subject to U.S. federal, state and local
income taxes, as applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">iOx is subject to U.K. taxes.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The (expense) benefit from income taxes consists of the following:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zWnMyD12RJkk" summary="xdx: Disclosure - INCOME TAXES (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-left: 10pt"><span id="xdx_8BE_zLsQxoQ5ljE1" style="display: none">Schedule of income taxes benefit</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49F_20220401__20221231_zsmYLl3pLi1f" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20210401__20211231_zbPTKMiKUAMi" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Current:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CurrentFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-left: 10pt">Federal</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1087">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--CurrentStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">State and local</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:CurrentStateAndLocalIncomeTaxBenefit" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--CurrentForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:CurrentForeignIncomeTaxBenefit" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CurrentForeignIncomeTaxBenefit" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CurrentTaxExpenseIncome_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Deferred:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-left: 10pt">Federal</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">State and local</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1105">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredForeignIncomeTaxBenefit" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,930</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:DeferredForeignIncomeTaxBenefit" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">444</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--AdjustmentsForDeferredTaxExpense_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total deferred</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDeferredTaxExpense" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,930</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDeferredTaxExpense" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">444</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_pn3n3_di_zUIk1Gkzq7kb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Benefit from income taxes</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,906</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">465</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zMmmvcaeSYsi" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a reconciliation of the U.S. taxes to the effective income
tax rates for the nine months ended December 31, 2022 and 2021 (U.S. Dollars in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_zvtghDqeHZw7" summary="xdx: Disclosure - INCOME TAXES (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BD_zovpDafCwnr3" style="display: none">Schedule of reconciliation income tax rates</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Income (loss) on ordinary activities before tax</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_983_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_pn3n3_c20220401__20221231_zeTzaA6AKANg" title="Income (loss) on ordinary activities before tax" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,230</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_pn3n3_c20210401__20211231_zNKCMsniQEhf" title="Income (loss) on ordinary activities before tax" style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,535</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Statutory U.S. income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_c20220401__20221231_zz7uNLmimiCb" title="Statutory U.S. income tax rate"><ix:nonFraction name="ptgef:StatutoryU.s.IncomeTaxRate" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_903_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_c20210401__20211231_z5NAJwlcIL14" title="Statutory U.S. income tax rate"><ix:nonFraction name="ptgef:StatutoryU.s.IncomeTaxRate" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Income tax benefit at statutory income tax rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--LossAtStatutoryIncomeTaxRate_c20220401__20221231_pn3n3" title="Income tax at statutory income tax rate" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossAtStatutoryIncomeTaxRate" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">258</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--LossAtStatutoryIncomeTaxRate_pn3n3_c20210401__20211231_zoj1uUZp0jMf" title="Income tax at statutory income tax rate" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:LossAtStatutoryIncomeTaxRate" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">322</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Losses recognized (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--LossesRecognized_c20220401__20221231_pn3n3" title="Losses recognized" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:LossesRecognized" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">282</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--LossesRecognized_pn3n3_c20210401__20211231_zCB3y6lDVIb4" title="Losses recognized" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:LossesRecognized" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">322</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--IncomeTaxBenefitExpense_pn3n3_c20220401__20221231_zGV70la4s5Wf" title="Income tax benefit (expense)" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:IncomeTaxBenefitExpense" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--IncomeTaxBenefitExpense_pn3n3_c20210401__20211231_zBDa7Nvj8unf" title="Income tax benefit (expense)" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1136">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z5GZjfAiiUh4" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23B_z4mFOYSiwK52" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zEVpfsfwgFle" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 21; Value: 1 -->
    <div id="xdx_230_zdVbslf7h1Ab" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td id="xdx_23B_zhfu3p31rvzi" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zXQxZYgpJVF" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zsVKySEO49vh" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zfPVUIUfgFvi" style="margin: 0pt 0; font-size: 10pt"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zxf9ch1gdsg1" style="margin: 0pt 0; font-size: 10pt"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zh2VL8e3kQ4g" style="margin: 0pt 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zVvgNMngceBk" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zUIR4ksddpNa" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 12. INCOME TAXES <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zjJSSfBNIaLd" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">At December 31, 2022, the Company had $0.9 million of federal net operating
losses, which carryforward indefinitely but are limited to 80% of taxable income when utilized. As of December 31, 2022 and March 31,
2022, the Company had U.S. deferred tax assets of $<span id="xdx_90E_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20221231_zzaA3lJq9Fe6" title="Deferred tax assets"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million and $<span id="xdx_905_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20220331_z5dsWLztVdDc" title="Deferred tax assets"><ix:nonFraction name="ifrs-full:DeferredTaxAssets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #1F497D">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a reconciliation of the U.K. taxes to the effective income
tax rates for the nine months ended December 31, 2022 and 2021 (U.S. Dollars in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfIncomeTaxExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfIncomeTaxExplanatory_pn3n3_zOoMLX3dTjW" summary="xdx: Disclosure - INCOME TAXES (Details 2)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span id="xdx_8B6_zzrxDOTPC8B4" style="display: none">&#160;Schedule of effective income tax rates</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20220401__20221231_zGqL2JUpbj8l" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20210401__20211231_zc4rKzHsfoEj" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr id="xdx_405_eifrs-full--AccountingProfit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss on ordinary activities before tax</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AccountingProfit" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,567</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AccountingProfit" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,434</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ApplicableTaxRate_pid_dp_zeIav8WAqTy7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Statutory U.K. income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.0</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.0</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr>
  <tr id="xdx_402_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss at statutory income tax rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">868</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">462</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ChangeIncreaseInDeferredIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change (increase) in deferred income tax rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ChangeIncreaseInDeferredIncomeTaxRate" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">274</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ForeignCurrencyEffect_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Foreign currency effect</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ForeignCurrencyEffect" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,788</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ForeignCurrencyEffect" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">444</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--TaxEffectOfRAndDCredit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Research and development credit</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:TaxEffectOfRAndDCredit" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LossesUnrecognized_z2xpuyn4xRJ8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Losses (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:LossesUnrecognized" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">462</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--TaxEffectOfTaxLosses_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax benefit</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,930</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">465</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zGolEEKzuxLc" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Research and development credit
receivables of $<span id="xdx_90D_ecustom--ResearchAndDevelopmentCreditReceivables_iI_pn3n3_dm_c20221231_zNz1gq6jatJj" title="Research and development credit receivables"><ix:nonFraction name="ptgef:ResearchAndDevelopmentCreditReceivables" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million and $<span id="xdx_90F_ecustom--ResearchAndDevelopmentCreditReceivables_iI_pn3n3_dm_c20220331_zCCqpkNUsNU1" title="Research and development credit receivables"><ix:nonFraction name="ptgef:ResearchAndDevelopmentCreditReceivables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million were included in prepaid expenses and other receivables on the condensed consolidated interim
statements of financial position as of December 31, 2022 and March 31, 2022, respectively.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a reconciliation of financial statement income (loss)
to tax basis income (loss) (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock_pn3n3_z7IndVRdypqi" summary="xdx: Disclosure - INCOME TAXES (Details 3)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BB_zrbbSQ2pe0bb" style="display: none">Schedule of reconciliation of financial statement loss to tax basis loss</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_499_20221231__dei--LegalEntityAxis__custom--UnitedStateMember_zxhjDvg6vdHd" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_490_20221231__dei--LegalEntityAxis__custom--BVIMember_zEPsYCKTKG32" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_491_20221231__dei--LegalEntityAxis__custom--ForeignMember_zuwCe5t6y37j" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_492_20221231_zHUbR7WxIEu8" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20211231__dei--LegalEntityAxis__custom--UnitedStateMember_z3TDGnFn1xW9" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_498_20211231__dei--LegalEntityAxis__custom--BVIMember_zYzlxStAIMJ9" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20211231__dei--LegalEntityAxis__custom--ForeignMember_zZquenW5xqSi" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_495_20211231_z7gJsOYoit1f" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br />States</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">BVI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br />Kingdom</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br />States</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">BVI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PretaxIncomeLoss_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-size: 10pt; font-weight: bold; text-align: left">Pre-tax loss</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PretaxIncomeLoss" contextRef="AsOf2022-12-31_custom_UnitedStateMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,230</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PretaxIncomeLoss" contextRef="AsOf2022-12-31_custom_BVIMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,320</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PretaxIncomeLoss" contextRef="AsOf2022-12-31_custom_ForeignMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,567</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PretaxIncomeLoss" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,117</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:PretaxIncomeLoss" contextRef="AsOf2021-12-31_custom_UnitedStateMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,535</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:PretaxIncomeLoss" contextRef="AsOf2021-12-31_custom_BVIMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,802</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:PretaxIncomeLoss" contextRef="AsOf2021-12-31_custom_ForeignMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,434</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:PretaxIncomeLoss" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,771</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--LossForWhichNoBenefitWasTaken_pn3n3_z4kVYIP7k9b5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss for which no benefit was taken</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossForWhichNoBenefitWasTaken" contextRef="AsOf2022-12-31_custom_UnitedStateMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,622</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1193">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossForWhichNoBenefitWasTaken" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,622</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1197">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1198">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LossesNotSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Losses not subject to tax</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1201">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossesNotSubjectToTax" contextRef="AsOf2022-12-31_custom_BVIMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,320</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:LossesNotSubjectToTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,320</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1205">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:LossesNotSubjectToTax" contextRef="AsOf2021-12-31_custom_BVIMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,802</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:LossesNotSubjectToTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,802</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Utilization of losses not previously benefitted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:UtilizationOfLossesNotPreviouslyBenefitted" contextRef="AsOf2022-12-31_custom_UnitedStateMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">314</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:UtilizationOfLossesNotPreviouslyBenefitted" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">314</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1214">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1217">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PretaxLossSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Taxable income (loss)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PretaxLossSubjectToTax" contextRef="AsOf2022-12-31_custom_UnitedStateMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PretaxLossSubjectToTax" contextRef="AsOf2022-12-31_custom_ForeignMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,567</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PretaxLossSubjectToTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,489</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:PretaxLossSubjectToTax" contextRef="AsOf2021-12-31_custom_UnitedStateMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,535</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1224">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:PretaxLossSubjectToTax" contextRef="AsOf2021-12-31_custom_ForeignMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,434</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:PretaxLossSubjectToTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,969</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z3eeQbUsJo25" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<ix:exclude><p id="xdx_230_z5ZaiaA9IPV8" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zz7ukYiU73Y7" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 22; Value: 1 -->
    <div id="xdx_235_z0lKuOtP0D4g" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td id="xdx_238_zD9wS2F6Oita" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zjf1GHKAko37" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zVLfx5lcOvrb" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zZkFZcNoWUaf" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zCIzwmskCjb7" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zs9WBliCgLOj" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zksFhW9U6tjf" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zUONS0Kt2Azh" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 12. INCOME TAXES <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zubnBb598KUh" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">As of December 31, 2022 and March
31, 2022, the Company&#8217;s deferred tax assets and liabilities in the U.K. consisted of the effects of temporary differences attributable
to the following (in thousands):</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfDeferredTaxAssetsExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfDeferredTaxAssetsExplanatory_pn3n3_zE4USusoNe38" summary="xdx: Disclosure - INCOME TAXES (Details 4)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B9_z7JyF3riiBA2" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_496_20221231_zlDcuXrMBvSk" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20220331_z48oVMtUAIPf" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31,</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzWJe_z6TrbHwZwXx7" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Net operating loss</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:DeferredTaxAssetsNetOperatingLossCarryforward" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,394</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:DeferredTaxAssetsNetOperatingLossCarryforward" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,253</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetUnrecognized_i01I_pn3n3_maNDTAzWJe_zYp0TC44lH8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax asset (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredTaxAssetUnrecognized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:DeferredTaxAssetUnrecognized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--NetDeferredTaxAssets_iTI_pn3n3_mtNDTAzWJe_z3zoecpXzh76" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax asset</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NetDeferredTaxAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,894</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NetDeferredTaxAssets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,753</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxLiabiltiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax liabilities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxLiabilitiesInProcessRAndD_i01I_pn3n3_maDTLzCvC_zibvpvnpmh92" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">In-process research and development</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredTaxLiabilitiesInProcessRAndD" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,409</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:DeferredTaxLiabilitiesInProcessRAndD" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,198</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxLiability1_iTI_pn3n3_mtDTLzCvC_zbQ6HykEfA9f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredTaxLiability1" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,409</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:DeferredTaxLiability1" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,198</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--NetDeferredTaxLiabilities_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NetDeferredTaxLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,515</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NetDeferredTaxLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,445</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z8gYtpTVU167" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">iOx generated research and development cash credits of approximately $<span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseCashCredits_pn3n3_dm_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zHDxojvWPDHc" title="Research and development cash credits"><ix:nonFraction name="ptgef:ResearchAndDevelopmentExpenseCashCredits" contextRef="From2021-04-012021-12-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.02</ix:nonFraction></span>
million that have been recorded for the nine months ended December 31, 2021. There were <span id="xdx_90A_ecustom--ResearchAndDevelopmentExpenseCashCredits_pn3n3_do_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zUAtGiHgZ5b9" title="Research and development cash credits"><ix:nonFraction name="ptgef:ResearchAndDevelopmentExpenseCashCredits" contextRef="From2022-04-012022-12-31_custom_IOXMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD">no</ix:nonFraction></span> research and development cash credits recorded
for the nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022 and March 31, 2022, iOx had a net deferred tax
liability of approximately $<span id="xdx_904_eifrs-full--DeferredTaxLiabilities_iI_pn3n3_dm_c20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zZpopbcaCRui" title="Deferred tax liabilities"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2022-12-31_custom_IOXMember327150515" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">25.5</ix:nonFraction></span> million and approximately $<span id="xdx_900_eifrs-full--DeferredTaxLiabilities_iI_pn3n3_dm_c20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_z5wkmarFxo56" title="Deferred tax liabilities"><ix:nonFraction name="ifrs-full:DeferredTaxLiabilities" contextRef="AsOf2022-03-31_custom_IOXMember327152796" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">28.4</ix:nonFraction></span> million, respectively. On January 8, 2019, the Company originally recognized
a $19.8 million deferred tax liability for the difference between the book and income tax basis of IPR&amp;D acquired as part of the SalvaRx
Acquisition. As the iOx IPR&amp;D is in the U.K., the deferred tax was recorded at 17%, the prevailing tax rate applicable in the U.K.
at the time. In fiscal 2022, the Company recorded $<span id="xdx_908_eifrs-full--DeferredTaxExpenseIncome_pn3n3_dm_c20190401__20200331_z6goouUGzaye" title="Deferred tax expense (income)"><ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncome" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">7.0</ix:nonFraction></span> million increase in deferred income taxes to reflect a future change in the U.K.
income tax rate and recognized $<span id="xdx_902_ecustom--CurrentYearLosses_pn3n3_dm_c20210401__20220331_zcni1JRcLTs2" title="Current year losses"><ix:nonFraction name="ptgef:CurrentYearLosses" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million of current year losses and $0.8 million of prior year losses. The Company also recognized
a $<span id="xdx_905_eifrs-full--IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_pn3n3_dm_c20210401__20220331_zhcVd587PT5i" title="Increase (Decrease) in deferred tax liability"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" contextRef="From2021-04-012022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million decrease in deferred tax liability in fiscal 2022 to reflect the effect of the change in exchange rates on the liability
settleable in British pound sterling. For the nine months ended December 31, 2022, the Company recognized the reduction in deferred tax
liability of $1.8 million to reflect the effect of the change in exchange rates on the liability in the period and recognized $0.8 million
of current period losses, as well as the tax rate change effect of $0.3 million on the current period losses.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">There is no expiration date for accumulated tax losses in the U.K. entities<span style="font-size: 10pt">.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<ix:exclude><p id="xdx_233_zzp1T65yFxq5" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zqtcg3YVpx32" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zu0TvlDc0sT2" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 23; Value: 1 -->
    <div id="xdx_23D_ziUq6XtFb4K" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td id="xdx_23C_z44BLvUp93Xb" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_ztdb6LUqRv07" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zHPnOEycwcIj" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zhBky9ItqIjl" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_znR5pwFEcG63" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zrIu5KZo7d7h" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zAnrTH4vrAy7" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:WarrantLiabilitytextblock"><p id="xdx_80F_ecustom--WarrantLiabilitytextblock_zHX6kbOh9ngj" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 13. <span id="xdx_821_z3vPvHFugKW5">WARRANT LIABILITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Below is the roll-forward of warrants issued by entity:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfWarrantLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_pn3n3_zxcB3wcLeByb" summary="xdx: Disclosure - WARRANT LIABILITY (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BF_zQgm2v6c02Gc" style="display: none">Schedule of warrant liability</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">PBI</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Warrants</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Warrants outstanding, April 1, 2022</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsOutstandingExercisePrice_iS_pid_c20220401__20221231_zQbIg6yikcg4" title="Warrants outstanding exercise price at beginning" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantsOutstandingExercisePrice" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.64</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--WarrantsOutstandingShares_iS_pid_c20220401__20221231_zIoaa2z7ywMj" title="Warrants outstanding, shares at beginning" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantsOutstandingShares" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,888</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--WarrantsOutstandingAmount_iS_pn3n3_c20220401__20221231_zaaQ4g8NQj4k" title="Warrants outstanding, amount at beginning" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantsOutstandingAmount" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Fair value adjustment as of December 31, 2022 (1)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--FairValueAdjustmentExercisePriceAtEnd_pid_c20220401__20221231_zAJdKDhAkp2e" title="Fair value adjustment , exercise price" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1295">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueAdjustmentShares_pid_c20220401__20221231_zgFdc2AUkvu5" title="Fair value adjustment, shares" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:FairValueAdjustmentShares" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">33,888</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--FairValueAdjustmentAmount_pn3n3_c20220401__20221231_zDEv3jQWO052" title="Fair value adjustment, amount" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:FairValueAdjustmentAmount" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">33</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants outstanding, December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--WarrantsOutstandingExercisePrice_iE_pid_c20220401__20221231_zEaPgWvmIgmh" title="Warrants outstanding exercise price at ending" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1301">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--WarrantsOutstandingShares_iE_pid_c20220401__20221231_zMTJlKzObOkb" title="Warrants outstanding, shares at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_ecustom--WarrantsOutstandingAmount_iE_pn3n3_c20220401__20221231_zOTXaB6KFa2k" title="Warrants outstanding, amount at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(1)</td><td>The Company recognized a gain of $<span id="xdx_904_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20221001__20221231_zr8knCLfZCT6" title="Gain (loss) of change in fair value of warrants"><ix:nonFraction name="ptgef:GainLossOfChangeInFairValueOfWarrants" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.001</ix:nonFraction></span> million and $<span id="xdx_906_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20220401__20221231_zPoJT2wsQ1zd" title="Gain (loss) of change in fair value of warrants"><ix:nonFraction name="ptgef:GainLossOfChangeInFairValueOfWarrants" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.033</ix:nonFraction></span> million in the three and nine months ended December 31, 2022, respectively,
to reflect the change in fair value of the underlying warrants. The Company recognized a gain of $<span id="xdx_90B_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20211001__20211231_zvqu1A8VguE3" title="Gain (loss) of change in fair value of warrants"><ix:nonFraction name="ptgef:GainLossOfChangeInFairValueOfWarrants" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.342</ix:nonFraction></span> million and $<span id="xdx_905_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20210401__20211231_zS7MXaJrKphk" title="Gain (loss) of change in fair value of warrants"><ix:nonFraction name="ptgef:GainLossOfChangeInFairValueOfWarrants" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.726</ix:nonFraction></span> million in
the three and nine months ended December 31, 2021, respectively, to reflect the change in fair value of the underlying warrants. The warrants
expired in October 2022 unexercised.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:CapitalStockTextBlock"><p id="xdx_804_ecustom--CapitalStockTextBlock_zr5NQqtc0LVe" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 14. <span id="xdx_820_zkh6cjkWNqa5">CAPITAL STOCK</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(a)</td><td>Authorized ordinary shares<b>: </b>Unlimited number of Portage ordinary shares without par value.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(b)</td><td>The following is a roll-forward of Portage ordinary shares for the nine months ended December 31, 2022 and 2021:</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_zzVIVgdj9y0h" summary="xdx: Disclosure - CAPITAL STOCK (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8BF_zrNZHUUfoUO2" style="display: none">Common shares: Unlimited number of common shares without par value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary<br /> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary <br /> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CommonStockShares_iS_pn3n3_c20220401__20221231_zfp2FkaXBDLf" title="Balance, Shares" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CommonStockShares" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,349</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--CommonStockValues_iS_pn3n3_c20220401__20221231_zTy7JC62NNGb" title="Balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CommonStockValues" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158,324</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--CommonStockShares_iS_pn3n3_c20210401__20211231_zHynUDgOFYFe" title="Balance, Shares" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CommonStockShares" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">12,084</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--CommonStockValues_iS_pn3n3_c20210401__20211231_zeGlHTVH4o2b" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CommonStockValues" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130,649</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued in Tarus acquisition</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20220401__20221231_zo8EvsEc7O5i" title="Shares issued in Tarus acquisition, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,426</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--AcquisitionsThroughBusinessCombinationsOtherProvisions_pn3n3_c20220401__20221231_z7EL8FH1Fvud" title="Shares issued in Tarus acquisition" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,200</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20210401__20211231_zpkgXx9v4htb" title="Shares issued in Tarus acquisition, shares" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1331">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--AcquisitionsThroughBusinessCombinationsOtherProvisions_pn3n3_c20210401__20211231_zh0xHGyYSfmi" title="Shares issued in Tarus acquisition" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued in iOx exchange</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuedInIoxExchangesShares_pn3n3_c20220401__20221231_zjnikFrYhKc8" title="Shares issued in iOx exchange, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedInIoxExchangesShares" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,070</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareIssuedInIoxExchange_pn3n3_c20220401__20221231_z2J5nt8zQGVe" title="Shares issued in iOx exchange" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ShareIssuedInIoxExchange" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,737</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesIssuedInIoxExchangesShares_pn3n3_c20210401__20211231_zmifDxtU3LEa" title="Shares issued in iOx exchange, shares" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1339">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareIssuedInIoxExchange_pn3n3_c20210401__20211231_ztcNjF12a95l" title="Shares issued in iOx exchange" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1341">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Excess of non-controlling interest acquired over consideration &#8211; iOx</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_pn3n3_c20220401__20221231_zG0G6GbgAnR5" title="Excess of non-controlling interest acquired over consideration iOx, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_pn3n3_c20220401__20221231_ze8yb5MaaMrc" title="Excess of non-controlling interest acquired over consideration iOx" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,609</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_pn3n3_c20210401__20211231_zgVZygUEAuo3" title="Excess of non-controlling interest acquired over consideration iOx, shares" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_pn3n3_c20210401__20211231_zi12atFtIGC1" title="Excess of non-controlling interest acquired over consideration iOx, shares" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1349">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued to Lincoln for commitment fee under Committed Purchase Agreement</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesIssuedToLincolnParksCommittedPurchaseShares_pn3n3_c20220401__20221231_zbzzld47r9Bj" title="Shares issued to Lincoln Parks Committed Purchase, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedToLincolnParksCommittedPurchaseShares" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">94</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--SharesIssuedToLincolnParksCommittedPurchase_pn3n3_c20220401__20221231_zjCpUMm4zLr1" title="Shares issued to Lincoln Parks Committed Purchase" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedToLincolnParksCommittedPurchase" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">900</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesIssuedToLincolnParksCommittedPurchaseShares_pn3n3_c20210401__20211231_zgG4x05qRDDi" title="Shares issued to Lincoln Parks Committed Purchase, shares" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharesIssuedToLincolnParksCommittedPurchase_pn3n3_c20210401__20211231_zeJkmbAqm8Bb" title="Shares issued to Lincoln Parks Committed Purchase, shares" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1357">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued under public offering and ATM, net of issue costs</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_pn3n3_c20220401__20221231_zygzjapS0dw7" title="Shares issued under public offering and ATM, net of issue costs , shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">88</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20220401__20221231_zPjY8TAPsMR7" title="Shares issued under public offering and ATM, net of issue costs" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">586</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_pn3n3_c20210401__20211231_z44w1w5iidf8" title="Shares issued under public offering and ATM, net of issue costs , shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,241</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20210401__20211231_z8E33AYeVFUj" title="Shares issued under public offering and ATM, net of issue costs" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,216</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Purchase of shares issued under Committed Purchase Agreement, net of issue costs</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_pn3n3_c20220401__20221231_z7WYF4rX7PN6" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">30</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_pn3n3_c20220401__20221231_zKpZ3xLEhIl3" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_pn3n3_c20210401__20211231_zauzHGW2W1R6" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_pn3n3_c20210401__20211231_z3fmcpxsLElb" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1373">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued or accrued for services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pn3n3_c20220401__20221231_zYSZpA8pWOO7" title="Shares issued or accrued for services" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20220401__20221231_zmeY5KkkdKy1" title="Shares issued or accrued for services" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:SaleOrIssueOfTreasuryShares" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pn3n3_c20210401__20211231_zm532sEf4CY1" title="Shares issued or accrued for services" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20210401__20211231_zqyuD0UB4FH8" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:SaleOrIssueOfTreasuryShares" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Warrants exercised</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--WarrantsExercisedShares_pn3n3_c20220401__20221231_zup27D4RVdnc" title="Warrants exercised, shares" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1383">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_pn3n3_c20220401__20221231_zsU1T5GDBhAk" title="Warrants exercised" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1385">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantsExercisedShares1_pn3n3_c20210401__20211231_z0wiD5IFUMH9" title="Warrants exercised, shares" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantsExercisedShares1" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">16</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_pn3n3_c20210401__20211231_zt2fg6EwFy1c" title="Warrants exercised" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">339</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--CommonStockShares_iE_pn3n3_c20220401__20221231_z75Uw8y5Gjck" title="Balance, Shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CommonStockShares" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">17,070</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_ecustom--CommonStockValues_iE_pn3n3_c20220401__20221231_zdRlDweUR1s2" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CommonStockValues" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216,630</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CommonStockShares_iE_pn3n3_c20210401__20211231_zSwVG2ENQRsg" title="Balance, Shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CommonStockShares" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">13,345</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_ecustom--CommonStockValues_iE_pn3n3_c20210401__20211231_z5TOiiDo2doe" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CommonStockValues" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158,294</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 16, 2020, the Company completed a private placement of <span id="xdx_907_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_pdd" title="Shares issued in a private placement, net of issue costs, shares"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares" contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">698,145</ix:nonFraction></span>
restricted ordinary shares at a price of $<span id="xdx_902_ecustom--PricePerShare_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_pdd" title="Shares price"><ix:nonFraction name="ptgef:PricePerShare" contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share for gross proceeds of $<span id="xdx_902_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zlFxI6kDfZdf" title="Shares issued in a private placement, net of issue costs"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts" contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">6.98</ix:nonFraction></span> million to accredited investors. Directors of the
Company subscribed for <span id="xdx_900_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_pdd" title="Shares issued in a private placement, net of issue costs, shares"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares" contextRef="From2020-06-022020-06-16_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">215,000</ix:nonFraction></span> shares, or approximately 30.8% of the private placement, for proceeds of $<span id="xdx_905_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_zHbVlffGQNs8" title="Shares issued in a private placement, net of issue costs"><ix:nonFraction name="ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts" contextRef="From2020-06-022020-06-16_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.15</ix:nonFraction></span> million. The Company incurred
costs of approximately $0.25 million in connection with the offering, which was treated as contra-equity on the Company&#8217;s balance
sheet.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>

<ix:exclude><p id="xdx_239_ztT76NnPmded" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 24; Value: 1 -->
    <div id="xdx_232_zgsEDMrqHkF" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td id="xdx_23D_zGHWuADqQo05" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zjJQGyz9oZsc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zOQeC2wEXHPj" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zf53Oqy8mH0g" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zbFCYUK25DVf" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zIgMed2noRma" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zdg7cMISOOqg" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zKJMwK2XBtB1" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 14. CAPITAL STOCK <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zHIgZ0JWa9Sl" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">During the quarter ended June 30, 2021, the Company commenced an &#8220;at
the market&#8221; offering, under which it sold <span id="xdx_901_ecustom--NumberOfStockSold_c20210401__20210630_z0SdwjdGzYwj" title="Number of stock sold"><ix:nonFraction name="ptgef:NumberOfStockSold" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,888</ix:nonFraction></span> ordinary shares generating gross proceeds of approximately $<span id="xdx_90C_ecustom--GrossProceedsFromStockSold_pn3n3_dm_c20210401__20210630_zPrRy0UiIOi4" title="Gross proceeds from stock sold"><ix:nonFraction name="ptgef:GrossProceedsFromStockSold" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.6</ix:nonFraction></span> million ($<span id="xdx_904_ecustom--NetProceedsFromStockSold_pn3n3_dm_c20210401__20210630_z66gXdry42lc" title="Net proceeds from stock sold"><ix:nonFraction name="ptgef:NetProceedsFromStockSold" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million,
net of commissions).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 24, 2021, the Company completed a firm commitment underwritten
public offering of <span id="xdx_902_ecustom--NumberOfStockSold_c20210601__20210624_z1llgvOdhgL2" title="Number of stock sold"><ix:nonFraction name="ptgef:NumberOfStockSold" contextRef="From2021-06-012021-06-24" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,150,000</ix:nonFraction></span> ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $<span id="xdx_905_ecustom--GrossProceedsFromStockSold_pn3n3_dm_c20210601__20210624_zH5Ma8XGUELe" title="Gross proceeds from stock sold"><ix:nonFraction name="ptgef:GrossProceedsFromStockSold" contextRef="From2021-06-012021-06-24" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">26.5</ix:nonFraction></span>
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $<span id="xdx_900_ecustom--OfferingExpenses_pn3n3_dm_c20210601__20210624_zj7ZP17AaDM8" title="Offering Cost"><ix:nonFraction name="ptgef:OfferingExpenses" contextRef="From2021-06-012021-06-24" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.8</ix:nonFraction></span>
million, including approximately $<span id="xdx_902_ecustom--ManagementUnderwritingAndSellingExpenses_pn3n3_dm_c20210601__20210624_zGUUdLmwhvLc" title="Management, underwriting and selling expenses"><ix:nonFraction name="ptgef:ManagementUnderwritingAndSellingExpenses" contextRef="From2021-06-012021-06-24" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million of management, underwriting and selling expenses.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has issued <span id="xdx_90C_ecustom--NumberOfSharesSold_c20220401__20221231_zib7KB7wamPl" title="Number of shares issued"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,425,999</ix:nonFraction></span> ordinary shares in connection with the
acquisition of Tarus Therapeutics, Inc. and in connection with the Tarus Therapeutics, Inc.&#8217;s acquisition we may issue additional
ordinary shares. <span style="background-color: white">See Note 8, &#8220;Acquisition of Tarus,&#8221; for a further discussion.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 18, 2022, the Company completed the iOx Share Exchange Agreement
under which it exchanged <span id="xdx_904_ecustom--NumberOfSharesExchanged_c20220701__20220718_pdd" title="Number of shares exchanged"><ix:nonFraction name="ptgef:NumberOfSharesExchanged" contextRef="From2022-07-012022-07-18" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,070,000</ix:nonFraction></span> ordinary shares for the remaining minority interest of <span id="xdx_901_ecustom--MinorityInterestPercentage_iI_pid_dp_c20220718_zx1LPwuwMRrj" title="Minority interest, percentage"><ix:nonFraction name="ptgef:MinorityInterestPercentage" contextRef="AsOf2022-07-18" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.68</ix:nonFraction></span>% of iOx. <span style="background-color: white">See
Note 18, &#8220;Related Party Transactions &#8211; Share Exchange Agreement &#8211; iOx,&#8221; for a further discussion.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Additionally, on August 19, 2022, the Company issued <span id="xdx_909_ecustom--NumberOfSharesSold_c20220801__20220819__ifrs-full--CounterpartiesAxis__custom--LincolnMember_pdd" title="Number of shares issued"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2022-08-012022-08-19_custom_LincolnMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">94,508</ix:nonFraction></span> ordinary shares
to Lincoln in consideration for entering into the $<span id="xdx_90C_eifrs-full--ProceedsFromIssueOfOrdinaryShares_pn3n3_dm_c20220801__20220819__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zivIQX3tmhaj" title="Proceeds from offering"><ix:nonFraction name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" contextRef="From2022-08-012022-08-19_custom_LincolnMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">30</ix:nonFraction></span> million Committed Purchase Agreement. See Note 17, &#8220;Commitments and Contingent
Liabilities &#8211; Committed Purchase Agreement,&#8221; for a further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In October 2022, the Company restarted the ATM and commenced sales of
ordinary shares pursuant to the Sales Agreement. Through December 31, 2022, the Company sold <span id="xdx_90C_ecustom--NumberOfSharesSold_pid_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zE6NGUFL0fXf" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2022-12-302022-12-31_custom_ATMMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,072</ix:nonFraction></span> ordinary shares under the ATM, generating
net proceeds of approximately $<span id="xdx_908_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zxzTdxVCSnGh" title="Net proceeds from sale"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfBiologicalAssets" contextRef="From2022-12-302022-12-31_custom_ATMMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million and sold <span id="xdx_907_ecustom--NumberOfSharesSold_pid_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zNo1l4vYwCWc" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2022-12-302022-12-31_custom_LincolnMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span> ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds
totaling approximately $<span id="xdx_907_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zxbYg5WF1qu7" title="Net proceeds from sale"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfBiologicalAssets" contextRef="From2022-12-302022-12-31_custom_LincolnMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory"><p id="xdx_801_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zwCWsz0gwXIf" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 15. <span id="xdx_821_z76FFjLaAnyk">STOCK OPTION RESERVE</span></b></p>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td>The following table provides the activity for the Company&#8217;s stock option reserve for the nine months ended December 31, 2022
and 2021:</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfTermsStockOptionReserveExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_zeA2xnrNPxZe" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BD_zGV7nxLtU6ad" style="display: none">Disclosure Of Terms Stock Option Reserve Explanatory</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zVTLTJYq6Jig" title="Balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2022-03-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,659</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_ziRFOq5sbuNh" title="Balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2022-03-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,928</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zkDqJIL5TfE" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,468</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z9TizhLV2sM6" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2021-03-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,977</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--AdjustmentsForSharebasedPayments_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pdn3" title="Stock based compensation expense" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1461">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--AdjustmentsForSharebasedPayments_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,614</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">191</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,248</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Settled in iOx exchange</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--SettledInIoxExchange_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" title="Settled in iOx exchange" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:SettledInIoxExchange" contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,659</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--SettledInIoxExchange_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pdn3" title="Settled in iOx exchange" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1471">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--SettledInIoxExchange_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pdn3" title="Settled in iOx exchange" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1473">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--SettledInIoxExchange_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pdn3" title="Settled in iOx exchange" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1475">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zcPmyMmC7tAb" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1477">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zZiO4J0OjKK6" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2022-12-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,542</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zTyW1N75gsc5" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2021-12-31_ifrs-full_NoncontrollingInterestsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,659</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zMtZAF3y94o4" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2021-12-31_custom_StockOptionReserveMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,225</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zTtLbm6SqEwd" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Stock Options</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 25, 2020, at the annual meeting of shareholders, the Company&#8217;s
new incentive stock option plan (the &#8220;2020 Stock Option Plan&#8221;) was approved, which authorized the Company&#8217;s directors
to fix the option exercise price and to issue stock options under the plan as they see fit. The Company&#8217;s 2020 Stock Option Plan
is a 10% rolling stock option plan under which the Company&#8217;s directors are authorized to grant up to a maximum of 10% of the issued
and outstanding ordinary shares on the date of grant.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_232_zjnoCZpPQF73" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_z0xaQ2fRW5Bl" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_z09w3zAu6VGe" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 25; Value: 1 -->
    <div id="xdx_23C_z3KWzoJvYWS9" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td id="xdx_23A_z8V7n91AdhCd" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zXC0K71Xn9Dj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zmBrM6uJbqig" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zSqVAcVlQWo2" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zrMXgdr7BjQc" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zAMdJVj8IzP1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_znrVbhYypiOj" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_z4bIkGfi8qz9" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 15. STOCK OPTION RESERVE <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zrRme0qxKnLk" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Effective January 13, 2021, the
Company amended and restated its 2020 Stock Option Plan to permit the grant of additional types of equity compensation securities, including
restricted stock units (&#8220;RSUs&#8221;) and dividend equivalent rights (the &#8220;2021 Equity Incentive Plan&#8221;). The aggregate
number of equity securities, which may be issued under the 2021 Equity Incentive Plan has not been changed.&#160; Pursuant to the 2021
Equity Incentive Plan, on January 13, 2021, the Company granted an aggregate of <span id="xdx_90E_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_pdd" title="Option issued"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">868,000</ix:nonFraction></span> stock options exercisable at a price of $<span id="xdx_90C_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_pdd" title="Exercise price"><ix:nonFraction name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" contextRef="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.75</ix:nonFraction></span>
per share, representing the closing price of the shares on the day immediately preceding the grant date, which expire on January 13, 2031
to various directors, officers and consultants of the Company. <span id="xdx_900_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember_pdd" title="Option issued"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2021-01-13_custom_BoardOfDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> options granted to members of the Board vest 1/3 on grant date,
1/3 on the first anniversary of the grant and 1/3 on the second anniversary of the grant. <span id="xdx_907_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--ConsultantsMember_pdd" title="Option issued"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2021-01-13_custom_ConsultantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">518,000</ix:nonFraction></span> options granted to consultants (one
of whom is also a director of the Company) vest 1/3 on each of the first three anniversaries of the grant date.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Additionally, the Company granted
<span id="xdx_90D_ecustom--StockGranted_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_pdd" title="Stock granted"><ix:nonFraction name="ptgef:StockGranted" contextRef="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">243,000</ix:nonFraction></span> RSUs on January 13, 2021, with a fair value of $<span id="xdx_90C_ecustom--FairValuePerShare_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_pdd" title="Fair value per share"><ix:nonFraction name="ptgef:FairValuePerShare" contextRef="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.75</ix:nonFraction></span> per share, which was the closing price on the day immediately preceding
the grant date. The RSUs vested on the date of grant, but underlying shares cannot be sold until one of four of the following conditions
are met: (1) a Change in Control (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)), (2) the participant&#8217;s
Separation from Service (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)), (3) the participant&#8217;s
death, or (4) the participant&#8217;s Disability (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)).&#160;
In accordance with IFRS 2, &#8220;Share-based Payment,&#8221; the Company recognized compensation expense of $<span id="xdx_900_eifrs-full--CommunicationExpense_pn3n3_dm_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zyNOz5hg8wOg" title="Compensation expense"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million in the year
ended March 31, 2021, in connection with the RSU grants.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Amended and Restated 2021 Equity Incentive Plan and Grants of Stock Options and Restricted
Stock Units</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On January 19, 2022, the Board unanimously approved the Amended and Restated
2021 Equity Incentive Plan (the &#8220;Amended and Restated 2021 Equity Incentive Plan&#8221;). The Amended and Restated 2021 Equity Incentive
Plan provides for:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-size: 10pt"><b>(1)</b></span></td><td>An increase of aggregate number of shares available for awards to 2,001,812, which is equal to 15% of the issued and outstanding ordinary
shares of the Company as of January 19, 2022 subject to discretionary annual increases (on a cumulative basis) as may be approved by the
Board in future years by a number of shares not to exceed an additional 5% of the aggregate number of shares then outstanding;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-size: 10pt"><b>(2)</b></span></td><td>The authorization of incentive stock options (should shareholder approval be sought and obtained) under the Amended and Restated 2021
Equity Incentive Plan; and</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-size: 10pt"><b>(3)</b></span></td><td>The provision of dividend equivalent rights to be issued when authorized.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Pursuant to the Amended and Restated 2021 Equity Incentive Plan, on January
19, 2022, the Company granted an aggregate of <span id="xdx_905_ecustom--StockGranted_c20220101__20220119__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"><ix:nonFraction name="ptgef:StockGranted" contextRef="From2022-01-012022-01-19_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">302,000</ix:nonFraction></span> stock options exercisable at a price of $<span id="xdx_904_ecustom--FairValuePerShare_c20220101__20220119__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share"><ix:nonFraction name="ptgef:FairValuePerShare" contextRef="From2022-01-012022-01-19_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.22</ix:nonFraction></span> per share, representing the average
price of the shares on the grant date (January 19, 2022), which expire on January 19, 2032, to various directors, officers and consultants
of the Company. A total of <span id="xdx_909_ecustom--StockGranted_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--TwoMembersMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"><ix:nonFraction name="ptgef:StockGranted" contextRef="From2022-01-012022-01-19_custom_TwoMembersMember_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,800</ix:nonFraction></span> of the 302,000 stock options were granted to two members of the Board and vest on the first anniversary
of the grant date. The balance of <span id="xdx_906_ecustom--StockGranted_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--EmployeesMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"><ix:nonFraction name="ptgef:StockGranted" contextRef="From2022-01-012022-01-19_custom_EmployeesMember_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">288,200</ix:nonFraction></span> stock options was granted to employees (one of whom is also a director of the Company), and
a consultant, and such stock options vest ratably on each of the first four annual anniversaries of the grant date.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Additionally, the Company granted
<span id="xdx_902_ecustom--StockGranted_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"><ix:nonFraction name="ptgef:StockGranted" contextRef="From2022-01-012022-01-19_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">135,740</ix:nonFraction></span> RSUs to employees (one of whom is also a director of the Company) on January 19, 2022, with a fair value of $<span id="xdx_901_ecustom--FairValuePerShare_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share"><ix:nonFraction name="ptgef:FairValuePerShare" contextRef="From2022-01-012022-01-19_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.22</ix:nonFraction></span> per share,
representing the average price of the shares on the grant date (January 19, 2022). The RSUs were </span>fully vested and nonforfeitable
as of the <span style="background-color: white">grant date and will expire on January 19, 2032.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_238_zgEEzE8VmDd" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zIF92JJbuSf1" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 26; Value: 1 -->
    <div id="xdx_230_zRwNyjiGcoZh" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td id="xdx_23E_z6cDhzBFxli7" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zQLPbmFwsCi9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_z8AEhEF5P6Ml" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zZrxp4jH3vkl" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zY1WnbZ9Rh2" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zI9p0MT2YFF4" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zE1L1gG3eMo7" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_z6goDTOrv0rl" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 15. STOCK OPTION RESERVE <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zeIHfrIOnn6e" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On February 15, 2022, James Mellon, Linda Kozick and Mark Simon were appointed
to the Board. Mr. Mellon owned approximately 23.9% of the Company&#8217;s outstanding shares at that date. Additionally, Mr. Mellon had
previously served as a member of the Board from 2016 to August 14, 2020. On February 15, 2022, in connection with the appointments, each
of these directors were granted <span id="xdx_90C_ecustom--StockGranted_c20220201__20220215__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"><ix:nonFraction name="ptgef:StockGranted" contextRef="From2022-02-012022-02-15_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,800</ix:nonFraction></span> non-qualified stock options, which vest ratably monthly over a three-year period. The options have
an exercise price of $<span id="xdx_90F_ecustom--FairValuePerShare_c20220201__20220215__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share"><ix:nonFraction name="ptgef:FairValuePerShare" contextRef="From2022-02-012022-02-15_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.59</ix:nonFraction></span> per share, the average price of the stock on February 15, 2022, the day immediately preceding the grant date,
and will expire, if unexercised, on February 15, 2032.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 8, 2022, the Company granted <span id="xdx_908_ecustom--StockGranted_c20220601__20220608__ifrs-full--CounterpartiesAxis__custom--ExecutiveMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"><ix:nonFraction name="ptgef:StockGranted" contextRef="From2022-06-012022-06-08_custom_ExecutiveMember_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> options to purchase shares
to an executive of the Company. The options have an exercise price of $<span id="xdx_909_ecustom--FairValuePerShare_c20220601__20220608__ifrs-full--CounterpartiesAxis__custom--ExecutiveMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share"><ix:nonFraction name="ptgef:FairValuePerShare" contextRef="From2022-06-012022-06-08_custom_ExecutiveMember_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.00</ix:nonFraction></span>, the average price of the stock on that date, vest ratably
on each of the first four anniversaries of the grant date and will expire, if unexercised, on June 8, 2032.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is the weighted average assumptions used in connection with
the June 8, 2022 option grant with respect to the Company&#8217;s Amended and Restated 2021 Equity Incentive Plan:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_89D_eifrs-full--DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_pn3n3_z0PXr0XQXgy5" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_8BD_zkMLVnMurtWf" style="display: none">Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Assumption</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unvested Options</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-size: 10pt; text-align: left">Risk free interest rate</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 49%; font-size: 10pt; text-align: center"><span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zwlMc8xm8834" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.05</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected dividend</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">Nil</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected volatility</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_908_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zx9aHxnRe9Zi" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">111</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected life</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_907_ecustom--OptionLifeShareOptionsGranted_dtY_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z8aU8Pw0VW7i" title="Expected life"><ix:nonNumeric contextRef="From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember" format="ixt-sec:duryear" name="ptgef:OptionLifeShareOptionsGranted">6.25</ix:nonNumeric></span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Fair value of Portage option</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">$<span id="xdx_90D_ecustom--FairValueOfPortageOption_pid_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zo88QbFX6Cg3" title="Fair value of Portage option"><ix:nonFraction name="ptgef:FairValueOfPortageOption" contextRef="From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.36</ix:nonFraction></span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AA_zK5eitRLRgt9" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 27, 2022, the Company granted <span id="xdx_907_ecustom--StockGranted_c20220701__20220727__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"><ix:nonFraction name="ptgef:StockGranted" contextRef="From2022-07-012022-07-27_custom_BoardOfDirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,900</ix:nonFraction></span> options to purchase shares
to a member of the Board. The options have an exercise price of $<span id="xdx_90E_ecustom--FairValuePerShare_c20220601__20220727__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share"><ix:nonFraction name="ptgef:FairValuePerShare" contextRef="From2022-06-012022-07-27_custom_BoardOfDirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.06</ix:nonFraction></span>, the average price of the stock on that date, vest ratably on each
of the first four anniversaries of the grant date and will expire, if unexercised, on July 27, 2032.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is the weighted average assumptions used in connection with
the July 27, 2022 option grant with respect to the Company&#8217;s Amended and Restated 2021 Equity Incentive Plan:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_89B_eifrs-full--ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory_zM8amTAE1ue" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B9_z3NhZxUvbnf9" style="display: none">Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Assumption</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unvested Options</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-size: 10pt; text-align: left">Risk free interest rate</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 49%; font-size: 10pt; text-align: center"><span id="xdx_905_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zRXmqEnLkFh9" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2022-07-012022-07-27_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.83</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected dividend</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">Nil</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected volatility</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_902_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zyhuhdC7d8H8" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2022-07-012022-07-27_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">112</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected life</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_900_ecustom--OptionLifeShareOptionsGranted_dtY_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z7rEhj6JJHK" title="Expected life"><ix:nonNumeric contextRef="From2022-07-012022-07-27_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember" format="ixt-sec:duryear" name="ptgef:OptionLifeShareOptionsGranted">5.75</ix:nonNumeric></span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Fair value of Portage option</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">$<span id="xdx_90C_ecustom--FairValueOfPortageOption_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_pdd" title="Fair value of Portage option"><ix:nonFraction name="ptgef:FairValueOfPortageOption" contextRef="From2022-07-012022-07-27_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.38</ix:nonFraction></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zmdyiiBs1uGf" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td>The movements in the number of options issued for the nine months ended December 31, 2022 and 2021 were:</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_pn3n3_zpqWwIO2cFHa" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 3)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BC_znNG4X0YuXGj" style="display: none">Schedule of outstanding stock options</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated 2021 Equity Incentive Plan</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">iOx Option Plan<br /> (Subsidiary Plan)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--NumberOfOutstandingShareOption_iS_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zrsA014IiTp2" title="Balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2022-03-31_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,151,400</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--NumberOfOutstandingShareOption_iS_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zUOtQyrLwbO7" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2021-03-31_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">868,000</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iS_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_z3HJtOyq5itf" title="Balance" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2022-03-31_custom_StockOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,275</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--NumberOfOutstandingShareOption_iS_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zJJGebQ4jSV8" title="Balance" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2021-03-31_custom_StockOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,924</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Granted</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcQwhLH0L2ge" title="Granted" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" contextRef="From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,900</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zUQPCdkUQekf" title="Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1574">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zrhjuw4FtqRj" title="Granted" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1576">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zelSUFznsim9" title="Granted" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1578">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Expired or forfeited</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zmhHETlc5SD3" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1580">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zlANHiWHq4P2" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1582">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zbgbuSiqxKH2" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2022-04-012022-12-31_custom_StockOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,275</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zxvSZjn3hC8" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2021-04-012021-12-31_custom_StockOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">649</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5ceqnOjbBP2" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2022-12-31_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,217,300</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zIEj46lAcwR7" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2021-12-31_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">868,000</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfOutstandingShareOption_iE_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zKK6tNOhjOLa" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1592">&#8211;</span></b></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--NumberOfOutstandingShareOption_iE_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zw9b79ON8Y51" title="Balance" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2021-12-31_custom_StockOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,275</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Exercisable, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zevhBsJO8lFb" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="AsOf2022-12-31_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">419,705</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zf7yuWU9UoWf" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="AsOf2021-12-31_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,666</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zGyK7Xi8axE" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1600">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zV5kxgj5Z7Aj" title="Exercisable as at end" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="AsOf2021-12-31_custom_StockOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,275</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zehUNg5QJDjb" style="margin: 0pt 0; font-size: 10pt">&#160;&#160;</p>

<ix:exclude><p id="xdx_23A_zyxS1gTQj91k" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zSiOuEqcKmgl" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 27; Value: 1 -->
    <div id="xdx_230_zVhYJmGxz9n5" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td id="xdx_234_zPd0RERCewS1" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zBEa6NWYN2K7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_z7IingfpQ1N" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z6td6WI8gUkj" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zPNMcIZ7Zx0f" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_z1vEt8i73mJl" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zbdvZK7AxiO3" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zCKxOlwJKOH9" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 15. STOCK OPTION RESERVE <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zXJyNepShZ97" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(c)</td><td>The following is the weighted average exercise price and the remaining contractual life for outstanding options by plan as of December
31, 2022 and 2021:</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_pn3n3_zYqSDIN62r89" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 4)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B8_zy114S1FX6X6" style="display: none">Schedule of weighted average exercise price and remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated <br />2021 Equity Incentive Plan</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx Option Plan<br /> (Subsidiary Plan)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zsSiPYyJiDJ7" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.19</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcK0Lrpjxw8g" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2021-04-012021-12-31_custom_PBI2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.75</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zKctCx28Y2tb" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1619">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zf7SXsWg1JXa" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2021-04-012021-12-31_custom_StockOptionsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">162.14</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life (in years)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zLsPw9gMiO62" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">8.41</ix:nonNumeric></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcshMRx6Rf55" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-04-012021-12-31_custom_PBI2021EquityIncentivePlanMember" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">9.04</ix:nonNumeric></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zvB5Qd59wDy1" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2021-04-012021-12-31_custom_StockOptionsTwoMember" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">0.30</ix:nonNumeric></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zzLiTngfB2cb" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The vested options can be exercised at any time in accordance with the
applicable option agreement. The exercise price was greater than the market price on the date of the grants for all options outstanding
as of December 31, 2022 and March 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company recorded approximately $<span id="xdx_90A_eifrs-full--CommunicationExpense_pn3n3_dm_c20221001__20221231_z3ZMcXAubzLk" title="Compensation expense"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million and $<span id="xdx_908_eifrs-full--CommunicationExpense_pn3n3_dm_c20220401__20221231_zyB5BXavfFLg" title="Compensation expense"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">3.6</ix:nonFraction></span> million of share-based
compensation expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the three and nine months ended December 31,
2022, respectively. The Company recorded approximately $<span id="xdx_90E_eifrs-full--CommunicationExpense_pn3n3_dm_c20211001__20211231_zKH9xTIWRBXc" title="Compensation expense"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million and $<span id="xdx_902_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20211231_zlijdNLZ5tNf" title="Compensation expense"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">6.2</ix:nonFraction></span> million of share-based compensation expense with respect
to the Amended and Restated 2021 Equity Incentive Plan in the three and nine months ended December 31, 2021, respectively. The Company
expects to record additional share-based compensation expense of approximately $<span id="xdx_905_eifrs-full--CommunicationExpense_pn3n3_dm_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zVXruMFqG0jk" title="Compensation expense"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2022-04-012022-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.9</ix:nonFraction></span> million through June 2026 with respect to the Amended
and Restated 2021 Equity Incentive Plan. Additionally, there was <span id="xdx_906_ecustom--IntrinsicValueOfStockOptions_iI_pn3n3_do_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_z74DEzpR0l22" title="Intrinsic value of stock options"><span id="xdx_90F_ecustom--IntrinsicValueOfStockOptions_iI_pn3n3_do_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zqYN6o8mSXM8" title="Intrinsic value of stock options"><ix:nonFraction name="ptgef:IntrinsicValueOfStockOptions" contextRef="AsOf2022-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="ptgef:IntrinsicValueOfStockOptions" contextRef="AsOf2021-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> intrinsic value with respect to the stock options granted under the
Amended and Restated 2021 Equity Incentive Plan at December 31, 2022 and was nil at December 31, 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company recorded approximately $<span id="xdx_902_eifrs-full--CommunicationExpense_pn3n3_dm_c20211001__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zILIVGaQUDV4" title="Compensation expense"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2021-10-012021-12-31_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.03</ix:nonFraction></span> million and $<span id="xdx_90D_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zNqYqk2NMrC6" title="Compensation expense"><ix:nonFraction name="ifrs-full:CommunicationExpense" contextRef="From2021-04-012021-12-31_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million of share-based
compensation expense related to the iOx stock option plan in the three and nine months ended December 31, 2021, respectively. As of December
31, 2021, the Company&#8217;s iOx stock option plan was fully vested. Additionally, the intrinsic value of the iOx stock options was approximately
$<span id="xdx_909_ecustom--IntrinsicValueOfStockOptions_iI_pn3n3_dm_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zQNuJnXdUaQg" title="Intrinsic value of stock options"><ix:nonFraction name="ptgef:IntrinsicValueOfStockOptions" contextRef="AsOf2021-12-31_custom_IOxOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million at December 31, 2021, all of which was associated with vested exercisable options.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:EarningsPerShareExplanatory"><p id="xdx_806_eifrs-full--EarningsPerShareExplanatory_zHfD4iyDTxq8" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 16. <span id="xdx_822_zresQLOZ4ZDk">(LOSS) PER SHARE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Basic earnings per share (&#8220;EPS&#8221;) is calculated by dividing
the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding
during the period.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Diluted EPS is calculated by dividing the net income (loss) attributable
to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period plus the weighted
average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table reflects the loss and share data used in the basic
and diluted EPS calculations (U.S. Dollars in thousands, except per share amounts):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:EarningsPerShareTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--EarningsPerShareTableTextBlock_pn3n3_zTcQDz7nnwD7" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B2_zpIatBYYIWs7" style="display: none">Schedule of basic and diluted EPS calculations</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_497_20221001__20221231_zjglLULkusIb" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_499_20211001__20211231_zz6OpCrbVXI3" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20220401__20221231_zeTqFzQcdnx8" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_496_20210401__20211231_zRr5vg062j98" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended<br /> December 31,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended<br /> December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">2021</td></tr>
  <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Numerator (in 000&#8217;$)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to owners of the Company</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,485</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,512</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,163</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,553</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Denominator (in 000&#8217;)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--WeightedAverageShares_i01_pid_zIoQ9lrRsQJf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average number of shares &#8211; Basic and Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,039</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,344</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,719</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,966</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--BasicAndDilutedLossPerShare_i01_pid_zEYG7Kd8HOsi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted (loss) per share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:BasicAndDilutedLossPerShare" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:BasicAndDilutedLossPerShare" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:BasicAndDilutedLossPerShare" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.65</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:BasicAndDilutedLossPerShare" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.74</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zdqeYx7Uw2w5" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_232_zmp5JsCT3hr2" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zjuCELhPKAy7" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 28; Value: 1 -->
    <div id="xdx_239_z99TfVXoNld8" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td id="xdx_230_zPufZ9oC1mSd" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zUOrVMemt4Z4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zgdSKq8D5Hid" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zQOnoeCWEfR1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zPHQOVSlHu9h" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zqSZWHIF3N4d" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zFmWvawXmQ36" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zzBwGykfNW24" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 16. (LOSS) PER SHARE <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zNUuWb4PDFLg" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The inclusion of the Company&#8217;s stock options, RSUs and share purchase
warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore excluded
from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the three and nine
months ended December 31, 2022 and 2021. The following table reflects the outstanding securities by year that would have an anti-dilutive
effect on loss per share and, accordingly, were excluded from the calculation.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_896_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_pn3n3_zQfmZIH8HUBj" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="vertical-align: bottom"><span id="xdx_8B4_zoAsgyZtmiob" style="display: none">Schedule of anti-dilutive share</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>As of December 31,</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="border-top: Black 1pt solid; vertical-align: top; text-align: center">&#160;</td>
    <td style="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; width: 67%"><span style="font-size: 10pt"><b>Stock options</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" title="Anti-dilutive effect on loss per share" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; vertical-align: bottom; width: 16%; text-align: right"><span style="font-size: 10pt"><b><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="From2022-04-012022-12-31_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,217,300</ix:nonFraction></b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; width: 1%">&#160;</td>
    <td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" title="Anti-dilutive effect on loss per share" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; vertical-align: bottom; width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="From2021-04-012021-12-31_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">868,000</ix:nonFraction></span></td>
    <td style="vertical-align: top; width: 1%; text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Restricted stock units</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><b><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember327165015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">378,740</ix:nonFraction></b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="From2021-04-012021-12-31_custom_RestrictedStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">243,000</ix:nonFraction></span></td>
    <td style="vertical-align: top; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Warrants</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_980_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1697">&#8211;</span></b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="From2021-04-012021-12-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,888</ix:nonFraction></span></td>
    <td style="vertical-align: top; text-align: right">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_zd5iB02rMppd" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Inclusion of outstanding options or other common stock equivalents in
the computation of diluted loss per share would have an anti-dilutive effect on the loss per share and are therefore excluded from the
computation. Consequently, there is no difference between loss per share and diluted loss per share.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"><p id="xdx_80B_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zwPa6iZ7H3ll" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 17. <span id="xdx_822_zVV1p7v3XVG2">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Effective March 15, 2022, iOx entered into a Master Services Agreement
(the &#8220;MSA&#8221;) with Parexel International (IRE) Limited (&#8220;Parexel&#8221;) under which Parexel agrees to provide services
as CRO provided in a work order (&#8220;Work Order&#8221;) effective June 1, 2022 under which Parexel will operate a Phase 2 trial of
IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer (&#8220;NSCLC&#8221;). The MSA provides for a five-year term, and
the Work Order provides for a term to be ended upon the completion of the services required. The budget provides for service fees and
pass-through expenses and clinical sites totaling $11.5 million. During the three months ended December 31, 2022, the Company executed
two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"><b><i>Stimunity Convertible Note</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 13, 2022, the Company entered into a commitment with Stimunity
to provide &#8364;<span id="xdx_90A_ecustom--ConvertibleNote_iI_pn3n3_uEUR_c20220713_z2zJNKFzLEdi" title="Convertible note"><ix:nonFraction name="ptgef:ConvertibleNote" contextRef="AsOf2022-07-13" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="EUR">600,000</ix:nonFraction></span> under the Stimunity Convertible Note. The Stimunity Convertible Note provides for simple interest at <span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220713_zC10wuouL4fb" title="Interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2022-07-13" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>% per annum.
The Convertible Note is automatically converted into Series A shares upon Stimunity completing a Series A round for at least &#8364;<span id="xdx_908_ecustom--ConversionOfDebt_iI_pn3n3_dm_uEUR_c20220713_zhC1H9XDnyv6" title="Conversion of debt"><ix:nonFraction name="ptgef:ConversionOfDebt" contextRef="AsOf2022-07-13" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="EUR">20</ix:nonFraction></span>
million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible
Note into Series A shares at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category
of shares (other than Common Shares or Series A shares) for at least &#8364;<span id="xdx_900_ecustom--ConversionOfDebtIntoShares_iI_pn3n3_dm_uEUR_c20220713_zEawQMbRT4b7" title="Conversion of debt into shares"><ix:nonFraction name="ptgef:ConversionOfDebtIntoShares" contextRef="AsOf2022-07-13" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="EUR">5</ix:nonFraction></span> million (the &#8220;Minimum Raise&#8221;), the Company will
have the right to convert the Stimunity Convertible Note and the historical Series A shares owned into the new category of shares. In
the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will
have the right to convert the Stimunity Convertible Note into Series A shares at &#8364;<span id="xdx_904_ecustom--SharePricePerShare_iI_pid_uEURPShares_c20220713_zRBZTVXYDSoj" title="Share price, per share"><ix:nonFraction name="ptgef:SharePricePerShare" contextRef="AsOf2022-07-13" format="ixt:numdotdecimal" decimals="INF" unitRef="EURPShares">363.00</ix:nonFraction></span> per share or the raise price less 15%, whichever
is lower. The Stimunity Convertible Note was funded by the Company on September 12, 2022. In addition, the Company has eliminated 100%
of the interest earned on the Stimunity Convertible Note in reporting its condensed consolidated financial results.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Committed Purchase Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 6, 2022 (the &#8220;Signing Date&#8221;), the Company entered
into the Committed Purchase Agreement with Lincoln, pursuant to which the Company may require Lincoln to purchase ordinary shares having
an aggregate value of up to $<span id="xdx_903_ecustom--AggregateValue_pn3n3_dm_c20220701__20220706__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zNQJvPblcIHc" title="Aggregate value"><ix:nonFraction name="ptgef:AggregateValue" contextRef="From2022-07-012022-07-06_custom_LincolnMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">30</ix:nonFraction></span> million over a period of 36 months. Pursuant to the Committed Purchase Agreement, Lincoln will be obligated
to purchase ordinary shares in three different scenarios that are based on various market criteria and share amounts.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23E_zRwXMlWVYdE3" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zV79ZWiH60Fg" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 29; Value: 1 -->
    <div id="xdx_23C_zicCcuNm3sO2" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td id="xdx_23E_zhdCH6jEWKD" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zv5S0DXRphpk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zBs4WtHNKqnb" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_z6GlMeKVQFR5" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_z0sAH9ZzSR1c" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zfvudpRUlAye" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z4wC1m3QZ6P4" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zaf8y0GhZlE6" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 17. COMMITMENTS AND CONTINGENT LIABILITIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zk2JUgyH0VRg" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Upon execution of the Committed Purchase Agreement, the Company issued
to Lincoln <span id="xdx_901_ecustom--NumberOfSharesSold_c20220401__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zxn8u3jTtFR" title="Number of shares issued"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2022-04-012022-12-31_custom_LincolnMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">94,508</ix:nonFraction></span> ordinary shares, representing a 3% commitment fee valued at $<span id="xdx_900_ecustom--CommitmentFee_pn3n3_dm_c20220401__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zwsWMj5CT36c" title="Commitment fee"><ix:nonFraction name="ptgef:CommitmentFee" contextRef="From2022-04-012022-12-31_custom_LincolnMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million. The Company has the right to terminate the
Committed Purchase Agreement for any reason, effective upon one business day prior written notice to Lincoln. Lincoln has no right to
terminate the Committed Purchase Agreement. The Company is accounting for the commitment fee as a deferred commitment fee on the condensed
consolidated interim statement of financial position as of December 31, 2022 and will amortize it pro-rata against equity sold under the
Committed Purchase Agreement. Any unamortized balance will be written-off to operations at the expiration of the commitment.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Committed Purchase Agreement does not impose any financial or business
covenants on the Company and there are no limitations on the use of proceeds received by the Company from Lincoln. The Company may raise
capital from other sources in its sole discretion; provided, however, that the Company shall not enter into any similar agreement for
the issuance of variable priced equity-like securities until the three-year anniversary of the Signing Date, excluding, however, an at-the-market
transaction with a registered broker-dealer.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the Committed Purchase Agreement, the Company and Lincoln
entered into a Registration Rights Agreement, dated July 6, 2022 (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the Registration
Rights Agreement, the Company agreed, that it will file with the SEC the prospectus supplement to the Company&#8217;s shelf registration
statement pursuant to Rule 424(b) for the purpose of registering for resale the ordinary shares to be issued to Lincoln under the Committed
Purchase Agreement. The prospectus supplement was filed on August 19, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company is obligated under the Tarus Merger Agreement
and the iOx Share Exchange Agreement for certain third party earnouts based on the achievement of certain milestones. See Note 8, &#8220;Acquisition
of Tarus,&#8221; and Note 18<span style="background-color: white">, &#8220;Related Party Transactions &#8211; Share Exchange Agreement
&#8211; iOx,&#8221;</span> for further discussions.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"><p id="xdx_804_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_zzH19t1LvC16" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 18. <span id="xdx_82C_zelntueJkh14">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Investments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has entered into related party transactions and certain services
agreements with its investees.&#160; Key management personnel of the Company have also entered into related party transactions with investees.
Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities
of the Company. The Board, Chairman, Chief Executive Officer (the &#8220;CEO&#8221;) and Chief Financial Officer are key management personnel.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following subsidiaries and associates are considered related parties:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td><b>Stimunity</b>. The CEO of Portage is one of three members of the board of directors of Stimunity (see Note 6, &#8220;Investment
in Associate,&#8221; and Note 17, &#8220;Commitments and Contingent Liabilities &#8211; Stimunity Convertible Note&#8221;).</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td><b>iOx</b>. Upon the iOx Share Exchange on July 18, 2022, the non-Portage director resigned leaving two Portage insiders as directors.
The CEO of Portage is also the CEO of iOx, and the management team of Portage comprises the management team of iOx. See below for a discussion
of the Company&#8217;s purchase of the non-controlling interest in iOx.</td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(c)</td><td><b>Saugatuck</b>. One of the three directorships on the board of directors of Saugatuck is controlled by Portage. Additionally, the
CEO of Portage is also the CEO of Saugatuck, and the management team of Portage comprises the management team of Saugatuck.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23F_zjHsWzYeD8Di" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zOu3qXFUgzq" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 30; Value: 1 -->
    <div id="xdx_238_zKzz5r7eNYN8" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td id="xdx_231_zH0sxVla7wj5" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zFppXAi3ss3g" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zWayz42Kc4hb" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zflOBY5mndA4" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zvXHaDPqCMN8" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zo2ma8zbSesh" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z5pzkpW36AX1" style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_z7KdDAiGAT9h" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 18. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zW9NJhb5rz9g" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(d)</td><td><b>Intensity</b>. The CEO of Portage is an officer of Intensity and from time to time, he provides consulting services to Intensity. The Company also sublets a portion of Intensity&#8217;s office space.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(e)</td><td><b>Portage Development Services Inc</b>. PDS is a 100% owned subsidiary incorporated in Delaware, which provides human resources and
other services to each operating subsidiary of Portage via a shared services agreement.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Transactions between the parent company and its subsidiaries, which are
related parties, have been eliminated in consolidation and are not disclosed in this note.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">On September 8, 2021,<span id="xdx_906_ecustom--IssuanceOfUnsecuredNotesDescriptions_c20210901__20210908__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember" title="Issuance of unsecured notes, description"> <ix:nonNumeric contextRef="From2021-09-012021-09-08_custom_IOXMember" name="ptgef:IssuanceOfUnsecuredNotesDescriptions">the&#160;Company,
through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for
23,772 ordinary shares of iOx at a price of &#163;162. Simultaneously, the Company entered into an agreement with OSI, the holder of
$0.15&#160;million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for&#160;820&#160;shares of iOx.
The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets
of IAS 39, &#8220;Financial Instruments: Recognition and Measurement,&#8221; and IFRIC 19, &#8220;Extinguishing Financial Liabilities
with Equity Instruments,&#8221; and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection
with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from&#160;60.49% to&#160;78.32%.</ix:nonNumeric></span></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Share Exchange Agreement &#8211; iOx</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 18, 2022, the Company and SalvaRx entered into a Share Exchange
Agreement (the &#8220;Share Exchange Agreement&#8221;) with each of the minority shareholders of iOx (the &#8220;Sellers&#8221;) resulting
in the acquisition of the outstanding non-controlling ownership interest (approximately 22%) of iOx, which is developing the iNKT agonist
platform. The Company followed IFRS 3, &#8220;Business Combinations,&#8221; and IAS 27, &#8220;Separate Financial Statements,&#8221; (which
substantially replaced IAS 3) to account for this transaction. The Company achieved control of iOx, as defined, on January 8, 2019 upon
the completion of the SalvaRx Acquisition. Further transactions whereby the parent entity acquires further equity interests from non-controlling
interests, or disposes of equity interests but without losing control, are accounted for as equity transactions (i.e., transactions with
owners in their capacity as owners). As such:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>the carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative interests
in the subsidiary;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>any difference between the amount by which the non-controlling interests is adjusted and the fair value of the consideration paid
or received is recognized directly in equity and attributed to the owners of the parent; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>there is no consequential adjustment to the carrying amount of goodwill, and no gain or loss is recognized in profit or loss.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company now owns the worldwide rights to its small molecule iNKT agonists,
including lead programs PORT-2 and PORT-3. Under the terms of the Share Exchange Agreement, each Seller sold to the Company, and the Company
acquired from each Seller, legal and beneficial ownership of the number of iOx shares held by each Seller, free and clear of any share
encumbrances, in exchange for the issuance in an aggregate of <span id="xdx_906_ecustom--PortageOrdinaryShares_c20220401__20221231_pdd" title="Portage ordinary shares"><ix:nonFraction name="ptgef:PortageOrdinaryShares" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,070,000</ix:nonFraction></span> Portage ordinary shares to be allocated among the Sellers based
upon their relative ownership. As a result of the Share Exchange Agreement, the Company owns 100% of the issued and outstanding shares
of iOx.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23D_zXUEXYNnBO0e" style="margin: 0pt 0; font-size: 10pt; text-align: center; text-indent: 0in">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zHlm17IjCbI9" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 31; Value: 1 -->
    <div id="xdx_238_zeBTbWa7mIue" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td id="xdx_238_z0LvKkSYe8Zd" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zhHLqfYr3iGg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_z8br71bm9eGl" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zvfIOm7nanXi" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zOmk47oNhiA8" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zJZ49xUDOJpg" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zwUagpH7Prvk" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zmLM9f7ioJz" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 18. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zAFW1iQW5gfi" style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">As additional consideration for the sale of the iOx
shares to the Company under the Share Exchange Agreement, the Sellers shall have the contingent right to receive additional shares (&#8220;Earnout
Shares&#8221;) from the Company having an aggregate value equal to $25 million calculated at the Per Share Earnout Price, as defined in
the Share Exchange Agreement, upon the achievement of certain milestones defined as the dosing of the first patient in a Phase 3 clinical
trial for either PORT-2 (IMM60 iNKT cell activator/agonist) or PORT-3 (PLGA-nanoparticle formulation of IMM60 combined with a NY-ESO-1
peptide vaccine). The Company shall have the option, in its sole and absolute discretion, to settle the Earnout Shares in cash. The Company
followed IFRS 3 and IAS 32, &#8220;Financial Instruments: Presentation,&#8221; to account for the fair value of the Earnout Shares. The
principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount
rate used. The fundamental principle of IAS 32 is that a financial instrument should be classified as either a financial liability or
an equity instrument according to the substance of the contract, not its legal form, and the definitions of financial liability and equity
instrument. A financial instrument is an equity instrument if, and only if, both conditions (a) and (b) below are met:</p>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td style="text-align: left">the instrument includes no contractual obligation to deliver cash or another financial asset to another entity,
and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td style="text-align: left">if the instrument will or may be settled in the issuer&#8217;s own equity instruments, it is either:</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 41.05pt"></td><td style="width: 18pt">(i)</td><td style="text-align: left">a non-derivative that includes no contractual obligation for the issuer to deliver a variable number of its
own equity instruments; or</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 41.05pt"></td><td style="width: 18pt">(ii)</td><td style="text-align: left">a derivative that will be settled only by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">When a derivative financial instrument gives one party a choice over how
it is settled (for instance, the issuer or the holder can choose settlement net in cash or by exchanging shares for cash), it is a financial
asset or a financial liability unless all of the settlement alternatives would result in it being an equity instrument. The financial
instrument includes the exclusive right of the Company to settle the obligation with cash or equity and, accordingly, accounted for the
fair value of the Earnout Shares as a non-current liability.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company recorded $5.478 million as the fair value estimate of the
Earnout Shares, which is reflected as deferred obligation - iOx milestone on the condensed consolidated balance sheet included herein.
The Company will determine the fair value of the Earnout Shares at each balance sheet date. Any change to the fair value will be recorded
in the Company&#8217;s statements of operations and other comprehensive income (loss). The Company recorded a (loss) from the change (increase)
in fair value of the liability of $0.144 million and $0.090 million for the three and nine months ended December 31, 2022, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Employment Agreements</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">PDS entered into a Services Agreement with our CEO effective December
15, 2021 (the &#8220;CEO Services Agreement&#8221;). The CEO Services Agreement provides that the CEO will receive a base salary of $<span id="xdx_90D_ecustom--BaseSalary_pn3n3_c20211201__20211215__ifrs-full--CounterpartiesAxis__custom--ChiefExecutiveOfficersMember_zRGHwqO8kGr5" title="Base Salary"><ix:nonFraction name="ptgef:BaseSalary" contextRef="From2021-12-012021-12-15_custom_ChiefExecutiveOfficersMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">618,000</ix:nonFraction></span>,
plus cost-of-living increases. The CEO Services Agreement provides for annual increases based upon the review of the base salary by the
Board prior to the anniversary of the CEO Services Agreement provided that the annual increase cannot be less than the cost-of-living
increase. The CEO Services Agreement also provides that the CEO is eligible to receive an annual performance-based bonus targeted at 59%
of the applicable year&#8217;s base salary, which bonus is earned based on the achievement of performance targets, as determined annually
by the Board and communicated to the CEO in the first quarter of the year. Any annual bonus, to the extent earned, is to be paid no later
than March 15 of the following year. The CEO Services Agreement is for an initial term of three years, after which it will automatically
renew annually unless terminated in accordance with the CEO Services Agreement.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_237_zZlfrRjvVCg8" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zSEZ0D5Lo6Qg" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 32; Value: 1 -->
    <div id="xdx_231_z28pWk5lL7w4" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td id="xdx_23F_z84ZNLH4gwAj" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zMXpjV7vA7s2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zbEfRXDd0ym8" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zkOkRP3Yaqfi" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_z3OB4jMQFdci" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zD0kGtupEZlb" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z5rkMm119aH2" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zeNbV6J3e1Y6" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 18. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zm22oyh1YeNc" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Under the CEO Services Agreement, the CEO may terminate his employment
with PDS at any time for Good Reason (as defined in the CEO Services Agreement). PDS may terminate the CEO&#8217;s employment immediately
upon his death, upon a period of disability or without Just Cause (as defined in the CEO Services Agreement). In the event that the CEO&#8217;s
employment is terminated due to his death or Disability (as defined in the CEO Services Agreement), for Good Reason or without Just Cause,
he will be entitled to accrued obligations (accrued unpaid portion of base salary, accrued unused vacation time and any unpaid expenses).
Additionally, he may be entitled to Severance Benefits (as defined in the CEO Services Agreement), which include his then current base
salary and the average of his annual bonus for the prior two completed performance years, paid over 12 monthly installments. Additionally,
the CEO will be entitled to life insurance benefits and medical and dental benefits for a period of 12 months at the same rate the CEO
and PDS shared such costs during his period of employment.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Additionally, all stock options (and any other unvested equity incentive
award) held by the CEO relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as defined
in the CEO Services Agreement), and the exercise period for such stock options will be increased by a period of two years from the Termination
Date.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">If the CEO&#8217;s employment by PDS is terminated by PDS or any successor
entity without Just Cause (not including termination by virtue of the CEO&#8217;s death or Disability) or by the CEO for Good Reason within
12 months following the effective date of a Change in Control (as defined in the CEO Services Agreement), then, in addition to paying
or providing the CEO with the Accrued Obligations (as defined in the CEO Services Agreement), the Company will provide the following Change
in Control Severance Benefits (as defined in the CEO Services Agreement):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(1)</td><td>PDS will pay the base salary continuation benefit for 18 months;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(2)</td><td>PDS will pay the life insurance benefit for 18 months;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(3)</td><td>PDS will pay an additional amount equivalent to the CEO&#8217;s target annual bonus calculated using the bonus percentage for the
performance year in which the CEO&#8217;s termination occurs. This bonus will be paid in 12 equal installments commencing on the first
payroll date that is more than 60 days following the date of termination of the CEO&#8217;s employment, with the remaining installments
occurring on the first day of the month for the 11 months thereafter;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(4)</td><td>PDS will provide the CEO with continued medical and dental benefits, as described above, for 18 months; and</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(5)</td><td>All stock options (and any other unvested equity incentive award) held by the CEO relating to shares of the Company or its parent
will be deemed fully vested and exercisable on the Termination Date, as defined, and the exercise period for such stock options will be
increased by a period of two years from the Termination Date.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">PDS entered into services agreements (individually, an &#8220;Executive
Service Agreement,&#8221; and collectively, the &#8220;Executive Service Agreements&#8221;) with each of our five other senior officers
(individually, &#8220;Executive&#8221; and collectively, &#8220;Executives&#8221;), three of which are dated as of December 1, 2021, one
of which is dated December 15, 2021 and one of which is dated June 1, 2022. Each of the Executive Services Agreements provides for an
initial term of two years that is automatically renewed for one-year periods (except two of the Executive Services Agreement, which provides
for an initial term of one year and that is automatically renewed for one-year periods). The Executive Services Agreements initially provide
for annual base salaries ranging from $175,000 to $348,000 (pro-rated for services rendered) and annual bonus targets ranging from 30%
to 40%. They also provide for long-term incentives in the form of equity awards from time to time under the Portage Biotech Inc. Amended
and Restated 2021 Equity Incentive Plan.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23C_zVDXXQ51fLZh" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zfyfgJrihqg5" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 33; Value: 1 -->
    <div id="xdx_238_zZ1sCcJNBzq7" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td id="xdx_234_zQlhNgiueMj1" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zWxDWF2vJuT2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_z0GLc4q2foBl" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zdhyt5ZOSLo5" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zykg5pEkpaUh" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zvFTx98jYLii" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zTVipaHseyD2" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zYkS9XK4DtS8" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 18. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_232_z4CPPTATWhXd" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Executive Services Agreements can be terminated by PDS without Just
Cause, by death or Disability, or by the Executive (except one) for Good Reason (each as defined in the respective Executive Services
Agreements). In such instances, the Executive Services Agreements provide for the payment of accrued obligations (accrued unpaid portion
of base salary, accrued unused vacation time and any unpaid expenses). Additionally, the Executives (except two) are entitled to 50% of
base salary plus 50% of average annual bonus earned over the prior two performance years, as well as prevailing life insurance benefits
for a period of six months and medical and dental benefits for a period of six months at the prevailing rate PDS and the Executive were
sharing such expenses.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Additionally, all stock options (and any other unvested equity incentive
award) held by the Executives relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as
defined in the respective Executive Services Agreements), and the exercise period for such stock options will be increased by a period
of two years from the Termination Date.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">If an Executive&#8217;s employment by PDS is terminated by the Company
or any successor entity without Just Cause (not including termination by virtue of the Executive&#8217;s death or Disability) or by the
Executive (except one) for Good Reason within 12 months following the effective date of a Change in Control (as defined in the respective
Executive Services Agreements), then, in addition to paying or providing the Executive with the Accrued Obligations (as defined in the
respective Executive Services Agreements), the Company will provide the following Change in Control Severance Benefits (as defined in
the respective Executive Services Agreements), except in two cases in which the Executive is entitled to Item (5) and 50% of Items (1)
and (3) below:</p>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(1)</td><td>PDS will pay the Base Salary continuation benefit for 12 months;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(2)</td><td>PDS will pay the life insurance benefit for 12 months;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(3)</td><td>The Company will pay an additional amount equivalent to the Executive&#8217;s target annual bonus calculated using the bonus percentage
for the performance year in which the Executive&#8217;s termination occurs. This bonus will be payable in 12 equal installments commencing
on the first payroll date that is more than 60 days following the date of termination of the Executive&#8217;s employment, with the remaining
installments occurring on the first day of the month for the 11 months thereafter;</td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(4)</td><td>PDS will provide the Executive with continued medical and dental benefits, as described above, for 12 months; and</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(5)</td><td>All stock options (and any other unvested equity incentive award) held by the Executive relating to shares of the Company or its parent
will be deemed fully vested and exercisable on the Termination Date and the exercise period for such stock options will be increased by
a period of two years from the Termination Date.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Executive Services Agreements also include customary confidentiality,
as well as provisions relating to assignment of inventions. The Executive Services Agreements also includes non-competition&#160;and non-solicitation&#160;of
employees and customers provision that run during the Executive&#8217;s employment with PDS and for a period of one year after termination
of employment.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23C_z9Ph8oNK2dD7" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zp1eRzVD3xcd" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 34; Value: 1 -->
    <div id="xdx_23D_z5uyYx49gLl9" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td id="xdx_234_zbwFfYMIflnh" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zWF2B9OBGHWc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zd58pq2duLR2" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zAP2l9PC1yUh" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_z5au2fgDW0wk" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zbKXgwgp66fc" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zCb0gPWHaBi3" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zt61ZtOI5Lpb" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 18. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zbL2XaafAHTj" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><span style="background-color: white"><b><i>Bonuses &amp; Board Compensation Arrangements</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">In December 2021, the Compensation
Committee approved performance bonuses payable to senior management totaling $0.7 million. The bonuses were paid in December 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In addition, the Compensation Committee of the Board established director
compensation. Effective January 1, 2022, each non-executive Board member will be entitled to receive cash Board fees of $40,000 per annum,
payable quarterly in arrears. Additionally, each non-executive Board member will be entitled to an annual grant of 6,900 options to purchase
Portage ordinary shares, which would vest the first annual anniversary of the grant date. The Company incurred Board fees totaling $78,750
and $236,250 during the three and nine months ended December 31, 2022, respectively. There were no Board fees incurred during the three
and nine months ended December 31, 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Non-executive Board chairpersons will be entitled to an annual cash fee
of $30,000, payable quarterly in arrears. In lieu of a non-executive chairperson, the lead director will be entitled to an annual cash
fee of $20,000 per annum paid quarterly in arrears. <span id="xdx_904_ecustom--AnnualFeesdescription_c20220401__20221231" title="Annual feesDescription"><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" name="ptgef:AnnualFeesdescription">Additionally, the chairperson of each of the Audit Committee, Compensation Committee
and Nomination Committee will be entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members
of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.</ix:nonNumeric></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">In December 2022, the Board approved
executive performance bonuses, as recommended by the Compensation Committee, totaling $<span id="xdx_909_ecustom--CompensationCommittee_pn3n3_dm_c20211201__20211231_zw5XlaKU8Fw1" title="Compensation committee"><ix:nonFraction name="ptgef:CompensationCommittee" contextRef="From2021-12-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million, which is equivalent to <span id="xdx_907_ecustom--OriginalAnnualTargetsPercentage_pid_dp_c20211201__20211231_zjUl9FS3SLM4" title="Original annual targets percentage"><ix:nonFraction name="ptgef:OriginalAnnualTargetsPercentage" contextRef="From2021-12-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">73.5</ix:nonFraction></span>% of original
annual targets established by the Board in December 2021. The bonuses were approved based upon the original performance targets established.
The Board further approved a payment structure of 25% of approved bonuses, which were paid in January 2023, with the balance of amounts due
payable upon a new financing.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory"><p id="xdx_80C_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zHeAhhXcGkL1" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 19. <span id="xdx_825_zUoLpSqffpN3">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s financial instruments recognized in the Company&#8217;s
condensed consolidated interim statements of financial position consist of the following:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Fair value estimates are made at a specific point in time, based on relevant
market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of
significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could significantly affect
these estimates.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23A_zd63A5yhJeqi" style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zFZnYSGEHiRf" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 35; Value: 1 -->
    <div id="xdx_236_ziHcXJhlw9W2" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td id="xdx_230_zGlKNojIQUUk" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_znDLLfPCSPm" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_235_zHJLFtlCXw17" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zrQoXNa1LZLg" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zGkH9TujXZv7" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zhkhWvYSYEfg" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_z6KGJCZkbzEb" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zSLGwbY7Lkq6" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zCx4WVcAanc3" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 19. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zMPx32qTdABk" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table summarizes the Company&#8217;s financial instruments
as of December 31, 2022 and March 31, 2022:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory_pn3n3_zkPsGNEDvFN9" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BE_zYUV3DrLCaR3" style="display: none">Schedule of financial instruments</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49C_20221231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zU75MA5YgBq3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49D_20221231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zaGOgs0d3Ou5" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_498_20220331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zhMnrMQ8D1Xf" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_490_20220331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z6TQFEmhz8f2" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value through Other Comprehensive <br />Income (&#8220;FVTOCI&#8221;)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-12-31_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,104</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1806">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-03-31_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,352</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2022-12-31_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,786</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2022-03-31_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,480</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1813">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ConvertibleNoteReceivableIncludingAccruedInterest_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Convertible note receivable, including accrued interest</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1815">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ConvertibleNoteReceivableIncludingAccruedInterest" contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">642</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1817">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1818">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--CurrentInvestments_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Investments</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1820">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentInvestments" contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,768</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1822">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentInvestments" contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,082</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value through Profit or Loss (&#8220;FVTPL&#8221;)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2022-12-31_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,422</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1831">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2022-03-31_custom_AmortizedCostMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1833">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--WarrantLiability_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1835">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1837">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredPurchasePricePayableTarus_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred purchase price payable - Tarus</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1840">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredPurchasePricePayableTarus" contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,876</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1842">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1843">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredObligationIoxMilestone_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred obligation - iOx milestone</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1845">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:DeferredObligationIoxMilestone" contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,568</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1847">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1848">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zHt4OUzsIO61" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">A summary of the Company&#8217;s risk exposures as it relates to financial
instruments are reflected below.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Fair value of Financial Instruments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s financial assets and liabilities are comprised of
cash and cash equivalents, receivables and investments in equities and private entities, accounts payable, warrant liability and unsecured
notes payable.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company classifies the fair value of these transactions according
to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>Level 1 &#8211; Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of
the reporting date.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>Level 2 &#8211; Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which
can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of
the reporting date.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>Level 3 &#8211; Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified
as Level 3 financial instrument.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Assessment of the significance of a particular input to the fair value
measurement requires judgment and may affect the placement within the fair value hierarchy.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Management has assessed that the fair values of cash and cash equivalents,
other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<ix:exclude><p id="xdx_23B_z8fWBaVukYoe" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zLxAXotLdAMh" style="margin: 0pt 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 36; Value: 1 -->
    <div id="xdx_237_zVY5uECNUH6k" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td id="xdx_23C_zpVvSs4ZgeZ9" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zaS9LoGZ3Vnl" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zdz8LSYY7fAk" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zQsN3tMliZvb" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zmWGxPrOniKc" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zCgR9GCsEnp3" style="margin: 0pt 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zpJWGNZbYC17" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_z4lTTx2sriAe" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 19. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z8SfShFStii5" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following methods and assumptions were used to estimate their fair
values:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt"><b>Convertible Note Receivable:</b> The fair
value of the Stimunity Convertible Note receivable denominated in euros at initial recognition is the transaction price for the instrument
adjusted for the effect of the currency translation rate on the reporting date (Level 3) (see Note 17, &#8220;Commitments and Contingent
Liabilities &#8211; Stimunity Convertible Note&#8221;). The Company recognized an unrealized gain through OCI on the change in fair value
of the Stimunity Convertible Note receivable of $<span id="xdx_906_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_pn3n3_dm_c20221001__20221231_z0tET2hILWu9" title="Convertible Note receivable"><span id="xdx_901_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_pn3n3_dm_c20220401__20221231_zLV0SqenCrFi" title="Convertible Note receivable"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="From2022-10-012022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.29</ix:nonFraction></ix:nonFraction></span></span> million for the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Investment in Intensity</b>: Fair value of the asset is determined
by considering other comparable equity funding transactions by Intensity with unrelated investors (Level 3).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Accrued Equity Issuable: </b>The fair value is estimated based on the
average of the quoted market prices for the period in which the shares were earned (Level 1).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Warrant Liability</b>: The fair value is estimated using a Black-Scholes
model (Level 3) (see Note 13, &#8220;Warrant Liability&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Deferred Purchase Price Payable - Tarus:</b> The fair value is the
estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 at acquisition
date, adjusted at each reporting date for any change in fair value (Level 3) (see Note 8, &#8220;Acquisition of Tarus&#8221;). The fair
value was determined using the Income Approach and was based upon the analysis on the Tarus clinical plan, the timing of development events
and the probabilities of success determined primarily based upon empirical third party data and Company experience, as well as the relevant
cost of capital. The Company recorded a (loss) from the change (increase) in fair value of the liability of $0.354 million and $0.338
million for the three and nine months ended December 31, 2022, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Deferred Obligation - iOx Milestone:</b> The fair value is the estimated
value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 as of July 18, 2022, the
date of the Share Exchange Agreement, adjusted at each reporting date for any change in fair value (Level 3) (see Note 18, &#8220;Related
Party Transactions &#8211; Share Exchange Agreement &#8211; iOx&#8221;). The fair value was determined using the Income Approach and based
on factors including the clinical plan, the timing of development events and the probabilities of success determined primarily based upon
empirical third party data and Company experience, as well as the relevant cost of capital. The Company recorded a (loss) from the change
(increase) in fair value of the liability of $0.144 million and $0.090 million for the three and nine months ended December 31, 2022,
respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">There have been no transfers between levels of the fair value hierarchy
for the nine months ended December 31, 2022 and the year ended March 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s financial instruments are exposed to certain financial
risks: Credit Risk, Liquidity Risk and Foreign Currency Risk.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Credit Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Credit risk is the risk of loss associated with a counterparty&#8217;s
inability to fulfil its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&#8217;s condensed consolidated interim statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b><i>Cash and cash equivalents</i>.</b> Cash and cash equivalents comprise
cash on hand and on-demand deposits that are readily convertible to a known amount of cash with three months or less from date of acquisition
and are subject to an insignificant risk of change in value. <span style="background-color: white">As of December 31, 2022 and March&#160;31,
2022, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. </span>Cash
and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_231_z4XW7SY8RFY1" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zhJDd5pGTbUg" style="margin: 0pt 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 37; Value: 1 -->
    <div id="xdx_232_zmWpxARO1Yk5" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td id="xdx_23B_zYEWFPpmrY82" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zlpxXFouPqsd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zjsMUnzrADPh" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zD2aLQ76BNj4" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zvPs8e3Rwmw6" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zRCMGejxMW23" style="margin: 0pt 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zwxCpm4s97Ej" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zXy50sRUUbRk" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 19. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_238_z0BYzZHAngS2" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Liquidity Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Liquidity risk is the risk that the Company will encounter difficulty
in satisfying financial obligations as they become due.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s approach to managing liquidity is to ensure, as far
as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without
incurring unacceptable losses or risking harm to the Company&#8217;s reputation. The Company holds sufficient cash and cash equivalents
to satisfy obligations under accounts payable and accruals.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company monitors its liquidity position regularly to assess whether
it has the funds necessary to meet its operating needs and needs for investing in new projects. The Company believes that it has sufficient
funding to finance the committed drug development work, apart from meeting its operational needs for the foreseeable future.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">However, as a biotech company at an early stage of development and without
significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may
not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty in global
markets could have an impact on the Company&#8217;s future ability to access capital on terms that are acceptable to the Company. There
can be no assurance that required financing will be available to the Company. See Note 2, &#8220;Liquidity,&#8221; and Note 14, &#8220;Capital
Stock,&#8221; for a discussion of the Company&#8217;s share offering and Note 17, &#8220;Commitments and Contingent Liabilities &#8211;
Committed Purchase Agreement,&#8221; for a further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Foreign Currency Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">While the Company operates in various jurisdictions, substantially all
of the Company&#8217;s transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K. settleable
in British pound sterling and the Stimunity Convertible Note receivable settleable in euros.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock"><p id="xdx_800_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zXA5IydAGrll" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 20. <span id="xdx_823_z3POdxHUjoX6">CAPITAL DISCLOSURES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company considers the items included in shareholders&#8217; equity
as capital. The Company had accounts payable and accrued expenses of approximately $<span id="xdx_901_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20221231_zTE3RNb79J38" title="Payables and accrued expenses"><ix:nonFraction name="ptgef:PayablesAndAccruedExpense" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million as of December 31, 2022 (approximately
$<span id="xdx_901_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20220331_zNdMM54oPht9" title="Payables and accrued expenses"><ix:nonFraction name="ptgef:PayablesAndAccruedExpense" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million as of March 31, 2022) and current assets of approximately $<span id="xdx_90D_ecustom--CurrentAsset_iI_pn3n3_dm_c20221231_zcwy1LaiWpji" title="Current assets"><ix:nonFraction name="ptgef:CurrentAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">15.5</ix:nonFraction></span> million as of December 31, 2022 (approximately $<span id="xdx_90A_ecustom--CurrentAsset_iI_pn3n3_dm_c20220331_z7uNPnmhUs7k" title="Current assets"><ix:nonFraction name="ptgef:CurrentAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">24.8</ix:nonFraction></span> million
as of March 31, 2022). The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as
a going concern in order to pursue new business opportunities and to maintain a flexible capital structure, which optimizes the costs
of capital at an acceptable risk.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company manages the capital structure and makes adjustments to it
in light of changes in economic conditions and the risk characteristics of the underlying assets.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022, shareholders&#8217; equity attributable to the
owners of the company was approximately $<span id="xdx_907_ecustom--ShareholdersEquityAttributableToOwners_iI_pn3n3_dm_c20221231_zP1xQNhI5ZAi" title="Shareholders&apos; equity attributable to owners"><ix:nonFraction name="ptgef:ShareholdersEquityAttributableToOwners" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">168.9</ix:nonFraction></span> million (approximately $<span id="xdx_906_ecustom--ShareholdersEquityAttributableToOwners_iI_pn3n3_dm_c20220331_zIi6QIux48F7" title="Shareholders&apos; equity attributable to owners"><ix:nonFraction name="ptgef:ShareholdersEquityAttributableToOwners" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">121.2</ix:nonFraction></span> million as of March 31, 2022).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company is not subject to any externally imposed capital requirements
and does not presently utilize any quantitative measures to monitor its capital. There have been no changes to the Company&#8217;s approach
to capital management during the nine months ended December 31, 2022 and 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in">&#160;</p>

<ix:exclude><p id="xdx_23C_zpQhSixP256a" style="margin: 0pt 0; font-size: 10pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zVc19zsmlxs5" style="margin: 0pt 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 38; Value: 1 -->
    <div id="xdx_23D_zdhdnTzbj5L" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td id="xdx_23C_zx3Pbm7CbQKi" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zQdhQ553X0C9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zz78E3eLAVte" style="margin: 0pt 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zat6VK7REZc8" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zOhd2P95CWN8" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zU3JmClPwFrd" style="margin: 0pt 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated March 1, 2023)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zzqSog0sURu8" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory"><p id="xdx_806_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zA3wDJi97AOb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. <span id="xdx_82B_zUOrNJSrF3lb">NON-CONTROLLING INTEREST</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:ScheduleOfNoncontrollingInterestTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zRGrdWEf3B7h" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BF_zVq12XLVJqTb" style="display: none">Schedule of non-controlling interest</span></td><td style="text-align: justify; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Saugatuck <br />and subsidiary</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2022</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zi826xxTHcmi" title="Non-controlling interest, at beginning" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2022-03-31_custom_IOXMember327152796" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,701</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_987_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zcB6nOkdtrF7" title="Non-controlling interest, at beginning" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2022-03-31_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">472</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231_zSGjEDkZJcNh" title="Non-controlling interest, at beginning" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44,229</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net income (loss) attributable to non-controlling interest</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2022-04-012022-12-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2022-04-012022-12-31_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">171</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231_pn3n3" title="Net income (loss) attributable to non-controlling interest" style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">48</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10.1pt; padding-left: 10.1pt">Purchase of non-controlling interest pursuant to Share Exchange Agreement</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" contextRef="From2022-04-012022-12-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44,824</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_znTeJD3WhW9b" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1911">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_c20220401__20221231_pn3n3" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" contextRef="From2022-04-01to2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44,824</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zJYgGcTc8Sde" title="Non-controlling interest, at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1915">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zXgu9h5zKWXl" title="Non-controlling interest, at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2022-12-31_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">643</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231_zmjnE3OGUW6c" title="Non-controlling interest, at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">643</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table></ix:nonNumeric>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Saugatuck</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2021</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_znGz0pDUXvv5" title="Non-controlling interest, at beginning" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-03-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,173</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zfH9IGdM7bga" title="Non-controlling interest, at beginning" style="width: 12%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-03-31_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20211231_zLltgmqhsQe" title="Non-controlling interest, at beginning" style="width: 12%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,153</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockBasedCompensationExpense_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2021-04-012021-12-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">191</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--StockBasedCompensationExpense_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_ztUsR3nx9MW9" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1929">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--StockBasedCompensationExpense_c20210401__20211231_pn3n3" title="Stock based compensation expense" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockBasedCompensationExpense" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">191</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Exchange of notes payable, accrued interest and warrants for iOx shares</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" title="Exchange of notes payable, accrued interest and warrants for iOx shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" contextRef="From2021-04-012021-12-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z2PV9oZZPGq9" title="Exchange of notes payable, accrued interest and warrants for iOx shares" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1935">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_c20210401__20211231_pn3n3" title="Exchange of notes payable, accrued interest and warrants for iOx shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net (loss) attributable to non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zsChvEIh4Icb" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2021-04-012021-12-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">436</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4FliM9yUwhh" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2021-04-012021-12-31_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">317</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20210401__20211231_zfCSQxIM3t4d" title="Net income (loss) attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2021-04-012021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">753</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of December 31, 2021</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zXvFxENmVmv8" title="Non-controlling interest, at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-12-31_custom_IOXMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,112</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zsXn4HSX4BB6" title="Non-controlling interest, at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-12-31_custom_SaugatuckMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">337</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20211231_zxNbtgVdx5si" title="Non-controlling interest, at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,775</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On September 8, 2021, the Company, through SalvaRx, completed a settlement
of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price
of &#163;162. On July 18, 2022, the Company completed the acquisition of the remaining non-controlling interest in iOx, by issuing 1,070,000
shares of its ordinary shares and assuming certain milestone obligations. See Note 11, &#8220;Unsecured Notes Payable &#8211; iOx Unsecured
Notes Payable,&#8221; and <span style="background-color: white">Note 18, &#8220;Related Party Transactions &#8211; Share Exchange Agreement
&#8211; iOx,</span>&#8221; for further discussions.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary,
Saugatuck Rx LLC.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-04-01to2022-12-31" escape="true" name="ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock"><p id="xdx_803_ecustom--DisclosureOfEventAfterBalanceSheetDateTextBlock_z9cCKRCqRHD4" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 22. <span id="xdx_82B_zNbVwecrtfSh">EVENT AFTER THE BALANCE SHEET DATE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Sale of Ordinary Shares</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In January and February 2023, the Company continued its share offering
pursuant to the ATM and the Committed Purchase Agreement. From January 1, 2023 through February 24, 2023, the Company sold <span id="xdx_907_ecustom--NumberOfSharesSold_pid_c20230101__20230131__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zfpLAOrWMbv7" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2023-01-012023-01-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,279</ix:nonFraction></span> ordinary
shares under the ATM and generated net proceeds of approximately $<span id="xdx_90B_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20230101__20230131__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zNbxqAktnkdc" title="Net proceeds from sale"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfBiologicalAssets" contextRef="From2023-01-012023-01-31_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million and sold <span id="xdx_905_ecustom--NumberOfSharesSold_pid_c20230201__20230228__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zJfZCVnu0EHl" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2023-02-012023-02-28_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">270,000</ix:nonFraction></span> ordinary shares under the Committed Purchase
Agreement for net proceeds totaling approximately $<span id="xdx_90D_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20230201__20230228__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zpwzn6MaLWfd" title="Net proceeds from sale"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfBiologicalAssets" contextRef="From2023-02-012023-02-28_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

</ix:nonNumeric><p id="xdx_81F_z3S2eX8GLtEh" style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">F-37</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0; font-size: 10pt; text-align: center"></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exh_992.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 99.2</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>PORTAGE BIOTECH INC.</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>THREE AND NINE MONTHS ENDED DECEMBER 31, 2022</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0">Prepared as of March 1, 2023</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<P STYLE="font-size: 18pt; margin: 0pt 0">Index</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt">Forward-Looking Statements</FONT></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Nature of Operations and Overview</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Summary of Results</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Number of Ordinary Shares and Warrants</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Business Environment &ndash; Risk Factors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Our Programs and Technology &ndash; Recent Developments</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Results of Operations</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Liquidity and Capital Resources</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Key Contractual Obligations</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Off-balance Sheet Arrangements</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Transactions with Related Parties</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Financial and Derivative Instruments</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Use of Estimates and Judgments</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">New Accounting Standards, Interpretations and Amendments</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Internal Controls over Financial Reporting</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Public Securities Filings</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>Management Discussion and Analysis</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following discussion and analysis by management of the financial condition
and financial results for Portage Biotech Inc. for the three and nine months ended December 31, 2022, should be read in conjunction with
the unaudited condensed consolidated interim financial statements for the three and nine months ended December 31, 2022, together with
the related Management&rsquo;s Discussion and Analysis and audited consolidated financial statements for the year ended March 31, 2022,
and Annual Report on Form 20-F for the year ended March 31, 2022.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Forward-Looking Statements</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">This document includes &ldquo;forward-looking statements.&rdquo; All statements,
other than statements of historical facts, included herein or incorporated by reference herein, including without limitation, statements
regarding our business strategy, plans and objectives of management for future operations and those statements preceded by, followed by
or that otherwise include the words &ldquo;believe,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates&rdquo;
or similar expressions or variations on such expressions are forward-looking statements. We can give no assurances that such forward-looking
statements will prove to be correct.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Each forward-looking statement reflects our current view of future events
and is subject to risks, uncertainties and other factors that could cause actual results to differ materially from any results expressed
or implied by our forward-looking statements.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Risks and uncertainties include, but are not limited to:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our plans and ability to develop and commercialize product candidates and the timing of these development programs;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>clinical development of our product candidates, including the results of current and future clinical trials;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the benefits and risks of our product candidates as compared to others;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our maintenance and establishment of intellectual property rights in our product candidates;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our need for financing and our estimates regarding our capital requirements and future revenues and profitability;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our estimates of the size of the potential markets for our product candidates; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our selection and licensing of product candidates.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">These statements are based on assumptions and analyses made by us in light
of our experience and our perception of historical trends, current conditions and expected future developments based on the focus of our
business activities on biotechnology, as well as other factors we believe are appropriate in particular circumstances. However, whether
actual results and developments will meet our expectations and predictions depends on a number of risks and uncertainties, which could
cause actual results to differ materially from our expectations, including the risks set forth in &ldquo;Item 3 - Key Information - Risk
Factors&rdquo; in the Company&rsquo;s Annual Report on Form 20-F for the year ended March 31, 2022.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Our business focus is that of being primarily a pharmaceutical development
business subject to all of the risks of a pharmaceutical development business. We do not anticipate directly engaging in the post pharmaceutical
development endeavors of manufacturing, marketing and distribution of the products we develop.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Consequently, all of the forward-looking statements made in this Management&rsquo;s
Discussion and Analysis are qualified by these cautionary statements. We cannot assure you that the actual results or developments anticipated
by us will be realized or, even if substantially realized, that they will have the expected effect on us or our business or operations.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Unless the context indicates otherwise the terms &ldquo;Portage Biotech
Inc.,&rdquo; &ldquo;the Company,&rdquo; &ldquo;our Company,&rdquo; &ldquo;Portage,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; or &ldquo;our&rdquo;
are used interchangeably in this Management&rsquo;s Discussion and Analysis and mean Portage Biotech Inc. and its subsidiaries. Capitalized
terms used but not defined herein have the meaning ascribed to such terms in the Company&rsquo;s unaudited condensed consolidated interim
financial statements for the three and nine months ended December 31, 2022.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Nature of Operations and Overview</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Portage is a clinical stage immune-oncology company advancing
treatments it believes will be first-in-class therapies that target known checkpoint resistance pathways to improve long-term
treatment response and quality of life in patients with evasive cancers. Our access to next-generation technologies coupled with a
deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies that
accelerate these medicines through the translational pipeline. We currently are working on 14 immuno-oncology assets, of which ten
are at various development stages, four of which are clinical stage. We source, nurture and develop the creation of early- to
mid-stage treatments that we believe will be first-in-class therapies for a variety of cancers, by funding, implementing viable, cost
effective product development strategies, clinical counsel/trial design, shared services, financial and project management to enable
efficient, turnkey execution of commercially informed development plans. Our drug development pipeline portfolio encompasses
products or technologies based on biology addressing known resistance pathways/mechanisms of current checkpoint inhibitors with
established scientific rationales, including intratumoral delivery, nanoparticles, liposomes, aptamers, and virus-like
particles.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><B>The Portage Approach</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">Our mission is to advance and grow a portfolio
of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding
the addressable patient population. Given these foundations, we manage capital allocation and risk as much as we oversee drug development.
By focusing our efforts on translational medicine and pipeline diversification, we seek to mitigate overall exposure to many of the inherent
risks of drug development.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">Our approach is guided by the following core
elements:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Portfolio diversification to mitigate risk and maximize optionality;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Capital allocation based on risk-adjusted potential, including staged funding to pre-specified scientific and clinical results;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Virtual infrastructure and key external relationships to maintain a lean operating base;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Internal development capabilities complemented by external business development;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Rigorous asset selection for broad targets with disciplined ongoing evaluation;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Focus on translational medicine and therapeutic candidates with single agent activity;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Conduct randomized trials early and test non-overlapping mechanisms of action; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Improve potential outcomes for patients with evasive cancers.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><FONT STYLE="background-color: white">Our execution is achieved, in part,
through our internal core team and our large network of experts, contract labs, and academic partners.</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><FONT STYLE="background-color: white">The Company believes that it is
not subject to the regulation of the Investment Company Act of 1940, as amended (&ldquo;40 Act&rdquo;), based on the definition of investment
companies. Notwithstanding the foregoing, as the Company primarily operates within the biomedical industry as a research and development
(&ldquo;R&amp;D&rdquo;) business, the Company believes that it is also able to take advantage of the non-exclusive safe harbor of Rule
3a-8 promulgated under the 40 Act so as not to be characterized as an investment company. The Company has adopted a capital preservation
policy referenced in that rule.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B>Our Science Strategy</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">Our goal is to develop immuno-oncology therapeutics
that will dramatically improve the standard-of-care for patients with cancer. The key elements of our scientific strategy are to:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Build a pipeline of differentiated oncology therapeutic candidates that are diversified by mechanism, broad targets, therapeutic approach,
modality, stage of development, leading to a variety of deal types that can be executed with partners;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Expand our pipeline through research collaborations, business development, and internally designed programs;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Continue to advance and evolve our pipeline with a goal of advancing one therapeutic candidate into the clinic and one program into
Investigational New Drug (&ldquo;IND&rdquo;)-enabling studies each year; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Evaluate strategic opportunities to accelerate development timelines and maximize the value of our portfolio.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"><B>Our Pipeline</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">We have built a pipeline of immuno-oncology therapeutic
candidates and programs that are diversified by mechanism, therapeutic approach, modality, and stage of development. On an ongoing basis,
we rigorously assess each of our programs using internally defined success criteria to justify continued investment and determine proper
capital allocation. When certain programs do not meet our de-risking criteria for advancement, we look to monetize or terminate those
programs and preserve our capital and resources to invest in programs with greater potential. As a result, our pipeline will continue
to be dynamic.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">The charts below set forth, as of February 1,
2023, the current state of our immuno-oncology therapeutic candidates and programs.&nbsp; The chart contains forward-looking information
and projections based on management&rsquo;s current estimates. The chart information is based on and subject to many assumptions, as determined
by management and not verified by any independent third party, which may change or may not occur as modeled. We undertake no obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.&nbsp; Before you
make an investment decision regarding the Company, you should make your own analysis of forward-looking statements and our projections
about candidate and program development and results.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; background-color: white"><IMG SRC="pipe.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; background-color: white"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: Red"><IMG SRC="devprog.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"><B>Our Business Model</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">Portage is a development organization that is
structured to facilitate flexibility in financing and ease of partnering, licensing, and merger/acquisition of individual assets and or
technology platforms.&nbsp; The intellectual property (&ldquo;IP&rdquo;) for each platform is held in separate private entities.&nbsp;
Our employees and consultants work across the pipeline and we believe that this can (i) enhance operational efficiency, (ii) maintain
an optimal cost structure, (iii) attract leading collaborators, and (iv) promote asset flexibility, as further described below.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Enhance operational efficiency</I>: We allocate resources while empowering managers to make program-level decisions in order to
increase productivity and speed. We believe this model enables a flexible organizational structure that can achieve scale through the
addition of programs without increasing burdensome bureaucracy or redundant infrastructure.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Maintain an optimal cost structure</I>: We have a relatively small number of employees and have partnered with a number of
                                                                                                              contract research organizations to leverage their infrastructure and expertise as needed instead of embarking on capital-intensive
                                                                                                              lab, manufacturing, and equipment expenditures. By reducing overhead costs, we believe we can increase the likelihood that we can
                                                                                                              generate a return on invested capital.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Attract leading collaborators and licensors</I>: Our pipeline is comprised of therapies we believe will be first-in-class
                                                                                                              therapies for a variety of cancers sourced via our extensive industry contacts and relationships (e.g., academia and pharmaceutical
                                                                                                              industry executives). On preclinical programs/technology, we initially established development structures enabling us to keep
                                                                                                              licensors economically incentivized at the program level. We believe that the experienced drug development leadership team and
                                                                                                              approach to resource allocation differentiate us from other potential licensees.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Leverage unique commoditized checkpoint marketplace and explore the potential to further enhance long-term clinical benefit
                                                                                                              for patients with cancer and also expand the eligible population to include those who do not currently receive anti-PD-1
                                                                                                              therapy</I>: Presently there are multiple approved checkpoint therapeutics that lack differentiation, resulting in a competitive
                                                                                                              market dynamic, which will favor combination therapy. There is substantial opportunity for potential expansion in the PD-1 market
                                                                                                              with our invariant natural killer T-cell (&ldquo;iNKT&rdquo;) agonists and adenosine inhibitors. Studies show that 70-80% of
                                                                                                              patients do not respond or have a limited response to existing monotherapies, such as PD-1 checkpoint inhibitors. We see potential
                                                                                                              for our unique approach of using iNKT agonists to initiate an immune response in tumors that have become refractory to checkpoint
                                                                                                              therapy or to increase the number of front-line patients achieving more durable responses. Combinations can improve this but often
                                                                                                              come at the cost of significant additional toxicity. The market is saturated with 14 approved PD-1 antibodies, and every major
                                                                                                              pharmaceutical company competes in this space. One illustrative example of potentially expanding eligible patients is with iNKT
                                                                                                              agonists upregulating expression of PD-L1. Patient populations that are typically not good candidates for PD-1 antibodies due to
                                                                                                              their lack or low expression of PD-L1 may be able to utilize iNKTs to sensitize tumors to PD-1 agents. Extending the use of PD-1
                                                                                                              antibodies represents a significant potential upside for one of these companies competing for market share, should they choose to
                                                                                                              partner with Portage.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Promote asset flexibility</I>: Our structure is designed to maximize flexibility and cost efficiency. This allows us to efficiently
pursue various subsidiary-level transactions, such as stock or asset sales, licensing transactions, strategic partnerships and/or co-development
arrangements. It also provides us with the flexibility to terminate programs with minimal costs if results do not meet our de-risking
criteria for advancement.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company is a BVI business company incorporated under the BVI Act with
its registered office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development
Services Inc., is located at 61 Wilton Road, Westport, CT 06880.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company currently is a foreign private issuer under the United States
Securities and Exchange Commission (&ldquo;SEC&rdquo;) rules. It is also a reporting issuer under the securities legislation of the provinces
of Ontario and British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (&ldquo;CSE&rdquo;) under the symbol
&ldquo;PBT.U&rdquo;. On February 25, 2021, the ordinary shares of the Company began trading on the NASDAQ Capital Market (&ldquo;NASDAQ&rdquo;)
under the symbol &ldquo;PRTG&rdquo;. As the principal market for the Company&rsquo;s ordinary shares is NASDAQ, the Company voluntarily
delisted from the CSE on April 23, 2021.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">Summary of Results</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following table summarizes financial information for the quarter ended
December 31, 2022, and the preceding eight quarters (all amounts in 000&rsquo;US$ except net loss per share, which are actual amounts).
All share and per share amounts reflect the 1:100 reverse stock split effected June 5, 2020.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Dec. 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Sept. 30</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">June 30,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Mar. 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Dec. 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Sept. 30,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">June 30,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Mar. 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right">Dec. 31,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Quarter ended</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2021</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2021</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2021</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2021</TD><TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">2020</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net (loss) attributable to owners of the Company</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt; font-weight: bold; text-align: right">(7,485</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt; font-weight: bold; text-align: right">(949</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt; font-weight: bold; text-align: right">(1,729</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt; font-weight: bold; text-align: right">(7,317</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt; font-weight: bold; text-align: right">(3,512</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt; font-weight: bold; text-align: right">(2,975</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt; font-weight: bold; text-align: right">(3,066</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt; font-weight: bold; text-align: right">(11,498</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; font-size: 10pt; font-weight: bold; text-align: right">(1,184</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Working capital (1) to (8)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">13,110</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">15,737</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">21,138</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">24,049</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">25,639</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">27,301</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">28,106</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">1,738</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">2,875</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Equity attributable to owners of the Company</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">168,945</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">178,434</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">120,682</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">121,205</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">125,789</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">127,140</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">127,711</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">101,449</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">104,945</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Net (loss) per share - Basic</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.44</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.06</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.13</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.55</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.26</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.22</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.25</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.95</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.10</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Net (loss) per share - Diluted</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.44</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.06</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.13</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.55</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.26</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.22</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.25</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.95</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(0.10</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>



<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">(1)</TD><TD>September 30, 2022 working capital is net of warrant liability of $8 settleable on a non-cash basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">(2)</TD><TD>June 30, 2022 working capital is net of warrant liability of $32 settleable on a non-cash basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">(3)</TD><TD>March 31, 2022 working capital is net of warrant liability of $33 settleable on a non-cash basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">(4)</TD><TD>December 31, 2021 working capital is net of warrant liability of $159 settleable on a non-cash basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">(5)</TD><TD>September 30, 2021 working capital is net of warrant liability of $535 settleable on a non-cash basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">(6)</TD><TD>June 30, 2021 working capital is net of warrant liability of $751 settleable on a non-cash basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">(7)</TD><TD>March 31, 2021 working capital is net of warrant liability of $1,120 settleable on a non-cash basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">(8)</TD><TD>December 31, 2020 working capital is net of warrant liability of $771 settleable on a non-cash basis.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Number of Ordinary Shares and Warrants</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following table summarizes the number of the Company&rsquo;s ordinary
shares issued and outstanding and warrants at December 31, 2022 and March 1, 2023:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">As of,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">December 31, 2022</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">March 1, 2023</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left">Shares issued and outstanding (a) (b)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">17,065,379</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">17,403,594</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">(a)</TD><TD>This amount excludes an aggregate 243,000 restricted stock units granted to the executive chairman and an employee on January 13,
2021, which vested immediately on the date of grant and are subject to certain restrictions and 135,740 restricted stock units granted
to <FONT STYLE="background-color: white">employees (one of whom is also a director) on January 19, 2022</FONT>, which vested immediately
on the date of grant and are subject to certain restrictions.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">(b)</TD><TD>The December 31, 2022 amount excluded 4,936 shares earned for services rendered from October 1, 2022 to December 31, 2022,
                                                                accrued at December 31, 2022 for financial statement purposes and issued in January 2023. The March 1, 2023 amount excludes 4,127
                                                                shares earned for services rendered in January and February 2023, accrued at February 28, 2023 but not yet issued.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>Business Environment &ndash; Risk Factors</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Please refer to the Annual Report on Form 20-F for the year ended March
31, 2022 for detailed information as the economic and industry factors that are substantially unchanged as of the date hereof.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Our Programs and Technology &ndash; Recent Developments</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Invariant Natural Killer T-cells (iNKT cells) Platform</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">iNKT cells play an important role in anti-tumor immune responses and are
a distinct class of T lymphocyte displaying a limited diversity of T-cell receptors. They recognize lipid antigens on the surface of tumor
cells and produce large amounts of cytokines within hours of stimulation without the need for clonal expansion. Furthermore, iNKT cells
activate multiple immune system components, including dendritic cells, T-cells and B-cells and stimulate an antigen-specific expansion
of these cells. An operating subsidiary holds an exclusive license (with the right to sub-license) from the Ludwig Institute to use, research,
develop and commercialize iNKT cell agonists, for the treatment of various forms of human disease, including cancer, under the Ludwig
Institute&rsquo;s intellectual property and know-how.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>PORT-2 (IMM60)</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">PORT-2 is an iNKT cell activator/agonist formulated in a liposome with
a six-member carbon head structure that has been shown to activate both human and murine iNKT cells, resulting in dendritic cell (&ldquo;DC&rdquo;)
maturation and the priming of Ag-specific T and B cells.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In animal models, PORT-2 enhanced the frequency of tumor specific immune
responses. iNKT cells are unique lymphocytes defined by their co-expression of surface markers associated with NK cells along with a T-cell
antigen receptor. They recognize amphipathic ligands such as glycolipids or phospholipids presented in the context of the non-polymorphic,
MHC class I-like molecule CD1d. Activated iNKT cells rapidly produce IFN-gamma and IL-4 and induce DC maturation and IL-12 production.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In August 2021, we dosed the first patient in the IMP-MEL PORT-2 clinical
trial, a Phase 1/2 dose escalation and randomized expansion trial. The PORT-2 trial is expected to enroll up to 88 patients with melanoma
or non-small cell lung carcinoma (&ldquo;NSCLC&rdquo;) in order to evaluate safety and efficacy.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Preliminary Phase 1 data, presented at the Society for the Immunotherapy
of Cancer (&ldquo;SITC&rdquo;) Annual Meeting in November 2022, suggests PORT-2 was well tolerated when administered as a monotherapy,
with no related severe or serious adverse events. All possibly related adverse events were mild to moderate and did not limit dosing.
This has enabled a plan to accelerate opening of the combination safety cohort with pembrolizumab, in parallel with the ongoing high dose
monotherapy cohort. Biomarker data presented at the SITC meeting in 2022 confirmed the mechanism of action (i.e., both activation of the
innate and adaptive arms of the immune system). One of the two patients treated at the 3mg/m<SUP>2</SUP> dose had a mixed response with
several tumors showing &gt;50% reduction in diameter indicating single agent activity. We are encouraged by the growing patient data set
that supports proof of concept for using an iNKT agonist in cancer treatment. PORT-2 has a favorable safety and tolerability profile as
a monotherapy at all doses tested to date, has demonstrated evidence of single agent activity, and biomarkers confirm mechanistic potential
of PORT-2 to activate both the adaptive and innate immune systems.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">With the enhanced management team, efficient
organization, and financial resources obtained in 2021, Portage has decided to expand the PORT-2 trial beyond the U.K. to accelerate clinical
trials while addressing COVID-19 headwinds. The Company has hired a global clinical research organization, CRO-Parexel, and has submitted
regulatory applications in other countries. By expanding the regions and sites contributing to the trial, Portage expects to accelerate
enrollment in the planned Phase 2 portions of this trial. The Company entered into a clinical collaboration with Merck to supply pembrolizumab
for this trial. Should there be delays in recruiting patients, it could
result in increasing overall costs of program administration and ultimately, slow down the completion of the study and achievement
of results.</P>
<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In December 2022, the PORT-2 IND was accepted by the FDA and we
anticipate the Phase 2 portion of the study to commence in the 2<SUP>nd</SUP> quarter of 2023. The Phase 2 portion of the study is
an explanatory study.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B><I>PORT-3 (IMM65)</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">PORT-3 is a PLGA-nanoparticle formulation of IMM60 combined with a NY-ESO-1
peptide vaccine. Biodegradable PLGA-nanoparticles function as a delivery platform for immunomodulators and tumor antigens to induce a
specific anti-tumor immune response. PLGA has minimal (systemic) toxicity and is used in various drug-carrying platforms as an encapsulating
agent. Furthermore, co-formulating an iNKT inhibitor with a peptide vaccine in a particle has shown to be approximately five times more
potent in killing cancer cells and generating an antigen-specific CD8 T-cell response than giving the two agents individually.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">NY-ESO-1 is a cancer-testis antigen expressed during embryogenesis and
in the testis, an immune privileged site. Furthermore, NY-ESO-1 expression is observed in several advanced cancers: Lung (2-32%), melanoma
(40%), bladder (32-35%), prostate (38%), ovarian (30%), esophageal (24-33%), and gastric cancers (8-12%). Clinical trials have shown the
safety and tolerability of Good Manufacturing Practices (&ldquo;GMP&rdquo;)-grade NY-ESO-1 peptides in patients with cancer.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">The first patient was dosed in 2021 and patients
continue to enroll in the PRECIOUS Phase 1 trial of PORT-3 in patients with solid tumors. The Phase 1 portion of the trial is expected
to enroll 15 patients. The trial was having difficulty identifying tumors that expressed NY-ESO-1, so it was amended to include all solid
tumors regardless of expression to facilitate assessment of safety. This platform is designed to demonstrate proof of concept. The combination
product has the ability to prime and boost an anti-tumor immune response. Our patent position extends to other known tumor antigens, and
we are prepared to rapidly launch other assets into the clinic if we see strong activity of this formulation. Notably, Portage received
additional grant support from the Horizon 2020 program to explore next generation targeted nanoparticles. Preliminary safety data for
repeat dosing of PORT-3, a nanoparticle co-formulation of PORT-2 and NY-ESO-1 immunogenic peptides developed for the treatment of NY-ESO-1
positive solid tumors shows a favorable safety profile. We are evaluating opportunities and awaiting more data.</P>


<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Adenosine Receptor Antagonist Platform</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">A critical mechanism of cancer immune evasion is the generation of high
levels of immunosuppressive adenosine within the tumor microenvironment (&ldquo;TME&rdquo;). Research suggests that the TME has significantly
elevated concentrations of extracellular adenosine. Engagement with adenosine receptors A2A and A2B triggers a dampening
effect on the immune response, suppressing effector cell function and stabilizing immunosuppressive regulatory cells. Over-expression
of the A2A and A2B receptors leads to poor prognosis in multiple cancers, including prostate cancer, colorectal cancer and lung adenocarcinoma,
driven by a reduced ability to generate an immune response against the tumor.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">These findings have made A2A and A2B high-priority targets for immunotherapeutic
intervention. Portage is advancing the following four first-in-class adenosine inhibitors, which together represent a broad suite of adenosine-targeting
approaches and will enable a comprehensive exploration of how targeting the adenosine pathway could potentially improve response in multiple
cancer and non-cancer indications:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>PORT-6 (TT-10)</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Adenosine receptor type 2A (&ldquo;A2A&rdquo;) inhibitor to treat A2A
expressing solid tumors. We believe PORT-6 is more potent, more durable and more selective than other clinical stage A2A agents.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Institutional Review Board has approved PORT-6, which should enable
the Phase 1 study to commence by the end of Fiscal 2023 (March 2023).</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>PORT-7 (TT-4)</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Adenosine receptor type 2B (&ldquo;A2B&rdquo;) inhibitor to treat solid
tumors; PORT-7 has a very selective profile that focuses on A2B. We expect to commence the study in late calendar 2023 or early calendar
2024.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>PORT-8 (TT-53)</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to treat solid
tumors; Portage has the ability to combine these two to titrate the levels of A2A and A2B or has the ability to give the dual inhibitor
(PORT-08). The PORT-8 program is a pre-clinical stage program.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B><I>PORT-9 (TT-3)</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">An A2B inhibitor to treat colorectal and gastrointestinal cancers.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In preparation for entering clinical trials for the adenosine programs,
Portage will conduct an examination of which solid tumor types have a high expression of receptors A2A and A2B and enrich for patients
that have high expression and therefore have potential to benefit most from treatment. Portage has designed the ADPORT-601 trial to evaluate
the activity and safety of PORT-6 and PORT-7 alone and in combination. This trial will adapt over time and also include safety cohorts
for these two agents with other immune activating agents including others from the Portage internal pipeline. Depending on the data, it
can be expanded to evaluate either agent as monotherapy or a randomized comparison of either agent plus standard of care versus standard
of care alone. The PORT-9 program is currently in the pre-clinical stage.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: -4.5pt; margin: 0pt 0 0pt 4.5pt"><B><I>Other Programs in Development</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Amphiphilic platform</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">DfuseRx SM, identifies combinations of anti cancer agents with amphiphilic
diffuse enhancers that can passively enter into cancer cells.&nbsp; These novel formulations with unique IP can be directly injected into
any solid tumors, and the payloads will diffuse across the membrane and disperse throughout the tumor, while sparing healthy cells. Once
inside the cells, the technology is diluted away and the payloads are stuck inside the cells. The payloads are able to disperse to areas
of the tumor that do not have blood supply and hence oral or IV drugs will not reach.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>PORT-1 (INT230-6)</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Intensity Therapeutics, Inc., our affiliate (&ldquo;Intensity&rdquo;), is developing INT230-6
(which we refer to as PORT-1) as a fixed dose formulation of cisplatin, vinblastine and a penetration enhancer.&nbsp; In animal models,
the drug has shown efficacy in the majority of the animals, by a combination of direct killing of the cancer, and also a CD4 and CD8 T-cell
response.&nbsp; Newly released interim safety and survival data from the Phase 1/2 IT-01 trial presented at ASCO 2021 demonstrated that
both INT230-6 (PORT-1) monotherapy and combination therapy with immune checkpoint drugs are well-tolerated. The proven mechanism of action
includes direct tumor-killing effects, as well as responses generated in non-injected tumors (abscopal responses) resulting from antigen
presentation and immune activation. PORT-1 is the first of Portage&rsquo;s assets that entered the clinic and has demonstrated proof-of-concept
in humans. The specific rapid local killing in the normal three-dimensional environment inside the body Portage believes is critical for
robust antigen presentation and immune activation.&nbsp; Animal studies also showed synergy when combined with checkpoint inhibition.
The product candidate has been dosed into 80 subjects in a Phase 1 and Phase 2 trial. This has shown proof of concept that the vast majority
of the drug stays in the tumor, and a dose equivalent to three times the approved dose of the cytotoxic agent was very well tolerated
without the typical chemo side effects.&nbsp; The most common adverse event related to the treatment was pain at the injection site.&nbsp;
As a result, PORT-1 is being studied in nine Phase 2 trials including seven clinical collaborations with the two largest immuno-oncology
drug manufacturers, BMS and Merck, in combination with their respective checkpoints in high unmet need medical types (pancreatic, gall
bladder, sarcoma, non-microsatellite unstable colorectal, etc.).&nbsp; Intensity has also launched a randomized Phase 2 trial of INT230-6
vs. no treatment in early stage breast cancer (the &ldquo;INVINCIBLE Trial&rdquo;) and has expanded its collaboration efforts with the
INVINCIBLE Trial, conducted by the Ottawa Hospital and the Ontario Institute for Cancer Research. Intensity made three presentations on
INT230-6 at the ASCO Annual Meeting in June 2022, with clinical data suggesting INT230-6 has potential to prolong survival when compared
to historical results.&nbsp; An innovative window of opportunity trial in pre-surgical early stage breast cancer confirmed that one treatment
with PORT-1, can result in near complete necrosis of breast tumors with an influx of key immune cells to process the dying tumor. In December
2022, Intensity presented <FONT STYLE="background-color: white">INT230-6, which demonstrated the ability to cause up to 100% necrosis
of presurgical breast cancer tumors in the window period from diagnosis to surgery and a Pathway enrichment analysis that demonstrated
changes in T-cell activation, lymphocyte activation and inflammatory response</FONT> from the INVINCIBLE Trial in a live Spotlight Session
Poster Presentation at the San Antonio Breast Cancer Symposium, highlighting a new approach for the treatment of pre-surgical cancer patients.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December 31, 2022, the Company owned approximately 7.00% of Intensity&rsquo;s
outstanding shares on a fully diluted basis.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B><I>PORT-4, Nanolipogel (&ldquo;NLG&rdquo;) co-formulation Platform</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Scientists are interested in novel ways to deliver multiple signals to
the immune system in order to better activate an anti-tumor response.&nbsp; We have been impressed with a platform from Yale University
that allows different types of agents to be packaged together and will concentrate them in tumors.&nbsp; We have licensed the platform
for delivery of DNA aptamers and certain aptamer-small molecule-based combination products. In order to have multiple proprietary agents
with known mechanisms of action, we have licensed rights to create DNA aptamers for immune-oncology targets and the first one developed
is a proprietary PD1 aptamer, which has been placed in the NLG formulation.&nbsp; Early testing has shown the formulation properly modulates
PD1 signaling in vitro similar to a PD1 antibody I.&nbsp; In non-clinical, in vivo experiments, the NLG-PD1 performed favorably compared
to a mouse PD1 antibody.&nbsp; The current level of funding is expected to support exploration of multiple PD1 based co-formulations with
small molecules and other DNA aptamers. The Company has conducted further research with the technology licensed from Yale University to
co-deliver a PD1 blocking signal with a small molecule vascular endothelial growth factor inhibitor. We are looking to accelerate preclinical
development of our PORT-4 platform, which may potentially increase the potency and improve the safety of numerous anti-cancer drugs through
co-delivery of combination treatments to the tumor.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December 31, 2022, the Company owned approximately 70% of the outstanding
shares of Saugatuck Therapeutics, Ltd., the subsidiary on which the PORT-4 Platform is managed.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>PORT-5, STING Agonist Platform</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Proprietary immune priming and boosting technology (using a STING agonist
delivered in a virus-like particle) have shown proof of concept in animal models and Stimunity S.A. (&ldquo;Stimunity&rdquo;) is beginning
to progress the lead asset towards the clinic.&nbsp; This platform offers multiple ways to target immune stimulation towards the cancer,
as well as to co-deliver multiple signals in a single product.&nbsp; Our researchers have developed a way to administer the product systemically
and does not require direct tumor injections.&nbsp; The PORT-5 STING platform provides distinct advantages over chemical intratumoral
approaches by offering a potent immune priming and boosting pathway within a virus-like particle (&ldquo;VLP&rdquo;) to enable convenient
systemic administration and traffic to the correct targets. This technology preferentially targets dendritic cells, which is differentiated
from other chemical STING approaches.&nbsp; Stimunity is progressing this project towards clinical trials as well as developing next generation
compounds.&nbsp; Given that this is a simple way to boost the immune response to any target, we are also pursuing a project to boost immune
response to COVID and other pathogens. To that end, the team has received grant funding to study this technology with any COVID-19 vaccine
to evaluate if it is possible to boost the immune response for immunocompromised or elderly patients. During April 2022, the American
Association for Cancer Research showcased PORT-5 preclinical data at a late-breaking session that shows that one or more targeted immunotherapy
agents could be packaged within a virus-like particle to increase potency, while enabling a selective immune activation. Given the progress
to date, Stimunity is preparing the product to be able to file an IND.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December 31, 2022, the Company owned approximately 44% of the outstanding
shares of Stimunity, the subsidiary on which the PORT-5 platform is managed.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B><I>Early-Stage R&amp;D Collaborations</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">We continue to evaluate and test new antibody targets.&nbsp; Our interest
here lies in the suppressive tumor micro-environment, and how we can down regulate or remove MDSC, TAMs, Tregs and other signals that
impede the immune response from clearing cancer cells.&nbsp; One new effort that we have initiated is collaborations with two leading
artificial intelligence/machine learning companies in order to screen for agents with specific attributes in this area.&nbsp; This may
allow us a fast track an asset to the clinic with a re-purposed product.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Portage is collaborating with Dr. Robert Negrin and his team at Stanford University in an IST study to evaluate the use of PORT-2
with iNKT cell therapies in animals. This work will evaluate if an agonist co-administered with expanded or transformed iNKT cells can
further activate the transplanted and endogenous cells inside the patient. The Stanford collaboration will also study the impact iNKT
agonists have on driving an adaptive immune response and correcting the suppressive tumor microenvironment.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Portage entered into a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) with the U.S. National Cancer Institute
(&ldquo;NCI&rdquo;). Portage and NCI will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents
for cancer vaccines. Portage and NCI will develop agents to enhance the efficacy of proprietary cancer vaccines and mouse model cancer
vaccines developed by NCI. After the Tarus acquisition, Portage amended the CRADA to include exploration of the different adenosine compounds.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Three Months Ended December 31, 2022 Compared to the Three Months Ended
December 31, 2021</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>(All Amounts in 000&rsquo;$)</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Results of Operations</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following details major expenses for the three months ended December
31, 2022, compared to the three months ended December 31, 2021:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Three months ended December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Operating expenses</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(4,759</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(4,169</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(498</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Share of loss in associate accounted for using equity method</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(152</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(261</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">8</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">342</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Foreign exchange transaction gain</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">50</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Depreciation expense</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(1</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest income (expense), net</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">50</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Loss before provision for income taxes</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(5,302</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,089</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax expense</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(2,199</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(117</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net loss</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(7,501</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,206</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Other comprehensive income (loss)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net unrealized loss on investments</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(4,017</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(11,518</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,206</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive loss attributable to:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Owners of the Company</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(11,502</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(3,512</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Non-controlling interest</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(16</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(694</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(11,518</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,206</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><I>Results of Operations for the Three Months Ended December 31, 2022, Compared
to the Three Months Ended December 31, 2021</I></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company generated a net loss of approximately $7.5 million and other
comprehensive loss of approximately $11.5 million during the three months ended December 31, 2022 (the &ldquo;Fiscal 2023 Quarter&rdquo;),
compared to a net loss and other comprehensive loss of approximately $4.2 million during the three months ended December 31, 2021 (the
&ldquo;Fiscal 2022 Quarter&rdquo;), an increase in net loss of $3.3 million and an increase in other comprehensive loss of $7.3 million,
year-over-year.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The components of the change in net loss and other comprehensive loss
are as follows:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Operating expenses, which include R&amp;D and general and administrative (&ldquo;G&amp;A&rdquo;) expenses, were $4.8 million in the
Fiscal 2023 Quarter, compared to $4.2 million in the Fiscal 2022 Quarter, an increase of $0.6 million, which is discussed more fully below.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The Company&rsquo;s other items of income and expense were substantially non-cash in nature and aggregated approximately $0.54 million
net loss in the Fiscal 2023 Quarter, compared to approximately $0.08 million net income in the Fiscal 2022 Quarter, a change in other
items of income and expense of approximately $0.62 million, quarter-over-quarter. The primary reason for the quarter-over-quarter difference
in other items of income and expense was the difference in the fair value of warrants outstanding recognized in the quarter-over-quarter
period, which expired in October 2022, and a loss from the change (increase) in fair value of the deferred purchase price payable - Tarus
and deferred obligation - iOx milestone, partially offset by the change in the Company&rsquo;s share of an associate accounted for under
the equity method.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Additionally, the Company reflected a net deferred income tax expense of $2.2 million in the Fiscal 2023 Quarter, compared to a net
deferred income tax expense of $0.1 million in the Fiscal 2022 Quarter. The Fiscal 2023 Quarter includes the foreign currency effect on
deferred tax liability balance settleable in British pound sterling of $2.5 million partially offset by the recognition of current period
losses in the U.K. of $0.2 million and the related tax rate change effect of $0.1 million. The Fiscal 2022 Quarter reflected the foreign
currency effect on deferred tax liability balance settleable in British pound sterling at December 31, 2021, and the recoverable R&amp;D
tax credits generated in the U.K.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 23.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>In the Fiscal 2023 Quarter, the Company performed a fair value analysis on its investment in Intensity, and determined a fair
                                                                                                              value of $3.363 million, which was $4.046 million less than the then carrying value. Accordingly, the Company recognized an
                                                                                                              unrealized loss in value in Intensity of $4.046 million through other comprehensive income (&ldquo;OCI&rdquo;) in the Fiscal 2023
                                                                                                              Quarter, which was partially offset by an unrealized gain on the change in fair value of the Stimunity Convertible Note (as defined
                                                                                                              below) of $0.29 million.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Operating Expenses</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The overall analysis of the operating expenses is as follows:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Three months ended December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 70%; font-size: 10pt; text-align: left">Research and development</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,535</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,928</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,224</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,241</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total operating expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">4,759</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,169</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">R&amp;D costs are comprised of the following:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Three months ended December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 70%; font-size: 10pt; text-align: left">Share-based compensation expense</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">627</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,037</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Payroll-related expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">242</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">830</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Research and development &ndash; Clinical</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">1,392</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Research and development services and storage</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">39</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">39</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Consulting fees</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">93</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Research and development &ndash; CRADA</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">31</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Other outside services &ndash; lab testing, peptide handling, etc.</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">84</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Legal regarding Patents&rsquo; registration</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">27</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total research and development costs</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,535</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,928</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">R&amp;D costs increased by approximately $0.6 million, or approximately
32%, from approximately $1.9 million in the Fiscal 2022 Quarter, to approximately $2.5 million in the Fiscal 2023 Quarter. The increase
was primarily attributable to clinical trial costs of $0.6 million associated with the iNKT clinical trial and the start-up and manufacturing
costs associated with the adenosine assets (PORT-6 and PORT-7) acquired in the Tarus acquisition of $0.8 million. There were no such costs
incurred in the Fiscal 2022 Quarter. The Fiscal 2023 Quarter also included $0.1 million in other R&amp;D costs relating to outside services
and an increase in compensation of $0.1 million for consultants involved in R&amp;D activities. The Fiscal 2022 Quarter included $0.6
million for bonuses to employees and consultants, reflected in payroll-related expenses, which was approved and paid in the Fiscal 2022
Quarter. There was no such amount in the Fiscal 2023 Quarter. Additionally, the Fiscal 2022 Quarter included a higher amount of non-cash
share-based compensation expense of $0.4 million, which was primarily attributable to (a) the continued vesting over time of grants; and
(b) the decrease in the fair value of grants made after the Fiscal 2022 Quarter.<BR STYLE="clear: both">
</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 23.05pt"><FONT STYLE="font-weight: normal">Key components of G&amp;A expenses are
the following:</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Three months ended December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 70%; font-size: 10pt; text-align: left">Professional fees</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">683</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">493</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Share-based compensation expense</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">587</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,076</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">D&amp;O insurance</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">309</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">413</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Payroll-related expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">465</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">177</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Directors fees</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">78</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Office and general expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">90</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">57</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Consulting fees</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">12</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,224</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,241</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">G&amp;A expenses were substantially the same in the year-over-year periods,
as they decreased by approximately $0.02 million, or approximately 0.9%, from approximately $2.24 million in the Fiscal 2022 Quarter,
to approximately $2.22 million in the Fiscal 2023 Quarter. Professional fees increased by $0.2 million due to legal fees and audit related
fees associated with the updating of public filings and payroll-related expenses increased by $0.3 million due to the continued build-up
of the Company&rsquo;s infrastructure. The Fiscal 2023 Quarter also included director&rsquo;s fees of $0.1 million (director&rsquo;s fees
were approved and commenced January 2022). These increases were partially offset by a decrease in non-cash share-based compensation expense
of $0.5 million attributable to the vesting of certain options granted in prior years and lower fair value associated with more recent
grants and the decrease of $0.1 million associated with directors and officers (&ldquo;D&amp;O&rdquo;) insurance due to a decrease in
the D&amp;O premium market year-over-year.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Nine Months Ended December 31, 2022 Compared to the Nine Months Ended
December 31, 2021</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>(All Amounts in 000&rsquo;$)</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Results of Operations</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following details major expenses for the nine months ended December
31, 2022, compared to the nine months ended December 31, 2021:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Nine months ended December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Operating expenses</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(12,499</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(11,092</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(428</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Share of loss in associate accounted for using equity method</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(268</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(363</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">33</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">726</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Foreign exchange transaction loss</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(60</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Depreciation expense</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(1</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest income (expense), net</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">106</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(42</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Loss before provision for income taxes</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(13,117</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(10,771</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax benefit</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,906</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">465</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net loss</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(10,211</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(10,306</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Other comprehensive income (loss)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net unrealized loss on investments</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(4,017</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(14,228</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(10,306</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive loss attributable to:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Owners of the Company</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(14,180</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(9,553</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Non-controlling interest</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(48</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(753</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(14,228</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(10,306</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold"><I>Results of Operations for the Nine Months Ended December 31, 2022, Compared
to the Nine Months Ended December 31, 2021</I></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company generated a net loss of approximately $10.2 million and other
comprehensive loss of approximately $14.2 million during the nine months ended December 31, 2022 (the &ldquo;Fiscal 2023 Nine Months&rdquo;),
compared to a net loss and other comprehensive loss of approximately $10.3 million during the nine months ended December 31, 2021 (the
&ldquo;Fiscal 2022 Nine Months&rdquo;), a decrease in net loss of $0.1 million and an increase in other comprehensive loss of $3.9 million,
year-over-year.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The components of the change in net loss and other comprehensive loss
are as follows:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Operating expenses, which include R&amp;D and G&amp;A expenses, were $12.5 million in the Fiscal 2023 Nine Months, compared to $11.1
million in the Fiscal 2022 Nine Months, an increase of $1.4 million, which is discussed more fully below.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The Company&rsquo;s other items of income and expense were substantially non-cash in nature and aggregated approximately $0.6 million
net loss in the Fiscal 2023 Nine Months, compared to approximately $0.3 million net income in the Fiscal 2022 Nine Months, a change in
other items of income and expense of approximately $0.9 million, year-over-year. The primary reason for the year-over-year difference
in other items of income and expense was the reduction in the fair value of warrants recognized in the year-over-year period, which expired
in October 2022, and a loss from the change (increase) in fair value of the deferred purchase price payable - Tarus and deferred obligation
- iOx milestone, partially offset by a gain in interest income (expense), net.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Additionally, the Company reflected a net deferred income tax benefit of $2.9 million in the Fiscal 2023 Nine Months, compared to
a net deferred income tax benefit of $0.5 million in the Fiscal 2022 Nine Months. The Fiscal 2023 Nine Months includes the foreign currency
effect on deferred tax liability balance settleable in British pound sterling of $1.8 million and the recognition of current period losses
in the U.K. of $0.8 million, as well as the tax rate change effect of $0.3 million. The Fiscal 2022 Nine Months reflected recoverable
R&amp;D tax credits generated in the U.K., partially offset by the foreign currency effect on deferred tax liability balance settleable
in British pound sterling at December 31, 2021.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>In the Fiscal 2023 Quarter, the Company performed a fair value analysis on its investment in Intensity, and determined a fair value
of $3.363 million, which was $4.046 million less than the then-carrying value. Accordingly, the Company recognized an unrealized loss
in value in Intensity of $4.046 million through OCI in the Fiscal 2023 Nine Months, which was partially offset by an unrealized gain on
the change in fair value of the Stimunity Convertible Note (as defined below) of $0.29 million.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Operating Expenses</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The overall analysis of the operating expenses is as follows:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Nine months ended December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 70%; font-size: 10pt; text-align: left">Research and development</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">5,976</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">4,804</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">6,523</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,288</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total operating expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">12,499</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11,092</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">R&amp;D costs are comprised of the following:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Nine months ended December 31,</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>In 000&rsquo;$</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">In 000&rsquo;$</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; width: 68%"><FONT STYLE="font-size: 10pt">Share-based compensation expense</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt"><B>1,838</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">3,195</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Payroll-related expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>1,147</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,271</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Research and development &ndash; Clinical</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>2,184</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Research and development services and storage</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>282</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">145</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Consulting fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>217</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">72</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Research and development &ndash; CRADA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>131</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&ndash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Legal regarding Patents&rsquo; registration</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><B>67</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">115</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">Other outside services &ndash; lab testing, peptide handling, etc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt"><B>110</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Total research and development costs</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double"><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>5,976</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">4,804</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">R&amp;D costs increased by approximately $1.2 million, or approximately
25%, from approximately $4.8 million in the Fiscal 2022 Nine Months, to approximately $6.0 million in the Fiscal 2023 Nine Months. The
increase was primarily attributable to clinical trial costs of $1.3 million associated with the iNKT clinical trial and the start-up and
manufacturing costs associated with the adenosine assets (PORT-6 and PORT-7) acquired in the Tarus acquisition of $0.9 million. There
were no such costs incurred in the Fiscal 2022 Quarter. Additionally, the Company incurred costs of $0.1 million associated with the National
Cancer Institute trial (CRADA program) in the Fiscal 2023 Nine Months. These increases were partially offset by a reduction in non-cash
share-based compensation expense of $1.4 million with respect to options to purchase ordinary shares granted to employees, which was attributable
to (a) the vesting over time of a portion of prior year grants; and (b) the decrease in the fair value of grants made in fiscal 2022.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 23.05pt"><FONT STYLE="font-weight: normal">Key components of G&amp;A expenses are
the following:</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Nine months ended December 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">In 000&rsquo;$</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt">Professional fees</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,353</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,171</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Share-based compensation expense</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">1,776</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,244</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">D&amp;O insurance</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">928</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,239</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Payroll-related expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">971</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">402</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Directors fees</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">236</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Office and general expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">206</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">172</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Consulting fees</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">53</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">60</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">6,523</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,288</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">G&amp;A expenses increased by approximately $0.2 million, or approximately
3%, from approximately $6.3 million in the Fiscal 2022 Nine Months, to approximately $6.5 million in the Fiscal 2023 Nine Months. Professional
fees increased by $1.2 million, of which approximately $0.7 million was attributable to legal fees associated with the Tarus acquisition
and $0.2 million was attributable to stamp fees in the U.K. related to acquiring the outstanding minority interest of our iNKT agonist
platform. There was also an increase in audit related expenses in the Fiscal 2023 Nine Months associated with the updating of public filings,
as well as costs associated with the Tarus acquisition review. Additionally, payroll-related expenses increased by $0.6 million due to
the formalization of a compensation program adopted in the Fiscal 2023 Nine Months designed to attract and retain management; along the
same lines, the Company incurred $0.2 million director&rsquo;s fees in Fiscal 2023 Nine Months. There were no director&rsquo;s fees in
the prior year period. These increases were partially offset by a decrease in non-cash share-based compensation expense of $1.5 million
attributable to the vesting of certain options granted in prior years and lower fair value associated with more recent grants and the
decrease of $0.3 million associated with D&amp;O insurance, which was attributable to a decrease in the D&amp;O premium market year-over-year.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">Liquidity and Capital Resources</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Capital Resources</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Portage filed a shelf registration statement with the SEC under which
it may sell ordinary shares, debt securities, warrants and units in one or more offerings from time to time, which became effective on
March 8, 2021 (&ldquo;Registration Statement&rdquo;). In connection with the Registration Statement, Portage has filed with the SEC:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a base prospectus, which covers the offering, issuance and sale by Portage of up to $200,000,000 in the aggregate of the securities
identified above from time to time in one or more offerings;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a prospectus supplement covering the offer, issuance and sale by Portage in an &ldquo;at the market&rdquo; (&ldquo;ATM&rdquo;) offering
of up to a maximum aggregate offering price of $50,000,000 of Portage&rsquo;s ordinary shares that may be issued and sold from time to
time under a Controlled Equity Offering Sales Agreement, dated February 24, 2021 (the &ldquo;Sales Agreement&rdquo;), with Cantor Fitzgerald
&amp; Co., the sales agent (&ldquo;Cantor Fitzgerald&rdquo;);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by Portage of 1,150,000 ordinary shares for gross proceeds
of approximately $26.5 million in a firm commitment underwriting with Cantor Fitzgerald; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a prospectus supplement dated August 19, 2022, for the resale by Portage of up to $30,000,000 in ordinary shares that Portage may
sell from time to time to Lincoln Park Capital Fund, LLC (&ldquo;Lincoln&rdquo;) and an additional 94,508 shares that were issued to Lincoln.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Sales Agreement permits the Company to sell in an ATM offering up
to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered,
issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an ATM
offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Upon termination of the Sales Agreement,
any portion of the $50,000,000 included in the Sales Agreement prospectus that is not sold pursuant to the Sales Agreement will be available
for sale in other offerings pursuant to the base prospectus.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">During the quarter ended June 30, 2021, the Company commenced an ATM offering,
under which it sold 90,888 ordinary shares generating gross proceeds of approximately $2.6 million ($2.5 million, net of commissions).</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On June 24, 2021, the Company completed the sale of 1,150,000 ordinary
shares, including the underwriters&rsquo; option, at a price of $23.00 per share, which generated gross proceeds of approximately $26.5
million and net proceeds of approximately $25.0 million, and was settled June 28, 2021.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On July 6, 2022, the Company entered into a Purchase Agreement (the &ldquo;Committed
Purchase Agreement&rdquo;) with Lincoln, under which it may require Lincoln to purchase ordinary shares of the Company having an aggregate
value of up to $30 million (the &ldquo;Purchase Shares&rdquo;) over a period of 36 months. Pursuant to the Committed Purchase Agreement,
Lincoln will be obligated to purchase the Purchase Shares in three different scenarios that are based on various market criteria and share
amounts. The Company has the right to terminate the Committed Purchase Agreement for any reason, effective upon one business day prior
written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The requirement that Lincoln must make
a purchase will be suspended based on various criteria such as there not being an effective registration statement for Lincoln to be able
to resell the ordinary shares it is committed to purchase and market criteria such as the Company continuing to be Depository Trust Company
eligible, among other things. The Committed Purchase Agreement does not impose any financial or business covenants on the Company, and
there are no limitations on the use of proceeds. The Company may raise capital from other sources in its sole discretion; provided, however,
that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year
anniversary of the date of the Committed Purchase Agreement, excluding, however, an ATM transaction with a registered broker-dealer.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Upon execution of the Committed Purchase Agreement, the Company issued
to Lincoln 94,508 ordinary shares, representing a 3% commitment fee.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><I>Liquidity</I></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The accompanying condensed consolidated interim financial statements for
the three and nine months ended December 31, 2022 have been prepared on a basis that assumes that the Company will continue as a going
concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments
in the normal course of business. Accordingly, the accompanying condensed consolidated interim financial statements for the three and
nine months ended December 31, 2022 do not include any adjustments relating to the recoverability and classification of recorded asset
amounts or amounts of liabilities that might result from the outcome of this uncertainty.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December 31, 2022, the Company had cash and cash equivalents of
approximately $13.1 million and total current liabilities of approximately $2.4 million. For the nine months ended December 31, 2022,
the Company is reporting a net loss of approximately $10.2 million, and cash used in operating activities of approximately $7.4 million.
As of January 31, 2023, the Company had approximately $13.2 million of cash and cash equivalents on hand. The Company believes its current
cash resources are sufficient to fund operations for at least 13 months from March 1, 2023, the date of this Management&rsquo;s Discussion
and Analysis.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">During the quarter ended June 30, 2021, the Company made an ATM offering,
under which it sold 90,888 ordinary shares generating gross proceeds of approximately $2.6 million ($2.5 million, net of commissions).
On June 24, 2021, the Company completed a firm commitment underwritten public offering of 1,150,000 ordinary shares at a public offering
price of $23.00 per share for gross proceeds of approximately $26.5 million and was settled June 28, 2021. The Company incurred aggregate
offering expenses for the public offering of approximately $1.8 million, including approximately $1.6 million of management, underwriting
and selling expenses.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In October 2022, the Company restarted the ATM and commenced sales of
ordinary shares pursuant to the Sales Agreement. Through December 31, 2022, the Company sold 88,072 ordinary shares under the ATM, generating
net proceeds of approximately $0.6 million and sold 30,000 ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds
totaling approximately $0.2 million.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company has incurred substantial operating losses since inception
and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result
primarily from its conduct of R&amp;D activities.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company historically has funded its operations principally from proceeds
from issuances of equity and debt securities and would expect to enter the capital markets when additional funding is required.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Cash Flows From Operating Activities</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">During the Fiscal 2023 Nine Months, the Company used cash of $7.4 million
to fund operating activities, compared to $4.5 million used during the Fiscal 2022 Nine Months. Operations in both the Fiscal 2023 Nine
Months and the Fiscal 2022 Nine Months were funded by existing cash from the ATM offering and the public offerings in 2022 and 2021.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&rsquo;s continuing operations are dependent upon any one of:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">1.</TD><TD>the development and identification of economically recoverable therapeutic solutions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">2.</TD><TD>the ability of the Company to obtain the necessary financing to complete the research; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt">3.</TD><TD>the future profitable production, or proceeds, from the disposition of intellectual property.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has incurred substantial operating losses since inception
due to significant R&amp;D spending and corporate overhead and expects to continue to incur significant operating losses for the foreseeable
future and may never become profitable. As of December 31, 2022, the Company had cash and cash equivalents of approximately $13.1 million,
working capital of approximately $13.1 million (including prepaid expenses of $1.8 million) and an accumulated deficit of approximately
$65.2 million.&nbsp; The Company has funded its operations from proceeds from the sale of equity and debt securities. The Company will
require significant additional capital to make the investments that it needs to execute its longer-term business plan. The Company&rsquo;s
ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and
uncertainties and, even if it were successful, future equity issuances would result in dilution to its existing stockholders and any future
debt securities may contain covenants that limit the Company&rsquo;s operations or ability to enter into certain transactions.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"><I>Cash Flows From Investing Activities</I></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">During the Fiscal 2023 Nine Months, the Company used cash of $0.6 million
to fund investing activities. During the Fiscal 2022 Nine Months, there were no investing cash flow activities.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 23.05pt"><FONT STYLE="font-weight: normal">On July 13, 2022, the Company entered
into a commitment with Stimunity to provide &euro;600,000 under a convertible note (the &ldquo;Stimunity Convertible Note&rdquo;) with
a maturity date of September 1, 2023. The Stimunity Convertible Note provides for interest at 7% per annum. The Stimunity Convertible
Note was funded by the Company on September 12, 2022 by existing cash and cash provided under the Committed Purchase Agreement described
above. See &ldquo;Key Contractual Obligations&rdquo; below for a further discussion.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: left; text-indent: 23.05pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Cash Flows From Financing Activities</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">During the Fiscal 2023 Nine Months, the Company used cash of $2.2 million
to fund financing activities. During the Fiscal 2022 Nine Months, the Company generated net cash of $27.3 million from financing activities.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">During the Fiscal 2023 Nine Months, as consideration for the Tarus acquisition,
the Company issued to Tarus shareholders an aggregate of 2,425,999 ordinary shares of Portage, calculated on the basis of $18 million
divided by the 60-day Volume Weighted Average Price per share. The shares have not been registered with the SEC and are subject to lock-up
agreements for terms ranging from six to twelve months. Additionally, milestone payments of up to $32 million in cash or Portage ordinary
shares would be triggered upon achievement of future development and sales milestones. As a result of the transaction:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The Company also assumed $2 million in short-term debt held by Tarus and deferred license milestones obligations ($1 million plus
interest). The short-term debt was repaid by the Company in July 2022 and the repayment of the milestone obligation was paid by the Company
in August 2022; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Upon enrolling the first patient in a Phase 2 clinical trial, the Company will pay an additional one-time milestone payment of $15
million. Payment will be in the form of cash or Portage ordinary shares (at the discretion of the Company). The remaining $17 million
milestone is based on targeted commercial sales.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">During the three months ended June 30, 2021, the Company commenced an
ATM offering, under which it sold 90,888 ordinary shares generating gross proceeds of approximately $2.6 million ($2.5 million, net of
commissions). On June 24, 2021, the Company completed a firm commitment underwritten public offering of 1,150,000 ordinary shares at a
public offering price of $23.00 per share for gross proceeds of approximately $26.5 million and was settled on June 28, 2021. The Company
incurred aggregate offering expenses for the public offering of approximately $1.8 million, including approximately $1.6 million of management,
underwriting and selling expenses.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">In October 2022, the Company restarted the ATM and commenced sales of
ordinary shares pursuant to the Sales Agreement. Through December 31, 2022, the Company sold 88,072 ordinary shares under the ATM, generating
net proceeds of approximately $0.6 million and sold 30,000 ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds
totaling approximately $0.2 million.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">Key Contractual Obligations</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Details of contractual obligations, commitments and contingent liabilities
are provided in Note 17, &ldquo;Commitments and Contingent Liabilities,&rdquo; to the unaudited condensed consolidated interim financial
statements for the three and nine months ended December 31, 2022.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On July 1, 2022, the Company, its wholly-owned subsidiary, Tarus Acquisition
Inc., and Tarus Therapeutics, Inc., a Delaware corporation advancing adenosine receptor agonists for the treatment of solid tumors, entered
into an Agreement and Plan of Merger and Reorganization (the &ldquo;Merger Agreement&rdquo;). Under the structure of the Merger Agreement,
Tarus Therapeutics, Inc. was ultimately merged into a wholly-owned subsidiary of the Company with the surviving entity renamed Tarus Therapeutics,
LLC (&ldquo;Tarus&rdquo;).</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As consideration for Tarus, the Company issued to Tarus shareholders an
aggregate of 2,425,999 ordinary shares of Portage, calculated on the basis of $18 million divided by the 60-day Volume Weighted Average
Price per share. The shares have not been registered with the SEC and are subject to lock-up agreements for terms ranging from six to
twelve months. Additionally, payments of up to $32 million in cash or Portage ordinary shares would be triggered upon achievement of future
development and sales milestones. As a result of the transaction:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The Company also assumed $2 million in short-term debt held by Tarus and deferred license milestones obligations ($1 million plus
interest), for an aggregate of $3 million in liabilities. The Company repaid the short-term debt in July 2022.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Upon enrolling the first patient in a Phase 2 clinical trial, the Company will pay an additional one-time
payment of $15 million. Payment will be in the form of cash or Portage ordinary shares (at the discretion of the Company). The remaining
$17 million milestone is based on target commercial sales.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On July 13, 2022, the Company entered into a commitment with Stimunity
to provide &euro;600,000 under the Stimunity Convertible Note with a maturity date of September 1, 2023 (the &ldquo;Maturity Date&rdquo;).
The Stimunity Convertible Note provides for interest at 7% per annum. The Stimunity Convertible Note is automatically converted into Series
A shares upon Stimunity completing a Series A round for at least &euro;20 million. If such subscription round is completed prior to the
Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into Series A shares at the subscription share price
less 15%. Additionally, if Stimunity completes a financing with a new category of shares (other than Common Shares or Series A shares)
for at least &euro;5 million (the &ldquo;Minimum Raise&rdquo;), the Company will have the right to convert the Stimunity Convertible Note
and the historical Series A shares owned into the new category of shares. In the event that Stimunity does not close a financing prior
to the Maturity Date or raises less than the Minimum Raise, the Company will have the right to convert the Stimunity Convertible Note
into Series A shares at &euro;363.00 per share or the raise price less 15%, whichever is lower. The Stimunity Convertible Note was funded
by the Company on September 12, 2022 by existing cash and cash provided under the Committed Purchase Agreement described above.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">On July 18, 2022, the Company and its wholly-owned subsidiary, SalvaRx
Ltd. (&ldquo;SalvaRx&rdquo;), entered into a Share Exchange Agreement (the &ldquo;Share Exchange Agreement&rdquo;) with each of the minority
shareholders of iOx (the &ldquo;Sellers&rdquo;) resulting in the acquisition of the outstanding non-controlling ownership interest (approximately
22%) of iOx, which is developing the iNKT agonist platform. The Company followed <FONT STYLE="color: #222222; background-color: white">International
Financial Reporting Standards (&ldquo;</FONT>IFRS&rdquo;) 3, &ldquo;Business Combinations,&rdquo; and IAS 27, &ldquo;Separate Financial
Statements,&rdquo; (which substantially replaced IAS 3) to account for this transaction. The Company achieved control of iOx, as defined,
on January 8, 2019 upon the completion of Portage&rsquo;s acquisition of SalvaRx. Further transactions whereby the parent entity acquires
further equity interests from non-controlling interests, or disposes of equity interests but without losing control, are accounted for
as equity transactions (i.e., transactions with owners in their capacity as owners). As such:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative interests
in the subsidiary;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any difference between the amount by which the non-controlling interests is adjusted and the fair value of the consideration paid
or received is recognized directly in equity and attributed to the owners of the parent; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>there is no consequential adjustment to the carrying amount of goodwill, and no gain or loss is recognized in profit or loss.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company now owns the worldwide rights to its small molecule iNKT agonists,
including lead programs PORT-2 and PORT-3. Under the terms of the Share Exchange Agreement, each Seller sold to the Company, and the Company
acquired from each Seller, legal and beneficial ownership of the number of iOx shares held by each Seller, free and clear of any share
encumbrances, in exchange for the issuance in an aggregate of 1,070,000 Portage ordinary shares to be allocated among the Sellers based
upon their relative ownership. As a result of the Share Exchange Agreement, the Company owns 100% of the issued and outstanding shares
of iOx.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As additional consideration for the sale of the iOx shares to the Company
under the Share Exchange Agreement, the Sellers shall have the contingent right to receive additional shares (&ldquo;Earnout Shares&rdquo;)
from the Company having an aggregate value equal to $25 million calculated at the Per Share Earnout Price, as defined in the Share Exchange
Agreement, upon the achievement of certain milestones defined as the dosing of the first patient in a Phase 3 clinical trial for either
PORT-2 (IMM60 iNKT cell activator/agonist) or PORT-3 (PLGA-nanoparticle formulation of IMM60 combined with a NY-ESO-1 peptide vaccine).
The Company shall have the option, in its sole and absolute discretion, to settle the Earnout Shares in cash.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Off-balance Sheet Arrangements</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">As of December 31, 2022 and March 31, 2022, the Company did not have any
off-balance sheet arrangements, including any relationships with unconsolidated entities or financial partnership to enhance perceived
liquidity.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Transactions with Related Parties</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Significant related party transactions are detailed in Note 18, &ldquo;Related
Party Transactions,&rdquo; to the unaudited condensed consolidated interim financial statements for the three and nine months ended December
31, 2022.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Financial and Derivative Instruments</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&rsquo;s financial instruments recognized in the Company&rsquo;s
condensed consolidated interim statements of financial position consist of the following:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Fair value estimates are made at a specific point in time, based on relevant
market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of
significant judgment, therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimates.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following table summarizes the Company&rsquo;s financial instruments
as of December 31, 2022 and March 31, 2022:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December 31, 2022</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of March 31, 2022</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">(In thousands)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value through Other Comprehensive <BR>Income (&ldquo;FVTOCI&rdquo;)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: left">Financial assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">13,104</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">23,352</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other receivables</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">1,786</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,480</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Convertible note receivable, including accrued interest</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">642</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Investments</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">4,768</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9,082</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value through Profit or Loss (&ldquo;FVTPL&rdquo;)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: left">Financial liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,422</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">750</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">33</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Deferred purchase price payable - Tarus</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">8,876</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Deferred obligation - iOx milestone</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">5,568</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&ndash;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">A summary of the Company&rsquo;s risk exposures as it relates to financial
instruments are reflected below.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B><I>Fair value of Financial Instruments</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&rsquo;s financial assets and liabilities are comprised of
cash and cash equivalents, receivables and investments in equities and private entities, accounts payable, warrant liability and unsecured
notes payable.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company classifies the fair value of these transactions according
to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Level 1 &ndash; Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of
the reporting date.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Level 2 &ndash; Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which
can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of
the reporting date.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Level 3 &ndash; Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified
as Level 3 financial instrument.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Assessment of the significance of a particular input to the fair value
measurement requires judgment and may affect the placement within the fair value hierarchy.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Management has assessed that the fair values of cash and cash equivalents,
other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The following methods and assumptions were used to estimate their fair
values:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>Convertible Note Receivable:</B> The fair value of the Stimunity Convertible
Note receivable denominated in euros at initial recognition is the transaction price for the instrument adjusted for the effect of the
currency translation rate on the reporting date (Level 3). The Company recognized an unrealized gain through OCI on the change in fair
value of the Stimunity Convertible Note receivable of $0.29 million for the three and nine months ended December 31, 2022.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>Investment in Intensity</B>: Fair value of the asset is determined
by considering other comparable equity funding transactions by Intensity with unrelated investors (Level 3).</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>Accrued Equity Issuable: </B>The fair value is estimated based on the
average of the quoted market prices for the period in which the shares were earned (Level 1).</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>Warrant Liability</B>: The fair value is estimated using a Black-Scholes
model (Level 3).</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>Deferred Purchase Price Payable - Tarus:</B> The fair value is the
estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 at acquisition
date, adjusted at each reporting date for any change in fair value (Level 3). The fair value was determined using the Income Approach
and was based upon the analysis on the Tarus clinical plan, the timing of development events and the probabilities of success determined
primarily based upon empirical third party data and Company experience, as well as the relevant cost of capital. The Company recorded
a (loss) from the change (increase) in fair value of the liability of $0.354 million and $0.338 million for the three and nine months
ended December 31, 2022, respectively.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>Deferred Obligation - iOx Milestone:</B> The fair value is the estimated
value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 as of July 18, 2022, the
date of the Share Exchange Agreement, adjusted at each reporting date for any change in fair value (Level 3). The fair value was determined
using the Income Approach and based on factors including the clinical plan, the timing of development events and the probabilities of
success determined primarily based upon empirical third party data and Company experience, as well as the relevant cost of capital. The
Company recorded a (loss) from the change (increase) in fair value of the liability of $0.144 million and $0.090 million for the three
and nine months ended December 31, 2022, respectively.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">There have been no transfers between levels of the fair value hierarchy
for the nine months ended December 31, 2022 and the year ended March 31, 2022.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&rsquo;s financial instruments are exposed to certain financial
risks: Credit Risk, Liquidity Risk and Foreign Currency Risk.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Credit Risk</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Credit risk is the risk of loss associated with a counterparty&rsquo;s
inability to fulfil its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&rsquo;s condensed consolidated interim statements of financial position.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B><I>Cash and cash equivalents</I>.</B> Cash and cash equivalents comprise
cash on hand and on-demand deposits that are readily convertible to a known amount of cash with three months or less from date of acquisition
and are subject to an insignificant risk of change in value. <FONT STYLE="background-color: white">As of December 31, 2022 and March&nbsp;31,
2022, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. </FONT>Cash
and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Liquidity Risk</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Liquidity risk is the risk that the Company will encounter difficulty
in satisfying financial obligations as they become due.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company&rsquo;s approach to managing liquidity is to ensure, as far
as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without
incurring unacceptable losses or risking harm to the Company&rsquo;s reputation. The Company holds sufficient cash and cash equivalents
to satisfy obligations under accounts payable and accruals.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company monitors its liquidity position regularly to assess whether
it has the funds necessary to meet its operating needs and needs for investing in new projects. The Company believes that it has sufficient
funding to finance the committed drug development work, apart from meeting its operational needs for the foreseeable future.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">However, as a biotech company at an early stage of development and without
significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may
not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty in global
markets could have an impact on the Company&rsquo;s future ability to access capital on terms that are acceptable to the Company. There
can be no assurance that required financing will be available to the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>Foreign Currency Risk</I></B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">While the Company operates in various jurisdictions, substantially all
of the Company&rsquo;s transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K. settleable
in British pound sterling and the Stimunity Convertible Note receivable settleable in euros.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Use of Estimates and Judgments</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The preparation of the condensed consolidated interim financial statements
in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies
and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Estimates and underlying assumptions are reviewed on an ongoing basis.
Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Significant areas where estimates are made include valuation of financial
instruments (including the convertible note receivable), deferred tax assets, deferred tax liability, R&amp;D costs, fair value used for
acquisition of intangible assets, contingent consideration assumed and measurement of share-based compensation. Significant areas where
critical judgments are applied include assessment of impairment of investments and goodwill and the determination of the accounting acquirer
and acquiree in the business combination accounting.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>New Accounting Standards, Interpretations and Amendments</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The Company is also unaware of any applicable but not-yet-adopted standards
that are expected to materially affect the Company&rsquo;s financial statements for future periods.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Internal Controls Over Financial Reporting</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">The management of the Company, including the Chief Executive Officer and
Chief Financial Officer, is responsible for establishing and maintaining adequate internal controls over financial reporting (as defined
in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended). The Company&rsquo;s internal control system was designed to
provide reasonable assurance to the Company&rsquo;s management and the Company&rsquo;s Board of Directors regarding the reliability of
financial reporting and preparation and fair presentation of published financial statements for external purposes in accordance with IFRS.
Internal control over financial reporting includes those policies and procedures that:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="color: windowtext">1.</FONT></TD><TD>pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of
the assets of the Company;</TD></TR></TABLE>

<P STYLE="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="color: windowtext">2.</FONT></TD><TD>provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and the
directors of the Company; and</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="color: windowtext">3.</FONT></TD><TD>provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&rsquo;s
assets that could have a material effect on the financial statements.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">All internal control systems, no matter how well designed, have inherent
limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial
statement preparation and presentation. Because of its inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Management assessed the effectiveness of the Company&rsquo;s internal
control over financial reporting as of December 31, 2022. In making this assessment, it used the criteria established in Internal Control
- Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the evaluation
under these criteria, management identified material weaknesses in the Company&rsquo;s internal controls over financial reporting and,
as a result, management concluded that the Company&rsquo;s internal control over financial reporting was not effective as of December
31, 2022.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Management identified the following material weaknesses in our internal
control over financial reporting.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Management was unable to perform an effective risk assessment or monitor internal controls
over financial reporting;</TD>
</TR></TABLE>

<P STYLE="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">Management lacks the number of skilled persons that it requires given the complexity of the
reporting requirements that it has to make, which more specifically include the staff and expertise to (i) properly segregate duties
and perform oversight of work performed and to perform compensating controls over the finance and accounting functions, (ii) establish
and perform fair value estimates or subsequently monitor fluctuations in fair value estimates, and (iii) apply complex accounting principles,
including those relating to business combination accounting, income taxes and fair value estimates; and</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0 0pt 41.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: right"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">There are insufficient written policies and procedures in place to ensure the correct application
of accounting and financial reporting with respect to the current requirements of IFRS and SEC disclosure requirements, some of which
specifically relate to investment accounting and fair value measures, assessment of in-process R&amp;D assets, share-based payments,
carrying amounts of goodwill and intangible assets and business combination accounting.</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">Public Securities Filings</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0">Additional information, including the Company&rsquo;s annual information
in the Annual Report on Form 20-F, is filed with the Canadian Securities Administrators at www.sedar.com and with the United States Securities
and Exchange Commission at www.edgar.com.</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">27</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ptgef-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSayDecPtxJFzCZkhv2p7fYnaTycmKh523i+Qv2MGsfcD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ptgef="http://portagebiotech.com/20221231" elementFormDefault="qualified" targetNamespace="http://portagebiotech.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://portagebiotech.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" id="CondensedConsolidatedInterimStatementsOfFinancialPosition">
	  <link:definition>00000002 - Statement -  Condensed Consolidated Interim Statements of Financial Position (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" id="StatementsOfOperationsAndComprehensiveIncomeLoss">
	  <link:definition>00000003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" id="InterimStatementsOfChangesInShareholdersEquity">
	  <link:definition>00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholder's Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" id="InterimStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/NatureOfOperations" id="NatureOfOperations">
	  <link:definition>00000006 - Disclosure - NATURE OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000007 - Disclosure - LIQUIDITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/BasisOfPresentation" id="BasisOfPresentation">
	  <link:definition>00000008 - Disclosure - BASIS OF PRESENTATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" id="PrepaidExpensesAndOtherReceivables">
	  <link:definition>00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInAssociate" id="InvestmentInAssociate">
	  <link:definition>00000011 - Disclosure - INVESTMENT IN ASSOCIATE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInPrivateCompany" id="InvestmentInPrivateCompany">
	  <link:definition>00000012 - Disclosure - INVESTMENT IN PRIVATE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/AcquisitionOfTarus" id="AcquisitionOfTarus">
	  <link:definition>00000013 - Disclosure - ACQUISITION OF TARUS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/Goodwill" id="Goodwill">
	  <link:definition>00000014 - Disclosure - GOODWILL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" id="In-processResearchAndDevelopmentAndDeferredTaxLiability">
	  <link:definition>00000015 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/UnsecuredNotesPayable" id="UnsecuredNotesPayable">
	  <link:definition>00000016 - Disclosure - UNSECURED NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000017 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/WarrantLiability" id="WarrantLiability">
	  <link:definition>00000018 - Disclosure - WARRANT LIABILITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalStock" id="CapitalStock">
	  <link:definition>00000019 - Disclosure - CAPITAL STOCK</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserve" id="StockOptionReserve">
	  <link:definition>00000020 - Disclosure - STOCK OPTION RESERVE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/LossPerShare" id="LossPerShare">
	  <link:definition>00000021 - Disclosure - (LOSS) PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
	  <link:definition>00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000023 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" id="FinancialInstrumentsAndRiskManagement">
	  <link:definition>00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalDisclosures" id="CapitalDisclosures">
	  <link:definition>00000025 - Disclosure - CAPITAL DISCLOSURES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterest" id="Non-controllingInterest">
	  <link:definition>00000026 - Disclosure - NON-CONTROLLING INTEREST</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/EventAfterBalanceSheetDate" id="EventAfterBalanceSheetDate">
	  <link:definition>00000027 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" id="PrepaidExpensesAndOtherReceivablesTables">
	  <link:definition>00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInAssociateTables" id="InvestmentInAssociateTables">
	  <link:definition>00000030 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/AcquisitionOfTarusTables" id="AcquisitionOfTarusTables">
	  <link:definition>00000031 - Disclosure - ACQUISITION OF TARUS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/GoodwillTables" id="GoodwillTables">
	  <link:definition>00000032 - Disclosure - GOODWILL (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" id="In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables">
	  <link:definition>00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableTables" id="UnsecuredNotesPayableTables">
	  <link:definition>00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000035 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" id="WarrantLiabilityTables">
	  <link:definition>00000036 - Disclosure - WARRANT LIABILITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalStockTables" id="CapitalStockTables">
	  <link:definition>00000037 - Disclosure - CAPITAL STOCK (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveTables" id="StockOptionReserveTables">
	  <link:definition>00000038 - Disclosure - STOCK OPTION RESERVE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/LossPerShareTables" id="LossPerShareTables">
	  <link:definition>00000039 - Disclosure - (LOSS) PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" id="FinancialInstrumentsAndRiskManagementTables">
	  <link:definition>00000040 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" id="Non-controllingInterestTables">
	  <link:definition>00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" id="NatureOfOperationsDetailsNarrative">
	  <link:definition>00000042 - Disclosure - NATURE OF OPERATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000043 - Disclosure - LIQUIDITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
	  <link:definition>00000044 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" id="PrepaidExpensesAndOtherReceivablesDetails">
	  <link:definition>00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails" id="InvestmentInAssociateDetails">
	  <link:definition>00000046 - Disclosure - INVESTMENT IN ASSOCIATE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails1" id="InvestmentInAssociateDetails1">
	  <link:definition>00000047 - Disclosure - INVESTMENT IN ASSOCIATE (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" id="InvestmentInAssociateDetailsNarrative">
	  <link:definition>00000048 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative" id="InvestmentInPrivateCompanyDetailsNarrative">
	  <link:definition>00000049 - Disclosure - INVESTMENT IN PRIVATE COMPANY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetails" id="AcquisitionOfTarusDetails">
	  <link:definition>00000050 - Disclosure - ACQUISITION OF TARUS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetails1" id="AcquisitionOfTarusDetails1">
	  <link:definition>00000051 - Disclosure - ACQUISITION OF TARUS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" id="AcquisitionOfTarusDetailsNarrative">
	  <link:definition>00000052 - Disclosure - ACQUISITION OF TARUS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/GoodwillDetails" id="GoodwillDetails">
	  <link:definition>00000053 - Disclosure - GOODWILL (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/GoodwillDetailsNarrative" id="GoodwillDetailsNarrative">
	  <link:definition>00000054 - Disclosure - GOODWILL (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" id="In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails">
	  <link:definition>00000055 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" id="In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative">
	  <link:definition>00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" id="UnsecuredNotesPayableDetails">
	  <link:definition>00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" id="UnsecuredNotesPayableDetailsNarrative">
	  <link:definition>00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000059 - Disclosure - INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000060 - Disclosure - INCOME TAXES (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
	  <link:definition>00000061 - Disclosure - INCOME TAXES (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetails3" id="IncomeTaxesDetails3">
	  <link:definition>00000062 - Disclosure - INCOME TAXES (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetails4" id="IncomeTaxesDetails4">
	  <link:definition>00000063 - Disclosure - INCOME TAXES (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000064 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" id="WarrantLiabilityDetails">
	  <link:definition>00000065 - Disclosure - WARRANT LIABILITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalStockDetails" id="CapitalStockDetails">
	  <link:definition>00000066 - Disclosure - CAPITAL STOCK (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalStockDetailsNarrative" id="CapitalStockDetailsNarrative">
	  <link:definition>00000067 - Disclosure - CAPITAL STOCK (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" id="StockOptionReserveDetails">
	  <link:definition>00000068 - Disclosure - STOCK OPTION RESERVE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" id="StockOptionReserveDetails1">
	  <link:definition>00000069 - Disclosure - STOCK OPTION RESERVE (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" id="StockOptionReserveDetails2">
	  <link:definition>00000070 - Disclosure - STOCK OPTION RESERVE (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails3" id="StockOptionReserveDetails3">
	  <link:definition>00000071 - Disclosure - STOCK OPTION RESERVE (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails4" id="StockOptionReserveDetails4">
	  <link:definition>00000072 - Disclosure - STOCK OPTION RESERVE (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" id="StockOptionReserveDetailsNarrative">
	  <link:definition>00000073 - Disclosure - STOCK OPTION RESERVE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/LossPerShareDetails" id="LossPerShareDetails">
	  <link:definition>00000074 - Disclosure - (LOSS) PER SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/LossPerShareDetails1" id="LossPerShareDetails1">
	  <link:definition>00000075 - Disclosure - (LOSS) PER SHARE (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" id="CommitmentsAndContingentLiabilitiesDetailsNarrative">
	  <link:definition>00000076 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000077 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" id="FinancialInstrumentsAndRiskManagementDetails">
	  <link:definition>00000078 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" id="FinancialInstrumentsAndRiskManagementDetailsNarrative">
	  <link:definition>00000079 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" id="CapitalDisclosuresDetailsNarrative">
	  <link:definition>00000080 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" id="Non-controllingInterestDetails">
	  <link:definition>00000081 - Disclosure - NON-CONTROLLING INTEREST (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative" id="EventAfterBalanceSheetDateDetailsNarrative">
	  <link:definition>00000082 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="ptgef_StockOptionReserveMember" name="StockOptionReserveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SalvaRxGroupPlcMember" name="SalvaRxGroupPlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ATMMember" name="ATMMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LincolnMember" name="LincolnMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SubsidiariesOneMember" name="SubsidiariesOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SubsidiariesTwoMember" name="SubsidiariesTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StimunitySAMember" name="StimunitySAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StimunityMember" name="StimunityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AcquisitionOfSalvaRxMember" name="AcquisitionOfSalvaRxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IntensityMember" name="IntensityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AcquisitionOfIntensityHoldingLimitedMember" name="AcquisitionOfIntensityHoldingLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TarusAcquisitionMember" name="TarusAcquisitionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IMM60IOXMelanomaLungCancersMember" name="IMM60IOXMelanomaLungCancersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IMM65IOXOvarianProstateCancersMember" name="IMM65IOXOvarianProstateCancersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IOXMember" name="IOXMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OncomerSaugatuckDNAAptamersMember" name="OncomerSaugatuckDNAAptamersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TarusAdenosineReceptorsMember" name="TarusAdenosineReceptorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TarusAdenosineReceptors1Member" name="TarusAdenosineReceptors1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TarusAdenosineReceptors2Member" name="TarusAdenosineReceptors2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TarusMember" name="TarusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SalvaRxMember" name="SalvaRxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnitedStateMember" name="UnitedStateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BVIMember" name="BVIMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ForeignMember" name="ForeignMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccreditedInvestorsMember" name="AccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DirectorsMember" name="DirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_N2021EquityIncentivePlanMember" name="N2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ConsultantsMember" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RestrictedStockUnitsMember" name="RestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AmendedAndRestated2021EquityIncentivePlanMember" name="AmendedAndRestated2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TwoMembersMember" name="TwoMembersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExecutiveMember" name="ExecutiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IOxOptionPlanMember" name="IOxOptionPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnvestedOptionsMember" name="UnvestedOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PBI2021EquityIncentivePlanMember" name="PBI2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionsTwoMember" name="StockOptionsTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChiefExecutiveOfficersMember" name="ChiefExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AmortizedCostMember" name="AmortizedCostMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueToOtherComprehensiveIncomeMember" name="FairValueToOtherComprehensiveIncomeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SaugatuckMember" name="SaugatuckMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ConvertibleNoteReceivable" name="ConvertibleNoteReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InprocessResearchAndDevelopment" name="InprocessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredCommitmentFee" name="DeferredCommitmentFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantLiabilityCurrent" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredPurchasePricePayableTarus" name="DeferredPurchasePricePayableTarus" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredObligationIoxMilestone" name="DeferredObligationIoxMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommitmentAndContingencies" name="CommitmentAndContingencies" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" name="ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainsLossesOnChangeInFairValueOfWarrants" name="GainsLossesOnChangeInFairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_Netloss" name="Netloss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetUnrealizedLossOnInvestments" name="NetUnrealizedLossOnInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BasicAndDilutedEarningsLossPerShare" name="BasicAndDilutedEarningsLossPerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" name="WeightedAveragesSharesoutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IfrsStatementLineItems" name="IfrsStatementLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInTarusAcquisition" name="SharesIssuedInTarusAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInTarusAcquisitionShares" name="SharesIssuedInTarusAcquisitionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInIoxExchange" name="SharesIssuedInIoxExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInIoxExchangeShares" name="SharesIssuedInIoxExchangeShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredObligationIoxMilestoneValue" name="DeferredObligationIoxMilestoneValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" name="ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" name="SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares" name="SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderAtm" name="SharesIssuedUnderAtm" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderAtmShares" name="SharesIssuedUnderAtmShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderOffering" name="SharesIssuedUnderOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderOfferingShares" name="SharesIssuedUnderOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" name="PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares" name="PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareIssuanceCosts" name="ShareIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedOrAccruedForServices" name="SharesIssuedOrAccruedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedOrAccruedForServicesShares" name="SharesIssuedOrAccruedForServicesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsExercised" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsExercisedShares" name="WarrantsExercisedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares" name="ExchangeOfNotesPayableAndAccruedInterestForIoxShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetUnrealizedLossOnInvestmentsValue" name="NetUnrealizedLossOnInvestmentsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncomeOnFairValueOfWarrantLiability" name="IncomeOnFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" name="ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfStockIssuedForServices" name="FairValueOfStockIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetChangeInWorkingCapitalComponentsAbstract" name="NetChangeInWorkingCapitalComponentsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncreasingDecreasingAccountsReceivable" name="IncreasingDecreasingAccountsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchaseOfConvertibleNoteReceivable" name="PurchaseOfConvertibleNoteReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition" name="RepaymentOfNotesPayableAssumedInTarusAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition" name="RepaymentOfMilestoneObligationAssumedInTarusAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" name="ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" name="ProceedsFromSharesIssuedUnderRegisteredOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromExerciseOfStockPurchaseWarrants" name="ProceedsFromExerciseOfStockPurchaseWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SupplementalCashFlowInformationsAbstract" name="SupplementalCashFlowInformationsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashPaidForInterest" name="CashPaidForInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncreaseInAccountsPayableForStockIssuanceCosts" name="IncreaseInAccountsPayableForStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NoncashInvestingItemsAbstract" name="NoncashInvestingItemsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfSharesIssuedForTarus" name="FairValueOfSharesIssuedForTarus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox" name="FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfDeferredPurchasePricePayabletarus" name="FairValueOfDeferredPurchasePricePayabletarus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfDeferredObligationIoxMilestone" name="FairValueOfDeferredObligationIoxMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LiabilitiesAssumedInTarusAcquisition" name="LiabilitiesAssumedInTarusAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase" name="FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants" name="ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NatureOfOperationsAbstract" name="NatureOfOperationsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NatureOfOperationsExplanatory" name="NatureOfOperationsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LiquidityAbstract" name="LiquidityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LiquidityTextBlock" name="LiquidityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfBasisOfPresentationExplanatory" name="DisclosureOfBasisOfPresentationExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SignificantAccountingPoliciesAbstract" name="SignificantAccountingPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidExpensesAndOtherReceivablesAbstract" name="PrepaidExpensesAndOtherReceivablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentInAssociateAbstract" name="InvestmentInAssociateAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentInAssociateDisclosureTextBlock" name="InvestmentInAssociateDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureInvestmentInPrivateCompanyAbstract" name="DisclosureInvestmentInPrivateCompanyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock" name="DisclosureOfPrivateCompaniesExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AcquisitionOfTarusAbstract" name="AcquisitionOfTarusAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AcquisitionsOfTarusExplanatory" name="AcquisitionsOfTarusExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GoodwillAbstract" name="GoodwillAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GoodwillExplanatory" name="GoodwillExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" name="InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability" name="InProcessResearchAndDevelopmentAndDeferredTaxLiability" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnsecuredNotesPayableAbstract" name="UnsecuredNotesPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnsecuredNotesPayableAndWarrantsTextBlock" name="UnsecuredNotesPayableAndWarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncomeTaxesAbstract" name="IncomeTaxesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantLiabilityAbstract" name="WarrantLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantLiabilitytextblock" name="WarrantLiabilitytextblock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalStockAbstract" name="CapitalStockAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalStockTextBlock" name="CapitalStockTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionReserveAbstract" name="StockOptionReserveAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LosPerShareAbstract" name="LosPerShareAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommitmentsAndContingentLiabilitiesAbstract" name="CommitmentsAndContingentLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FinancialInstrumentsAndRiskManagementAbstract" name="FinancialInstrumentsAndRiskManagementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalDisclosuresAbstract" name="CapitalDisclosuresAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" name="DisclosureOfCapitalManagementExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NonControllingInterestAbstract" name="NonControllingInterestAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EventAfterTheBalanceSheetDateAbstract" name="EventAfterTheBalanceSheetDateAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock" name="DisclosureOfEventAfterBalanceSheetDateTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" name="DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" name="DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfInvestmentAssociatetableTextBlock" name="DisclosureOfInvestmentAssociatetableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock" name="ScheduleOfInvestmentInStimunitySaTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" name="ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfProformaInformationTableTextBlock" name="ScheduleOfProformaInformationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" name="DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" name="ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfNotesPayableTableTextBlock" name="ScheduleOfNotesPayableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock" name="ScheduleOfIncomeTaxesBenefitTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" name="ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfIncomeTaxExplanatory" name="ScheduleOfIncomeTaxExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock" name="ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfDeferredTaxAssetsExplanatory" name="DisclosureOfDeferredTaxAssetsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" name="ScheduleOfWarrantLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" name="CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfTermsStockOptionReserveExplanatory" name="DisclosureOfTermsStockOptionReserveExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" name="DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EarningsPerShareTableTextBlock" name="EarningsPerShareTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" name="ScheduleOfAntiDilutiveEffectTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory" name="DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" name="ScheduleOfNoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TotalCurrentLiabilities" name="TotalCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetLossIncome" name="NetLossIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashUsedInOperatingActivities" name="CashUsedInOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IssuanceAndSales" name="IssuanceAndSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashFundDescription" name="CashFundDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfStockSold" name="NumberOfStockSold" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GrossProceedsFromStockSold" name="GrossProceedsFromStockSold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetProceedsFromStockSold" name="NetProceedsFromStockSold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OfferingAndThroughThatProcessDescription" name="OfferingAndThroughThatProcessDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfSharesSold" name="NumberOfSharesSold" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ResearchAndDevelopmentCredit" name="ResearchAndDevelopmentCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TaxDeposits" name="TaxDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AdditionalInvestment" name="AdditionalInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SubscribingClassShares" name="SubscribingClassShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ConvertibleNoteDescription" name="ConvertibleNoteDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EquityInLossIncome" name="EquityInLossIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrivateInvestments" name="PrivateInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentOwnedShares" name="InvestmentOwnedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_InvestmentOwnershipPercentage" name="InvestmentOwnershipPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" name="NumberOfPrivateCompanyShareConsistsInSoleAsset" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OfferingPrice" name="OfferingPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnrealizedLoss" name="UnrealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EarningLossPerShare" name="EarningLossPerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_MilestonePayment" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TarusGoodwill" name="TarusGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxesLiability" name="DeferredTaxesLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxLiability" name="DeferredTaxLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncreaseInDeferredIncomeTaxes" name="IncreaseInDeferredIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ReductionInDeferredTaxLiability" name="ReductionInDeferredTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NotePayable" name="NotePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare" name="ExchangeOfNotesPayableAndAccruedInterestForIoxShare" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfBusinessCombination" name="DescriptionOfBusinessCombination" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IssuanceOfUnsecuredNotesDescription" name="IssuanceOfUnsecuredNotesDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CurrentFederalIncomeTaxBenefit" name="CurrentFederalIncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CurrentStateAndLocalIncomeTaxBenefit" name="CurrentStateAndLocalIncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CurrentForeignIncomeTaxBenefit" name="CurrentForeignIncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredFederalIncomeTaxBenefit" name="DeferredFederalIncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredStateAndLocalIncomeTaxBenefit" name="DeferredStateAndLocalIncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredForeignIncomeTaxBenefit" name="DeferredForeignIncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax" name="IncomeLossOnOrdinaryActivitiesBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StatutoryU.s.IncomeTaxRate" name="StatutoryU.s.IncomeTaxRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossAtStatutoryIncomeTaxRate" name="LossAtStatutoryIncomeTaxRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossesRecognized" name="LossesRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncomeTaxBenefitExpense" name="IncomeTaxBenefitExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeIncreaseInDeferredIncomeTaxRate" name="ChangeIncreaseInDeferredIncomeTaxRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ForeignCurrencyEffect" name="ForeignCurrencyEffect" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TaxEffectOfRAndDCredit" name="TaxEffectOfRAndDCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossesUnrecognized" name="LossesUnrecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PretaxIncomeLoss" name="PretaxIncomeLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossForWhichNoBenefitWasTaken" name="LossForWhichNoBenefitWasTaken" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossesNotSubjectToTax" name="LossesNotSubjectToTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UtilizationOfLossesNotPreviouslyBenefitted" name="UtilizationOfLossesNotPreviouslyBenefitted" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PretaxLossSubjectToTax" name="PretaxLossSubjectToTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxAssetsAbstract" name="DeferredTaxAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" name="DeferredTaxAssetsNetOperatingLossCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxAssetUnrecognized" name="DeferredTaxAssetUnrecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxLiabiltiesAbstract" name="DeferredTaxLiabiltiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxLiabilitiesInProcessRAndD" name="DeferredTaxLiabilitiesInProcessRAndD" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DeferredTaxLiability1" name="DeferredTaxLiability1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ResearchAndDevelopmentCreditReceivables" name="ResearchAndDevelopmentCreditReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ResearchAndDevelopmentExpenseCashCredits" name="ResearchAndDevelopmentExpenseCashCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CurrentYearLosses" name="CurrentYearLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsOutstandingExercisePrice" name="WarrantsOutstandingExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsOutstandingShares" name="WarrantsOutstandingShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsOutstandingAmount" name="WarrantsOutstandingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueAdjustmentExercisePriceAtEnd" name="FairValueAdjustmentExercisePriceAtEnd" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueAdjustmentShares" name="FairValueAdjustmentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueAdjustmentAmount" name="FairValueAdjustmentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainLossOfChangeInFairValueOfWarrants" name="GainLossOfChangeInFairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommonStockShares" name="CommonStockShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommonStockValues" name="CommonStockValues" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInIoxExchangesShares" name="SharesIssuedInIoxExchangesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareIssuedInIoxExchange" name="ShareIssuedInIoxExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares" name="ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" name="ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares" name="SharesIssuedToLincolnParksCommittedPurchaseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedToLincolnParksCommittedPurchase" name="SharesIssuedToLincolnParksCommittedPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares" name="SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts" name="SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares" name="PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts" name="PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsExercisedShares1" name="WarrantsExercisedShares1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" name="SharesIssuedInPrivatePlacementNetOfIssueCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PricePerShare" name="PricePerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" name="SharesIssuedInPrivatePlacementNetOfIssueCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OfferingExpenses" name="OfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ManagementUnderwritingAndSellingExpenses" name="ManagementUnderwritingAndSellingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfSharesExchanged" name="NumberOfSharesExchanged" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_MinorityInterestPercentage" name="MinorityInterestPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionReserve" name="StockOptionReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SettledInIoxExchange" name="SettledInIoxExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OptionLifeShareOptionsGranted" name="OptionLifeShareOptionsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfPortageOption" name="FairValueOfPortageOption" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfOutstandingShareOption" name="NumberOfOutstandingShareOption" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" name="NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" name="NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" name="NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockGranted" name="StockGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValuePerShare" name="FairValuePerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IntrinsicValueOfStockOptions" name="IntrinsicValueOfStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumeratorAbstract" name="NumeratorAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DenominatorAbstract" name="DenominatorAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BasicAndDilutedLossPerShare" name="BasicAndDilutedLossPerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AntidilutiveEffectOnLossPerShare" name="AntidilutiveEffectOnLossPerShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ConvertibleNote" name="ConvertibleNote" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ConversionOfDebt" name="ConversionOfDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ConversionOfDebtIntoShares" name="ConversionOfDebtIntoShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharePricePerShare" name="SharePricePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AggregateValue" name="AggregateValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommitmentFee" name="CommitmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IssuanceOfUnsecuredNotesDescriptions" name="IssuanceOfUnsecuredNotesDescriptions" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PortageOrdinaryShares" name="PortageOrdinaryShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BaseSalary" name="BaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AnnualFeesdescription" name="AnnualFeesdescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CompensationCommittee" name="CompensationCommittee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OriginalAnnualTargetsPercentage" name="OriginalAnnualTargetsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidExpensesAndOtherReceivable" name="PrepaidExpensesAndOtherReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ConvertibleNoteReceivableIncludingAccruedInterest" name="ConvertibleNoteReceivableIncludingAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedLiabilities" name="AccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PayablesAndAccruedExpense" name="PayablesAndAccruedExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CurrentAsset" name="CurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareholdersEquityAttributableToOwners" name="ShareholdersEquityAttributableToOwners" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetLossAttributableToNoncontrollingInterest" name="NetLossAttributableToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" name="PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockBasedCompensationExpense" name="StockBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" name="ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IfrsStatementTable" name="IfrsStatementTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>ptgef-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://portagebiotech.com/role/Cover" xlink:href="ptgef-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:href="ptgef-20221231.xsd#CondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="ptgef-20221231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:href="ptgef-20221231.xsd#InterimStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:href="ptgef-20221231.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperations" xlink:href="ptgef-20221231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Liquidity" xlink:href="ptgef-20221231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentation" xlink:href="ptgef-20221231.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:href="ptgef-20221231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="ptgef-20221231.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociate" xlink:href="ptgef-20221231.xsd#InvestmentInAssociate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInPrivateCompany" xlink:href="ptgef-20221231.xsd#InvestmentInPrivateCompany" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarus" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarus" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Goodwill" xlink:href="ptgef-20221231.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxes" xlink:href="ptgef-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiability" xlink:href="ptgef-20221231.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStock" xlink:href="ptgef-20221231.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserve" xlink:href="ptgef-20221231.xsd#StockOptionReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShare" xlink:href="ptgef-20221231.xsd#LossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:href="ptgef-20221231.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:href="ptgef-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosures" xlink:href="ptgef-20221231.xsd#CapitalDisclosures" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterest" xlink:href="ptgef-20221231.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventAfterBalanceSheetDate" xlink:href="ptgef-20221231.xsd#EventAfterBalanceSheetDate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:href="ptgef-20221231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="ptgef-20221231.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusTables" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillTables" xlink:href="ptgef-20221231.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesTables" xlink:href="ptgef-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:href="ptgef-20221231.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockTables" xlink:href="ptgef-20221231.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveTables" xlink:href="ptgef-20221231.xsd#StockOptionReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareTables" xlink:href="ptgef-20221231.xsd#LossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:href="ptgef-20221231.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:href="ptgef-20221231.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:href="ptgef-20221231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ptgef-20221231.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:href="ptgef-20221231.xsd#PrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative" xlink:href="ptgef-20221231.xsd#InvestmentInPrivateCompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetails" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetails1" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetails" xlink:href="ptgef-20221231.xsd#GoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:href="ptgef-20221231.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails1" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails2" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails3" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails4" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:href="ptgef-20221231.xsd#WarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetails" xlink:href="ptgef-20221231.xsd#CapitalStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:href="ptgef-20221231.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails3" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails4" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails" xlink:href="ptgef-20221231.xsd#LossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails1" xlink:href="ptgef-20221231.xsd#LossPerShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="ptgef-20221231.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ptgef-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:href="ptgef-20221231.xsd#CapitalDisclosuresDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:href="ptgef-20221231.xsd#Non-controllingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative" xlink:href="ptgef-20221231.xsd#EventAfterBalanceSheetDateDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:title="00000002 - Statement -  Condensed Consolidated Interim Statements of Financial Position (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNoteReceivable" xlink:label="loc_ptgefConvertibleNoteReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ptgefConvertibleNoteReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentProperty" xlink:label="loc_ifrs-fullInvestmentProperty" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullInvestmentProperty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-fullGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InprocessResearchAndDevelopment" xlink:label="loc_ptgefInprocessResearchAndDevelopment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ptgefInprocessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredCommitmentFee" xlink:label="loc_ptgefDeferredCommitmentFee" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ptgefDeferredCommitmentFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-fullOtherAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullNoncurrentAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantLiabilityCurrent" xlink:label="loc_ptgefWarrantLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ptgefWarrantLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-fullNoncurrentLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-fullDeferredTaxLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentLiabilities" xlink:to="loc_ifrs-fullDeferredTaxLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredPurchasePricePayableTarus" xlink:label="loc_ptgefDeferredPurchasePricePayableTarus" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentLiabilities" xlink:to="loc_ptgefDeferredPurchasePricePayableTarus" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredObligationIoxMilestone" xlink:label="loc_ptgefDeferredObligationIoxMilestone" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentLiabilities" xlink:to="loc_ptgefDeferredObligationIoxMilestone" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullNoncurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullIssuedCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullOtherReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-fullAccumulatedOtherComprehensiveIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullAccumulatedOtherComprehensiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-fullEquityAndLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAndLiabilities" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAndLiabilities" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-fullProfitLossFromOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-fullGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:to="loc_ifrs-fullGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="loc_ifrs-fullForeignExchangeLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullForeignExchangeLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullDepreciationAndAmortisationExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullDepreciationAndAmortisationExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-fullRevenueFromInterest" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullRevenueFromInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-fullInterestExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_Netloss" xlink:label="loc_ptgefNetloss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefNetloss" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefNetloss" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-fullOtherComprehensiveIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullOtherComprehensiveIncome" xlink:to="loc_ptgefNetloss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetUnrealizedLossOnInvestments" xlink:label="loc_ptgefNetUnrealizedLossOnInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullOtherComprehensiveIncome" xlink:to="loc_ptgefNetUnrealizedLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToOwnersOfParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullComprehensiveIncome" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToNoncontrollingInterests" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullComprehensiveIncome" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholder&apos;s Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="loc_ifrs-fullProfitLossFromDiscontinuedOperations" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullProfitLossFromDiscontinuedOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeOnFairValueOfWarrantLiability" xlink:label="loc_ptgefIncomeOnFairValueOfWarrantLiability" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefIncomeOnFairValueOfWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfStockIssuedForServices" xlink:label="loc_ptgefFairValueOfStockIssuedForServices" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefFairValueOfStockIssuedForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnHedgeIneffectiveness" xlink:label="loc_ifrs-fullGainLossOnHedgeIneffectiveness" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullGainLossOnHedgeIneffectiveness" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullAdjustmentsForDepreciationAndAmortisationExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncreasingDecreasingAccountsReceivable" xlink:label="loc_ptgefIncreasingDecreasingAccountsReceivable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefIncreasingDecreasingAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfConvertibleNoteReceivable" xlink:label="loc_ptgefPurchaseOfConvertibleNoteReceivable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ptgefPurchaseOfConvertibleNoteReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition" xlink:label="loc_ptgefRepaymentOfNotesPayableAssumedInTarusAcquisition" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefRepaymentOfNotesPayableAssumedInTarusAcquisition" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition" xlink:label="loc_ptgefRepaymentOfMilestoneObligationAssumedInTarusAcquisition" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefRepaymentOfMilestoneObligationAssumedInTarusAcquisition" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderRegisteredOffering" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderRegisteredOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-fullPaymentsForShareIssueCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullPaymentsForShareIssueCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ProceedsFromExerciseOfStockPurchaseWarrants" xlink:label="loc_ptgefProceedsFromExerciseOfStockPurchaseWarrants" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefProceedsFromExerciseOfStockPurchaseWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="00000006 - Disclosure - NATURE OF OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Liquidity" xlink:title="00000007 - Disclosure - LIQUIDITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociate" xlink:title="00000011 - Disclosure - INVESTMENT IN ASSOCIATE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInPrivateCompany" xlink:title="00000012 - Disclosure - INVESTMENT IN PRIVATE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarus" xlink:title="00000013 - Disclosure - ACQUISITION OF TARUS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Goodwill" xlink:title="00000014 - Disclosure - GOODWILL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:title="00000015 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:title="00000016 - Disclosure - UNSECURED NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="00000018 - Disclosure - WARRANT LIABILITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStock" xlink:title="00000019 - Disclosure - CAPITAL STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="00000020 - Disclosure - STOCK OPTION RESERVE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="00000021 - Disclosure - (LOSS) PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="00000023 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosures" xlink:title="00000025 - Disclosure - CAPITAL DISCLOSURES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="00000026 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventAfterBalanceSheetDate" xlink:title="00000027 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:title="00000030 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusTables" xlink:title="00000031 - Disclosure - ACQUISITION OF TARUS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillTables" xlink:title="00000032 - Disclosure - GOODWILL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:title="00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:title="00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesTables" xlink:title="00000035 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="00000036 - Disclosure - WARRANT LIABILITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockTables" xlink:title="00000037 - Disclosure - CAPITAL STOCK (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="00000038 - Disclosure - STOCK OPTION RESERVE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="00000039 - Disclosure - (LOSS) PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="00000040 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:title="00000042 - Disclosure - NATURE OF OPERATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:title="00000043 - Disclosure - LIQUIDITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000044 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepayments" xlink:label="loc_ifrs-fullCurrentPrepayments" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="loc_ifrs-fullCurrentAdvancesToSuppliers" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ifrs-fullCurrentAdvancesToSuppliers" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ResearchAndDevelopmentCredit" xlink:label="loc_ptgefResearchAndDevelopmentCredit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ptgefResearchAndDevelopmentCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TaxDeposits" xlink:label="loc_ptgefTaxDeposits" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ptgefTaxDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-fullCurrentPrepaidExpenses" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ifrs-fullCurrentPrepaidExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ifrs-fullOtherCurrentReceivables" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:title="00000046 - Disclosure - INVESTMENT IN ASSOCIATE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:title="00000047 - Disclosure - INVESTMENT IN ASSOCIATE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:title="00000048 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative" xlink:title="00000049 - Disclosure - INVESTMENT IN PRIVATE COMPANY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusDetails" xlink:title="00000050 - Disclosure - ACQUISITION OF TARUS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusDetails1" xlink:title="00000051 - Disclosure - ACQUISITION OF TARUS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" xlink:title="00000052 - Disclosure - ACQUISITION OF TARUS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetails" xlink:title="00000053 - Disclosure - GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:title="00000054 - Disclosure - GOODWILL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:title="00000055 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:title="00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:title="00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:title="00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:title="00000059 - Disclosure - INCOME TAXES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails1" xlink:title="00000060 - Disclosure - INCOME TAXES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails2" xlink:title="00000061 - Disclosure - INCOME TAXES (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails3" xlink:title="00000062 - Disclosure - INCOME TAXES (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails4" xlink:title="00000063 - Disclosure - INCOME TAXES (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="loc_ifrs-fullNetDeferredTaxAssets" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" xlink:label="loc_ptgefDeferredTaxAssetsNetOperatingLossCarryforward" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNetDeferredTaxAssets" xlink:to="loc_ptgefDeferredTaxAssetsNetOperatingLossCarryforward" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxAssetUnrecognized" xlink:label="loc_ptgefDeferredTaxAssetUnrecognized" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNetDeferredTaxAssets" xlink:to="loc_ptgefDeferredTaxAssetUnrecognized" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxLiability1" xlink:label="loc_ptgefDeferredTaxLiability1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxLiabilitiesInProcessRAndD" xlink:label="loc_ptgefDeferredTaxLiabilitiesInProcessRAndD" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefDeferredTaxLiability1" xlink:to="loc_ptgefDeferredTaxLiabilitiesInProcessRAndD" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="00000065 - Disclosure - WARRANT LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetails" xlink:title="00000066 - Disclosure - CAPITAL STOCK (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:title="00000067 - Disclosure - CAPITAL STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="00000068 - Disclosure - STOCK OPTION RESERVE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="00000069 - Disclosure - STOCK OPTION RESERVE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="00000070 - Disclosure - STOCK OPTION RESERVE (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails3" xlink:title="00000071 - Disclosure - STOCK OPTION RESERVE (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails4" xlink:title="00000072 - Disclosure - STOCK OPTION RESERVE (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="00000073 - Disclosure - STOCK OPTION RESERVE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="00000074 - Disclosure - (LOSS) PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="00000075 - Disclosure - (LOSS) PER SHARE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000076 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000077 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="00000078 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:title="00000079 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:title="00000080 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="00000081 - Disclosure - NON-CONTROLLING INTEREST (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative" xlink:title="00000082 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>ptgef-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://portagebiotech.com/role/Cover" xlink:href="ptgef-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:href="ptgef-20221231.xsd#CondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="ptgef-20221231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:href="ptgef-20221231.xsd#InterimStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:href="ptgef-20221231.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperations" xlink:href="ptgef-20221231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Liquidity" xlink:href="ptgef-20221231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentation" xlink:href="ptgef-20221231.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:href="ptgef-20221231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="ptgef-20221231.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociate" xlink:href="ptgef-20221231.xsd#InvestmentInAssociate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInPrivateCompany" xlink:href="ptgef-20221231.xsd#InvestmentInPrivateCompany" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarus" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarus" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Goodwill" xlink:href="ptgef-20221231.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxes" xlink:href="ptgef-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiability" xlink:href="ptgef-20221231.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStock" xlink:href="ptgef-20221231.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserve" xlink:href="ptgef-20221231.xsd#StockOptionReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShare" xlink:href="ptgef-20221231.xsd#LossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:href="ptgef-20221231.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:href="ptgef-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosures" xlink:href="ptgef-20221231.xsd#CapitalDisclosures" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterest" xlink:href="ptgef-20221231.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventAfterBalanceSheetDate" xlink:href="ptgef-20221231.xsd#EventAfterBalanceSheetDate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:href="ptgef-20221231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="ptgef-20221231.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusTables" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillTables" xlink:href="ptgef-20221231.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesTables" xlink:href="ptgef-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:href="ptgef-20221231.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockTables" xlink:href="ptgef-20221231.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveTables" xlink:href="ptgef-20221231.xsd#StockOptionReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareTables" xlink:href="ptgef-20221231.xsd#LossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:href="ptgef-20221231.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:href="ptgef-20221231.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:href="ptgef-20221231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ptgef-20221231.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:href="ptgef-20221231.xsd#PrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative" xlink:href="ptgef-20221231.xsd#InvestmentInPrivateCompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetails" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetails1" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetails" xlink:href="ptgef-20221231.xsd#GoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:href="ptgef-20221231.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails1" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails2" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails3" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails4" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:href="ptgef-20221231.xsd#WarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetails" xlink:href="ptgef-20221231.xsd#CapitalStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:href="ptgef-20221231.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails3" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails4" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails" xlink:href="ptgef-20221231.xsd#LossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails1" xlink:href="ptgef-20221231.xsd#LossPerShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="ptgef-20221231.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ptgef-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:href="ptgef-20221231.xsd#CapitalDisclosuresDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:href="ptgef-20221231.xsd#Non-controllingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative" xlink:href="ptgef-20221231.xsd#EventAfterBalanceSheetDateDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:title="00000002 - Statement -  Condensed Consolidated Interim Statements of Financial Position (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholder&apos;s Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullIssuedCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ptgefStockOptionReserveMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInTarusAcquisition" xlink:label="loc_ptgefSharesIssuedInTarusAcquisition_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInTarusAcquisition_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInTarusAcquisitionShares" xlink:label="loc_ptgefSharesIssuedInTarusAcquisitionShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInTarusAcquisitionShares_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInIoxExchange" xlink:label="loc_ptgefSharesIssuedInIoxExchange_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInIoxExchange_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInIoxExchangeShares" xlink:label="loc_ptgefSharesIssuedInIoxExchangeShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInIoxExchangeShares_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredObligationIoxMilestoneValue" xlink:label="loc_ptgefDeferredObligationIoxMilestoneValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDeferredObligationIoxMilestoneValue_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" xlink:label="loc_ptgefExcessOfNoncontrollingInterestAcquiredOverConsiderationIox_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExcessOfNoncontrollingInterestAcquiredOverConsiderationIox_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefSharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares" xlink:label="loc_ptgefSharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderAtm" xlink:label="loc_ptgefSharesIssuedUnderAtm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtm_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderAtmShares" xlink:label="loc_ptgefSharesIssuedUnderAtmShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtmShares_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderOffering" xlink:label="loc_ptgefSharesIssuedUnderOffering_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderOffering_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderOfferingShares" xlink:label="loc_ptgefSharesIssuedUnderOfferingShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderOfferingShares_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreement_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreement_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares" xlink:label="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares_80" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ShareIssuanceCosts" xlink:label="loc_ptgefShareIssuanceCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefShareIssuanceCosts_80" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="loc_ptgefSharesIssuedOrAccruedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServices_80" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="loc_ptgefSharesIssuedOrAccruedForServicesShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServicesShares_80" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsExercised" xlink:label="loc_ptgefWarrantsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsExercised_80" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsExercisedShares" xlink:label="loc_ptgefWarrantsExercisedShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsExercisedShares_80" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares" xlink:label="loc_ptgefExchangeOfNotesPayableAndAccruedInterestForIoxShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExchangeOfNotesPayableAndAccruedInterestForIoxShares_80" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetUnrealizedLossOnInvestmentsValue" xlink:label="loc_ptgefNetUnrealizedLossOnInvestmentsValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetUnrealizedLossOnInvestmentsValue_80" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss_80" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="00000006 - Disclosure - NATURE OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Liquidity" xlink:title="00000007 - Disclosure - LIQUIDITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociate" xlink:title="00000011 - Disclosure - INVESTMENT IN ASSOCIATE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInPrivateCompany" xlink:title="00000012 - Disclosure - INVESTMENT IN PRIVATE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarus" xlink:title="00000013 - Disclosure - ACQUISITION OF TARUS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Goodwill" xlink:title="00000014 - Disclosure - GOODWILL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:title="00000015 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:title="00000016 - Disclosure - UNSECURED NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="00000018 - Disclosure - WARRANT LIABILITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStock" xlink:title="00000019 - Disclosure - CAPITAL STOCK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="00000020 - Disclosure - STOCK OPTION RESERVE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="00000021 - Disclosure - (LOSS) PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="00000023 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosures" xlink:title="00000025 - Disclosure - CAPITAL DISCLOSURES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="00000026 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventAfterBalanceSheetDate" xlink:title="00000027 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:title="00000030 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusTables" xlink:title="00000031 - Disclosure - ACQUISITION OF TARUS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillTables" xlink:title="00000032 - Disclosure - GOODWILL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:title="00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:title="00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesTables" xlink:title="00000035 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="00000036 - Disclosure - WARRANT LIABILITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockTables" xlink:title="00000037 - Disclosure - CAPITAL STOCK (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="00000038 - Disclosure - STOCK OPTION RESERVE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="00000039 - Disclosure - (LOSS) PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="00000040 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:title="00000042 - Disclosure - NATURE OF OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SalvaRxGroupPlcMember" xlink:label="loc_ptgefSalvaRxGroupPlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxGroupPlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:title="00000043 - Disclosure - LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ATMMember" xlink:label="loc_ptgefATMMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefATMMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LincolnMember" xlink:label="loc_ptgefLincolnMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefLincolnMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-fullCash_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCash_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TotalCurrentLiabilities" xlink:label="loc_ptgefTotalCurrentLiabilities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTotalCurrentLiabilities_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetLossIncome" xlink:label="loc_ptgefNetLossIncome_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetLossIncome_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CashUsedInOperatingActivities" xlink:label="loc_ptgefCashUsedInOperatingActivities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCashUsedInOperatingActivities_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOnHand" xlink:label="loc_ifrs-fullCashOnHand_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashOnHand_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IssuanceAndSales" xlink:label="loc_ptgefIssuanceAndSales_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuanceAndSales_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_MaximumAggregateOfferingPrice" xlink:label="loc_ptgefMaximumAggregateOfferingPrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefMaximumAggregateOfferingPrice_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CashFundDescription" xlink:label="loc_ptgefCashFundDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCashFundDescription_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfStockSold" xlink:label="loc_ptgefNumberOfStockSold_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfStockSold_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GrossProceedsFromStockSold" xlink:label="loc_ptgefGrossProceedsFromStockSold_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGrossProceedsFromStockSold_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetProceedsFromStockSold" xlink:label="loc_ptgefNetProceedsFromStockSold_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetProceedsFromStockSold_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OfferingAndThroughThatProcessDescription" xlink:label="loc_ptgefOfferingAndThroughThatProcessDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingAndThroughThatProcessDescription_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:label="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets_80" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000044 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SubsidiariesOneMember" xlink:label="loc_ptgefSubsidiariesOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSubsidiariesOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SubsidiariesTwoMember" xlink:label="loc_ptgefSubsidiariesTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSubsidiariesTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:title="00000046 - Disclosure - INVESTMENT IN ASSOCIATE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StimunitySAMember" xlink:label="loc_ptgefStimunitySAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:to="loc_ptgefStimunitySAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfAssociate" xlink:label="loc_ifrs-fullNameOfAssociate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNameOfAssociate_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:label="loc_ifrs-fullPrincipalPlaceOfBusinessOfAssociate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPrincipalPlaceOfBusinessOfAssociate_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:label="loc_ifrs-fullCountryOfIncorporationOrResidenceOfAssociate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCountryOfIncorporationOrResidenceOfAssociate_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:title="00000047 - Disclosure - INVESTMENT IN ASSOCIATE (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:title="00000048 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StimunitySAMember" xlink:label="loc_ptgefStimunitySAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:to="loc_ptgefStimunitySAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StimunityMember" xlink:label="loc_ptgefStimunityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefStimunityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AdditionalInvestment" xlink:label="loc_ptgefAdditionalInvestment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalInvestment_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SubscribingClassShares" xlink:label="loc_ptgefSubscribingClassShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSubscribingClassShares_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInAssociate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInAssociate_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNoteDescription" xlink:label="loc_ptgefConvertibleNoteDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefConvertibleNoteDescription_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EquityInLossIncome" xlink:label="loc_ptgefEquityInLossIncome_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefEquityInLossIncome_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative" xlink:title="00000049 - Disclosure - INVESTMENT IN PRIVATE COMPANY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-fullBusinessCombinationsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ifrs-fullBusinessCombinationsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullBusinessCombinationsAxis" xlink:to="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullBusinessCombinationsAxis" xlink:to="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfSalvaRxMember" xlink:label="loc_ptgefAcquisitionOfSalvaRxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" xlink:to="loc_ptgefAcquisitionOfSalvaRxMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfIntensityHoldingLimitedMember" xlink:label="loc_ptgefAcquisitionOfIntensityHoldingLimitedMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" xlink:to="loc_ptgefAcquisitionOfIntensityHoldingLimitedMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInvestmentPropertyAxis" xlink:label="loc_ifrs-fullTypesOfInvestmentPropertyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ifrs-fullTypesOfInvestmentPropertyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentPropertyMember" xlink:label="loc_ifrs-fullInvestmentPropertyMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTypesOfInvestmentPropertyAxis" xlink:to="loc_ifrs-fullInvestmentPropertyMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentPropertyMember" xlink:label="loc_ifrs-fullInvestmentPropertyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTypesOfInvestmentPropertyAxis" xlink:to="loc_ifrs-fullInvestmentPropertyMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IntensityMember" xlink:label="loc_ptgefIntensityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullInvestmentPropertyMember" xlink:to="loc_ptgefIntensityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ifrs-fullRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PrivateInvestments" xlink:label="loc_ptgefPrivateInvestments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrivateInvestments_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentOwnedShares" xlink:label="loc_ptgefInvestmentOwnedShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInvestmentOwnedShares_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentOwnershipPercentage" xlink:label="loc_ptgefInvestmentOwnershipPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInvestmentOwnershipPercentage_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:label="loc_ptgefNumberOfPrivateCompanyShareConsistsInSoleAsset_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfPrivateCompanyShareConsistsInSoleAsset_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OfferingPrice" xlink:label="loc_ptgefOfferingPrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingPrice_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets" xlink:label="loc_ifrs-fullChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied" xlink:label="loc_ifrs-fullAmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnrealizedLoss" xlink:label="loc_ptgefUnrealizedLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnrealizedLoss_110" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusDetails" xlink:title="00000050 - Disclosure - ACQUISITION OF TARUS (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAcquisitionMember" xlink:label="loc_ptgefTarusAcquisitionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:to="loc_ptgefTarusAcquisitionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-fullAssetsAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAssetsAbstract_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullIdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-fullGoodwill_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullGoodwill_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTangibleOrIntangibleAssetsTransferred" xlink:label="loc_ifrs-fullOtherTangibleOrIntangibleAssetsTransferred_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherTangibleOrIntangibleAssetsTransferred_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:label="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferred_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferred_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-fullIdentifiableAssetsAcquiredLiabilitiesAssumed_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIdentifiableAssetsAcquiredLiabilitiesAssumed_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-fullContingentLiabilitiesRecognisedInBusinessCombination_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullContingentLiabilitiesRecognisedInBusinessCombination_20" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusDetails1" xlink:title="00000051 - Disclosure - ACQUISITION OF TARUS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAcquisitionMember" xlink:label="loc_ptgefTarusAcquisitionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:to="loc_ptgefTarusAcquisitionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-fullProfitLossFromContinuingOperations_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLossFromContinuingOperations_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLossBeforeTax_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullComprehensiveIncome_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EarningLossPerShare" xlink:label="loc_ptgefEarningLossPerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefEarningLossPerShare_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" xlink:title="00000052 - Disclosure - ACQUISITION OF TARUS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetails" xlink:title="00000053 - Disclosure - GOODWILL (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:title="00000054 - Disclosure - GOODWILL (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:title="00000055 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IMM60IOXMelanomaLungCancersMember" xlink:label="loc_ptgefIMM60IOXMelanomaLungCancersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIMM60IOXMelanomaLungCancersMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IMM65IOXOvarianProstateCancersMember" xlink:label="loc_ptgefIMM65IOXOvarianProstateCancersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIMM65IOXOvarianProstateCancersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIOXMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OncomerSaugatuckDNAAptamersMember" xlink:label="loc_ptgefOncomerSaugatuckDNAAptamersMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefOncomerSaugatuckDNAAptamersMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAdenosineReceptorsMember" xlink:label="loc_ptgefTarusAdenosineReceptorsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefTarusAdenosineReceptorsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAdenosineReceptors1Member" xlink:label="loc_ptgefTarusAdenosineReceptors1Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefTarusAdenosineReceptors1Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAdenosineReceptors2Member" xlink:label="loc_ptgefTarusAdenosineReceptors2Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefTarusAdenosineReceptors2Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusMember" xlink:label="loc_ptgefTarusMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefTarusMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InprocessResearchAndDevelopment" xlink:label="loc_ptgefInprocessResearchAndDevelopment_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInprocessResearchAndDevelopment_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxesLiability" xlink:label="loc_ptgefDeferredTaxesLiability_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDeferredTaxesLiability_190" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:title="00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:title="00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIOXMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NotePayable" xlink:label="loc_ptgefNotePayable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNotePayable_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare" xlink:label="loc_ptgefExchangeOfNotesPayableAndAccruedInterestForIoxShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExchangeOfNotesPayableAndAccruedInterestForIoxShare_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:title="00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIOXMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DescriptionOfBusinessCombination" xlink:label="loc_ptgefDescriptionOfBusinessCombination_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDescriptionOfBusinessCombination_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IssuanceOfUnsecuredNotesDescription" xlink:label="loc_ptgefIssuanceOfUnsecuredNotesDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuanceOfUnsecuredNotesDescription_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:title="00000059 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails1" xlink:title="00000060 - Disclosure - INCOME TAXES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails2" xlink:title="00000061 - Disclosure - INCOME TAXES (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails3" xlink:title="00000062 - Disclosure - INCOME TAXES (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReserveQuantitiesLineItems" xlink:label="loc_srtReserveQuantitiesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" xlink:label="loc_srtProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_srtProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnitedStateMember" xlink:label="loc_ptgefUnitedStateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ptgefUnitedStateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BVIMember" xlink:label="loc_ptgefBVIMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ptgefBVIMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ForeignMember" xlink:label="loc_ptgefForeignMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ptgefForeignMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PretaxIncomeLoss" xlink:label="loc_ptgefPretaxIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_ptgefPretaxIncomeLoss_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossForWhichNoBenefitWasTaken" xlink:label="loc_ptgefLossForWhichNoBenefitWasTaken_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_ptgefLossForWhichNoBenefitWasTaken_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossesNotSubjectToTax" xlink:label="loc_ptgefLossesNotSubjectToTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_ptgefLossesNotSubjectToTax_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UtilizationOfLossesNotPreviouslyBenefitted" xlink:label="loc_ptgefUtilizationOfLossesNotPreviouslyBenefitted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_ptgefUtilizationOfLossesNotPreviouslyBenefitted_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PretaxLossSubjectToTax" xlink:label="loc_ptgefPretaxLossSubjectToTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_ptgefPretaxLossSubjectToTax_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails4" xlink:title="00000063 - Disclosure - INCOME TAXES (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIOXMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-fullDeferredTaxAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeferredTaxAssets_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ResearchAndDevelopmentCreditReceivables" xlink:label="loc_ptgefResearchAndDevelopmentCreditReceivables_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefResearchAndDevelopmentCreditReceivables_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ResearchAndDevelopmentExpenseCashCredits" xlink:label="loc_ptgefResearchAndDevelopmentExpenseCashCredits_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefResearchAndDevelopmentExpenseCashCredits_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-fullDeferredTaxLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeferredTaxLiabilities_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncome_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeferredTaxExpenseIncome_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentYearLosses" xlink:label="loc_ptgefCurrentYearLosses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCurrentYearLosses_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_90" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="00000065 - Disclosure - WARRANT LIABILITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetails" xlink:title="00000066 - Disclosure - CAPITAL STOCK (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:title="00000067 - Disclosure - CAPITAL STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AccreditedInvestorsMember" xlink:label="loc_ptgefAccreditedInvestorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefAccreditedInvestorsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DirectorsMember" xlink:label="loc_ptgefDirectorsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefDirectorsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LincolnMember" xlink:label="loc_ptgefLincolnMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefLincolnMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ATMMember" xlink:label="loc_ptgefATMMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefATMMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostsShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostsShares_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PricePerShare" xlink:label="loc_ptgefPricePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPricePerShare_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCosts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCosts_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfStockSold" xlink:label="loc_ptgefNumberOfStockSold_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfStockSold_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GrossProceedsFromStockSold" xlink:label="loc_ptgefGrossProceedsFromStockSold_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGrossProceedsFromStockSold_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetProceedsFromStockSold" xlink:label="loc_ptgefNetProceedsFromStockSold_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetProceedsFromStockSold_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OfferingExpenses" xlink:label="loc_ptgefOfferingExpenses_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingExpenses_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ManagementUnderwritingAndSellingExpenses" xlink:label="loc_ptgefManagementUnderwritingAndSellingExpenses_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefManagementUnderwritingAndSellingExpenses_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesExchanged" xlink:label="loc_ptgefNumberOfSharesExchanged_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesExchanged_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_MinorityInterestPercentage" xlink:label="loc_ptgefMinorityInterestPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefMinorityInterestPercentage_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:label="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets_110" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="00000068 - Disclosure - STOCK OPTION RESERVE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ptgefStockOptionReserveMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserve" xlink:label="loc_ptgefStockOptionReserve_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockOptionReserve_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SettledInIoxExchange" xlink:label="loc_ptgefSettledInIoxExchange_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSettledInIoxExchange_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="00000069 - Disclosure - STOCK OPTION RESERVE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOxOptionPlanMember" xlink:label="loc_ptgefIOxOptionPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefIOxOptionPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-fullMeasurementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullMeasurementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-fullAggregatedMeasurementMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullAggregatedMeasurementMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-fullAggregatedMeasurementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullAggregatedMeasurementMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnvestedOptionsMember" xlink:label="loc_ptgefUnvestedOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAggregatedMeasurementMember" xlink:to="loc_ptgefUnvestedOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OptionLifeShareOptionsGranted" xlink:label="loc_ptgefOptionLifeShareOptionsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptionsGranted_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfPortageOption" xlink:label="loc_ptgefFairValueOfPortageOption_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfPortageOption_20" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="00000070 - Disclosure - STOCK OPTION RESERVE (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOxOptionPlanMember" xlink:label="loc_ptgefIOxOptionPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefIOxOptionPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-fullMeasurementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullMeasurementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-fullAggregatedMeasurementMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullAggregatedMeasurementMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-fullAggregatedMeasurementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullAggregatedMeasurementMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnvestedOptionsMember" xlink:label="loc_ptgefUnvestedOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAggregatedMeasurementMember" xlink:to="loc_ptgefUnvestedOptionsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OptionLifeShareOptionsGranted" xlink:label="loc_ptgefOptionLifeShareOptionsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptionsGranted_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfPortageOption" xlink:label="loc_ptgefFairValueOfPortageOption_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfPortageOption_20" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails3" xlink:title="00000071 - Disclosure - STOCK OPTION RESERVE (Details 3)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionsTwoMember" xlink:label="loc_ptgefStockOptionsTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefStockOptionsTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails4" xlink:title="00000072 - Disclosure - STOCK OPTION RESERVE (Details 4)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionsTwoMember" xlink:label="loc_ptgefStockOptionsTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefStockOptionsTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="00000073 - Disclosure - STOCK OPTION RESERVE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_N2021EquityIncentivePlanMember" xlink:label="loc_ptgefN2021EquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefN2021EquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefRestrictedStockUnitsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AmendedAndRestated2021EquityIncentivePlanMember" xlink:label="loc_ptgefAmendedAndRestated2021EquityIncentivePlanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefAmendedAndRestated2021EquityIncentivePlanMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOxOptionPlanMember" xlink:label="loc_ptgefIOxOptionPlanMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefIOxOptionPlanMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BoardOfDirectorsMember" xlink:label="loc_ptgefBoardOfDirectorsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefBoardOfDirectorsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConsultantsMember" xlink:label="loc_ptgefConsultantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefConsultantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TwoMembersMember" xlink:label="loc_ptgefTwoMembersMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefTwoMembersMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EmployeesMember" xlink:label="loc_ptgefEmployeesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefEmployeesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DirectorsMember" xlink:label="loc_ptgefDirectorsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefDirectorsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExecutiveMember" xlink:label="loc_ptgefExecutiveMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefExecutiveMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockGranted" xlink:label="loc_ptgefStockGranted_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockGranted_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValuePerShare" xlink:label="loc_ptgefFairValuePerShare_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValuePerShare_230" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommunicationExpense" xlink:label="loc_ifrs-fullCommunicationExpense_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCommunicationExpense_230" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IntrinsicValueOfStockOptions" xlink:label="loc_ptgefIntrinsicValueOfStockOptions_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIntrinsicValueOfStockOptions_230" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="00000074 - Disclosure - (LOSS) PER SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="00000075 - Disclosure - (LOSS) PER SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionsMember" xlink:label="loc_ptgefStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefRestrictedStockUnitsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsMember" xlink:label="loc_ptgefWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AntidilutiveEffectOnLossPerShare" xlink:label="loc_ptgefAntidilutiveEffectOnLossPerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAntidilutiveEffectOnLossPerShare_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000076 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LincolnMember" xlink:label="loc_ptgefLincolnMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefLincolnMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNote" xlink:label="loc_ptgefConvertibleNote_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefConvertibleNote_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-fullBorrowingsInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowingsInterestRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConversionOfDebt" xlink:label="loc_ptgefConversionOfDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefConversionOfDebt_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConversionOfDebtIntoShares" xlink:label="loc_ptgefConversionOfDebtIntoShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefConversionOfDebtIntoShares_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharePricePerShare" xlink:label="loc_ptgefSharePricePerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePricePerShare_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AggregateValue" xlink:label="loc_ptgefAggregateValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregateValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommitmentFee" xlink:label="loc_ptgefCommitmentFee_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCommitmentFee_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000077 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIOXMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChiefExecutiveOfficersMember" xlink:label="loc_ptgefChiefExecutiveOfficersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefChiefExecutiveOfficersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IssuanceOfUnsecuredNotesDescriptions" xlink:label="loc_ptgefIssuanceOfUnsecuredNotesDescriptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuanceOfUnsecuredNotesDescriptions_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PortageOrdinaryShares" xlink:label="loc_ptgefPortageOrdinaryShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPortageOrdinaryShares_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BaseSalary" xlink:label="loc_ptgefBaseSalary_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefBaseSalary_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AnnualFeesdescription" xlink:label="loc_ptgefAnnualFeesdescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAnnualFeesdescription_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CompensationCommittee" xlink:label="loc_ptgefCompensationCommittee_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCompensationCommittee_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OriginalAnnualTargetsPercentage" xlink:label="loc_ptgefOriginalAnnualTargetsPercentage_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOriginalAnnualTargetsPercentage_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="00000078 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AmortizedCostMember" xlink:label="loc_ptgefAmortizedCostMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefAmortizedCostMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="loc_ptgefFairValueToOtherComprehensiveIncomeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefFairValueToOtherComprehensiveIncomeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_50" xlink:to="loc_ifrs-fullCashAndCashEquivalents_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PrepaidExpensesAndOtherReceivable" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_50" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivable_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNoteReceivableIncludingAccruedInterest" xlink:label="loc_ptgefConvertibleNoteReceivableIncludingAccruedInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_50" xlink:to="loc_ptgefConvertibleNoteReceivableIncludingAccruedInterest_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInvestments" xlink:label="loc_ifrs-fullCurrentInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_50" xlink:to="loc_ifrs-fullCurrentInvestments_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_50" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilities_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WarrantLiability" xlink:label="loc_ifrs-fullWarrantLiability_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_50" xlink:to="loc_ifrs-fullWarrantLiability_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredPurchasePricePayableTarus" xlink:label="loc_ptgefDeferredPurchasePricePayableTarus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_50" xlink:to="loc_ptgefDeferredPurchasePricePayableTarus_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredObligationIoxMilestone" xlink:label="loc_ptgefDeferredObligationIoxMilestone_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_50" xlink:to="loc_ptgefDeferredObligationIoxMilestone_50" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:title="00000079 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:title="00000080 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="00000081 - Disclosure - NON-CONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIOXMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSaugatuckMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="loc_ptgefNetLossAttributableToNoncontrollingInterest_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetLossAttributableToNoncontrollingInterest_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" xlink:label="loc_ptgefPurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockBasedCompensationExpense" xlink:label="loc_ptgefStockBasedCompensationExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockBasedCompensationExpense_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" xlink:label="loc_ptgefExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_190" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative" xlink:title="00000082 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementTable" xlink:label="loc_ptgefIfrsStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIfrsStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ptgefIfrsStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:label="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets_30" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>ptgef-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Issued capital [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveMember" xlink:label="ptgef_StockOptionReserveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserveMember" xlink:to="ptgef_StockOptionReserveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionReserveMember_lbl" xml:lang="en-US">Stock Option Reserve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Retained earnings [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="ifrs-full_NoncontrollingInterestsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non-controlling interests [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SalvaRxGroupPlcMember" xlink:label="ptgef_SalvaRxGroupPlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SalvaRxGroupPlcMember" xlink:to="ptgef_SalvaRxGroupPlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SalvaRxGroupPlcMember_lbl" xml:lang="en-US">Salva Rx Group Plc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US">Counterparties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ATMMember" xlink:label="ptgef_ATMMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ATMMember" xlink:to="ptgef_ATMMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ATMMember_lbl" xml:lang="en-US">A T M [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LincolnMember" xlink:label="ptgef_LincolnMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LincolnMember" xlink:to="ptgef_LincolnMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LincolnMember_lbl" xml:lang="en-US">Lincoln [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SubsidiariesOneMember" xlink:label="ptgef_SubsidiariesOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SubsidiariesOneMember" xlink:to="ptgef_SubsidiariesOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SubsidiariesOneMember_lbl" xml:lang="en-US">Subsidiaries One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SubsidiariesTwoMember" xlink:label="ptgef_SubsidiariesTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SubsidiariesTwoMember" xlink:to="ptgef_SubsidiariesTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SubsidiariesTwoMember_lbl" xml:lang="en-US">Subsidiaries Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xml:lang="en-US">Associates [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StimunitySAMember" xlink:label="ptgef_StimunitySAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StimunitySAMember" xlink:to="ptgef_StimunitySAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StimunitySAMember_lbl" xml:lang="en-US">Stimunity S A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StimunityMember" xlink:label="ptgef_StimunityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StimunityMember" xlink:to="ptgef_StimunityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StimunityMember_lbl" xml:lang="en-US">Stimunity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US">Business combinations [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfSalvaRxMember" xlink:label="ptgef_AcquisitionOfSalvaRxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AcquisitionOfSalvaRxMember" xlink:to="ptgef_AcquisitionOfSalvaRxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AcquisitionOfSalvaRxMember_lbl" xml:lang="en-US">Acquisition Of Salva Rx [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInvestmentPropertyAxis" xlink:label="ifrs-full_TypesOfInvestmentPropertyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInvestmentPropertyAxis" xlink:to="ifrs-full_TypesOfInvestmentPropertyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfInvestmentPropertyAxis_lbl" xml:lang="en-US">Types of investment property [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IntensityMember" xlink:label="ptgef_IntensityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IntensityMember" xlink:to="ptgef_IntensityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IntensityMember_lbl" xml:lang="en-US">Intensity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfIntensityHoldingLimitedMember" xlink:label="ptgef_AcquisitionOfIntensityHoldingLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AcquisitionOfIntensityHoldingLimitedMember" xlink:to="ptgef_AcquisitionOfIntensityHoldingLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AcquisitionOfIntensityHoldingLimitedMember_lbl" xml:lang="en-US">Acquisition Of Intensity Holding Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:label="ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis_lbl" xml:lang="en-US">Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAcquisitionMember" xlink:label="ptgef_TarusAcquisitionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TarusAcquisitionMember" xlink:to="ptgef_TarusAcquisitionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TarusAcquisitionMember_lbl" xml:lang="en-US">Tarus Acquisition [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IMM60IOXMelanomaLungCancersMember" xlink:label="ptgef_IMM60IOXMelanomaLungCancersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IMM60IOXMelanomaLungCancersMember" xlink:to="ptgef_IMM60IOXMelanomaLungCancersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IMM60IOXMelanomaLungCancersMember_lbl" xml:lang="en-US">I M M 60 I O X Melanoma Lung Cancers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IMM65IOXOvarianProstateCancersMember" xlink:label="ptgef_IMM65IOXOvarianProstateCancersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IMM65IOXOvarianProstateCancersMember" xlink:to="ptgef_IMM65IOXOvarianProstateCancersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IMM65IOXOvarianProstateCancersMember_lbl" xml:lang="en-US">I M M 65 I O X Ovarian Prostate Cancers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="ptgef_IOXMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IOXMember" xlink:to="ptgef_IOXMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IOXMember_lbl" xml:lang="en-US">I O X [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OncomerSaugatuckDNAAptamersMember" xlink:label="ptgef_OncomerSaugatuckDNAAptamersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OncomerSaugatuckDNAAptamersMember" xlink:to="ptgef_OncomerSaugatuckDNAAptamersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OncomerSaugatuckDNAAptamersMember_lbl" xml:lang="en-US">Oncomer Saugatuck D N A Aptamers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAdenosineReceptorsMember" xlink:label="ptgef_TarusAdenosineReceptorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TarusAdenosineReceptorsMember" xlink:to="ptgef_TarusAdenosineReceptorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TarusAdenosineReceptorsMember_lbl" xml:lang="en-US">Tarus Adenosine Receptors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAdenosineReceptors1Member" xlink:label="ptgef_TarusAdenosineReceptors1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TarusAdenosineReceptors1Member" xlink:to="ptgef_TarusAdenosineReceptors1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TarusAdenosineReceptors1Member_lbl" xml:lang="en-US">Tarus Adenosine Receptors 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAdenosineReceptors2Member" xlink:label="ptgef_TarusAdenosineReceptors2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TarusAdenosineReceptors2Member" xlink:to="ptgef_TarusAdenosineReceptors2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TarusAdenosineReceptors2Member_lbl" xml:lang="en-US">Tarus Adenosine Receptors 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusMember" xlink:label="ptgef_TarusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TarusMember" xlink:to="ptgef_TarusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TarusMember_lbl" xml:lang="en-US">Tarus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SalvaRxMember" xlink:label="ptgef_SalvaRxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SalvaRxMember" xlink:to="ptgef_SalvaRxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SalvaRxMember_lbl" xml:lang="en-US">Salva Rx [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnitedStateMember" xlink:label="ptgef_UnitedStateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnitedStateMember" xlink:to="ptgef_UnitedStateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnitedStateMember_lbl" xml:lang="en-US">United State [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BVIMember" xlink:label="ptgef_BVIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BVIMember" xlink:to="ptgef_BVIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BVIMember_lbl" xml:lang="en-US">B V I [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ForeignMember" xlink:label="ptgef_ForeignMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ForeignMember" xlink:to="ptgef_ForeignMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ForeignMember_lbl" xml:lang="en-US">Foreign [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AccreditedInvestorsMember" xlink:label="ptgef_AccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccreditedInvestorsMember" xlink:to="ptgef_AccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccreditedInvestorsMember_lbl" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DirectorsMember" xlink:label="ptgef_DirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DirectorsMember" xlink:to="ptgef_DirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DirectorsMember_lbl" xml:lang="en-US">Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="ifrs-full_DefinedBenefitPlansAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefinedBenefitPlansAxis_lbl" xml:lang="en-US">Defined benefit plans [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_N2021EquityIncentivePlanMember" xlink:label="ptgef_N2021EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_N2021EquityIncentivePlanMember" xlink:to="ptgef_N2021EquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_N2021EquityIncentivePlanMember_lbl" xml:lang="en-US">N 2021 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BoardOfDirectorsMember" xlink:label="ptgef_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BoardOfDirectorsMember" xlink:to="ptgef_BoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board Of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConsultantsMember" xlink:label="ptgef_ConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ConsultantsMember" xlink:to="ptgef_ConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="ptgef_RestrictedStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RestrictedStockUnitsMember" xlink:to="ptgef_RestrictedStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RestrictedStockUnitsMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AmendedAndRestated2021EquityIncentivePlanMember" xlink:label="ptgef_AmendedAndRestated2021EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AmendedAndRestated2021EquityIncentivePlanMember" xlink:to="ptgef_AmendedAndRestated2021EquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AmendedAndRestated2021EquityIncentivePlanMember_lbl" xml:lang="en-US">Amended And Restated 2021 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TwoMembersMember" xlink:label="ptgef_TwoMembersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TwoMembersMember" xlink:to="ptgef_TwoMembersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TwoMembersMember_lbl" xml:lang="en-US">Two Members [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EmployeesMember" xlink:label="ptgef_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EmployeesMember" xlink:to="ptgef_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExecutiveMember" xlink:label="ptgef_ExecutiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExecutiveMember" xlink:to="ptgef_ExecutiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExecutiveMember_lbl" xml:lang="en-US">Executive [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOxOptionPlanMember" xlink:label="ptgef_IOxOptionPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IOxOptionPlanMember" xlink:to="ptgef_IOxOptionPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IOxOptionPlanMember_lbl" xml:lang="en-US">I Ox Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MeasurementAxis_lbl" xml:lang="en-US">Measurement [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnvestedOptionsMember" xlink:label="ptgef_UnvestedOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnvestedOptionsMember" xlink:to="ptgef_UnvestedOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnvestedOptionsMember_lbl" xml:lang="en-US">Unvested Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="ptgef_PBI2021EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PBI2021EquityIncentivePlanMember" xlink:to="ptgef_PBI2021EquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PBI2021EquityIncentivePlanMember_lbl" xml:lang="en-US">P B I 2021 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionsTwoMember" xlink:label="ptgef_StockOptionsTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionsTwoMember" xlink:to="ptgef_StockOptionsTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionsTwoMember_lbl" xml:lang="en-US">Stock Options Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionsMember" xlink:label="ptgef_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionsMember" xlink:to="ptgef_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsMember" xlink:label="ptgef_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsMember" xlink:to="ptgef_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChiefExecutiveOfficersMember" xlink:label="ptgef_ChiefExecutiveOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChiefExecutiveOfficersMember" xlink:to="ptgef_ChiefExecutiveOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChiefExecutiveOfficersMember_lbl" xml:lang="en-US">Chief Executive Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AmortizedCostMember" xlink:label="ptgef_AmortizedCostMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AmortizedCostMember" xlink:to="ptgef_AmortizedCostMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AmortizedCostMember_lbl" xml:lang="en-US">Amortized Cost [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="ptgef_FairValueToOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:to="ptgef_FairValueToOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueToOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Fair Value To Other Comprehensive Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SaugatuckMember" xlink:label="ptgef_SaugatuckMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SaugatuckMember" xlink:to="ptgef_SaugatuckMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SaugatuckMember_lbl" xml:lang="en-US">Saugatuck [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNoteReceivable" xlink:label="ptgef_ConvertibleNoteReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ConvertibleNoteReceivable" xlink:to="ptgef_ConvertibleNoteReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ConvertibleNoteReceivable_lbl" xml:lang="en-US">Convertible note receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Long-term assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_lbl" xml:lang="en-US">Investment in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentProperty" xlink:label="ifrs-full_InvestmentProperty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentProperty" xlink:to="ifrs-full_InvestmentProperty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentProperty_lbl" xml:lang="en-US">Investment in private company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="ifrs-full_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Goodwill" xlink:to="ifrs-full_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InprocessResearchAndDevelopment" xlink:label="ptgef_InprocessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InprocessResearchAndDevelopment" xlink:to="ptgef_InprocessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InprocessResearchAndDevelopment_lbl" xml:lang="en-US">In-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredCommitmentFee" xlink:label="ptgef_DeferredCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredCommitmentFee" xlink:to="ptgef_DeferredCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredCommitmentFee_lbl" xml:lang="en-US">Deferred commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Other assets, including equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total long-term assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantLiabilityCurrent" xlink:label="ptgef_WarrantLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiabilityCurrent" xlink:to="ptgef_WarrantLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantLiabilityCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredPurchasePricePayableTarus" xlink:label="ptgef_DeferredPurchasePricePayableTarus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredPurchasePricePayableTarus" xlink:to="ptgef_DeferredPurchasePricePayableTarus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredPurchasePricePayableTarus_lbl" xml:lang="en-US">Deferred purchase price payable - Tarus</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredObligationIoxMilestone" xlink:label="ptgef_DeferredObligationIoxMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredObligationIoxMilestone" xlink:to="ptgef_DeferredObligationIoxMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredObligationIoxMilestone_lbl" xml:lang="en-US">Deferred obligation - iOx milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Capital stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Stock option reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Total equity attributable to owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="ifrs-full_NoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommitmentAndContingencies" xlink:label="ptgef_CommitmentAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentAndContingencies" xlink:to="ptgef_CommitmentAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommitmentAndContingencies_lbl" xml:lang="en-US">Commitments and Contingent Liabilities (Note 17)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAbstract" xlink:label="ifrs-full_ProfitLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="ifrs-full_ProfitLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAbstract_lbl" xml:lang="en-US">Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:to="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_lbl" xml:lang="en-US">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Share of loss in associate accounted for using equity method</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="ptgef_GainsLossesOnChangeInFairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:to="ptgef_GainsLossesOnChangeInFairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainsLossesOnChangeInFairValueOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="ifrs-full_ForeignExchangeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeLoss" xlink:to="ifrs-full_ForeignExchangeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ForeignExchangeLoss_lbl" xml:lang="en-US">Foreign exchange transaction gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Income tax (expense) benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_Netloss" xlink:label="ptgef_Netloss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Netloss" xlink:to="ptgef_Netloss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgef_Netloss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetUnrealizedLossOnInvestments" xlink:label="ptgef_NetUnrealizedLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetUnrealizedLossOnInvestments" xlink:to="ptgef_NetUnrealizedLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetUnrealizedLossOnInvestments_lbl" xml:lang="en-US">Net unrealized loss on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US">Total comprehensive loss for period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">Net loss attributable to:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xml:lang="en-US">Comprehensive loss attributable to:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Total comprehensive loss for period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BasicAndDilutedEarningsLossPerShare" xlink:label="ptgef_BasicAndDilutedEarningsLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BasicAndDilutedEarningsLossPerShare" xlink:to="ptgef_BasicAndDilutedEarningsLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BasicAndDilutedEarningsLossPerShare_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xml:lang="en-US">Weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" xlink:label="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" xlink:to="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="ptgef_IfrsStatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IfrsStatementLineItems" xlink:to="ptgef_IfrsStatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IfrsStatementLineItems_lbl" xml:lang="en-US">IfrsStatementLineItems [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInTarusAcquisition" xlink:label="ptgef_SharesIssuedInTarusAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInTarusAcquisition" xlink:to="ptgef_SharesIssuedInTarusAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInTarusAcquisition_lbl" xml:lang="en-US">Shares issued in Tarus acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInTarusAcquisitionShares" xlink:label="ptgef_SharesIssuedInTarusAcquisitionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInTarusAcquisitionShares" xlink:to="ptgef_SharesIssuedInTarusAcquisitionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInTarusAcquisitionShares_lbl" xml:lang="en-US">Shares issued in Tarus acquisition , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInIoxExchange" xlink:label="ptgef_SharesIssuedInIoxExchange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInIoxExchange" xlink:to="ptgef_SharesIssuedInIoxExchange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInIoxExchange_lbl" xml:lang="en-US">Shares issued in iOx exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInIoxExchangeShares" xlink:label="ptgef_SharesIssuedInIoxExchangeShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInIoxExchangeShares" xlink:to="ptgef_SharesIssuedInIoxExchangeShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInIoxExchangeShares_lbl" xml:lang="en-US">Shares issued in iOx exchange , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredObligationIoxMilestoneValue" xlink:label="ptgef_DeferredObligationIoxMilestoneValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredObligationIoxMilestoneValue" xlink:to="ptgef_DeferredObligationIoxMilestoneValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DeferredObligationIoxMilestoneValue_lbl" xml:lang="en-US">Deferred obligation - iOx milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" xlink:label="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" xlink:to="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox_lbl" xml:lang="en-US">Excess of non-controlling interest acquired over consideration - iOx</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" xlink:to="ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement_lbl" xml:lang="en-US">Shares issued to Lincoln for commitment fee under Committed Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares" xlink:label="ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares" xlink:to="ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares_lbl" xml:lang="en-US">Shares issued to Lincoln for commitment fee under Committed Purchase Agreement , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderAtm" xlink:label="ptgef_SharesIssuedUnderAtm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderAtm" xlink:to="ptgef_SharesIssuedUnderAtm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderAtm_lbl" xml:lang="en-US">Shares issued under ATM</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderAtmShares" xlink:label="ptgef_SharesIssuedUnderAtmShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderAtmShares" xlink:to="ptgef_SharesIssuedUnderAtmShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderAtmShares_lbl" xml:lang="en-US">Shares issued under ATM, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderOffering" xlink:label="ptgef_SharesIssuedUnderOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderOffering" xlink:to="ptgef_SharesIssuedUnderOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderOffering_lbl" xml:lang="en-US">Shares issued under public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderOfferingShares" xlink:label="ptgef_SharesIssuedUnderOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderOfferingShares" xlink:to="ptgef_SharesIssuedUnderOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderOfferingShares_lbl" xml:lang="en-US">Shares issued under public offering , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" xlink:label="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" xlink:to="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement_lbl" xml:lang="en-US">Purchase of shares issued under Committed Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares" xlink:label="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares" xlink:to="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares_lbl" xml:lang="en-US">Purchase of shares issued under Committed Purchase Agreement , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ShareIssuanceCosts" xlink:label="ptgef_ShareIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareIssuanceCosts" xlink:to="ptgef_ShareIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareIssuanceCosts_lbl" xml:lang="en-US">Share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="ptgef_SharesIssuedOrAccruedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedOrAccruedForServices" xlink:to="ptgef_SharesIssuedOrAccruedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedOrAccruedForServices_lbl" xml:lang="en-US">Shares issued or accrued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="ptgef_SharesIssuedOrAccruedForServicesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedOrAccruedForServicesShares" xlink:to="ptgef_SharesIssuedOrAccruedForServicesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedOrAccruedForServicesShares_lbl" xml:lang="en-US">Shares issued or accrued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsExercised" xlink:label="ptgef_WarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsExercised" xlink:to="ptgef_WarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsExercisedShares" xlink:label="ptgef_WarrantsExercisedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsExercisedShares" xlink:to="ptgef_WarrantsExercisedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsExercisedShares_lbl" xml:lang="en-US">Warrants exercised , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares" xlink:label="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares" xlink:to="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares_lbl" xml:lang="en-US">Exchange of notes payable and accrued interest for iOx shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetUnrealizedLossOnInvestmentsValue" xlink:label="ptgef_NetUnrealizedLossOnInvestmentsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetUnrealizedLossOnInvestmentsValue" xlink:to="ptgef_NetUnrealizedLossOnInvestmentsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_NetUnrealizedLossOnInvestmentsValue_lbl" xml:lang="en-US">Net unrealized loss on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Net loss for period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="ifrs-full_ProfitLossFromDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:to="ifrs-full_ProfitLossFromDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromDiscontinuedOperations_lbl" xml:lang="en-US">Net loss for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments for non-cash items:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xml:lang="en-US">Decrease in deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeOnFairValueOfWarrantLiability" xlink:label="ptgef_IncomeOnFairValueOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeOnFairValueOfWarrantLiability" xlink:to="ptgef_IncomeOnFairValueOfWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_IncomeOnFairValueOfWarrantLiability_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:to="ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone_lbl" xml:lang="en-US">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfStockIssuedForServices" xlink:label="ptgef_FairValueOfStockIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfStockIssuedForServices" xlink:to="ptgef_FairValueOfStockIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfStockIssuedForServices_lbl" xml:lang="en-US">Fair value of shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnHedgeIneffectiveness" xlink:label="ifrs-full_GainLossOnHedgeIneffectiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainLossOnHedgeIneffectiveness" xlink:to="ifrs-full_GainLossOnHedgeIneffectiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GainLossOnHedgeIneffectiveness_lbl" xml:lang="en-US">Share of loss in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Foreign exchange transaction gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetChangeInWorkingCapitalComponentsAbstract" xlink:label="ptgef_NetChangeInWorkingCapitalComponentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetChangeInWorkingCapitalComponentsAbstract" xlink:to="ptgef_NetChangeInWorkingCapitalComponentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetChangeInWorkingCapitalComponentsAbstract_lbl" xml:lang="en-US">Changes in operating working capital:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncreasingDecreasingAccountsReceivable" xlink:label="ptgef_IncreasingDecreasingAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncreasingDecreasingAccountsReceivable" xlink:to="ptgef_IncreasingDecreasingAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_IncreasingDecreasingAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfConvertibleNoteReceivable" xlink:label="ptgef_PurchaseOfConvertibleNoteReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseOfConvertibleNoteReceivable" xlink:to="ptgef_PurchaseOfConvertibleNoteReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_PurchaseOfConvertibleNoteReceivable_lbl" xml:lang="en-US">Purchase of convertible note receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition" xlink:label="ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition" xlink:to="ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition_lbl" xml:lang="en-US">Repayment of notes payable assumed in Tarus acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition" xlink:label="ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition" xlink:to="ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition_lbl" xml:lang="en-US">Repayment of milestone obligation assumed in Tarus acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" xlink:label="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" xlink:to="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase_lbl" xml:lang="en-US">Proceeds from shares issued under ATM and Committed Purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" xlink:label="ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" xlink:to="ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering_lbl" xml:lang="en-US">Proceeds from shares issued under registered offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US">Share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ProceedsFromExerciseOfStockPurchaseWarrants" xlink:label="ptgef_ProceedsFromExerciseOfStockPurchaseWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromExerciseOfStockPurchaseWarrants" xlink:to="ptgef_ProceedsFromExerciseOfStockPurchaseWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromExerciseOfStockPurchaseWarrants_lbl" xml:lang="en-US">Proceeds from exercise of stock purchase warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">(Decrease) increase in cash and cash equivalents during period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_3_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SupplementalCashFlowInformationsAbstract" xlink:label="ptgef_SupplementalCashFlowInformationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SupplementalCashFlowInformationsAbstract" xlink:to="ptgef_SupplementalCashFlowInformationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SupplementalCashFlowInformationsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CashPaidForInterest" xlink:label="ptgef_CashPaidForInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashPaidForInterest" xlink:to="ptgef_CashPaidForInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashPaidForInterest_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncreaseInAccountsPayableForStockIssuanceCosts" xlink:label="ptgef_IncreaseInAccountsPayableForStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncreaseInAccountsPayableForStockIssuanceCosts" xlink:to="ptgef_IncreaseInAccountsPayableForStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncreaseInAccountsPayableForStockIssuanceCosts_lbl" xml:lang="en-US">Increase in accounts payable for stock issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NoncashInvestingItemsAbstract" xlink:label="ptgef_NoncashInvestingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NoncashInvestingItemsAbstract" xlink:to="ptgef_NoncashInvestingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NoncashInvestingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfSharesIssuedForTarus" xlink:label="ptgef_FairValueOfSharesIssuedForTarus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfSharesIssuedForTarus" xlink:to="ptgef_FairValueOfSharesIssuedForTarus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfSharesIssuedForTarus_lbl" xml:lang="en-US">Fair value of shares issued for Tarus</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox" xlink:label="ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox" xlink:to="ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox_lbl" xml:lang="en-US">Fair value of shares issued for non-controlling interest purchase of iOx</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfDeferredPurchasePricePayabletarus" xlink:label="ptgef_FairValueOfDeferredPurchasePricePayabletarus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfDeferredPurchasePricePayabletarus" xlink:to="ptgef_FairValueOfDeferredPurchasePricePayabletarus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfDeferredPurchasePricePayabletarus_lbl" xml:lang="en-US">Fair value of deferred purchase price payable-Tarus</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfDeferredObligationIoxMilestone" xlink:label="ptgef_FairValueOfDeferredObligationIoxMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfDeferredObligationIoxMilestone" xlink:to="ptgef_FairValueOfDeferredObligationIoxMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfDeferredObligationIoxMilestone_lbl" xml:lang="en-US">Fair value of deferred obligation - iOx milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LiabilitiesAssumedInTarusAcquisition" xlink:label="ptgef_LiabilitiesAssumedInTarusAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LiabilitiesAssumedInTarusAcquisition" xlink:to="ptgef_LiabilitiesAssumedInTarusAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LiabilitiesAssumedInTarusAcquisition_lbl" xml:lang="en-US">Liabilities assumed in Tarus acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase" xlink:label="ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase" xlink:to="ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase_lbl" xml:lang="en-US">Fair value of shares issued for commitment fees - Committed Purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants" xlink:label="ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants" xlink:to="ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants_lbl" xml:lang="en-US">Exchange of iOx shares for settlement of notes payable, accrued interest and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NatureOfOperationsAbstract" xlink:label="ptgef_NatureOfOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NatureOfOperationsAbstract" xlink:to="ptgef_NatureOfOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NatureOfOperationsAbstract_lbl" xml:lang="en-US">Nature Of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NatureOfOperationsExplanatory" xlink:label="ptgef_NatureOfOperationsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NatureOfOperationsExplanatory" xlink:to="ptgef_NatureOfOperationsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NatureOfOperationsExplanatory_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LiquidityAbstract" xlink:label="ptgef_LiquidityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LiquidityAbstract" xlink:to="ptgef_LiquidityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LiquidityAbstract_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LiquidityTextBlock" xlink:label="ptgef_LiquidityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LiquidityTextBlock" xlink:to="ptgef_LiquidityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LiquidityTextBlock_lbl" xml:lang="en-US">LIQUIDITY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BasisOfPresentationAbstract" xlink:label="ptgef_BasisOfPresentationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BasisOfPresentationAbstract" xlink:to="ptgef_BasisOfPresentationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BasisOfPresentationAbstract_lbl" xml:lang="en-US">Basis Of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfBasisOfPresentationExplanatory" xlink:label="ptgef_DisclosureOfBasisOfPresentationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfBasisOfPresentationExplanatory" xlink:to="ptgef_DisclosureOfBasisOfPresentationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfBasisOfPresentationExplanatory_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SignificantAccountingPoliciesAbstract" xlink:label="ptgef_SignificantAccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SignificantAccountingPoliciesAbstract" xlink:to="ptgef_SignificantAccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PrepaidExpensesAndOtherReceivablesAbstract" xlink:label="ptgef_PrepaidExpensesAndOtherReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="ptgef_PrepaidExpensesAndOtherReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidExpensesAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER RECEIVABLES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentInAssociateAbstract" xlink:label="ptgef_InvestmentInAssociateAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentInAssociateAbstract" xlink:to="ptgef_InvestmentInAssociateAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentInAssociateAbstract_lbl" xml:lang="en-US">Investment In Associate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentInAssociateDisclosureTextBlock" xlink:label="ptgef_InvestmentInAssociateDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentInAssociateDisclosureTextBlock" xlink:to="ptgef_InvestmentInAssociateDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentInAssociateDisclosureTextBlock_lbl" xml:lang="en-US">INVESTMENT IN ASSOCIATE</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureInvestmentInPrivateCompanyAbstract" xlink:label="ptgef_DisclosureInvestmentInPrivateCompanyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureInvestmentInPrivateCompanyAbstract" xlink:to="ptgef_DisclosureInvestmentInPrivateCompanyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureInvestmentInPrivateCompanyAbstract_lbl" xml:lang="en-US">Investment In Private Company</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock" xlink:label="ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock" xlink:to="ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock_lbl" xml:lang="en-US">INVESTMENT IN PRIVATE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfTarusAbstract" xlink:label="ptgef_AcquisitionOfTarusAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AcquisitionOfTarusAbstract" xlink:to="ptgef_AcquisitionOfTarusAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AcquisitionOfTarusAbstract_lbl" xml:lang="en-US">Acquisition Of Tarus</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionsOfTarusExplanatory" xlink:label="ptgef_AcquisitionsOfTarusExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AcquisitionsOfTarusExplanatory" xlink:to="ptgef_AcquisitionsOfTarusExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AcquisitionsOfTarusExplanatory_lbl" xml:lang="en-US">ACQUISITION OF TARUS</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GoodwillAbstract" xlink:label="ptgef_GoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GoodwillAbstract" xlink:to="ptgef_GoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_GoodwillAbstract_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GoodwillExplanatory" xlink:label="ptgef_GoodwillExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GoodwillExplanatory" xlink:to="ptgef_GoodwillExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GoodwillExplanatory_lbl" xml:lang="en-US">GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:label="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract_lbl" xml:lang="en-US">In-process Research And Development And Deferred Tax Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability" xlink:label="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability" xlink:to="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability_lbl" xml:lang="en-US">IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnsecuredNotesPayableAbstract" xlink:label="ptgef_UnsecuredNotesPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnsecuredNotesPayableAbstract" xlink:to="ptgef_UnsecuredNotesPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnsecuredNotesPayableAbstract_lbl" xml:lang="en-US">Unsecured Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnsecuredNotesPayableAndWarrantsTextBlock" xlink:label="ptgef_UnsecuredNotesPayableAndWarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnsecuredNotesPayableAndWarrantsTextBlock" xlink:to="ptgef_UnsecuredNotesPayableAndWarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnsecuredNotesPayableAndWarrantsTextBlock_lbl" xml:lang="en-US">UNSECURED NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxesAbstract" xlink:label="ptgef_IncomeTaxesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeTaxesAbstract" xlink:to="ptgef_IncomeTaxesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncomeTaxesAbstract_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantLiabilityAbstract" xlink:label="ptgef_WarrantLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiabilityAbstract" xlink:to="ptgef_WarrantLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantLiabilityAbstract_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantLiabilitytextblock" xlink:label="ptgef_WarrantLiabilitytextblock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiabilitytextblock" xlink:to="ptgef_WarrantLiabilitytextblock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantLiabilitytextblock_lbl" xml:lang="en-US">WARRANT LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CapitalStockAbstract" xlink:label="ptgef_CapitalStockAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalStockAbstract" xlink:to="ptgef_CapitalStockAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalStockAbstract_lbl" xml:lang="en-US">Capital Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CapitalStockTextBlock" xlink:label="ptgef_CapitalStockTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalStockTextBlock" xlink:to="ptgef_CapitalStockTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalStockTextBlock_lbl" xml:lang="en-US">CAPITAL STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveAbstract" xlink:label="ptgef_StockOptionReserveAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserveAbstract" xlink:to="ptgef_StockOptionReserveAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionReserveAbstract_lbl" xml:lang="en-US">Stock Option Reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">STOCK OPTION RESERVE</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LosPerShareAbstract" xlink:label="ptgef_LosPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LosPerShareAbstract" xlink:to="ptgef_LosPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LosPerShareAbstract_lbl" xml:lang="en-US">Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">(LOSS) PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommitmentsAndContingentLiabilitiesAbstract" xlink:label="ptgef_CommitmentsAndContingentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentsAndContingentLiabilitiesAbstract" xlink:to="ptgef_CommitmentsAndContingentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommitmentsAndContingentLiabilitiesAbstract_lbl" xml:lang="en-US">Commitments And Contingent Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related party transactions [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="ptgef_FinancialInstrumentsAndRiskManagementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ptgef_FinancialInstrumentsAndRiskManagementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US">Financial Instruments And Risk Management</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CapitalDisclosuresAbstract" xlink:label="ptgef_CapitalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalDisclosuresAbstract" xlink:to="ptgef_CapitalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalDisclosuresAbstract_lbl" xml:lang="en-US">Capital Disclosures</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:label="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:to="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock_lbl" xml:lang="en-US">CAPITAL DISCLOSURES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NonControllingInterestAbstract" xlink:label="ptgef_NonControllingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NonControllingInterestAbstract" xlink:to="ptgef_NonControllingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NonControllingInterestAbstract_lbl" xml:lang="en-US">Non-controlling Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl" xml:lang="en-US">NON-CONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EventAfterTheBalanceSheetDateAbstract" xlink:label="ptgef_EventAfterTheBalanceSheetDateAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EventAfterTheBalanceSheetDateAbstract" xlink:to="ptgef_EventAfterTheBalanceSheetDateAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EventAfterTheBalanceSheetDateAbstract_lbl" xml:lang="en-US">Event After Balance Sheet Date</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock" xlink:label="ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock" xlink:to="ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock_lbl" xml:lang="en-US">EVENT AFTER THE BALANCE SHEET DATE</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:label="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:to="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfInvestmentAssociatetableTextBlock" xlink:label="ptgef_DisclosureOfInvestmentAssociatetableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfInvestmentAssociatetableTextBlock" xlink:to="ptgef_DisclosureOfInvestmentAssociatetableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfInvestmentAssociatetableTextBlock_lbl" xml:lang="en-US">Schedule of investment associate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock" xlink:label="ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock" xlink:to="ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock_lbl" xml:lang="en-US">Schedule of investment in Stimunity S.A.</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of assets acquired and liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfProformaInformationTableTextBlock" xlink:label="ptgef_ScheduleOfProformaInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfProformaInformationTableTextBlock" xlink:to="ptgef_ScheduleOfProformaInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfProformaInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of pro forma information</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" xlink:label="ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" xlink:to="ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Schedule of IPR&amp;D projects</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" xlink:label="ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" xlink:to="ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_lbl" xml:lang="en-US">Schedule of In process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfNotesPayableTableTextBlock" xlink:label="ptgef_ScheduleOfNotesPayableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfNotesPayableTableTextBlock" xlink:to="ptgef_ScheduleOfNotesPayableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfNotesPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock" xlink:label="ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock" xlink:to="ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of income taxes benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:label="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:to="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation income tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfIncomeTaxExplanatory" xlink:label="ptgef_ScheduleOfIncomeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfIncomeTaxExplanatory" xlink:to="ptgef_ScheduleOfIncomeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfIncomeTaxExplanatory_lbl" xml:lang="en-US">Schedule of effective income tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock" xlink:label="ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock" xlink:to="ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of financial statement loss to tax basis loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfDeferredTaxAssetsExplanatory" xlink:label="ptgef_DisclosureOfDeferredTaxAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfDeferredTaxAssetsExplanatory" xlink:to="ptgef_DisclosureOfDeferredTaxAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfDeferredTaxAssetsExplanatory_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:to="ptgef_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" xlink:label="ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" xlink:to="ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_lbl" xml:lang="en-US">Common shares: Unlimited number of common shares without par value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfTermsStockOptionReserveExplanatory" xlink:label="ptgef_DisclosureOfTermsStockOptionReserveExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfTermsStockOptionReserveExplanatory" xlink:to="ptgef_DisclosureOfTermsStockOptionReserveExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfTermsStockOptionReserveExplanatory_lbl" xml:lang="en-US">Disclosure Of Terms Stock Option Reserve Explanatory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US">Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory" xlink:label="ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory" xlink:to="ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory_lbl" xml:lang="en-US">Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" xlink:label="ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" xlink:to="ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_lbl" xml:lang="en-US">Schedule of outstanding stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of weighted average exercise price and remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EarningsPerShareTableTextBlock" xlink:label="ptgef_EarningsPerShareTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EarningsPerShareTableTextBlock" xlink:to="ptgef_EarningsPerShareTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EarningsPerShareTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted EPS calculations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" xlink:label="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" xlink:to="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:to="ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:label="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:to="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock_lbl" xml:lang="en-US">Schedule of non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xml:lang="en-US">Percentage of acquire</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable_lbl" xml:lang="en-US">Disclosure of offsetting of financial assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TotalCurrentLiabilities" xlink:label="ptgef_TotalCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TotalCurrentLiabilities" xlink:to="ptgef_TotalCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TotalCurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetLossIncome" xlink:label="ptgef_NetLossIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLossIncome" xlink:to="ptgef_NetLossIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetLossIncome_lbl" xml:lang="en-US">Net (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CashUsedInOperatingActivities" xlink:label="ptgef_CashUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashUsedInOperatingActivities" xlink:to="ptgef_CashUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOnHand" xlink:label="ifrs-full_CashOnHand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOnHand_lbl" xml:lang="en-US">Cash on hand</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IssuanceAndSales" xlink:label="ptgef_IssuanceAndSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IssuanceAndSales" xlink:to="ptgef_IssuanceAndSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IssuanceAndSales_lbl" xml:lang="en-US">Issuance and sales</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_MaximumAggregateOfferingPrice" xlink:label="ptgef_MaximumAggregateOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_MaximumAggregateOfferingPrice" xlink:to="ptgef_MaximumAggregateOfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US">Maximum aggregate offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CashFundDescription" xlink:label="ptgef_CashFundDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashFundDescription" xlink:to="ptgef_CashFundDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashFundDescription_lbl" xml:lang="en-US">Cash fund, description</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfStockSold" xlink:label="ptgef_NumberOfStockSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfStockSold" xlink:to="ptgef_NumberOfStockSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfStockSold_lbl" xml:lang="en-US">Number of stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GrossProceedsFromStockSold" xlink:label="ptgef_GrossProceedsFromStockSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GrossProceedsFromStockSold" xlink:to="ptgef_GrossProceedsFromStockSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GrossProceedsFromStockSold_lbl" xml:lang="en-US">Gross proceeds from stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetProceedsFromStockSold" xlink:label="ptgef_NetProceedsFromStockSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetProceedsFromStockSold" xlink:to="ptgef_NetProceedsFromStockSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetProceedsFromStockSold_lbl" xml:lang="en-US">Net proceeds from stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OfferingAndThroughThatProcessDescription" xlink:label="ptgef_OfferingAndThroughThatProcessDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OfferingAndThroughThatProcessDescription" xlink:to="ptgef_OfferingAndThroughThatProcessDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OfferingAndThroughThatProcessDescription_lbl" xml:lang="en-US">Offering and through that process, description</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesSold" xlink:label="ptgef_NumberOfSharesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfSharesSold" xlink:to="ptgef_NumberOfSharesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfSharesSold_lbl" xml:lang="en-US">Number of shares sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:label="ifrs-full_ProceedsFromSalesOfBiologicalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:to="ifrs-full_ProceedsFromSalesOfBiologicalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOfBiologicalAssets_lbl" xml:lang="en-US">Net proceeds from sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:to="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentReceivablesFromSaleOfProperties" xlink:label="ifrs-full_CurrentReceivablesFromSaleOfProperties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentReceivablesFromSaleOfProperties" xlink:to="ifrs-full_CurrentReceivablesFromSaleOfProperties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentReceivablesFromSaleOfProperties_lbl" xml:lang="en-US">Prepaid clinical research costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvancesToSuppliers" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ResearchAndDevelopmentCredit" xlink:label="ptgef_ResearchAndDevelopmentCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ResearchAndDevelopmentCredit" xlink:to="ptgef_ResearchAndDevelopmentCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ResearchAndDevelopmentCredit_lbl" xml:lang="en-US">Research &amp; development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TaxDeposits" xlink:label="ptgef_TaxDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TaxDeposits" xlink:to="ptgef_TaxDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TaxDeposits_lbl" xml:lang="en-US">Tax deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentPrepayments_lbl" xml:lang="en-US">Total prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl" xml:lang="en-US">Disclosure of associates [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfAssociate" xlink:label="ifrs-full_NameOfAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NameOfAssociate" xlink:to="ifrs-full_NameOfAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NameOfAssociate_lbl" xml:lang="en-US">Name of associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:to="ifrs-full_PrincipalPlaceOfBusinessOfAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PrincipalPlaceOfBusinessOfAssociate_lbl" xml:lang="en-US">Principal place of business of associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:to="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CountryOfIncorporationOrResidenceOfAssociate_lbl" xml:lang="en-US">Country of incorporation of associate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="ifrs-full_ProportionOfVotingPowerHeldInAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:to="ifrs-full_ProportionOfVotingPowerHeldInAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfVotingPowerHeldInAssociate_lbl" xml:lang="en-US">Proportion of voting rights held in associate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnrecognisedShareOfLossesOfAssociates" xlink:label="ifrs-full_UnrecognisedShareOfLossesOfAssociates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnrecognisedShareOfLossesOfAssociates" xlink:to="ifrs-full_UnrecognisedShareOfLossesOfAssociates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_UnrecognisedShareOfLossesOfAssociates_lbl" xml:lang="en-US">Share of (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AdditionalInvestment" xlink:label="ptgef_AdditionalInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdditionalInvestment" xlink:to="ptgef_AdditionalInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AdditionalInvestment_lbl" xml:lang="en-US">Additional investments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SubscribingClassShares" xlink:label="ptgef_SubscribingClassShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SubscribingClassShares" xlink:to="ptgef_SubscribingClassShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SubscribingClassShares_lbl" xml:lang="en-US">Subscribing class A shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNoteDescription" xlink:label="ptgef_ConvertibleNoteDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ConvertibleNoteDescription" xlink:to="ptgef_ConvertibleNoteDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ConvertibleNoteDescription_lbl" xml:lang="en-US">Convertible Note description</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EquityInLossIncome" xlink:label="ptgef_EquityInLossIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EquityInLossIncome" xlink:to="ptgef_EquityInLossIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EquityInLossIncome_lbl" xml:lang="en-US">Equity in (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PrivateInvestments" xlink:label="ptgef_PrivateInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrivateInvestments" xlink:to="ptgef_PrivateInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrivateInvestments_lbl" xml:lang="en-US">Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentOwnedShares" xlink:label="ptgef_InvestmentOwnedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentOwnedShares" xlink:to="ptgef_InvestmentOwnedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentOwnedShares_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentOwnershipPercentage" xlink:label="ptgef_InvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_InvestmentOwnershipPercentage" xlink:to="ptgef_InvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_InvestmentOwnershipPercentage_lbl" xml:lang="en-US">Percentage of equity held</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:to="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_lbl" xml:lang="en-US">Number of ordinary shares issued in acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:label="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:to="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset_lbl" xml:lang="en-US">Number of private company share consists in sole asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_2_lbl" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OfferingPrice" xlink:label="ptgef_OfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OfferingPrice" xlink:to="ptgef_OfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OfferingPrice_lbl" xml:lang="en-US">Offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets" xlink:label="ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets" xlink:to="ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied" xlink:label="ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied" xlink:to="ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied_lbl" xml:lang="en-US">Carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnrealizedLoss" xlink:label="ptgef_UnrealizedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnrealizedLoss" xlink:to="ptgef_UnrealizedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnrealizedLoss_lbl" xml:lang="en-US">Unrealized loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:label="ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable_lbl" xml:lang="en-US">Disclosure of transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AssetsAbstract_2_lbl" xml:lang="en-US">Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Identifiable intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTangibleOrIntangibleAssetsTransferred" xlink:label="ifrs-full_OtherTangibleOrIntangibleAssetsTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherTangibleOrIntangibleAssetsTransferred" xlink:to="ifrs-full_OtherTangibleOrIntangibleAssetsTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherTangibleOrIntangibleAssetsTransferred_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_lbl" xml:lang="en-US">Consideration:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_lbl" xml:lang="en-US">Fair value of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_lbl" xml:lang="en-US">Liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_lbl" xml:lang="en-US">Deferred purchase consideration at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="ifrs-full_ProfitLossFromContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromContinuingOperations" xlink:to="ifrs-full_ProfitLossFromContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromContinuingOperations_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_2_lbl" xml:lang="en-US">Loss before provision for income taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_2_lbl" xml:lang="en-US">Net loss and other comprehensive loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_2_lbl" xml:lang="en-US">Total comprehensive loss for year</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EarningLossPerShare" xlink:label="ptgef_EarningLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EarningLossPerShare" xlink:to="ptgef_EarningLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_EarningLossPerShare_lbl" xml:lang="en-US">Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US">Proceeds from offering</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_MilestonePayment" xlink:label="ptgef_MilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_MilestonePayment" xlink:to="ptgef_MilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Goodwill" xlink:to="ifrs-full_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Goodwill_2_lbl" xml:lang="en-US">Balance, beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusGoodwill" xlink:label="ptgef_TarusGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TarusGoodwill" xlink:to="ptgef_TarusGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TarusGoodwill_lbl" xml:lang="en-US">Tarus goodwill</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Goodwill" xlink:to="ifrs-full_Goodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Goodwill_3_lbl" xml:lang="en-US">Balance, ending of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="ifrs-full_ConsiderationPaidReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl" xml:lang="en-US">Consideration paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_2_lbl" xml:lang="en-US">Fair value of identifiable assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:to="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections_lbl" xml:lang="en-US">Discount rate applied to cash flow projections</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxesLiability" xlink:label="ptgef_DeferredTaxesLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxesLiability" xlink:to="ptgef_DeferredTaxesLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DeferredTaxesLiability_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxLiability" xlink:label="ptgef_DeferredTaxLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxLiability" xlink:to="ptgef_DeferredTaxLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DeferredTaxLiability_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncreaseInDeferredIncomeTaxes" xlink:label="ptgef_IncreaseInDeferredIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncreaseInDeferredIncomeTaxes" xlink:to="ptgef_IncreaseInDeferredIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Increase in deferred income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_lbl" xml:lang="en-US">Increase (Decrease) in deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ReductionInDeferredTaxLiability" xlink:label="ptgef_ReductionInDeferredTaxLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ReductionInDeferredTaxLiability" xlink:to="ptgef_ReductionInDeferredTaxLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ReductionInDeferredTaxLiability_lbl" xml:lang="en-US">Reduction in deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="ifrs-full_TaxEffectFromChangeInTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectFromChangeInTaxRate" xlink:to="ifrs-full_TaxEffectFromChangeInTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectFromChangeInTaxRate_lbl" xml:lang="en-US">Change in tax effect rate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NotePayable" xlink:label="ptgef_NotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NotePayable" xlink:to="ptgef_NotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_NotePayable_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare" xlink:label="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare" xlink:to="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare_lbl" xml:lang="en-US">Exchange of notes payable and accrued interest for iOx shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NotePayable" xlink:to="ptgef_NotePayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_NotePayable_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DescriptionOfBusinessCombination" xlink:label="ptgef_DescriptionOfBusinessCombination" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfBusinessCombination" xlink:to="ptgef_DescriptionOfBusinessCombination_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfBusinessCombination_lbl" xml:lang="en-US">Description of business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IssuanceOfUnsecuredNotesDescription" xlink:label="ptgef_IssuanceOfUnsecuredNotesDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IssuanceOfUnsecuredNotesDescription" xlink:to="ptgef_IssuanceOfUnsecuredNotesDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_IssuanceOfUnsecuredNotesDescription_lbl" xml:lang="en-US">Description of business combination</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_lbl" xml:lang="en-US">Current:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentFederalIncomeTaxBenefit" xlink:label="ptgef_CurrentFederalIncomeTaxBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentFederalIncomeTaxBenefit" xlink:to="ptgef_CurrentFederalIncomeTaxBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CurrentFederalIncomeTaxBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentStateAndLocalIncomeTaxBenefit" xlink:label="ptgef_CurrentStateAndLocalIncomeTaxBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentStateAndLocalIncomeTaxBenefit" xlink:to="ptgef_CurrentStateAndLocalIncomeTaxBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CurrentStateAndLocalIncomeTaxBenefit_lbl" xml:lang="en-US">State and local</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentForeignIncomeTaxBenefit" xlink:label="ptgef_CurrentForeignIncomeTaxBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentForeignIncomeTaxBenefit" xlink:to="ptgef_CurrentForeignIncomeTaxBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CurrentForeignIncomeTaxBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US">Total current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="ifrs-full_DeferredTaxExpenseIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DeferredTaxExpenseIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncomeAbstract_lbl" xml:lang="en-US">Deferred:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredFederalIncomeTaxBenefit" xlink:label="ptgef_DeferredFederalIncomeTaxBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredFederalIncomeTaxBenefit" xlink:to="ptgef_DeferredFederalIncomeTaxBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DeferredFederalIncomeTaxBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredStateAndLocalIncomeTaxBenefit" xlink:label="ptgef_DeferredStateAndLocalIncomeTaxBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredStateAndLocalIncomeTaxBenefit" xlink:to="ptgef_DeferredStateAndLocalIncomeTaxBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DeferredStateAndLocalIncomeTaxBenefit_lbl" xml:lang="en-US">State and local</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredForeignIncomeTaxBenefit" xlink:label="ptgef_DeferredForeignIncomeTaxBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredForeignIncomeTaxBenefit" xlink:to="ptgef_DeferredForeignIncomeTaxBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DeferredForeignIncomeTaxBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xml:lang="en-US">Total deferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xml:lang="en-US">Benefit from income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax" xlink:label="ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax" xlink:to="ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax_lbl" xml:lang="en-US">Income (loss) on ordinary activities before tax</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StatutoryU.s.IncomeTaxRate" xlink:label="ptgef_StatutoryU.s.IncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StatutoryU.s.IncomeTaxRate" xlink:to="ptgef_StatutoryU.s.IncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StatutoryU.s.IncomeTaxRate_lbl" xml:lang="en-US">Statutory U.S. income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossAtStatutoryIncomeTaxRate" xlink:label="ptgef_LossAtStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossAtStatutoryIncomeTaxRate" xlink:to="ptgef_LossAtStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossAtStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax at statutory income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossesRecognized" xlink:label="ptgef_LossesRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossesRecognized" xlink:to="ptgef_LossesRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossesRecognized_lbl" xml:lang="en-US">Losses recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxBenefitExpense" xlink:label="ptgef_IncomeTaxBenefitExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeTaxBenefitExpense" xlink:to="ptgef_IncomeTaxBenefitExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncomeTaxBenefitExpense_lbl" xml:lang="en-US">Income tax benefit (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccountingProfit" xlink:to="ifrs-full_AccountingProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccountingProfit_lbl" xml:lang="en-US">Loss on ordinary activities before tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US">Statutory U.K. income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xml:lang="en-US">Loss at statutory income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChangeIncreaseInDeferredIncomeTaxRate" xlink:label="ptgef_ChangeIncreaseInDeferredIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeIncreaseInDeferredIncomeTaxRate" xlink:to="ptgef_ChangeIncreaseInDeferredIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeIncreaseInDeferredIncomeTaxRate_lbl" xml:lang="en-US">Change (increase) in deferred income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ForeignCurrencyEffect" xlink:label="ptgef_ForeignCurrencyEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ForeignCurrencyEffect" xlink:to="ptgef_ForeignCurrencyEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ForeignCurrencyEffect_lbl" xml:lang="en-US">Foreign currency effect</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TaxEffectOfRAndDCredit" xlink:label="ptgef_TaxEffectOfRAndDCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TaxEffectOfRAndDCredit" xlink:to="ptgef_TaxEffectOfRAndDCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TaxEffectOfRAndDCredit_lbl" xml:lang="en-US">Research and development credit</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossesUnrecognized" xlink:label="ptgef_LossesUnrecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossesUnrecognized" xlink:to="ptgef_LossesUnrecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossesUnrecognized_lbl" xml:lang="en-US">Losses (unrecognized)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="ifrs-full_TaxEffectOfTaxLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" xlink:label="srt_ProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" xlink:to="srt_ProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable_lbl" xml:lang="en-US">Proved Developed and Undeveloped Oil and Gas Reserve Quantities [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReserveQuantitiesLineItems" xlink:label="srt_ReserveQuantitiesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ReserveQuantitiesLineItems" xlink:to="srt_ReserveQuantitiesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ReserveQuantitiesLineItems_lbl" xml:lang="en-US">Reserve Quantities [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PretaxIncomeLoss" xlink:label="ptgef_PretaxIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PretaxIncomeLoss" xlink:to="ptgef_PretaxIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PretaxIncomeLoss_lbl" xml:lang="en-US">Pre-tax loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossForWhichNoBenefitWasTaken" xlink:label="ptgef_LossForWhichNoBenefitWasTaken" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossForWhichNoBenefitWasTaken" xlink:to="ptgef_LossForWhichNoBenefitWasTaken_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossForWhichNoBenefitWasTaken_lbl" xml:lang="en-US">Loss for which no benefit was taken</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossesNotSubjectToTax" xlink:label="ptgef_LossesNotSubjectToTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossesNotSubjectToTax" xlink:to="ptgef_LossesNotSubjectToTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossesNotSubjectToTax_lbl" xml:lang="en-US">Losses not subject to tax</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UtilizationOfLossesNotPreviouslyBenefitted" xlink:label="ptgef_UtilizationOfLossesNotPreviouslyBenefitted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UtilizationOfLossesNotPreviouslyBenefitted" xlink:to="ptgef_UtilizationOfLossesNotPreviouslyBenefitted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UtilizationOfLossesNotPreviouslyBenefitted_lbl" xml:lang="en-US">Utilization of losses not previously benefitted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PretaxLossSubjectToTax" xlink:label="ptgef_PretaxLossSubjectToTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PretaxLossSubjectToTax" xlink:to="ptgef_PretaxLossSubjectToTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PretaxLossSubjectToTax_lbl" xml:lang="en-US">Taxable income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxAssetsAbstract" xlink:label="ptgef_DeferredTaxAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxAssetsAbstract" xlink:to="ptgef_DeferredTaxAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" xlink:label="ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" xlink:to="ptgef_DeferredTaxAssetsNetOperatingLossCarryforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxAssetsNetOperatingLossCarryforward_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxAssetUnrecognized" xlink:label="ptgef_DeferredTaxAssetUnrecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxAssetUnrecognized" xlink:to="ptgef_DeferredTaxAssetUnrecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxAssetUnrecognized_lbl" xml:lang="en-US">Deferred tax asset (unrecognized)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxLiabiltiesAbstract" xlink:label="ptgef_DeferredTaxLiabiltiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxLiabiltiesAbstract" xlink:to="ptgef_DeferredTaxLiabiltiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxLiabiltiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxLiabilitiesInProcessRAndD" xlink:label="ptgef_DeferredTaxLiabilitiesInProcessRAndD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxLiabilitiesInProcessRAndD" xlink:to="ptgef_DeferredTaxLiabilitiesInProcessRAndD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DeferredTaxLiabilitiesInProcessRAndD_lbl" xml:lang="en-US">In-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxLiability1" xlink:label="ptgef_DeferredTaxLiability1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxLiability1" xlink:to="ptgef_DeferredTaxLiability1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgef_DeferredTaxLiability1_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxLiabilities" xlink:label="ifrs-full_NetDeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxLiabilities" xlink:to="ifrs-full_NetDeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ResearchAndDevelopmentCreditReceivables" xlink:label="ptgef_ResearchAndDevelopmentCreditReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ResearchAndDevelopmentCreditReceivables" xlink:to="ptgef_ResearchAndDevelopmentCreditReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ResearchAndDevelopmentCreditReceivables_lbl" xml:lang="en-US">Research and development credit receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ResearchAndDevelopmentExpenseCashCredits" xlink:label="ptgef_ResearchAndDevelopmentExpenseCashCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ResearchAndDevelopmentExpenseCashCredits" xlink:to="ptgef_ResearchAndDevelopmentExpenseCashCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ResearchAndDevelopmentExpenseCashCredits_lbl" xml:lang="en-US">Research and development cash credits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncome" xlink:to="ifrs-full_DeferredTaxExpenseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncome_lbl" xml:lang="en-US">Deferred tax expense (income)</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentYearLosses" xlink:label="ptgef_CurrentYearLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentYearLosses" xlink:to="ptgef_CurrentYearLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CurrentYearLosses_lbl" xml:lang="en-US">Current year losses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsOutstandingExercisePrice" xlink:label="ptgef_WarrantsOutstandingExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingExercisePrice" xlink:to="ptgef_WarrantsOutstandingExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_WarrantsOutstandingExercisePrice_lbl" xml:lang="en-US">Warrants outstanding exercise price at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsOutstandingShares" xlink:label="ptgef_WarrantsOutstandingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingShares" xlink:to="ptgef_WarrantsOutstandingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_WarrantsOutstandingShares_lbl" xml:lang="en-US">Warrants outstanding, shares at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsOutstandingAmount" xlink:label="ptgef_WarrantsOutstandingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingAmount" xlink:to="ptgef_WarrantsOutstandingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_WarrantsOutstandingAmount_lbl" xml:lang="en-US">Warrants outstanding, amount at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueAdjustmentExercisePriceAtEnd" xlink:label="ptgef_FairValueAdjustmentExercisePriceAtEnd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueAdjustmentExercisePriceAtEnd" xlink:to="ptgef_FairValueAdjustmentExercisePriceAtEnd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueAdjustmentExercisePriceAtEnd_lbl" xml:lang="en-US">Fair value adjustment , exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueAdjustmentShares" xlink:label="ptgef_FairValueAdjustmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueAdjustmentShares" xlink:to="ptgef_FairValueAdjustmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueAdjustmentShares_lbl" xml:lang="en-US">Fair value adjustment, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueAdjustmentAmount" xlink:label="ptgef_FairValueAdjustmentAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueAdjustmentAmount" xlink:to="ptgef_FairValueAdjustmentAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueAdjustmentAmount_lbl" xml:lang="en-US">Fair value adjustment, amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingExercisePrice" xlink:to="ptgef_WarrantsOutstandingExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_WarrantsOutstandingExercisePrice_2_lbl" xml:lang="en-US">Warrants outstanding exercise price at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingShares" xlink:to="ptgef_WarrantsOutstandingShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_WarrantsOutstandingShares_2_lbl" xml:lang="en-US">Warrants outstanding, shares at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingAmount" xlink:to="ptgef_WarrantsOutstandingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_WarrantsOutstandingAmount_2_lbl" xml:lang="en-US">Warrants outstanding, amount at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GainLossOfChangeInFairValueOfWarrants" xlink:label="ptgef_GainLossOfChangeInFairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainLossOfChangeInFairValueOfWarrants" xlink:to="ptgef_GainLossOfChangeInFairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainLossOfChangeInFairValueOfWarrants_lbl" xml:lang="en-US">Gain (loss) of change in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommonStockShares" xlink:label="ptgef_CommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockShares" xlink:to="ptgef_CommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_CommonStockShares_lbl" xml:lang="en-US">Balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommonStockValues" xlink:label="ptgef_CommonStockValues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockValues" xlink:to="ptgef_CommonStockValues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_CommonStockValues_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Shares issued in Tarus acquisition, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions_lbl" xml:lang="en-US">Shares issued in Tarus acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInIoxExchangesShares" xlink:label="ptgef_SharesIssuedInIoxExchangesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInIoxExchangesShares" xlink:to="ptgef_SharesIssuedInIoxExchangesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInIoxExchangesShares_lbl" xml:lang="en-US">Shares issued in iOx exchange, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ShareIssuedInIoxExchange" xlink:label="ptgef_ShareIssuedInIoxExchange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareIssuedInIoxExchange" xlink:to="ptgef_ShareIssuedInIoxExchange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_ShareIssuedInIoxExchange_lbl" xml:lang="en-US">Shares issued in iOx exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares" xlink:label="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares" xlink:to="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_lbl" xml:lang="en-US">Excess of non-controlling interest acquired over consideration iOx, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" xlink:label="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" xlink:to="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_lbl" xml:lang="en-US">Excess of non-controlling interest acquired over consideration iOx, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares" xlink:label="ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares" xlink:to="ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares_lbl" xml:lang="en-US">Shares issued to Lincoln Parks Committed Purchase, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedToLincolnParksCommittedPurchase" xlink:label="ptgef_SharesIssuedToLincolnParksCommittedPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedToLincolnParksCommittedPurchase" xlink:to="ptgef_SharesIssuedToLincolnParksCommittedPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_SharesIssuedToLincolnParksCommittedPurchase_lbl" xml:lang="en-US">Shares issued to Lincoln Parks Committed Purchase, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares" xlink:label="ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares" xlink:to="ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_lbl" xml:lang="en-US">Shares issued under public offering and ATM, net of issue costs , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts" xlink:label="ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts" xlink:to="ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_lbl" xml:lang="en-US">Shares issued under public offering and ATM, net of issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares" xlink:label="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares" xlink:to="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_lbl" xml:lang="en-US">Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts" xlink:label="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts" xlink:to="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_lbl" xml:lang="en-US">Purchase of shares issued under Committed Purchase Agreement, net of issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US">Shares issued or accrued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xml:lang="en-US">Purchase of shares issued under Committed Purchase Agreement, net of issue costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsExercisedShares" xlink:to="ptgef_WarrantsExercisedShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_WarrantsExercisedShares_2_lbl" xml:lang="en-US">Warrants exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsExercisedShares1" xlink:label="ptgef_WarrantsExercisedShares1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsExercisedShares1" xlink:to="ptgef_WarrantsExercisedShares1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsExercisedShares1_lbl" xml:lang="en-US">Warrants exercised, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockShares" xlink:to="ptgef_CommonStockShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_CommonStockShares_2_lbl" xml:lang="en-US">Balance, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockValues" xlink:to="ptgef_CommonStockValues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_CommonStockValues_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:to="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares_lbl" xml:lang="en-US">Shares issued in a private placement, net of issue costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PricePerShare" xlink:label="ptgef_PricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PricePerShare" xlink:to="ptgef_PricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PricePerShare_lbl" xml:lang="en-US">Shares price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:to="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts_lbl" xml:lang="en-US">Shares issued in a private placement, net of issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OfferingExpenses" xlink:label="ptgef_OfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OfferingExpenses" xlink:to="ptgef_OfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OfferingExpenses_lbl" xml:lang="en-US">Offering Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ManagementUnderwritingAndSellingExpenses" xlink:label="ptgef_ManagementUnderwritingAndSellingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ManagementUnderwritingAndSellingExpenses" xlink:to="ptgef_ManagementUnderwritingAndSellingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ManagementUnderwritingAndSellingExpenses_lbl" xml:lang="en-US">Management, underwriting and selling expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesExchanged" xlink:label="ptgef_NumberOfSharesExchanged" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfSharesExchanged" xlink:to="ptgef_NumberOfSharesExchanged_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfSharesExchanged_lbl" xml:lang="en-US">Number of shares exchanged</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_MinorityInterestPercentage" xlink:label="ptgef_MinorityInterestPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_MinorityInterestPercentage" xlink:to="ptgef_MinorityInterestPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_MinorityInterestPercentage_lbl" xml:lang="en-US">Minority interest, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserve" xlink:label="ptgef_StockOptionReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_StockOptionReserve_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_2_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SettledInIoxExchange" xlink:label="ptgef_SettledInIoxExchange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SettledInIoxExchange" xlink:to="ptgef_SettledInIoxExchange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SettledInIoxExchange_lbl" xml:lang="en-US">Settled in iOx exchange</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_StockOptionReserve_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OptionLifeShareOptionsGranted" xlink:label="ptgef_OptionLifeShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OptionLifeShareOptionsGranted" xlink:to="ptgef_OptionLifeShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OptionLifeShareOptionsGranted_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfPortageOption" xlink:label="ptgef_FairValueOfPortageOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfPortageOption" xlink:to="ptgef_FairValueOfPortageOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfPortageOption_lbl" xml:lang="en-US">Fair value of Portage option</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="ptgef_NumberOfOutstandingShareOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_NumberOfOutstandingShareOption_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:label="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:to="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:to="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Expired or forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_NumberOfOutstandingShareOption_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:to="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_lbl" xml:lang="en-US">Exercisable as at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockGranted" xlink:label="ptgef_StockGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockGranted" xlink:to="ptgef_StockGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockGranted_lbl" xml:lang="en-US">Stock granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValuePerShare" xlink:label="ptgef_FairValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValuePerShare" xlink:to="ptgef_FairValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValuePerShare_lbl" xml:lang="en-US">Fair value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommunicationExpense" xlink:label="ifrs-full_CommunicationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommunicationExpense" xlink:to="ifrs-full_CommunicationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommunicationExpense_lbl" xml:lang="en-US">Compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IntrinsicValueOfStockOptions" xlink:label="ptgef_IntrinsicValueOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IntrinsicValueOfStockOptions" xlink:to="ptgef_IntrinsicValueOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IntrinsicValueOfStockOptions_lbl" xml:lang="en-US">Intrinsic value of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumeratorAbstract" xlink:label="ptgef_NumeratorAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumeratorAbstract" xlink:to="ptgef_NumeratorAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumeratorAbstract_lbl" xml:lang="en-US">Numerator (in 000&#8217;$)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Net loss attributable to owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DenominatorAbstract" xlink:label="ptgef_DenominatorAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DenominatorAbstract" xlink:to="ptgef_DenominatorAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DenominatorAbstract_lbl" xml:lang="en-US">Denominator (in 000&#8217;)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average number of shares &#8211; Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BasicAndDilutedLossPerShare" xlink:label="ptgef_BasicAndDilutedLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BasicAndDilutedLossPerShare" xlink:to="ptgef_BasicAndDilutedLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BasicAndDilutedLossPerShare_lbl" xml:lang="en-US">Basic and diluted (loss) per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AntidilutiveEffectOnLossPerShare" xlink:label="ptgef_AntidilutiveEffectOnLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AntidilutiveEffectOnLossPerShare" xlink:to="ptgef_AntidilutiveEffectOnLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AntidilutiveEffectOnLossPerShare_lbl" xml:lang="en-US">Anti-dilutive effect on loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNote" xlink:label="ptgef_ConvertibleNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ConvertibleNote" xlink:to="ptgef_ConvertibleNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ConvertibleNote_lbl" xml:lang="en-US">Convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConversionOfDebt" xlink:label="ptgef_ConversionOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ConversionOfDebt" xlink:to="ptgef_ConversionOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ConversionOfDebt_lbl" xml:lang="en-US">Conversion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConversionOfDebtIntoShares" xlink:label="ptgef_ConversionOfDebtIntoShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ConversionOfDebtIntoShares" xlink:to="ptgef_ConversionOfDebtIntoShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ConversionOfDebtIntoShares_lbl" xml:lang="en-US">Conversion of debt into shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharePricePerShare" xlink:label="ptgef_SharePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharePricePerShare" xlink:to="ptgef_SharePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharePricePerShare_lbl" xml:lang="en-US">Share price, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AggregateValue" xlink:label="ptgef_AggregateValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AggregateValue" xlink:to="ptgef_AggregateValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AggregateValue_lbl" xml:lang="en-US">Aggregate value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfSharesSold" xlink:to="ptgef_NumberOfSharesSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_NumberOfSharesSold_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommitmentFee" xlink:label="ptgef_CommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentFee" xlink:to="ptgef_CommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommitmentFee_lbl" xml:lang="en-US">Commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IssuanceOfUnsecuredNotesDescriptions" xlink:label="ptgef_IssuanceOfUnsecuredNotesDescriptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IssuanceOfUnsecuredNotesDescriptions" xlink:to="ptgef_IssuanceOfUnsecuredNotesDescriptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IssuanceOfUnsecuredNotesDescriptions_lbl" xml:lang="en-US">Issuance of unsecured notes, description</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PortageOrdinaryShares" xlink:label="ptgef_PortageOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PortageOrdinaryShares" xlink:to="ptgef_PortageOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PortageOrdinaryShares_lbl" xml:lang="en-US">Portage ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BaseSalary" xlink:label="ptgef_BaseSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BaseSalary" xlink:to="ptgef_BaseSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BaseSalary_lbl" xml:lang="en-US">Base Salary</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AnnualFeesdescription" xlink:label="ptgef_AnnualFeesdescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AnnualFeesdescription" xlink:to="ptgef_AnnualFeesdescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AnnualFeesdescription_lbl" xml:lang="en-US">Annual feesDescription</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CompensationCommittee" xlink:label="ptgef_CompensationCommittee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CompensationCommittee" xlink:to="ptgef_CompensationCommittee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CompensationCommittee_lbl" xml:lang="en-US">Compensation committee</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OriginalAnnualTargetsPercentage" xlink:label="ptgef_OriginalAnnualTargetsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OriginalAnnualTargetsPercentage" xlink:to="ptgef_OriginalAnnualTargetsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OriginalAnnualTargetsPercentage_lbl" xml:lang="en-US">Original annual targets percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PrepaidExpensesAndOtherReceivable" xlink:label="ptgef_PrepaidExpensesAndOtherReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivable" xlink:to="ptgef_PrepaidExpensesAndOtherReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_PrepaidExpensesAndOtherReceivable_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNoteReceivableIncludingAccruedInterest" xlink:label="ptgef_ConvertibleNoteReceivableIncludingAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ConvertibleNoteReceivableIncludingAccruedInterest" xlink:to="ptgef_ConvertibleNoteReceivableIncludingAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ConvertibleNoteReceivableIncludingAccruedInterest_lbl" xml:lang="en-US">Convertible note receivable, including accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInvestments" xlink:label="ifrs-full_CurrentInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInvestments_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilities" xlink:to="ptgef_AccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WarrantLiability" xlink:label="ifrs-full_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WarrantLiability_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xml:lang="en-US">Convertible Note receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PayablesAndAccruedExpense" xlink:label="ptgef_PayablesAndAccruedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PayablesAndAccruedExpense" xlink:to="ptgef_PayablesAndAccruedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PayablesAndAccruedExpense_lbl" xml:lang="en-US">Payables and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentAsset" xlink:label="ptgef_CurrentAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentAsset" xlink:to="ptgef_CurrentAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_CurrentAsset_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ShareholdersEquityAttributableToOwners" xlink:label="ptgef_ShareholdersEquityAttributableToOwners" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareholdersEquityAttributableToOwners" xlink:to="ptgef_ShareholdersEquityAttributableToOwners_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareholdersEquityAttributableToOwners_lbl" xml:lang="en-US">Shareholders' equity attributable to owners</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NoncontrollingInterests_2_lbl" xml:lang="en-US">Non-controlling interest, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="ptgef_NetLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLossAttributableToNoncontrollingInterest" xlink:to="ptgef_NetLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net income (loss) attributable to non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" xlink:label="ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" xlink:to="ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_lbl" xml:lang="en-US">Purchase of non-controlling interest pursuant to Share Exchange Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NoncontrollingInterests_3_lbl" xml:lang="en-US">Non-controlling interest, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockBasedCompensationExpense" xlink:label="ptgef_StockBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockBasedCompensationExpense" xlink:to="ptgef_StockBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_StockBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" xlink:label="ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" xlink:to="ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_lbl" xml:lang="en-US">Exchange of notes payable, accrued interest and warrants for iOx shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementTable" xlink:label="ptgef_IfrsStatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IfrsStatementTable" xlink:to="ptgef_IfrsStatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IfrsStatementTable_lbl" xml:lang="en-US">IfrsStatementTable [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_2_lbl" xml:lang="en-US">Current assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_2_lbl" xml:lang="en-US">Non-current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_2_lbl" xml:lang="en-US">Current liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_2_lbl" xml:lang="en-US">Non-current liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Equity attributable to owners of parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_4_lbl" xml:lang="en-US">Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_2_lbl" xml:lang="en-US">Equity and liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_2_lbl" xml:lang="en-US">Profit (loss) from operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeLoss" xlink:to="ifrs-full_ForeignExchangeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeLoss_2_lbl" xml:lang="en-US">Foreign exchange loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_2_lbl" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpense_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_3_lbl" xml:lang="en-US">Tax expense (income)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_Netloss" xlink:to="ptgef_Netloss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_Netloss_2_lbl" xml:lang="en-US">Netloss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_2_lbl" xml:lang="en-US">Other comprehensive income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2_lbl" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests_2_lbl" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" xlink:to="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">WeightedAveragesSharesoutstandingBasicAndDiluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_3_lbl" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredObligationIoxMilestoneValue" xlink:to="ptgef_DeferredObligationIoxMilestoneValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredObligationIoxMilestoneValue_2_lbl" xml:lang="en-US">DeferredObligationIoxMilestoneValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetUnrealizedLossOnInvestmentsValue" xlink:to="ptgef_NetUnrealizedLossOnInvestmentsValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetUnrealizedLossOnInvestmentsValue_2_lbl" xml:lang="en-US">NetUnrealizedLossOnInvestmentsValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_2_lbl" xml:lang="en-US">Increase (decrease) in deferred tax liability (asset)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeOnFairValueOfWarrantLiability" xlink:to="ptgef_IncomeOnFairValueOfWarrantLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncomeOnFairValueOfWarrantLiability_2_lbl" xml:lang="en-US">IncomeOnFairValueOfWarrantLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:to="ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone_2_lbl" xml:lang="en-US">ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainLossOnHedgeIneffectiveness" xlink:to="ifrs-full_GainLossOnHedgeIneffectiveness_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainLossOnHedgeIneffectiveness_2_lbl" xml:lang="en-US">Gain (loss) on hedge ineffectiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_2_lbl" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncreasingDecreasingAccountsReceivable" xlink:to="ptgef_IncreasingDecreasingAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncreasingDecreasingAccountsReceivable_2_lbl" xml:lang="en-US">IncreasingDecreasingAccountsReceivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_2_lbl" xml:lang="en-US">Adjustments for decrease (increase) in prepaid expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2_lbl" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseOfConvertibleNoteReceivable" xlink:to="ptgef_PurchaseOfConvertibleNoteReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchaseOfConvertibleNoteReceivable_2_lbl" xml:lang="en-US">PurchaseOfConvertibleNoteReceivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2_lbl" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition" xlink:to="ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition_2_lbl" xml:lang="en-US">RepaymentOfNotesPayableAssumedInTarusAcquisition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition" xlink:to="ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition_2_lbl" xml:lang="en-US">RepaymentOfMilestoneObligationAssumedInTarusAcquisition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_2_lbl" xml:lang="en-US">Payments for share issue costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory" xlink:to="ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory_2_lbl" xml:lang="en-US">Explanation of inputs, assumptions and estimation techniques used to apply impairment requirements [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_2_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:to="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_2_lbl" xml:lang="en-US">Proportion of ownership interests held by non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepayments_2_lbl" xml:lang="en-US">Current prepayments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnrecognisedShareOfLossesOfAssociates" xlink:to="ifrs-full_UnrecognisedShareOfLossesOfAssociates_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnrecognisedShareOfLossesOfAssociates_2_lbl" xml:lang="en-US">Unrecognised share of losses of associates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EarningLossPerShare" xlink:to="ptgef_EarningLossPerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EarningLossPerShare_2_lbl" xml:lang="en-US">EarningLossPerShare</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxesLiability" xlink:to="ptgef_DeferredTaxesLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxesLiability_2_lbl" xml:lang="en-US">DeferredTaxesLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxLiability" xlink:to="ptgef_DeferredTaxLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxLiability_2_lbl" xml:lang="en-US">DeferredTaxLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NotePayable" xlink:to="ptgef_NotePayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NotePayable_3_lbl" xml:lang="en-US">NotePayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare" xlink:to="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare_2_lbl" xml:lang="en-US">ExchangeOfNotesPayableAndAccruedInterestForIoxShare</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IssuanceOfUnsecuredNotesDescription" xlink:to="ptgef_IssuanceOfUnsecuredNotesDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IssuanceOfUnsecuredNotesDescription_2_lbl" xml:lang="en-US">IssuanceOfUnsecuredNotesDescription</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredFederalIncomeTaxBenefit" xlink:to="ptgef_DeferredFederalIncomeTaxBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredFederalIncomeTaxBenefit_2_lbl" xml:lang="en-US">DeferredFederalIncomeTaxBenefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredStateAndLocalIncomeTaxBenefit" xlink:to="ptgef_DeferredStateAndLocalIncomeTaxBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredStateAndLocalIncomeTaxBenefit_2_lbl" xml:lang="en-US">DeferredStateAndLocalIncomeTaxBenefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredForeignIncomeTaxBenefit" xlink:to="ptgef_DeferredForeignIncomeTaxBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredForeignIncomeTaxBenefit_2_lbl" xml:lang="en-US">DeferredForeignIncomeTaxBenefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDeferredTaxAssets_2_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxLiabilitiesInProcessRAndD" xlink:to="ptgef_DeferredTaxLiabilitiesInProcessRAndD_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxLiabilitiesInProcessRAndD_2_lbl" xml:lang="en-US">DeferredTaxLiabilitiesInProcessRAndD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DeferredTaxLiability1" xlink:to="ptgef_DeferredTaxLiability1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DeferredTaxLiability1_2_lbl" xml:lang="en-US">DeferredTaxLiability1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingExercisePrice" xlink:to="ptgef_WarrantsOutstandingExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsOutstandingExercisePrice_3_lbl" xml:lang="en-US">WarrantsOutstandingExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingShares" xlink:to="ptgef_WarrantsOutstandingShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsOutstandingShares_3_lbl" xml:lang="en-US">WarrantsOutstandingShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsOutstandingAmount" xlink:to="ptgef_WarrantsOutstandingAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsOutstandingAmount_3_lbl" xml:lang="en-US">WarrantsOutstandingAmount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockShares" xlink:to="ptgef_CommonStockShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommonStockShares_3_lbl" xml:lang="en-US">CommonStockShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommonStockValues" xlink:to="ptgef_CommonStockValues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommonStockValues_3_lbl" xml:lang="en-US">CommonStockValues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:to="ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions_2_lbl" xml:lang="en-US">Acquisitions through business combinations, other provisions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareIssuedInIoxExchange" xlink:to="ptgef_ShareIssuedInIoxExchange_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareIssuedInIoxExchange_2_lbl" xml:lang="en-US">ShareIssuedInIoxExchange</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" xlink:to="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_2_lbl" xml:lang="en-US">ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedToLincolnParksCommittedPurchase" xlink:to="ptgef_SharesIssuedToLincolnParksCommittedPurchase_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedToLincolnParksCommittedPurchase_2_lbl" xml:lang="en-US">Shares issued to Lincoln Park&amp;amp;#8217;s Committed Purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_2_lbl" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_2_lbl" xml:lang="en-US">Sale or issue of treasury shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_2_lbl" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionReserve_3_lbl" xml:lang="en-US">StockOptionReserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfOutstandingShareOption_3_lbl" xml:lang="en-US">NumberOfOutstandingShareOption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivable" xlink:to="ptgef_PrepaidExpensesAndOtherReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidExpensesAndOtherReceivable_2_lbl" xml:lang="en-US">PrepaidExpensesAndOtherReceivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilities" xlink:to="ptgef_AccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">AccountsPayableAndAccruedLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantLiability_2_lbl" xml:lang="en-US">Warrant liability [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentAsset" xlink:to="ptgef_CurrentAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CurrentAsset_2_lbl" xml:lang="en-US">CurrentAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockBasedCompensationExpense" xlink:to="ptgef_StockBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockBasedCompensationExpense_2_lbl" xml:lang="en-US">StockBasedCompensationExpense</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>ptgef-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://portagebiotech.com/role/Cover" xlink:href="ptgef-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:href="ptgef-20221231.xsd#CondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="ptgef-20221231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:href="ptgef-20221231.xsd#InterimStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:href="ptgef-20221231.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperations" xlink:href="ptgef-20221231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Liquidity" xlink:href="ptgef-20221231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentation" xlink:href="ptgef-20221231.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:href="ptgef-20221231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="ptgef-20221231.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociate" xlink:href="ptgef-20221231.xsd#InvestmentInAssociate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInPrivateCompany" xlink:href="ptgef-20221231.xsd#InvestmentInPrivateCompany" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarus" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarus" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Goodwill" xlink:href="ptgef-20221231.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxes" xlink:href="ptgef-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiability" xlink:href="ptgef-20221231.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStock" xlink:href="ptgef-20221231.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserve" xlink:href="ptgef-20221231.xsd#StockOptionReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShare" xlink:href="ptgef-20221231.xsd#LossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:href="ptgef-20221231.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:href="ptgef-20221231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosures" xlink:href="ptgef-20221231.xsd#CapitalDisclosures" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterest" xlink:href="ptgef-20221231.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventAfterBalanceSheetDate" xlink:href="ptgef-20221231.xsd#EventAfterBalanceSheetDate" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:href="ptgef-20221231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="ptgef-20221231.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusTables" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillTables" xlink:href="ptgef-20221231.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesTables" xlink:href="ptgef-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:href="ptgef-20221231.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockTables" xlink:href="ptgef-20221231.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveTables" xlink:href="ptgef-20221231.xsd#StockOptionReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareTables" xlink:href="ptgef-20221231.xsd#LossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:href="ptgef-20221231.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:href="ptgef-20221231.xsd#NatureOfOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:href="ptgef-20221231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ptgef-20221231.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:href="ptgef-20221231.xsd#PrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:href="ptgef-20221231.xsd#InvestmentInAssociateDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative" xlink:href="ptgef-20221231.xsd#InvestmentInPrivateCompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetails" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetails1" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" xlink:href="ptgef-20221231.xsd#AcquisitionOfTarusDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetails" xlink:href="ptgef-20221231.xsd#GoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:href="ptgef-20221231.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:href="ptgef-20221231.xsd#In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:href="ptgef-20221231.xsd#UnsecuredNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails1" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails2" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails3" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails4" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:href="ptgef-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:href="ptgef-20221231.xsd#WarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetails" xlink:href="ptgef-20221231.xsd#CapitalStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:href="ptgef-20221231.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails3" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails4" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:href="ptgef-20221231.xsd#StockOptionReserveDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails" xlink:href="ptgef-20221231.xsd#LossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails1" xlink:href="ptgef-20221231.xsd#LossPerShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="ptgef-20221231.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ptgef-20221231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:href="ptgef-20221231.xsd#FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:href="ptgef-20221231.xsd#CapitalDisclosuresDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:href="ptgef-20221231.xsd#Non-controllingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative" xlink:href="ptgef-20221231.xsd#EventAfterBalanceSheetDateDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:title="00000002 - Statement -  Condensed Consolidated Interim Statements of Financial Position (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-fullStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-fullAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-fullCurrentAssetsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNoteReceivable" xlink:label="loc_ptgefConvertibleNoteReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ptgefConvertibleNoteReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-fullNoncurrentAssetsAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentProperty" xlink:label="loc_ifrs-fullInvestmentProperty" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullInvestmentProperty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-fullGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InprocessResearchAndDevelopment" xlink:label="loc_ptgefInprocessResearchAndDevelopment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ptgefInprocessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredCommitmentFee" xlink:label="loc_ptgefDeferredCommitmentFee" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ptgefDeferredCommitmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-fullOtherAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:to="loc_ifrs-fullNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-fullEquityAndLiabilitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullCurrentLiabilitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantLiabilityCurrent" xlink:label="loc_ptgefWarrantLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ptgefWarrantLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullNoncurrentLiabilitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-fullDeferredTaxLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullDeferredTaxLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredPurchasePricePayableTarus" xlink:label="loc_ptgefDeferredPurchasePricePayableTarus" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ptgefDeferredPurchasePricePayableTarus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredObligationIoxMilestone" xlink:label="loc_ptgefDeferredObligationIoxMilestone" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ptgefDeferredObligationIoxMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-fullNoncurrentLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-fullEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullIssuedCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullOtherReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="loc_ifrs-fullAccumulatedOtherComprehensiveIncome" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullAccumulatedOtherComprehensiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-fullEquityAndLiabilities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullEquityAndLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommitmentAndContingencies" xlink:label="loc_ptgefCommitmentAndContingencies" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ptgefCommitmentAndContingencies" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-fullProfitLossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-fullGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-fullProfitLossFromOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GainsLossesOnChangeInFairValueOfWarrants" xlink:label="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefGainsLossesOnChangeInFairValueOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="loc_ifrs-fullForeignExchangeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullForeignExchangeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullDepreciationAndAmortisationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullDepreciationAndAmortisationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-fullRevenueFromInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullRevenueFromInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="loc_ifrs-fullInterestExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_Netloss" xlink:label="loc_ptgefNetloss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefNetloss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetUnrealizedLossOnInvestments" xlink:label="loc_ptgefNetUnrealizedLossOnInvestments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefNetUnrealizedLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="loc_ifrs-fullOtherComprehensiveIncome" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullOtherComprehensiveIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-fullProfitLossAttributableToAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToOwnersOfParent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToNoncontrollingInterests" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullComprehensiveIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-fullEarningsPerShareAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_ptgefBasicAndDilutedEarningsLossPerShare" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEarningsPerShareAbstract" xlink:to="loc_ptgefBasicAndDilutedEarningsLossPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="loc_ifrs-fullWeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullWeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted" xlink:label="loc_ptgefWeightedAveragesSharesoutstandingBasicAndDiluted" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullWeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="loc_ptgefWeightedAveragesSharesoutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholder&apos;s Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-fullStatementOfChangesInEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullIssuedCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ptgefStockOptionReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_ifrs-fullAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInTarusAcquisition" xlink:label="loc_ptgefSharesIssuedInTarusAcquisition" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInTarusAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInTarusAcquisitionShares" xlink:label="loc_ptgefSharesIssuedInTarusAcquisitionShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInTarusAcquisitionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInIoxExchange" xlink:label="loc_ptgefSharesIssuedInIoxExchange" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInIoxExchange" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInIoxExchangeShares" xlink:label="loc_ptgefSharesIssuedInIoxExchangeShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInIoxExchangeShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredObligationIoxMilestoneValue" xlink:label="loc_ptgefDeferredObligationIoxMilestoneValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDeferredObligationIoxMilestoneValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" xlink:label="loc_ptgefExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExcessOfNoncontrollingInterestAcquiredOverConsiderationIox" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefSharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares" xlink:label="loc_ptgefSharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderAtm" xlink:label="loc_ptgefSharesIssuedUnderAtm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderAtmShares" xlink:label="loc_ptgefSharesIssuedUnderAtmShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtmShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderOffering" xlink:label="loc_ptgefSharesIssuedUnderOffering" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderOfferingShares" xlink:label="loc_ptgefSharesIssuedUnderOfferingShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" xlink:label="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares" xlink:label="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ShareIssuanceCosts" xlink:label="loc_ptgefShareIssuanceCosts" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefShareIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="loc_ptgefSharesIssuedOrAccruedForServices" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="loc_ptgefSharesIssuedOrAccruedForServicesShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServicesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsExercised" xlink:label="loc_ptgefWarrantsExercised" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsExercisedShares" xlink:label="loc_ptgefWarrantsExercisedShares" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsExercisedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares" xlink:label="loc_ptgefExchangeOfNotesPayableAndAccruedInterestForIoxShares" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExchangeOfNotesPayableAndAccruedInterestForIoxShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetUnrealizedLossOnInvestmentsValue" xlink:label="loc_ptgefNetUnrealizedLossOnInvestmentsValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetUnrealizedLossOnInvestmentsValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-fullStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="loc_ifrs-fullProfitLossFromDiscontinuedOperations" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullProfitLossFromDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeOnFairValueOfWarrantLiability" xlink:label="loc_ptgefIncomeOnFairValueOfWarrantLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ptgefIncomeOnFairValueOfWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ptgefChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfStockIssuedForServices" xlink:label="loc_ptgefFairValueOfStockIssuedForServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ptgefFairValueOfStockIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnHedgeIneffectiveness" xlink:label="loc_ifrs-fullGainLossOnHedgeIneffectiveness" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullGainLossOnHedgeIneffectiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullAdjustmentsForDepreciationAndAmortisationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetChangeInWorkingCapitalComponentsAbstract" xlink:label="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncreasingDecreasingAccountsReceivable" xlink:label="loc_ptgefIncreasingDecreasingAccountsReceivable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ptgefIncreasingDecreasingAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNetChangeInWorkingCapitalComponentsAbstract" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfConvertibleNoteReceivable" xlink:label="loc_ptgefPurchaseOfConvertibleNoteReceivable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ptgefPurchaseOfConvertibleNoteReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition" xlink:label="loc_ptgefRepaymentOfNotesPayableAssumedInTarusAcquisition" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefRepaymentOfNotesPayableAssumedInTarusAcquisition" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition" xlink:label="loc_ptgefRepaymentOfMilestoneObligationAssumedInTarusAcquisition" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefRepaymentOfMilestoneObligationAssumedInTarusAcquisition" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderRegisteredOffering" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderRegisteredOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-fullPaymentsForShareIssueCosts" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullPaymentsForShareIssueCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ProceedsFromExerciseOfStockPurchaseWarrants" xlink:label="loc_ptgefProceedsFromExerciseOfStockPurchaseWarrants" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ptgefProceedsFromExerciseOfStockPurchaseWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SupplementalCashFlowInformationsAbstract" xlink:label="loc_ptgefSupplementalCashFlowInformationsAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefSupplementalCashFlowInformationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CashPaidForInterest" xlink:label="loc_ptgefCashPaidForInterest" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSupplementalCashFlowInformationsAbstract" xlink:to="loc_ptgefCashPaidForInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncreaseInAccountsPayableForStockIssuanceCosts" xlink:label="loc_ptgefIncreaseInAccountsPayableForStockIssuanceCosts" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSupplementalCashFlowInformationsAbstract" xlink:to="loc_ptgefIncreaseInAccountsPayableForStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NoncashInvestingItemsAbstract" xlink:label="loc_ptgefNoncashInvestingItemsAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefNoncashInvestingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfSharesIssuedForTarus" xlink:label="loc_ptgefFairValueOfSharesIssuedForTarus" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefFairValueOfSharesIssuedForTarus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox" xlink:label="loc_ptgefFairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefFairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfDeferredPurchasePricePayabletarus" xlink:label="loc_ptgefFairValueOfDeferredPurchasePricePayabletarus" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefFairValueOfDeferredPurchasePricePayabletarus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfDeferredObligationIoxMilestone" xlink:label="loc_ptgefFairValueOfDeferredObligationIoxMilestone" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefFairValueOfDeferredObligationIoxMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LiabilitiesAssumedInTarusAcquisition" xlink:label="loc_ptgefLiabilitiesAssumedInTarusAcquisition" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefLiabilitiesAssumedInTarusAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase" xlink:label="loc_ptgefFairValueOfSharesIssuedForCommitmentFeesCommittedPurchase" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefFairValueOfSharesIssuedForCommitmentFeesCommittedPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants" xlink:label="loc_ptgefExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="00000006 - Disclosure - NATURE OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NatureOfOperationsAbstract" xlink:label="loc_ptgefNatureOfOperationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NatureOfOperationsExplanatory" xlink:label="loc_ptgefNatureOfOperationsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNatureOfOperationsAbstract" xlink:to="loc_ptgefNatureOfOperationsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Liquidity" xlink:title="00000007 - Disclosure - LIQUIDITY">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LiquidityAbstract" xlink:label="loc_ptgefLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LiquidityTextBlock" xlink:label="loc_ptgefLiquidityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefLiquidityAbstract" xlink:to="loc_ptgefLiquidityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BasisOfPresentationAbstract" xlink:label="loc_ptgefBasisOfPresentationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfBasisOfPresentationExplanatory" xlink:label="loc_ptgefDisclosureOfBasisOfPresentationExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefBasisOfPresentationAbstract" xlink:to="loc_ptgefDisclosureOfBasisOfPresentationExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSignificantAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PrepaidExpensesAndOtherReceivablesAbstract" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfOtherAssetsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullDisclosureOfOtherAssetsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociate" xlink:title="00000011 - Disclosure - INVESTMENT IN ASSOCIATE">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentInAssociateAbstract" xlink:label="loc_ptgefInvestmentInAssociateAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentInAssociateDisclosureTextBlock" xlink:label="loc_ptgefInvestmentInAssociateDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInAssociateAbstract" xlink:to="loc_ptgefInvestmentInAssociateDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInPrivateCompany" xlink:title="00000012 - Disclosure - INVESTMENT IN PRIVATE COMPANY">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureInvestmentInPrivateCompanyAbstract" xlink:label="loc_ptgefDisclosureInvestmentInPrivateCompanyAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock" xlink:label="loc_ptgefDisclosureOfPrivateCompaniesExplanatoryTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInPrivateCompanyAbstract" xlink:to="loc_ptgefDisclosureOfPrivateCompaniesExplanatoryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarus" xlink:title="00000013 - Disclosure - ACQUISITION OF TARUS">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfTarusAbstract" xlink:label="loc_ptgefAcquisitionOfTarusAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionsOfTarusExplanatory" xlink:label="loc_ptgefAcquisitionsOfTarusExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefAcquisitionOfTarusAbstract" xlink:to="loc_ptgefAcquisitionsOfTarusExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Goodwill" xlink:title="00000014 - Disclosure - GOODWILL">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GoodwillAbstract" xlink:label="loc_ptgefGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GoodwillExplanatory" xlink:label="loc_ptgefGoodwillExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwillAbstract" xlink:to="loc_ptgefGoodwillExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" xlink:title="00000015 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:label="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability" xlink:label="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayable" xlink:title="00000016 - Disclosure - UNSECURED NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnsecuredNotesPayableAbstract" xlink:label="loc_ptgefUnsecuredNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnsecuredNotesPayableAndWarrantsTextBlock" xlink:label="loc_ptgefUnsecuredNotesPayableAndWarrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefUnsecuredNotesPayableAbstract" xlink:to="loc_ptgefUnsecuredNotesPayableAndWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxesAbstract" xlink:label="loc_ptgefIncomeTaxesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-fullDisclosureOfIncomeTaxExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullDisclosureOfIncomeTaxExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="00000018 - Disclosure - WARRANT LIABILITY">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantLiabilityAbstract" xlink:label="loc_ptgefWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantLiabilitytextblock" xlink:label="loc_ptgefWarrantLiabilitytextblock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefWarrantLiabilitytextblock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStock" xlink:title="00000019 - Disclosure - CAPITAL STOCK">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CapitalStockAbstract" xlink:label="loc_ptgefCapitalStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CapitalStockTextBlock" xlink:label="loc_ptgefCapitalStockTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefCapitalStockTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="00000020 - Disclosure - STOCK OPTION RESERVE">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveAbstract" xlink:label="loc_ptgefStockOptionReserveAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfSharebasedPaymentArrangementsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ifrs-fullDisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="00000021 - Disclosure - (LOSS) PER SHARE">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LosPerShareAbstract" xlink:label="loc_ptgefLosPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-fullEarningsPerShareExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefLosPerShareAbstract" xlink:to="loc_ifrs-fullEarningsPerShareExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommitmentsAndContingentLiabilitiesAbstract" xlink:label="loc_ptgefCommitmentsAndContingentLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCommitmentsAndContingentLiabilitiesAbstract" xlink:to="loc_ifrs-fullDisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="00000023 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-fullRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRelatedPartyTransactionsAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFinancialInstrumentsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosures" xlink:title="00000025 - Disclosure - CAPITAL DISCLOSURES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CapitalDisclosuresAbstract" xlink:label="loc_ptgefCapitalDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:label="loc_ptgefDisclosureOfCapitalManagementExplanatoryTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalDisclosuresAbstract" xlink:to="loc_ptgefDisclosureOfCapitalManagementExplanatoryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="00000026 - Disclosure - NON-CONTROLLING INTEREST">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NonControllingInterestAbstract" xlink:label="loc_ptgefNonControllingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfInterestsInOtherEntitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNonControllingInterestAbstract" xlink:to="loc_ifrs-fullDisclosureOfInterestsInOtherEntitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventAfterBalanceSheetDate" xlink:title="00000027 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EventAfterTheBalanceSheetDateAbstract" xlink:label="loc_ptgefEventAfterTheBalanceSheetDateAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock" xlink:label="loc_ptgefDisclosureOfEventAfterBalanceSheetDateTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefEventAfterTheBalanceSheetDateAbstract" xlink:to="loc_ptgefDisclosureOfEventAfterBalanceSheetDateTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PrepaidExpensesAndOtherReceivablesAbstract" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:label="loc_ptgefDisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ptgefDisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateTables" xlink:title="00000030 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentInAssociateAbstract" xlink:label="loc_ptgefInvestmentInAssociateAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfInvestmentAssociatetableTextBlock" xlink:label="loc_ptgefDisclosureOfInvestmentAssociatetableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInAssociateAbstract" xlink:to="loc_ptgefDisclosureOfInvestmentAssociatetableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock" xlink:label="loc_ptgefScheduleOfInvestmentInStimunitySaTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInAssociateAbstract" xlink:to="loc_ptgefScheduleOfInvestmentInStimunitySaTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusTables" xlink:title="00000031 - Disclosure - ACQUISITION OF TARUS (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfTarusAbstract" xlink:label="loc_ptgefAcquisitionOfTarusAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_ptgefScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefAcquisitionOfTarusAbstract" xlink:to="loc_ptgefScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfProformaInformationTableTextBlock" xlink:label="loc_ptgefScheduleOfProformaInformationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefAcquisitionOfTarusAbstract" xlink:to="loc_ptgefScheduleOfProformaInformationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillTables" xlink:title="00000032 - Disclosure - GOODWILL (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GoodwillAbstract" xlink:label="loc_ptgefGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" xlink:label="loc_ptgefDisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwillAbstract" xlink:to="loc_ptgefDisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" xlink:title="00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:label="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock" xlink:label="loc_ptgefScheduleOfInProcessResearchAndDevelopmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ptgefScheduleOfInProcessResearchAndDevelopmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableTables" xlink:title="00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnsecuredNotesPayableAbstract" xlink:label="loc_ptgefUnsecuredNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfNotesPayableTableTextBlock" xlink:label="loc_ptgefScheduleOfNotesPayableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefUnsecuredNotesPayableAbstract" xlink:to="loc_ptgefScheduleOfNotesPayableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesTables" xlink:title="00000035 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxesAbstract" xlink:label="loc_ptgefIncomeTaxesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock" xlink:label="loc_ptgefScheduleOfIncomeTaxesBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefScheduleOfIncomeTaxesBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:label="loc_ptgefScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfIncomeTaxExplanatory" xlink:label="loc_ptgefScheduleOfIncomeTaxExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefScheduleOfIncomeTaxExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock" xlink:label="loc_ptgefScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfDeferredTaxAssetsExplanatory" xlink:label="loc_ptgefDisclosureOfDeferredTaxAssetsExplanatory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefDisclosureOfDeferredTaxAssetsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="00000036 - Disclosure - WARRANT LIABILITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantLiabilityAbstract" xlink:label="loc_ptgefWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="loc_ptgefScheduleOfWarrantLiabilityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefScheduleOfWarrantLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockTables" xlink:title="00000037 - Disclosure - CAPITAL STOCK (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CapitalStockAbstract" xlink:label="loc_ptgefCapitalStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" xlink:label="loc_ptgefCommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefCommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="00000038 - Disclosure - STOCK OPTION RESERVE (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveAbstract" xlink:label="loc_ptgefStockOptionReserveAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfTermsStockOptionReserveExplanatory" xlink:label="loc_ptgefDisclosureOfTermsStockOptionReserveExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ptgefDisclosureOfTermsStockOptionReserveExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="loc_ifrs-fullDisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ifrs-fullDisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory" xlink:label="loc_ifrs-fullExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ifrs-fullExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" xlink:label="loc_ptgefDisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ptgefDisclosureOfShareBasedCompensationStockOptionsActivityExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ifrs-fullDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="00000039 - Disclosure - (LOSS) PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LosPerShareAbstract" xlink:label="loc_ptgefLosPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EarningsPerShareTableTextBlock" xlink:label="loc_ptgefEarningsPerShareTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefLosPerShareAbstract" xlink:to="loc_ptgefEarningsPerShareTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" xlink:label="loc_ptgefScheduleOfAntiDilutiveEffectTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefLosPerShareAbstract" xlink:to="loc_ptgefScheduleOfAntiDilutiveEffectTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="00000040 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="loc_ptgefDisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ptgefDisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NonControllingInterestAbstract" xlink:label="loc_ptgefNonControllingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:label="loc_ptgefScheduleOfNoncontrollingInterestTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNonControllingInterestAbstract" xlink:to="loc_ptgefScheduleOfNoncontrollingInterestTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" xlink:title="00000042 - Disclosure - NATURE OF OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NatureOfOperationsAbstract" xlink:label="loc_ptgefNatureOfOperationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNatureOfOperationsAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SalvaRxGroupPlcMember" xlink:label="loc_ptgefSalvaRxGroupPlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxGroupPlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LiquidityDetailsNarrative" xlink:title="00000043 - Disclosure - LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LiquidityAbstract" xlink:label="loc_ptgefLiquidityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefLiquidityAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ATMMember" xlink:label="loc_ptgefATMMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefATMMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LincolnMember" xlink:label="loc_ptgefLincolnMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefLincolnMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-fullCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TotalCurrentLiabilities" xlink:label="loc_ptgefTotalCurrentLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefTotalCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetLossIncome" xlink:label="loc_ptgefNetLossIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetLossIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CashUsedInOperatingActivities" xlink:label="loc_ptgefCashUsedInOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCashUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOnHand" xlink:label="loc_ifrs-fullCashOnHand" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashOnHand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IssuanceAndSales" xlink:label="loc_ptgefIssuanceAndSales" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuanceAndSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_MaximumAggregateOfferingPrice" xlink:label="loc_ptgefMaximumAggregateOfferingPrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefMaximumAggregateOfferingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CashFundDescription" xlink:label="loc_ptgefCashFundDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCashFundDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfStockSold" xlink:label="loc_ptgefNumberOfStockSold" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfStockSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GrossProceedsFromStockSold" xlink:label="loc_ptgefGrossProceedsFromStockSold" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGrossProceedsFromStockSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetProceedsFromStockSold" xlink:label="loc_ptgefNetProceedsFromStockSold" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetProceedsFromStockSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OfferingAndThroughThatProcessDescription" xlink:label="loc_ptgefOfferingAndThroughThatProcessDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingAndThroughThatProcessDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:label="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000044 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BasisOfPresentationAbstract" xlink:label="loc_ptgefBasisOfPresentationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefBasisOfPresentationAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SubsidiariesOneMember" xlink:label="loc_ptgefSubsidiariesOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSubsidiariesOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SubsidiariesTwoMember" xlink:label="loc_ptgefSubsidiariesTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSubsidiariesTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PrepaidExpensesAndOtherReceivablesAbstract" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentReceivablesFromSaleOfProperties" xlink:label="loc_ifrs-fullCurrentReceivablesFromSaleOfProperties" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullCurrentReceivablesFromSaleOfProperties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="loc_ifrs-fullCurrentAdvancesToSuppliers" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullCurrentAdvancesToSuppliers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ResearchAndDevelopmentCredit" xlink:label="loc_ptgefResearchAndDevelopmentCredit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ptgefResearchAndDevelopmentCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TaxDeposits" xlink:label="loc_ptgefTaxDeposits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ptgefTaxDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-fullCurrentPrepaidExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullCurrentPrepaidExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepayments" xlink:label="loc_ifrs-fullCurrentPrepayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefPrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullCurrentPrepayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails" xlink:title="00000046 - Disclosure - INVESTMENT IN ASSOCIATE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentInAssociateAbstract" xlink:label="loc_ptgefInvestmentInAssociateAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInAssociateAbstract" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StimunitySAMember" xlink:label="loc_ptgefStimunitySAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:to="loc_ptgefStimunitySAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfAssociate" xlink:label="loc_ifrs-fullNameOfAssociate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNameOfAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PrincipalPlaceOfBusinessOfAssociate" xlink:label="loc_ifrs-fullPrincipalPlaceOfBusinessOfAssociate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPrincipalPlaceOfBusinessOfAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfAssociate" xlink:label="loc_ifrs-fullCountryOfIncorporationOrResidenceOfAssociate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCountryOfIncorporationOrResidenceOfAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfVotingPowerHeldInAssociate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetails1" xlink:title="00000047 - Disclosure - INVESTMENT IN ASSOCIATE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentInAssociateAbstract" xlink:label="loc_ptgefInvestmentInAssociateAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInAssociateAbstract" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnrecognisedShareOfLossesOfAssociates" xlink:label="loc_ifrs-fullUnrecognisedShareOfLossesOfAssociates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInAssociateAbstract" xlink:to="loc_ifrs-fullUnrecognisedShareOfLossesOfAssociates" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInAssociateAbstract" xlink:to="loc_ifrs-fullInvestmentsInSubsidiariesJointVenturesAndAssociates_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" xlink:title="00000048 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentInAssociateAbstract" xlink:label="loc_ptgefInvestmentInAssociateAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInvestmentInAssociateAbstract" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="loc_ifrs-fullEntitysTotalForAssociatesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSignificantInvestmentsInAssociatesAxis" xlink:to="loc_ifrs-fullEntitysTotalForAssociatesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StimunitySAMember" xlink:label="loc_ptgefStimunitySAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForAssociatesMember" xlink:to="loc_ptgefStimunitySAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StimunityMember" xlink:label="loc_ptgefStimunityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefStimunityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AdditionalInvestment" xlink:label="loc_ptgefAdditionalInvestment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SubscribingClassShares" xlink:label="loc_ptgefSubscribingClassShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSubscribingClassShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInAssociate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInAssociate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNoteDescription" xlink:label="loc_ptgefConvertibleNoteDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefConvertibleNoteDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EquityInLossIncome" xlink:label="loc_ptgefEquityInLossIncome" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefEquityInLossIncome" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative" xlink:title="00000049 - Disclosure - INVESTMENT IN PRIVATE COMPANY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DisclosureInvestmentInPrivateCompanyAbstract" xlink:label="loc_ptgefDisclosureInvestmentInPrivateCompanyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureInvestmentInPrivateCompanyAbstract" xlink:to="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="loc_ifrs-fullBusinessCombinationsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ifrs-fullBusinessCombinationsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullBusinessCombinationsAxis" xlink:to="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfSalvaRxMember" xlink:label="loc_ptgefAcquisitionOfSalvaRxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" xlink:to="loc_ptgefAcquisitionOfSalvaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfIntensityHoldingLimitedMember" xlink:label="loc_ptgefAcquisitionOfIntensityHoldingLimitedMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForBusinessCombinationsMember" xlink:to="loc_ptgefAcquisitionOfIntensityHoldingLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInvestmentPropertyAxis" xlink:label="loc_ifrs-fullTypesOfInvestmentPropertyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ifrs-fullTypesOfInvestmentPropertyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentPropertyMember" xlink:label="loc_ifrs-fullInvestmentPropertyMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfInvestmentPropertyAxis" xlink:to="loc_ifrs-fullInvestmentPropertyMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IntensityMember" xlink:label="loc_ptgefIntensityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullInvestmentPropertyMember" xlink:to="loc_ptgefIntensityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfBusinessCombinationsTable" xlink:to="loc_ifrs-fullRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PrivateInvestments" xlink:label="loc_ptgefPrivateInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrivateInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentOwnedShares" xlink:label="loc_ptgefInvestmentOwnedShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInvestmentOwnedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InvestmentOwnershipPercentage" xlink:label="loc_ptgefInvestmentOwnershipPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:label="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:label="loc_ptgefNumberOfPrivateCompanyShareConsistsInSoleAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfPrivateCompanyShareConsistsInSoleAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OfferingPrice" xlink:label="loc_ptgefOfferingPrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets" xlink:label="loc_ifrs-fullChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied" xlink:label="loc_ifrs-fullAmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnrealizedLoss" xlink:label="loc_ptgefUnrealizedLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefUnrealizedLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusDetails" xlink:title="00000050 - Disclosure - ACQUISITION OF TARUS (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfTarusAbstract" xlink:label="loc_ptgefAcquisitionOfTarusAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefAcquisitionOfTarusAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAcquisitionMember" xlink:label="loc_ptgefTarusAcquisitionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:to="loc_ptgefTarusAcquisitionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-fullAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAssetsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullIdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-fullGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTangibleOrIntangibleAssetsTransferred" xlink:label="loc_ifrs-fullOtherTangibleOrIntangibleAssetsTransferred" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherTangibleOrIntangibleAssetsTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:label="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferred" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-fullIdentifiableAssetsAcquiredLiabilitiesAssumed" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="loc_ifrs-fullDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="loc_ifrs-fullContingentLiabilitiesRecognisedInBusinessCombination" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusDetails1" xlink:title="00000051 - Disclosure - ACQUISITION OF TARUS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfTarusAbstract" xlink:label="loc_ptgefAcquisitionOfTarusAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefAcquisitionOfTarusAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAcquisitionMember" xlink:label="loc_ptgefTarusAcquisitionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:to="loc_ptgefTarusAcquisitionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="loc_ifrs-fullProfitLossFromContinuingOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLossFromContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullComprehensiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EarningLossPerShare" xlink:label="loc_ptgefEarningLossPerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefEarningLossPerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" xlink:title="00000052 - Disclosure - ACQUISITION OF TARUS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AcquisitionOfTarusAbstract" xlink:label="loc_ptgefAcquisitionOfTarusAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefAcquisitionOfTarusAbstract" xlink:to="loc_ptgefNumberOfSharesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefAcquisitionOfTarusAbstract" xlink:to="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_MilestonePayment" xlink:label="loc_ptgefMilestonePayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefAcquisitionOfTarusAbstract" xlink:to="loc_ptgefMilestonePayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetails" xlink:title="00000053 - Disclosure - GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GoodwillAbstract" xlink:label="loc_ptgefGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-fullGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwillAbstract" xlink:to="loc_ifrs-fullGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusGoodwill" xlink:label="loc_ptgefTarusGoodwill" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwillAbstract" xlink:to="loc_ptgefTarusGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-fullGoodwill_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwillAbstract" xlink:to="loc_ifrs-fullGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoodwillDetailsNarrative" xlink:title="00000054 - Disclosure - GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GoodwillAbstract" xlink:label="loc_ptgefGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="loc_ifrs-fullGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwillAbstract" xlink:to="loc_ifrs-fullGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-fullConsiderationPaidReceived" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwillAbstract" xlink:to="loc_ifrs-fullConsiderationPaidReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="loc_ifrs-fullIdentifiableAssetsAcquiredLiabilitiesAssumed" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwillAbstract" xlink:to="loc_ifrs-fullIdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="loc_ifrs-fullDescriptionOfDiscountRatesAppliedToCashFlowProjections" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefGoodwillAbstract" xlink:to="loc_ifrs-fullDescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" xlink:title="00000055 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:label="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IMM60IOXMelanomaLungCancersMember" xlink:label="loc_ptgefIMM60IOXMelanomaLungCancersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIMM60IOXMelanomaLungCancersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IMM65IOXOvarianProstateCancersMember" xlink:label="loc_ptgefIMM65IOXOvarianProstateCancersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIMM65IOXOvarianProstateCancersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefIOXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OncomerSaugatuckDNAAptamersMember" xlink:label="loc_ptgefOncomerSaugatuckDNAAptamersMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefOncomerSaugatuckDNAAptamersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAdenosineReceptorsMember" xlink:label="loc_ptgefTarusAdenosineReceptorsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefTarusAdenosineReceptorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAdenosineReceptors1Member" xlink:label="loc_ptgefTarusAdenosineReceptors1Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefTarusAdenosineReceptors1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusAdenosineReceptors2Member" xlink:label="loc_ptgefTarusAdenosineReceptors2Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefTarusAdenosineReceptors2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TarusMember" xlink:label="loc_ptgefTarusMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefTarusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InprocessResearchAndDevelopment" xlink:label="loc_ptgefInprocessResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefInprocessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxesLiability" xlink:label="loc_ptgefDeferredTaxesLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDeferredTaxesLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" xlink:title="00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:label="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxLiability" xlink:label="loc_ptgefDeferredTaxLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ptgefDeferredTaxLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncreaseInDeferredIncomeTaxes" xlink:label="loc_ptgefIncreaseInDeferredIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ptgefIncreaseInDeferredIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ReductionInDeferredTaxLiability" xlink:label="loc_ptgefReductionInDeferredTaxLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ptgefReductionInDeferredTaxLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="loc_ifrs-fullTaxEffectFromChangeInTaxRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefInProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract" xlink:to="loc_ifrs-fullTaxEffectFromChangeInTaxRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetails" xlink:title="00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnsecuredNotesPayableAbstract" xlink:label="loc_ptgefUnsecuredNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefUnsecuredNotesPayableAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIOXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NotePayable" xlink:label="loc_ptgefNotePayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNotePayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare" xlink:label="loc_ptgefExchangeOfNotesPayableAndAccruedInterestForIoxShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExchangeOfNotesPayableAndAccruedInterestForIoxShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NotePayable" xlink:label="loc_ptgefNotePayable_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNotePayable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative" xlink:title="00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnsecuredNotesPayableAbstract" xlink:label="loc_ptgefUnsecuredNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefUnsecuredNotesPayableAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SalvaRxMember" xlink:label="loc_ptgefSalvaRxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSalvaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIOXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DescriptionOfBusinessCombination" xlink:label="loc_ptgefDescriptionOfBusinessCombination" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDescriptionOfBusinessCombination" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IssuanceOfUnsecuredNotesDescription" xlink:label="loc_ptgefIssuanceOfUnsecuredNotesDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuanceOfUnsecuredNotesDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:title="00000059 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxesAbstract" xlink:label="loc_ptgefIncomeTaxesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:label="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentFederalIncomeTaxBenefit" xlink:label="loc_ptgefCurrentFederalIncomeTaxBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="loc_ptgefCurrentFederalIncomeTaxBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentStateAndLocalIncomeTaxBenefit" xlink:label="loc_ptgefCurrentStateAndLocalIncomeTaxBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="loc_ptgefCurrentStateAndLocalIncomeTaxBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentForeignIncomeTaxBenefit" xlink:label="loc_ptgefCurrentForeignIncomeTaxBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract" xlink:to="loc_ptgefCurrentForeignIncomeTaxBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-fullCurrentTaxExpenseIncome" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullCurrentTaxExpenseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredFederalIncomeTaxBenefit" xlink:label="loc_ptgefDeferredFederalIncomeTaxBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ptgefDeferredFederalIncomeTaxBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredStateAndLocalIncomeTaxBenefit" xlink:label="loc_ptgefDeferredStateAndLocalIncomeTaxBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ptgefDeferredStateAndLocalIncomeTaxBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredForeignIncomeTaxBenefit" xlink:label="loc_ptgefDeferredForeignIncomeTaxBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDeferredTaxExpenseIncomeAbstract" xlink:to="loc_ptgefDeferredForeignIncomeTaxBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="loc_ifrs-fullAdjustmentsForDeferredTaxExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDeferredTaxExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails1" xlink:title="00000060 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxesAbstract" xlink:label="loc_ptgefIncomeTaxesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax" xlink:label="loc_ptgefIncomeLossOnOrdinaryActivitiesBeforeTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefIncomeLossOnOrdinaryActivitiesBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StatutoryU.s.IncomeTaxRate" xlink:label="loc_ptgefStatutoryU.s.IncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefStatutoryU.s.IncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossAtStatutoryIncomeTaxRate" xlink:label="loc_ptgefLossAtStatutoryIncomeTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefLossAtStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossesRecognized" xlink:label="loc_ptgefLossesRecognized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefLossesRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxBenefitExpense" xlink:label="loc_ptgefIncomeTaxBenefitExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefIncomeTaxBenefitExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails2" xlink:title="00000061 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxesAbstract" xlink:label="loc_ptgefIncomeTaxesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccountingProfit" xlink:label="loc_ifrs-fullAccountingProfit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullAccountingProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-fullApplicableTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullApplicableTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="loc_ifrs-fullTaxExpenseIncomeAtApplicableTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullTaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChangeIncreaseInDeferredIncomeTaxRate" xlink:label="loc_ptgefChangeIncreaseInDeferredIncomeTaxRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefChangeIncreaseInDeferredIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ForeignCurrencyEffect" xlink:label="loc_ptgefForeignCurrencyEffect" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefForeignCurrencyEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TaxEffectOfRAndDCredit" xlink:label="loc_ptgefTaxEffectOfRAndDCredit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefTaxEffectOfRAndDCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossesUnrecognized" xlink:label="loc_ptgefLossesUnrecognized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefLossesUnrecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="loc_ifrs-fullTaxEffectOfTaxLosses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullTaxEffectOfTaxLosses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails3" xlink:title="00000062 - Disclosure - INCOME TAXES (Details 3)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxesAbstract" xlink:label="loc_ptgefIncomeTaxesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" xlink:label="loc_srtProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_srtProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReserveQuantitiesLineItems" xlink:label="loc_srtReserveQuantitiesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" xlink:to="loc_srtReserveQuantitiesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnitedStateMember" xlink:label="loc_ptgefUnitedStateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ptgefUnitedStateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BVIMember" xlink:label="loc_ptgefBVIMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ptgefBVIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ForeignMember" xlink:label="loc_ptgefForeignMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ptgefForeignMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PretaxIncomeLoss" xlink:label="loc_ptgefPretaxIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_ptgefPretaxIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossForWhichNoBenefitWasTaken" xlink:label="loc_ptgefLossForWhichNoBenefitWasTaken" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_ptgefLossForWhichNoBenefitWasTaken" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LossesNotSubjectToTax" xlink:label="loc_ptgefLossesNotSubjectToTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_ptgefLossesNotSubjectToTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UtilizationOfLossesNotPreviouslyBenefitted" xlink:label="loc_ptgefUtilizationOfLossesNotPreviouslyBenefitted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_ptgefUtilizationOfLossesNotPreviouslyBenefitted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PretaxLossSubjectToTax" xlink:label="loc_ptgefPretaxLossSubjectToTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReserveQuantitiesLineItems" xlink:to="loc_ptgefPretaxLossSubjectToTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails4" xlink:title="00000063 - Disclosure - INCOME TAXES (Details 4)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxesAbstract" xlink:label="loc_ptgefIncomeTaxesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxAssetsAbstract" xlink:label="loc_ptgefDeferredTaxAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefDeferredTaxAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxAssetsNetOperatingLossCarryforward" xlink:label="loc_ptgefDeferredTaxAssetsNetOperatingLossCarryforward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDeferredTaxAssetsAbstract" xlink:to="loc_ptgefDeferredTaxAssetsNetOperatingLossCarryforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxAssetUnrecognized" xlink:label="loc_ptgefDeferredTaxAssetUnrecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDeferredTaxAssetsAbstract" xlink:to="loc_ptgefDeferredTaxAssetUnrecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="loc_ifrs-fullNetDeferredTaxAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullNetDeferredTaxAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxLiabiltiesAbstract" xlink:label="loc_ptgefDeferredTaxLiabiltiesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefDeferredTaxLiabiltiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxLiabilitiesInProcessRAndD" xlink:label="loc_ptgefDeferredTaxLiabilitiesInProcessRAndD" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDeferredTaxLiabiltiesAbstract" xlink:to="loc_ptgefDeferredTaxLiabilitiesInProcessRAndD" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredTaxLiability1" xlink:label="loc_ptgefDeferredTaxLiability1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ptgefDeferredTaxLiability1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxLiabilities" xlink:label="loc_ifrs-fullNetDeferredTaxLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullNetDeferredTaxLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IncomeTaxesAbstract" xlink:label="loc_ptgefIncomeTaxesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIncomeTaxesAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIOXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="loc_ifrs-fullDeferredTaxAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeferredTaxAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ResearchAndDevelopmentCreditReceivables" xlink:label="loc_ptgefResearchAndDevelopmentCreditReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefResearchAndDevelopmentCreditReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ResearchAndDevelopmentExpenseCashCredits" xlink:label="loc_ptgefResearchAndDevelopmentExpenseCashCredits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefResearchAndDevelopmentExpenseCashCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="loc_ifrs-fullDeferredTaxLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncome" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeferredTaxExpenseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentYearLosses" xlink:label="loc_ptgefCurrentYearLosses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCurrentYearLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="00000065 - Disclosure - WARRANT LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantLiabilityAbstract" xlink:label="loc_ptgefWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsOutstandingExercisePrice" xlink:label="loc_ptgefWarrantsOutstandingExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefWarrantsOutstandingExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsOutstandingShares" xlink:label="loc_ptgefWarrantsOutstandingShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefWarrantsOutstandingShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsOutstandingAmount" xlink:label="loc_ptgefWarrantsOutstandingAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefWarrantsOutstandingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueAdjustmentExercisePriceAtEnd" xlink:label="loc_ptgefFairValueAdjustmentExercisePriceAtEnd" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefFairValueAdjustmentExercisePriceAtEnd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueAdjustmentShares" xlink:label="loc_ptgefFairValueAdjustmentShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefFairValueAdjustmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueAdjustmentAmount" xlink:label="loc_ptgefFairValueAdjustmentAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefFairValueAdjustmentAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsOutstandingExercisePrice" xlink:label="loc_ptgefWarrantsOutstandingExercisePrice_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefWarrantsOutstandingExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsOutstandingShares" xlink:label="loc_ptgefWarrantsOutstandingShares_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefWarrantsOutstandingShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsOutstandingAmount" xlink:label="loc_ptgefWarrantsOutstandingAmount_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefWarrantsOutstandingAmount_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GainLossOfChangeInFairValueOfWarrants" xlink:label="loc_ptgefGainLossOfChangeInFairValueOfWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefWarrantLiabilityAbstract" xlink:to="loc_ptgefGainLossOfChangeInFairValueOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetails" xlink:title="00000066 - Disclosure - CAPITAL STOCK (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CapitalStockAbstract" xlink:label="loc_ptgefCapitalStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommonStockShares" xlink:label="loc_ptgefCommonStockShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefCommonStockShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommonStockValues" xlink:label="loc_ptgefCommonStockValues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefCommonStockValues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-fullAdjustedWeightedAverageShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ifrs-fullAdjustedWeightedAverageShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="loc_ifrs-fullAcquisitionsThroughBusinessCombinationsOtherProvisions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ifrs-fullAcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInIoxExchangesShares" xlink:label="loc_ptgefSharesIssuedInIoxExchangesShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefSharesIssuedInIoxExchangesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ShareIssuedInIoxExchange" xlink:label="loc_ptgefShareIssuedInIoxExchange" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefShareIssuedInIoxExchange" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares" xlink:label="loc_ptgefExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" xlink:label="loc_ptgefExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares" xlink:label="loc_ptgefSharesIssuedToLincolnParksCommittedPurchaseShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefSharesIssuedToLincolnParksCommittedPurchaseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedToLincolnParksCommittedPurchase" xlink:label="loc_ptgefSharesIssuedToLincolnParksCommittedPurchase" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefSharesIssuedToLincolnParksCommittedPurchase" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares" xlink:label="loc_ptgefSharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefSharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts" xlink:label="loc_ptgefSharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefSharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares" xlink:label="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts" xlink:label="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefPurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="loc_ifrs-fullIncreaseDecreaseInNumberOfOrdinarySharesIssued" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="loc_ifrs-fullSaleOrIssueOfTreasuryShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ifrs-fullSaleOrIssueOfTreasuryShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsExercisedShares" xlink:label="loc_ptgefWarrantsExercisedShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefWarrantsExercisedShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfWarrantsEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsExercisedShares1" xlink:label="loc_ptgefWarrantsExercisedShares1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefWarrantsExercisedShares1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommonStockShares" xlink:label="loc_ptgefCommonStockShares_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefCommonStockShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommonStockValues" xlink:label="loc_ptgefCommonStockValues_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ptgefCommonStockValues_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockDetailsNarrative" xlink:title="00000067 - Disclosure - CAPITAL STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CapitalStockAbstract" xlink:label="loc_ptgefCapitalStockAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalStockAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AccreditedInvestorsMember" xlink:label="loc_ptgefAccreditedInvestorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DirectorsMember" xlink:label="loc_ptgefDirectorsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LincolnMember" xlink:label="loc_ptgefLincolnMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefLincolnMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ATMMember" xlink:label="loc_ptgefATMMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefATMMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostsShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PricePerShare" xlink:label="loc_ptgefPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:label="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedInPrivatePlacementNetOfIssueCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfStockSold" xlink:label="loc_ptgefNumberOfStockSold" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfStockSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_GrossProceedsFromStockSold" xlink:label="loc_ptgefGrossProceedsFromStockSold" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefGrossProceedsFromStockSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetProceedsFromStockSold" xlink:label="loc_ptgefNetProceedsFromStockSold" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetProceedsFromStockSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OfferingExpenses" xlink:label="loc_ptgefOfferingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ManagementUnderwritingAndSellingExpenses" xlink:label="loc_ptgefManagementUnderwritingAndSellingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefManagementUnderwritingAndSellingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesExchanged" xlink:label="loc_ptgefNumberOfSharesExchanged" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesExchanged" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_MinorityInterestPercentage" xlink:label="loc_ptgefMinorityInterestPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefMinorityInterestPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromIssueOfOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:label="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="00000068 - Disclosure - STOCK OPTION RESERVE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveAbstract" xlink:label="loc_ptgefStockOptionReserveAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ptgefStockOptionReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserve" xlink:label="loc_ptgefStockOptionReserve" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockOptionReserve" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SettledInIoxExchange" xlink:label="loc_ptgefSettledInIoxExchange" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSettledInIoxExchange" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserve" xlink:label="loc_ptgefStockOptionReserve_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockOptionReserve_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="00000069 - Disclosure - STOCK OPTION RESERVE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveAbstract" xlink:label="loc_ptgefStockOptionReserveAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOxOptionPlanMember" xlink:label="loc_ptgefIOxOptionPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefIOxOptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-fullMeasurementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullMeasurementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-fullAggregatedMeasurementMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullAggregatedMeasurementMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnvestedOptionsMember" xlink:label="loc_ptgefUnvestedOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAggregatedMeasurementMember" xlink:to="loc_ptgefUnvestedOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OptionLifeShareOptionsGranted" xlink:label="loc_ptgefOptionLifeShareOptionsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfPortageOption" xlink:label="loc_ptgefFairValueOfPortageOption" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfPortageOption" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="00000070 - Disclosure - STOCK OPTION RESERVE (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveAbstract" xlink:label="loc_ptgefStockOptionReserveAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOxOptionPlanMember" xlink:label="loc_ptgefIOxOptionPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefIOxOptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="loc_ifrs-fullMeasurementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullMeasurementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="loc_ifrs-fullAggregatedMeasurementMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMeasurementAxis" xlink:to="loc_ifrs-fullAggregatedMeasurementMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_UnvestedOptionsMember" xlink:label="loc_ptgefUnvestedOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAggregatedMeasurementMember" xlink:to="loc_ptgefUnvestedOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OptionLifeShareOptionsGranted" xlink:label="loc_ptgefOptionLifeShareOptionsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueOfPortageOption" xlink:label="loc_ptgefFairValueOfPortageOption" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfPortageOption" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails3" xlink:title="00000071 - Disclosure - STOCK OPTION RESERVE (Details 3)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveAbstract" xlink:label="loc_ptgefStockOptionReserveAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionsTwoMember" xlink:label="loc_ptgefStockOptionsTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefStockOptionsTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsGrantedInSharebasedPaymentsArrangement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails4" xlink:title="00000072 - Disclosure - STOCK OPTION RESERVE (Details 4)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveAbstract" xlink:label="loc_ptgefStockOptionReserveAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionsTwoMember" xlink:label="loc_ptgefStockOptionsTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefStockOptionsTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="00000073 - Disclosure - STOCK OPTION RESERVE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionReserveAbstract" xlink:label="loc_ptgefStockOptionReserveAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefStockOptionReserveAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_N2021EquityIncentivePlanMember" xlink:label="loc_ptgefN2021EquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefN2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AmendedAndRestated2021EquityIncentivePlanMember" xlink:label="loc_ptgefAmendedAndRestated2021EquityIncentivePlanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefAmendedAndRestated2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOxOptionPlanMember" xlink:label="loc_ptgefIOxOptionPlanMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefIOxOptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BoardOfDirectorsMember" xlink:label="loc_ptgefBoardOfDirectorsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConsultantsMember" xlink:label="loc_ptgefConsultantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_TwoMembersMember" xlink:label="loc_ptgefTwoMembersMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefTwoMembersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EmployeesMember" xlink:label="loc_ptgefEmployeesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DirectorsMember" xlink:label="loc_ptgefDirectorsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExecutiveMember" xlink:label="loc_ptgefExecutiveMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefExecutiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockGranted" xlink:label="loc_ptgefStockGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValuePerShare" xlink:label="loc_ptgefFairValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommunicationExpense" xlink:label="loc_ifrs-fullCommunicationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCommunicationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IntrinsicValueOfStockOptions" xlink:label="loc_ptgefIntrinsicValueOfStockOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIntrinsicValueOfStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="00000074 - Disclosure - (LOSS) PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LosPerShareAbstract" xlink:label="loc_ptgefLosPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumeratorAbstract" xlink:label="loc_ptgefNumeratorAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefLosPerShareAbstract" xlink:to="loc_ptgefNumeratorAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNumeratorAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DenominatorAbstract" xlink:label="loc_ptgefDenominatorAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefLosPerShareAbstract" xlink:to="loc_ptgefDenominatorAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-fullWeightedAverageShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDenominatorAbstract" xlink:to="loc_ifrs-fullWeightedAverageShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BasicAndDilutedLossPerShare" xlink:label="loc_ptgefBasicAndDilutedLossPerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDenominatorAbstract" xlink:to="loc_ptgefBasicAndDilutedLossPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="00000075 - Disclosure - (LOSS) PER SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LosPerShareAbstract" xlink:label="loc_ptgefLosPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefLosPerShareAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockOptionsMember" xlink:label="loc_ptgefStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_WarrantsMember" xlink:label="loc_ptgefWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AntidilutiveEffectOnLossPerShare" xlink:label="loc_ptgefAntidilutiveEffectOnLossPerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAntidilutiveEffectOnLossPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000076 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommitmentsAndContingentLiabilitiesAbstract" xlink:label="loc_ptgefCommitmentsAndContingentLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCommitmentsAndContingentLiabilitiesAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_LincolnMember" xlink:label="loc_ptgefLincolnMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefLincolnMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNote" xlink:label="loc_ptgefConvertibleNote" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefConvertibleNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-fullBorrowingsInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowingsInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConversionOfDebt" xlink:label="loc_ptgefConversionOfDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefConversionOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConversionOfDebtIntoShares" xlink:label="loc_ptgefConversionOfDebtIntoShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefConversionOfDebtIntoShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SharePricePerShare" xlink:label="loc_ptgefSharePricePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AggregateValue" xlink:label="loc_ptgefAggregateValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregateValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CommitmentFee" xlink:label="loc_ptgefCommitmentFee" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCommitmentFee" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000077 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract" xlink:label="loc_ifrs-fullRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRelatedPartyTransactionsAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIOXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ChiefExecutiveOfficersMember" xlink:label="loc_ptgefChiefExecutiveOfficersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefChiefExecutiveOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IssuanceOfUnsecuredNotesDescriptions" xlink:label="loc_ptgefIssuanceOfUnsecuredNotesDescriptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefIssuanceOfUnsecuredNotesDescriptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PortageOrdinaryShares" xlink:label="loc_ptgefPortageOrdinaryShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPortageOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_BaseSalary" xlink:label="loc_ptgefBaseSalary" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefBaseSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AnnualFeesdescription" xlink:label="loc_ptgefAnnualFeesdescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAnnualFeesdescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CompensationCommittee" xlink:label="loc_ptgefCompensationCommittee" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCompensationCommittee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_OriginalAnnualTargetsPercentage" xlink:label="loc_ptgefOriginalAnnualTargetsPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOriginalAnnualTargetsPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="00000078 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AmortizedCostMember" xlink:label="loc_ptgefAmortizedCostMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefAmortizedCostMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="loc_ptgefFairValueToOtherComprehensiveIncomeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefFairValueToOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PrepaidExpensesAndOtherReceivable" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ConvertibleNoteReceivableIncludingAccruedInterest" xlink:label="loc_ptgefConvertibleNoteReceivableIncludingAccruedInterest" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:to="loc_ptgefConvertibleNoteReceivableIncludingAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInvestments" xlink:label="loc_ifrs-fullCurrentInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:to="loc_ifrs-fullCurrentInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WarrantLiability" xlink:label="loc_ifrs-fullWarrantLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ifrs-fullWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredPurchasePricePayableTarus" xlink:label="loc_ptgefDeferredPurchasePricePayableTarus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ptgefDeferredPurchasePricePayableTarus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_DeferredObligationIoxMilestone" xlink:label="loc_ptgefDeferredObligationIoxMilestone" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ptgefDeferredObligationIoxMilestone" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" xlink:title="00000079 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughConversionOfConvertibleInstruments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" xlink:title="00000080 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CapitalDisclosuresAbstract" xlink:label="loc_ptgefCapitalDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PayablesAndAccruedExpense" xlink:label="loc_ptgefPayablesAndAccruedExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalDisclosuresAbstract" xlink:to="loc_ptgefPayablesAndAccruedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_CurrentAsset" xlink:label="loc_ptgefCurrentAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalDisclosuresAbstract" xlink:to="loc_ptgefCurrentAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ShareholdersEquityAttributableToOwners" xlink:label="loc_ptgefShareholdersEquityAttributableToOwners" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefCapitalDisclosuresAbstract" xlink:to="loc_ptgefShareholdersEquityAttributableToOwners" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="00000081 - Disclosure - NON-CONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NonControllingInterestAbstract" xlink:label="loc_ptgefNonControllingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefNonControllingInterestAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IOXMember" xlink:label="loc_ptgefIOXMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefIOXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSaugatuckMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="loc_ptgefNetLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" xlink:label="loc_ptgefPurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_StockBasedCompensationExpense" xlink:label="loc_ptgefStockBasedCompensationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefStockBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" xlink:label="loc_ptgefExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative" xlink:title="00000082 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_EventAfterTheBalanceSheetDateAbstract" xlink:label="loc_ptgefEventAfterTheBalanceSheetDateAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementTable" xlink:label="loc_ptgefIfrsStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefEventAfterTheBalanceSheetDateAbstract" xlink:to="loc_ptgefIfrsStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20221231.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:label="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>devprog.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 devprog.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'A SP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP[XTU]O%6J^$?%%OIG]IQZ6-4M[O26D\J6(NT;*R/DJRL%[D$,.F#4/[,_\
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M50 J-YSSD8XKN/#&H:AJWA^PN]6TMM%U.6(-<6#S)+Y+]U#H2&&>0?0C(!R
M 6H=4L[F^NK&&[@EO;54:>W213)"'SL+J#E0VUL9ZX..E6J\G\2?$8>%=0^+
M%[:Z+8_;?#>C6NH&Y"[9+TF&=U25@,E5\L@>F\U6U+XF^.=!T6S\7ZGH>CP^
M$IGMS-8+<2?VE;0S.B+(3CRV8%P6C&,#(#DCD ]AHHKR/0_B-XZ\9Z;/XH\/
M:#I,WA3>YLK2ZN9%U#4(48@RH0/+CW[3L5LYXR5S0!ZEINJ6>M6,5[I]W!?6
M<H)CN+:19(WP2#AE)!Y!'X5:KY]^$OCZ\T7X&_#K3]"T]-0\1>(//CL+>\<Q
M0QJLDDDDLS $A47LH))*J.N1V$WCKQIX>OIM#UC3-(O-<O-.N;O19]->5;>Z
MGA7<UM(CY9&P5(8$@C=T*X(!ZE17G^J_%JVB^#T7C?3;?[6]Y:0R6-BS8:6Y
MF*I% ?0^:ZH?3GTJI<^-/%WB+Q/J6B>%+/1T_L3RH=4U+53*T+73QK)Y,")@
MG:CH2S$8W@8)S@ ]!U#5+/284FOKN"RBDE2%)+B18U:1V"H@)/+,Q  ZDD 5
M:KPCQ_XRG\6^ ;:'4;--.US2?&6DZ?J-K%(9(UE%[;NK1L0"R/')&X) /S8/
M(-==J'C;Q3XD\7:SHG@RSTI(-#:.&_U/6FD:-[AXUD\F)(R"=J.A9B0 6  /
M) !Z317C&N?'ZY\/?#G7=8O-$"^(O#VJ6VEZII,,GF#=)-$H>%N"ZO'*'3('
M)P<8-:&H>/O'/@UM-UCQ5HVBQ>&KJYAM;J/3;B62[TTS.$B=RP"2J'9%;:!C
M=D;@* /5Z*\JF^(GB_Q!\1?%?A/PWI6EQ_V"ULTNJ:I))Y16:!9%0(GS,^2_
M.0%"CJ3BL?1_BSX^\5>#]1\1:9X<T:RCT5[BWOK+4+J0R74]N6$X@=5PB;E(
M5G!)(.0HY(![;17FNL?%.]U8^%=.\'6-O>:SXBL/[6B?4F9+>SLPJ$RR[/F8
MEI(U"+U).2 *6R^(>NZ/?:UHGB:QL5UJSTF36+.XTUG^S7D*?*XP_P R,CE
M02<AU(/4  ])I*\._P"%N^/V^&]O\1?^$>T2+PRNGIJ<^FRW4HOWMM@=Y$8
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M&:P/$.K7?Q<UCPOI>F>']:T_3M/U:WU?4;_6;"6R2,6[;TBC$B@R.TFSE<J
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MW;N,>M1:]%?>%_&GPSUZ;2-3O;"UT>[TR\_L^SDN9+:246IC+I&"VTF)P3C
MQS7L=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 445YS\<-0&GZ#H9EU:YT6SFUFVAN[NUNFMF
M6$A]^74@@<?I0!Z-17BFB>+M.\/^*#/HGBG4?$?A:UTVYNM8ENKEKV.U*;3$
M4E(SO;YQL#'('3I7;:7\0KQ]5T>UUC0)M%BU@,+*9KA)<N$+B.4 ?(Y0$@9(
MX(SF@#M:*\@NOBWKWB#X9:WXCTCP[)I]K'I\TMO?3WD9/F)E6*Q[22%(8C.,
ME,8Y!KIH/&6NP:/HJ_\ "./<7]Q:F>XDDO%2VA52 NZ8K@N^00H'<YZ4 =S1
M7 6?Q676M-T!M'TF2^U/5UF=;-IU1(%A;9,SR8(P'PHP#NR/>H[;XO(VEZE-
M=:-<6FH6NJ+HZ6#2H6FN#&CX#\*%^9CN)QM7/?% 'H=%>=S>(+WQY9ZSX:59
M?#NOPK!.LEK?;E,)D'[Q)4&3]Q@5P">G ;(MZ;\2Y=7UZ\L[/19+JQM-0;3I
MKB&Y1IHW5MK2-#U$8;^+.<<XH [FBN?\=>+D\#>')-7DM);Y(YH8C! 1O;S)
M5C^7/4C=G'?&,BN?U+Q]<00ZIINMZ1<Z+>-I5Q?6QM[Q7\Y(U_>!)%'R2+N7
ML>N03B@#T"BO.=/^(MXUSI.B:3H5SJUU)HEMJGG7-ZJ@1ON7$DA&2^4'./F+
M$\8JS_PMJUN--TTVFGRR:O?7$]H--GE6(PRPDB822'*@*<<C.=RX'- '>T5Y
M;K7CZ;7+'34A6?2-2M/$=A97UM'/N&UW5L!UX='1A^H(XJ:/XB?V):N+73K_
M %:XO/$5WI<<,UX&82+YC#:S !8\I@+_  @]\8(!Z917 _\ "UET_2]<EUG2
M9M.U+2IH8&L(YEF,S38\G8XP/F)QSC&#FM#PYX\;5/$+Z'J.GKIFI&V^V0K'
M=+<1RQ!@K8=0,,I9<J1W!!(H ZZBN>\3>);_ $>Z@M=/T674I)(VF>>286]M
M$JD##2D'YB3PH!Z$\"N,3Q^WB/7/A]JELUS96-XNI&ZLUEW!FAC*E6"G#[75
ML'\1UH ]4HKAO!_Q+D\50VMZVCM;:3=0/<17T5TDZQ*H!VSA?]6Q4YQSR",Y
M%06/Q5EN(M)U&YT&>S\.ZM<);VFHO.I;]X<1/)$!E%<X .3C<,XH ] HKE?B
M)JB:3I>FR2-=J)-5LX!]CN/);+S*H#'!RG/S+W&16#??%R[M1X@NHO#-S<Z3
MH-U+;WUZMU&N%0!F9$/+84Y(X]B3Q0!Z117':IX[O/[9N]-T'1'UR:R@CGNG
M^TK B;P2B*6!W.0,XX !&2,URVL_$6?1?%&H:T\%^+"W\*1ZB=)N2T++)Y[@
MAD.0KX^4G';TH ]:HKG-8\9P:+KVB:=-"=FI07,YN-W$*PHKG(QSD-^E<)XC
M^(FL:OIWA6\MM'O=+TG5-:T\6]\ETN^2%IT.)8UP561,\9.<@'&: /7J*\]U
M;XN)I[:K<P:2]YH^DW#V][>"Y1) 4_UK1Q'EPAR#R,D'&<5->?%%CXBU#3=+
MT=]773TADG,-TBSN)$#@Q1'F0!6!SD<Y SB@#O**IZKJ/]EZ7=7OV:XN_(B:
M06]K&7EDP,[57NQZ8KC[3XF7":M/IVJZ(=-NQITNHPHEXDVY8\;T?:/D?YE]
M1UYXH [RBO.=)^+%YJ"^'[FX\-3V6EZZ5CL;M[N-BTK1-(BL@Y56"MAOID#-
M<[H7CK6=0T,7&O6]U ?^$KCL8)+*^"$YNRGE-M7F-,*I'\8)Z4 >T45Y!X:^
M(&N:;%XRN'T>\UG3=+UJ]\Z[>\4-'"KYV0HV2P1><94=ADUU5S\1);[4'M/#
M>COK[PVL5W<2?:%MT195W1*I8?,[*"<< #&2,T =K17"P_%*/6(=%30=+FU2
M_P!3MY+H6TL@@%O'&P1S*Q!P0YV8 .2#VYKD_"_B^\O1?3:F-4MY7\:BQCM?
MMA!M_P!Q&?+)&0T6=QVC .0: /9J*\ZO/C##:I=Z@NEM+X=L[EK:?4?M*"3Y
M7V/(L/WF16R"<@X!(!%6YOB9+)XCU+3;#19-1BTVXCMKEHKE!<9958ND!Y9%
M#C+9&<' .* .ZHHKA]:^),UCXFO]&T_17U6;3X8Y[A4NDCF<."0(8VYD( YY
M SQUH [BBN UKXG7UGKVKZ7IOAN?5)=-M(KV9S<I"!&ZL<<C._Y3@=\'D8Y-
M#^*SZQJ?A]9-!N;/2M?5CI]]+,A9RL9DP\8Y4%5;!R>V<9X ._HK@6^*%S:Z
MII<=_P"'Y].T_4;[[!!-<W"K<;R65':#&0C%>#G/(.*Y/2?$&J2:SI"/J5VZ
M2>-=3M75IV(:%%GV1D9Y1=HPO08'I0![517,^.O&C>#+?2633I=3FU*_33XH
M89 AWNCLIR>,93!],Y[5RT_Q@U2WAU\-X/N#<^'QYFIQB]CVQQF,2*T;8_>$
MID[<#&.O(H ]/HKC+KXA37FI0V'A_1Y-:N391W\Q>=;=(8I,^6"Q!R[;6PN.
MW)%8R^/$UWQ)X*U&WGN+'3Y[;4S>6LC%=CP^6K+(H."48.._<CK0!Z917GNF
M_%Q+R;1I[C27L]'UB=;>RO#<H\FYP3$9(AR@?'!R<$@'&:FM_B9>:AY][IWA
MN[U'08+PV;7L$H,SE7V/)' !ED5L@\@X!('% '>45QK_ !&C7P[XOU;["Q7P
M[/<P/%Y@S/Y4:N2#CY<[L=^E8"^/AHOBOQ;JE_-<MIEMI.FW$=FKEPLDK2C:
MBYP&9MBYXSQGI0!ZC17!0_%1;.ZN;?7-*;3)4L9M1A^SW*70FCB ,BY7&' (
M^7H<\$U?\%^.+OQ5Y#S:,UI:W%O]HAO+>Z2YA/3Y&9<;7P<XP1P>: .NHK \
M3>([[1[BTMK#1IM3EG5W:9I1!;P*N/\ 62D'!.[@ $G!]*Y9/C(+K3=!ELM#
MFO+[5;NXL19I<(/*FA#;AO\ NE<H?F';G':@#TBBN 7XK"UTW5#J.C7%GK-C
M>PZ?_9D<JRF>:8*80CC PP8')QC!STJMH?B76M0^+RZ=J=A/I"1Z))-]E6Z$
MUO*3/&%D4C W#YEY4$?0T >D45R/BGQQ=:'XFTO0K'1I-6O=1@FGC*SK$D8C
M* [R0<##=1DY &.>,;4/C$-/TM)&T*Z?5EU9-&FTM94WI.Z%T*O]UE8;<'@8
M;G&#0!Z/17$-X^U9[^'2K?PTT^N+;?:[RT^W(L5K&798P9=N&9]I( '8Y(KG
MKCXF:MK7BKP.-(T]UT[4&NEO+>:=8Y!+$&22-Q@X\L@MP<-Q]: /6**\YF^,
M<,4<NHC2W;PY%=&U?4OM*"3A_+,HA^\8P_&<YP"<8J*Y^(D7AJ[\22K::AJ3
MIKEOIPMVN@^7EBCVB%6 "+EA\N<9).1F@#TNBN6\,^-+C5M<O-$U32)-&U6W
MMX[ORC.DZ20NS*&5E[AD((('XUEWGB37H_C%9Z-%9K)H[:8\S'[0JY_>1@RX
MVYRN=NW/.XF@#O:*\@^&OQ)U2'P?X8DU;2KR:PO)4L1K$]VLDCS/(44LA);:
M6PNXG/MCFMS5OBZFGMJMU!I3W>C:3.UO>W@N420%/]:8XCRX0Y!Y&<'&<4 >
MAT5Q"_$:ZU#QE/H.DZ%)J*6RVTUQ??:5CBCAF&0^",DXR=HZ[3TXJ!?BA<P:
MII,6H>'Y],L-3O#96\MS<*MP'^;8SP8RJL5.#D]1D<T =]17FR?%Z[DL=8U-
M/#%T^C:/=SVUY=K<)NQ$Y5Y(X\9<!1N/([@9Q6AJGQ-*ZI=V.BZ7_;+V4$<]
MR[726ZCS%WHB;AEW*X;' Y'.3B@#N:*Y3PY\1+'Q5JUE:V$3O;7>EKJD=PYP
M=K2%-A7L01SS7':K\3M;U/5O"AT;3,6USJ]Y93PM=*OG&%95VDE>!\F_\ *
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M1N$74(XA#O=T* L,,04//&<T 1VO@O7_  Q?PW^A2Z=<S3:;:V%[;W[R(FZ
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MX)L>50=Q&0,9ZXYH&>,^$M#\4Z_X;\6:387&F1Z/J6L:E!+<7'F?:+9&F=)
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M_ABRU#XG^+=3U:QAU'4[%-/\EI(P_DR"W#,T>?NL2!\PY^4<UYQH.I6$FI>
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MI/+0R"0HI<# ;'./3- SSGP"+IM:^)@L6A2]_M=O(:X4M&)/LT6TL 02N<9
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MC,$;[2D><CS/,P2!\QRM<GI^]?#'PYDGGTZS\/K'J $GB*!IK1;@S'R_.&]
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MB]GXYGMX]#TW58;]B$N%>YUB5XRA$L9+ PQX4,,!E"Y/&:],\-^%](UOXO\
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M&BJUGJ5IJ*S-:74-TL,K02F&0.$D4X9&P>&!Z@\BJ^E^(M)UN6>/3M3L[^2
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MJP900<@\@B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O*_B)X+U'Q=\1=+CMO+MK,Z-=0S7ESI_VN)=TD
M7R#)"JY&2"2> >#7I-]->0[/LEK'<YSN\R;R\>G\)S53[;K'_0+M_P#P,/\
M\10!Y=X1A/PK\=:SIS:3KNH:?+8Z79VM];:=).C^3'(K%G4;1C<,^G/I6+I>
MB^*QXU@\=W>B%K+4]0EM+FS(E:\6PDVPQK+;F/ 5/*20\D_,<CKCVO[;K'_0
M+M__  ,/_P 11]MUC_H%V_\ X&'_ .(H&>,:SX)N_P#A6_Q(@M=#ECOKKQ Y
MM%CLB9)(/.MR"@VY9/E8\<?*?2MOQ'X'U+05\.7=\G_"6:=8ZF]S>VEAI<<3
MLAA9(V\E/]9L<[NY^;IQ7IGVW6/^@7;_ /@8?_B*/MNL?] NW_\  P__ !%
M'B6J^$-5U]KN[TO2KO1=-U+Q+83VMO/I^6@5(666Y> C"JS8R&QG&3UK.OOA
MKJ]YH2Z+)87AU9=?O+J:\BM=EL\GV.0V\\050J(6$0QV?()R17OWVW6/^@7;
M_P#@8?\ XBC[;K'_ $"[?_P,/_Q% 'E'P=T?6V^(6H^)=8TNZL+C6]--Q,L\
M+J(G^TLJ0DD<,(DC.WK@]*]MK)^VZQ_T"[?_ ,##_P#$4?;=8_Z!=O\ ^!A_
M^(H$:U%8-OK6K7%U=PC2[?=;NJM_IA[J&_N>]6/MNL?] NW_ / P_P#Q% &M
M163]MUC_ *!=O_X&'_XBC[;K'_0+M_\ P,/_ ,10!K45D_;=8_Z!=O\ ^!A_
M^(H^VZQ_T"[?_P ##_\ $4 <E\2O#2ZMXF\$W":4+P1ZKFZE6W\S;%Y$@!D.
M.%R1UXSBN2TNSN-)^+VMM-I^K1VMQJD!MS#H/GVSKY,2!OM!3]VH(Y(.!MS7
MK7VW6/\ H%V__@8?_B*/MNL?] NW_P# P_\ Q% 'E7@731HR:7HFI^"[R_\
M$-OJTUQ-J[VVR$9E=A="XZ-\A4;,Y[8K%\/^"?$]OI'A6>:YU(V<?BDS-HKV
M"J+=/M$Q\XOL\S;@[LDX^?TQ7M_VW6/^@7;_ /@8?_B*/MNL?] NW_\  P__
M !% '@WAWP3XD\/WGA9X;"\DTG4=>:]OK>2)]]E-'-,JRXQ\L<D17)/&5!SR
M*MP^&KW_ (1NQ\,_\(O?+XNAUE;E]>-IB$8N?,:Y^T]#NC&W;G=SC%>W?;=8
M_P"@7;_^!A_^(H^VZQ_T"[?_ ,##_P#$4#/'[1M5E\._$#PG;Z/K5MJVJZGJ
MLEG=M82I:LKLQ0^<0% 8# .<?,*ECT:X\3:QH9\->&[[PI)I^E7EO<W%W9FT
M7=)!LBA!_P"6F),/D9 VYSDUZW]MUC_H%V__ (&'_P"(H^VZQ_T"[?\ \##_
M /$4 >->#=+NUUGP;IL'@]K.WL[-K353?:.8_+)B9976ZW[91(V/E"MG).?3
MK?@WX-D\/W7B&:\CO#):WDFE::]\IRFGQD-$L9(Y4EV^8==H]*[C[;K'_0+M
M_P#P,/\ \11]MUC_ *!=O_X&'_XB@1K45D_;=8_Z!=O_ .!A_P#B*/MNL?\
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MV_\ X&'_ .(H^VZQ_P! NW_\##_\10!K5F^)(GG\.ZI'&C22/:RJJ*,EB4(
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M"[?_ ,##_P#$4 :U%9/VW6/^@7;_ /@8?_B*KZAK6K:?:M.^EV^U2HXO">K
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MUC_H%V__ (&'_P"(H UJ*R?MNL?] NW_ / P_P#Q%'VW6/\ H%V__@8?_B*
M-:BLG[;K'_0+M_\ P,/_ ,11]MUC_H%V_P#X&'_XB@#6HK)^VZQ_T"[?_P #
M#_\ $4?;=8_Z!=O_ .!A_P#B* -:BLG[;K'_ $"[?_P,/_Q%'VW6/^@7;_\
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M ?,0',9;YQPO()&: /H1;J%UE*S1L(B1(0P.PCJ#Z4U[ZVCA65KB)8F&5=G
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MZ"-I_P!_U_QKY+HJO[ C_P _/P_X)'^MD_\ GROO_P" ?6G]O:9_T$;3_O\
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M<<D 8SZ-I7_(8UK_ *[1_P#HI*Y;QE\-]6\37&LQ6OB=K31]:@%O?:?>68O
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M-IG6U1EC4@%B$' SZU:U#_D'W/\ UR;^1JII]J+WPS;6[/)$LUHL9>%RCKE
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M\;0>(I-5AO+B&.ZAWC3UCN;E9G5LW$^]FD==@ (VJ!P%'6@#U"BBB@ HHHH
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M#Z5H"\MV$A$\9$:AG^<?*",@GT&* (/.U'_GUM?_  );_P"-T>=J/_/K:_\
M@2W_ ,;JIK7BS3=!MK6>YGS%<WD5@C188"61PB@XZ#)Y]*M3:Q;PW%M'DO'<
M1R2"X7!B54 )+-GCKQ]#0 OG:C_SZVO_ ($M_P#&Z/.U'_GUM?\ P);_ .-U
M6UCQ/I^AVL%Q<3;HIKN*Q5HOFQ+(X10?3YF&?2J_B;QIIWA/1[C5+SS9+"WL
M[B^EGMT$BK%#&9'/!Y. <8ZT :/G:C_SZVO_ ($M_P#&Z/.U'_GUM?\ P);_
M .-TVVUJWN(;B5BUM%!)Y;27&$4Y56!!ST^8#ZYJ]0!3\[4?^?6U_P# EO\
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M6_\ C=7:* *7G:C_ ,^MK_X$M_\ &Z/.U'_GUM?_  );_P"-U=HH I>=J/\
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M6U_\"6_^-UA^&?B%8^)M6ETS[#J6E:@MNMVEOJ=J86EA+;=Z\D$ X!&01D9
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MI]01D4 ?.'B'X7^,M8D\1O#X9^R3WVCZ_9$6[V4<$TERK>1A]YFD+E5+-*5
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MQJ-CH^C-=6=K8KINA.[V_P"Y,I\YBT<?S,) H4+\JH!N;MZ!0 4444 %%%%
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MOLW%I^-S#**"V-CPQ\/]>L=3\/WU[X4$MO8^(Y+A$:.QANTMY+/RS<2I%)Y
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MJ +M%4O^)C_TZ_\ CU'_ !,?^G7_ ,>H NT52_XF/_3K_P"/4?\ $Q_Z=?\
MQZ@"[15+_B8_].O_ (]1_P 3'_IU_P#'J +M%4O^)C_TZ_\ CU'_ !,?^G7_
M ,>H K:5_P AC6O^NT?_ **2N8\8?#C4_$LFM0VWB62TTK6H%M[VPN[07:QK
MLV,UON8")BN,Y5USEMN236[IOVW^U-7V_9]_G1[\[L9\I.GX8K3_ .)C_P!.
MO_CU '#2_!\+-<V=KK#6_AR\N[:^O-.:W#RO+ (@H28M\J-Y$>\%6)^;#+FL
MG4O@/<S:?J-GIWB3^STU73[K3-0=[ 3/)!-<3S#R_G 1E-S(N2&!!Z X(]/_
M .)C_P!.O_CU'_$Q_P"G7_QZ@#@)?@NDVNS7<FKE[";4K;5'LS;#)EBLA:$;
M]WW615.,<$'DYXJ2_ V;4-)M]-U+Q&UY:Z?ICZ3IFVS5'AA8Q9>8[CYLFV%%
MW (,9^7)S7I7_$Q_Z=?_ !ZC_B8_].O_ (]0!QOBSX5KXEO-8N?MEHW]HM;%
M[/4M.2\M6$*2*%DC9@6!\S=\K*04'/45T?@GPS_PAOA33=%^VS:A]CB\O[1-
M]YN2>!DX49P%R<  9.,U?_XF/_3K_P"/4?\ $Q_Z=?\ QZ@"[15+_B8_].O_
M (]1_P 3'_IU_P#'J +M%4O^)C_TZ_\ CU'_ !,?^G7_ ,>H NT52_XF/_3K
M_P"/4?\ $Q_Z=?\ QZ@"[15+_B8_].O_ (]1_P 3'_IU_P#'J +M%4O^)C_T
MZ_\ CU'_ !,?^G7_ ,>H NT52_XF/_3K_P"/4?\ $Q_Z=?\ QZ@"[63J?_(:
MT;_?E_\ 19JS_P 3'_IU_P#'JS-0^V_VOI.[[/OWR;<;L?<.<T =!15+_B8_
M].O_ (]1_P 3'_IU_P#'J +M%4O^)C_TZ_\ CU'_ !,?^G7_ ,>H NT52_XF
M/_3K_P"/4?\ $Q_Z=?\ QZ@"[15+_B8_].O_ (]1_P 3'_IU_P#'J +M%4O^
M)C_TZ_\ CU'_ !,?^G7_ ,>H NT52_XF/_3K_P"/4?\ $Q_Z=?\ QZ@"[15+
M_B8_].O_ (]1_P 3'_IU_P#'J +M%4O^)C_TZ_\ CU'_ !,?^G7_ ,>H NT5
M2_XF/_3K_P"/4?\ $Q_Z=?\ QZ@"74/^0?<_]<F_D:AT/_D"Z?\ ]>\?_H(J
M&^^W_8;C=]FV^6V<;L]#46C_ &_^R+'9]GV>0FW=NSC:,9H Y:^^%+R23W=C
MJXM=2&OMX@M9IK7S8XI3;&W,;('4NI1G_B4_-[53T'X*#1_.DGUR2]N)K/5K
M665K94W-?70N'DP#@;6! '?/:O0?^)C_ -.O_CU'_$Q_Z=?_ !Z@#AK_ .#J
M74MO<0ZO);7MI9:;;6LP@#".2SEE=9&4GY@_G%67CC."#R)]%^%;6'BBU\1W
MNK?;=7%U<7=VZ6WE12O+!% JHNYBBI' @ )8DY)/-=E_Q,?^G7_QZC_B8_\
M3K_X]0!Q?A7X4'PWX\O/$AU&"1KB.>-HK6P2U>X\V59 ]RZ-MF= NU&V*0&;
M.2<UZ#5+_B8_].O_ (]1_P 3'_IU_P#'J +M%4O^)C_TZ_\ CU'_ !,?^G7_
M ,>H NT52_XF/_3K_P"/4?\ $Q_Z=?\ QZ@"[15+_B8_].O_ (]1_P 3'_IU
M_P#'J +M%4O^)C_TZ_\ CU'_ !,?^G7_ ,>H NT52_XF/_3K_P"/4?\ $Q_Z
M=?\ QZ@"[15+_B8_].O_ (]1_P 3'_IU_P#'J +M9/BC_D"S?[\7_HQ:L_\
M$Q_Z=?\ QZLSQ']M_LB7S/L^S?'G;NS]]<4 ;SHLBLK*&5A@JPR"/2N'U/X,
M^&]2NGG$4]F6.3';2!4S[ @X^@XKK?\ B8_].O\ X]1_Q,?^G7_QZMZ5>K0=
MZ4FCEKX6ABDE6@I6[G#_ /"BO#O_ #UO_P#O\O\ \31_PHKP[_SUO_\ O\O_
M ,37<?\ $Q_Z=?\ QZC_ (F/_3K_ ./5T_VAB_\ GXSC_LG ?\^8_<</_P *
M*\._\];_ /[_ "__ !-'_"BO#O\ SUO_ /O\O_Q-=Q_Q,?\ IU_\>H_XF/\
MTZ_^/4?VAB_^?C#^R<!_SYC]QP__  HKP[_SUO\ _O\ +_\ $T?\**\._P#/
M6_\ ^_R__$UW'_$Q_P"G7_QZC_B8_P#3K_X]1_:&+_Y^,/[)P'_/F/W'#_\
M"BO#O_/6_P#^_P O_P 31_PHKP[_ ,];_P#[_+_\37<?\3'_ *=?_'J/^)C_
M -.O_CU']H8O_GXP_LG ?\^8_<</_P **\._\];_ /[_ "__ !-'_"BO#O\
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M,]P#5HKG/ /C2/Q]X>_M:*QNM-3[5<VOV:\7;,IAF>([E_A)*9VGD9P:Z.@
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M,Y-*.28>3:4WIZ?Y#EQ-C().5..OK_F?3G_"S/"__09M_P#Q[_"C_A9GA?\
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MH_MS"]G]W_!#_5G'=X_?_P  ^>Z*^A/^%(^&O[MW_P!_O_K4?\*1\-?W;O\
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MHE]?,4G\L$5#MU'_ )ZVO_?MO_BJNT4 4MNH_P#/6U_[]M_\51MU'_GK:_\
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M_P">MK_W[;_XJL36?B3H&CZ?#>_;X;VU>_BTV26SFCD6"61]O[P[@%"G[W<
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MY]R^YA]?PG_/Z/\ X$O\S?VZC_SUM?\ OVW_ ,51MU'_ )ZVO_?MO_BJP/\
MA:OA7_H+Q_\ ?J3_ .)H_P"%J^%?^@O'_P!^I/\ XFCZKB/^?<ON8?7\)_S^
MC_X$O\S?VZC_ ,];7_OVW_Q5&W4?^>MK_P!^V_\ BJP/^%J^%?\ H+Q_]^I/
M_B:/^%J^%?\ H+Q_]^I/_B:/JN(_Y]R^YA]?PG_/Z/\ X$O\S?VZC_SUM?\
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MS#;V F"$XW;8\XS^%:.H?\@^Y_ZY-_(UG1V+:GX.6S5@C7%AY08] 6CQG]:
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M':M]H-MK<9B@MYKIYY8I(HC'$0)661E"OL)&X*25SSBL"+X3ZM$\FF#5+/\
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M15+RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\ X#-_\<H NT52\K4?^?JU_P# 9O\
MXY1Y6H_\_5K_ . S?_'* +M%4O*U'_GZM?\ P&;_ ..4>5J/_/U:_P#@,W_Q
MR@"[15+RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\ X#-_\<H K:5_R&-:_P"NT?\
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MC:3&<9)Z   9/"@  8 &!5[RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\ X#-_\<H
MNT52\K4?^?JU_P# 9O\ XY1Y6H_\_5K_ . S?_'* +M%4O*U'_GZM?\ P&;_
M ..4>5J/_/U:_P#@,W_QR@"[15+RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\ X#-_
M\<H NT52\K4?^?JU_P# 9O\ XY1Y6H_\_5K_ . S?_'* +M%4O*U'_GZM?\
MP&;_ ..4>5J/_/U:_P#@,W_QR@"[15+RM1_Y^K7_ ,!F_P#CE'E:C_S]6O\
MX#-_\<H NUDZG_R&M&_WY?\ T6:L^5J/_/U:_P#@,W_QRLS4([W^U])#7%N7
M+R;2(& 'R'.1OY_2@#H**I>5J/\ S]6O_@,W_P <H\K4?^?JU_\  9O_ (Y0
M!=HJEY6H_P#/U:_^ S?_ !RCRM1_Y^K7_P !F_\ CE %VBJ7E:C_ ,_5K_X#
M-_\ '*/*U'_GZM?_  &;_P".4 7:*I>5J/\ S]6O_@,W_P <H\K4?^?JU_\
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M* +M%4O*U'_GZM?_  &;_P".4>5J/_/U:_\ @,W_ ,<H NT52\K4?^?JU_\
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MJ47>G)KT.>MAZ.(7+6@I+S5SC?\ A2/AK^[=_P#?[_ZU'_"D?#7]V[_[_?\
MUJ[+RM1_Y^K7_P !F_\ CE'E:C_S]6O_ (#-_P#'*Z?K^*_Y^/[SC_LK _\
M/F/W'&_\*1\-?W;O_O\ ?_6H_P"%(^&O[MW_ -_O_K5V7E:C_P _5K_X#-_\
M<H\K4?\ GZM?_ 9O_CE'U_%?\_']X?V5@?\ GS'[CC?^%(^&O[MW_P!_O_K4
M?\*1\-?W;O\ [_?_ %J[+RM1_P"?JU_\!F_^.4>5J/\ S]6O_@,W_P <H^OX
MK_GX_O#^RL#_ ,^8_<<;_P *1\-?W;O_ +_?_6H_X4CX:_NW?_?[_P"M79>5
MJ/\ S]6O_@,W_P <H\K4?^?JU_\  9O_ (Y1]?Q7_/Q_>']E8'_GS'[CC?\
MA2/AK^[=_P#?[_ZU'_"D?#7]V[_[_?\ UJ[+RM1_Y^K7_P !F_\ CE'E:C_S
M]6O_ (#-_P#'*/K^*_Y^/[P_LK _\^8_<<;_ ,*1\-?W;O\ [_?_ %J/^%(^
M&O[MW_W^_P#K5V7E:C_S]6O_ (#-_P#'*/*U'_GZM?\ P&;_ ..4?7\5_P _
M']X?V5@?^?,?N.-_X4CX:_NW?_?[_P"M1_PI'PU_=N_^_P!_]:NR\K4?^?JU
M_P# 9O\ XY1Y6H_\_5K_ . S?_'*/K^*_P"?C^\/[*P/_/F/W'&_\*1\-?W;
MO_O]_P#6H_X4CX:_NW?_ '^_^M79>5J/_/U:_P#@,W_QRCRM1_Y^K7_P&;_X
MY1]?Q7_/Q_>']E8'_GS'[CD(?@KX8CD#-#<2C^Z\YQ^F*Z.V\):;9PI#!$8H
ME&%1#@"KGE:C_P _5K_X#-_\<H\K4?\ GZM?_ 9O_CE85,16K?Q)M^K.FCA,
M/AKNC!1OV17_ .$;L_1_^^J/^$;L_1_^^JL>5J/_ #]6O_@,W_QRCRM1_P"?
MJU_\!F_^.5A=G65_^$;L_1_^^J/^$;L_1_\ OJK'E:C_ ,_5K_X#-_\ '*/*
MU'_GZM?_  &;_P".478%?_A&[/T?_OJC_A&[/T?_ +ZJQY6H_P#/U:_^ S?_
M !RCRM1_Y^K7_P !F_\ CE%V!7_X1NS]'_[ZH_X1NS]'_P"^JL>5J/\ S]6O
M_@,W_P <H\K4?^?JU_\  9O_ (Y1=@+:Z3:V;;HX_G_O,<FKE4O*U'_GZM?_
M  &;_P".5);QW:R9FGAD3'2.$J?S+G^5("S1110 445P?C/QKXBTOQEIF@>'
MM(TO499]/N-2GDU34)+15CBDB0JK)#+R3*.H X- '>45Y=X?^,6H^.+72H_#
M/A^";4[G3QJ-U'J5^8;>T0RO$H\R..0R%WBEVD* 50L2,@&IJ'QGU>9M)L=,
MT73;?7)M0NM.OK;6=2:""VD@C$C;9DB<N&5E93M&0PR <@ 'KE%>,ZI\9_$\
MW@O_ (271- T6YM+:];3KQ+G5I,><+D6X:!T@998B6!W':>HVY&*]/TG4-0M
M?#HO/$R:?IMY"DDEW]CN6EMHE4L=PD=$.-@!.5&#GJ!F@#7HKDOAOX]_X6%I
MNI7RZ?-IT-O?R6L,=QQ))&%1ED9<90L'!VGD9P><BNMH **** ,G2O\ D,:U
M_P!=H_\ T4E<]'\5M-_X3[7/"<MO-!?Z;:+=Q228$=VNP.ZQG^\@9,CT8'H#
MCH=*_P"0QK7_ %VC_P#125PWB[X2WGB2;Q7=P7D%EJ=U/;WNC7@R6MIXK<1'
MS!C[CC>C 9RCMT- '1:'\4/#VJZ;X<FN-4LM,OM=L[>\M=-NKJ-9V$R@HH4G
M+$D[1@<D'%:&F^//#6L:M+I=AX@TN]U*+=YEG;WD<DJ[3ALJ#D;3U],C/6O'
MY?@KXQ.EZ)I0NM--K96NC1M)%?2P('LS$9=T:0YG+%#L9WPH(^0$<[J_!6_F
M\,Z5I+W=K:O#>ZU/<7-N6+JEZ+L(R949=?M$9(.!\IP3@9 .PO/BIX=_LB6_
MTK5++7DAN[.TE33KN.4QFXN$@1FVDX&7)]PIQ4K?$_PUI]G'+K&NZ1HTDCR!
M8KC4H>525X]P.[&,H<_W2"#@J:X:X^%WB;Q UA/?Q:-I<NGVNG644-C<R2I,
ML%];W$CL3$NS"P81,-R[9(K%T_P9XG\.^.Y;*QT[2=4GDT&\C>2]FDBA43ZC
M-*H#B)BV%==R8&<<'@9 /9;KQGH%AK5OI%SK>G6^JW(5H;*6Z19I Q(7:A.3
MD@XQUP<=#4<'CKPW=:X=%A\0:7+K D:+^STO(S/O569DV9W;@JL2,9 !)KRV
MQ^"NOZ+HEYX9MI].OM*U"32Y9M8N9G2\@^RPVL+!8PC!R1:AT.]=K2-G[HW8
M-OX<U+7/$'A_PE!'"MCI.IZQ)+J4=O<)=Q1SV][$'=7B5%^>X7!$C>;@., &
M@#UK5/BUX<M]&NM0TS5+'7_LMS:6T\.G7<<K1F>=(4+;2<#+D\]=IJ_XM\9#
MPW=:9I]KI\^KZQJ;NMK8P,J95%#22.[$!$4%<GDY90 2:\KL_@=K\VEPQ7?]
MGP7MG;:=9PS?VI<W*O'!>03R8#1J(UVP#:@#8+$;@,D^C>-O#6L77B+P_P"(
M] %G-J6E+<6[V>H2O#%<6\XC+J)%5RC!H8F!VL.".,Y !8L_B%90:/-?>(XF
M\(-!<FTD36)$B1I-NX>5)G9*I7D%2>C @%2!KWGB"TA\-W&MVTL=_91VK7<<
MEO('29 A8%6'!! X/3FN%NO"WC6\UC2?$EV^D7FI6%Y</#HWGO';06\D C"K
M<>46>0%=Q9HP")'48 !*:+\);W3_  >UG-K$\>H207VZRM;AETX27,D\FW85
MR50S[0< X13@=* -?PS\1+O4='36M>T>'POH4EHEVFH7FI1,F'V[0W3;D-U)
MZ\=ZT[CXE>$K32;;4YO$^D1:=<LR073WT0CE96"LJG=\Q#$ @<@\&N)C^!MI
MH7A'0(M"TS2;;Q!ILMC<SDADAO'@QN5G"E@"<LK;3A@IQ5CP]\,=4C\<V_BC
M4QI\4SW]YJ$ME;RO(MLTMM;VZ"-BB[B5@+,Q"\R'&>M '4W'Q4\&6=Q<03^+
M-$BFMP3-&^H1!H\-M.1NXPQ /H2/45K?\)-H_P!FGN/[6L?L\$"7,LOVE-D<
M+@E)&.<!6 )#'@X.*X/PY\*KS1]4\)7,QL671[K6+B;RRQ)^URNZ%,KR<-\V
M<=\9KE%^#GC'2_!]QX?L/[%N%U#PUI^C7%S/=RQBVEMQ(K%%$)\Q&608)VD%
M>0: /2X_BEX>M[2\N=7U*ST&*WU"XT]6U&ZCB$K1-M9E+$<=_8=:9!\5-#U#
M7M0T>PN[>ZOM/N[:TN%-W$@S, 04RV6QN P!DG@9-<1X@^%/BNXEO(["?3VM
M+Z?5'E O'M956YDC:,F586<J K;HT9 QVY8@9#]#^$7B'3Y($GETTQ"YT:\E
MECN)"V^T@CBE15,70^7E6)YSR%H ]'A\?^&+B748XO$6E22::CR7JK>QDVRH
M<.TGS?*%.02> 00:BA^)'A.XTFYU2+Q-I$NG6T@BFNDOHC'&Y^ZK,&P">,#O
MD8ZUY7??!+Q+JW@FS\,S'2+:'1] O=%L[R.XD9[YIHEB5YE\H>6"%WN 7)?&
M.F3U'C+X8W^L:UJ^H64-E+'-!IJVL)O)K.6*2W>Y+NDL2YC;;.@5L,#AE9<&
M@#TBPU"UU6RAO+*YAO+2=0\5Q;R!XY%/0JPX(]Q5'4_^0UHW^_+_ .BS5'X=
MZ+JOAWP?8:?K5U'>ZE"9/,FBP1M:1F12P1-Q5"JE]J[B"V!FKVI_\AK1O]^7
M_P!%F@#6HKC?B5\0/^$#M=*VQV?G:G>?8X[C5+LVEG WEN^Z678V,[-JKC+,
MP&1UJCJOQ&U?2_ ?]J2^'XQXAFNUT^STQ+P207<SR!$>.;:"8BI,FXH"%5LK
MQ0!Z!17$:+\3(/$.K^#X+*VS9^(=(NM5$KMAX3"UJ/+*XZYN"#TP4Q],J'XN
M7>H7USI6G:-%=:XVL7FF6L$MT8H3';JC23RR;&*J-ZC"JQRRCN2 #TRBL/PI
MJVKZI;7::WHRZ/?6TYA*PW'VB"==JL)(GVJ2IW8PRJ05(QW.;X?\>/KWCK7_
M  __ &3=6,6EV\$R7=V-GVK?+/&2B==@,!PQQNSD#;@D ZZBO/\ XA?%";PC
M'X@%AI\>H2Z+I(U&X\Z8QJ'DD*01Y /WO+F)/\(5>#NXYW7OC-XD\,?;]*U'
MP[I7_"30QV$D"6>JR36;BYO8[1?,<P*\9!DW8V-D X/!H ]BHKA-)^(6I6M_
M?Z3XFT-;/6;6Q&H)'HL[W\5W%N*'RLQQOO#8!4I@;E.XC)&Q\/O%DOC;PG;:
MQ/8-I<LLMQ&UG)(':(QS/'AF'!/R<XR,]">M '1T5BZ1XPTK7-6U/3K.[CEN
MM/D2*90PY+1K(-O/(VN/QS6%>_$R+0[KQO%JUL+5/#EK'J*,KY-S:O$S!P".
M&\R*:/ SR@]<4 =O17CFF_%CQ=JGB:XT@:7X6TV:S-G%=P:IK<L-QYLUO%,Z
MQ((&WA3*4!R,E>@K?D^(OB'49=6NO#_A:'5]&TN\ELII)-0,-U<O$VV;[/%Y
M3*VU@RC?(A8HPXX) /1**\KO/BAXAN/B%K&@:9:^&8[33;FWMF;5]8DMKJ8R
M0Q2DQQ+"X./,VCYADCM6M\6O&'B?P/I*:IHFDZ3J=BC1Q7 U"^EMY \DJ1)L
M"0N&&7!))& . : .^HKRJ_\ C)?>$=471_$^EV2ZY+8Q36MGH]VT_P!LN99Y
M8X[>(R)&22(PQ8@!?F)X7-79/BAJ6DWFIVVKZ7:PMI%MIMSJ+VURSK&MR\R2
M%25&X1>6&S@;EW< X! /0-0_Y!]S_P!<F_D:AT/_ ) NG_\ 7O'_ .@BIM0_
MY!]S_P!<F_D:JZ9-]F\.VDVQI/+M$?9&,LV$!P!W- &E17F?P^^+5WXT6WOI
MM/TN+0KBT:Z:^L-76Y:P*A28;M#&GE/@MT+8*,#C )T+_P"+VC/I:W.CR_VA
M-]NTVV:":.2W;RKN\BMUF4.H+)^\9E8 JVS&: .\HKSS6OC-H_A_PG/J=Y<P
M37JVMU=);V2S3)MB=DW.PCS&A90I=P%!S@G&:T?%7B;Q#:>!X-=T#3=,O)Q;
M?;+BWU*\D@58_*+G8R1/N;.!@@#WH [*BO._!/Q/N+[P_?ZCXK72=(DM-/@U
M>2+3KF:Y\FSF1V1Y"T*8/[J087=]SZ5I:A\7O"6EZI+IUQJI6[BN#9LBVLSC
M[1LWB ,J$&4KR(P2S9X!H [*BN2NOBMX6M-.L[Y]4W6]TDLL?EV\LCA(FVRN
MZ*I9%1N&9@ IX.*2\^+'A.QU"\LI=8C,]G"MQ<>7%)(D4;('1F=5*C<K#;S\
MQ.!D\4 ==16;H/B*P\36;W.GRO)''*T,BRPO#)'(O571P&4C(X('45I4 %%%
M% !1110 4444 %%%% !63XH_Y LW^_%_Z,6M:LGQ1_R!9O\ ?B_]&+0!K5RF
MJ_%'PUH]RUO-J*R3*<,L"-(!^(&/UK#^-OB:XT70;:QMF,;Z@S*\BG!"+C('
MUW#\,UXGX?TV/6-7M[261H8Y-Q9T7<0 I/ R,]*^CP&5PKT77K-J.NWD?'9K
MG=3"XA83#13EI>_GLNGWGO7_  N;PM_S]S?]^'_PH_X7-X6_Y^YO^_#_ .%>
M+3>$_MEO;W.CR37L4[R(([B(0R#8%+'[Q!7##G/;G%4)/#NH1VTDYM\Q(&)*
MR*254[2P .2H/&X<>]>G'*<#+[;^]?Y'BRS_ #..]./R3:^],]X_X7-X6_Y^
MYO\ OP_^%'_"YO"W_/W-_P!^'_PKY^L--N=2D=+>/>47>[,P547IDL2 !DCJ
M>]:G_"+RPV/FSK,LX:X5H553M\J.-PQ)(X/F=1V&1G-.63X.+LY._JO\B8<1
M9C-<T81MZ/\ S/;?^%S>%O\ G[F_[\/_ (4?\+F\+?\ /W-_WX?_  KP]?">
MH17=K'=6TB)-/' 1$R/("Y^4;=W!(SC=@'UJJN@7[6/VP6Y\@KO!W#<5SC<%
MSN*YXSC%"RC!/:;^]?Y ^(,S6]-?^ O_ #/>O^%S>%O^?N;_ +\/_A5W3?BE
MX;U:80P7^)6. DD;*3],CFO!(/"=XMR([M/LZ%)CN5E<J\<3.48 _*>!P<'F
ML.C^Q<+--4YN_P G^@_]9,?2:=6G&W:S3Z>?GV/K'_A(;'_GHW_?!H_X2&Q_
MYZ-_WP:\K\ ZU+J^A@3G=-;MY18]6& 03[_X5TU?)UL.Z-25.6Z/T/#8B.*H
MQK0VDKG7?\)#8_\ /1O^^#1_PD-C_P ]&_[X-<C16/*CI.N_X2&Q_P">C?\
M?!H_X2&Q_P">C?\ ?!KD:*.5 ==_PD-C_P ]&_[X-'_"0V/_ #T;_O@UR-%'
M*@.N_P"$AL?^>C?]\&C_ (2&Q_YZ-_WP:Y&BCE0'7?\ "0V/_/1O^^#1_P )
M#8_\]&_[X-<C11RH#KO^$AL?^>C?]\&C_A(;'_GHW_?!KD:*.5 ==_PD-C_S
MT;_O@T?\)#8_\]&_[X-<C11RH#KO^$AL?^>C?]\&C_A(;'_GHW_?!KD:*.5
M=K:ZI:WC;8I06_ND$']:MUY^K%6!!P1R"*[/2;MKRQCD;[_1OJ*F4; 7:***
M@ KAO%7PJTCQMXZTO6==TW3-:T^QTZXM%LM2M$N )9)87$BAP0"!&PSU^:NY
MHH XC6/!.I:?XDCU[PI<:?87+6,>FW-C>V[&WEAC9VA*^6049#)(.A!#XP,
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M&M7Q1\)--_X0NYTCP?I6C>&[B2^L;X?9[)8(9'M[J*<!Q$ 3D1E<]MU>@T4
M<=X9\):M'XGN?$GB&_M+K4WM%L;>WT^!HX+:'?O899F9V9MN6^4850%').CX
M'\,R>%?#:Z9/*ERPN;J<LH(!$MQ)*!@^@<#\*Z"B@#DO#/PK\+^$=>U'6-*T
M:RM+V]=7W16L2>1B-8RL15054A<D9Y))[UG?$#X8'QKXDT'44O%M;>W81:E
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MZY-_(U4L+=KKPS;0)-);M)9J@FBQO0E -RY[CK5S4/\ D'W/_7)OY&H=#_Y
MNG_]>\?_ *"* /*KGX'ZGXDF)\0ZGI;2_P!EW6F3ZMI-@UM>Z@L\!B+3G>1@
M9W[1D%PI&W&#>O?A7KWB*\M]0UG4]/\ MMJ=-BA6Q@=(C';7\-W(S L?F?R0
MJJ.$]3DUZK10!XZOP;U[2].U&'2=6TY9]5TR72KQKVW>140SW,L<D8##D"ZD
M!4\'"G/&#Z-/X?DE\$R:&)5$K:>;+S<';N,>S=CT[UN44 >/ZW\&=:GT74+#
M3-5L(O[5\,VOAZ]:Z@=MOD+,%DCVL/O>>X(/3 //0['_  JNY.I&Y^VP[?\
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MH?"7_0)_\F9O_BZN:?\ #CPWI4HEM=+CCD'1R[L1]"2:(YQA:,7[*$K^=O\
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MWO#=C!%_:VJ6=E=2><XAAD>?$4<SQ&0D("%!0[B0 IR">A(!U7V>^_Y_(_\
MOQ_]E1]GOO\ G\C_ ._'_P!E63=?$3PW9ZQ#I<NL6RWDWE[5!+(#)_J@S@;5
M+Y&T$@MD8SFHX?B9X7N-?CT6/6K=]2DED@CA&<221JS2JK8VL4"-N /RXP<&
M@#:^SWW_ #^1_P#?C_[*C[/??\_D?_?C_P"RKC]6^,N@0Z)<7VCW,.M20SV4
M;01R&/='<7*0+,I*G<GSDAE!5MN >]:OC#QA<Z#?:5I6EZ:NKZWJAE-O;27'
MV>)8XP#)+))M8JHWH.%8DNO'4@ V_L]]_P _D?\ WX_^RH^SWW_/Y'_WX_\
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MD/;=S6KI.K6>N:;;W^GW$=W9W"[XIHSE6%5-3_Y#6C?[\O\ Z+- %G[/??\
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M_/1O^^#19@2_9[[_ )_(_P#OQ_\ 94?9[[_G\C_[\?\ V51?\)#8_P#/1O\
MO@T?\)#8_P#/1O\ O@T68$OV>^_Y_(_^_'_V5'V>^_Y_(_\ OQ_]E47_  D-
MC_ST;_O@T?\ "0V/_/1O^^#19@2_9[[_ )_(_P#OQ_\ 94?9[[_G\C_[\?\
MV51?\)#8_P#/1O\ O@T?\)#8_P#/1O\ O@T68$OV>^_Y_(_^_'_V5'V>^_Y_
M(_\ OQ_]E47_  D-C_ST;_O@T?\ "0V/_/1O^^#19@2_9[[_ )_(_P#OQ_\
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MV^:14C8$9X"_O/KQ7HWCGQ./!OA+4M8\G[3-;Q8@M\X\^=B$BBSV+R,B_P#
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MR;CX(WOB3R8O%OB&WUF&WT^YTV*XL]-^RWDL<\)A<SS&63S#L8G"J@WX8C@
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M!!(K3KD?AKX%E^'^D7MD]_'=I<7;7,<-M \%M:*41?*AC>20HF4+8W$;G8@
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M*254[2P .2H/&X<>]30>);M[BXFOKFYO9)+:2W5YI2[+N&.I/2KJ^+5_LF*
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MO/\ G^_\@K1]EO/^?[_R"M %VBJ7V6\_Y_O_ ""M'V6\_P"?[_R"M %;2O\
MD,:U_P!=H_\ T4E86I?#V/5/$.L2SL'T?6(+9KJ$.5D6YMY 8W7 Y#+@-D\>
M4F =QQIZ;;W+:IJX6[VL)H]S>6#N_=)^5:?V6\_Y_O\ R"M &#J7PO\ #>K>
M*+_7[O3DGO[_ $M]&O-WW+BU9@Q1U[GC&>N./2J5C\(=%M;B"6:[U?4OLL4D
M-I'J&I2SI:J\9C8H&/+;&*[FW, 3@\G/5_9;S_G^_P#(*T?9;S_G^_\ (*T
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M!6C[+>?\_P!_Y!6@"[15+[+>?\_W_D%:/LMY_P _W_D%: +M%4OLMY_S_?\
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M\_Y_O_(*U<9RIN\'9F=2G"JN6I%->>IB_P#"L_"__0&M_P#Q[_&C_A6?A?\
MZ UO_P"/?XUM?9;S_G^_\@K1]EO/^?[_ ,@K6WUFO_._O9S_ %+"_P#/J/W(
MQ?\ A6?A?_H#6_\ X]_C1_PK/PO_ - :W_\ 'O\ &MK[+>?\_P!_Y!6C[+>?
M\_W_ )!6CZS7_G?WL/J6%_Y]1^Y&+_PK/PO_ - :W_\ 'O\ &C_A6?A?_H#6
M_P#X]_C6U]EO/^?[_P @K1]EO/\ G^_\@K1]9K_SO[V'U+"_\^H_<C%_X5GX
M7_Z UO\ ^/?XU:L/ ^@Z7)YEKI5O#)_?"Y;\S6A]EO/^?[_R"M'V6\_Y_O\
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MOI<!EE.M1>(KMVUV\CXO-<[K8;$K"86*YM+M]WLCVS_A>OAW_GE?_P#?E?\
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MD*O'$S[&P3@\#]?2L&C^Q\'434&_O%_K%F%%IU8JW:UNWGYGU;_PDUGZ2?\
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M[>->O';VZV]O$S(B%885XC7Y-Q&3EF8]ZZRBB@ HHHH **** "BBB@ HHHH
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M_"C^S[7_ )]H?^_8_P *.8#AZ*[C^S[7_GVA_P"_8_PH_L^U_P"?:'_OV/\
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MH?\ 0:N/^_,7_P 31_96H?\ 0:N/^_,7_P 36M10!D_V5J'_ $&KC_OS%_\
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MH?\ 0:N/^_,7_P 31_96H?\ 0:N/^_,7_P 36M10!D_V5J'_ $&KC_OS%_\
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MFD2&,$ O(P4#)P.3[D4]F"*68A5 R2>@H 6BBB@ HHJ)[F*-8V>5%60A4+,
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M(9D57:,,-RJQ(4D=@2K8/^R?2I* "BBHYIX[=-\LBQ)D+N=@!DD #ZDD#\:
M)**** "BBB@ HJNVH6J03SM<PK#;[O.D+@+'M&6W'M@=<]*L4 %%%1S3QV\9
MDED6),@;G8 9)P!D^I('XT 245'!<174?F0R)+'DKNC8,,@D$9'H01^%$-Q%
M<Q[X9$E3<R[D8$9!((X[@@@^XH DHHI&8*I). .230 M%1QW$4SR)'*DCQ$*
MZJP)0D @'T."#]"*DH ***B:ZACF\IIHUEV[_++ -MSC./3)'- $M%1PSQW
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MCN#.H+H&"_+!SC"L2%P<@9'BJ37]6NM;TN!=6:WFM=0LVAD\U]X6)_)(Q&$
M8J-NUF9@WS')P/;J* /)K>^O_M[AI-7B\//=H'N;>"7[05%C!Y><)YFTOOR<
M?> 4]<4VWD\5R6+W]W=:FEW:0:>T5L$"B0M,PE,B <L8]NY?X><8->MT4#.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>pipe.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pipe.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '( SP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^--]J'A'2!8:9;OXQU+5I=!6R>4M:Q740<S2EQRT*I$T@Q\S J."> #UNBN
MT34/'^C^+K+3?$$.EZ]HU]'*1JVCVDEH;*11N"3122R95LE596R"HR.<U?\
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M]U^'1KS5=9NK:PT31[%)(Q#=2[LQSS,Y#JH&XNJKD(^!R* /5Z*\PF\5>,_
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M.L?#GXEGP]\,;#P;!?Z+-8Z9#%I\-KJ5\YB?<9$CX1"Q0*K'=P20,@5] 44
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MK<E2&&&Z&@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"VF@ZY_R$E\@;;KY]_SKT/S?-TZ\U<\4_#+PGXVTVTT_7O#VGZK:68VVT=S
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MS-KC//$S:U MO?$W/,B+&8P!SP=I/(I]]HOAO4_#*>'[IK:?2TA2%8FGY54
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MV?3Y=(UZ^@MCI,-NPDMHYV*QLLNX[V'RE@5 /.,8KJK/P3X0L+CP[/"+=9]
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MQ5NS\&^$;#4- OH!;I=Z';&SLIOM/S+$4V;6Y^;@G&<XR?6@#LJ*J?VM8_\
M/Y;_ /?U?\:/[6L?^?RW_P"_J_XT"+=%5/[6L?\ G\M_^_J_XT?VM8_\_EO_
M -_5_P : +=%5/[6L?\ G\M_^_J_XT?VM8_\_EO_ -_5_P : +=%5/[6L?\
MG\M_^_J_XT?VM8_\_EO_ -_5_P : +=%5/[6L?\ G\M_^_J_XT?VM8_\_EO_
M -_5_P : +=%5/[6L?\ G\M_^_J_XT?VM8_\_EO_ -_5_P : +=%5/[6L?\
MG\M_^_J_XT?VO8_\_MO_ -_5_P : )[B1HK>5T"LZJ2H8[02!W/:O(/!/C3Q
M7XCU*;1]3U2+1M8GM//6WNM)9&A=77<86W&.>+:2,[@>0?6O5FU73IXB#>6L
MD;C!!E4A@?QY%<KX9\#^%?">H)>65V\DL,36]LMUJ#3):Q,03'$K,0J\#WP
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MX5E^(-+LTM[0K:0+F\@!Q&O3S%XZ5OUD^(O^/>S_ .OVW_\ 1BT 6_[)L?\
MGRM_^_2_X4?V38_\^5O_ -^E_P *J>(_$MIX7M;2>\$A2ZO;>PC\I03YDTJQ
MIGGIN89/I7'2?'KPQ#\.]:\9N+Y-+TBX>UN83 //\Q2HPJ;N00ZL#G[ISQ0!
MWG]DV/\ SY6__?I?\*/[)L?^?*W_ ._2_P"%<U#\5-"EN_&%NS7$+^%4$FH&
M2/ V&,R;DY^885AVY'TJK9?&#2M3ATV:RT_5;R.ZL[:_F,%L&-E#.2(C,-V<
MDALJ@<@*20!S0!U_]DV/_/E;_P#?I?\ "C^R;'_GRM_^_2_X5@:7\1M,U;Q
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ML]]#.VB64M_>VEM(CW$<4:%V^3.0<#C.,T :O]DV/_/E;_\ ?I?\*/[)L?\
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M_P +X^$7_0V^'?\ OZG^%?E-11_JOA_^?C_ /]>\7_SYC^)^K/\ POCX1?\
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MFMND,<=QIL=@MLJDA88HDFE&P#');));(S\QY2OTA_X8.^%O_/+5_P#P._\
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M/B7XE>*[+1-=O=/UJXEUN&TUN2XT@6<31Z9'!#.UI.O[O<<LD&"[,LGFD@8
M  /=VTNQ0J&C"ECA07/)QG Y] ?RIW]CV?\ SQ_\>;_&O'O$&I>(]$\4VFE2
M:K)K/V?4(IH+R^TZ&62$R:=?E@HBB' >)2-HWX<IDAL'!T;Q5K.N7_@R?4]?
MOFBT_P 3K%/?1&"6UF\W3;G:GF+;QY'FE8RA1&4S;3\VPH >_P#]CV?_ #Q_
M\>;_ !IG]FZ?Y?F;5\O^]YAQZ=<UYU\#O%VM>(/[5M-:U"35KBUAMI3>*J>3
MOD$F]%Q%$T; H"T,BEH]R@LV>.:\-^.M)_X4^FBV>H6=QKUL_P"\T]T25T'V
MP;MT; C@'/(XX- 'MO\ 8]G_ ,\?_'F_QH_L>S_YX_\ CS?XUX/;?$SQ7):Z
MA<Z-JLWB374NM<ADT%[.,1VL5L;H6KC8BO\ ,\5O'EF(?S6QRO%K5/'&NPVM
M_P#V1XODU/0XGLI%UV\CAMSYCK<F>V\];9HH]OEV[9>/Y3(8RP++M /;O['L
M_P#GC_X\W^-']CV?_/'_ ,>;_&O%8/B-XCOA:W!U"_T_4F@TQ]/T2XLHE;5%
MEV?:'D786R"7!\MU$80,>#S2_P"$@\<W5G%<_P#"5ZA"]SH^N:D8X[*UVQ26
M=S%';HF82<,LI+;B2VS@KS0![LVDV2J6:(  9)+GC]:%TFR90RQ @C((<\_K
M7@'BKXG:[J&NM9)>2)9W236EUID@C7:C:7)+YBQ^49 IFV@2M*H8DJ$/WJ]R
M\#J5\%^'U8$$:?;@@_\ 7-: +W]CV?\ SQ_\>;_&C^Q[/_GC_P"/-_C5VB@"
ME_8]G_SQ_P#'F_QH_L>S_P">/_CS?XU=HH I?V/9_P#/'_QYO\:/['L_^>/_
M (\W^-7:* *7]CV?_/'_ ,>;_&LS7M,MH;>U*18+7<"GYCT,@![UT%9/B+_C
MWL_^OVW_ /1BT 6?['L_^>/_ (\W^-']CV?_ #Q_\>;_ !I-6UJRT*&"6_N%
MMXY[B*TC9@3NEE<)&O [LP'XU@_\+6\)CPAJ'BDZU - T^1X;J]*N%B=7",I
M&-V=Q Z<Y&.M &__ &/9_P#/'_QYO\:/['L_^>/_ (\W^-4+?QOH5U<:]!%J
M432Z%C^TE((^S93>"V1TVY.1D<'TJA_PM3PJ8])D&L1&/5((KFU;8^#%*0L4
MCG;^[5F.T%]H)X'/% &]_8]G_P \?_'F_P :/['L_P#GC_X\W^-4;'QIHNI:
MY-H]M?I+J$6_,05@&V,%D"L1M8H2 P4DJ2,XK8::-9EA,BB5E+K&2-Q4$ D#
MT&Y?S'K0!5_L>S_YX_\ CS?XT?V/9_\ /'_QYO\ &J^I>*=)T>XN(+Z_AM'M
M[1K^8S':L<"G!D+'@ 'WJ[I]]#JEC;WEN7,$\:R1F2-HV*D9&58 CCL0#0!%
M_8]G_P \?_'F_P :/['L_P#GC_X\W^-27VHVNEPI+=W$=M&\L<"M(P4-([A$
M4>[,P 'J:LT 4O['L_\ GC_X\W^-']CV?_/'_P >;_&EUC6+/P_I-YJ>H3BV
ML;.)IYYF!(1%&6; YX [5)?WT6FV4UU.6$42EVVJ6)QV '))[ =: (O['L_^
M>/\ X\W^-']CV?\ SQ_\>;_&LKP;XXT_QQ9O<V"3Q*H5MMPJ@E26 8%21@E&
M'7/R].F>BH I?V/9_P#/'_QYO\:/['L_^>/_ (\W^-7:* *$NCV@C<^3V/\
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M /%T?\)1X+_Z#VD?^#&/_P"+K\DO#?AO4_%VM6NDZ/93:AJ-R^R*"%<D^Y]
M.I)X !)K0T?P#K6O75[;6=NDD]I.MO*K3*@#G><;F(4 +'(Q8D *C$G J)<-
M48WYJ]K>2_S-8\;XFI;EPM[^;_R/U=_X2CP7_P!![2/_  8Q_P#Q='_"4>"_
M^@]I'_@QC_\ BZ_);Q%X8O\ PM=00WRPD7$(N()K:=)XIHRS+O1T)4C<K*>>
M"I!P016351X8IR5U6T]/^"1+CJM!\LL,D_\ $_\ (_7_ /X2CP7_ -![2/\
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M%H_A+3+.'3KS2DABV_9=0DCDN%.3DR-&[JS,<L2&.2U;M%% !1110!D^%?\
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M\?W6LB_ABTN7[4S6=NTI65II5D#&-V*1,,-N:/'F%MS#->@T %%%% !1110
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M8\R.)HU#Y(7E0Q')O>*? /B"UEU32].T*2\\.S:JT]I&LRS>4AL8%^6-YT4
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M'?$O_?\ M_\ XS6#S+*W?WI:^7]=CK629[&UH0T\_5=_,^(='\40V?Q&M]<
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MCTR>U?H=3O!'P6\.?#K1UTS0+9;&VZNRKF25O[SL>6/U_#BNA_X16+_GN_\
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M_B:LV]Q%>6\4\$BS0RJ'22-@RLI&001U!%24 4O[.?\ Y_KK\U_^)H_LY_\
MG^NOS7_XFKM% %"73W\M_P#3;D\'NO\ \35#P[8O)X?TQQ=W$8:UB.U2N!\@
MX''2MN;_ %3_ .Z:SO#+!?#.E$G %I$23_N"@"?^SG_Y_KK\U_\ B:/[.?\
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M?_G^NOS7_P")H_LY_P#G^NOS7_XFOR%UG4_%_AV^:RU6\UK3;Q0&:"ZEEC<
MC(.&(.".0>]4O^$OU[_H-ZC_ .!<G^--<+R:NJR^[_@BEQW"+M+#-/\ Q?\
M /V'_LY_^?ZZ_-?_ (FC^SG_ .?ZZ_-?_B:_'C_A+]>_Z#>H_P#@7)_C1_PE
M^O?]!O4?_ N3_&G_ *K3_P"?R^[_ ((O]?*?_0.__ O^ ?L/_9S_ //]=?FO
M_P 31_9S_P#/]=?FO_Q-?CQ_PE^O?]!O4?\ P+D_QH_X2_7O^@WJ/_@7)_C1
M_JM/_G\ON_X(?Z^4_P#H'?\ X%_P#]A_[.?_ )_KK\U_^)H_LY_^?ZZ_-?\
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M'6(H;;-/=/LSL_[.?_G^NOS7_P")H_LY_P#G^NOS7_XFN,HKBY#U3L_[.?\
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M** "BBB@ HHHH **** "H;O_ (]9O]QOY5-4-W_QZS?[C?RH J^'O^0!IO\
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M_BZ/^'<NL?\ 0[6/_@ __P 71_;F7_\ /W\'_D'^JV<?\^/QC_F?'E%?8?\
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M_'_V5'V>^_Y_(_\ OQ_]E5VB@"E]GOO^?R/_ +\?_94?9[[_ )_(_P#OQ_\
M95=HH I?9[[_ )_(_P#OQ_\ 94?9[[_G\C_[\?\ V57:* *7V>^_Y_(_^_'_
M -E1]GOO^?R/_OQ_]E5VB@"E]GOO^?R/_OQ_]E1]GOO^?R/_ +\?_95=HH I
M?9[[_G\C_P"_'_V5'V>^_P"?R/\ [\?_ &57:* *7V>^_P"?R/\ [\?_ &5'
MV>^_Y_(_^_'_ -E5VB@"E]GOO^?R/_OQ_P#94?9[[_G\C_[\?_95=HH I?9[
M[_G\C_[\?_95%=6][]FES=QD;#G]Q[?[U:50W?\ QZS?[C?RH RM"AO&T33R
MEU&B&WCVJ8<D#:.,[JO?9[[_ )_(_P#OQ_\ 94SP]_R --_Z]H__ $$5\_?M
M9?M03_!V.W\/>&Q!+XGNXO-DFF7>ME$>%;;T+L<X!X &2#D5U87#5<955&DK
MMG!CL=0RZA+$8AVBOZLO,^A/L]]_S^1_]^/_ +*C[/??\_D?_?C_ .RK\JO^
M%P?%CQ=<RR6_BKQ1>R(=SK874X"Y]5C( ''I60_QD^(4;,K>./$RLIP5;5K@
M$'_ONOJEPQ6>GM5?YGP,N.L,M50E;Y'ZV?9[[_G\C_[\?_94?9[[_G\C_P"_
M'_V5?DE_PN;X@?\ 0]>)?_!O<?\ Q=3#XL_$AK<SCQEXJ,(!8R?VI<[< @$Y
MW^K*/J1ZU7^J]7_GZON9/^O6'?\ RXE]Z/UG^SWW_/Y'_P!^/_LJ/L]]_P _
MD?\ WX_^RK\E8OB_\19]_E^-O$\FQ2[;=5N3M4=2?GZ4S_A<WQ _Z'KQ+_X-
M[C_XNC_5>M_S]7W,/]>\-_SXE]Z/UM^SWW_/Y'_WX_\ LJ/L]]_S^1_]^/\
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M>!\N<N\TSQAJ7B"SL([77;>S):RN8-]TL+6QTMU5MX=8$'GE  JM(&&6=>A
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M=HI 4MVH_P#/*U_[^-_\31NU'_GE:_\ ?QO_ (FKM% %+=J/_/*U_P"_C?\
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M^"^#_P"(H_U9QG\T?O?^0?Z[Y9_+/[E_\D?I5NU'_GE:_P#?QO\ XFC=J/\
MSRM?^_C?_$U^:O\ PVO\6_\ H8(/_!?!_P#$4?\ #:_Q;_Z&"#_P7P?_ !%'
M^K.,_FC][_R#_7?+/Y9_<O\ Y(_2K=J/_/*U_P"_C?\ Q-&[4?\ GE:_]_&_
M^)K\U?\ AM?XM_\ 0P0?^"^#_P"(H_X;7^+?_0P0?^"^#_XBC_5G&?S1^]_Y
M!_KOEG\L_N7_ ,D?I5NU'_GE:_\ ?QO_ (FC=J/_ #RM?^_C?_$U^:O_  VO
M\6_^A@@_\%\'_P 11_PVO\6_^A@@_P#!?!_\11_JSC/YH_>_\@_UWRS^6?W+
M_P"2/TJW:C_SRM?^_C?_ !-&[4?^>5K_ -_&_P#B:_-7_AM?XM_]#!!_X+X/
M_B*/^&U_BW_T,$'_ (+X/_B*/]6<9_-'[W_D'^N^6?RS^Y?_ "1^E6[4?^>5
MK_W\;_XFC=J/_/*U_P"_C?\ Q-?FK_PVO\6_^A@@_P#!?!_\11_PVO\ %O\
MZ&"#_P %\'_Q%'^K.,_FC][_ ,@_UWRS^6?W+_Y(_2K=J/\ SRM?^_C?_$T;
MM1_YY6O_ '\;_P")K\U?^&U_BW_T,$'_ (+X/_B*?'^VU\6HY%9M=MI #DHU
MA#@^QPH-'^K6-_FC][_R#_7?+/Y9_<O_ )(_2?=J/_/*U_[^-_\ $T;M1_YY
M6O\ W\;_ .)KYN_9^_:KD^+WF:5J*KIOB.WB\QHXR/*N5!P6CSR".,J<]<@G
MG'MG]N7W_/<_D*^>Q&%JX6HZ556:/M,'C:&845B,/*\7_5F=+NU'_GE:_P#?
MQO\ XFC=J/\ SRM?^_C?_$US7]N7W_/<_D*/[<OO^>Y_(5S\K.TZ7=J/_/*U
M_P"_C?\ Q-&[4?\ GE:_]_&_^)KFO[<OO^>Y_(4?VY??\]S^0HY6!TN[4?\
MGE:_]_&_^)HW:C_SRM?^_C?_ !-<U_;E]_SW/Y"C^W+[_GN?R%'*P.EW:C_S
MRM?^_C?_ !-&[4?^>5K_ -_&_P#B:YK^W+[_ )[G\A1_;E]_SW/Y"CE8'2[M
M1_YY6O\ W\;_ .)HW:C_ ,\K7_OXW_Q-<U_;E]_SW/Y"K5CXCGBD N#YL9Z\
M8(HY6!M[M1_YY6O_ '\;_P")J:%KG:?-CB#9_@<X_E4J.LBJRG<K#(([TZH
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MQE6(F9FZ\D-@$DG9TWP'H^F^&])T?[.MU'I=E'86UU<HCSHB1A 0VWAL '(
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M "H;O_CUF_W&_E4U0W?_ !ZS?[C?RH J^'O^0!IO_7M'_P"@BOS:_;:^V?\
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MA)M+^[)_:OV:VTT]>B+6F_!30W\/:7=7T&HK<_:=.6YCLWDEED2Y@>4C!A"
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M0!D_VS>?] '4/^_EO_\ ':/[9O/^@#J'_?RW_P#CM:U% &3_ &S>?] '4/\
MOY;_ /QVC^V;S_H ZA_W\M__ ([6M10!D_VS>?\ 0!U#_OY;_P#QVC^V;S_H
M ZA_W\M__CM:U% &3_;-Y_T =0_[^6__ ,=H_MF\_P"@#J'_ '\M_P#X[6M1
M0!D_VS>?] '4/^_EO_\ ':/[9O/^@#J'_?RW_P#CM:U% &3_ &S>?] '4/\
MOY;_ /QVC^V;S_H ZA_W\M__ ([6M10!D_VS>?\ 0!U#_OY;_P#QVC^V;S_H
M ZA_W\M__CM:U% &3_;-Y_T =0_[^6__ ,=H_MF\_P"@#J'_ '\M_P#X[6M1
M0!D_VS>?] '4/^_EO_\ ':/[9O/^@#J'_?RW_P#CM:U% &3_ &S>?] '4/\
MOY;_ /QVJ.KWU_>0VZIH5^"ES%*<O;]%<$])?:NDHH R?[9O/^@#J'_?RW_^
M.T?VS>?] '4/^_EO_P#':UJ* .8MK=+77+W6(_#NJ'4;N..&662ZB<!$SM5%
M:<K&,DDA ,GDY/-:/]LWG_0!U#_OY;__ !VM:B@#)_MF\_Z .H?]_+?_ ..T
M?VS>?] '4/\ OY;_ /QVM:B@#)_MF\_Z .H?]_+?_P".T?VS>?\ 0!U#_OY;
M_P#QVM:B@#)_MF\_Z .H?]_+?_X[1_;-Y_T =0_[^6__ ,=K6HH R?[9O/\
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MVS>?] '4/^_EO_\ ':UJ* ,G^V;S_H ZA_W\M_\ X[1_;-Y_T =0_P"_EO\
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M_OAB#Z9%.O?A/<:UI>HVFL>*=4U3[>L,,S2!(T\B-]Q18T 4%^C/C.#CB@#
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M@1U!'>I: ,G_ (1;2_\ GU_\B-_C1_PBVE_\^O\ Y$;_ !K6HH R?^$6TO\
MY]?_ "(W^-'_  BVE_\ /K_Y$;_&M:B@#)_X1;2_^?7_ ,B-_C1_PBVE_P#/
MK_Y$;_&M:B@#)_X1;2_^?7_R(W^-'_"+:7_SZ_\ D1O\:UJ* ,G_ (1;2_\
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M&:WMVNYX[!'CMU95,K",$*"Q !)XR3CFM>;_ %3_ .Z:S_"__(M:3_UZ1?\
MH H \CT/P#XP\#75GJSVECXK>]TZZM]7TVTA6V>:9S)=(7DFF*2#SWFC& H
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MTL#AJ>%H_#!**]$K'XYB*\\56G7J?%)MOYG,T5TW_"+V_P#SUD_2C_A%[?\
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M_P#3W=?]_/\ ZU7:* .?\,V/FZ!8/]HN$W0J=J/@#Z5I_P!F_P#3W=?]_/\
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M_K5=HH I?V;_ -/=U_W\_P#K5F:]8^7;VI^T7#9NX%^9\XS(.?K705D^(O\
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M?V;_ -/=U_W\_P#K4?V;_P!/=U_W\_\ K5=HH I?V;_T]W7_ '\_^M1_9O\
MT]W7_?S_ .M5VB@"E_9O_3W=?]_/_K4?V;_T]W7_ '\_^M5VB@"A+IO[M_\
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M[-_Z>[K_ +^?_6H_LW_I[NO^_G_UJNT4 4O[-_Z>[K_OY_\ 6H_LW_I[NO\
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MX7..#[?10!X+X?L_$OAW3_#>EBXU2_M7L= GE^U0[A#-]K1)U7Y?D'EXRO\
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MX@VEMKC=AUVX*XW#=@]_'IMK#J$]\EO&EY<1QQ2SA?G=$+%%)[@%WQ_O&K-
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M+,KX;Z+-H?A"RM[A=D[;I70]5W'(!]\8KIZZ'_A%%_Y^3_WQ_P#7H_X15?\
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M\?:X /W8&#Y@P:Z"LGQ%_P >]G_U^V__ *,6@"S]EO/^?[_R"M'V6\_Y_O\
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MF.W'&!@#ODUU:V%LK(PMH0T9+(0@RI/4CT)J946,$*H4$DG QR>2: '4444
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MV$G]:DO:5&FTMDELK]7J[]#\UXESFGF^(C[!>Y!-*^[ON_3L8]%;'_"+W?\
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MM?\ OXW_ ,31NU'_ )Y6O_?QO_B:NT4 4MVH_P#/*U_[^-_\31NU'_GE:_\
M?QO_ (FKM% %+=J/_/*U_P"_C?\ Q-&[4?\ GE:_]_&_^)J[10!2W:C_ ,\K
M7_OXW_Q-9FO->_9[7S([<#[7!C:['GS!CMTS705D^(O^/>S_ .OVW_\ 1BT
M6=VH_P#/*U_[^-_\31NU'_GE:_\ ?QO_ (FKM% %+=J/_/*U_P"_C?\ Q-&[
M4?\ GE:_]_&_^)J[10!2W:C_ ,\K7_OXW_Q-&[4?^>5K_P!_&_\ B:NT4 4M
MVH_\\K7_ +^-_P#$T;M1_P">5K_W\;_XFKM% %+=J/\ SRM?^_C?_$T;M1_Y
MY6O_ '\;_P")J[10!2W:C_SRM?\ OXW_ ,31NU'_ )Y6O_?QO_B:NT4 4MVH
M_P#/*U_[^-_\31NU'_GE:_\ ?QO_ (FKM% %+=J/_/*U_P"_C?\ Q-&[4?\
MGE:_]_&_^)J[10!0E;4/+?,5MC!_Y:-_\35#PZU[_P (_IGEQVYC^RQ;2SL#
MC8,9XZUMS?ZI_P#=-9_A?_D6M)_Z](O_ $ 4 3;M1_YY6O\ W\;_ .)HW:C_
M ,\K7_OXW_Q-7:* *6[4?^>5K_W\;_XFC=J/_/*U_P"_C?\ Q-7:* *6[4?^
M>5K_ -_&_P#B:-VH_P#/*U_[^-_\35VB@"ENU'_GE:_]_&_^)HW:C_SRM?\
MOXW_ ,35VB@"ENU'_GE:_P#?QO\ XFC=J/\ SRM?^_C?_$U=HH I;M1_YY6O
M_?QO_B:-VH_\\K7_ +^-_P#$U=HH I;M1_YY6O\ W\;_ .)HW:C_ ,\K7_OX
MW_Q-7:* *6[4?^>5K_W\;_XFC=J/_/*U_P"_C?\ Q-7:* *6[4?^>5K_ -_&
M_P#B:-VH_P#/*U_[^-_\35VB@"ENU'_GE:_]_&_^)HW:C_SRM?\ OXW_ ,35
MVB@"ENU'_GE:_P#?QO\ XFHKIM0^S2YCML;#G$C>G^[6E4-W_P >LW^XW\J
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M>3_OLU^H9'G6$X@POUG"O9V:>Z?G^C/A\TRO$937]A7]4ULT=;NU'_GE:_\
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M=<_Z"5I^35^'4N'^):%.-#ZG>*TM>&OO.6KO?9N.^S9^HU,WR6K-U?K%F_\
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M[J?]]5^E71\89E%:?_".7O\ =3_OJC_A'+W^ZG_?5%T!F45I_P#".7O]U/\
MOJC_ (1R]_NI_P!]470&916G_P (Y>_W4_[ZH_X1R]_NI_WU1= 9E%:?_".7
MO]U/^^J/^$<O?[J?]]470&916G_PCE[_ '4_[ZH_X1R]_NI_WU1= 9E%:?\
MPCE[_=3_ +ZH_P"$<O?[J?\ ?5%T!F45I_\ ".7O]U/^^J/^$<O?[J?]]470
M&916G_PCE[_=3_OJK=CX9?S URP"C^!3R:.9 :6@JRZ7"&&.I'TR:T*15"J
M!@#@"EK$"M?7$UM&K06DEVQ."L;*N!Z_,15+^U=0_P"@+<?]_HO_ (JBBD ?
MVKJ'_0%N/^_T7_Q5']JZA_T!;C_O]%_\5110 ?VKJ'_0%N/^_P!%_P#%4?VK
MJ'_0%N/^_P!%_P#%444 ']JZA_T!;C_O]%_\51_:NH?] 6X_[_1?_%444 ']
MJZA_T!;C_O\ 1?\ Q5']JZA_T!;C_O\ 1?\ Q5%% %'0[K4M/T>SMGT6X+Q1
MA3B:+_XJKW]JZA_T!;C_ +_1?_%444 ']JZA_P! 6X_[_1?_ !5']JZA_P!
M6X_[_1?_ !5%% !_:NH?] 6X_P"_T7_Q5']JZA_T!;C_ +_1?_%444 ']JZA
M_P! 6X_[_1?_ !5']JZA_P! 6X_[_1?_ !5%% !_:NH?] 6X_P"_T7_Q5']J
MZA_T!;C_ +_1?_%444 ']JZA_P! 6X_[_1?_ !5']JZA_P! 6X_[_1?_ !5%
M% !_:NH?] 6X_P"_T7_Q5']JZA_T!;C_ +_1?_%444 ']JZA_P! 6X_[_1?_
M !5']JZA_P! 6X_[_1?_ !5%% !_:NH?] 6X_P"_T7_Q5']JZA_T!;C_ +_1
M?_%444 ']JZA_P! 6X_[_1?_ !5']JZA_P! 6X_[_1?_ !5%% !_:NH?] 6X
M_P"_T7_Q54=6NM2O(;=4T6X!2XBE/[Z+HK@G^+VHHH O?VKJ'_0%N/\ O]%_
M\51_:NH?] 6X_P"_T7_Q5%% !_:NH?\ 0%N/^_T7_P 51_:NH?\ 0%N/^_T7
M_P 5110 ?VKJ'_0%N/\ O]%_\51_:NH?] 6X_P"_T7_Q5%% !_:NH?\ 0%N/
M^_T7_P 51_:NH?\ 0%N/^_T7_P 5110 ?VKJ'_0%N/\ O]%_\51_:NH?] 6X
M_P"_T7_Q5%% !_:NH?\ 0%N/^_T7_P 51_:NH?\ 0%N/^_T7_P 5110 ?VKJ
M'_0%N/\ O]%_\51_:NH?] 6X_P"_T7_Q5%% !_:NH?\ 0%N/^_T7_P 51_:N
MH?\ 0%N/^_T7_P 5110 DFJ:@T; :+<<C'^NB_\ BJJ:+=:E8Z/8VSZ+<%X8
M(XV_?1=0H']ZBB@"Y_:NH?\ 0%N/^_T7_P 51_:NH?\ 0%N/^_T7_P 5110
M?VKJ'_0%N/\ O]%_\51_:NH?] 6X_P"_T7_Q5%% !_:NH?\ 0%N/^_T7_P 5
M1_:NH?\ 0%N/^_T7_P 5110 ?VKJ'_0%N/\ O]%_\51_:NH?] 6X_P"_T7_Q
M5%% !_:NH?\ 0%N/^_T7_P 51_:NH?\ 0%N/^_T7_P 5110 ?VKJ'_0%N/\
MO]%_\51_:NH?] 6X_P"_T7_Q5%% !_:NH?\ 0%N/^_T7_P 51_:NH?\ 0%N/
M^_T7_P 5110 ?VKJ'_0%N/\ O]%_\51_:NH?] 6X_P"_T7_Q5%% !_:NH?\
M0%N/^_T7_P 51_:NH?\ 0%N/^_T7_P 5110 ?VKJ'_0%N/\ O]%_\51_:NH?
M] 6X_P"_T7_Q5%% !_:NH?\ 0%N/^_T7_P 53)]2U"2&1!HMQEE(_P!=%Z?[
MU%% $&DWFI6>EV<#Z+<%XH40_OHNH4#^]5K^U=0_Z MQ_P!_HO\ XJBB@ _M
M74/^@+<?]_HO_BJ/[5U#_H"W'_?Z+_XJBB@ _M74/^@+<?\ ?Z+_ .*H_M74
M/^@+<?\ ?Z+_ .*HHH /[5U#_H"W'_?Z+_XJC^U=0_Z MQ_W^B_^*HHH /[5
MU#_H"W'_ '^B_P#BJ/[5U#_H"W'_ '^B_P#BJ** #^U=0_Z MQ_W^B_^*H_M
M74/^@+<?]_HO_BJ** #^U=0_Z MQ_P!_HO\ XJC^U=0_Z MQ_P!_HO\ XJBB
M@ _M74/^@+<?]_HO_BJ/[5U#_H"W'_?Z+_XJBB@ _M74/^@+<?\ ?Z+_ .*H
M_M74/^@+<?\ ?Z+_ .*HHH /[5U#_H"W'_?Z+_XJC^U=0_Z MQ_W^B_^*HHH
M /[5U#_H"W'_ '^B_P#BJ/[5U#_H"W'_ '^B_P#BJ** #^U=0_Z MQ_W^B_^
M*H_M74/^@+<?]_HO_BJ** #^U=0_Z MQ_P!_HO\ XJC^U=0_Z MQ_P!_HO\
MXJBB@ _M74/^@+<?]_HO_BJ/[5U#_H"W'_?Z+_XJBB@ _M74/^@+<?\ ?Z+_
M .*H_M74/^@+<?\ ?Z+_ .*HHH /[5U#_H"W'_?Z+_XJK-M>W,T9,NGS0-G&
+UI(S^/#444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052720464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Portage Biotech Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Clarence Thomas Building<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">P.O. Box 4649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Road Town<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tortola<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">VG1110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052120928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Financial Position (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="nump">$ 23,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">1,786<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ConvertibleNoteReceivable', window );">Convertible note receivable</a></td>
<td class="nump">642<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">15,532<span></span>
</td>
<td class="nump">24,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Long-term assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Investment in associate</a></td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentProperty', window );">Investment in private company</a></td>
<td class="nump">3,363<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">43,862<span></span>
</td>
<td class="nump">43,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">145,588<span></span>
</td>
<td class="nump">117,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredCommitmentFee', window );">Deferred commitment fee</a></td>
<td class="nump">894<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other assets, including equipment, net</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total long-term assets</a></td>
<td class="nump">195,151<span></span>
</td>
<td class="nump">169,830<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">210,683<span></span>
</td>
<td class="nump">194,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">25,515<span></span>
</td>
<td class="nump">28,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredPurchasePricePayableTarus', window );">Deferred purchase price payable - Tarus</a></td>
<td class="nump">8,876<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredObligationIoxMilestone', window );">Deferred obligation - iOx milestone</a></td>
<td class="nump">5,568<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">39,959<span></span>
</td>
<td class="nump">28,445<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">42,381<span></span>
</td>
<td class="nump">29,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Capital stock</a></td>
<td class="nump">216,630<span></span>
</td>
<td class="nump">158,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Stock option reserve</a></td>
<td class="nump">20,542<span></span>
</td>
<td class="nump">16,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(3,059)<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(65,168)<span></span>
</td>
<td class="num">(55,005)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total equity attributable to owners of the Company</a></td>
<td class="nump">168,945<span></span>
</td>
<td class="nump">121,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">(643)<span></span>
</td>
<td class="nump">44,229<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">168,302<span></span>
</td>
<td class="nump">165,434<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 210,683<span></span>
</td>
<td class="nump">$ 194,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2022-03-24<br> -Paragraph 76<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_76&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 40<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=40&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ConvertibleNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ConvertibleNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredObligationIoxMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredObligationIoxMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredPurchasePricePayableTarus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredPurchasePricePayableTarus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InprocessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InprocessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052126384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,535<span></span>
</td>
<td class="nump">$ 1,928<span></span>
</td>
<td class="nump">$ 5,976<span></span>
</td>
<td class="nump">$ 4,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">6,523<span></span>
</td>
<td class="nump">6,288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss from operations</a></td>
<td class="num">(4,759)<span></span>
</td>
<td class="num">(4,169)<span></span>
</td>
<td class="num">(12,499)<span></span>
</td>
<td class="num">(11,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone', window );">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</a></td>
<td class="num">(498)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of loss in associate accounted for using equity method</a></td>
<td class="num">(152)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainsLossesOnChangeInFairValueOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeLoss', window );">Foreign exchange transaction gain (loss)</a></td>
<td class="nump">50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before provision for income taxes</a></td>
<td class="num">(5,302)<span></span>
</td>
<td class="num">(4,089)<span></span>
</td>
<td class="num">(13,117)<span></span>
</td>
<td class="num">(10,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax (expense) benefit</a></td>
<td class="num">(2,199)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="nump">2,906<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_Netloss', window );">Net loss</a></td>
<td class="num">(7,501)<span></span>
</td>
<td class="num">(4,206)<span></span>
</td>
<td class="num">(10,211)<span></span>
</td>
<td class="num">(10,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetUnrealizedLossOnInvestments', window );">Net unrealized loss on investments</a></td>
<td class="num">(4,017)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,017)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Total comprehensive loss for period</a></td>
<td class="num">(11,518)<span></span>
</td>
<td class="num">(4,206)<span></span>
</td>
<td class="num">(14,228)<span></span>
</td>
<td class="num">(10,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Net loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="num">(7,485)<span></span>
</td>
<td class="num">(3,512)<span></span>
</td>
<td class="num">(10,163)<span></span>
</td>
<td class="num">(9,553)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(694)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Comprehensive loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="num">(11,502)<span></span>
</td>
<td class="num">(3,512)<span></span>
</td>
<td class="num">(14,180)<span></span>
</td>
<td class="num">(9,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(694)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for period</a></td>
<td class="num">$ (11,518)<span></span>
</td>
<td class="num">$ (4,206)<span></span>
</td>
<td class="num">$ (14,228)<span></span>
</td>
<td class="num">$ (10,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_BasicAndDilutedEarningsLossPerShare', window );">Basic and diluted</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">$ 17,039<span></span>
</td>
<td class="nump">$ 13,344<span></span>
</td>
<td class="nump">$ 15,719<span></span>
</td>
<td class="nump">$ 12,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainsLossesOnChangeInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainsLossesOnChangeInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetUnrealizedLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetUnrealizedLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_Netloss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_Netloss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049068624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Changes in Shareholder's Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Issued capital [member]</div></th>
<th class="th"><div>Stock Option Reserve [Member]</div></th>
<th class="th"><div>Accumulated other comprehensive income [member]</div></th>
<th class="th"><div>Retained earnings [member]</div></th>
<th class="th"><div>Equity attributable to owners of parent [member]</div></th>
<th class="th"><div>Non-controlling interests [member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 130,649<span></span>
</td>
<td class="nump">$ 7,977<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
<td class="num">$ (38,135)<span></span>
</td>
<td class="nump">$ 101,449<span></span>
</td>
<td class="nump">$ 46,153<span></span>
</td>
<td class="nump">$ 147,602<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="nump">12,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,248<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,248<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">6,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderAtm', window );">Shares issued under ATM</a></td>
<td class="nump">$ 2,643<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,643<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderAtmShares', window );">Shares issued under ATM, shares</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderOffering', window );">Shares issued under public offering</a></td>
<td class="nump">$ 26,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderOfferingShares', window );">Shares issued under public offering , shares</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">$ (1,877)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,877)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedOrAccruedForServices', window );">Shares issued or accrued for services</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedOrAccruedForServicesShares', window );">Shares issued or accrued for services, shares</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsExercisedShares', window );">Warrants exercised , shares</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares', window );">Exchange of notes payable and accrued interest for iOx shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,553)<span></span>
</td>
<td class="num">(9,553)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
<td class="num">(10,306)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 158,294<span></span>
</td>
<td class="nump">14,225<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="num">(47,688)<span></span>
</td>
<td class="nump">125,789<span></span>
</td>
<td class="nump">45,775<span></span>
</td>
<td class="nump">171,564<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">13,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 158,324<span></span>
</td>
<td class="nump">16,928<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="num">(55,005)<span></span>
</td>
<td class="nump">121,205<span></span>
</td>
<td class="nump">44,229<span></span>
</td>
<td class="nump">165,434<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="nump">13,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,614<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,614<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedInTarusAcquisition', window );">Shares issued in Tarus acquisition</a></td>
<td class="nump">$ 17,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedInTarusAcquisitionShares', window );">Shares issued in Tarus acquisition , shares</a></td>
<td class="nump">2,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedInIoxExchange', window );">Shares issued in iOx exchange</a></td>
<td class="nump">$ 9,737<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,737<span></span>
</td>
<td class="num">(9,737)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedInIoxExchangeShares', window );">Shares issued in iOx exchange , shares</a></td>
<td class="nump">1,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredObligationIoxMilestoneValue', window );">Deferred obligation - iOx milestone</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,478)<span></span>
</td>
<td class="num">(5,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox', window );">Excess of non-controlling interest acquired over consideration - iOx</a></td>
<td class="nump">29,609<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">29,609<span></span>
</td>
<td class="num">(29,609)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement', window );">Shares issued to Lincoln for commitment fee under Committed Purchase Agreement</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares', window );">Shares issued to Lincoln for commitment fee under Committed Purchase Agreement , shares</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderAtm', window );">Shares issued under ATM</a></td>
<td class="nump">$ 604<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderAtmShares', window );">Shares issued under ATM, shares</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement', window );">Purchase of shares issued under Committed Purchase Agreement</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares', window );">Purchase of shares issued under Committed Purchase Agreement , shares</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">$ (24)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedOrAccruedForServices', window );">Shares issued or accrued for services</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedOrAccruedForServicesShares', window );">Shares issued or accrued for services, shares</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsExercisedShares', window );">Warrants exercised , shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetUnrealizedLossOnInvestmentsValue', window );">Net unrealized loss on investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,017)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,017)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (4,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,163)<span></span>
</td>
<td class="num">(10,163)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(10,211)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 216,630<span></span>
</td>
<td class="nump">$ 20,542<span></span>
</td>
<td class="num">$ (3,059)<span></span>
</td>
<td class="num">$ (65,168)<span></span>
</td>
<td class="nump">$ 168,945<span></span>
</td>
<td class="num">$ (643)<span></span>
</td>
<td class="nump">$ 168,302<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="nump">17,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredObligationIoxMilestoneValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredObligationIoxMilestoneValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetUnrealizedLossOnInvestmentsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetUnrealizedLossOnInvestmentsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInIoxExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInIoxExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInIoxExchangeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInIoxExchangeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInTarusAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInTarusAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInTarusAcquisitionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInTarusAcquisitionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedOrAccruedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedOrAccruedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedOrAccruedForServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedOrAccruedForServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderAtm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderAtm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderAtmShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderAtmShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052386992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromDiscontinuedOperations', window );">Net loss for the period</a></td>
<td class="num">$ (10,211)<span></span>
</td>
<td class="num">$ (10,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation expense</a></td>
<td class="nump">3,614<span></span>
</td>
<td class="nump">6,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset', window );">Decrease in deferred tax liability</a></td>
<td class="num">(2,930)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeOnFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone', window );">Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone</a></td>
<td class="nump">428<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfStockIssuedForServices', window );">Fair value of shares issued for services</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnHedgeIneffectiveness', window );">Share of loss in associate</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange transaction gain</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetChangeInWorkingCapitalComponentsAbstract', window );"><strong>Changes in operating working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncreasingDecreasingAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaid expenses and other receivables</a></td>
<td class="num">(354)<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Other assets</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,671<span></span>
</td>
<td class="num">(1,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities', window );">Other</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,392)<span></span>
</td>
<td class="num">(4,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseOfConvertibleNoteReceivable', window );">Purchase of convertible note receivable</a></td>
<td class="num">(614)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of equipment</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(617)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition', window );">Repayment of notes payable assumed in Tarus acquisition</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition', window );">Repayment of milestone obligation assumed in Tarus acquisition</a></td>
<td class="num">(1,009)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase', window );">Proceeds from shares issued under ATM and Committed Purchase</a></td>
<td class="nump">794<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering', window );">Proceeds from shares issued under registered offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Share issuance costs</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(1,852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromExerciseOfStockPurchaseWarrants', window );">Proceeds from exercise of stock purchase warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(2,239)<span></span>
</td>
<td class="nump">27,346<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">(Decrease) increase in cash and cash equivalents during period</a></td>
<td class="num">(10,248)<span></span>
</td>
<td class="nump">22,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">23,352<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">13,104<span></span>
</td>
<td class="nump">25,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SupplementalCashFlowInformationsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashPaidForInterest', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncreaseInAccountsPayableForStockIssuanceCosts', window );">Increase in accounts payable for stock issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NoncashInvestingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfSharesIssuedForTarus', window );">Fair value of shares issued for Tarus</a></td>
<td class="nump">17,200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox', window );">Fair value of shares issued for non-controlling interest purchase of iOx</a></td>
<td class="nump">9,737<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfDeferredPurchasePricePayabletarus', window );">Fair value of deferred purchase price payable-Tarus</a></td>
<td class="nump">8,538<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfDeferredObligationIoxMilestone', window );">Fair value of deferred obligation - iOx milestone</a></td>
<td class="nump">5,478<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LiabilitiesAssumedInTarusAcquisition', window );">Liabilities assumed in Tarus acquisition</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase', window );">Fair value of shares issued for commitment fees - Committed Purchase</a></td>
<td class="nump">900<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants', window );">Exchange of iOx shares for settlement of notes payable, accrued interest and warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnHedgeIneffectiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) on hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24C<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24C_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnHedgeIneffectiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_vii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph ea<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_ea&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashPaidForInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashPaidForInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfDeferredObligationIoxMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfDeferredObligationIoxMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfDeferredPurchasePricePayabletarus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfDeferredPurchasePricePayabletarus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfSharesIssuedForTarus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfSharesIssuedForTarus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfStockIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfStockIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeOnFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeOnFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncreaseInAccountsPayableForStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncreaseInAccountsPayableForStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncreasingDecreasingAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncreasingDecreasingAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LiabilitiesAssumedInTarusAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LiabilitiesAssumedInTarusAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetChangeInWorkingCapitalComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetChangeInWorkingCapitalComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NoncashInvestingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NoncashInvestingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromExerciseOfStockPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromExerciseOfStockPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchaseOfConvertibleNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchaseOfConvertibleNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SupplementalCashFlowInformationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SupplementalCashFlowInformationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504075878288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NatureOfOperationsAbstract', window );"><strong>Nature Of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NatureOfOperationsExplanatory', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p id="xdx_801_ecustom--NatureOfOperationsExplanatory_z6pMnldN2zCc" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 1. <span id="xdx_825_zX60qVGRiP8j">NATURE OF OPERATIONS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Portage Biotech Inc. (the &#8220;Company&#8221; or &#8220;Portage&#8221;)
is incorporated in the British Virgin Islands (&#8220;BVI&#8221;) with its registered office located at Clarence Thomas Building, P.O.
Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development Services Inc. (&#8220;PDS&#8221;), is located at 61 Wilton Road,
Westport, CT, 06880, USA.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company is a foreign private issuer under the Securities and Exchange
Commission (the &#8220;SEC&#8221;) rules. It is also a reporting issuer under the securities legislation of the provinces of Ontario and
British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (&#8220;CSE&#8221;) under the symbol &#8220;PBT.U&#8221;.
On February 25, 2021, the ordinary shares of the Company began trading on the NASDAQ Capital Market (&#8220;NASDAQ&#8221;) under the symbol
&#8220;PRTG&#8221;. As the principal market for the Company&#8217;s ordinary shares is NASDAQ, the Company voluntarily delisted from the
CSE on April 23, 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Portage is a clinical-stage immuno-oncology company advancing therapies
that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive
cancers. Portage&#8217;s access to next-generation technologies coupled with a deep understanding of biological mechanisms enable the
identification of clinical therapies and product development strategies that accelerate these medicines through the translational pipeline.
Portage&#8217;s portfolio consists of six diverse platforms, with lead programs including invariant natural killer T-cell (&#8220;iNKT&#8221;)
agonists and a suite of treatments targeting the adenosine pathway. Additional programs leverage delivery by intratumorals, nanoparticles,
liposomes, aptamers, and virus-like particles. Within these six platforms, Portage has 16 products currently in development with multiple
clinical readouts expected through the end of 2023.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On August 13, 2018, the Company reached a definitive agreement to acquire
<span id="xdx_906_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zLLowsn1Im5l" title="Percentage of acquire">100</span>% of SalvaRx Limited (&#8220;SalvaRx&#8221;) in exchange for 8,050,701 ordinary shares of the Company (the &#8220;SalvaRx Acquisition&#8221;).
The SalvaRx Acquisition was completed on January 8, 2019 (the &#8220;Acquisition Date&#8221;) upon receiving shareholder and regulatory
approval. In connection with the SalvaRx Acquisition, the Company acquired interests in SalvaRx&#8217;s five research and development
invested entities and subsidiaries: iOx Therapeutics Ltd. (&#8220;iOx&#8221;), Nekonal Oncology Limited (&#8220;Nekonal&#8221;), Intensity
Therapeutics, Inc. (&#8220;Intensity&#8221;), Saugatuck Therapeutics, Ltd. (&#8220;Saugatuck&#8221;) and Rift Biotherapeutics Inc. (&#8220;Rift&#8221;).&#160;
The Company also acquired an option in Nekonal SARL, a Luxembourg-based company holding intellectual property rights for therapeutics
and diagnostics in the field of autoimmune disorders and oncology, to participate in the funding of its autoimmune programs. During fiscal
2021, the Company abandoned its interests in Nekonal and Nekonal SARL.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NatureOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NatureOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NatureOfOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NatureOfOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504077604336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LiquidityTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p id="xdx_805_ecustom--LiquidityTextBlock_zy8ODAk1nwCb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 2. <span id="xdx_821_zRxtRqqKiaIh">LIQUIDITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022, the Company had cash and cash equivalents of
approximately $<span id="xdx_90D_eifrs-full--Cash_iI_pn3n3_dm_c20221231_znof1qtzSALe" title="Cash and cash equivalents">13.1</span> million and total current liabilities of approximately $<span id="xdx_90B_ecustom--TotalCurrentLiabilities_iI_pn3n3_dm_c20221231_ztUDFGjzDzlk" title="Total current liabilities">2.4</span> million. For the nine months ended December 31, 2022,
the Company is reporting a net loss of approximately $<span id="xdx_908_ecustom--NetLossIncome_pn3n3_dm_c20220401__20221231_zfJF0K8rpYD6" title="Net (loss) income">10.2</span> million and cash used in operating activities of approximately $<span id="xdx_902_ecustom--CashUsedInOperatingActivities_pn3n3_dm_c20220401__20221231_zgFoveIn5FPh" title="Cash used in operating activities">7.4</span> million.
As of January 31, 2023, the Company had approximately $<span id="xdx_90D_eifrs-full--CashOnHand_iI_pn3n3_dm_c20220731_zZg6oGlyWLyd" title="Cash on hand">13.2</span> million of cash and cash equivalents on hand. The Company believes its current
cash resources, including its access to the ATM and Committed Purchase (each as defined below, are sufficient to fund operations for at
least 13 months from March 1, 2023, the date when the Company&#8217;s management prepared the Company&#8217;s condensed consolidated
interim financial statements for the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Portage filed a shelf registration statement and prospectus with the SEC
under which it may sell shares, debt securities, warrants and units in one or more offerings from time to time, which became effective
on March 8, 2021 (&#8220;Registration Statement&#8221; or &#8220;Prospectus&#8221;). In connection with the Registration Statement, Portage
has filed with the SEC:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>




















<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>a base prospectus, which covers the offering, issuance and sale by Portage of up to $<span id="xdx_904_ecustom--IssuanceAndSales_c20220401__20221231_pn3n3" title="Issuance and sales">200,000,000</span> in the aggregate of the securities
identified above from time to time in one or more offerings;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>a prospectus supplement covering the offer, issuance and sale by Portage in an &#8220;at the market&#8221; (the &#8220;ATM&#8221;)
offering of up to a maximum aggregate offering price of up to $<span id="xdx_905_ecustom--MaximumAggregateOfferingPrice_c20220401__20221231_pn3n3" title="Maximum aggregate offering price">50,000,000</span> of Portage&#8217;s ordinary shares that may be issued and sold
from time to time under a Controlled Equity Offering Sales Agreement dated February 24, 2021 (the &#8220;Sales Agreement&#8221;), with
Cantor Fitzgerald &amp; Co., the sales agent (&#8220;Cantor Fitzgerald&#8221;);</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by Portage of 1,150,000 ordinary shares for gross proceeds
of approximately $26.5 million in a firm commitment underwriting with Cantor Fitzgerald; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>a prospectus supplement dated August 19, 2022, for the resale of up to $30,000,000 of Portage&#8217;s ordinary shares that Portage
may sell from time to time to Lincoln Park Capital Fund, LLC (&#8220;Lincoln&#8221;) and an additional 94,508 shares that were issued
to Lincoln.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span id="xdx_90F_ecustom--CashFundDescription_c20220401__20221231" title="Cash fund, description">The Sales Agreement permits the Company to sell in an ATM offering up
to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered,
issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an &#8220;at
the market&#8221; offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;). Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is
not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus. See Note 14, &#8220;Capital
Stock,&#8221; and Note 22, &#8220;Event After the Balance Sheet Date,&#8221; for a further discussion.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">During the quarter ended June 30, 2021, the Company commenced an &#8220;at
the market&#8221; offering, under which it sold <span id="xdx_907_ecustom--NumberOfStockSold_c20210401__20210630_pdd" title="Number of stock sold">90,888</span> ordinary shares generating gross proceeds of approximately $<span id="xdx_903_ecustom--GrossProceedsFromStockSold_pn3n3_dm_c20210401__20210630_zhj8CbgEcpL2" title="Gross proceeds from stock sold">2.6</span> million ($<span id="xdx_901_ecustom--NetProceedsFromStockSold_pn3n3_dm_c20210401__20210630_zHMJ1jsgGfQb" title="Net proceeds from stock sold">2.5</span> million,
net of commissions).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 24, 2021, <span id="xdx_906_ecustom--OfferingAndThroughThatProcessDescription_c20210601__20210624_zakxQr2tWLcc" title="Offering and through that process, description">the Company completed a firm commitment underwritten
public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8
million, including approximately $1.6 million of management, underwriting and selling expenses.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 6, 2022, the Company entered into a Purchase Agreement (the &#8220;Committed
Purchase Agreement&#8221;) with Lincoln, under which it may require Lincoln to purchase ordinary shares of the Company having an aggregate
value of up to $30 million (the &#8220;Purchase Shares&#8221;) over a period of 36 months. Pursuant to the Committed Purchase Agreement,
Lincoln will be obligated to purchase the Purchase Shares in three different scenarios that are based on various market criteria and share
amounts. The Company has the right to terminate the Committed Purchase Agreement for any reason, effective upon one business day prior
written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The requirement that Lincoln must make
a purchase will be suspended based on various criteria such as there not being an effective registration statement for Lincoln to be able
to resell the ordinary shares it is committed to purchase and market criteria such as the Company continuing to be Depository Trust Company
eligible, among other things. The Committed Purchase Agreement does not impose any financial or business covenants on the Company, and
there are no limitations on the use of proceeds. The Company may raise capital from other sources in its sole discretion; provided, however,
that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year
anniversary of the date of the Committed Purchase Agreement, excluding, however, an at-the-market transaction with a registered broker-dealer.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In October 2022, the Company restarted the ATM and commenced sales of
ordinary shares pursuant to the Sales Agreement. Through December 31, 2022, the Company sold <span id="xdx_90A_ecustom--NumberOfSharesSold_pid_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zGMvhkSMlFt6" title="Number of shares sold">88,072</span> ordinary shares under the ATM, generating
net proceeds of approximately $<span id="xdx_904_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zAzoqx3bPCa9" title="Net proceeds from sale">0.6</span> million and sold <span id="xdx_908_ecustom--NumberOfSharesSold_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zvfIIFT9hVsk" title="Number of shares sold">30,000</span> ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds
totaling approximately $<span id="xdx_901_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zIws2MS0r0ci" title="Net proceeds from sale">0.2</span> million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has incurred substantial operating losses since inception
and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result
primarily from its conduct of research and development activities.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company historically has funded its operations principally from proceeds
from issuances of equity and debt securities and would expect to enter the capital markets if additional funding is required.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>COVID-19 Effect</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Beginning in early March 2020, the COVID-19 pandemic and the measures
imposed to contain this pandemic have disrupted and are expected to continue to impact the Company&#8217;s business operations. The magnitude
of the impact of the COVID-19 pandemic on the Company&#8217;s productivity, results of operations and financial position, and its disruption
to the Company&#8217;s business and clinical programs and timelines, will depend, in part, on the length and severity of these restrictions
and on the Company&#8217;s ability to conduct business in the ordinary course. There was a slowdown and temporary lack of research and
development resources, principally due to the focus of third party research on the pandemic. The research and development environment has substantially normalized
in  calendar 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504050005328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_BasisOfPresentationAbstract', window );"><strong>Basis Of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfBasisOfPresentationExplanatory', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_800_ecustom--DisclosureOfBasisOfPresentationExplanatory_zL5nVY97c0dd" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 3. <span id="xdx_82D_zNOInjuubg2f">BASIS OF PRESENTATION</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Statement of Compliance and Basis of Presentation</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These condensed consolidated interim financial statements have been prepared
in accordance with the International Financial Reporting Standards (&#8220;IFRS&#8221;) issued by the International Accounting Standards
Board (&#8220;IASB&#8221;), IAS 34 <i>Interim Financial Reporting</i> and interpretations of the International Financial Reporting Interpretations
Committee. These condensed consolidated interim financial statements do not include all of the information required for full annual financial
statements and should be read in conjunction with the audited consolidated financial statements of the Company for the year ended March
31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These condensed consolidated interim financial statements have been prepared
on an historical cost basis except for items disclosed herein at fair value (see Note 19, &#8220;Financial Instruments and Risk Management&#8221;).
In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except
for cash flow information.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has only one reportable operating segment.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These condensed consolidated interim financial statements were approved
and authorized for issuance by the Audit Committee and Board of Directors of the Company (the &#8220;Board&#8221;) on March 1, 2023.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Consolidation</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The condensed consolidated interim financial statements include the accounts
of the Company and:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(a)</td><td>SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>



















<p style="margin: 0pt 0; font-size: 10pt"><b><i>Consolidation (Cont&#8217;d)</i></b></p>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(b)</td><td>iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company, through SalvaRx, exchanged
certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing <span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20150201__20150210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesOneMember_zQxiaxfG6Slb" title="Proportion of ownership interest in subsidiary">60.49</span>% of the outstanding shares
of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to <span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20211201__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesOneMember_zeCOhznC0y6" title="Proportion of ownership interest in subsidiary">78.32</span>%. On July 18,
2022, the Company purchased the remaining non-controlling interest of iOx. <span style="background-color: white">See Note 18, &#8220;Related
Party Transactions &#8211; Share Exchange Agreement &#8211; iOx,&#8221; for a further discussion;</span></td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(c)</td><td>Saugatuck, a <span id="xdx_904_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_z0oi2gSXwMF3" title="Proportion of ownership interest in subsidiary">70</span>% owned subsidiary incorporated in the British Virgin Islands. Saugatuck and subsidiary refers to Saugatuck and Saugatuck
Rx LLC;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(d)</td><td>PDS, a 100% owned subsidiary incorporated in Delaware, which provides human resources, and other services to each operating subsidiary
via a shared services agreement;</td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(e)</td><td>SalvaRx LLC, a wholly-owned subsidiary through SalvaRx;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(f)</td><td>Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck; and</td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(g)</td><td>Tarus Therapeutics, LLC (&#8220;Tarus&#8221;), a wholly-owned subsidiary of Portage.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">All inter-company balances and transactions have been eliminated in consolidation.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Non-controlling interest in the equity of a subsidiary
is accounted for and reported as a component of stockholders&#8217; equity. As of December 31, 2022, non-controlling interest represents
the <span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pid_dp_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_z0pwkgNrPylb" title="Non-controlling interest">30</span>% shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company. See Note 11, &#8220;Unsecured Notes Payable
&#8211; iOx Unsecured Notes Payable,&#8221; for a discussion of the Company&#8217;s settlement of loans with iOx and Note 18, &#8220;Related
Party Transactions &#8211; Share Exchange Agreement &#8211; iOx&#8221; for a discussion of the Company&#8217;s purchase of the balance
of the non-controlling interest in iOx.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Functional and Presentation Currency</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s functional and presentation currency is the U.S. Dollar.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Use of Estimates and Judgments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The preparation of the condensed consolidated interim financial statements
in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies
and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Estimates and underlying assumptions are reviewed on an ongoing basis.
Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Significant areas where estimates are made include valuation of financial
instruments (including the convertible note receivable), deferred tax assets, deferred tax liability, research and development costs,
fair value used for acquisition of intangible assets, contingent consideration assumed and measurement of share-based compensation. Significant
areas where critical judgments are applied include assessment of impairment of investments and goodwill and the determination of the accounting
acquirer and acquiree in the business combination accounting.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfBasisOfPresentationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfBasisOfPresentationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052852368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80C_eifrs-full--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zDYaOYLpbLo2" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4. <span id="xdx_82D_zWbEFd9RM9O">SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The accounting policies are set out in Note 4 to the fiscal 2022 audited
consolidated financial statements of the Company. These policies have been applied consistently to all periods presented in these condensed
consolidated interim financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zWCyteK9gkH4" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86F_zboD0Nhcx4Bf">Recent Accounting Pronouncements</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>IFRS Pronouncements Issued</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Impact of Adoption of Significant New IFRS Standards in 2022</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(a)</b></td><td><b>Annual Improvements to IFRS Standards 2018-2020</b></td></tr></table>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The annual improvements process addresses issues in the 2018-2020 reporting
cycles including changes to IFRS 9, &#8220;Financial Instruments,&#8221; IFRS 1, &#8220;First Time Adoption of IFRS,&#8221; IFRS 16, &#8220;Leases,&#8221;
and IAS 41, &#8220;Biological Assets&#8221;.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right">i)</td><td style="width: 5pt"/><td style="text-align: justify">The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition
of financial liabilities.</td>
</tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right">ii)</td><td style="width: 5pt"/><td style="text-align: justify">The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent
to also measure cumulative translation differences using the amounts reported by the parent based on the parent&#8217;s date of transition
to IFRS.</td>
</tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right">iii)</td><td style="width: 5pt"/><td style="text-align: justify">The amendment to IFRS 16&#8217;s illustrative example 13 removes the illustration of payments
from the lessor related to leasehold improvements.</td>
</tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These amendments were effective for annual periods beginning on or after
January 1, 2022. The adoption of these amendments did not have a material effect on the Company&#8217;s annual consolidated financial
statements or the condensed consolidated interim financial statements for the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(b)</b></td><td><b>IAS 37: Onerous Contracts &#8211; Cost of Fulfilling a Contract</b></td></tr></table>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 37 clarifies the meaning of costs to fulfil a contract
and that before a separate provision for an onerous contract is established, an entity recognizes any impairment loss that has occurred
on assets used in fulfilling the contract, rather than on assets dedicated to the contract. This amendment is effective for annual periods
beginning January 1, 2022. The Company&#8217;s adoption of IAS 37 did not have a material effect on its consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(c)</b></td><td><b>IAS 16: Proceeds Before Intended Use</b></td></tr></table>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 16 prohibits an entity from deducting from the cost
of an item of property, plant and equipment any proceeds received from selling items produced while the entity is preparing the assets
for its intended use (for example, the proceeds from selling samples produced when testing a machine to see if it is functioning properly).
It also clarifies that an entity is testing whether the asset is functioning properly when it assesses the technical and physical performance
of the asset. The amendment also requires certain related disclosures. This amendment is effective for annual periods beginning January
1, 2022. The Company&#8217;s adoption of IAS 16 did not have a material effect on its consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>New Accounting Standards, Interpretations and Amendments</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Standards issued but not yet effective up to the date of issuance of the
Company&#8217;s condensed consolidated interim financial statements are listed below. This listing is of standards and interpretations
issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they
become effective.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(a)</b></td><td><b>IAS 1: Presentation of Financial Statements</b></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 1 clarifies how to classify debt and other liabilities
as either current or non-current. The amendment is effective for annual periods beginning on or after January 1, 2023. The Company is
currently evaluating the new guidance and impacts on its consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(b)</b></td><td><b>Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture</b></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white">The amendment addresses the conflict between
IFRS 10, &#8220;Consolidated Financial Statements,&#8221; and IAS 28, &#8220;Investments in Associates and Joint Ventures,&#8221; in dealing
with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the
gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, &#8220;Business Combinations,&#8221;
between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution
of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors&#8217; interests in the
associate or joint venture. On September 11, 2014, the IASB issued narrow-scope amendments to IFRS 10&#160;and IAS 28. The amendments
were to be effective for annual periods commencing on or after January 1, 2016. In December 2015, the IASB decided to postpone the effective
date of these amendments indefinitely.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504053006128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Prepaid Expenses And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">PREPAID EXPENSES AND OTHER RECEIVABLES</a></td>
<td class="text"><p id="xdx_80C_eifrs-full--DisclosureOfOtherAssetsExplanatory_zPZjeqptTUt8" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 5. <span id="xdx_820_zYL7W0Gr7FRk">PREPAID EXPENSES AND OTHER RECEIVABLES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z9FYDvDSJNyd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B1_zeFC0uRP9RAd" style="display: none">Schedule of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49E_20221231_zLbLLnAjUTwa" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_495_20220331_zSSOlg8LFVxk" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of<br/> December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of<br/> March 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_pn3n3_z8Qszzkcd9Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Prepaid clinical research costs</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,286</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPzymm_z4uAeSWIsJm7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid insurance</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">164</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,084</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3_maCPzymm_zWNuB5Koc7ie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Research &amp; development tax credits</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">169</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">169</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TaxDeposits_iI_pn3n3_maCPzymm_zOtl5uuWIh23" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax deposits</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">119</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">142</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPzymm_z4IwR0DtZmHj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other prepaid expenses</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">33</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">45</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPzymm_z6KVymZaNuxh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">15</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">40</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPzymm_zDi4bRBk7t6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,786</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,480</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052416400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN ASSOCIATE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InvestmentInAssociateAbstract', window );"><strong>Investment In Associate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InvestmentInAssociateDisclosureTextBlock', window );">INVESTMENT IN ASSOCIATE</a></td>
<td class="text"><p id="xdx_80C_ecustom--InvestmentInAssociateDisclosureTextBlock_z3T0Wmxqobdb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 6. <span id="xdx_82F_zNiBqGMdyEbg">INVESTMENT IN ASSOCIATE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Details of the Company&#8217;s associate as of December 31, 2022 and March
31, 2022 are as follows:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_pn3n3_zxPQaOlhb0Y8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_8B6_zONU6GDdLls9" style="display: none">Schedule of investment associate</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Name</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Principal Activity</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Place of Incorporation and <br/>Principal Place of Business</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Voting Rights Held as <br/>of December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Voting Rights Held as <br/>of March&#160;31, 2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-size: 10pt; text-align: center"><span id="xdx_906_eifrs-full--NameOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Name of associate">Associate: Stimunity S.A.</span></td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_907_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Principal place of business of associate">Biotechnology</span></td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90E_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Country of incorporation of associate">Paris, France</span></td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_908_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zs0v3uXnDvp" title="Proportion of voting rights held in associate">44.0</span>%</td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_907_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20210401__20220331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zICLOKswsrxa" title="Proportion of voting rights held in associate">44.0</span>%</td></tr>
  </table>

<p id="xdx_8AB_ztxSSjb86aB" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table is a roll-forward of the Company&#8217;s investment
in Stimunity S.A. (&#8220;Stimunity&#8221;) as of and for the nine months ended December 31, 2022 and 2021:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_zMYY2OvtWdm6" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B9_z2HYPQOUacGg" style="display: none">Schedule of investment in Stimunity S.A.</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">As of and for the</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Nine Months Ended December 31,</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20220401__20221231_zRDqryHTVI5j" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance">1,673</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20210401__20211231_zTQ1g6GD1uJf" style="width: 12%; font-size: 10pt; text-align: right" title="Beginning balance">1,735</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Share of (loss)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20220401__20221231_zDPvdJCnrqbd" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share of (loss)">(268</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20210401__20211231_zOSJCsuv8Ma3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share of (loss)">(363</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20220401__20221231_zGJq8kXDNG3k" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending  balance">1,405</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20210401__20211231_znG1sFoL91qi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending  balance">1,372</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z4His2IdycD3" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 1, 2020, the Company made an additional investment of &#8364;<span id="xdx_90B_ecustom--AdditionalInvestment_iI_pn3n3_dm_uEUR_c20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zHw1QvcpWG54" title="Additional investments">0.9</span>
million ($<span id="xdx_908_ecustom--AdditionalInvestment_iI_pn3n3_dm_uUSD_c20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zlqhTDDfCL25" title="Additional investments">1.0</span> million) by executing its subscription for <span id="xdx_905_ecustom--SubscribingClassShares_c20200529__20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pdd" title="Subscribing class A shares">2,479</span> Class A shares upon the achievement of certain milestones, as provided
in the Shareholders&#8217; Agreement, increasing its equity share in Stimunity to <span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInAssociate_pid_dp_c20200529__20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zYfJTbuLdkNg" title="Proportion of ownership interest in associate">44</span>%.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 13, 2022, <span id="xdx_900_ecustom--ConvertibleNoteDescription_c20220702__20220713__ifrs-full--CounterpartiesAxis__custom--StimunityMember_zrnQmBs9a5Nc" title="Convertible Note description">the Company entered into a commitment with Stimunity
to provide &#8364;600,000 under a convertible note (the &#8220;Stimunity Convertible Note&#8221;) with a maturity date of September 1,
2023 (the &#8220;Maturity Date&#8221;). The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible
Note is automatically converted into Series A shares upon Stimunity completing a Series A round for at least &#8364;20 million. If such
subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into
Series A shares at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares
(other than Common Shares or Series A shares) for at least &#8364;5 million (the &#8220;Minimum Raise&#8221;), the Company will have the
right to convert the Stimunity Convertible Note and the historical Series A shares owned into the new category of shares. In the event
that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the
right to convert the Stimunity Convertible Note into Series A shares at &#8364;363.00 per share or the raise price less 15%, whichever
is lower. The Stimunity Convertible Note was funded on September 12, 2022. See Note 17, &#8220;Commitments and Contingent Liabilities
&#8211; Stimunity Convertible Note,&#8221; for a further discussion.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company accounts for its investment in Stimunity under the equity
method and, accordingly, records its share of Stimunity&#8217;s earnings or loss based on its ownership percentage. The Company recorded
equity in loss in Stimunity of $<span id="xdx_902_ecustom--EquityInLossIncome_c20221001__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income">152,000</span> and $<span id="xdx_90C_ecustom--EquityInLossIncome_c20211001__20211231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income">261,000</span> for the three months ended December 31, 2022 and 2021, respectively, and $<span id="xdx_901_ecustom--EquityInLossIncome_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income">268,000</span>
and $<span id="xdx_903_ecustom--EquityInLossIncome_c20210401__20211231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income">363,000</span> for the nine months ended December 31, 2022 and 2021, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Under the Shareholders&#8217; Agreement, Portage has (i) a preferential
subscription right to maintain its equity interest in Stimunity in the event of a capital increase from the issuance of new securities
by Stimunity, except for issuances of new securities for stock options under a merger plan or for an acquisition, and (ii) the right to
vote against any (a) issuances of additional securities that would call for Portage to waive its preferential subscription right, or (b)
any dilutive issuance.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentInAssociateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentInAssociateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentInAssociateDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentInAssociateDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049050016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN PRIVATE COMPANY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureInvestmentInPrivateCompanyAbstract', window );"><strong>Investment In Private Company</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock', window );">INVESTMENT IN PRIVATE COMPANY</a></td>
<td class="text"><p id="xdx_80B_ecustom--DisclosureOfPrivateCompaniesExplanatoryTextBlock_zi7zMldnKqB2" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 7. <span id="xdx_82C_zSwib493zObd">INVESTMENT IN PRIVATE COMPANY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a discussion of the Company&#8217;s investment in private
company as of December 31, 2022 and March 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Intensity Therapeutics, Inc.</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the SalvaRx Acquisition in fiscal 2019, the Company
acquired a $<span id="xdx_907_ecustom--PrivateInvestments_iI_pn3n3_dm_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zxnC2VC1AK8" title="Investment">4.5</span> million interest in Intensity, a private clinical stage biotechnology company, of <span id="xdx_904_ecustom--InvestmentOwnedShares_iI_dm_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zGyhj4jMXfph" title="Number of shares purchased">1.0</span> million shares, which represented
a <span id="xdx_90D_ecustom--InvestmentOwnershipPercentage_iI_pid_dp_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zuMvIcYwCtX" title="Percentage of equity held">7.5</span>% equity interest in Intensity. The investment was recorded at fair value (which approximates cost) at the acquisition date. The
investment in Intensity has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through
other comprehensive income (&#8220;OCI&#8221;). The fair value of the asset is determined by considering other comparable equity funding
transactions by Intensity with unrelated investors.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 11, 2019, the Company entered into an agreement with Fast Forward
Innovations Limited (&#8220;Fast Forward&#8221;) to purchase Intensity Holdings Limited (&#8220;IHL&#8221;), a wholly-owned subsidiary
of Fast Forward. The Company paid $1.3 million for IHL through the issuance of <span id="xdx_909_eifrs-full--NumberOfInstrumentsOrInterestsIssuedOrIssuable_iI_pid_uPure_c20190711__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_z534hUYPNpP2" title="Number of ordinary shares issued in acquisition">129,806</span> ordinary shares. The sole asset of IHL consists
of <span id="xdx_908_ecustom--NumberOfPrivateCompanyShareConsistsInSoleAsset_iI_pid_c20190711__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zsLT7iubhcA" title="Number of private company share consists in sole asset">288,458</span> shares of Intensity. This transaction increased the Company&#8217;s ownership of Intensity to 1,288,458 shares.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">There was no unrealized gain or loss recognized during the three and nine
months ended December 31, 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022 and March 31, 2022, the Company owned approximately
<span id="xdx_901_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zpGEov3B10f8" title="Percentage of voting equity interests acquired">7.00</span>% and approximately <span id="xdx_90D_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20220331__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zOe7ynvONFKj" title="Percentage of voting equity interests acquired">7.35</span>%, respectively, of the outstanding shares of Intensity, on a fully diluted basis.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On October 28, 2021, Intensity filed a Form S-1 Registration Statement
with the SEC to register shares for an initial public offering, which was declared effective by the SEC, but subsequently withdrawn prior
to closing. Intensity is still evaluating market conditions to determine the timing of an initial public offering. As of March 31, 2022,
the Company had valued its investment in Intensity based on Intensity&#8217;s Series C Preferred Stock Offering completed in 2020. If
the initial public offering is successful, the Company will value its investment in Intensity based upon fair value (market price) and
will record periodic changes in carrying value through OCI.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In October and November of 2022, Intensity filed amendments to its
Form S-1 Registration Statement, which reflected a proposed offering price in the range of $<span id="xdx_900_ecustom--OfferingPrice_pid_c20221001__20221031__ifrs-full--RangeAxis__srt--MinimumMember_zsjy0CxMyG23" title="Offering price"><span id="xdx_907_ecustom--OfferingPrice_pid_c20221101__20221130__ifrs-full--RangeAxis__srt--MinimumMember_zv7YP90vslGe" title="Offering price">4.00</span></span>
- $<span id="xdx_903_ecustom--OfferingPrice_pid_c20221001__20221031__ifrs-full--RangeAxis__srt--MaximumMember_zhezDBoxcNv3" title="Offering price"><span id="xdx_902_ecustom--OfferingPrice_pid_c20221101__20221130__ifrs-full--RangeAxis__srt--MaximumMember_zTDIDHta0nX2" title="Offering price">5.00</span></span>
per share, which is less than the Company&#8217;s carrying value, which indicated impairment. Accordingly, the Company
performed a fair value analysis and determined a fair value of $<span id="xdx_900_eifrs-full--ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets_pn3n3_dm_c20221001__20221031_zXAbf0BvhQq9" title="Fair value"><span id="xdx_90D_eifrs-full--ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets_pn3n3_dm_c20221101__20221130_zCeOGHM5yy1l" title="Fair value">3.363</span></span>
million, which was $<span id="xdx_908_eifrs-full--AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied_pn3n3_dm_c20221001__20221031_ztBj0DDWrGpg" title="Carrying value"><span id="xdx_90C_eifrs-full--AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied_pn3n3_dm_c20221101__20221130_zNgYsCvetUVe" title="Carrying value">4.046</span></span>
million less than the then carrying value. The Company recognized an unrealized loss in value in Intensity of $<span id="xdx_907_ecustom--UnrealizedLoss_pn3n3_dm_c20220401__20221231_zHbzv0Tg3lvb" title="Unrealized loss">4.046</span>
million through OCI in the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureInvestmentInPrivateCompanyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureInvestmentInPrivateCompanyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504075878000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF TARUS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AcquisitionOfTarusAbstract', window );"><strong>Acquisition Of Tarus</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AcquisitionsOfTarusExplanatory', window );">ACQUISITION OF TARUS</a></td>
<td class="text"><p id="xdx_801_ecustom--AcquisitionsOfTarusExplanatory_zkabzFvg5gbb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 8. <span id="xdx_82F_z4XxMRKdSZqh">ACQUISITION OF TARUS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 1, 2022, the Company, its wholly-owned subsidiary, Tarus Acquisition
Inc., and Tarus Therapeutics, Inc., a Delaware corporation advancing adenosine receptor agonists for the treatment of solid tumors, entered
into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;). Under the structure of the Merger Agreement,
Tarus Therapeutics, Inc. was ultimately merged into a wholly-owned subsidiary of the Company with the surviving entity renamed Tarus Therapeutics,
LLC. The Tarus merger entitles the Company to the rights, know-how and/or ownership related to the assets developed by Tarus (the &#8220;Adenosine
Compounds&#8221;), including:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">1.</td><td>All rights and obligations related to the License Agreement between Tarus and Impetis Biosciences Limited, dated October 29, 2019,
and the Call Option under the License Agreement, which was exercised on November 5, 2020;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">2.</td><td>All intellectual property and related documents owned or controlled by Tarus, including issued or pending patents, patent applications
and trade secrets. Additionally, any draft submissions and/or correspondence with patent authorities;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">3.</td><td>All documents and supplies related to Adenosine Compounds including inventory, reagents, data, assays, reports, vendor agreements
and other information related to the preclinical development;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">4.</td><td style="text-align: left">All clinical supplies, manufacturing know-how, batch records, regulatory documents pertaining to the Adenosine
Compounds, certain reservations for manufacturing campaigns and any related agreements;</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">5.</td><td style="text-align: left">All regulatory documents and correspondence pertaining to the Adenosine Compounds;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">6.</td><td style="text-align: left">All Contract Research Organization (&#8220;CRO&#8221;) agreements and protocol related documents for Adenosine
Compounds;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">7.</td><td style="text-align: left">All current documents related to market research, forecasting, budgets and competitive intelligence; and</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">8.</td><td style="text-align: left">Rights to the use of Tarus Therapeutics&#8217; name for regulatory purposes.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">As consideration for Tarus, the Company issued to Tarus
shareholders an aggregate of <span id="xdx_903_ecustom--NumberOfSharesSold_c20220401__20221231_pdd" title="Number of shares sold">2,425,999</span> ordinary shares of Portage, calculated on the basis of $18 million divided by the 60-day Volume
Weighted Average Price per share. The shares have not been registered with the SEC and are subject to lock-up agreements for terms ranging
from six to twelve months. Additionally, milestone payments of up to $<span id="xdx_904_eifrs-full--ProceedsFromIssueOfOrdinaryShares_pn3n3_dm_c20220401__20221231_zrQSA4mhDjh2" title="Proceeds from offering">32</span> million in cash or Portage ordinary shares would be triggered
upon achievement of future development and sales milestones. As a result of the transaction:</p>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">The Company also assumed $2 million in short-term debt held by Tarus and deferred license milestones obligations
($1 million plus interest). The short-term debt was repaid by the Company in July 2022.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: left">Upon enrolling the first patient in a Phase 2 clinical trial, the Company will pay an additional one-time
milestone payment of $15 million. Payment will be in the form of cash or Portage ordinary shares (at the discretion of the Company). The
remaining $<span id="xdx_90F_ecustom--MilestonePayment_pn3n3_dm_c20220401__20221231_z1qt4rFfy5Ed" title="Milestone payment">17</span> million milestone is based on targeted commercial sales.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the acquisition of Tarus, the Company performed a fair
value analysis of the assets acquired and liabilities assumed. The Company based the analysis on its clinical plan and timing of development
events, and the probabilities of success determined primarily based upon empirical third party data and Company experience as well as
the relevant cost of capital. In its fair value analysis, the Company used the Multi-Period Excess Earnings Method for PORT-6 and PORT-7
and the Replacement Cost Method for PORT-8 and PORT-9, determined based upon the maturity of the assets and the availability of sufficient
data to measure fair value. The Company recorded the shares issued at $17.2 million, which represented the aggregate market value of the
shares issued on July 1, 2022. The Company followed the guidance of IAS 3 and IAS 32 and recorded a deferred purchase price payable -
Tarus of $8.538 million, which reflected the estimated acquisition date fair value of contractual milestone obligations incurred. The
principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount
rate used. The Company recorded the obligation as a non-current liability, in accordance with the provisions IAS 32 with respect to the
classification of financial assets and financial liabilities.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company will determine the fair value of the earnout shares at each
balance sheet date. Any change to the fair value will be recorded in the Company&#8217;s statements of operations and other comprehensive
income (loss).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table summarizes the preliminary purchase price allocation
to the fair value of assets acquired and liabilities assumed for Tarus:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_pn3n3_zcgJpov2ptab" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold"><span id="xdx_8B6_zBnEjiGJsVLb" style="display: none">Schedule of fair value of assets acquired and liabilities assumed</span></td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" id="xdx_499_20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zRfIBNUBk5Xj" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--AssetsAbstract_iB" style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">Assets:</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">(In thousands)</td></tr>
  <tr id="xdx_40F_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Identifiable intangible assets</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">28,200</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--Goodwill_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Goodwill</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--OtherTangibleOrIntangibleAssetsTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">28,738</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Consideration:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Fair value of shares issued</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">17,200</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities assumed</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,000</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred purchase consideration at fair value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">8,538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ContingentLiabilitiesRecognisedInBusinessCombination_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">28,738</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zD9luswZEGm7" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Pro forma Information</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Summary unaudited pro forma condensed
results of operations for the nine months ended December 31, 2022 and 2021, assuming the Tarus acquisition had occurred at the beginning
of the earliest period presented, are as follows:</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfProformaInformationTableTextBlock_pn3n3_z7CpBwzy6t86" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_zWRu7EqIHft5" style="display: none">Schedule of pro forma information</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eifrs-full--ProfitLossFromContinuingOperations_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Loss from operations">(12,200</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eifrs-full--ProfitLossFromContinuingOperations_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Loss from operations">(13,431</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss before provision for income taxes</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_983_eifrs-full--ProfitLossBeforeTax_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss before provision for income taxes">(12,833</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_985_eifrs-full--ProfitLossBeforeTax_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss before provision for income taxes">(13,110</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_985_eifrs-full--ProfitLoss_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net loss and other comprehensive loss">(9,927</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_983_eifrs-full--ProfitLoss_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Net loss and other comprehensive loss">(12,645</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total comprehensive loss for period</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--ComprehensiveIncome_pn3n3_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zmKaplj5POOe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total comprehensive loss for period">(13,945</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_981_eifrs-full--ComprehensiveIncome_pn3n3_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zaB8v3M1mJRf" style="font-size: 10pt; text-align: right" title="Total comprehensive loss for period">(12,645</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Loss per share</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--EarningLossPerShare_pid_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zJqemgtaRjoh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss per share">(0.60</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--EarningLossPerShare_pid_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zk2Ts7F4UjDc" style="font-size: 10pt; text-align: right" title="Loss per share">(0.77</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Summary unaudited pro forma condensed
results of operations for the three months ended December 31, 2022 and 2021, assuming the Tarus acquisition had occurred at the beginning
of the earliest period presented, are as follows:</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>





















<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Three Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>2022 <sup>(1)</sup></b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eifrs-full--ProfitLossFromContinuingOperations_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zHdfLCzdC7T3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Loss from operations">(4,759</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eifrs-full--ProfitLossFromContinuingOperations_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Loss from operations">(4,362</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss before provision for income taxes</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--ProfitLossBeforeTax_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zRs6TI3yaLDl" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss before provision for income taxes">(5,302</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eifrs-full--ProfitLossBeforeTax_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss before provision for income taxes">(4,281</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_eifrs-full--ProfitLoss_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zquh5ZicSRXe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net loss and other comprehensive loss">(7,501</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_980_eifrs-full--ProfitLoss_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Net loss and other comprehensive loss">(4,398</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total comprehensive loss for year</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eifrs-full--ComprehensiveIncome_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zov2r2vGJ3K7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total comprehensive loss for year">(11,518</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eifrs-full--ComprehensiveIncome_pn3n3_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zfzxq4miensg" style="font-size: 10pt; text-align: right" title="Total comprehensive loss for year">(4,398</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Loss per share</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--EarningLossPerShare_pid_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_z5cPInowNzre" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss per share">(0.44</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--EarningLossPerShare_pid_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zqNUVTjSNvR5" style="font-size: 10pt; text-align: right" title="Loss per share">(0.23</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><b><sup id="xdx_F05_zcAeLhLmlou">(1)</sup></b></td><td><span id="xdx_F10_zVMEtrMNyV8a" style="background-color: white">Includes the results of operations of Tarus for the period and, accordingly, there are no pro
forma adjustments for the three months ended December 31, 2022.</span></td></tr></table>

<p id="xdx_8A5_z5JuqaAE1sId" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">These pro forma results are not
necessarily indicative of what would have occurred if the acquisition had been in effect for the period presented, and they may not be
indicative of results expected in the future.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AcquisitionOfTarusAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AcquisitionOfTarusAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AcquisitionsOfTarusExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AcquisitionsOfTarusExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052925744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GoodwillAbstract', window );"><strong>Goodwill Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GoodwillExplanatory', window );">GOODWILL</a></td>
<td class="text"><p id="xdx_80C_ecustom--GoodwillExplanatory_zQMqwFKrF9Ed" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 9. <span id="xdx_821_zZ5bdKYv259f">GOODWILL</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a roll-forward of goodwill:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_pn3n3_zLudUd1v9bSd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - GOODWILL (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B4_zbIemXnbfJ7d" style="display: none">Schedule of IPR&amp;D projects</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>As of</b></p> <p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>December 31, 2022</b></p></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of <br/>March 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_eifrs-full--Goodwill_iS_pn3n3_c20220401__20221231_zKF2Isk5FSS7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period">43,324</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--Goodwill_iS_pn3n3_c20210401__20220331_znVRzPGwTWZi" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, beginning of period">43,324</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Tarus goodwill</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--TarusGoodwill_pn3n3_c20220401__20221231_zBDPxH24xyQ8" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Tarus goodwill">538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--TarusGoodwill_pn3n3_c20210401__20220331_znfWoPq6WaWl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Tarus goodwill"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_eifrs-full--Goodwill_iE_pn3n3_c20220401__20221231_zBDVkEbbyoea" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, ending of period">43,862</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--Goodwill_iE_pn3n3_c20210401__20220331_zU9JFoExOgSk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, ending of period">43,324</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s goodwill arose primarily from the acquisition of SalvaRx
and its portfolio of several projects and investments.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As a result of the acquisition of Tarus in July 2022, the Company recorded
$<span id="xdx_906_eifrs-full--Goodwill_iI_pn3n3_dm_c20220731_zMGxVvItlQK" title="Goodwill">0.538</span> million of goodwill, representing the difference between the consideration paid of $<span id="xdx_906_eifrs-full--ConsiderationPaidReceived_pn3n3_dm_c20220701__20220731_z50dkGllOPMe" title="Consideration paid">28.738</span> million and the fair value of identifiable
assets acquired of $<span id="xdx_907_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iI_pn3n3_dm_c20220731_zkw0GF8wYyO9" title="Fair value of identifiable assets acquired">28.2</span> million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Under purchase accounting as of July 1, 2022 (the acquisition date), the
assets and liabilities of Tarus Therapeutics, Inc., was recorded at their respective fair values and the excess of the acquisition consideration
is goodwill. The purchase was in the form of a merger in which Tarus Therapeutics, Inc. was merged into Tarus Therapeutics, LLC., which
is a wholly-owned subsidiary of Portage. All of the consideration for Tarus Therapeutics, LLC was paid or assumed by Portage and Portage
will control the voting rights, the board of directors and the operations of Tarus Therapeutics, LLC.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022, the Company determined that it has only one cash-generating
unit (&#8220;CGU&#8221;), the consolidated Portage Biotech Inc.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Impairment Review</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font-weight: normal">On an annual basis,
pursuant to IAS 36, &#8220;Impairment of Assets,&#8221; the Company assesses its long-lived assets with definite lives, which are not
yet available for use, for potential indicators of impairment.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">If any such indication exists, the Company estimates the recoverable amount
of the asset or CGU and compares it to the carrying value.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company performed its annual impairment test in each of fiscal 2022
and fiscal 2021 and estimated the recoverable amount of the above-noted CGU based on its value in use, which was determined using a capitalized
cash flow methodology and categorized within level 3 of the fair market value hierarchy.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The recoverable amount of the CGU has been determined based on its value
in use. The recoverable amount considered assumptions based on probabilities of technical, regulatory and clinical acceptances and financial
support. Further, management uses risk-adjusted cash flow projections based on financial budgets. Management believes that any reasonably
possible change in the key assumptions on which the recoverable amount is based would not cause the carrying amount to exceed its recoverable
amount. The discount rate has been determined based on the Company&#8217;s best estimate of a risk adjusted discount rate.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The key assumptions used in the calculation of the recoverable amount
include forecasts of the following:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.3in"/><td style="width: 0.25in">(a)</td><td>revenues;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.3in"/><td style="width: 0.25in">(b)</td><td>normalized operating expenses;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.3in"/><td style="width: 0.25in">(c)</td><td>income taxes; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.3in"/><td style="width: 0.25in">(d)</td><td>capital expenditures.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Discounted cash flows are determined with reference to undiscounted risk
adjusted cash flows, and the discount rate approximated <span id="xdx_902_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_pid_dp_c20220331_zCwNScr0c5p8" title="Discount rate applied to cash flow projections">20.5</span>% and <span id="xdx_90D_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_pid_dp_c20210331_zoiBrA98PB95" title="Discount rate applied to cash flow projections">20.0</span>% as of March 31, 2022 and 2021, respectively, based on the individual
characteristics of the Company&#8217;s CGU, the risk-free rate of return and other economic and operating factors.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"><span style="font-weight: normal">&#160;</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022, management assessed whether any indications of
impairment existed for the Company&#8217;s CGU. As of December 31, 2022, the Company&#8217;s market capitalization was less than its net
assets, which is an external indicator of potential impairment. The Company evaluated this factor in conjunction with its assessment of
the overall market environment and the progress made in developing the Company&#8217;s assets. The Company determined that a test for
impairment was not required and no impairment was recorded for the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504053066128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract', window );"><strong>In-process Research And Development And Deferred Tax Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability', window );">IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</a></td>
<td class="text"><p id="xdx_80A_ecustom--InProcessResearchAndDevelopmentAndDeferredTaxLiability_z0t3q4vCUoP7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 10. <span id="xdx_82F_zmF2B0HJBA6h">IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In-process research and development (&#8220;IPR&amp;D&#8221;) consists
of the following projects (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_pn3n3_zHScnRDnlYbb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BD_zbI1Fmg1K1Zd" style="display: none">Schedule of In process research and development</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Project #</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Description</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Value as of <br/>December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Value as of <br/>March 31, 2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">iOx:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 25%; font-size: 10pt">PORT 2 (IMM60)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: left">Melanoma &amp; Lung Cancers</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_pn3n3" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">84,213</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_pn3n3" style="width: 22%; font-size: 10pt; text-align: right" title="In-process research and development">84,213</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">PORT 3 (IMM65)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Ovarian/Prostate Cancers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">32,997</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">32,997</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">117,210</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">117,210</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Oncomer/Saugatuck</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">DNA Aptamers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">178</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">178</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Tarus:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">PORT 6 &amp; PORT 7</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">27,138</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_zxIggqMDOTqb" style="font-size: 10pt; text-align: right" title="In-process research and development"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">PORT 8</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">500</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_z2UTe8vC2o1h" style="font-size: 10pt; text-align: right" title="In-process research and development"><span style="-sec-ix-hidden: xdx2ixbrl1003">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">PORT 9</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">562</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_zc1SfRt7Efih" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"><span style="-sec-ix-hidden: xdx2ixbrl1007">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">28,200</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusMember_zF69TNYjLoka" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"><span style="-sec-ix-hidden: xdx2ixbrl1011">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">In-process research and development</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">145,588</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331_zXEtNRf72jZi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="In-process research and development">117,388</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Deferred tax liability</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--DeferredTaxesLiability_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Deferred tax liability">28,409</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_985_ecustom--DeferredTaxesLiability_iI_pn3n3_c20220331_zy2OYFg0dPOl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax liability">30,198</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Additionally, at the end of each reporting period, the Company is required
to assess whether there is any indication that an asset may be impaired. As indicated above, the Company identified an external indicator
of potential impairment as of December 31, 2022. Pursuant to IAS 36, the Company completed its review of underlying fundamentals, execution,
advancement of assets and value creation activities and concluded that no provision for impairment was required during the three and nine
months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Deferred tax liability represents iOx&#8217;s estimated tax on the difference
between book and tax basis of the IPR&amp;D, which is taxable in the U.K, and the effect of usable net operating loss carryforwards.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022 and March 31, 2022, iOx had a net deferred tax
liability of approximately $<span id="xdx_908_ecustom--DeferredTaxLiability_iI_pn3n3_dm_c20221231_zDJge99TLoe" title="Deferred tax liability">25.5</span> million and approximately $<span id="xdx_90B_ecustom--DeferredTaxLiability_iI_pn3n3_dm_c20220331_zwOLOdYSRosl" title="Deferred tax liability">28.4</span> million, respectively. On January 8, 2019, the Company originally recognized
a $<span id="xdx_905_ecustom--DeferredTaxLiability_iI_pn3n3_dm_c20190108_z1ULMKngf0jf" title="Deferred tax liability">19.8</span> million deferred tax liability for the difference between the book and income tax basis of IPR&amp;D acquired as part of the SalvaRx
Acquisition. As the iOx IPR&amp;D is in the U.K., the deferred tax was recorded at 17%, the prevailing tax rate applicable in the U.K.
at the time. In fiscal 2022, the Company recorded $<span id="xdx_908_ecustom--IncreaseInDeferredIncomeTaxes_pn3n3_dm_c20220401__20221231_zSnMRswCpnH8" title="Increase in deferred income taxes">7.0</span> million increase in deferred income taxes to reflect a future change in the U.K.
income tax rate and recognized $0.7 million of current year losses and $0.8 million of prior year losses. The Company also recognized
a $<span id="xdx_906_eifrs-full--IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_pn3n3_dm_c20210401__20220331_zdAI4qGBrvEe" title="Increase (Decrease) in deferred tax liability">1.1</span> million decrease in deferred tax liability in fiscal 2022 to reflect the effect of the change in exchange rates on the liability
settleable in British pound sterling. For the nine months ended December 31, 2022, the Company recognized the reduction in deferred tax
liability of $<span id="xdx_904_ecustom--ReductionInDeferredTaxLiability_pn3n3_dm_c20220401__20221231_z54kYTYHrhX7" title="Reduction in deferred tax liability">1.8</span> million to reflect the effect of the change in exchange rates on the liability in the period and recognized $0.8 million
of current period losses, as well as the tax rate change effect of $<span id="xdx_906_eifrs-full--TaxEffectFromChangeInTaxRate_pn3n3_dm_c20221001__20221231_zT3cMvasNGw5" title="Change in tax effect rate">0.3</span> million on the current period losses.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052719248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNSECURED NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnsecuredNotesPayableAbstract', window );"><strong>Unsecured Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnsecuredNotesPayableAndWarrantsTextBlock', window );">UNSECURED NOTES PAYABLE</a></td>
<td class="text"><p id="xdx_806_ecustom--UnsecuredNotesPayableAndWarrantsTextBlock_zSsTtfMNdY1i" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 11. <span id="xdx_821_zPAGPseEZqk5">UNSECURED NOTES PAYABLE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a roll-forward of current notes payable:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfNotesPayableTableTextBlock_pn3n3_zeWFs1sHNQe9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - UNSECURED NOTES PAYABLE (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B6_zA0fi5D1dvOj" style="display: none">Schedule of notes payable</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt">Balance, April 1, 2021</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--NotePayable_iS_pn3n3_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zestGKdqCeS9" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">150</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--NotePayable_iS_pn3n3_c20210401__20220331_zfs96051DQC9" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">150</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Exchange of notes payable and accrued interest for iOx shares</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zhbajFJGiK68" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares">(150</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20210401__20220331_z5sKKS9dM8D" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares">(150</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, March 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_985_ecustom--NotePayable_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zotCZUI590z6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="-sec-ix-hidden: xdx2ixbrl1056">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--NotePayable_iE_pn3n3_c20220401__20221231_z3hA9dz5u2b5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; font-weight: bold">Exchange of notes payable and accrued interest for iOx shares</td><td style="display: none; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="display: none; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zOU9l9CUtJ2a" style="display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares">(150)</td><td style="display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="display: none; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20220401__20221231_z4iu4zFeibZ1" style="display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares">(150)</td><td style="display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98D_ecustom--NotePayable_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zCQQK7FxQfHb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--NotePayable_iE_pn3n3_c20220401__20221231_zlxI21CXaGN8" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="-sec-ix-hidden: xdx2ixbrl1066">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>iOx Unsecured Notes Payable</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the SalvaRx Acquisition in January 2019, <span id="xdx_90B_ecustom--DescriptionOfBusinessCombination_c20190103__20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember" title="Description of business combination">the Company
assumed $2.0 million of 7% convertible notes issued by iOx, a wholly-owned subsidiary of SalvaRx (the &#8220;Convertible Notes&#8221;),
of which the Company holds $1.9 million. As a result of the SalvaRx Acquisition, iOx became a subsidiary of the Company during the year
ended March 31, 2019. In accordance with IFRS 3, the fair value, including interest receivable, of the Convertible Notes were effectively
settled against the note receivable upon the business combination.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">On September 8, 2021, <span id="xdx_90B_ecustom--IssuanceOfUnsecuredNotesDescription_c20210901__20210908__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember" title="Description of business combination">the&#160;Company,
through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for
23,772 ordinary shares of iOx at a price of &#163;162. Simultaneously, the Company entered into an agreement with Oxford Sciences Innovation,
Plc (&#8220;OSI&#8221;), the holder of $0.15&#160;million notes plus accrued interest under which OSI exchanged the notes plus accrued
interest for&#160;820&#160;shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated
November 29, 2016, following the general tenets of IAS 39, &#8220;Financial Instruments: Recognition and Measurement,&#8221; and IFRIC
19, &#8220;Extinguishing Financial Liabilities with Equity Instruments,&#8221; and recorded the exchange at historical cost. Additionally,
no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased
its ownership of iOx from&#160;60.49% to&#160;78.32%.</span> See Note 18, &#8220;Related Party Transactions &#8211; Share Exchange Agreement
&#8211; iOx,&#8221; for a further discussion.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnsecuredNotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnsecuredNotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnsecuredNotesPayableAndWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnsecuredNotesPayableAndWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052709488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeTaxesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_809_eifrs-full--DisclosureOfIncomeTaxExplanatory_z2bbpo4LmRrf" style="margin: 0pt 0; font-size: 10pt"><span style="background-color: white"><b>NOTE 12. <span id="xdx_824_zYRUCl5i95jj">INCOME TAXES</span></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company is a BVI business company. The BVI government does not, under
existing legislation, impose any income or corporate tax on corporations.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">PDS is a U.S. corporation and is subject to U.S. federal, state and local
income taxes, as applicable.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">iOx is subject to U.K. taxes.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The (expense) benefit from income taxes consists of the following:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zWnMyD12RJkk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-left: 10pt"><span id="xdx_8BE_zLsQxoQ5ljE1" style="display: none">Schedule of income taxes benefit</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49F_20220401__20221231_zsmYLl3pLi1f" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20210401__20211231_zbPTKMiKUAMi" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Current:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CurrentFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-left: 10pt">Federal</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1087">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--CurrentStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">State and local</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(16</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--CurrentForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(8</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CurrentTaxExpenseIncome_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(24</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Deferred:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-left: 10pt">Federal</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">State and local</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1105">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,930</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">444</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--AdjustmentsForDeferredTaxExpense_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total deferred</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,930</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">444</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_pn3n3_di_zUIk1Gkzq7kb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Benefit from income taxes</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,906</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">465</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zMmmvcaeSYsi" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a reconciliation of the U.S. taxes to the effective income
tax rates for the nine months ended December 31, 2022 and 2021 (U.S. Dollars in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_zvtghDqeHZw7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BD_zovpDafCwnr3" style="display: none">Schedule of reconciliation income tax rates</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Income (loss) on ordinary activities before tax</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_983_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_pn3n3_c20220401__20221231_zeTzaA6AKANg" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Income (loss) on ordinary activities before tax">(1,230</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_pn3n3_c20210401__20211231_zNKCMsniQEhf" style="width: 12%; font-size: 10pt; text-align: right" title="Income (loss) on ordinary activities before tax">(1,535</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Statutory U.S. income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_c20220401__20221231_zz7uNLmimiCb" title="Statutory U.S. income tax rate">21.0</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_903_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_c20210401__20211231_z5NAJwlcIL14" title="Statutory U.S. income tax rate">21.0</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Income tax benefit at statutory income tax rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--LossAtStatutoryIncomeTaxRate_c20220401__20221231_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Income tax at statutory income tax rate">258</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--LossAtStatutoryIncomeTaxRate_pn3n3_c20210401__20211231_zoj1uUZp0jMf" style="font-size: 10pt; text-align: right" title="Income tax at statutory income tax rate">322</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Losses recognized (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--LossesRecognized_c20220401__20221231_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Losses recognized">(282</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--LossesRecognized_pn3n3_c20210401__20211231_zCB3y6lDVIb4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Losses recognized">(322</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--IncomeTaxBenefitExpense_pn3n3_c20220401__20221231_zGV70la4s5Wf" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Income tax benefit (expense)">(24</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--IncomeTaxBenefitExpense_pn3n3_c20210401__20211231_zBDa7Nvj8unf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Income tax benefit (expense)"><span style="-sec-ix-hidden: xdx2ixbrl1136">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z5GZjfAiiUh4" style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">At December 31, 2022, the Company had $0.9 million of federal net operating
losses, which carryforward indefinitely but are limited to 80% of taxable income when utilized. As of December 31, 2022 and March 31,
2022, the Company had U.S. deferred tax assets of $<span id="xdx_90E_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20221231_zzaA3lJq9Fe6" title="Deferred tax assets">0.2</span> million and $<span id="xdx_905_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20220331_z5dsWLztVdDc" title="Deferred tax assets">0.3</span> million, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #1F497D">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a reconciliation of the U.K. taxes to the effective income
tax rates for the nine months ended December 31, 2022 and 2021 (U.S. Dollars in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfIncomeTaxExplanatory_pn3n3_zOoMLX3dTjW" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span id="xdx_8B6_zzrxDOTPC8B4" style="display: none">&#160;Schedule of effective income tax rates</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20220401__20221231_zGqL2JUpbj8l" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20210401__20211231_zc4rKzHsfoEj" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr id="xdx_405_eifrs-full--AccountingProfit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss on ordinary activities before tax</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">4,567</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">2,434</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ApplicableTaxRate_pid_dp_zeIav8WAqTy7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Statutory U.K. income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">19.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr>
  <tr id="xdx_402_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss at statutory income tax rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">868</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">462</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ChangeIncreaseInDeferredIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change (increase) in deferred income tax rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">274</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ForeignCurrencyEffect_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Foreign currency effect</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,788</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">444</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--TaxEffectOfRAndDCredit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Research and development credit</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">21</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LossesUnrecognized_z2xpuyn4xRJ8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Losses (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(462</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--TaxEffectOfTaxLosses_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax benefit</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,930</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">465</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zGolEEKzuxLc" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Research and development credit
receivables of $<span id="xdx_90D_ecustom--ResearchAndDevelopmentCreditReceivables_iI_pn3n3_dm_c20221231_zNz1gq6jatJj" title="Research and development credit receivables">0.2</span> million and $<span id="xdx_90F_ecustom--ResearchAndDevelopmentCreditReceivables_iI_pn3n3_dm_c20220331_zCCqpkNUsNU1" title="Research and development credit receivables">0.2</span> million were included in prepaid expenses and other receivables on the condensed consolidated interim
statements of financial position as of December 31, 2022 and March 31, 2022, respectively.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a reconciliation of financial statement income (loss)
to tax basis income (loss) (in thousands):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock_pn3n3_z7IndVRdypqi" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BB_zrbbSQ2pe0bb" style="display: none">Schedule of reconciliation of financial statement loss to tax basis loss</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_499_20221231__dei--LegalEntityAxis__custom--UnitedStateMember_zxhjDvg6vdHd" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_490_20221231__dei--LegalEntityAxis__custom--BVIMember_zEPsYCKTKG32" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_491_20221231__dei--LegalEntityAxis__custom--ForeignMember_zuwCe5t6y37j" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_492_20221231_zHUbR7WxIEu8" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20211231__dei--LegalEntityAxis__custom--UnitedStateMember_z3TDGnFn1xW9" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_498_20211231__dei--LegalEntityAxis__custom--BVIMember_zYzlxStAIMJ9" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20211231__dei--LegalEntityAxis__custom--ForeignMember_zZquenW5xqSi" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_495_20211231_z7gJsOYoit1f" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>States</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">BVI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>Kingdom</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>States</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">BVI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PretaxIncomeLoss_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-size: 10pt; font-weight: bold; text-align: left">Pre-tax loss</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(1,230</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(7,320</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(4,567</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(13,117</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(1,535</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(6,802</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(2,434</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(10,771</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--LossForWhichNoBenefitWasTaken_pn3n3_z4kVYIP7k9b5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss for which no benefit was taken</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,622</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1193">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,622</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1197">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1198">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LossesNotSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Losses not subject to tax</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1201">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">7,320</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">7,320</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1205">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,802</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,802</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Utilization of losses not previously benefitted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(314</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(314</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1214">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1217">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PretaxLossSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Taxable income (loss)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">78</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(4,567</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(4,489</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,535</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1224">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,434</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,969</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AD_z3eeQbUsJo25" style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">As of December 31, 2022 and March
31, 2022, the Company&#8217;s deferred tax assets and liabilities in the U.K. consisted of the effects of temporary differences attributable
to the following (in thousands):</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfDeferredTaxAssetsExplanatory_pn3n3_zE4USusoNe38" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B9_z7JyF3riiBA2" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_496_20221231_zlDcuXrMBvSk" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20220331_z48oVMtUAIPf" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31,</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzWJe_z6TrbHwZwXx7" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Net operating loss</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(4,394</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(3,253</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetUnrecognized_i01I_pn3n3_maNDTAzWJe_zYp0TC44lH8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax asset (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,500</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,500</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--NetDeferredTaxAssets_iTI_pn3n3_mtNDTAzWJe_z3zoecpXzh76" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax asset</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(2,894</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,753</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxLiabiltiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax liabilities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxLiabilitiesInProcessRAndD_i01I_pn3n3_maDTLzCvC_zibvpvnpmh92" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">In-process research and development</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">28,409</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,198</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxLiability1_iTI_pn3n3_mtDTLzCvC_zbQ6HykEfA9f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">28,409</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,198</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--NetDeferredTaxLiabilities_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">25,515</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">28,445</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z8gYtpTVU167" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">iOx generated research and development cash credits of approximately $<span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseCashCredits_pn3n3_dm_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zHDxojvWPDHc" title="Research and development cash credits">0.02</span>
million that have been recorded for the nine months ended December 31, 2021. There were <span id="xdx_90A_ecustom--ResearchAndDevelopmentExpenseCashCredits_pn3n3_do_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zUAtGiHgZ5b9" title="Research and development cash credits">no</span> research and development cash credits recorded
for the nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022 and March 31, 2022, iOx had a net deferred tax
liability of approximately $<span id="xdx_904_eifrs-full--DeferredTaxLiabilities_iI_pn3n3_dm_c20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zZpopbcaCRui" title="Deferred tax liabilities">25.5</span> million and approximately $<span id="xdx_900_eifrs-full--DeferredTaxLiabilities_iI_pn3n3_dm_c20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_z5wkmarFxo56" title="Deferred tax liabilities">28.4</span> million, respectively. On January 8, 2019, the Company originally recognized
a $19.8 million deferred tax liability for the difference between the book and income tax basis of IPR&amp;D acquired as part of the SalvaRx
Acquisition. As the iOx IPR&amp;D is in the U.K., the deferred tax was recorded at 17%, the prevailing tax rate applicable in the U.K.
at the time. In fiscal 2022, the Company recorded $<span id="xdx_908_eifrs-full--DeferredTaxExpenseIncome_pn3n3_dm_c20190401__20200331_z6goouUGzaye" title="Deferred tax expense (income)">7.0</span> million increase in deferred income taxes to reflect a future change in the U.K.
income tax rate and recognized $<span id="xdx_902_ecustom--CurrentYearLosses_pn3n3_dm_c20210401__20220331_zcni1JRcLTs2" title="Current year losses">0.7</span> million of current year losses and $0.8 million of prior year losses. The Company also recognized
a $<span id="xdx_905_eifrs-full--IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_pn3n3_dm_c20210401__20220331_zhcVd587PT5i" title="Increase (Decrease) in deferred tax liability">1.1</span> million decrease in deferred tax liability in fiscal 2022 to reflect the effect of the change in exchange rates on the liability
settleable in British pound sterling. For the nine months ended December 31, 2022, the Company recognized the reduction in deferred tax
liability of $1.8 million to reflect the effect of the change in exchange rates on the liability in the period and recognized $0.8 million
of current period losses, as well as the tax rate change effect of $0.3 million on the current period losses.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">There is no expiration date for accumulated tax losses in the U.K. entities<span style="font-size: 10pt">.</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>



















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88__IAS12_g79-88_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052706560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantLiabilitytextblock', window );">WARRANT LIABILITY</a></td>
<td class="text"><p id="xdx_80F_ecustom--WarrantLiabilitytextblock_zHX6kbOh9ngj" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 13. <span id="xdx_821_z3vPvHFugKW5">WARRANT LIABILITY</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Below is the roll-forward of warrants issued by entity:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_pn3n3_zxcB3wcLeByb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BF_zQgm2v6c02Gc" style="display: none">Schedule of warrant liability</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">PBI</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Warrants</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Warrants outstanding, April 1, 2022</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsOutstandingExercisePrice_iS_pid_c20220401__20221231_zQbIg6yikcg4" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at beginning">6.64</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--WarrantsOutstandingShares_iS_pid_c20220401__20221231_zIoaa2z7ywMj" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at beginning">33,888</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--WarrantsOutstandingAmount_iS_pn3n3_c20220401__20221231_zaaQ4g8NQj4k" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at beginning">33</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Fair value adjustment as of December 31, 2022 (1)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--FairValueAdjustmentExercisePriceAtEnd_pid_c20220401__20221231_zAJdKDhAkp2e" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment , exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1295">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueAdjustmentShares_pid_c20220401__20221231_zgFdc2AUkvu5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, shares">(33,888</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--FairValueAdjustmentAmount_pn3n3_c20220401__20221231_zDEv3jQWO052" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, amount">(33</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants outstanding, December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--WarrantsOutstandingExercisePrice_iE_pid_c20220401__20221231_zEaPgWvmIgmh" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at ending"><span style="-sec-ix-hidden: xdx2ixbrl1301">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--WarrantsOutstandingShares_iE_pid_c20220401__20221231_zMTJlKzObOkb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at ending"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_ecustom--WarrantsOutstandingAmount_iE_pn3n3_c20220401__20221231_zOTXaB6KFa2k" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at ending"><span style="-sec-ix-hidden: xdx2ixbrl1305">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(1)</td><td>The Company recognized a gain of $<span id="xdx_904_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20221001__20221231_zr8knCLfZCT6" title="Gain (loss) of change in fair value of warrants">0.001</span> million and $<span id="xdx_906_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20220401__20221231_zPoJT2wsQ1zd" title="Gain (loss) of change in fair value of warrants">0.033</span> million in the three and nine months ended December 31, 2022, respectively,
to reflect the change in fair value of the underlying warrants. The Company recognized a gain of $<span id="xdx_90B_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20211001__20211231_zvqu1A8VguE3" title="Gain (loss) of change in fair value of warrants">0.342</span> million and $<span id="xdx_905_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20210401__20211231_zS7MXaJrKphk" title="Gain (loss) of change in fair value of warrants">0.726</span> million in
the three and nine months ended December 31, 2021, respectively, to reflect the change in fair value of the underlying warrants. The warrants
expired in October 2022 unexercised.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilitytextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilitytextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504073830112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalStockAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalStockTextBlock', window );">CAPITAL STOCK</a></td>
<td class="text"><p id="xdx_804_ecustom--CapitalStockTextBlock_zr5NQqtc0LVe" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 14. <span id="xdx_820_zkh6cjkWNqa5">CAPITAL STOCK</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(a)</td><td>Authorized ordinary shares<b>: </b>Unlimited number of Portage ordinary shares without par value.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(b)</td><td>The following is a roll-forward of Portage ordinary shares for the nine months ended December 31, 2022 and 2021:</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_zzVIVgdj9y0h" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8BF_zrNZHUUfoUO2" style="display: none">Common shares: Unlimited number of common shares without par value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary<br/> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary <br/> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CommonStockShares_iS_pn3n3_c20220401__20221231_zfp2FkaXBDLf" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares">13,349</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--CommonStockValues_iS_pn3n3_c20220401__20221231_zTy7JC62NNGb" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">158,324</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--CommonStockShares_iS_pn3n3_c20210401__20211231_zHynUDgOFYFe" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, Shares">12,084</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--CommonStockValues_iS_pn3n3_c20210401__20211231_zeGlHTVH4o2b" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">130,649</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued in Tarus acquisition</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20220401__20221231_zo8EvsEc7O5i" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in Tarus acquisition, shares">2,426</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--AcquisitionsThroughBusinessCombinationsOtherProvisions_pn3n3_c20220401__20221231_z7EL8FH1Fvud" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in Tarus acquisition">17,200</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20210401__20211231_zpkgXx9v4htb" style="font-size: 10pt; text-align: right" title="Shares issued in Tarus acquisition, shares"><span style="-sec-ix-hidden: xdx2ixbrl1331">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--AcquisitionsThroughBusinessCombinationsOtherProvisions_pn3n3_c20210401__20211231_zh0xHGyYSfmi" style="font-size: 10pt; text-align: right" title="Shares issued in Tarus acquisition"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued in iOx exchange</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuedInIoxExchangesShares_pn3n3_c20220401__20221231_zjnikFrYhKc8" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in iOx exchange, shares">1,070</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareIssuedInIoxExchange_pn3n3_c20220401__20221231_z2J5nt8zQGVe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in iOx exchange">9,737</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesIssuedInIoxExchangesShares_pn3n3_c20210401__20211231_zmifDxtU3LEa" style="font-size: 10pt; text-align: right" title="Shares issued in iOx exchange, shares"><span style="-sec-ix-hidden: xdx2ixbrl1339">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareIssuedInIoxExchange_pn3n3_c20210401__20211231_ztcNjF12a95l" style="font-size: 10pt; text-align: right" title="Shares issued in iOx exchange"><span style="-sec-ix-hidden: xdx2ixbrl1341">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Excess of non-controlling interest acquired over consideration &#8211; iOx</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_pn3n3_c20220401__20221231_zG0G6GbgAnR5" style="font-size: 10pt; font-weight: bold; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_pn3n3_c20220401__20221231_ze8yb5MaaMrc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx">29,609</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_pn3n3_c20210401__20211231_zgVZygUEAuo3" style="font-size: 10pt; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"><span style="-sec-ix-hidden: xdx2ixbrl1347">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_pn3n3_c20210401__20211231_zi12atFtIGC1" style="font-size: 10pt; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"><span style="-sec-ix-hidden: xdx2ixbrl1349">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued to Lincoln for commitment fee under Committed Purchase Agreement</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesIssuedToLincolnParksCommittedPurchaseShares_pn3n3_c20220401__20221231_zbzzld47r9Bj" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares">94</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--SharesIssuedToLincolnParksCommittedPurchase_pn3n3_c20220401__20221231_zjCpUMm4zLr1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase">900</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesIssuedToLincolnParksCommittedPurchaseShares_pn3n3_c20210401__20211231_zgG4x05qRDDi" style="font-size: 10pt; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharesIssuedToLincolnParksCommittedPurchase_pn3n3_c20210401__20211231_zeJkmbAqm8Bb" style="font-size: 10pt; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares"><span style="-sec-ix-hidden: xdx2ixbrl1357">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued under public offering and ATM, net of issue costs</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_pn3n3_c20220401__20221231_zygzjapS0dw7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue costs , shares">88</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20220401__20221231_zPjY8TAPsMR7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue costs">586</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_pn3n3_c20210401__20211231_z44w1w5iidf8" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue costs , shares">1,241</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20210401__20211231_z8E33AYeVFUj" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue costs">27,216</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Purchase of shares issued under Committed Purchase Agreement, net of issue costs</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_pn3n3_c20220401__20221231_z7WYF4rX7PN6" style="font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares">30</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_pn3n3_c20220401__20221231_zKpZ3xLEhIl3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs">184</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_pn3n3_c20210401__20211231_zauzHGW2W1R6" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares"><span style="-sec-ix-hidden: xdx2ixbrl1371">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_pn3n3_c20210401__20211231_z3fmcpxsLElb" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs"><span style="-sec-ix-hidden: xdx2ixbrl1373">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued or accrued for services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pn3n3_c20220401__20221231_zYSZpA8pWOO7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services">13</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20220401__20221231_zmeY5KkkdKy1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services">90</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pn3n3_c20210401__20211231_zm532sEf4CY1" style="font-size: 10pt; text-align: right" title="Shares issued or accrued for services">4</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20210401__20211231_zqyuD0UB4FH8" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs">90</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Warrants exercised</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--WarrantsExercisedShares_pn3n3_c20220401__20221231_zup27D4RVdnc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants exercised, shares"><span style="-sec-ix-hidden: xdx2ixbrl1383">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_pn3n3_c20220401__20221231_zsU1T5GDBhAk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1385">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantsExercisedShares1_pn3n3_c20210401__20211231_z0wiD5IFUMH9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised, shares">16</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_pn3n3_c20210401__20211231_zt2fg6EwFy1c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised">339</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--CommonStockShares_iE_pn3n3_c20220401__20221231_z75Uw8y5Gjck" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares">17,070</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_ecustom--CommonStockValues_iE_pn3n3_c20220401__20221231_zdRlDweUR1s2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">216,630</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CommonStockShares_iE_pn3n3_c20210401__20211231_zSwVG2ENQRsg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, Shares">13,345</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_ecustom--CommonStockValues_iE_pn3n3_c20210401__20211231_z5TOiiDo2doe" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance">158,294</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 16, 2020, the Company completed a private placement of <span id="xdx_907_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_pdd" title="Shares issued in a private placement, net of issue costs, shares">698,145</span>
restricted ordinary shares at a price of $<span id="xdx_902_ecustom--PricePerShare_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_pdd" title="Shares price">10.00</span> per share for gross proceeds of $<span id="xdx_902_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zlFxI6kDfZdf" title="Shares issued in a private placement, net of issue costs">6.98</span> million to accredited investors. Directors of the
Company subscribed for <span id="xdx_900_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_pdd" title="Shares issued in a private placement, net of issue costs, shares">215,000</span> shares, or approximately 30.8% of the private placement, for proceeds of $<span id="xdx_905_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_zHbVlffGQNs8" title="Shares issued in a private placement, net of issue costs">2.15</span> million. The Company incurred
costs of approximately $0.25 million in connection with the offering, which was treated as contra-equity on the Company&#8217;s balance
sheet.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: center">&#160;</p>



















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">During the quarter ended June 30, 2021, the Company commenced an &#8220;at
the market&#8221; offering, under which it sold <span id="xdx_901_ecustom--NumberOfStockSold_c20210401__20210630_z0SdwjdGzYwj" title="Number of stock sold">90,888</span> ordinary shares generating gross proceeds of approximately $<span id="xdx_90C_ecustom--GrossProceedsFromStockSold_pn3n3_dm_c20210401__20210630_zPrRy0UiIOi4" title="Gross proceeds from stock sold">2.6</span> million ($<span id="xdx_904_ecustom--NetProceedsFromStockSold_pn3n3_dm_c20210401__20210630_z66gXdry42lc" title="Net proceeds from stock sold">2.5</span> million,
net of commissions).</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 24, 2021, the Company completed a firm commitment underwritten
public offering of <span id="xdx_902_ecustom--NumberOfStockSold_c20210601__20210624_z1llgvOdhgL2" title="Number of stock sold">1,150,000</span> ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $<span id="xdx_905_ecustom--GrossProceedsFromStockSold_pn3n3_dm_c20210601__20210624_zH5Ma8XGUELe" title="Gross proceeds from stock sold">26.5</span>
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $<span id="xdx_900_ecustom--OfferingExpenses_pn3n3_dm_c20210601__20210624_zj7ZP17AaDM8" title="Offering Cost">1.8</span>
million, including approximately $<span id="xdx_902_ecustom--ManagementUnderwritingAndSellingExpenses_pn3n3_dm_c20210601__20210624_zGUUdLmwhvLc" title="Management, underwriting and selling expenses">1.6</span> million of management, underwriting and selling expenses.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has issued <span id="xdx_90C_ecustom--NumberOfSharesSold_c20220401__20221231_zib7KB7wamPl" title="Number of shares issued">2,425,999</span> ordinary shares in connection with the
acquisition of Tarus Therapeutics, Inc. and in connection with the Tarus Therapeutics, Inc.&#8217;s acquisition we may issue additional
ordinary shares. <span style="background-color: white">See Note 8, &#8220;Acquisition of Tarus,&#8221; for a further discussion.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 18, 2022, the Company completed the iOx Share Exchange Agreement
under which it exchanged <span id="xdx_904_ecustom--NumberOfSharesExchanged_c20220701__20220718_pdd" title="Number of shares exchanged">1,070,000</span> ordinary shares for the remaining minority interest of <span id="xdx_901_ecustom--MinorityInterestPercentage_iI_pid_dp_c20220718_zx1LPwuwMRrj" title="Minority interest, percentage">21.68</span>% of iOx. <span style="background-color: white">See
Note 18, &#8220;Related Party Transactions &#8211; Share Exchange Agreement &#8211; iOx,&#8221; for a further discussion.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Additionally, on August 19, 2022, the Company issued <span id="xdx_909_ecustom--NumberOfSharesSold_c20220801__20220819__ifrs-full--CounterpartiesAxis__custom--LincolnMember_pdd" title="Number of shares issued">94,508</span> ordinary shares
to Lincoln in consideration for entering into the $<span id="xdx_90C_eifrs-full--ProceedsFromIssueOfOrdinaryShares_pn3n3_dm_c20220801__20220819__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zivIQX3tmhaj" title="Proceeds from offering">30</span> million Committed Purchase Agreement. See Note 17, &#8220;Commitments and Contingent
Liabilities &#8211; Committed Purchase Agreement,&#8221; for a further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In October 2022, the Company restarted the ATM and commenced sales of
ordinary shares pursuant to the Sales Agreement. Through December 31, 2022, the Company sold <span id="xdx_90C_ecustom--NumberOfSharesSold_pid_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zE6NGUFL0fXf" title="Number of shares sold">88,072</span> ordinary shares under the ATM, generating
net proceeds of approximately $<span id="xdx_908_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zxzTdxVCSnGh" title="Net proceeds from sale">0.6</span> million and sold <span id="xdx_907_ecustom--NumberOfSharesSold_pid_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zNo1l4vYwCWc" title="Number of shares sold">30,000</span> ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds
totaling approximately $<span id="xdx_907_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zxbYg5WF1qu7" title="Net proceeds from sale">0.2</span> million.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504073829984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockOptionReserveAbstract', window );"><strong>Stock Option Reserve</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">STOCK OPTION RESERVE</a></td>
<td class="text"><p id="xdx_801_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zwCWsz0gwXIf" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 15. <span id="xdx_821_z76FFjLaAnyk">STOCK OPTION RESERVE</span></b></p>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(a)</td><td>The following table provides the activity for the Company&#8217;s stock option reserve for the nine months ended December 31, 2022
and 2021:</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_zeA2xnrNPxZe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BD_zGV7nxLtU6ad" style="display: none">Disclosure Of Terms Stock Option Reserve Explanatory</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zVTLTJYq6Jig" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">11,659</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_ziRFOq5sbuNh" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">16,928</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zkDqJIL5TfE" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">11,468</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z9TizhLV2sM6" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">7,977</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--AdjustmentsForSharebasedPayments_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pdn3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1461">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--AdjustmentsForSharebasedPayments_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense">3,614</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense">191</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense">6,248</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Settled in iOx exchange</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--SettledInIoxExchange_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Settled in iOx exchange">(11,659</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--SettledInIoxExchange_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Settled in iOx exchange"><span style="-sec-ix-hidden: xdx2ixbrl1471">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--SettledInIoxExchange_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Settled in iOx exchange"><span style="-sec-ix-hidden: xdx2ixbrl1473">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--SettledInIoxExchange_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Settled in iOx exchange"><span style="-sec-ix-hidden: xdx2ixbrl1475">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zcPmyMmC7tAb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="-sec-ix-hidden: xdx2ixbrl1477">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zZiO4J0OjKK6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">20,542</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zTyW1N75gsc5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance">11,659</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zMtZAF3y94o4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance">14,225</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zTtLbm6SqEwd" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Stock Options</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 25, 2020, at the annual meeting of shareholders, the Company&#8217;s
new incentive stock option plan (the &#8220;2020 Stock Option Plan&#8221;) was approved, which authorized the Company&#8217;s directors
to fix the option exercise price and to issue stock options under the plan as they see fit. The Company&#8217;s 2020 Stock Option Plan
is a 10% rolling stock option plan under which the Company&#8217;s directors are authorized to grant up to a maximum of 10% of the issued
and outstanding ordinary shares on the date of grant.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>























<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Effective January 13, 2021, the
Company amended and restated its 2020 Stock Option Plan to permit the grant of additional types of equity compensation securities, including
restricted stock units (&#8220;RSUs&#8221;) and dividend equivalent rights (the &#8220;2021 Equity Incentive Plan&#8221;). The aggregate
number of equity securities, which may be issued under the 2021 Equity Incentive Plan has not been changed.&#160; Pursuant to the 2021
Equity Incentive Plan, on January 13, 2021, the Company granted an aggregate of <span id="xdx_90E_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_pdd" title="Option issued">868,000</span> stock options exercisable at a price of $<span id="xdx_90C_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_pdd" title="Exercise price">17.75</span>
per share, representing the closing price of the shares on the day immediately preceding the grant date, which expire on January 13, 2031
to various directors, officers and consultants of the Company. <span id="xdx_900_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember_pdd" title="Option issued">350,000</span> options granted to members of the Board vest 1/3 on grant date,
1/3 on the first anniversary of the grant and 1/3 on the second anniversary of the grant. <span id="xdx_907_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--ConsultantsMember_pdd" title="Option issued">518,000</span> options granted to consultants (one
of whom is also a director of the Company) vest 1/3 on each of the first three anniversaries of the grant date.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Additionally, the Company granted
<span id="xdx_90D_ecustom--StockGranted_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_pdd" title="Stock granted">243,000</span> RSUs on January 13, 2021, with a fair value of $<span id="xdx_90C_ecustom--FairValuePerShare_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_pdd" title="Fair value per share">17.75</span> per share, which was the closing price on the day immediately preceding
the grant date. The RSUs vested on the date of grant, but underlying shares cannot be sold until one of four of the following conditions
are met: (1) a Change in Control (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)), (2) the participant&#8217;s
Separation from Service (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)), (3) the participant&#8217;s
death, or (4) the participant&#8217;s Disability (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)).&#160;
In accordance with IFRS 2, &#8220;Share-based Payment,&#8221; the Company recognized compensation expense of $<span id="xdx_900_eifrs-full--CommunicationExpense_pn3n3_dm_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zyNOz5hg8wOg" title="Compensation expense">4.3</span> million in the year
ended March 31, 2021, in connection with the RSU grants.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Amended and Restated 2021 Equity Incentive Plan and Grants of Stock Options and Restricted
Stock Units</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On January 19, 2022, the Board unanimously approved the Amended and Restated
2021 Equity Incentive Plan (the &#8220;Amended and Restated 2021 Equity Incentive Plan&#8221;). The Amended and Restated 2021 Equity Incentive
Plan provides for:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-size: 10pt"><b>(1)</b></span></td><td>An increase of aggregate number of shares available for awards to 2,001,812, which is equal to 15% of the issued and outstanding ordinary
shares of the Company as of January 19, 2022 subject to discretionary annual increases (on a cumulative basis) as may be approved by the
Board in future years by a number of shares not to exceed an additional 5% of the aggregate number of shares then outstanding;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-size: 10pt"><b>(2)</b></span></td><td>The authorization of incentive stock options (should shareholder approval be sought and obtained) under the Amended and Restated 2021
Equity Incentive Plan; and</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-size: 10pt"><b>(3)</b></span></td><td>The provision of dividend equivalent rights to be issued when authorized.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Pursuant to the Amended and Restated 2021 Equity Incentive Plan, on January
19, 2022, the Company granted an aggregate of <span id="xdx_905_ecustom--StockGranted_c20220101__20220119__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted">302,000</span> stock options exercisable at a price of $<span id="xdx_904_ecustom--FairValuePerShare_c20220101__20220119__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share">10.22</span> per share, representing the average
price of the shares on the grant date (January 19, 2022), which expire on January 19, 2032, to various directors, officers and consultants
of the Company. A total of <span id="xdx_909_ecustom--StockGranted_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--TwoMembersMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted">13,800</span> of the 302,000 stock options were granted to two members of the Board and vest on the first anniversary
of the grant date. The balance of <span id="xdx_906_ecustom--StockGranted_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--EmployeesMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted">288,200</span> stock options was granted to employees (one of whom is also a director of the Company), and
a consultant, and such stock options vest ratably on each of the first four annual anniversaries of the grant date.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Additionally, the Company granted
<span id="xdx_902_ecustom--StockGranted_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted">135,740</span> RSUs to employees (one of whom is also a director of the Company) on January 19, 2022, with a fair value of $<span id="xdx_901_ecustom--FairValuePerShare_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share">10.22</span> per share,
representing the average price of the shares on the grant date (January 19, 2022). The RSUs were </span>fully vested and nonforfeitable
as of the <span style="background-color: white">grant date and will expire on January 19, 2032.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On February 15, 2022, James Mellon, Linda Kozick and Mark Simon were appointed
to the Board. Mr. Mellon owned approximately 23.9% of the Company&#8217;s outstanding shares at that date. Additionally, Mr. Mellon had
previously served as a member of the Board from 2016 to August 14, 2020. On February 15, 2022, in connection with the appointments, each
of these directors were granted <span id="xdx_90C_ecustom--StockGranted_c20220201__20220215__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted">13,800</span> non-qualified stock options, which vest ratably monthly over a three-year period. The options have
an exercise price of $<span id="xdx_90F_ecustom--FairValuePerShare_c20220201__20220215__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share">8.59</span> per share, the average price of the stock on February 15, 2022, the day immediately preceding the grant date,
and will expire, if unexercised, on February 15, 2032.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 8, 2022, the Company granted <span id="xdx_908_ecustom--StockGranted_c20220601__20220608__ifrs-full--CounterpartiesAxis__custom--ExecutiveMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted">50,000</span> options to purchase shares
to an executive of the Company. The options have an exercise price of $<span id="xdx_909_ecustom--FairValuePerShare_c20220601__20220608__ifrs-full--CounterpartiesAxis__custom--ExecutiveMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share">11.00</span>, the average price of the stock on that date, vest ratably
on each of the first four anniversaries of the grant date and will expire, if unexercised, on June 8, 2032.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is the weighted average assumptions used in connection with
the June 8, 2022 option grant with respect to the Company&#8217;s Amended and Restated 2021 Equity Incentive Plan:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eifrs-full--DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_pn3n3_z0PXr0XQXgy5" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_8BD_zkMLVnMurtWf" style="display: none">Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Assumption</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unvested Options</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-size: 10pt; text-align: left">Risk free interest rate</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 49%; font-size: 10pt; text-align: center"><span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zwlMc8xm8834" title="Risk free interest rate">3.05</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected dividend</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">Nil</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected volatility</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_908_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zx9aHxnRe9Zi" title="Expected volatility">111</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected life</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_907_ecustom--OptionLifeShareOptionsGranted_dtY_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z8aU8Pw0VW7i" title="Expected life">6.25</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Fair value of Portage option</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">$<span id="xdx_90D_ecustom--FairValueOfPortageOption_pid_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zo88QbFX6Cg3" title="Fair value of Portage option">9.36</span></td></tr>
  </table>


<p id="xdx_8AA_zK5eitRLRgt9" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 27, 2022, the Company granted <span id="xdx_907_ecustom--StockGranted_c20220701__20220727__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted">15,900</span> options to purchase shares
to a member of the Board. The options have an exercise price of $<span id="xdx_90E_ecustom--FairValuePerShare_c20220601__20220727__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share">10.06</span>, the average price of the stock on that date, vest ratably on each
of the first four anniversaries of the grant date and will expire, if unexercised, on July 27, 2032.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is the weighted average assumptions used in connection with
the July 27, 2022 option grant with respect to the Company&#8217;s Amended and Restated 2021 Equity Incentive Plan:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eifrs-full--ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory_zM8amTAE1ue" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B9_z3NhZxUvbnf9" style="display: none">Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Assumption</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unvested Options</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-size: 10pt; text-align: left">Risk free interest rate</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 49%; font-size: 10pt; text-align: center"><span id="xdx_905_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zRXmqEnLkFh9" title="Risk free interest rate">2.83</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected dividend</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">Nil</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected volatility</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_902_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zyhuhdC7d8H8" title="Expected volatility">112</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected life</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_900_ecustom--OptionLifeShareOptionsGranted_dtY_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z7rEhj6JJHK" title="Expected life">5.75</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Fair value of Portage option</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">$<span id="xdx_90C_ecustom--FairValueOfPortageOption_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_pdd" title="Fair value of Portage option">8.38</span></td></tr>
  </table>

<p id="xdx_8AA_zmdyiiBs1uGf" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(b)</td><td>The movements in the number of options issued for the nine months ended December 31, 2022 and 2021 were:</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_pn3n3_zpqWwIO2cFHa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BC_znNG4X0YuXGj" style="display: none">Schedule of outstanding stock options</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated 2021 Equity Incentive Plan</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">iOx Option Plan<br/> (Subsidiary Plan)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--NumberOfOutstandingShareOption_iS_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zrsA014IiTp2" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">1,151,400</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--NumberOfOutstandingShareOption_iS_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zUOtQyrLwbO7" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">868,000</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iS_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_z3HJtOyq5itf" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">1,275</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--NumberOfOutstandingShareOption_iS_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zJJGebQ4jSV8" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">1,924</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Granted</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcQwhLH0L2ge" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted">65,900</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zUQPCdkUQekf" style="font-size: 10pt; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1574">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zrhjuw4FtqRj" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1576">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zelSUFznsim9" style="font-size: 10pt; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1578">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Expired or forfeited</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zmhHETlc5SD3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1580">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zlANHiWHq4P2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1582">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zbgbuSiqxKH2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited">(1,275</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zxvSZjn3hC8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited">(649</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5ceqnOjbBP2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">1,217,300</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zIEj46lAcwR7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance">868,000</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfOutstandingShareOption_iE_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zKK6tNOhjOLa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1592">&#8211;</span></b></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--NumberOfOutstandingShareOption_iE_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zw9b79ON8Y51" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance">1,275</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Exercisable, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zevhBsJO8lFb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end">419,705</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zf7yuWU9UoWf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end">116,666</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zGyK7Xi8axE" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"><span style="-sec-ix-hidden: xdx2ixbrl1600">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zV5kxgj5Z7Aj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end">1,275</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zehUNg5QJDjb" style="margin: 0pt 0; font-size: 10pt">&#160;&#160;</p>





















<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(c)</td><td>The following is the weighted average exercise price and the remaining contractual life for outstanding options by plan as of December
31, 2022 and 2021:</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_pn3n3_zYqSDIN62r89" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B8_zy114S1FX6X6" style="display: none">Schedule of weighted average exercise price and remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated <br/>2021 Equity Incentive Plan</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx Option Plan<br/> (Subsidiary Plan)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zsSiPYyJiDJ7" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price">15.19</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcK0Lrpjxw8g" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price">17.75</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zKctCx28Y2tb" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1619">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zf7SXsWg1JXa" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price">162.14</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life (in years)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zLsPw9gMiO62" title="Weighted average remaining contractual life (in years)">8.41</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcshMRx6Rf55" title="Weighted average remaining contractual life (in years)">9.04</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zvB5Qd59wDy1" title="Weighted average remaining contractual life (in years)">0.30</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zzLiTngfB2cb" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The vested options can be exercised at any time in accordance with the
applicable option agreement. The exercise price was greater than the market price on the date of the grants for all options outstanding
as of December 31, 2022 and March 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company recorded approximately $<span id="xdx_90A_eifrs-full--CommunicationExpense_pn3n3_dm_c20221001__20221231_z3ZMcXAubzLk" title="Compensation expense">1.2</span> million and $<span id="xdx_908_eifrs-full--CommunicationExpense_pn3n3_dm_c20220401__20221231_zyB5BXavfFLg" title="Compensation expense">3.6</span> million of share-based
compensation expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the three and nine months ended December 31,
2022, respectively. The Company recorded approximately $<span id="xdx_90E_eifrs-full--CommunicationExpense_pn3n3_dm_c20211001__20211231_zKH9xTIWRBXc" title="Compensation expense">2.0</span> million and $<span id="xdx_902_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20211231_zlijdNLZ5tNf" title="Compensation expense">6.2</span> million of share-based compensation expense with respect
to the Amended and Restated 2021 Equity Incentive Plan in the three and nine months ended December 31, 2021, respectively. The Company
expects to record additional share-based compensation expense of approximately $<span id="xdx_905_eifrs-full--CommunicationExpense_pn3n3_dm_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zVXruMFqG0jk" title="Compensation expense">2.9</span> million through June 2026 with respect to the Amended
and Restated 2021 Equity Incentive Plan. Additionally, there was <span id="xdx_906_ecustom--IntrinsicValueOfStockOptions_iI_pn3n3_do_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_z74DEzpR0l22" title="Intrinsic value of stock options"><span id="xdx_90F_ecustom--IntrinsicValueOfStockOptions_iI_pn3n3_do_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zqYN6o8mSXM8" title="Intrinsic value of stock options">no</span></span> intrinsic value with respect to the stock options granted under the
Amended and Restated 2021 Equity Incentive Plan at December 31, 2022 and was nil at December 31, 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company recorded approximately $<span id="xdx_902_eifrs-full--CommunicationExpense_pn3n3_dm_c20211001__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zILIVGaQUDV4" title="Compensation expense">0.03</span> million and $<span id="xdx_90D_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zNqYqk2NMrC6" title="Compensation expense">0.2</span> million of share-based
compensation expense related to the iOx stock option plan in the three and nine months ended December 31, 2021, respectively. As of December
31, 2021, the Company&#8217;s iOx stock option plan was fully vested. Additionally, the intrinsic value of the iOx stock options was approximately
$<span id="xdx_909_ecustom--IntrinsicValueOfStockOptions_iI_pn3n3_dm_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zQNuJnXdUaQg" title="Intrinsic value of stock options">0.1</span> million at December 31, 2021, all of which was associated with vested exercisable options.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockOptionReserveAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockOptionReserveAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052119600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LosPerShareAbstract', window );"><strong>Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">(LOSS) PER SHARE</a></td>
<td class="text"><p id="xdx_806_eifrs-full--EarningsPerShareExplanatory_zHfD4iyDTxq8" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 16. <span id="xdx_822_zresQLOZ4ZDk">(LOSS) PER SHARE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Basic earnings per share (&#8220;EPS&#8221;) is calculated by dividing
the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding
during the period.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Diluted EPS is calculated by dividing the net income (loss) attributable
to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period plus the weighted
average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table reflects the loss and share data used in the basic
and diluted EPS calculations (U.S. Dollars in thousands, except per share amounts):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--EarningsPerShareTableTextBlock_pn3n3_zTcQDz7nnwD7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B2_zpIatBYYIWs7" style="display: none">Schedule of basic and diluted EPS calculations</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_497_20221001__20221231_zjglLULkusIb" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_499_20211001__20211231_zz6OpCrbVXI3" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20220401__20221231_zeTqFzQcdnx8" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_496_20210401__20211231_zRr5vg062j98" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended<br/> December 31,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended<br/> December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">2021</td></tr>
  <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Numerator (in 000&#8217;$)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to owners of the Company</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(7,485</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right">(3,512</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(10,163</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right">(9,553</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Denominator (in 000&#8217;)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--WeightedAverageShares_i01_pid_zIoQ9lrRsQJf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average number of shares &#8211; Basic and Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">17,039</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13,344</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">15,719</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,966</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--BasicAndDilutedLossPerShare_i01_pid_zEYG7Kd8HOsi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted (loss) per share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.44</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.26</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.65</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.74</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AE_zdqeYx7Uw2w5" style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The inclusion of the Company&#8217;s stock options, RSUs and share purchase
warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore excluded
from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the three and nine
months ended December 31, 2022 and 2021. The following table reflects the outstanding securities by year that would have an anti-dilutive
effect on loss per share and, accordingly, were excluded from the calculation.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_pn3n3_zQfmZIH8HUBj" style="width: 100%; border-collapse: collapse; font-size: 10pt" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)">
  <tr>
    <td style="vertical-align: bottom"><span id="xdx_8B4_zoAsgyZtmiob" style="display: none">Schedule of anti-dilutive share</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>As of December 31,</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="border-top: Black 1pt solid; vertical-align: top; text-align: center">&#160;</td>
    <td style="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; width: 67%"><span style="font-size: 10pt"><b>Stock options</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; vertical-align: bottom; width: 16%; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt"><b>1,217,300</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; width: 1%">&#160;</td>
    <td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; vertical-align: bottom; width: 11%; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt">868,000</span></td>
    <td style="vertical-align: top; width: 1%; text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Restricted stock units</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt"><b>378,740</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt">243,000</span></td>
    <td style="vertical-align: top; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Warrants</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_980_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1697">&#8211;</span></b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt">33,888</span></td>
    <td style="vertical-align: top; text-align: right">&#160;</td></tr>
  </table>
<p id="xdx_8A9_zd5iB02rMppd" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Inclusion of outstanding options or other common stock equivalents in
the computation of diluted loss per share would have an anti-dilutive effect on the loss per share and are therefore excluded from the
computation. Consequently, there is no difference between loss per share and diluted loss per share.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LosPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LosPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052119728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommitmentsAndContingentLiabilitiesAbstract', window );"><strong>Commitments And Contingent Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><p id="xdx_80B_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zwPa6iZ7H3ll" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 17. <span id="xdx_822_zVV1p7v3XVG2">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Effective March 15, 2022, iOx entered into a Master Services Agreement
(the &#8220;MSA&#8221;) with Parexel International (IRE) Limited (&#8220;Parexel&#8221;) under which Parexel agrees to provide services
as CRO provided in a work order (&#8220;Work Order&#8221;) effective June 1, 2022 under which Parexel will operate a Phase 2 trial of
IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer (&#8220;NSCLC&#8221;). The MSA provides for a five-year term, and
the Work Order provides for a term to be ended upon the completion of the services required. The budget provides for service fees and
pass-through expenses and clinical sites totaling $11.5 million. During the three months ended December 31, 2022, the Company executed
two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"><b><i>Stimunity Convertible Note</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 13, 2022, the Company entered into a commitment with Stimunity
to provide &#8364;<span id="xdx_90A_ecustom--ConvertibleNote_iI_pn3n3_uEUR_c20220713_z2zJNKFzLEdi" title="Convertible note">600,000</span> under the Stimunity Convertible Note. The Stimunity Convertible Note provides for simple interest at <span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220713_zC10wuouL4fb" title="Interest rate">7</span>% per annum.
The Convertible Note is automatically converted into Series A shares upon Stimunity completing a Series A round for at least &#8364;<span id="xdx_908_ecustom--ConversionOfDebt_iI_pn3n3_dm_uEUR_c20220713_zhC1H9XDnyv6" title="Conversion of debt">20</span>
million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible
Note into Series A shares at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category
of shares (other than Common Shares or Series A shares) for at least &#8364;<span id="xdx_900_ecustom--ConversionOfDebtIntoShares_iI_pn3n3_dm_uEUR_c20220713_zEawQMbRT4b7" title="Conversion of debt into shares">5</span> million (the &#8220;Minimum Raise&#8221;), the Company will
have the right to convert the Stimunity Convertible Note and the historical Series A shares owned into the new category of shares. In
the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will
have the right to convert the Stimunity Convertible Note into Series A shares at &#8364;<span id="xdx_904_ecustom--SharePricePerShare_iI_pid_uEURPShares_c20220713_zRBZTVXYDSoj" title="Share price, per share">363.00</span> per share or the raise price less 15%, whichever
is lower. The Stimunity Convertible Note was funded by the Company on September 12, 2022. In addition, the Company has eliminated 100%
of the interest earned on the Stimunity Convertible Note in reporting its condensed consolidated financial results.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Committed Purchase Agreement</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 6, 2022 (the &#8220;Signing Date&#8221;), the Company entered
into the Committed Purchase Agreement with Lincoln, pursuant to which the Company may require Lincoln to purchase ordinary shares having
an aggregate value of up to $<span id="xdx_903_ecustom--AggregateValue_pn3n3_dm_c20220701__20220706__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zNQJvPblcIHc" title="Aggregate value">30</span> million over a period of 36 months. Pursuant to the Committed Purchase Agreement, Lincoln will be obligated
to purchase ordinary shares in three different scenarios that are based on various market criteria and share amounts.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Upon execution of the Committed Purchase Agreement, the Company issued
to Lincoln <span id="xdx_901_ecustom--NumberOfSharesSold_c20220401__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zxn8u3jTtFR" title="Number of shares issued">94,508</span> ordinary shares, representing a 3% commitment fee valued at $<span id="xdx_900_ecustom--CommitmentFee_pn3n3_dm_c20220401__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zwsWMj5CT36c" title="Commitment fee">0.9</span> million. The Company has the right to terminate the
Committed Purchase Agreement for any reason, effective upon one business day prior written notice to Lincoln. Lincoln has no right to
terminate the Committed Purchase Agreement. The Company is accounting for the commitment fee as a deferred commitment fee on the condensed
consolidated interim statement of financial position as of December 31, 2022 and will amortize it pro-rata against equity sold under the
Committed Purchase Agreement. Any unamortized balance will be written-off to operations at the expiration of the commitment.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Committed Purchase Agreement does not impose any financial or business
covenants on the Company and there are no limitations on the use of proceeds received by the Company from Lincoln. The Company may raise
capital from other sources in its sole discretion; provided, however, that the Company shall not enter into any similar agreement for
the issuance of variable priced equity-like securities until the three-year anniversary of the Signing Date, excluding, however, an at-the-market
transaction with a registered broker-dealer.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the Committed Purchase Agreement, the Company and Lincoln
entered into a Registration Rights Agreement, dated July 6, 2022 (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the Registration
Rights Agreement, the Company agreed, that it will file with the SEC the prospectus supplement to the Company&#8217;s shelf registration
statement pursuant to Rule 424(b) for the purpose of registering for resale the ordinary shares to be issued to Lincoln under the Committed
Purchase Agreement. The prospectus supplement was filed on August 19, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company is obligated under the Tarus Merger Agreement
and the iOx Share Exchange Agreement for certain third party earnouts based on the achievement of certain milestones. See Note 8, &#8220;Acquisition
of Tarus,&#8221; and Note 18<span style="background-color: white">, &#8220;Related Party Transactions &#8211; Share Exchange Agreement
&#8211; iOx,&#8221;</span> for further discussions.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommitmentsAndContingentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommitmentsAndContingentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504075876496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_804_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_zzH19t1LvC16" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 18. <span id="xdx_82C_zelntueJkh14">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Investments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has entered into related party transactions and certain services
agreements with its investees.&#160; Key management personnel of the Company have also entered into related party transactions with investees.
Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities
of the Company. The Board, Chairman, Chief Executive Officer (the &#8220;CEO&#8221;) and Chief Financial Officer are key management personnel.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following subsidiaries and associates are considered related parties:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(a)</td><td><b>Stimunity</b>. The CEO of Portage is one of three members of the board of directors of Stimunity (see Note 6, &#8220;Investment
in Associate,&#8221; and Note 17, &#8220;Commitments and Contingent Liabilities &#8211; Stimunity Convertible Note&#8221;).</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(b)</td><td><b>iOx</b>. Upon the iOx Share Exchange on July 18, 2022, the non-Portage director resigned leaving two Portage insiders as directors.
The CEO of Portage is also the CEO of iOx, and the management team of Portage comprises the management team of iOx. See below for a discussion
of the Company&#8217;s purchase of the non-controlling interest in iOx.</td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(c)</td><td><b>Saugatuck</b>. One of the three directorships on the board of directors of Saugatuck is controlled by Portage. Additionally, the
CEO of Portage is also the CEO of Saugatuck, and the management team of Portage comprises the management team of Saugatuck.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(d)</td><td><b>Intensity</b>. The CEO of Portage is an officer of Intensity and from time to time, he provides consulting services to Intensity. The Company also sublets a portion of Intensity&#8217;s office space.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(e)</td><td><b>Portage Development Services Inc</b>. PDS is a 100% owned subsidiary incorporated in Delaware, which provides human resources and
other services to each operating subsidiary of Portage via a shared services agreement.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Transactions between the parent company and its subsidiaries, which are
related parties, have been eliminated in consolidation and are not disclosed in this note.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">On September 8, 2021,<span id="xdx_906_ecustom--IssuanceOfUnsecuredNotesDescriptions_c20210901__20210908__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember" title="Issuance of unsecured notes, description"> the&#160;Company,
through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for
23,772 ordinary shares of iOx at a price of &#163;162. Simultaneously, the Company entered into an agreement with OSI, the holder of
$0.15&#160;million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for&#160;820&#160;shares of iOx.
The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets
of IAS 39, &#8220;Financial Instruments: Recognition and Measurement,&#8221; and IFRIC 19, &#8220;Extinguishing Financial Liabilities
with Equity Instruments,&#8221; and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection
with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from&#160;60.49% to&#160;78.32%.</span></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Share Exchange Agreement &#8211; iOx</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 18, 2022, the Company and SalvaRx entered into a Share Exchange
Agreement (the &#8220;Share Exchange Agreement&#8221;) with each of the minority shareholders of iOx (the &#8220;Sellers&#8221;) resulting
in the acquisition of the outstanding non-controlling ownership interest (approximately 22%) of iOx, which is developing the iNKT agonist
platform. The Company followed IFRS 3, &#8220;Business Combinations,&#8221; and IAS 27, &#8220;Separate Financial Statements,&#8221; (which
substantially replaced IAS 3) to account for this transaction. The Company achieved control of iOx, as defined, on January 8, 2019 upon
the completion of the SalvaRx Acquisition. Further transactions whereby the parent entity acquires further equity interests from non-controlling
interests, or disposes of equity interests but without losing control, are accounted for as equity transactions (i.e., transactions with
owners in their capacity as owners). As such:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>the carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative interests
in the subsidiary;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>any difference between the amount by which the non-controlling interests is adjusted and the fair value of the consideration paid
or received is recognized directly in equity and attributed to the owners of the parent; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>there is no consequential adjustment to the carrying amount of goodwill, and no gain or loss is recognized in profit or loss.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company now owns the worldwide rights to its small molecule iNKT agonists,
including lead programs PORT-2 and PORT-3. Under the terms of the Share Exchange Agreement, each Seller sold to the Company, and the Company
acquired from each Seller, legal and beneficial ownership of the number of iOx shares held by each Seller, free and clear of any share
encumbrances, in exchange for the issuance in an aggregate of <span id="xdx_906_ecustom--PortageOrdinaryShares_c20220401__20221231_pdd" title="Portage ordinary shares">1,070,000</span> Portage ordinary shares to be allocated among the Sellers based
upon their relative ownership. As a result of the Share Exchange Agreement, the Company owns 100% of the issued and outstanding shares
of iOx.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">As additional consideration for the sale of the iOx
shares to the Company under the Share Exchange Agreement, the Sellers shall have the contingent right to receive additional shares (&#8220;Earnout
Shares&#8221;) from the Company having an aggregate value equal to $25 million calculated at the Per Share Earnout Price, as defined in
the Share Exchange Agreement, upon the achievement of certain milestones defined as the dosing of the first patient in a Phase 3 clinical
trial for either PORT-2 (IMM60 iNKT cell activator/agonist) or PORT-3 (PLGA-nanoparticle formulation of IMM60 combined with a NY-ESO-1
peptide vaccine). The Company shall have the option, in its sole and absolute discretion, to settle the Earnout Shares in cash. The Company
followed IFRS 3 and IAS 32, &#8220;Financial Instruments: Presentation,&#8221; to account for the fair value of the Earnout Shares. The
principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount
rate used. The fundamental principle of IAS 32 is that a financial instrument should be classified as either a financial liability or
an equity instrument according to the substance of the contract, not its legal form, and the definitions of financial liability and equity
instrument. A financial instrument is an equity instrument if, and only if, both conditions (a) and (b) below are met:</p>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(a)</td><td style="text-align: left">the instrument includes no contractual obligation to deliver cash or another financial asset to another entity,
and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(b)</td><td style="text-align: left">if the instrument will or may be settled in the issuer&#8217;s own equity instruments, it is either:</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 41.05pt"/><td style="width: 18pt">(i)</td><td style="text-align: left">a non-derivative that includes no contractual obligation for the issuer to deliver a variable number of its
own equity instruments; or</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 41.05pt"/><td style="width: 18pt">(ii)</td><td style="text-align: left">a derivative that will be settled only by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">When a derivative financial instrument gives one party a choice over how
it is settled (for instance, the issuer or the holder can choose settlement net in cash or by exchanging shares for cash), it is a financial
asset or a financial liability unless all of the settlement alternatives would result in it being an equity instrument. The financial
instrument includes the exclusive right of the Company to settle the obligation with cash or equity and, accordingly, accounted for the
fair value of the Earnout Shares as a non-current liability.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company recorded $5.478 million as the fair value estimate of the
Earnout Shares, which is reflected as deferred obligation - iOx milestone on the condensed consolidated balance sheet included herein.
The Company will determine the fair value of the Earnout Shares at each balance sheet date. Any change to the fair value will be recorded
in the Company&#8217;s statements of operations and other comprehensive income (loss). The Company recorded a (loss) from the change (increase)
in fair value of the liability of $0.144 million and $0.090 million for the three and nine months ended December 31, 2022, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Employment Agreements</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">PDS entered into a Services Agreement with our CEO effective December
15, 2021 (the &#8220;CEO Services Agreement&#8221;). The CEO Services Agreement provides that the CEO will receive a base salary of $<span id="xdx_90D_ecustom--BaseSalary_pn3n3_c20211201__20211215__ifrs-full--CounterpartiesAxis__custom--ChiefExecutiveOfficersMember_zRGHwqO8kGr5" title="Base Salary">618,000</span>,
plus cost-of-living increases. The CEO Services Agreement provides for annual increases based upon the review of the base salary by the
Board prior to the anniversary of the CEO Services Agreement provided that the annual increase cannot be less than the cost-of-living
increase. The CEO Services Agreement also provides that the CEO is eligible to receive an annual performance-based bonus targeted at 59%
of the applicable year&#8217;s base salary, which bonus is earned based on the achievement of performance targets, as determined annually
by the Board and communicated to the CEO in the first quarter of the year. Any annual bonus, to the extent earned, is to be paid no later
than March 15 of the following year. The CEO Services Agreement is for an initial term of three years, after which it will automatically
renew annually unless terminated in accordance with the CEO Services Agreement.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Under the CEO Services Agreement, the CEO may terminate his employment
with PDS at any time for Good Reason (as defined in the CEO Services Agreement). PDS may terminate the CEO&#8217;s employment immediately
upon his death, upon a period of disability or without Just Cause (as defined in the CEO Services Agreement). In the event that the CEO&#8217;s
employment is terminated due to his death or Disability (as defined in the CEO Services Agreement), for Good Reason or without Just Cause,
he will be entitled to accrued obligations (accrued unpaid portion of base salary, accrued unused vacation time and any unpaid expenses).
Additionally, he may be entitled to Severance Benefits (as defined in the CEO Services Agreement), which include his then current base
salary and the average of his annual bonus for the prior two completed performance years, paid over 12 monthly installments. Additionally,
the CEO will be entitled to life insurance benefits and medical and dental benefits for a period of 12 months at the same rate the CEO
and PDS shared such costs during his period of employment.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Additionally, all stock options (and any other unvested equity incentive
award) held by the CEO relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as defined
in the CEO Services Agreement), and the exercise period for such stock options will be increased by a period of two years from the Termination
Date.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">If the CEO&#8217;s employment by PDS is terminated by PDS or any successor
entity without Just Cause (not including termination by virtue of the CEO&#8217;s death or Disability) or by the CEO for Good Reason within
12 months following the effective date of a Change in Control (as defined in the CEO Services Agreement), then, in addition to paying
or providing the CEO with the Accrued Obligations (as defined in the CEO Services Agreement), the Company will provide the following Change
in Control Severance Benefits (as defined in the CEO Services Agreement):</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(1)</td><td>PDS will pay the base salary continuation benefit for 18 months;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(2)</td><td>PDS will pay the life insurance benefit for 18 months;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(3)</td><td>PDS will pay an additional amount equivalent to the CEO&#8217;s target annual bonus calculated using the bonus percentage for the
performance year in which the CEO&#8217;s termination occurs. This bonus will be paid in 12 equal installments commencing on the first
payroll date that is more than 60 days following the date of termination of the CEO&#8217;s employment, with the remaining installments
occurring on the first day of the month for the 11 months thereafter;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(4)</td><td>PDS will provide the CEO with continued medical and dental benefits, as described above, for 18 months; and</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(5)</td><td>All stock options (and any other unvested equity incentive award) held by the CEO relating to shares of the Company or its parent
will be deemed fully vested and exercisable on the Termination Date, as defined, and the exercise period for such stock options will be
increased by a period of two years from the Termination Date.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">PDS entered into services agreements (individually, an &#8220;Executive
Service Agreement,&#8221; and collectively, the &#8220;Executive Service Agreements&#8221;) with each of our five other senior officers
(individually, &#8220;Executive&#8221; and collectively, &#8220;Executives&#8221;), three of which are dated as of December 1, 2021, one
of which is dated December 15, 2021 and one of which is dated June 1, 2022. Each of the Executive Services Agreements provides for an
initial term of two years that is automatically renewed for one-year periods (except two of the Executive Services Agreement, which provides
for an initial term of one year and that is automatically renewed for one-year periods). The Executive Services Agreements initially provide
for annual base salaries ranging from $175,000 to $348,000 (pro-rated for services rendered) and annual bonus targets ranging from 30%
to 40%. They also provide for long-term incentives in the form of equity awards from time to time under the Portage Biotech Inc. Amended
and Restated 2021 Equity Incentive Plan.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Executive Services Agreements can be terminated by PDS without Just
Cause, by death or Disability, or by the Executive (except one) for Good Reason (each as defined in the respective Executive Services
Agreements). In such instances, the Executive Services Agreements provide for the payment of accrued obligations (accrued unpaid portion
of base salary, accrued unused vacation time and any unpaid expenses). Additionally, the Executives (except two) are entitled to 50% of
base salary plus 50% of average annual bonus earned over the prior two performance years, as well as prevailing life insurance benefits
for a period of six months and medical and dental benefits for a period of six months at the prevailing rate PDS and the Executive were
sharing such expenses.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Additionally, all stock options (and any other unvested equity incentive
award) held by the Executives relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as
defined in the respective Executive Services Agreements), and the exercise period for such stock options will be increased by a period
of two years from the Termination Date.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">If an Executive&#8217;s employment by PDS is terminated by the Company
or any successor entity without Just Cause (not including termination by virtue of the Executive&#8217;s death or Disability) or by the
Executive (except one) for Good Reason within 12 months following the effective date of a Change in Control (as defined in the respective
Executive Services Agreements), then, in addition to paying or providing the Executive with the Accrued Obligations (as defined in the
respective Executive Services Agreements), the Company will provide the following Change in Control Severance Benefits (as defined in
the respective Executive Services Agreements), except in two cases in which the Executive is entitled to Item (5) and 50% of Items (1)
and (3) below:</p>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(1)</td><td>PDS will pay the Base Salary continuation benefit for 12 months;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(2)</td><td>PDS will pay the life insurance benefit for 12 months;</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(3)</td><td>The Company will pay an additional amount equivalent to the Executive&#8217;s target annual bonus calculated using the bonus percentage
for the performance year in which the Executive&#8217;s termination occurs. This bonus will be payable in 12 equal installments commencing
on the first payroll date that is more than 60 days following the date of termination of the Executive&#8217;s employment, with the remaining
installments occurring on the first day of the month for the 11 months thereafter;</td></tr></table>

<p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(4)</td><td>PDS will provide the Executive with continued medical and dental benefits, as described above, for 12 months; and</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(5)</td><td>All stock options (and any other unvested equity incentive award) held by the Executive relating to shares of the Company or its parent
will be deemed fully vested and exercisable on the Termination Date and the exercise period for such stock options will be increased by
a period of two years from the Termination Date.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Executive Services Agreements also include customary confidentiality,
as well as provisions relating to assignment of inventions. The Executive Services Agreements also includes non-competition&#160;and non-solicitation&#160;of
employees and customers provision that run during the Executive&#8217;s employment with PDS and for a period of one year after termination
of employment.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt"><span style="background-color: white"><b><i>Bonuses &amp; Board Compensation Arrangements</i></b></span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">In December 2021, the Compensation
Committee approved performance bonuses payable to senior management totaling $0.7 million. The bonuses were paid in December 2021.</span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In addition, the Compensation Committee of the Board established director
compensation. Effective January 1, 2022, each non-executive Board member will be entitled to receive cash Board fees of $40,000 per annum,
payable quarterly in arrears. Additionally, each non-executive Board member will be entitled to an annual grant of 6,900 options to purchase
Portage ordinary shares, which would vest the first annual anniversary of the grant date. The Company incurred Board fees totaling $78,750
and $236,250 during the three and nine months ended December 31, 2022, respectively. There were no Board fees incurred during the three
and nine months ended December 31, 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Non-executive Board chairpersons will be entitled to an annual cash fee
of $30,000, payable quarterly in arrears. In lieu of a non-executive chairperson, the lead director will be entitled to an annual cash
fee of $20,000 per annum paid quarterly in arrears. <span id="xdx_904_ecustom--AnnualFeesdescription_c20220401__20221231" title="Annual feesDescription">Additionally, the chairperson of each of the Audit Committee, Compensation Committee
and Nomination Committee will be entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members
of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">In December 2022, the Board approved
executive performance bonuses, as recommended by the Compensation Committee, totaling $<span id="xdx_909_ecustom--CompensationCommittee_pn3n3_dm_c20211201__20211231_zw5XlaKU8Fw1" title="Compensation committee">0.6</span> million, which is equivalent to <span id="xdx_907_ecustom--OriginalAnnualTargetsPercentage_pid_dp_c20211201__20211231_zjUl9FS3SLM4" title="Original annual targets percentage">73.5</span>% of original
annual targets established by the Board in December 2021. The bonuses were approved based upon the original performance targets established.
The Board further approved a payment structure of 25% of approved bonuses, which were paid in January 2023, with the balance of amounts due
payable upon a new financing.</span></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052451040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Financial Instruments And Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</a></td>
<td class="text"><p id="xdx_80C_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zHeAhhXcGkL1" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 19. <span id="xdx_825_zUoLpSqffpN3">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s financial instruments recognized in the Company&#8217;s
condensed consolidated interim statements of financial position consist of the following:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Fair value estimates are made at a specific point in time, based on relevant
market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of
significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could significantly affect
these estimates.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table summarizes the Company&#8217;s financial instruments
as of December 31, 2022 and March 31, 2022:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory_pn3n3_zkPsGNEDvFN9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BE_zYUV3DrLCaR3" style="display: none">Schedule of financial instruments</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49C_20221231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zU75MA5YgBq3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49D_20221231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zaGOgs0d3Ou5" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_498_20220331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zhMnrMQ8D1Xf" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_490_20220331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z6TQFEmhz8f2" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value through Other Comprehensive <br/>Income (&#8220;FVTOCI&#8221;)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">13,104</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1806">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">23,352</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,786</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1,480</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1813">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ConvertibleNoteReceivableIncludingAccruedInterest_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Convertible note receivable, including accrued interest</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1815">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">642</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1817">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1818">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--CurrentInvestments_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Investments</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1820">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4,768</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1822">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9,082</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value through Profit or Loss (&#8220;FVTPL&#8221;)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,422</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1831">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">750</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1833">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--WarrantLiability_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1835">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1837">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">33</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredPurchasePricePayableTarus_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred purchase price payable - Tarus</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1840">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">8,876</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1842">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1843">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredObligationIoxMilestone_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred obligation - iOx milestone</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1845">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">5,568</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1847">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1848">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zHt4OUzsIO61" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">A summary of the Company&#8217;s risk exposures as it relates to financial
instruments are reflected below.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Fair value of Financial Instruments</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s financial assets and liabilities are comprised of
cash and cash equivalents, receivables and investments in equities and private entities, accounts payable, warrant liability and unsecured
notes payable.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company classifies the fair value of these transactions according
to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>Level 1 &#8211; Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of
the reporting date.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>Level 2 &#8211; Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which
can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of
the reporting date.</td></tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td>Level 3 &#8211; Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified
as Level 3 financial instrument.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Assessment of the significance of a particular input to the fair value
measurement requires judgment and may affect the placement within the fair value hierarchy.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Management has assessed that the fair values of cash and cash equivalents,
other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>





















<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following methods and assumptions were used to estimate their fair
values:</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt"><b>Convertible Note Receivable:</b> The fair
value of the Stimunity Convertible Note receivable denominated in euros at initial recognition is the transaction price for the instrument
adjusted for the effect of the currency translation rate on the reporting date (Level 3) (see Note 17, &#8220;Commitments and Contingent
Liabilities &#8211; Stimunity Convertible Note&#8221;). The Company recognized an unrealized gain through OCI on the change in fair value
of the Stimunity Convertible Note receivable of $<span id="xdx_906_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_pn3n3_dm_c20221001__20221231_z0tET2hILWu9" title="Convertible Note receivable"><span id="xdx_901_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_pn3n3_dm_c20220401__20221231_zLV0SqenCrFi" title="Convertible Note receivable">0.29</span></span> million for the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Investment in Intensity</b>: Fair value of the asset is determined
by considering other comparable equity funding transactions by Intensity with unrelated investors (Level 3).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Accrued Equity Issuable: </b>The fair value is estimated based on the
average of the quoted market prices for the period in which the shares were earned (Level 1).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Warrant Liability</b>: The fair value is estimated using a Black-Scholes
model (Level 3) (see Note 13, &#8220;Warrant Liability&#8221;).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Deferred Purchase Price Payable - Tarus:</b> The fair value is the
estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 at acquisition
date, adjusted at each reporting date for any change in fair value (Level 3) (see Note 8, &#8220;Acquisition of Tarus&#8221;). The fair
value was determined using the Income Approach and was based upon the analysis on the Tarus clinical plan, the timing of development events
and the probabilities of success determined primarily based upon empirical third party data and Company experience, as well as the relevant
cost of capital. The Company recorded a (loss) from the change (increase) in fair value of the liability of $0.354 million and $0.338
million for the three and nine months ended December 31, 2022, respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Deferred Obligation - iOx Milestone:</b> The fair value is the estimated
value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 as of July 18, 2022, the
date of the Share Exchange Agreement, adjusted at each reporting date for any change in fair value (Level 3) (see Note 18, &#8220;Related
Party Transactions &#8211; Share Exchange Agreement &#8211; iOx&#8221;). The fair value was determined using the Income Approach and based
on factors including the clinical plan, the timing of development events and the probabilities of success determined primarily based upon
empirical third party data and Company experience, as well as the relevant cost of capital. The Company recorded a (loss) from the change
(increase) in fair value of the liability of $0.144 million and $0.090 million for the three and nine months ended December 31, 2022,
respectively.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">There have been no transfers between levels of the fair value hierarchy
for the nine months ended December 31, 2022 and the year ended March 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s financial instruments are exposed to certain financial
risks: Credit Risk, Liquidity Risk and Foreign Currency Risk.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Credit Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Credit risk is the risk of loss associated with a counterparty&#8217;s
inability to fulfil its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&#8217;s condensed consolidated interim statements of financial position.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b><i>Cash and cash equivalents</i>.</b> Cash and cash equivalents comprise
cash on hand and on-demand deposits that are readily convertible to a known amount of cash with three months or less from date of acquisition
and are subject to an insignificant risk of change in value. <span style="background-color: white">As of December 31, 2022 and March&#160;31,
2022, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. </span>Cash
and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<p style="margin: 0pt 0; font-size: 10pt"><b><i>Liquidity Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Liquidity risk is the risk that the Company will encounter difficulty
in satisfying financial obligations as they become due.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company&#8217;s approach to managing liquidity is to ensure, as far
as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without
incurring unacceptable losses or risking harm to the Company&#8217;s reputation. The Company holds sufficient cash and cash equivalents
to satisfy obligations under accounts payable and accruals.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company monitors its liquidity position regularly to assess whether
it has the funds necessary to meet its operating needs and needs for investing in new projects. The Company believes that it has sufficient
funding to finance the committed drug development work, apart from meeting its operational needs for the foreseeable future.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">However, as a biotech company at an early stage of development and without
significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may
not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty in global
markets could have an impact on the Company&#8217;s future ability to access capital on terms that are acceptable to the Company. There
can be no assurance that required financing will be available to the Company. See Note 2, &#8220;Liquidity,&#8221; and Note 14, &#8220;Capital
Stock,&#8221; for a discussion of the Company&#8217;s share offering and Note 17, &#8220;Commitments and Contingent Liabilities &#8211;
Committed Purchase Agreement,&#8221; for a further discussion.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Foreign Currency Risk</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">While the Company operates in various jurisdictions, substantially all
of the Company&#8217;s transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K. settleable
in British pound sterling and the Stimunity Convertible Note receivable settleable in euros.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052451168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL DISCLOSURES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalDisclosuresAbstract', window );"><strong>Capital Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock', window );">CAPITAL DISCLOSURES</a></td>
<td class="text"><p id="xdx_800_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zXA5IydAGrll" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 20. <span id="xdx_823_z3POdxHUjoX6">CAPITAL DISCLOSURES</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company considers the items included in shareholders&#8217; equity
as capital. The Company had accounts payable and accrued expenses of approximately $<span id="xdx_901_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20221231_zTE3RNb79J38" title="Payables and accrued expenses">2.4</span> million as of December 31, 2022 (approximately
$<span id="xdx_901_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20220331_zNdMM54oPht9" title="Payables and accrued expenses">0.8</span> million as of March 31, 2022) and current assets of approximately $<span id="xdx_90D_ecustom--CurrentAsset_iI_pn3n3_dm_c20221231_zcwy1LaiWpji" title="Current assets">15.5</span> million as of December 31, 2022 (approximately $<span id="xdx_90A_ecustom--CurrentAsset_iI_pn3n3_dm_c20220331_z7uNPnmhUs7k" title="Current assets">24.8</span> million
as of March 31, 2022). The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as
a going concern in order to pursue new business opportunities and to maintain a flexible capital structure, which optimizes the costs
of capital at an acceptable risk.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company manages the capital structure and makes adjustments to it
in light of changes in economic conditions and the risk characteristics of the underlying assets.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of December 31, 2022, shareholders&#8217; equity attributable to the
owners of the company was approximately $<span id="xdx_907_ecustom--ShareholdersEquityAttributableToOwners_iI_pn3n3_dm_c20221231_zP1xQNhI5ZAi" title="Shareholders' equity attributable to owners">168.9</span> million (approximately $<span id="xdx_906_ecustom--ShareholdersEquityAttributableToOwners_iI_pn3n3_dm_c20220331_zIi6QIux48F7" title="Shareholders' equity attributable to owners">121.2</span> million as of March 31, 2022).</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company is not subject to any externally imposed capital requirements
and does not presently utilize any quantitative measures to monitor its capital. There have been no changes to the Company&#8217;s approach
to capital management during the nine months ended December 31, 2022 and 2021.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in">&#160;</p>

















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052451168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NonControllingInterestAbstract', window );"><strong>Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory', window );">NON-CONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_806_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zA3wDJi97AOb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 21. <span id="xdx_82B_zUOrNJSrF3lb">NON-CONTROLLING INTEREST</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zRGrdWEf3B7h" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BF_zVq12XLVJqTb" style="display: none">Schedule of non-controlling interest</span></td><td style="text-align: justify; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Saugatuck <br/>and subsidiary</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2022</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zi826xxTHcmi" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">44,701</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_987_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zcB6nOkdtrF7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">(472</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231_zSGjEDkZJcNh" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">44,229</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net income (loss) attributable to non-controlling interest</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest">123</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest">(171</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest">(48</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10.1pt; padding-left: 10.1pt">Purchase of non-controlling interest pursuant to Share Exchange Agreement</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement">(44,824</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_znTeJD3WhW9b" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement"><span style="-sec-ix-hidden: xdx2ixbrl1911">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_c20220401__20221231_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement">(44,824</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zJYgGcTc8Sde" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"><span style="-sec-ix-hidden: xdx2ixbrl1915">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zXgu9h5zKWXl" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(643</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231_zmjnE3OGUW6c" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(643</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Saugatuck</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2021</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_znGz0pDUXvv5" style="width: 12%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">46,173</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zfH9IGdM7bga" style="width: 12%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(20</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20211231_zLltgmqhsQe" style="width: 12%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">46,153</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockBasedCompensationExpense_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense">191</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--StockBasedCompensationExpense_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_ztUsR3nx9MW9" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1929">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--StockBasedCompensationExpense_c20210401__20211231_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense">191</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Exchange of notes payable, accrued interest and warrants for iOx shares</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="font-size: 10pt; text-align: right" title="Exchange of notes payable, accrued interest and warrants for iOx shares">184</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z2PV9oZZPGq9" style="font-size: 10pt; text-align: right" title="Exchange of notes payable, accrued interest and warrants for iOx shares"><span style="-sec-ix-hidden: xdx2ixbrl1935">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_c20210401__20211231_pn3n3" style="font-size: 10pt; text-align: right" title="Exchange of notes payable, accrued interest and warrants for iOx shares">184</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net (loss) attributable to non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zsChvEIh4Icb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest">(436</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4FliM9yUwhh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest">(317</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20210401__20211231_zfCSQxIM3t4d" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest">(753</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of December 31, 2021</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zXvFxENmVmv8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">46,112</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zsXn4HSX4BB6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">(337</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20211231_zxNbtgVdx5si" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">45,775</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On September 8, 2021, the Company, through SalvaRx, completed a settlement
of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price
of &#163;162. On July 18, 2022, the Company completed the acquisition of the remaining non-controlling interest in iOx, by issuing 1,070,000
shares of its ordinary shares and assuming certain milestone obligations. See Note 11, &#8220;Unsecured Notes Payable &#8211; iOx Unsecured
Notes Payable,&#8221; and <span style="background-color: white">Note 18, &#8220;Related Party Transactions &#8211; Share Exchange Agreement
&#8211; iOx,</span>&#8221; for further discussions.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary,
Saugatuck Rx LLC.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interests in other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 1<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_1&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NonControllingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NonControllingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052460640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EVENT AFTER THE BALANCE SHEET DATE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EventAfterTheBalanceSheetDateAbstract', window );"><strong>Event After Balance Sheet Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock', window );">EVENT AFTER THE BALANCE SHEET DATE</a></td>
<td class="text"><p id="xdx_803_ecustom--DisclosureOfEventAfterBalanceSheetDateTextBlock_z9cCKRCqRHD4" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 22. <span id="xdx_82B_zNbVwecrtfSh">EVENT AFTER THE BALANCE SHEET DATE</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>Sale of Ordinary Shares</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In January and February 2023, the Company continued its share offering
pursuant to the ATM and the Committed Purchase Agreement. From January 1, 2023 through February 24, 2023, the Company sold <span id="xdx_907_ecustom--NumberOfSharesSold_pid_c20230101__20230131__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zfpLAOrWMbv7" title="Number of shares sold">63,279</span> ordinary
shares under the ATM and generated net proceeds of approximately $<span id="xdx_90B_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20230101__20230131__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zNbxqAktnkdc" title="Net proceeds from sale">0.3</span> million and sold <span id="xdx_905_ecustom--NumberOfSharesSold_pid_c20230201__20230228__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zJfZCVnu0EHl" title="Number of shares sold">270,000</span> ordinary shares under the Committed Purchase
Agreement for net proceeds totaling approximately $<span id="xdx_90D_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20230201__20230228__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zpwzn6MaLWfd" title="Net proceeds from sale">1.3</span> million.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_EventAfterTheBalanceSheetDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_EventAfterTheBalanceSheetDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504053030336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zWCyteK9gkH4" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_86F_zboD0Nhcx4Bf">Recent Accounting Pronouncements</span></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>IFRS Pronouncements Issued</i></b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>Impact of Adoption of Significant New IFRS Standards in 2022</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(a)</b></td><td><b>Annual Improvements to IFRS Standards 2018-2020</b></td></tr></table>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The annual improvements process addresses issues in the 2018-2020 reporting
cycles including changes to IFRS 9, &#8220;Financial Instruments,&#8221; IFRS 1, &#8220;First Time Adoption of IFRS,&#8221; IFRS 16, &#8220;Leases,&#8221;
and IAS 41, &#8220;Biological Assets&#8221;.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right">i)</td><td style="width: 5pt"/><td style="text-align: justify">The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition
of financial liabilities.</td>
</tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right">ii)</td><td style="width: 5pt"/><td style="text-align: justify">The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent
to also measure cumulative translation differences using the amounts reported by the parent based on the parent&#8217;s date of transition
to IFRS.</td>
</tr></table>

<p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right">iii)</td><td style="width: 5pt"/><td style="text-align: justify">The amendment to IFRS 16&#8217;s illustrative example 13 removes the illustration of payments
from the lessor related to leasehold improvements.</td>
</tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These amendments were effective for annual periods beginning on or after
January 1, 2022. The adoption of these amendments did not have a material effect on the Company&#8217;s annual consolidated financial
statements or the condensed consolidated interim financial statements for the three and nine months ended December 31, 2022.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>





















<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(b)</b></td><td><b>IAS 37: Onerous Contracts &#8211; Cost of Fulfilling a Contract</b></td></tr></table>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 37 clarifies the meaning of costs to fulfil a contract
and that before a separate provision for an onerous contract is established, an entity recognizes any impairment loss that has occurred
on assets used in fulfilling the contract, rather than on assets dedicated to the contract. This amendment is effective for annual periods
beginning January 1, 2022. The Company&#8217;s adoption of IAS 37 did not have a material effect on its consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(c)</b></td><td><b>IAS 16: Proceeds Before Intended Use</b></td></tr></table>

<p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 16 prohibits an entity from deducting from the cost
of an item of property, plant and equipment any proceeds received from selling items produced while the entity is preparing the assets
for its intended use (for example, the proceeds from selling samples produced when testing a machine to see if it is functioning properly).
It also clarifies that an entity is testing whether the asset is functioning properly when it assesses the technical and physical performance
of the asset. The amendment also requires certain related disclosures. This amendment is effective for annual periods beginning January
1, 2022. The Company&#8217;s adoption of IAS 16 did not have a material effect on its consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>New Accounting Standards, Interpretations and Amendments</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Standards issued but not yet effective up to the date of issuance of the
Company&#8217;s condensed consolidated interim financial statements are listed below. This listing is of standards and interpretations
issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they
become effective.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(a)</b></td><td><b>IAS 1: Presentation of Financial Statements</b></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 1 clarifies how to classify debt and other liabilities
as either current or non-current. The amendment is effective for annual periods beginning on or after January 1, 2023. The Company is
currently evaluating the new guidance and impacts on its consolidated financial statements.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(b)</b></td><td><b>Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture</b></td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white">The amendment addresses the conflict between
IFRS 10, &#8220;Consolidated Financial Statements,&#8221; and IAS 28, &#8220;Investments in Associates and Joint Ventures,&#8221; in dealing
with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the
gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, &#8220;Business Combinations,&#8221;
between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution
of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors&#8217; interests in the
associate or joint venture. On September 11, 2014, the IASB issued narrow-scope amendments to IFRS 10&#160;and IAS 28. The amendments
were to be effective for annual periods commencing on or after January 1, 2016. In December 2015, the IASB decided to postpone the effective
date of these amendments indefinitely.</p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>

















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052918144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Prepaid Expenses And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock', window );">Schedule of prepaid expenses and other receivables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z9FYDvDSJNyd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B1_zeFC0uRP9RAd" style="display: none">Schedule of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49E_20221231_zLbLLnAjUTwa" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_495_20220331_zSSOlg8LFVxk" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of<br/> December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of<br/> March 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_pn3n3_z8Qszzkcd9Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Prepaid clinical research costs</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">1,286</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPzymm_z4uAeSWIsJm7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid insurance</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">164</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1,084</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3_maCPzymm_zWNuB5Koc7ie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Research &amp; development tax credits</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">169</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">169</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--TaxDeposits_iI_pn3n3_maCPzymm_zOtl5uuWIh23" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax deposits</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">119</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">142</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPzymm_z4IwR0DtZmHj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other prepaid expenses</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">33</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">45</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPzymm_z6KVymZaNuxh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">15</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">40</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPzymm_zDi4bRBk7t6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1,786</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,480</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052834048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN ASSOCIATE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InvestmentInAssociateAbstract', window );"><strong>Investment In Associate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfInvestmentAssociatetableTextBlock', window );">Schedule of investment associate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_pn3n3_zxPQaOlhb0Y8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_8B6_zONU6GDdLls9" style="display: none">Schedule of investment associate</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Name</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Principal Activity</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Place of Incorporation and <br/>Principal Place of Business</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Voting Rights Held as <br/>of December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Voting Rights Held as <br/>of March&#160;31, 2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-size: 10pt; text-align: center"><span id="xdx_906_eifrs-full--NameOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Name of associate">Associate: Stimunity S.A.</span></td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_907_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Principal place of business of associate">Biotechnology</span></td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90E_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Country of incorporation of associate">Paris, France</span></td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_908_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zs0v3uXnDvp" title="Proportion of voting rights held in associate">44.0</span>%</td><td style="text-align: center; width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_907_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20210401__20220331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zICLOKswsrxa" title="Proportion of voting rights held in associate">44.0</span>%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock', window );">Schedule of investment in Stimunity S.A.</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_zMYY2OvtWdm6" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B9_z2HYPQOUacGg" style="display: none">Schedule of investment in Stimunity S.A.</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">As of and for the</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Nine Months Ended December 31,</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20220401__20221231_zRDqryHTVI5j" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance">1,673</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20210401__20211231_zTQ1g6GD1uJf" style="width: 12%; font-size: 10pt; text-align: right" title="Beginning balance">1,735</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Share of (loss)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20220401__20221231_zDPvdJCnrqbd" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share of (loss)">(268</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20210401__20211231_zOSJCsuv8Ma3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share of (loss)">(363</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20220401__20221231_zGJq8kXDNG3k" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending  balance">1,405</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20210401__20211231_znG1sFoL91qi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending  balance">1,372</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfInvestmentAssociatetableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfInvestmentAssociatetableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentInAssociateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentInAssociateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049023088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF TARUS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AcquisitionOfTarusAbstract', window );"><strong>Acquisition Of Tarus</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of fair value of assets acquired and liabilities assumed</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_pn3n3_zcgJpov2ptab" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold"><span id="xdx_8B6_zBnEjiGJsVLb" style="display: none">Schedule of fair value of assets acquired and liabilities assumed</span></td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" id="xdx_499_20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zRfIBNUBk5Xj" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--AssetsAbstract_iB" style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">Assets:</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">(In thousands)</td></tr>
  <tr id="xdx_40F_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left">Identifiable intangible assets</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">28,200</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--Goodwill_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Goodwill</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--OtherTangibleOrIntangibleAssetsTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">28,738</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Consideration:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Fair value of shares issued</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">17,200</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities assumed</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,000</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred purchase consideration at fair value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">8,538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ContingentLiabilitiesRecognisedInBusinessCombination_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">28,738</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfProformaInformationTableTextBlock', window );">Schedule of pro forma information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfProformaInformationTableTextBlock_pn3n3_z7CpBwzy6t86" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_zWRu7EqIHft5" style="display: none">Schedule of pro forma information</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eifrs-full--ProfitLossFromContinuingOperations_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Loss from operations">(12,200</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eifrs-full--ProfitLossFromContinuingOperations_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Loss from operations">(13,431</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss before provision for income taxes</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_983_eifrs-full--ProfitLossBeforeTax_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss before provision for income taxes">(12,833</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_985_eifrs-full--ProfitLossBeforeTax_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss before provision for income taxes">(13,110</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_985_eifrs-full--ProfitLoss_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net loss and other comprehensive loss">(9,927</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_983_eifrs-full--ProfitLoss_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Net loss and other comprehensive loss">(12,645</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total comprehensive loss for period</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--ComprehensiveIncome_pn3n3_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zmKaplj5POOe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total comprehensive loss for period">(13,945</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_981_eifrs-full--ComprehensiveIncome_pn3n3_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zaB8v3M1mJRf" style="font-size: 10pt; text-align: right" title="Total comprehensive loss for period">(12,645</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Loss per share</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--EarningLossPerShare_pid_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zJqemgtaRjoh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss per share">(0.60</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--EarningLossPerShare_pid_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zk2Ts7F4UjDc" style="font-size: 10pt; text-align: right" title="Loss per share">(0.77</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Summary unaudited pro forma condensed
results of operations for the three months ended December 31, 2022 and 2021, assuming the Tarus acquisition had occurred at the beginning
of the earliest period presented, are as follows:</span></p>

<p style="margin: 0pt 0; font-size: 10pt"><b>&#160;</b></p>





















<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Three Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>2022 <sup>(1)</sup></b></span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eifrs-full--ProfitLossFromContinuingOperations_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zHdfLCzdC7T3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Loss from operations">(4,759</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eifrs-full--ProfitLossFromContinuingOperations_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Loss from operations">(4,362</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss before provision for income taxes</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--ProfitLossBeforeTax_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zRs6TI3yaLDl" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss before provision for income taxes">(5,302</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_986_eifrs-full--ProfitLossBeforeTax_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss before provision for income taxes">(4,281</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_eifrs-full--ProfitLoss_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zquh5ZicSRXe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net loss and other comprehensive loss">(7,501</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_980_eifrs-full--ProfitLoss_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Net loss and other comprehensive loss">(4,398</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total comprehensive loss for year</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eifrs-full--ComprehensiveIncome_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zov2r2vGJ3K7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total comprehensive loss for year">(11,518</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eifrs-full--ComprehensiveIncome_pn3n3_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zfzxq4miensg" style="font-size: 10pt; text-align: right" title="Total comprehensive loss for year">(4,398</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Loss per share</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--EarningLossPerShare_pid_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_z5cPInowNzre" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss per share">(0.44</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--EarningLossPerShare_pid_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zqNUVTjSNvR5" style="font-size: 10pt; text-align: right" title="Loss per share">(0.23</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><b><sup id="xdx_F05_zcAeLhLmlou">(1)</sup></b></td><td><span id="xdx_F10_zVMEtrMNyV8a" style="background-color: white">Includes the results of operations of Tarus for the period and, accordingly, there are no pro
forma adjustments for the three months ended December 31, 2022.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AcquisitionOfTarusAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AcquisitionOfTarusAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfProformaInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfProformaInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052862080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GoodwillAbstract', window );"><strong>Goodwill Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory', window );">Schedule of IPR&amp;D projects</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_pn3n3_zLudUd1v9bSd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - GOODWILL (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B4_zbIemXnbfJ7d" style="display: none">Schedule of IPR&amp;D projects</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>As of</b></p> <p style="margin: 0pt 0; font-size: 10pt; text-align: center"><b>December 31, 2022</b></p></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of <br/>March 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_eifrs-full--Goodwill_iS_pn3n3_c20220401__20221231_zKF2Isk5FSS7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period">43,324</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--Goodwill_iS_pn3n3_c20210401__20220331_znVRzPGwTWZi" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, beginning of period">43,324</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Tarus goodwill</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--TarusGoodwill_pn3n3_c20220401__20221231_zBDPxH24xyQ8" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Tarus goodwill">538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--TarusGoodwill_pn3n3_c20210401__20220331_znfWoPq6WaWl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Tarus goodwill"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_eifrs-full--Goodwill_iE_pn3n3_c20220401__20221231_zBDVkEbbyoea" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, ending of period">43,862</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--Goodwill_iE_pn3n3_c20210401__20220331_zU9JFoExOgSk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, ending of period">43,324</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504053127104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract', window );"><strong>In-process Research And Development And Deferred Tax Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock', window );">Schedule of In process research and development</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_pn3n3_zHScnRDnlYbb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BD_zbI1Fmg1K1Zd" style="display: none">Schedule of In process research and development</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Project #</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Description</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Value as of <br/>December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Value as of <br/>March 31, 2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">iOx:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 25%; font-size: 10pt">PORT 2 (IMM60)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 24%; font-size: 10pt; text-align: left">Melanoma &amp; Lung Cancers</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_pn3n3" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">84,213</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_pn3n3" style="width: 22%; font-size: 10pt; text-align: right" title="In-process research and development">84,213</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">PORT 3 (IMM65)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Ovarian/Prostate Cancers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">32,997</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">32,997</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">117,210</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">117,210</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Oncomer/Saugatuck</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">DNA Aptamers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">178</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">178</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Tarus:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">PORT 6 &amp; PORT 7</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">27,138</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_zxIggqMDOTqb" style="font-size: 10pt; text-align: right" title="In-process research and development"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">PORT 8</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">500</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_z2UTe8vC2o1h" style="font-size: 10pt; text-align: right" title="In-process research and development"><span style="-sec-ix-hidden: xdx2ixbrl1003">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">PORT 9</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">562</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_zc1SfRt7Efih" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"><span style="-sec-ix-hidden: xdx2ixbrl1007">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">28,200</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusMember_zF69TNYjLoka" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"><span style="-sec-ix-hidden: xdx2ixbrl1011">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">In-process research and development</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">145,588</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331_zXEtNRf72jZi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="In-process research and development">117,388</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Deferred tax liability</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--DeferredTaxesLiability_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Deferred tax liability">28,409</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_985_ecustom--DeferredTaxesLiability_iI_pn3n3_c20220331_zy2OYFg0dPOl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax liability">30,198</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504075862848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNSECURED NOTES PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnsecuredNotesPayableAbstract', window );"><strong>Unsecured Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfNotesPayableTableTextBlock', window );">Schedule of notes payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfNotesPayableTableTextBlock_pn3n3_zeWFs1sHNQe9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - UNSECURED NOTES PAYABLE (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B6_zA0fi5D1dvOj" style="display: none">Schedule of notes payable</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt">Balance, April 1, 2021</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--NotePayable_iS_pn3n3_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zestGKdqCeS9" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">150</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--NotePayable_iS_pn3n3_c20210401__20220331_zfs96051DQC9" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">150</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Exchange of notes payable and accrued interest for iOx shares</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zhbajFJGiK68" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares">(150</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20210401__20220331_z5sKKS9dM8D" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares">(150</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, March 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_985_ecustom--NotePayable_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zotCZUI590z6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="-sec-ix-hidden: xdx2ixbrl1056">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--NotePayable_iE_pn3n3_c20220401__20221231_z3hA9dz5u2b5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; font-size: 10pt; font-weight: bold">Exchange of notes payable and accrued interest for iOx shares</td><td style="display: none; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="display: none; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zOU9l9CUtJ2a" style="display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares">(150)</td><td style="display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="display: none; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="display: none; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20220401__20221231_z4iu4zFeibZ1" style="display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares">(150)</td><td style="display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98D_ecustom--NotePayable_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zCQQK7FxQfHb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--NotePayable_iE_pn3n3_c20220401__20221231_zlxI21CXaGN8" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="-sec-ix-hidden: xdx2ixbrl1066">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfNotesPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfNotesPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnsecuredNotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnsecuredNotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049952944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeTaxesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock', window );">Schedule of income taxes benefit</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zWnMyD12RJkk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-left: 10pt"><span id="xdx_8BE_zLsQxoQ5ljE1" style="display: none">Schedule of income taxes benefit</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49F_20220401__20221231_zsmYLl3pLi1f" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20210401__20211231_zbPTKMiKUAMi" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Current:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CurrentFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-left: 10pt">Federal</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1087">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--CurrentStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">State and local</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(16</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--CurrentForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(8</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--CurrentTaxExpenseIncome_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(24</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Deferred:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-left: 10pt">Federal</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">State and local</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1105">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,930</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">444</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--AdjustmentsForDeferredTaxExpense_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total deferred</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,930</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">444</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_pn3n3_di_zUIk1Gkzq7kb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Benefit from income taxes</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,906</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">465</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock', window );">Schedule of reconciliation income tax rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_zvtghDqeHZw7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BD_zovpDafCwnr3" style="display: none">Schedule of reconciliation income tax rates</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Income (loss) on ordinary activities before tax</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_983_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_pn3n3_c20220401__20221231_zeTzaA6AKANg" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Income (loss) on ordinary activities before tax">(1,230</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98F_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_pn3n3_c20210401__20211231_zNKCMsniQEhf" style="width: 12%; font-size: 10pt; text-align: right" title="Income (loss) on ordinary activities before tax">(1,535</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Statutory U.S. income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_c20220401__20221231_zz7uNLmimiCb" title="Statutory U.S. income tax rate">21.0</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_903_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_c20210401__20211231_z5NAJwlcIL14" title="Statutory U.S. income tax rate">21.0</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Income tax benefit at statutory income tax rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--LossAtStatutoryIncomeTaxRate_c20220401__20221231_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Income tax at statutory income tax rate">258</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--LossAtStatutoryIncomeTaxRate_pn3n3_c20210401__20211231_zoj1uUZp0jMf" style="font-size: 10pt; text-align: right" title="Income tax at statutory income tax rate">322</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Losses recognized (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--LossesRecognized_c20220401__20221231_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Losses recognized">(282</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--LossesRecognized_pn3n3_c20210401__20211231_zCB3y6lDVIb4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Losses recognized">(322</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--IncomeTaxBenefitExpense_pn3n3_c20220401__20221231_zGV70la4s5Wf" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Income tax benefit (expense)">(24</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_ecustom--IncomeTaxBenefitExpense_pn3n3_c20210401__20211231_zBDa7Nvj8unf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Income tax benefit (expense)"><span style="-sec-ix-hidden: xdx2ixbrl1136">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfIncomeTaxExplanatory', window );">Schedule of effective income tax rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfIncomeTaxExplanatory_pn3n3_zOoMLX3dTjW" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span id="xdx_8B6_zzrxDOTPC8B4" style="display: none">&#160;Schedule of effective income tax rates</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20220401__20221231_zGqL2JUpbj8l" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20210401__20211231_zc4rKzHsfoEj" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr id="xdx_405_eifrs-full--AccountingProfit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Loss on ordinary activities before tax</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">4,567</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">2,434</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--ApplicableTaxRate_pid_dp_zeIav8WAqTy7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Statutory U.K. income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">19.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr>
  <tr id="xdx_402_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss at statutory income tax rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">868</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">462</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ChangeIncreaseInDeferredIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Change (increase) in deferred income tax rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">274</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ForeignCurrencyEffect_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Foreign currency effect</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,788</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">444</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--TaxEffectOfRAndDCredit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Research and development credit</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">21</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LossesUnrecognized_z2xpuyn4xRJ8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Losses (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(462</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--TaxEffectOfTaxLosses_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax benefit</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,930</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">465</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock', window );">Schedule of reconciliation of financial statement loss to tax basis loss</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock_pn3n3_z7IndVRdypqi" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BB_zrbbSQ2pe0bb" style="display: none">Schedule of reconciliation of financial statement loss to tax basis loss</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_499_20221231__dei--LegalEntityAxis__custom--UnitedStateMember_zxhjDvg6vdHd" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_490_20221231__dei--LegalEntityAxis__custom--BVIMember_zEPsYCKTKG32" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_491_20221231__dei--LegalEntityAxis__custom--ForeignMember_zuwCe5t6y37j" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_492_20221231_zHUbR7WxIEu8" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20211231__dei--LegalEntityAxis__custom--UnitedStateMember_z3TDGnFn1xW9" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_498_20211231__dei--LegalEntityAxis__custom--BVIMember_zYzlxStAIMJ9" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20211231__dei--LegalEntityAxis__custom--ForeignMember_zZquenW5xqSi" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_495_20211231_z7gJsOYoit1f" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31, 2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>States</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">BVI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>Kingdom</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>States</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">BVI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PretaxIncomeLoss_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-size: 10pt; font-weight: bold; text-align: left">Pre-tax loss</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(1,230</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(7,320</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(4,567</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(13,117</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(1,535</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(6,802</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(2,434</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(10,771</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--LossForWhichNoBenefitWasTaken_pn3n3_z4kVYIP7k9b5" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss for which no benefit was taken</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,622</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1193">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,622</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1197">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1198">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LossesNotSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Losses not subject to tax</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1201">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">7,320</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">7,320</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1205">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,802</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1207">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">6,802</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Utilization of losses not previously benefitted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(314</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(314</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1214">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1217">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PretaxLossSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Taxable income (loss)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">78</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(4,567</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(4,489</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,535</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1224">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,434</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,969</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfDeferredTaxAssetsExplanatory', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfDeferredTaxAssetsExplanatory_pn3n3_zE4USusoNe38" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B9_z7JyF3riiBA2" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_496_20221231_zlDcuXrMBvSk" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20220331_z48oVMtUAIPf" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31,</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzWJe_z6TrbHwZwXx7" style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Net operating loss</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(4,394</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(3,253</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetUnrecognized_i01I_pn3n3_maNDTAzWJe_zYp0TC44lH8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax asset (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,500</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,500</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--NetDeferredTaxAssets_iTI_pn3n3_mtNDTAzWJe_z3zoecpXzh76" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax asset</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(2,894</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,753</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxLiabiltiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred tax liabilities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxLiabilitiesInProcessRAndD_i01I_pn3n3_maDTLzCvC_zibvpvnpmh92" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">In-process research and development</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">28,409</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,198</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxLiability1_iTI_pn3n3_mtDTLzCvC_zbQ6HykEfA9f" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">28,409</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">30,198</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--NetDeferredTaxLiabilities_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">25,515</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">28,445</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfDeferredTaxAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfDeferredTaxAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504053033040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfWarrantLiabilityTableTextBlock', window );">Schedule of warrant liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_pn3n3_zxcB3wcLeByb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BF_zQgm2v6c02Gc" style="display: none">Schedule of warrant liability</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">PBI</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Warrants</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Warrants outstanding, April 1, 2022</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsOutstandingExercisePrice_iS_pid_c20220401__20221231_zQbIg6yikcg4" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at beginning">6.64</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--WarrantsOutstandingShares_iS_pid_c20220401__20221231_zIoaa2z7ywMj" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at beginning">33,888</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--WarrantsOutstandingAmount_iS_pn3n3_c20220401__20221231_zaaQ4g8NQj4k" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at beginning">33</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Fair value adjustment as of December 31, 2022 (1)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--FairValueAdjustmentExercisePriceAtEnd_pid_c20220401__20221231_zAJdKDhAkp2e" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment , exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1295">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueAdjustmentShares_pid_c20220401__20221231_zgFdc2AUkvu5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, shares">(33,888</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--FairValueAdjustmentAmount_pn3n3_c20220401__20221231_zDEv3jQWO052" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, amount">(33</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants outstanding, December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_ecustom--WarrantsOutstandingExercisePrice_iE_pid_c20220401__20221231_zEaPgWvmIgmh" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at ending"><span style="-sec-ix-hidden: xdx2ixbrl1301">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--WarrantsOutstandingShares_iE_pid_c20220401__20221231_zMTJlKzObOkb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at ending"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_ecustom--WarrantsOutstandingAmount_iE_pn3n3_c20220401__20221231_zOTXaB6KFa2k" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at ending"><span style="-sec-ix-hidden: xdx2ixbrl1305">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(1)</td><td>The Company recognized a gain of $<span id="xdx_904_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20221001__20221231_zr8knCLfZCT6" title="Gain (loss) of change in fair value of warrants">0.001</span> million and $<span id="xdx_906_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20220401__20221231_zPoJT2wsQ1zd" title="Gain (loss) of change in fair value of warrants">0.033</span> million in the three and nine months ended December 31, 2022, respectively,
to reflect the change in fair value of the underlying warrants. The Company recognized a gain of $<span id="xdx_90B_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20211001__20211231_zvqu1A8VguE3" title="Gain (loss) of change in fair value of warrants">0.342</span> million and $<span id="xdx_905_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20210401__20211231_zS7MXaJrKphk" title="Gain (loss) of change in fair value of warrants">0.726</span> million in
the three and nine months ended December 31, 2021, respectively, to reflect the change in fair value of the underlying warrants. The warrants
expired in October 2022 unexercised.</td></tr></table>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052540816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalStockAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock', window );">Common shares: Unlimited number of common shares without par value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_zzVIVgdj9y0h" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8BF_zrNZHUUfoUO2" style="display: none">Common shares: Unlimited number of common shares without par value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary<br/> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary <br/> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000&#8217;$</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CommonStockShares_iS_pn3n3_c20220401__20221231_zfp2FkaXBDLf" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares">13,349</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--CommonStockValues_iS_pn3n3_c20220401__20221231_zTy7JC62NNGb" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">158,324</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--CommonStockShares_iS_pn3n3_c20210401__20211231_zHynUDgOFYFe" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, Shares">12,084</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--CommonStockValues_iS_pn3n3_c20210401__20211231_zeGlHTVH4o2b" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">130,649</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued in Tarus acquisition</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20220401__20221231_zo8EvsEc7O5i" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in Tarus acquisition, shares">2,426</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--AcquisitionsThroughBusinessCombinationsOtherProvisions_pn3n3_c20220401__20221231_z7EL8FH1Fvud" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in Tarus acquisition">17,200</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20210401__20211231_zpkgXx9v4htb" style="font-size: 10pt; text-align: right" title="Shares issued in Tarus acquisition, shares"><span style="-sec-ix-hidden: xdx2ixbrl1331">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--AcquisitionsThroughBusinessCombinationsOtherProvisions_pn3n3_c20210401__20211231_zh0xHGyYSfmi" style="font-size: 10pt; text-align: right" title="Shares issued in Tarus acquisition"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued in iOx exchange</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuedInIoxExchangesShares_pn3n3_c20220401__20221231_zjnikFrYhKc8" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in iOx exchange, shares">1,070</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareIssuedInIoxExchange_pn3n3_c20220401__20221231_z2J5nt8zQGVe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in iOx exchange">9,737</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--SharesIssuedInIoxExchangesShares_pn3n3_c20210401__20211231_zmifDxtU3LEa" style="font-size: 10pt; text-align: right" title="Shares issued in iOx exchange, shares"><span style="-sec-ix-hidden: xdx2ixbrl1339">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareIssuedInIoxExchange_pn3n3_c20210401__20211231_ztcNjF12a95l" style="font-size: 10pt; text-align: right" title="Shares issued in iOx exchange"><span style="-sec-ix-hidden: xdx2ixbrl1341">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Excess of non-controlling interest acquired over consideration &#8211; iOx</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_pn3n3_c20220401__20221231_zG0G6GbgAnR5" style="font-size: 10pt; font-weight: bold; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_pn3n3_c20220401__20221231_ze8yb5MaaMrc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx">29,609</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_pn3n3_c20210401__20211231_zgVZygUEAuo3" style="font-size: 10pt; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"><span style="-sec-ix-hidden: xdx2ixbrl1347">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_pn3n3_c20210401__20211231_zi12atFtIGC1" style="font-size: 10pt; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"><span style="-sec-ix-hidden: xdx2ixbrl1349">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued to Lincoln for commitment fee under Committed Purchase Agreement</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesIssuedToLincolnParksCommittedPurchaseShares_pn3n3_c20220401__20221231_zbzzld47r9Bj" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares">94</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--SharesIssuedToLincolnParksCommittedPurchase_pn3n3_c20220401__20221231_zjCpUMm4zLr1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase">900</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesIssuedToLincolnParksCommittedPurchaseShares_pn3n3_c20210401__20211231_zgG4x05qRDDi" style="font-size: 10pt; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharesIssuedToLincolnParksCommittedPurchase_pn3n3_c20210401__20211231_zeJkmbAqm8Bb" style="font-size: 10pt; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares"><span style="-sec-ix-hidden: xdx2ixbrl1357">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued under public offering and ATM, net of issue costs</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_pn3n3_c20220401__20221231_zygzjapS0dw7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue costs , shares">88</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20220401__20221231_zPjY8TAPsMR7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue costs">586</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_pn3n3_c20210401__20211231_z44w1w5iidf8" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue costs , shares">1,241</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20210401__20211231_z8E33AYeVFUj" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue costs">27,216</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Purchase of shares issued under Committed Purchase Agreement, net of issue costs</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_pn3n3_c20220401__20221231_z7WYF4rX7PN6" style="font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares">30</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_pn3n3_c20220401__20221231_zKpZ3xLEhIl3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs">184</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_pn3n3_c20210401__20211231_zauzHGW2W1R6" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares"><span style="-sec-ix-hidden: xdx2ixbrl1371">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_pn3n3_c20210401__20211231_z3fmcpxsLElb" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs"><span style="-sec-ix-hidden: xdx2ixbrl1373">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued or accrued for services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pn3n3_c20220401__20221231_zYSZpA8pWOO7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services">13</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20220401__20221231_zmeY5KkkdKy1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services">90</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pn3n3_c20210401__20211231_zm532sEf4CY1" style="font-size: 10pt; text-align: right" title="Shares issued or accrued for services">4</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20210401__20211231_zqyuD0UB4FH8" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs">90</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Warrants exercised</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--WarrantsExercisedShares_pn3n3_c20220401__20221231_zup27D4RVdnc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants exercised, shares"><span style="-sec-ix-hidden: xdx2ixbrl1383">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_pn3n3_c20220401__20221231_zsU1T5GDBhAk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1385">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantsExercisedShares1_pn3n3_c20210401__20211231_z0wiD5IFUMH9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised, shares">16</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_pn3n3_c20210401__20211231_zt2fg6EwFy1c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised">339</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--CommonStockShares_iE_pn3n3_c20220401__20221231_z75Uw8y5Gjck" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares">17,070</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_ecustom--CommonStockValues_iE_pn3n3_c20220401__20221231_zdRlDweUR1s2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">216,630</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_ecustom--CommonStockShares_iE_pn3n3_c20210401__20211231_zSwVG2ENQRsg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, Shares">13,345</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_ecustom--CommonStockValues_iE_pn3n3_c20210401__20211231_z5TOiiDo2doe" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance">158,294</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504051276096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockOptionReserveAbstract', window );"><strong>Stock Option Reserve</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfTermsStockOptionReserveExplanatory', window );">Disclosure Of Terms Stock Option Reserve Explanatory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_zeA2xnrNPxZe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BD_zGV7nxLtU6ad" style="display: none">Disclosure Of Terms Stock Option Reserve Explanatory</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zVTLTJYq6Jig" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">11,659</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_ziRFOq5sbuNh" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">16,928</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zkDqJIL5TfE" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">11,468</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z9TizhLV2sM6" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">7,977</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--AdjustmentsForSharebasedPayments_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pdn3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1461">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--AdjustmentsForSharebasedPayments_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense">3,614</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense">191</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense">6,248</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Settled in iOx exchange</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--SettledInIoxExchange_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Settled in iOx exchange">(11,659</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--SettledInIoxExchange_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Settled in iOx exchange"><span style="-sec-ix-hidden: xdx2ixbrl1471">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--SettledInIoxExchange_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Settled in iOx exchange"><span style="-sec-ix-hidden: xdx2ixbrl1473">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--SettledInIoxExchange_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Settled in iOx exchange"><span style="-sec-ix-hidden: xdx2ixbrl1475">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zcPmyMmC7tAb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="-sec-ix-hidden: xdx2ixbrl1477">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zZiO4J0OjKK6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">20,542</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zTyW1N75gsc5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance">11,659</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zMtZAF3y94o4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance">14,225</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eifrs-full--DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_pn3n3_z0PXr0XQXgy5" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_8BD_zkMLVnMurtWf" style="display: none">Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Assumption</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unvested Options</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-size: 10pt; text-align: left">Risk free interest rate</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 49%; font-size: 10pt; text-align: center"><span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zwlMc8xm8834" title="Risk free interest rate">3.05</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected dividend</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">Nil</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected volatility</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_908_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zx9aHxnRe9Zi" title="Expected volatility">111</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected life</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_907_ecustom--OptionLifeShareOptionsGranted_dtY_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z8aU8Pw0VW7i" title="Expected life">6.25</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Fair value of Portage option</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">$<span id="xdx_90D_ecustom--FairValueOfPortageOption_pid_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zo88QbFX6Cg3" title="Fair value of Portage option">9.36</span></td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory', window );">Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eifrs-full--ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory_zM8amTAE1ue" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B9_z3NhZxUvbnf9" style="display: none">Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Assumption</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Unvested Options</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-size: 10pt; text-align: left">Risk free interest rate</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 49%; font-size: 10pt; text-align: center"><span id="xdx_905_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zRXmqEnLkFh9" title="Risk free interest rate">2.83</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected dividend</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">Nil</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Expected volatility</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_902_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zyhuhdC7d8H8" title="Expected volatility">112</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected life</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_900_ecustom--OptionLifeShareOptionsGranted_dtY_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z7rEhj6JJHK" title="Expected life">5.75</span> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Fair value of Portage option</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">$<span id="xdx_90C_ecustom--FairValueOfPortageOption_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_pdd" title="Fair value of Portage option">8.38</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory', window );">Schedule of outstanding stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_pn3n3_zpqWwIO2cFHa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BC_znNG4X0YuXGj" style="display: none">Schedule of outstanding stock options</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated 2021 Equity Incentive Plan</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">iOx Option Plan<br/> (Subsidiary Plan)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--NumberOfOutstandingShareOption_iS_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zrsA014IiTp2" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">1,151,400</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--NumberOfOutstandingShareOption_iS_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zUOtQyrLwbO7" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">868,000</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iS_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_z3HJtOyq5itf" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">1,275</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--NumberOfOutstandingShareOption_iS_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zJJGebQ4jSV8" style="width: 12%; font-size: 10pt; text-align: right" title="Balance">1,924</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Granted</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcQwhLH0L2ge" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted">65,900</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zUQPCdkUQekf" style="font-size: 10pt; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1574">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zrhjuw4FtqRj" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1576">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zelSUFznsim9" style="font-size: 10pt; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1578">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Expired or forfeited</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zmhHETlc5SD3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1580">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zlANHiWHq4P2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1582">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zbgbuSiqxKH2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited">(1,275</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zxvSZjn3hC8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited">(649</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5ceqnOjbBP2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance">1,217,300</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zIEj46lAcwR7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance">868,000</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--NumberOfOutstandingShareOption_iE_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zKK6tNOhjOLa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"><span style="font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1592">&#8211;</span></b></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_ecustom--NumberOfOutstandingShareOption_iE_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zw9b79ON8Y51" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance">1,275</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Exercisable, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zevhBsJO8lFb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end">419,705</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zf7yuWU9UoWf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end">116,666</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zGyK7Xi8axE" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"><span style="-sec-ix-hidden: xdx2ixbrl1600">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zV5kxgj5Z7Aj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end">1,275</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average exercise price and remaining contractual life</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_pn3n3_zYqSDIN62r89" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B8_zy114S1FX6X6" style="display: none">Schedule of weighted average exercise price and remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated <br/>2021 Equity Incentive Plan</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx Option Plan<br/> (Subsidiary Plan)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zsSiPYyJiDJ7" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price">15.19</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcK0Lrpjxw8g" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price">17.75</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zKctCx28Y2tb" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1619">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zf7SXsWg1JXa" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price">162.14</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life (in years)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zLsPw9gMiO62" title="Weighted average remaining contractual life (in years)">8.41</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcshMRx6Rf55" title="Weighted average remaining contractual life (in years)">9.04</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zvB5Qd59wDy1" title="Weighted average remaining contractual life (in years)">0.30</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the inputs, assumptions and estimation techniques used to apply the impairment requirements for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35G<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35G&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfTermsStockOptionReserveExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfTermsStockOptionReserveExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockOptionReserveAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockOptionReserveAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504075876368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LosPerShareAbstract', window );"><strong>Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EarningsPerShareTableTextBlock', window );">Schedule of basic and diluted EPS calculations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--EarningsPerShareTableTextBlock_pn3n3_zTcQDz7nnwD7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B2_zpIatBYYIWs7" style="display: none">Schedule of basic and diluted EPS calculations</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_497_20221001__20221231_zjglLULkusIb" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_499_20211001__20211231_zz6OpCrbVXI3" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20220401__20221231_zeTqFzQcdnx8" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_496_20210401__20211231_zRr5vg062j98" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended<br/> December 31,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Nine Months Ended<br/> December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">2021</td></tr>
  <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Numerator (in 000&#8217;$)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to owners of the Company</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(7,485</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right">(3,512</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right">(10,163</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right">(9,553</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Denominator (in 000&#8217;)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--WeightedAverageShares_i01_pid_zIoQ9lrRsQJf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average number of shares &#8211; Basic and Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">17,039</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13,344</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">15,719</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,966</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--BasicAndDilutedLossPerShare_i01_pid_zEYG7Kd8HOsi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted (loss) per share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.44</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.26</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.65</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.74</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock', window );">Schedule of anti-dilutive share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_pn3n3_zQfmZIH8HUBj" style="width: 100%; border-collapse: collapse; font-size: 10pt" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)">
  <tr>
    <td style="vertical-align: bottom"><span id="xdx_8B4_zoAsgyZtmiob" style="display: none">Schedule of anti-dilutive share</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td></tr>
<tr>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>As of December 31,</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="border-top: Black 1pt solid; vertical-align: top; text-align: center">&#160;</td>
    <td style="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; width: 67%"><span style="font-size: 10pt"><b>Stock options</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; vertical-align: bottom; width: 16%; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt"><b>1,217,300</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; width: 1%">&#160;</td>
    <td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; vertical-align: bottom; width: 11%; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt">868,000</span></td>
    <td style="vertical-align: top; width: 1%; text-align: right">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Restricted stock units</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt"><b>378,740</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt">243,000</span></td>
    <td style="vertical-align: top; text-align: right">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-size: 10pt"><b>Warrants</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_980_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1697">&#8211;</span></b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center">&#160;</td>
    <td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"><span style="font-size: 10pt">33,888</span></td>
    <td style="vertical-align: top; text-align: right">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_EarningsPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_EarningsPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LosPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LosPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052719840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Financial Instruments And Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory', window );">Schedule of financial instruments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory_pn3n3_zkPsGNEDvFN9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BE_zYUV3DrLCaR3" style="display: none">Schedule of financial instruments</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49C_20221231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zU75MA5YgBq3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49D_20221231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zaGOgs0d3Ou5" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_498_20220331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zhMnrMQ8D1Xf" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_490_20220331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z6TQFEmhz8f2" style="font-size: 10pt; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value through Other Comprehensive <br/>Income (&#8220;FVTOCI&#8221;)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">13,104</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1806">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">23,352</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,786</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1,480</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1813">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ConvertibleNoteReceivableIncludingAccruedInterest_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Convertible note receivable, including accrued interest</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1815">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">642</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1817">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1818">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--CurrentInvestments_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Investments</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1820">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4,768</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1822">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">9,082</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value through Profit or Loss (&#8220;FVTPL&#8221;)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">2,422</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1831">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">750</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1833">&#8211;</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--WarrantLiability_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1835">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1837">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">33</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredPurchasePricePayableTarus_i01I_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred purchase price payable - Tarus</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1840">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">8,876</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1842">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1843">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredObligationIoxMilestone_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred obligation - iOx milestone</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1845">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">5,568</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1847">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1848">&#8211;</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504053126112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NonControllingInterestAbstract', window );"><strong>Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfNoncontrollingInterestTableTextBlock', window );">Schedule of non-controlling interest</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zRGrdWEf3B7h" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BF_zVq12XLVJqTb" style="display: none">Schedule of non-controlling interest</span></td><td style="text-align: justify; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Saugatuck <br/>and subsidiary</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2022</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zi826xxTHcmi" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">44,701</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_987_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zcB6nOkdtrF7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">(472</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231_zSGjEDkZJcNh" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">44,229</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net income (loss) attributable to non-controlling interest</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest">123</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest">(171</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest">(48</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10.1pt; padding-left: 10.1pt">Purchase of non-controlling interest pursuant to Share Exchange Agreement</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement">(44,824</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_znTeJD3WhW9b" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement"><span style="-sec-ix-hidden: xdx2ixbrl1911">&#8211;</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_c20220401__20221231_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement">(44,824</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of December 31, 2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zJYgGcTc8Sde" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"><span style="-sec-ix-hidden: xdx2ixbrl1915">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zXgu9h5zKWXl" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(643</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231_zmjnE3OGUW6c" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(643</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NonControllingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NonControllingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504075876368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details Narrative)<br></strong></div></th>
<th class="th"><div>Aug. 13, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxGroupPlcMember', window );">Salva Rx Group Plc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of acquire</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxGroupPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxGroupPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049482560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 19, 2022</div></th>
<th class="th"><div>Jun. 24, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TotalCurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetLossIncome', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">Cash on hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IssuanceAndSales', window );">Issuance and sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashFundDescription', window );">Cash fund, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Sales Agreement permits the Company to sell in an ATM offering up
to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered,
issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an &#8220;at
the market&#8221; offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;). Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is
not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus. See Note 14, &#8220;Capital
Stock,&#8221; and Note 22, &#8220;Event After the Balance Sheet Date,&#8221; for a further discussion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfStockSold', window );">Number of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="nump">90,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrossProceedsFromStockSold', window );">Gross proceeds from stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,500<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetProceedsFromStockSold', window );">Net proceeds from stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OfferingAndThroughThatProcessDescription', window );">Offering and through that process, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company completed a firm commitment underwritten
public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8
million, including approximately $1.6 million of management, underwriting and selling expenses.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,425,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_ATMMember', window );">A T M [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="nump">88,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfBiologicalAssets', window );">Net proceeds from sale</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_LincolnMember', window );">Lincoln [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">94,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfBiologicalAssets', window );">Net proceeds from sale</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOnHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held by the entity. This does not include demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOnHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfBiologicalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of biological assets. [Refer: Biological assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfBiologicalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashFundDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashFundDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GrossProceedsFromStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GrossProceedsFromStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IssuanceAndSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IssuanceAndSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetLossIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetLossIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetProceedsFromStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetProceedsFromStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OfferingAndThroughThatProcessDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OfferingAndThroughThatProcessDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TotalCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TotalCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_LincolnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_LincolnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049371568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesOneMember', window );">Subsidiaries One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">60.49%<span></span>
</td>
<td class="nump">78.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesTwoMember', window );">Subsidiaries Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SubsidiariesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049010992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Prepaid Expenses And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromSaleOfProperties', window );">Prepaid clinical research costs</a></td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Prepaid insurance</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ResearchAndDevelopmentCredit', window );">Research &amp; development tax credits</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TaxDeposits', window );">Tax deposits</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Other prepaid expenses</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Total prepaid expenses and other receivables</a></td>
<td class="nump">$ 1,786<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromSaleOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from sale of properties. [Refer: Receivables from sale of properties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromSaleOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ResearchAndDevelopmentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ResearchAndDevelopmentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TaxDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TaxDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052272288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN ASSOCIATE (Details) - Stimunity S A [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfAssociate', window );">Name of associate</a></td>
<td class="text">Associate: Stimunity S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfAssociate', window );">Principal place of business of associate</a></td>
<td class="text">Biotechnology<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfAssociate', window );">Country of incorporation of associate</a></td>
<td class="text">Paris, France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate', window );">Proportion of voting rights held in associate</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporationOrResidenceOfAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The country in which an associate of the entity is incorporated. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporationOrResidenceOfAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The name of an associate. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrincipalPlaceOfBusinessOfAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The principal place of business of an associate. [Refer: Principal place of business; Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrincipalPlaceOfBusinessOfAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_StimunitySAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_StimunitySAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504048954576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN ASSOCIATE (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InvestmentInAssociateAbstract', window );"><strong>Investment In Associate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Beginning balance</a></td>
<td class="nump">$ 1,673<span></span>
</td>
<td class="nump">$ 1,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnrecognisedShareOfLossesOfAssociates', window );">Share of (loss)</a></td>
<td class="num">(268)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates', window );">Ending balance</a></td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="nump">$ 1,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnrecognisedShareOfLossesOfAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognised share of associates' losses if the entity has stopped recognising its share of losses when applying the equity method. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 22<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_22_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnrecognisedShareOfLossesOfAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentInAssociateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentInAssociateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052327744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN ASSOCIATE (Details Narrative)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 13, 2022</div></th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_StimunityMember', window );">Stimunity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ConvertibleNoteDescription', window );">Convertible Note description</a></td>
<td class="text">the Company entered into a commitment with Stimunity
to provide &#8364;600,000 under a convertible note (the &#8220;Stimunity Convertible Note&#8221;) with a maturity date of September 1,
2023 (the &#8220;Maturity Date&#8221;). The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible
Note is automatically converted into Series A shares upon Stimunity completing a Series A round for at least &#8364;20 million. If such
subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into
Series A shares at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares
(other than Common Shares or Series A shares) for at least &#8364;5 million (the &#8220;Minimum Raise&#8221;), the Company will have the
right to convert the Stimunity Convertible Note and the historical Series A shares owned into the new category of shares. In the event
that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the
right to convert the Stimunity Convertible Note into Series A shares at &#8364;363.00 per share or the raise price less 15%, whichever
is lower. The Stimunity Convertible Note was funded on September 12, 2022. See Note 17, &#8220;Commitments and Contingent Liabilities
&#8211; Stimunity Convertible Note,&#8221; for a further discussion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_StimunitySAMember', window );">Stimunity S A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AdditionalInvestment', window );">Additional investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SubscribingClassShares', window );">Subscribing class A shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EquityInLossIncome', window );">Equity in (loss) income | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,000<span></span>
</td>
<td class="nump">$ 261,000<span></span>
</td>
<td class="nump">$ 268,000<span></span>
</td>
<td class="nump">$ 363,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ConvertibleNoteDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ConvertibleNoteDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_EquityInLossIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_EquityInLossIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SubscribingClassShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SubscribingClassShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_StimunityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_StimunityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_StimunitySAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ptgef_StimunitySAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049095760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN PRIVATE COMPANY (Details Narrative)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th">
<div>Jul. 11, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets', window );">Fair value</a></td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied', window );">Carrying value</a></td>
<td class="nump">$ 4,046<span></span>
</td>
<td class="nump">$ 4,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnrealizedLoss', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OfferingPrice', window );">Offering price | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OfferingPrice', window );">Offering price | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ptgef_AcquisitionOfSalvaRxMember', window );">Acquisition Of Salva Rx [Member] | Intensity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrivateInvestments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InvestmentOwnedShares', window );">Number of shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InvestmentOwnershipPercentage', window );">Percentage of equity held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ptgef_AcquisitionOfIntensityHoldingLimitedMember', window );">Acquisition Of Intensity Holding Limited [Member] | Intensity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Number of ordinary shares issued in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset', window );">Number of private company share consists in sole asset | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount removed from reserve of cash flow hedges and included in the initial cost or other carrying amount of a non-financial asset (liability) or a firm commitment for which fair value hedge accounting is applied. [Refer: Reserve of cash flow hedges]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24E<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24E_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 9<br> -IssueDate 2022-03-24<br> -Paragraph 6.5.11<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=9&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_6.5.11_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the fair value of a financial asset (or group of financial assets) designated as measured at fair value through profit or loss that is attributable to changes in the credit risk of that asset determined either: (a) as the amount of change in its fair value that is not attributable to changes in market conditions that give rise to market risk ; or (b) using an alternative method the entity believes more faithfully represents the amount of change in its fair value that is attributable to changes in the credit risk of the asset. [Refer: Credit risk [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 9<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_9_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentOwnedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentOwnedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrivateInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrivateInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ptgef_AcquisitionOfSalvaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ptgef_AcquisitionOfSalvaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInvestmentPropertyAxis=ptgef_IntensityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInvestmentPropertyAxis=ptgef_IntensityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ptgef_AcquisitionOfIntensityHoldingLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ptgef_AcquisitionOfIntensityHoldingLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049442720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITION OF TARUS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 43,862<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">$ 43,324<span></span>
</td>
<td class="nump">$ 43,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract', window );"><strong>Consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis=ptgef_TarusAcquisitionMember', window );">Tarus Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Identifiable intangible assets</a></td>
<td class="nump">28,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTangibleOrIntangibleAssetsTransferred', window );">Total assets</a></td>
<td class="nump">28,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract', window );"><strong>Consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Fair value of shares issued</a></td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Liabilities assumed</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred purchase consideration at fair value</a></td>
<td class="nump">8,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Total liabilities</a></td>
<td class="nump">$ 28,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTangibleOrIntangibleAssetsTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of other tangible or intangible assets (including a business or subsidiary of the acquirer) transferred as consideration in a business combination, that the entity does not separately disclose in the same note. [Refer: Intangible assets other than goodwill; Business combinations [member]; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTangibleOrIntangibleAssetsTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis=ptgef_TarusAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis=ptgef_TarusAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049004096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF TARUS (Details 1) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (5,302)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (4,089)<span></span>
</td>
<td class="num">$ (13,117)<span></span>
</td>
<td class="num">$ (10,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss and other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,211)<span></span>
</td>
<td class="num">(10,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for year</a></td>
<td class="num">(11,518)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,206)<span></span>
</td>
<td class="num">(14,228)<span></span>
</td>
<td class="num">(10,306)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis=ptgef_TarusAcquisitionMember', window );">Tarus Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperations', window );">Loss from operations</a></td>
<td class="num">(4,759)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,362)<span></span>
</td>
<td class="num">(12,200)<span></span>
</td>
<td class="num">(13,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before provision for income taxes</a></td>
<td class="num">(5,302)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,281)<span></span>
</td>
<td class="num">(12,833)<span></span>
</td>
<td class="num">(13,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss and other comprehensive loss</a></td>
<td class="num">(7,501)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,398)<span></span>
</td>
<td class="num">(9,927)<span></span>
</td>
<td class="num">(12,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for year</a></td>
<td class="num">$ (11,518)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (4,398)<span></span>
</td>
<td class="num">$ (13,945)<span></span>
</td>
<td class="num">$ (12,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EarningLossPerShare', window );">Loss per share</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes the results of operations of Tarus for the period and, accordingly, there are no pro
forma adjustments for the three months ended December 31, 2022.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_vi&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_EarningLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_EarningLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis=ptgef_TarusAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis=ptgef_TarusAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052813440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF TARUS (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AcquisitionOfTarusAbstract', window );"><strong>Acquisition Of Tarus</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold | shares</a></td>
<td class="nump">2,425,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from offering</a></td>
<td class="nump">$ 32,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AcquisitionOfTarusAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AcquisitionOfTarusAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052790544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GoodwillAbstract', window );"><strong>Goodwill Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Balance, beginning of period</a></td>
<td class="nump">$ 43,324<span></span>
</td>
<td class="nump">$ 43,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TarusGoodwill', window );">Tarus goodwill</a></td>
<td class="nump">538<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Balance, ending of period</a></td>
<td class="nump">$ 43,862<span></span>
</td>
<td class="nump">$ 43,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TarusGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TarusGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049364096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GoodwillAbstract', window );"><strong>Goodwill Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">$ 43,862<span></span>
</td>
<td class="nump">$ 43,324<span></span>
</td>
<td class="nump">$ 43,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration paid</a></td>
<td class="nump">28,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Fair value of identifiable assets acquired</a></td>
<td class="nump">$ 28,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate applied to cash flow projections</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_d_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049251536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">$ 145,588<span></span>
</td>
<td class="nump">$ 117,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxesLiability', window );">Deferred tax liability</a></td>
<td class="nump">28,409<span></span>
</td>
<td class="nump">30,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_IMM60IOXMelanomaLungCancersMember', window );">I M M 60 I O X Melanoma Lung Cancers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">84,213<span></span>
</td>
<td class="nump">84,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_IMM65IOXOvarianProstateCancersMember', window );">I M M 65 I O X Ovarian Prostate Cancers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">32,997<span></span>
</td>
<td class="nump">32,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_IOXMember', window );">I O X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">117,210<span></span>
</td>
<td class="nump">117,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_OncomerSaugatuckDNAAptamersMember', window );">Oncomer Saugatuck D N A Aptamers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_TarusAdenosineReceptorsMember', window );">Tarus Adenosine Receptors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">27,138<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_TarusAdenosineReceptors1Member', window );">Tarus Adenosine Receptors 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_TarusAdenosineReceptors2Member', window );">Tarus Adenosine Receptors 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">562<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_TarusMember', window );">Tarus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InprocessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">$ 28,200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InprocessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InprocessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_IMM60IOXMelanomaLungCancersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_IMM60IOXMelanomaLungCancersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_IMM65IOXOvarianProstateCancersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_IMM65IOXOvarianProstateCancersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_IOXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_IOXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_OncomerSaugatuckDNAAptamersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_OncomerSaugatuckDNAAptamersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_TarusAdenosineReceptorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_TarusAdenosineReceptorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_TarusAdenosineReceptors1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_TarusAdenosineReceptors1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_TarusAdenosineReceptors2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_TarusAdenosineReceptors2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_TarusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_TarusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049389888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 08, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract', window );"><strong>In-process Research And Development And Deferred Tax Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxLiability', window );">Deferred tax liability</a></td>
<td class="nump">$ 25,500<span></span>
</td>
<td class="nump">$ 25,500<span></span>
</td>
<td class="nump">$ 28,400<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncreaseInDeferredIncomeTaxes', window );">Increase in deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Increase (Decrease) in deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReductionInDeferredTaxLiability', window );">Reduction in deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Change in tax effect rate</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ReductionInDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ReductionInDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052333952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNSECURED NOTES PAYABLE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare', window );">Exchange of notes payable and accrued interest for iOx shares</a></td>
<td class="num">$ (150)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember', window );">I O X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare', window );">Exchange of notes payable and accrued interest for iOx shares</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NotePayable', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052439744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNSECURED NOTES PAYABLE (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 08, 2021</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember', window );">Salva Rx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfBusinessCombination', window );">Description of business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company
assumed $2.0 million of 7% convertible notes issued by iOx, a wholly-owned subsidiary of SalvaRx (the &#8220;Convertible Notes&#8221;),
of which the Company holds $1.9 million. As a result of the SalvaRx Acquisition, iOx became a subsidiary of the Company during the year
ended March 31, 2019. In accordance with IFRS 3, the fair value, including interest receivable, of the Convertible Notes were effectively
settled against the note receivable upon the business combination.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember', window );">I O X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IssuanceOfUnsecuredNotesDescription', window );">Description of business combination</a></td>
<td class="text">the&#160;Company,
through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for
23,772 ordinary shares of iOx at a price of &#163;162. Simultaneously, the Company entered into an agreement with Oxford Sciences Innovation,
Plc (&#8220;OSI&#8221;), the holder of $0.15&#160;million notes plus accrued interest under which OSI exchanged the notes plus accrued
interest for&#160;820&#160;shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated
November 29, 2016, following the general tenets of IAS 39, &#8220;Financial Instruments: Recognition and Measurement,&#8221; and IFRIC
19, &#8220;Extinguishing Financial Liabilities with Equity Instruments,&#8221; and recorded the exchange at historical cost. Additionally,
no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased
its ownership of iOx from&#160;60.49% to&#160;78.32%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IssuanceOfUnsecuredNotesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IssuanceOfUnsecuredNotesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SalvaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049072320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CurrentFederalIncomeTaxBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CurrentStateAndLocalIncomeTaxBenefit', window );">State and local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CurrentForeignIncomeTaxBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Total current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredFederalIncomeTaxBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredStateAndLocalIncomeTaxBenefit', window );">State and local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredForeignIncomeTaxBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,930<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Total deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,930<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Benefit from income taxes</a></td>
<td class="num">$ (2,199)<span></span>
</td>
<td class="num">$ (117)<span></span>
</td>
<td class="nump">$ 2,906<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CurrentFederalIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CurrentFederalIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CurrentForeignIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CurrentForeignIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CurrentStateAndLocalIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CurrentStateAndLocalIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredFederalIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredFederalIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredForeignIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredForeignIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredStateAndLocalIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredStateAndLocalIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049420896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeTaxesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax', window );">Income (loss) on ordinary activities before tax</a></td>
<td class="num">$ (1,230)<span></span>
</td>
<td class="num">$ (1,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StatutoryU.s.IncomeTaxRate', window );">Statutory U.S. income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossAtStatutoryIncomeTaxRate', window );">Income tax at statutory income tax rate</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossesRecognized', window );">Losses recognized</a></td>
<td class="num">(282)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeTaxBenefitExpense', window );">Income tax benefit (expense)</a></td>
<td class="num">$ (24)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeTaxBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeTaxBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossAtStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossAtStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StatutoryU.s.IncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StatutoryU.s.IncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049959584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeTaxesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss on ordinary activities before tax</a></td>
<td class="nump">$ 4,567<span></span>
</td>
<td class="nump">$ 2,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory U.K. income tax rate</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Loss at statutory income tax rate</a></td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">$ 462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeIncreaseInDeferredIncomeTaxRate', window );">Change (increase) in deferred income tax rate</a></td>
<td class="nump">274<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ForeignCurrencyEffect', window );">Foreign currency effect</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TaxEffectOfRAndDCredit', window );">Research and development credit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossesUnrecognized', window );">Losses (unrecognized)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Income tax benefit</a></td>
<td class="nump">$ 2,930<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeIncreaseInDeferredIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeIncreaseInDeferredIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ForeignCurrencyEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ForeignCurrencyEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossesUnrecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossesUnrecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TaxEffectOfRAndDCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TaxEffectOfRAndDCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049824880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ReserveQuantitiesLineItems', window );"><strong>Reserve Quantities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PretaxIncomeLoss', window );">Pre-tax loss</a></td>
<td class="num">$ (13,117)<span></span>
</td>
<td class="num">$ (10,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossForWhichNoBenefitWasTaken', window );">Loss for which no benefit was taken</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossesNotSubjectToTax', window );">Losses not subject to tax</a></td>
<td class="nump">7,320<span></span>
</td>
<td class="nump">6,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UtilizationOfLossesNotPreviouslyBenefitted', window );">Utilization of losses not previously benefitted</a></td>
<td class="num">(314)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PretaxLossSubjectToTax', window );">Taxable income (loss)</a></td>
<td class="num">(4,489)<span></span>
</td>
<td class="num">(3,969)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ptgef_UnitedStateMember', window );">United State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ReserveQuantitiesLineItems', window );"><strong>Reserve Quantities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PretaxIncomeLoss', window );">Pre-tax loss</a></td>
<td class="num">(1,230)<span></span>
</td>
<td class="num">(1,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossForWhichNoBenefitWasTaken', window );">Loss for which no benefit was taken</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossesNotSubjectToTax', window );">Losses not subject to tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UtilizationOfLossesNotPreviouslyBenefitted', window );">Utilization of losses not previously benefitted</a></td>
<td class="num">(314)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PretaxLossSubjectToTax', window );">Taxable income (loss)</a></td>
<td class="nump">78<span></span>
</td>
<td class="num">(1,535)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ptgef_BVIMember', window );">B V I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ReserveQuantitiesLineItems', window );"><strong>Reserve Quantities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PretaxIncomeLoss', window );">Pre-tax loss</a></td>
<td class="num">(7,320)<span></span>
</td>
<td class="num">(6,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossForWhichNoBenefitWasTaken', window );">Loss for which no benefit was taken</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossesNotSubjectToTax', window );">Losses not subject to tax</a></td>
<td class="nump">7,320<span></span>
</td>
<td class="nump">6,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UtilizationOfLossesNotPreviouslyBenefitted', window );">Utilization of losses not previously benefitted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PretaxLossSubjectToTax', window );">Taxable income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ptgef_ForeignMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ReserveQuantitiesLineItems', window );"><strong>Reserve Quantities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PretaxIncomeLoss', window );">Pre-tax loss</a></td>
<td class="num">(4,567)<span></span>
</td>
<td class="num">(2,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossForWhichNoBenefitWasTaken', window );">Loss for which no benefit was taken</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossesNotSubjectToTax', window );">Losses not subject to tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UtilizationOfLossesNotPreviouslyBenefitted', window );">Utilization of losses not previously benefitted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PretaxLossSubjectToTax', window );">Taxable income (loss)</a></td>
<td class="num">$ (4,567)<span></span>
</td>
<td class="num">$ (2,434)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossForWhichNoBenefitWasTaken">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossForWhichNoBenefitWasTaken</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossesNotSubjectToTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossesNotSubjectToTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PretaxIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PretaxIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PretaxLossSubjectToTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PretaxLossSubjectToTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UtilizationOfLossesNotPreviouslyBenefitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UtilizationOfLossesNotPreviouslyBenefitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ReserveQuantitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ReserveQuantitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ptgef_UnitedStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ptgef_UnitedStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ptgef_BVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ptgef_BVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ptgef_ForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ptgef_ForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052221904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details 4) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxAssetsNetOperatingLossCarryforward', window );">Net operating loss</a></td>
<td class="num">$ (4,394)<span></span>
</td>
<td class="num">$ (3,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxAssetUnrecognized', window );">Deferred tax asset (unrecognized)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax asset</a></td>
<td class="num">(2,894)<span></span>
</td>
<td class="num">(1,753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxLiabiltiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxLiabilitiesInProcessRAndD', window );">In-process research and development</a></td>
<td class="nump">28,409<span></span>
</td>
<td class="nump">30,198<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredTaxLiability1', window );">Deferred tax liability</a></td>
<td class="nump">28,409<span></span>
</td>
<td class="nump">30,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="nump">$ 25,515<span></span>
</td>
<td class="nump">$ 28,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxAssetUnrecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxAssetUnrecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxAssetsNetOperatingLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxAssetsNetOperatingLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxLiabilitiesInProcessRAndD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxLiabilitiesInProcessRAndD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredTaxLiabiltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredTaxLiabiltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052351040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ResearchAndDevelopmentCreditReceivables', window );">Research and development credit receivables</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">25,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CurrentYearLosses', window );">Current year losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Increase (Decrease) in deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember', window );">I O X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ResearchAndDevelopmentExpenseCashCredits', window );">Research and development cash credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CurrentYearLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CurrentYearLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ResearchAndDevelopmentCreditReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ResearchAndDevelopmentCreditReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ResearchAndDevelopmentExpenseCashCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ResearchAndDevelopmentExpenseCashCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049333600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsOutstandingExercisePrice', window );">Warrants outstanding exercise price at beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsOutstandingShares', window );">Warrants outstanding, shares at beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsOutstandingAmount', window );">Warrants outstanding, amount at beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueAdjustmentExercisePriceAtEnd', window );">Fair value adjustment , exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueAdjustmentShares', window );">Fair value adjustment, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,888)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueAdjustmentAmount', window );">Fair value adjustment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsOutstandingExercisePrice', window );">Warrants outstanding exercise price at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsOutstandingShares', window );">Warrants outstanding, shares at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsOutstandingAmount', window );">Warrants outstanding, amount at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainLossOfChangeInFairValueOfWarrants', window );">Gain (loss) of change in fair value of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueAdjustmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueAdjustmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueAdjustmentExercisePriceAtEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueAdjustmentExercisePriceAtEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueAdjustmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueAdjustmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainLossOfChangeInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainLossOfChangeInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsOutstandingExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsOutstandingExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049803552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK (Details) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalStockAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommonStockShares', window );">Balance, Shares</a></td>
<td class="nump">13,349<span></span>
</td>
<td class="nump">12,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommonStockValues', window );">Balance</a></td>
<td class="nump">$ 158,324<span></span>
</td>
<td class="nump">$ 130,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Shares issued in Tarus acquisition, shares</a></td>
<td class="nump">2,426<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions', window );">Shares issued in Tarus acquisition</a></td>
<td class="nump">$ 17,200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedInIoxExchangesShares', window );">Shares issued in iOx exchange, shares</a></td>
<td class="nump">1,070<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareIssuedInIoxExchange', window );">Shares issued in iOx exchange</a></td>
<td class="nump">$ 9,737<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares', window );">Excess of non-controlling interest acquired over consideration iOx, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox', window );">Excess of non-controlling interest acquired over consideration iOx, shares</a></td>
<td class="nump">$ 29,609<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares', window );">Shares issued to Lincoln Parks Committed Purchase, shares</a></td>
<td class="nump">94<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedToLincolnParksCommittedPurchase', window );">Shares issued to Lincoln Parks Committed Purchase, shares</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares', window );">Shares issued under public offering and ATM, net of issue costs , shares</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">1,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts', window );">Shares issued under public offering and ATM, net of issue costs</a></td>
<td class="nump">$ 586<span></span>
</td>
<td class="nump">$ 27,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares', window );">Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares</a></td>
<td class="nump">30<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts', window );">Purchase of shares issued under Committed Purchase Agreement, net of issue costs</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Shares issued or accrued for services</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Purchase of shares issued under Committed Purchase Agreement, net of issue costs</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsExercisedShares', window );">Warrants exercised, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsExercisedShares1', window );">Warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommonStockShares', window );">Balance, Shares</a></td>
<td class="nump">17,070<span></span>
</td>
<td class="nump">13,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommonStockValues', window );">Balance</a></td>
<td class="nump">$ 216,630<span></span>
</td>
<td class="nump">$ 158,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in other provisions resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SaleOrIssueOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SaleOrIssueOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommonStockValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommonStockValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareIssuedInIoxExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareIssuedInIoxExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInIoxExchangesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInIoxExchangesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedToLincolnParksCommittedPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedToLincolnParksCommittedPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsExercisedShares1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsExercisedShares1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504048666832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 19, 2022</div></th>
<th class="th"><div>Jul. 18, 2022</div></th>
<th class="th"><div>Jun. 24, 2021</div></th>
<th class="th"><div>Jun. 16, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfStockSold', window );">Number of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GrossProceedsFromStockSold', window );">Gross proceeds from stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetProceedsFromStockSold', window );">Net proceeds from stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OfferingExpenses', window );">Offering Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ManagementUnderwritingAndSellingExpenses', window );">Management, underwriting and selling expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,425,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesExchanged', window );">Number of shares exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_MinorityInterestPercentage', window );">Minority interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_AccreditedInvestorsMember', window );">Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares', window );">Shares issued in a private placement, net of issue costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PricePerShare', window );">Shares price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts', window );">Shares issued in a private placement, net of issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_DirectorsMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares', window );">Shares issued in a private placement, net of issue costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts', window );">Shares issued in a private placement, net of issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_LincolnMember', window );">Lincoln [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">94,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfBiologicalAssets', window );">Net proceeds from sale</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_ATMMember', window );">A T M [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="nump">88,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfBiologicalAssets', window );">Net proceeds from sale</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfBiologicalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of biological assets. [Refer: Biological assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfBiologicalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GrossProceedsFromStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GrossProceedsFromStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ManagementUnderwritingAndSellingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ManagementUnderwritingAndSellingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_MinorityInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_MinorityInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetProceedsFromStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetProceedsFromStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_AccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_AccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_LincolnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_LincolnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049807360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Stock based compensation expense</a></td>
<td class="nump">$ 3,614<span></span>
</td>
<td class="nump">$ 6,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember', window );">Non-controlling interests [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Balance</a></td>
<td class="nump">11,659<span></span>
</td>
<td class="nump">11,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Stock based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SettledInIoxExchange', window );">Settled in iOx exchange</a></td>
<td class="num">(11,659)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ptgef_StockOptionReserveMember', window );">Stock Option Reserve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Balance</a></td>
<td class="nump">16,928<span></span>
</td>
<td class="nump">7,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Stock based compensation expense</a></td>
<td class="nump">3,614<span></span>
</td>
<td class="nump">6,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SettledInIoxExchange', window );">Settled in iOx exchange</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Balance</a></td>
<td class="nump">$ 20,542<span></span>
</td>
<td class="nump">$ 14,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SettledInIoxExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SettledInIoxExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockOptionReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockOptionReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ptgef_StockOptionReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ptgef_StockOptionReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049364576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 1) - I Ox Option Plan [Member] - Unvested Options [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2019</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">3.05%<span></span>
</td>
<td class="nump">2.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">111.00%<span></span>
</td>
<td class="nump">112.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptionsGranted', window );">Expected life</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfPortageOption', window );">Fair value of Portage option</a></td>
<td class="nump">$ 9.36<span></span>
</td>
<td class="nump">$ 8.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfPortageOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfPortageOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ptgef_UnvestedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ptgef_UnvestedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504050026656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 2) - I Ox Option Plan [Member] - Unvested Options [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2019</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">3.05%<span></span>
</td>
<td class="nump">2.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">111.00%<span></span>
</td>
<td class="nump">112.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptionsGranted', window );">Expected life</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfPortageOption', window );">Fair value of Portage option</a></td>
<td class="nump">$ 9.36<span></span>
</td>
<td class="nump">$ 8.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfPortageOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfPortageOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ptgef_UnvestedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ptgef_UnvestedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052152352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 3) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember', window );">P B I 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="nump">1,151,400<span></span>
</td>
<td class="nump">868,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement', window );">Granted</a></td>
<td class="nump">65,900<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement', window );">Expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="nump">1,217,300<span></span>
</td>
<td class="nump">868,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements', window );">Exercisable as at end</a></td>
<td class="nump">419,705<span></span>
</td>
<td class="nump">116,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_StockOptionsTwoMember', window );">Stock Options Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">1,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement', window );">Expired or forfeited</a></td>
<td class="num">(1,275)<span></span>
</td>
<td class="num">(649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements', window );">Exercisable as at end</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_StockOptionsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_StockOptionsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049343168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 4) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember', window );">P B I 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price</a></td>
<td class="nump">$ 15.19<span></span>
</td>
<td class="nump">$ 17.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">8 years 4 months 28 days<span></span>
</td>
<td class="text">9 years 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_StockOptionsTwoMember', window );">Stock Options Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 162.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_StockOptionsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_StockOptionsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504047369392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Feb. 15, 2022</div></th>
<th class="th"><div>Jan. 19, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommunicationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_BoardOfDirectorsMember', window );">Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_N2021EquityIncentivePlanMember', window );">N 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">868,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockGranted', window );">Stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValuePerShare', window );">Fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommunicationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_AmendedAndRestated2021EquityIncentivePlanMember', window );">Amended And Restated 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockGranted', window );">Stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValuePerShare', window );">Fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommunicationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IntrinsicValueOfStockOptions', window );">Intrinsic value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_AmendedAndRestated2021EquityIncentivePlanMember', window );">Amended And Restated 2021 Equity Incentive Plan [Member] | Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockGranted', window );">Stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValuePerShare', window );">Fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_AmendedAndRestated2021EquityIncentivePlanMember', window );">Amended And Restated 2021 Equity Incentive Plan [Member] | Two Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockGranted', window );">Stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_AmendedAndRestated2021EquityIncentivePlanMember', window );">Amended And Restated 2021 Equity Incentive Plan [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockGranted', window );">Stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_AmendedAndRestated2021EquityIncentivePlanMember', window );">Amended And Restated 2021 Equity Incentive Plan [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockGranted', window );">Stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">135,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValuePerShare', window );">Fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.59<span></span>
</td>
<td class="nump">$ 10.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_AmendedAndRestated2021EquityIncentivePlanMember', window );">Amended And Restated 2021 Equity Incentive Plan [Member] | Executive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockGranted', window );">Stock granted</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValuePerShare', window );">Fair value per share</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember', window );">I Ox Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommunicationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IntrinsicValueOfStockOptions', window );">Intrinsic value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommunicationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from communication.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommunicationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IntrinsicValueOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IntrinsicValueOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_N2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_N2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_AmendedAndRestated2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_AmendedAndRestated2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_TwoMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_TwoMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_ExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_ExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_IOxOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052906160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumeratorAbstract', window );"><strong>Numerator (in 000&#8217;$)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Net loss attributable to owners of the Company</a></td>
<td class="num">$ (7,485)<span></span>
</td>
<td class="num">$ (3,512)<span></span>
</td>
<td class="num">$ (10,163)<span></span>
</td>
<td class="num">$ (9,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DenominatorAbstract', window );"><strong>Denominator (in 000&#8217;)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares &#8211; Basic and Diluted</a></td>
<td class="nump">17,039<span></span>
</td>
<td class="nump">13,344<span></span>
</td>
<td class="nump">15,719<span></span>
</td>
<td class="nump">12,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_BasicAndDilutedLossPerShare', window );">Basic and diluted (loss) per share</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BasicAndDilutedLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BasicAndDilutedLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049097312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(LOSS) PER SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShare', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">1,217,300<span></span>
</td>
<td class="nump">868,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShare', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">378,740<span></span>
</td>
<td class="nump">243,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShare', window );">Anti-dilutive effect on loss per share</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AntidilutiveEffectOnLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AntidilutiveEffectOnLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504047224064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)<br> &#8364; / shares in Units, &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 06, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 19, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 13, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ConvertibleNote', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ConversionOfDebt', window );">Conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ConversionOfDebtIntoShares', window );">Conversion of debt into shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePricePerShare', window );">Share price, per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 363.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,425,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_LincolnMember', window );">Lincoln [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AggregateValue', window );">Aggregate value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares issued | shares</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,508<span></span>
</td>
<td class="nump">94,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommitmentFee', window );">Commitment fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ConversionOfDebtIntoShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ConversionOfDebtIntoShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_LincolnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_LincolnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049309744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 15, 2021</div></th>
<th class="th"><div>Sep. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PortageOrdinaryShares', window );">Portage ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,070,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AnnualFeesdescription', window );">Annual feesDescription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Additionally, the chairperson of each of the Audit Committee, Compensation Committee
and Nomination Committee will be entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members
of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CompensationCommittee', window );">Compensation committee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OriginalAnnualTargetsPercentage', window );">Original annual targets percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_ChiefExecutiveOfficersMember', window );">Chief Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_BaseSalary', window );">Base Salary</a></td>
<td class="nump">$ 618,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember', window );">I O X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IssuanceOfUnsecuredNotesDescriptions', window );">Issuance of unsecured notes, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the&#160;Company,
through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for
23,772 ordinary shares of iOx at a price of &#163;162. Simultaneously, the Company entered into an agreement with OSI, the holder of
$0.15&#160;million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for&#160;820&#160;shares of iOx.
The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets
of IAS 39, &#8220;Financial Instruments: Recognition and Measurement,&#8221; and IFRIC 19, &#8220;Extinguishing Financial Liabilities
with Equity Instruments,&#8221; and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection
with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from&#160;60.49% to&#160;78.32%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AnnualFeesdescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AnnualFeesdescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CompensationCommittee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CompensationCommittee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IssuanceOfUnsecuredNotesDescriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IssuanceOfUnsecuredNotesDescriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OriginalAnnualTargetsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OriginalAnnualTargetsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PortageOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PortageOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_ChiefExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_ChiefExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049647024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="nump">$ 23,352<span></span>
</td>
<td class="nump">$ 25,603<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredPurchasePricePayableTarus', window );">Deferred purchase price payable - Tarus</a></td>
<td class="nump">8,876<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredObligationIoxMilestone', window );">Deferred obligation - iOx milestone</a></td>
<td class="nump">5,568<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember', window );">Amortized Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">13,104<span></span>
</td>
<td class="nump">23,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivable', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">1,786<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ConvertibleNoteReceivableIncludingAccruedInterest', window );">Convertible note receivable, including accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">2,422<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredPurchasePricePayableTarus', window );">Deferred purchase price payable - Tarus</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredObligationIoxMilestone', window );">Deferred obligation - iOx milestone</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember', window );">Fair Value To Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivable', window );">Prepaid expenses and other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ConvertibleNoteReceivableIncludingAccruedInterest', window );">Convertible note receivable, including accrued interest</a></td>
<td class="nump">642<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Investments</a></td>
<td class="nump">4,768<span></span>
</td>
<td class="nump">9,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredPurchasePricePayableTarus', window );">Deferred purchase price payable - Tarus</a></td>
<td class="nump">8,876<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DeferredObligationIoxMilestone', window );">Deferred obligation - iOx milestone</a></td>
<td class="nump">$ 5,568<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ConvertibleNoteReceivableIncludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ConvertibleNoteReceivableIncludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredObligationIoxMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredObligationIoxMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DeferredPurchasePricePayableTarus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DeferredPurchasePricePayableTarus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504076060128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Financial Instruments And Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Convertible Note receivable</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504052119600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CAPITAL DISCLOSURES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalDisclosuresAbstract', window );"><strong>Capital Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PayablesAndAccruedExpense', window );">Payables and accrued expenses</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CurrentAsset', window );">Current assets</a></td>
<td class="nump">15,500<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareholdersEquityAttributableToOwners', window );">Shareholders' equity attributable to owners</a></td>
<td class="nump">$ 168,900<span></span>
</td>
<td class="nump">$ 121,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PayablesAndAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PayablesAndAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareholdersEquityAttributableToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareholdersEquityAttributableToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049622752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at beginning</a></td>
<td class="nump">$ 44,229<span></span>
</td>
<td class="nump">$ 46,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interest</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement', window );">Purchase of non-controlling interest pursuant to Share Exchange Agreement</a></td>
<td class="num">(44,824)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at ending</a></td>
<td class="num">(643)<span></span>
</td>
<td class="nump">45,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares', window );">Exchange of notes payable, accrued interest and warrants for iOx shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember', window );">I O X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at beginning</a></td>
<td class="nump">44,701<span></span>
</td>
<td class="nump">46,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interest</a></td>
<td class="nump">123<span></span>
</td>
<td class="num">(436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement', window );">Purchase of non-controlling interest pursuant to Share Exchange Agreement</a></td>
<td class="num">(44,824)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">46,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares', window );">Exchange of notes payable, accrued interest and warrants for iOx shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember', window );">Saugatuck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at beginning</a></td>
<td class="num">(472)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to non-controlling interest</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement', window );">Purchase of non-controlling interest pursuant to Share Exchange Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at ending</a></td>
<td class="num">$ (643)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares', window );">Exchange of notes payable, accrued interest and warrants for iOx shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_IOXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140504049772960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EVENT AFTER THE BALANCE SHEET DATE (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,425,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">63,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfBiologicalAssets', window );">Net proceeds from sale</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfBiologicalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of biological assets. [Refer: Biological assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfBiologicalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>f6k_022823_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptgef="http://portagebiotech.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ptgef-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-04-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-08-13_custom_SalvaRxGroupPlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxGroupPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-13</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-06-012021-06-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="From2022-12-302022-12-31_custom_ATMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-30</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-12-302022-12-31_custom_LincolnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:LincolnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-30</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2015-02-012015-02-10_custom_SubsidiariesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-01</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-31_custom_SubsidiariesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_SubsidiariesTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SubsidiariesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-01_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="From2020-05-292020-06-01_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-29</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="From2022-07-022022-07-13_custom_StimunityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:StimunityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-07-13</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_StimunitySAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ptgef:StimunitySAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfSalvaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">ptgef:IntensityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-07-11_custom_AcquisitionOfIntensityHoldingLimitedMember_custom_IntensityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfIntensityHoldingLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">ptgef:IntensityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-11</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ptgef:AcquisitionOfSalvaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInvestmentPropertyAxis">ptgef:IntensityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-10-012022-10-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TarusAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:TarusAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_TarusAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:TarusAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_TarusAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:TarusAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-12-31_custom_TarusAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:TarusAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_TarusAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:TarusAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_IMM60IOXMelanomaLungCancersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM60IOXMelanomaLungCancersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_IMM60IOXMelanomaLungCancersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM60IOXMelanomaLungCancersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_IMM65IOXOvarianProstateCancersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM65IOXOvarianProstateCancersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_IMM65IOXOvarianProstateCancersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IMM65IOXOvarianProstateCancersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_IOXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_IOXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_OncomerSaugatuckDNAAptamersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:OncomerSaugatuckDNAAptamersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_OncomerSaugatuckDNAAptamersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:OncomerSaugatuckDNAAptamersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TarusAdenosineReceptorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TarusAdenosineReceptorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TarusAdenosineReceptors1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptors1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TarusAdenosineReceptors1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptors1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TarusAdenosineReceptors2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptors2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TarusAdenosineReceptors2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusAdenosineReceptors2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TarusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TarusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TarusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-01-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2019-01-08</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_IOXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_IOXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_IOXMember327150515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_IOXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-032019-01-31_custom_SalvaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SalvaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-03</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="From2021-09-012021-09-08_custom_IOXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_IOXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_IOXMember327152796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-012020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_UnitedStateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:UnitedStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_BVIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:BVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ForeignMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:ForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_UnitedStateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:UnitedStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BVIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:BVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ForeignMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ptgef:ForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2020-06-022020-06-16_custom_AccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:AccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-02</startDate>
            <endDate>2020-06-16</endDate>
        </period>
    </context>
    <context id="From2020-06-022020-06-16_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-02</startDate>
            <endDate>2020-06-16</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-07-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2022-07-18</instant>
        </period>
    </context>
    <context id="From2022-08-012022-08-19_custom_LincolnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:LincolnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-19</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:N2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="AsOf2021-01-13_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="AsOf2021-01-13_custom_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-19_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-19</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-19_custom_TwoMembersMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:TwoMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-19</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-19_custom_EmployeesMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-19</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-19_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:DirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-19</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-15_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:DirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="From2022-06-012022-06-08_custom_ExecutiveMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ExecutiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-07-27_custom_BoardOfDirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="From2022-06-012022-07-27_custom_BoardOfDirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:AmendedAndRestated2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_IOxOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_IOxOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_IOxOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ptgef:UnvestedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-08</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-07-27_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:IOxOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ptgef:UnvestedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_StockOptionsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_StockOptionsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_StockOptionsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_StockOptionsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_StockOptionsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_StockOptionsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:StockOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember327165015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2022-07-13</instant>
        </period>
    </context>
    <context id="From2022-07-012022-07-06_custom_LincolnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:LincolnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-06</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_LincolnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:LincolnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-15_custom_ChiefExecutiveOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ChiefExecutiveOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AmortizedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_AmortizedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-12-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_IOXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:IOXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-02-012023-02-28_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="EURPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-04-01to2022-12-31">0001095435</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-04-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-04-01to2022-12-31">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-04-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-04-01to2022-12-31">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="From2022-04-01to2022-12-31">6-K</dei:DocumentType>
    <dei:DocumentType contextRef="From2022-04-01to2022-12-31">6-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-04-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber contextRef="From2022-04-01to2022-12-31">001-40086</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-04-01to2022-12-31">Portage Biotech Inc.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="From2022-04-01to2022-12-31">Clarence Thomas Building</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-04-01to2022-12-31">P.O. Box 4649</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2022-04-01to2022-12-31">Road Town</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="From2022-04-01to2022-12-31">Tortola</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="From2022-04-01to2022-12-31">VG1110</dei:EntityAddressPostalZipCode>
    <dei:EntityCentralIndexKey contextRef="From2022-04-01to2022-12-31">0001095435</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-04-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-04-01to2022-12-31">6-K</dei:DocumentType>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-04-01to2022-12-31">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-04-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-04-01to2022-12-31">Q3</dei:DocumentFiscalPeriodFocus>
    <ptgef:ConvertibleNoteReceivable
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0042"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredCommitmentFee
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0063"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:WarrantLiabilityCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredPurchasePricePayableTarus
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredObligationIoxMilestone
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0158"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0160"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ForeignExchangeLoss
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ForeignExchangeLoss
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0175"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0178"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0180"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromInterest
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromInterest
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0185"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:InterestExpense
      contextRef="From2022-10-012022-12-31"
      id="xdx2ixbrl0187"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedInTarusAcquisition
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedInTarusAcquisition
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedInTarusAcquisition
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedInTarusAcquisition
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedInIoxExchange
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedInIoxExchange
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedInIoxExchange
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedInIoxExchange
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredObligationIoxMilestoneValue
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredObligationIoxMilestoneValue
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredObligationIoxMilestoneValue
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredObligationIoxMilestoneValue
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredObligationIoxMilestoneValue
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCosts
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCosts
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCosts
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCosts
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestmentsValue
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestmentsValue
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestmentsValue
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedLossOnInvestmentsValue
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCosts
      contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCosts
      contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCosts
      contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ShareIssuanceCosts
      contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:WarrantsExercised
      contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:WarrantsExercised
      contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:WarrantsExercised
      contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:WarrantsExercised
      contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares
      contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares
      contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares
      contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares
      contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchaseOfConvertibleNoteReceivable
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RepaymentOfNotesPayableAssumedInTarusAcquisition
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RepaymentOfMilestoneObligationAssumedInTarusAcquisition
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromExerciseOfStockPurchaseWarrants
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CashPaidForInterest
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IncreaseInAccountsPayableForStockIssuanceCosts
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl0607"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueOfSharesIssuedForTarus
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0614"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0617"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueOfDeferredPurchasePricePayabletarus
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueOfDeferredObligationIoxMilestone
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LiabilitiesAssumedInTarusAcquisition
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentReceivablesFromSaleOfProperties
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TarusGoodwill
      contextRef="From2021-04-012022-03-31"
      id="xdx2ixbrl0952"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-03-31_custom_TarusAdenosineReceptorsMember"
      id="xdx2ixbrl0999"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-03-31_custom_TarusAdenosineReceptors1Member"
      id="xdx2ixbrl1003"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-03-31_custom_TarusAdenosineReceptors2Member"
      id="xdx2ixbrl1007"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-03-31_custom_TarusMember"
      id="xdx2ixbrl1011"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NotePayable
      contextRef="AsOf2022-12-31_custom_IOXMember327150515"
      id="xdx2ixbrl1056"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NotePayable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1058"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NotePayable
      contextRef="AsOf2022-12-31_custom_IOXMember327150515"
      id="xdx2ixbrl1064"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NotePayable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1066"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CurrentFederalIncomeTaxBenefit
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl1086"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CurrentFederalIncomeTaxBenefit
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1087"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CurrentStateAndLocalIncomeTaxBenefit
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1090"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredFederalIncomeTaxBenefit
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl1101"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredFederalIncomeTaxBenefit
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1102"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredStateAndLocalIncomeTaxBenefit
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl1104"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredStateAndLocalIncomeTaxBenefit
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1105"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IncomeTaxBenefitExpense
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1136"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeIncreaseInDeferredIncomeTaxRate
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1163"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:TaxEffectOfRAndDCredit
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl1168"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossesUnrecognized
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl1171"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossForWhichNoBenefitWasTaken
      contextRef="AsOf2022-12-31_custom_BVIMember"
      id="xdx2ixbrl1193"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossForWhichNoBenefitWasTaken
      contextRef="AsOf2022-12-31_custom_ForeignMember"
      id="xdx2ixbrl1194"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossForWhichNoBenefitWasTaken
      contextRef="AsOf2021-12-31_custom_UnitedStateMember"
      id="xdx2ixbrl1196"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossForWhichNoBenefitWasTaken
      contextRef="AsOf2021-12-31_custom_BVIMember"
      id="xdx2ixbrl1197"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossForWhichNoBenefitWasTaken
      contextRef="AsOf2021-12-31_custom_ForeignMember"
      id="xdx2ixbrl1198"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossForWhichNoBenefitWasTaken
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1199"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossesNotSubjectToTax
      contextRef="AsOf2022-12-31_custom_UnitedStateMember"
      id="xdx2ixbrl1201"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossesNotSubjectToTax
      contextRef="AsOf2022-12-31_custom_ForeignMember"
      id="xdx2ixbrl1203"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossesNotSubjectToTax
      contextRef="AsOf2021-12-31_custom_UnitedStateMember"
      id="xdx2ixbrl1205"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LossesNotSubjectToTax
      contextRef="AsOf2021-12-31_custom_ForeignMember"
      id="xdx2ixbrl1207"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UtilizationOfLossesNotPreviouslyBenefitted
      contextRef="AsOf2022-12-31_custom_BVIMember"
      id="xdx2ixbrl1211"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UtilizationOfLossesNotPreviouslyBenefitted
      contextRef="AsOf2022-12-31_custom_ForeignMember"
      id="xdx2ixbrl1212"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UtilizationOfLossesNotPreviouslyBenefitted
      contextRef="AsOf2021-12-31_custom_UnitedStateMember"
      id="xdx2ixbrl1214"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UtilizationOfLossesNotPreviouslyBenefitted
      contextRef="AsOf2021-12-31_custom_BVIMember"
      id="xdx2ixbrl1215"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UtilizationOfLossesNotPreviouslyBenefitted
      contextRef="AsOf2021-12-31_custom_ForeignMember"
      id="xdx2ixbrl1216"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:UtilizationOfLossesNotPreviouslyBenefitted
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1217"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PretaxLossSubjectToTax
      contextRef="AsOf2022-12-31_custom_BVIMember"
      id="xdx2ixbrl1220"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PretaxLossSubjectToTax
      contextRef="AsOf2021-12-31_custom_BVIMember"
      id="xdx2ixbrl1224"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueAdjustmentExercisePriceAtEnd
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl1295"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ptgef:WarrantsOutstandingExercisePrice
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1301"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ptgef:WarrantsOutstandingShares
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1303"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:WarrantsOutstandingAmount
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1305"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1331"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1333"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedInIoxExchangesShares
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1339"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:ShareIssuedInIoxExchange
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1341"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl1343"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1347"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1349"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedToLincolnParksCommittedPurchaseShares
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1355"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:SharesIssuedToLincolnParksCommittedPurchase
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1357"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1371"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts
      contextRef="From2021-04-012021-12-31"
      id="xdx2ixbrl1373"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:WarrantsExercisedShares
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl1383"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="From2022-04-01to2022-12-31"
      id="xdx2ixbrl1385"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl1461"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SettledInIoxExchange
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl1471"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SettledInIoxExchange
      contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl1473"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SettledInIoxExchange
      contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl1475"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StockOptionReserve
      contextRef="AsOf2022-12-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl1477"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2021-04-012021-12-31_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl1574"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2022-04-012022-12-31_custom_StockOptionsTwoMember"
      id="xdx2ixbrl1576"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2021-04-012021-12-31_custom_StockOptionsTwoMember"
      id="xdx2ixbrl1578"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl1580"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2021-04-012021-12-31_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl1582"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2022-12-31_custom_StockOptionsTwoMember"
      id="xdx2ixbrl1592"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="AsOf2022-12-31_custom_StockOptionsTwoMember"
      id="xdx2ixbrl1600"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2022-04-012022-12-31_custom_StockOptionsTwoMember"
      id="xdx2ixbrl1619"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="From2022-04-012022-12-31_custom_WarrantsMember"
      id="xdx2ixbrl1697"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1806"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1808"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1811"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1813"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ConvertibleNoteReceivableIncludingAccruedInterest
      contextRef="AsOf2022-12-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1815"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ConvertibleNoteReceivableIncludingAccruedInterest
      contextRef="AsOf2022-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1817"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ConvertibleNoteReceivableIncludingAccruedInterest
      contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1818"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentInvestments
      contextRef="AsOf2022-12-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1820"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentInvestments
      contextRef="AsOf2022-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1822"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1831"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1833"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2022-12-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1835"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1836"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2022-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1837"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredPurchasePricePayableTarus
      contextRef="AsOf2022-12-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1840"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredPurchasePricePayableTarus
      contextRef="AsOf2022-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1842"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredPurchasePricePayableTarus
      contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1843"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredObligationIoxMilestone
      contextRef="AsOf2022-12-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1845"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredObligationIoxMilestone
      contextRef="AsOf2022-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1847"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:DeferredObligationIoxMilestone
      contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1848"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement
      contextRef="From2022-04-012022-12-31_custom_SaugatuckMember"
      id="xdx2ixbrl1911"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2022-12-31_custom_IOXMember327150515"
      id="xdx2ixbrl1915"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2021-04-012021-12-31_custom_SaugatuckMember"
      id="xdx2ixbrl1929"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares
      contextRef="From2021-04-012021-12-31_custom_SaugatuckMember"
      id="xdx2ixbrl1935"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentPeriodEndDate contextRef="From2022-04-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">13104000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">23352000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1786000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1480000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ptgef:ConvertibleNoteReceivable contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">642000</ptgef:ConvertibleNoteReceivable>
    <ifrs-full:CurrentAssets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">15532000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">24832000</ifrs-full:CurrentAssets>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1405000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1673000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentProperty contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3363000</ifrs-full:InvestmentProperty>
    <ifrs-full:InvestmentProperty contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">7409000</ifrs-full:InvestmentProperty>
    <ifrs-full:Goodwill contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">43862000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">43324000</ifrs-full:Goodwill>
    <ptgef:InprocessResearchAndDevelopment contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">145588000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">117388000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:DeferredCommitmentFee contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">894000</ptgef:DeferredCommitmentFee>
    <ifrs-full:OtherAssets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">39000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">36000</ifrs-full:OtherAssets>
    <ifrs-full:NoncurrentAssets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">195151000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">169830000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">210683000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">194662000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2422000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">750000</ifrs-full:TradeAndOtherCurrentPayables>
    <ptgef:WarrantLiabilityCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">33000</ptgef:WarrantLiabilityCurrent>
    <ifrs-full:CurrentLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2422000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">783000</ifrs-full:CurrentLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">25515000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">28445000</ifrs-full:DeferredTaxLiabilities>
    <ptgef:DeferredPurchasePricePayableTarus contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">8876000</ptgef:DeferredPurchasePricePayableTarus>
    <ptgef:DeferredObligationIoxMilestone contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">5568000</ptgef:DeferredObligationIoxMilestone>
    <ifrs-full:NoncurrentLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">39959000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">28445000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">42381000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">29228000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">216630000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">158324000</ifrs-full:IssuedCapital>
    <ifrs-full:OtherReserves contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">20542000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">16928000</ifrs-full:OtherReserves>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-3059000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">958000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:RetainedEarnings contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-65168000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">-55005000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">168945000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">121205000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-643000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">44229000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">168302000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">165434000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">210683000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">194662000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">2535000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">1928000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">5976000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">4804000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">2224000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">2241000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">6523000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">6288000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-4759000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-4169000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-12499000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-11092000</ifrs-full:ProfitLossFromOperatingActivities>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-498000</ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-428000</ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-152000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-261000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-268000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-363000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">8000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">342000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">33000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ptgef:GainsLossesOnChangeInFairValueOfWarrants
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">726000</ptgef:GainsLossesOnChangeInFairValueOfWarrants>
    <ifrs-full:ForeignExchangeLoss
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-50000</ifrs-full:ForeignExchangeLoss>
    <ifrs-full:ForeignExchangeLoss
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">60000</ifrs-full:ForeignExchangeLoss>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">1000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:RevenueFromInterest
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">50000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">115000</ifrs-full:RevenueFromInterest>
    <ifrs-full:InterestExpense
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">1000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">9000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">42000</ifrs-full:InterestExpense>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-5302000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-4089000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-13117000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-10771000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">2199000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">117000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-2906000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-465000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ptgef:Netloss
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-7501000</ptgef:Netloss>
    <ptgef:Netloss
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-4206000</ptgef:Netloss>
    <ptgef:Netloss
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10211000</ptgef:Netloss>
    <ptgef:Netloss
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-10306000</ptgef:Netloss>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-4017000</ptgef:NetUnrealizedLossOnInvestments>
    <ptgef:NetUnrealizedLossOnInvestments
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-4017000</ptgef:NetUnrealizedLossOnInvestments>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-11518000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-4206000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-14228000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-10306000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-7485000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-3512000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10163000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-9553000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-16000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-694000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-48000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-753000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ptgef:Netloss
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-7501000</ptgef:Netloss>
    <ptgef:Netloss
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-4206000</ptgef:Netloss>
    <ptgef:Netloss
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10211000</ptgef:Netloss>
    <ptgef:Netloss
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-10306000</ptgef:Netloss>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-11502000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-3512000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-14180000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-9553000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-16000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-694000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-48000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-753000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-11518000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-4206000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-14228000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-10306000</ifrs-full:ComprehensiveIncome>
    <ptgef:BasicAndDilutedEarningsLossPerShare
      contextRef="From2022-10-012022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.44</ptgef:BasicAndDilutedEarningsLossPerShare>
    <ptgef:BasicAndDilutedEarningsLossPerShare
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.26</ptgef:BasicAndDilutedEarningsLossPerShare>
    <ptgef:BasicAndDilutedEarningsLossPerShare
      contextRef="From2022-04-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.65</ptgef:BasicAndDilutedEarningsLossPerShare>
    <ptgef:BasicAndDilutedEarningsLossPerShare
      contextRef="From2021-04-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.74</ptgef:BasicAndDilutedEarningsLossPerShare>
    <ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted
      contextRef="From2022-10-012022-12-31"
      decimals="INF"
      unitRef="USDPShares">17039</ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted>
    <ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">13344</ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted>
    <ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted
      contextRef="From2022-04-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">15719</ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted>
    <ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted
      contextRef="From2021-04-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">12966</ptgef:WeightedAveragesSharesoutstandingBasicAndDiluted>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">13349000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">158324000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">16928000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">958000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-55005000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">121205000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">44229000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">165434000</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">3614000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">3614000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3614000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ptgef:SharesIssuedInTarusAcquisitionShares
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">2426000</ptgef:SharesIssuedInTarusAcquisitionShares>
    <ptgef:SharesIssuedInTarusAcquisition
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">17200000</ptgef:SharesIssuedInTarusAcquisition>
    <ptgef:SharesIssuedInTarusAcquisition
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">17200000</ptgef:SharesIssuedInTarusAcquisition>
    <ptgef:SharesIssuedInTarusAcquisition
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">17200000</ptgef:SharesIssuedInTarusAcquisition>
    <ptgef:SharesIssuedInIoxExchangeShares
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">1070000</ptgef:SharesIssuedInIoxExchangeShares>
    <ptgef:SharesIssuedInIoxExchange
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">9737000</ptgef:SharesIssuedInIoxExchange>
    <ptgef:SharesIssuedInIoxExchange
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">9737000</ptgef:SharesIssuedInIoxExchange>
    <ptgef:SharesIssuedInIoxExchange
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">-9737000</ptgef:SharesIssuedInIoxExchange>
    <ptgef:DeferredObligationIoxMilestoneValue
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">-5478000</ptgef:DeferredObligationIoxMilestoneValue>
    <ptgef:DeferredObligationIoxMilestoneValue
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-5478000</ptgef:DeferredObligationIoxMilestoneValue>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">29609000</ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">29609000</ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">-29609000</ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox>
    <ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">94000</ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares>
    <ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">900000</ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement>
    <ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">900000</ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement>
    <ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">900000</ptgef:SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement>
    <ptgef:SharesIssuedUnderAtmShares
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">88000</ptgef:SharesIssuedUnderAtmShares>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">604000</ptgef:SharesIssuedUnderAtm>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">604000</ptgef:SharesIssuedUnderAtm>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">604000</ptgef:SharesIssuedUnderAtm>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">30000</ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">190000</ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">190000</ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">190000</ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement>
    <ptgef:ShareIssuanceCosts
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">-24000</ptgef:ShareIssuanceCosts>
    <ptgef:ShareIssuanceCosts
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">-24000</ptgef:ShareIssuanceCosts>
    <ptgef:ShareIssuanceCosts
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-24000</ptgef:ShareIssuanceCosts>
    <ptgef:SharesIssuedOrAccruedForServicesShares
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">13000</ptgef:SharesIssuedOrAccruedForServicesShares>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2022-04-012022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">90000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">90000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">90000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:NetUnrealizedLossOnInvestmentsValue
      contextRef="From2022-04-012022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-4017000</ptgef:NetUnrealizedLossOnInvestmentsValue>
    <ptgef:NetUnrealizedLossOnInvestmentsValue
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">-4017000</ptgef:NetUnrealizedLossOnInvestmentsValue>
    <ptgef:NetUnrealizedLossOnInvestmentsValue
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-4017000</ptgef:NetUnrealizedLossOnInvestmentsValue>
    <ifrs-full:ProfitLoss
      contextRef="From2022-04-012022-12-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-10163000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2022-04-012022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">-10163000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">-48000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10211000</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">17070000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2022-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">216630000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-12-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">20542000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-3059000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-12-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-65168000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">168945000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">-643000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">168302000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">12084000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">130649000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">7977000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">958000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-38135000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">101449000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">46153000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">147602000</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">6248000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">6248000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">191000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">6439000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ptgef:SharesIssuedUnderAtmShares
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">91000</ptgef:SharesIssuedUnderAtmShares>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">2643000</ptgef:SharesIssuedUnderAtm>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">2643000</ptgef:SharesIssuedUnderAtm>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">2643000</ptgef:SharesIssuedUnderAtm>
    <ptgef:SharesIssuedUnderOfferingShares
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">1150000</ptgef:SharesIssuedUnderOfferingShares>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">26450000</ptgef:SharesIssuedUnderOffering>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">26450000</ptgef:SharesIssuedUnderOffering>
    <ptgef:SharesIssuedUnderOffering
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">26450000</ptgef:SharesIssuedUnderOffering>
    <ptgef:ShareIssuanceCosts
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">-1877000</ptgef:ShareIssuanceCosts>
    <ptgef:ShareIssuanceCosts
      contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">-1877000</ptgef:ShareIssuanceCosts>
    <ptgef:ShareIssuanceCosts
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-1877000</ptgef:ShareIssuanceCosts>
    <ptgef:SharesIssuedOrAccruedForServicesShares
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">4000</ptgef:SharesIssuedOrAccruedForServicesShares>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">90000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">90000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">90000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:WarrantsExercisedShares
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">16000</ptgef:WarrantsExercisedShares>
    <ptgef:WarrantsExercised
      contextRef="From2021-04-012021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">339000</ptgef:WarrantsExercised>
    <ptgef:WarrantsExercised
      contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">339000</ptgef:WarrantsExercised>
    <ptgef:WarrantsExercised
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">339000</ptgef:WarrantsExercised>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares
      contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">184000</ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">184000</ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShares>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-12-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-9553000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">-9553000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">-753000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-10306000</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="Shares">13345000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2021-12-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      unitRef="USD">158294000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-12-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">14225000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-12-31_ifrs-full_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">958000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-12-31_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-47688000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-12-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      unitRef="USD">125789000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">45775000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">171564000</ifrs-full:Equity>
    <ifrs-full:ProfitLossFromDiscontinuedOperations
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10211000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:ProfitLossFromDiscontinuedOperations
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-10306000</ifrs-full:ProfitLossFromDiscontinuedOperations>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3614000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">6439000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2930000</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">444000</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <ptgef:IncomeOnFairValueOfWarrantLiability
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-33000</ptgef:IncomeOnFairValueOfWarrantLiability>
    <ptgef:IncomeOnFairValueOfWarrantLiability
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-726000</ptgef:IncomeOnFairValueOfWarrantLiability>
    <ptgef:ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-428000</ptgef:ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone>
    <ptgef:FairValueOfStockIssuedForServices
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">90000</ptgef:FairValueOfStockIssuedForServices>
    <ptgef:FairValueOfStockIssuedForServices
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">90000</ptgef:FairValueOfStockIssuedForServices>
    <ifrs-full:GainLossOnHedgeIneffectiveness
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-268000</ifrs-full:GainLossOnHedgeIneffectiveness>
    <ifrs-full:GainLossOnHedgeIneffectiveness
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-363000</ifrs-full:GainLossOnHedgeIneffectiveness>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">15000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ptgef:IncreasingDecreasingAccountsReceivable
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-25000</ptgef:IncreasingDecreasingAccountsReceivable>
    <ptgef:IncreasingDecreasingAccountsReceivable
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-385000</ptgef:IncreasingDecreasingAccountsReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-354000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">1286000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">24000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-144000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1671000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-1486000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">30000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">30000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-7392000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-4513000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ptgef:PurchaseOfConvertibleNoteReceivable
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">614000</ptgef:PurchaseOfConvertibleNoteReceivable>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-617000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ptgef:RepaymentOfNotesPayableAssumedInTarusAcquisition
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2000000</ptgef:RepaymentOfNotesPayableAssumedInTarusAcquisition>
    <ptgef:RepaymentOfMilestoneObligationAssumedInTarusAcquisition
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1009000</ptgef:RepaymentOfMilestoneObligationAssumedInTarusAcquisition>
    <ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">794000</ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase>
    <ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">29093000</ptgef:ProceedsFromSharesIssuedUnderRegisteredOffering>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">24000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">1852000</ifrs-full:PaymentsForShareIssueCosts>
    <ptgef:ProceedsFromExerciseOfStockPurchaseWarrants
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">105000</ptgef:ProceedsFromExerciseOfStockPurchaseWarrants>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-2239000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">27346000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10248000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">22833000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">23352000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">2770000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">13104000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">25603000</ifrs-full:CashAndCashEquivalents>
    <ptgef:CashPaidForInterest
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">19000</ptgef:CashPaidForInterest>
    <ptgef:IncreaseInAccountsPayableForStockIssuanceCosts
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">25000</ptgef:IncreaseInAccountsPayableForStockIssuanceCosts>
    <ptgef:FairValueOfSharesIssuedForTarus
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">17200000</ptgef:FairValueOfSharesIssuedForTarus>
    <ptgef:FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">9737000</ptgef:FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox>
    <ptgef:FairValueOfDeferredPurchasePricePayabletarus
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">8538000</ptgef:FairValueOfDeferredPurchasePricePayabletarus>
    <ptgef:FairValueOfDeferredObligationIoxMilestone
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">5478000</ptgef:FairValueOfDeferredObligationIoxMilestone>
    <ptgef:LiabilitiesAssumedInTarusAcquisition
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3000000</ptgef:LiabilitiesAssumedInTarusAcquisition>
    <ptgef:FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">900000</ptgef:FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase>
    <ptgef:ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">184000</ptgef:ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants>
    <ptgef:NatureOfOperationsExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_801_ecustom--NatureOfOperationsExplanatory_z6pMnldN2zCc" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 1. &lt;span id="xdx_825_zX60qVGRiP8j"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Portage Biotech Inc. (the &#x201c;Company&#x201d; or &#x201c;Portage&#x201d;)
is incorporated in the British Virgin Islands (&#x201c;BVI&#x201d;) with its registered office located at Clarence Thomas Building, P.O.
Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development Services Inc. (&#x201c;PDS&#x201d;), is located at 61 Wilton Road,
Westport, CT, 06880, USA.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company is a foreign private issuer under the Securities and Exchange
Commission (the &#x201c;SEC&#x201d;) rules. It is also a reporting issuer under the securities legislation of the provinces of Ontario and
British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (&#x201c;CSE&#x201d;) under the symbol &#x201c;PBT.U&#x201d;.
On February 25, 2021, the ordinary shares of the Company began trading on the NASDAQ Capital Market (&#x201c;NASDAQ&#x201d;) under the symbol
&#x201c;PRTG&#x201d;. As the principal market for the Company&#x2019;s ordinary shares is NASDAQ, the Company voluntarily delisted from the
CSE on April 23, 2021.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Portage is a clinical-stage immuno-oncology company advancing therapies
that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with evasive
cancers. Portage&#x2019;s access to next-generation technologies coupled with a deep understanding of biological mechanisms enable the
identification of clinical therapies and product development strategies that accelerate these medicines through the translational pipeline.
Portage&#x2019;s portfolio consists of six diverse platforms, with lead programs including invariant natural killer T-cell (&#x201c;iNKT&#x201d;)
agonists and a suite of treatments targeting the adenosine pathway. Additional programs leverage delivery by intratumorals, nanoparticles,
liposomes, aptamers, and virus-like particles. Within these six platforms, Portage has 16 products currently in development with multiple
clinical readouts expected through the end of 2023.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On August 13, 2018, the Company reached a definitive agreement to acquire
&lt;span id="xdx_906_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxGroupPlcMember_zLLowsn1Im5l" title="Percentage of acquire"&gt;100&lt;/span&gt;% of SalvaRx Limited (&#x201c;SalvaRx&#x201d;) in exchange for 8,050,701 ordinary shares of the Company (the &#x201c;SalvaRx Acquisition&#x201d;).
The SalvaRx Acquisition was completed on January 8, 2019 (the &#x201c;Acquisition Date&#x201d;) upon receiving shareholder and regulatory
approval. In connection with the SalvaRx Acquisition, the Company acquired interests in SalvaRx&#x2019;s five research and development
invested entities and subsidiaries: iOx Therapeutics Ltd. (&#x201c;iOx&#x201d;), Nekonal Oncology Limited (&#x201c;Nekonal&#x201d;), Intensity
Therapeutics, Inc. (&#x201c;Intensity&#x201d;), Saugatuck Therapeutics, Ltd. (&#x201c;Saugatuck&#x201d;) and Rift Biotherapeutics Inc. (&#x201c;Rift&#x201d;).&#160;
The Company also acquired an option in Nekonal SARL, a Luxembourg-based company holding intellectual property rights for therapeutics
and diagnostics in the field of autoimmune disorders and oncology, to participate in the funding of its autoimmune programs. During fiscal
2021, the Company abandoned its interests in Nekonal and Nekonal SARL.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"&gt;&#160;&lt;/p&gt;

</ptgef:NatureOfOperationsExplanatory>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="AsOf2018-08-13_custom_SalvaRxGroupPlcMember"
      decimals="INF"
      unitRef="Pure">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ptgef:LiquidityTextBlock contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_805_ecustom--LiquidityTextBlock_zy8ODAk1nwCb" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 2. &lt;span id="xdx_821_zRxtRqqKiaIh"&gt;LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;As of December 31, 2022, the Company had cash and cash equivalents of
approximately $&lt;span id="xdx_90D_eifrs-full--Cash_iI_pn3n3_dm_c20221231_znof1qtzSALe" title="Cash and cash equivalents"&gt;13.1&lt;/span&gt; million and total current liabilities of approximately $&lt;span id="xdx_90B_ecustom--TotalCurrentLiabilities_iI_pn3n3_dm_c20221231_ztUDFGjzDzlk" title="Total current liabilities"&gt;2.4&lt;/span&gt; million. For the nine months ended December 31, 2022,
the Company is reporting a net loss of approximately $&lt;span id="xdx_908_ecustom--NetLossIncome_pn3n3_dm_c20220401__20221231_zfJF0K8rpYD6" title="Net (loss) income"&gt;10.2&lt;/span&gt; million and cash used in operating activities of approximately $&lt;span id="xdx_902_ecustom--CashUsedInOperatingActivities_pn3n3_dm_c20220401__20221231_zgFoveIn5FPh" title="Cash used in operating activities"&gt;7.4&lt;/span&gt; million.
As of January 31, 2023, the Company had approximately $&lt;span id="xdx_90D_eifrs-full--CashOnHand_iI_pn3n3_dm_c20220731_zZg6oGlyWLyd" title="Cash on hand"&gt;13.2&lt;/span&gt; million of cash and cash equivalents on hand. The Company believes its current
cash resources, including its access to the ATM and Committed Purchase (each as defined below, are sufficient to fund operations for at
least 13 months from March 1, 2023, the date when the Company&#x2019;s management prepared the Company&#x2019;s condensed consolidated
interim financial statements for the three and nine months ended December 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Portage filed a shelf registration statement and prospectus with the SEC
under which it may sell shares, debt securities, warrants and units in one or more offerings from time to time, which became effective
on March 8, 2021 (&#x201c;Registration Statement&#x201d; or &#x201c;Prospectus&#x201d;). In connection with the Registration Statement, Portage
has filed with the SEC:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;




















&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;a base prospectus, which covers the offering, issuance and sale by Portage of up to $&lt;span id="xdx_904_ecustom--IssuanceAndSales_c20220401__20221231_pn3n3" title="Issuance and sales"&gt;200,000,000&lt;/span&gt; in the aggregate of the securities
identified above from time to time in one or more offerings;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;a prospectus supplement covering the offer, issuance and sale by Portage in an &#x201c;at the market&#x201d; (the &#x201c;ATM&#x201d;)
offering of up to a maximum aggregate offering price of up to $&lt;span id="xdx_905_ecustom--MaximumAggregateOfferingPrice_c20220401__20221231_pn3n3" title="Maximum aggregate offering price"&gt;50,000,000&lt;/span&gt; of Portage&#x2019;s ordinary shares that may be issued and sold
from time to time under a Controlled Equity Offering Sales Agreement dated February 24, 2021 (the &#x201c;Sales Agreement&#x201d;), with
Cantor Fitzgerald &amp;amp; Co., the sales agent (&#x201c;Cantor Fitzgerald&#x201d;);&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by Portage of 1,150,000 ordinary shares for gross proceeds
of approximately $26.5 million in a firm commitment underwriting with Cantor Fitzgerald; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;a prospectus supplement dated August 19, 2022, for the resale of up to $30,000,000 of Portage&#x2019;s ordinary shares that Portage
may sell from time to time to Lincoln Park Capital Fund, LLC (&#x201c;Lincoln&#x201d;) and an additional 94,508 shares that were issued
to Lincoln.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span id="xdx_90F_ecustom--CashFundDescription_c20220401__20221231" title="Cash fund, description"&gt;The Sales Agreement permits the Company to sell in an ATM offering up
to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered,
issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an &#x201c;at
the market&#x201d; offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#x201c;Securities
Act&#x201d;). Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is
not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus. See Note 14, &#x201c;Capital
Stock,&#x201d; and Note 22, &#x201c;Event After the Balance Sheet Date,&#x201d; for a further discussion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;During the quarter ended June 30, 2021, the Company commenced an &#x201c;at
the market&#x201d; offering, under which it sold &lt;span id="xdx_907_ecustom--NumberOfStockSold_c20210401__20210630_pdd" title="Number of stock sold"&gt;90,888&lt;/span&gt; ordinary shares generating gross proceeds of approximately $&lt;span id="xdx_903_ecustom--GrossProceedsFromStockSold_pn3n3_dm_c20210401__20210630_zhj8CbgEcpL2" title="Gross proceeds from stock sold"&gt;2.6&lt;/span&gt; million ($&lt;span id="xdx_901_ecustom--NetProceedsFromStockSold_pn3n3_dm_c20210401__20210630_zHMJ1jsgGfQb" title="Net proceeds from stock sold"&gt;2.5&lt;/span&gt; million,
net of commissions).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On June 24, 2021, &lt;span id="xdx_906_ecustom--OfferingAndThroughThatProcessDescription_c20210601__20210624_zakxQr2tWLcc" title="Offering and through that process, description"&gt;the Company completed a firm commitment underwritten
public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8
million, including approximately $1.6 million of management, underwriting and selling expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On July 6, 2022, the Company entered into a Purchase Agreement (the &#x201c;Committed
Purchase Agreement&#x201d;) with Lincoln, under which it may require Lincoln to purchase ordinary shares of the Company having an aggregate
value of up to $30 million (the &#x201c;Purchase Shares&#x201d;) over a period of 36 months. Pursuant to the Committed Purchase Agreement,
Lincoln will be obligated to purchase the Purchase Shares in three different scenarios that are based on various market criteria and share
amounts. The Company has the right to terminate the Committed Purchase Agreement for any reason, effective upon one business day prior
written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The requirement that Lincoln must make
a purchase will be suspended based on various criteria such as there not being an effective registration statement for Lincoln to be able
to resell the ordinary shares it is committed to purchase and market criteria such as the Company continuing to be Depository Trust Company
eligible, among other things. The Committed Purchase Agreement does not impose any financial or business covenants on the Company, and
there are no limitations on the use of proceeds. The Company may raise capital from other sources in its sole discretion; provided, however,
that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year
anniversary of the date of the Committed Purchase Agreement, excluding, however, an at-the-market transaction with a registered broker-dealer.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;In October 2022, the Company restarted the ATM and commenced sales of
ordinary shares pursuant to the Sales Agreement. Through December 31, 2022, the Company sold &lt;span id="xdx_90A_ecustom--NumberOfSharesSold_pid_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zGMvhkSMlFt6" title="Number of shares sold"&gt;88,072&lt;/span&gt; ordinary shares under the ATM, generating
net proceeds of approximately $&lt;span id="xdx_904_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zAzoqx3bPCa9" title="Net proceeds from sale"&gt;0.6&lt;/span&gt; million and sold &lt;span id="xdx_908_ecustom--NumberOfSharesSold_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zvfIIFT9hVsk" title="Number of shares sold"&gt;30,000&lt;/span&gt; ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds
totaling approximately $&lt;span id="xdx_901_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zIws2MS0r0ci" title="Net proceeds from sale"&gt;0.2&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company has incurred substantial operating losses since inception
and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result
primarily from its conduct of research and development activities.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company historically has funded its operations principally from proceeds
from issuances of equity and debt securities and would expect to enter the capital markets if additional funding is required.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;COVID-19 Effect&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Beginning in early March 2020, the COVID-19 pandemic and the measures
imposed to contain this pandemic have disrupted and are expected to continue to impact the Company&#x2019;s business operations. The magnitude
of the impact of the COVID-19 pandemic on the Company&#x2019;s productivity, results of operations and financial position, and its disruption
to the Company&#x2019;s business and clinical programs and timelines, will depend, in part, on the length and severity of these restrictions
and on the Company&#x2019;s ability to conduct business in the ordinary course. There was a slowdown and temporary lack of research and
development resources, principally due to the focus of third party research on the pandemic. The research and development environment has substantially normalized
in  calendar 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ptgef:LiquidityTextBlock>
    <ifrs-full:Cash contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">13100000</ifrs-full:Cash>
    <ptgef:TotalCurrentLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2400000</ptgef:TotalCurrentLiabilities>
    <ptgef:NetLossIncome
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">10200000</ptgef:NetLossIncome>
    <ptgef:CashUsedInOperatingActivities
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">7400000</ptgef:CashUsedInOperatingActivities>
    <ifrs-full:CashOnHand contextRef="AsOf2022-07-31" decimals="-3" unitRef="USD">13200000</ifrs-full:CashOnHand>
    <ptgef:IssuanceAndSales
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">200000000000</ptgef:IssuanceAndSales>
    <ptgef:MaximumAggregateOfferingPrice
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">50000000000</ptgef:MaximumAggregateOfferingPrice>
    <ptgef:CashFundDescription contextRef="From2022-04-01to2022-12-31">The Sales Agreement permits the Company to sell in an ATM offering up
to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered,
issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an &#x201c;at
the market&#x201d; offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#x201c;Securities
Act&#x201d;). Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is
not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus. See Note 14, &#x201c;Capital
Stock,&#x201d; and Note 22, &#x201c;Event After the Balance Sheet Date,&#x201d; for a further discussion.</ptgef:CashFundDescription>
    <ptgef:NumberOfStockSold
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">90888</ptgef:NumberOfStockSold>
    <ptgef:GrossProceedsFromStockSold
      contextRef="From2021-04-012021-06-30"
      decimals="-3"
      unitRef="USD">2600000</ptgef:GrossProceedsFromStockSold>
    <ptgef:NetProceedsFromStockSold
      contextRef="From2021-04-012021-06-30"
      decimals="-3"
      unitRef="USD">2500000</ptgef:NetProceedsFromStockSold>
    <ptgef:OfferingAndThroughThatProcessDescription contextRef="From2021-06-012021-06-24">the Company completed a firm commitment underwritten
public offering of 1,150,000 ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $26.5
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $1.8
million, including approximately $1.6 million of management, underwriting and selling expenses.</ptgef:OfferingAndThroughThatProcessDescription>
    <ptgef:NumberOfSharesSold
      contextRef="From2022-12-302022-12-31_custom_ATMMember"
      decimals="INF"
      unitRef="Shares">88072</ptgef:NumberOfSharesSold>
    <ifrs-full:ProceedsFromSalesOfBiologicalAssets
      contextRef="From2022-12-302022-12-31_custom_ATMMember"
      decimals="-3"
      unitRef="USD">600000</ifrs-full:ProceedsFromSalesOfBiologicalAssets>
    <ptgef:NumberOfSharesSold
      contextRef="From2022-12-302022-12-31_custom_LincolnMember"
      decimals="INF"
      unitRef="Shares">30000</ptgef:NumberOfSharesSold>
    <ifrs-full:ProceedsFromSalesOfBiologicalAssets
      contextRef="From2022-12-302022-12-31_custom_LincolnMember"
      decimals="-3"
      unitRef="USD">200000</ifrs-full:ProceedsFromSalesOfBiologicalAssets>
    <ptgef:DisclosureOfBasisOfPresentationExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_800_ecustom--DisclosureOfBasisOfPresentationExplanatory_zL5nVY97c0dd" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 3. &lt;span id="xdx_82D_zNOInjuubg2f"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Statement of Compliance and Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;These condensed consolidated interim financial statements have been prepared
in accordance with the International Financial Reporting Standards (&#x201c;IFRS&#x201d;) issued by the International Accounting Standards
Board (&#x201c;IASB&#x201d;), IAS 34 &lt;i&gt;Interim Financial Reporting&lt;/i&gt; and interpretations of the International Financial Reporting Interpretations
Committee. These condensed consolidated interim financial statements do not include all of the information required for full annual financial
statements and should be read in conjunction with the audited consolidated financial statements of the Company for the year ended March
31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;These condensed consolidated interim financial statements have been prepared
on an historical cost basis except for items disclosed herein at fair value (see Note 19, &#x201c;Financial Instruments and Risk Management&#x201d;).
In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except
for cash flow information.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company has only one reportable operating segment.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;These condensed consolidated interim financial statements were approved
and authorized for issuance by the Audit Committee and Board of Directors of the Company (the &#x201c;Board&#x201d;) on March 1, 2023.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The condensed consolidated interim financial statements include the accounts
of the Company and:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(a)&lt;/td&gt;&lt;td&gt;SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Consolidation (Cont&#x2019;d)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(b)&lt;/td&gt;&lt;td&gt;iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company, through SalvaRx, exchanged
certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing &lt;span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20150201__20150210__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesOneMember_zQxiaxfG6Slb" title="Proportion of ownership interest in subsidiary"&gt;60.49&lt;/span&gt;% of the outstanding shares
of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to &lt;span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20211201__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesOneMember_zeCOhznC0y6" title="Proportion of ownership interest in subsidiary"&gt;78.32&lt;/span&gt;%. On July 18,
2022, the Company purchased the remaining non-controlling interest of iOx. &lt;span style="background-color: white"&gt;See Note 18, &#x201c;Related
Party Transactions &#x2013; Share Exchange Agreement &#x2013; iOx,&#x201d; for a further discussion;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(c)&lt;/td&gt;&lt;td&gt;Saugatuck, a &lt;span id="xdx_904_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_z0oi2gSXwMF3" title="Proportion of ownership interest in subsidiary"&gt;70&lt;/span&gt;% owned subsidiary incorporated in the British Virgin Islands. Saugatuck and subsidiary refers to Saugatuck and Saugatuck
Rx LLC;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(d)&lt;/td&gt;&lt;td&gt;PDS, a 100% owned subsidiary incorporated in Delaware, which provides human resources, and other services to each operating subsidiary
via a shared services agreement;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(e)&lt;/td&gt;&lt;td&gt;SalvaRx LLC, a wholly-owned subsidiary through SalvaRx;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(f)&lt;/td&gt;&lt;td&gt;Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(g)&lt;/td&gt;&lt;td&gt;Tarus Therapeutics, LLC (&#x201c;Tarus&#x201d;), a wholly-owned subsidiary of Portage.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;All inter-company balances and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Non-controlling interest in the equity of a subsidiary
is accounted for and reported as a component of stockholders&#x2019; equity. As of December 31, 2022, non-controlling interest represents
the &lt;span id="xdx_90D_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pid_dp_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_z0pwkgNrPylb" title="Non-controlling interest"&gt;30&lt;/span&gt;% shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company. See Note 11, &#x201c;Unsecured Notes Payable
&#x2013; iOx Unsecured Notes Payable,&#x201d; for a discussion of the Company&#x2019;s settlement of loans with iOx and Note 18, &#x201c;Related
Party Transactions &#x2013; Share Exchange Agreement &#x2013; iOx&#x201d; for a discussion of the Company&#x2019;s purchase of the balance
of the non-controlling interest in iOx.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Functional and Presentation Currency&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company&#x2019;s functional and presentation currency is the U.S. Dollar.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates and Judgments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The preparation of the condensed consolidated interim financial statements
in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies
and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Estimates and underlying assumptions are reviewed on an ongoing basis.
Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Significant areas where estimates are made include valuation of financial
instruments (including the convertible note receivable), deferred tax assets, deferred tax liability, research and development costs,
fair value used for acquisition of intangible assets, contingent consideration assumed and measurement of share-based compensation. Significant
areas where critical judgments are applied include assessment of impairment of investments and goodwill and the determination of the accounting
acquirer and acquiree in the business combination accounting.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;















</ptgef:DisclosureOfBasisOfPresentationExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2015-02-012015-02-10_custom_SubsidiariesOneMember"
      decimals="INF"
      unitRef="Pure">0.6049</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2021-12-012021-12-31_custom_SubsidiariesOneMember"
      decimals="INF"
      unitRef="Pure">0.7832</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2022-04-012022-12-31_custom_SubsidiariesTwoMember"
      decimals="INF"
      unitRef="Pure">0.70</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
      contextRef="From2022-04-012022-12-31_custom_SubsidiariesTwoMember"
      decimals="INF"
      unitRef="Pure">0.30</ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_80C_eifrs-full--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zDYaOYLpbLo2" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 4. &lt;span id="xdx_82D_zWbEFd9RM9O"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The accounting policies are set out in Note 4 to the fiscal 2022 audited
consolidated financial statements of the Company. These policies have been applied consistently to all periods presented in these condensed
consolidated interim financial statements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zWCyteK9gkH4" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zboD0Nhcx4Bf"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;IFRS Pronouncements Issued&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Impact of Adoption of Significant New IFRS Standards in 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Annual Improvements to IFRS Standards 2018-2020&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The annual improvements process addresses issues in the 2018-2020 reporting
cycles including changes to IFRS 9, &#x201c;Financial Instruments,&#x201d; IFRS 1, &#x201c;First Time Adoption of IFRS,&#x201d; IFRS 16, &#x201c;Leases,&#x201d;
and IAS 41, &#x201c;Biological Assets&#x201d;.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 35pt; text-align: right"&gt;i)&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition
of financial liabilities.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 35pt; text-align: right"&gt;ii)&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent
to also measure cumulative translation differences using the amounts reported by the parent based on the parent&#x2019;s date of transition
to IFRS.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 35pt; text-align: right"&gt;iii)&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;The amendment to IFRS 16&#x2019;s illustrative example 13 removes the illustration of payments
from the lessor related to leasehold improvements.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;These amendments were effective for annual periods beginning on or after
January 1, 2022. The adoption of these amendments did not have a material effect on the Company&#x2019;s annual consolidated financial
statements or the condensed consolidated interim financial statements for the three and nine months ended December 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;IAS 37: Onerous Contracts &#x2013; Cost of Fulfilling a Contract&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The amendment to IAS 37 clarifies the meaning of costs to fulfil a contract
and that before a separate provision for an onerous contract is established, an entity recognizes any impairment loss that has occurred
on assets used in fulfilling the contract, rather than on assets dedicated to the contract. This amendment is effective for annual periods
beginning January 1, 2022. The Company&#x2019;s adoption of IAS 37 did not have a material effect on its consolidated financial statements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;IAS 16: Proceeds Before Intended Use&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The amendment to IAS 16 prohibits an entity from deducting from the cost
of an item of property, plant and equipment any proceeds received from selling items produced while the entity is preparing the assets
for its intended use (for example, the proceeds from selling samples produced when testing a machine to see if it is functioning properly).
It also clarifies that an entity is testing whether the asset is functioning properly when it assesses the technical and physical performance
of the asset. The amendment also requires certain related disclosures. This amendment is effective for annual periods beginning January
1, 2022. The Company&#x2019;s adoption of IAS 16 did not have a material effect on its consolidated financial statements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;New Accounting Standards, Interpretations and Amendments&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Standards issued but not yet effective up to the date of issuance of the
Company&#x2019;s condensed consolidated interim financial statements are listed below. This listing is of standards and interpretations
issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they
become effective.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;IAS 1: Presentation of Financial Statements&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The amendment to IAS 1 clarifies how to classify debt and other liabilities
as either current or non-current. The amendment is effective for annual periods beginning on or after January 1, 2023. The Company is
currently evaluating the new guidance and impacts on its consolidated financial statements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white"&gt;The amendment addresses the conflict between
IFRS 10, &#x201c;Consolidated Financial Statements,&#x201d; and IAS 28, &#x201c;Investments in Associates and Joint Ventures,&#x201d; in dealing
with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the
gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, &#x201c;Business Combinations,&#x201d;
between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution
of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors&#x2019; interests in the
associate or joint venture. On September 11, 2014, the IASB issued narrow-scope amendments to IFRS 10&#160;and IAS 28. The amendments
were to be effective for annual periods commencing on or after January 1, 2016. In December 2015, the IASB decided to postpone the effective
date of these amendments indefinitely.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

















</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zWCyteK9gkH4" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zboD0Nhcx4Bf"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;IFRS Pronouncements Issued&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;Impact of Adoption of Significant New IFRS Standards in 2022&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Annual Improvements to IFRS Standards 2018-2020&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The annual improvements process addresses issues in the 2018-2020 reporting
cycles including changes to IFRS 9, &#x201c;Financial Instruments,&#x201d; IFRS 1, &#x201c;First Time Adoption of IFRS,&#x201d; IFRS 16, &#x201c;Leases,&#x201d;
and IAS 41, &#x201c;Biological Assets&#x201d;.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 35pt; text-align: right"&gt;i)&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition
of financial liabilities.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 35pt; text-align: right"&gt;ii)&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent
to also measure cumulative translation differences using the amounts reported by the parent based on the parent&#x2019;s date of transition
to IFRS.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 35pt; text-align: right"&gt;iii)&lt;/td&gt;&lt;td style="width: 5pt"/&gt;&lt;td style="text-align: justify"&gt;The amendment to IFRS 16&#x2019;s illustrative example 13 removes the illustration of payments
from the lessor related to leasehold improvements.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;These amendments were effective for annual periods beginning on or after
January 1, 2022. The adoption of these amendments did not have a material effect on the Company&#x2019;s annual consolidated financial
statements or the condensed consolidated interim financial statements for the three and nine months ended December 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;IAS 37: Onerous Contracts &#x2013; Cost of Fulfilling a Contract&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The amendment to IAS 37 clarifies the meaning of costs to fulfil a contract
and that before a separate provision for an onerous contract is established, an entity recognizes any impairment loss that has occurred
on assets used in fulfilling the contract, rather than on assets dedicated to the contract. This amendment is effective for annual periods
beginning January 1, 2022. The Company&#x2019;s adoption of IAS 37 did not have a material effect on its consolidated financial statements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;IAS 16: Proceeds Before Intended Use&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The amendment to IAS 16 prohibits an entity from deducting from the cost
of an item of property, plant and equipment any proceeds received from selling items produced while the entity is preparing the assets
for its intended use (for example, the proceeds from selling samples produced when testing a machine to see if it is functioning properly).
It also clarifies that an entity is testing whether the asset is functioning properly when it assesses the technical and physical performance
of the asset. The amendment also requires certain related disclosures. This amendment is effective for annual periods beginning January
1, 2022. The Company&#x2019;s adoption of IAS 16 did not have a material effect on its consolidated financial statements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;New Accounting Standards, Interpretations and Amendments&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Standards issued but not yet effective up to the date of issuance of the
Company&#x2019;s condensed consolidated interim financial statements are listed below. This listing is of standards and interpretations
issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they
become effective.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;IAS 1: Presentation of Financial Statements&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The amendment to IAS 1 clarifies how to classify debt and other liabilities
as either current or non-current. The amendment is effective for annual periods beginning on or after January 1, 2023. The Company is
currently evaluating the new guidance and impacts on its consolidated financial statements.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;b&gt;Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white"&gt;The amendment addresses the conflict between
IFRS 10, &#x201c;Consolidated Financial Statements,&#x201d; and IAS 28, &#x201c;Investments in Associates and Joint Ventures,&#x201d; in dealing
with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the
gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, &#x201c;Business Combinations,&#x201d;
between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution
of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors&#x2019; interests in the
associate or joint venture. On September 11, 2014, the IASB issued narrow-scope amendments to IFRS 10&#160;and IAS 28. The amendments
were to be effective for annual periods commencing on or after January 1, 2016. In December 2015, the IASB decided to postpone the effective
date of these amendments indefinitely.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

















</ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_80C_eifrs-full--DisclosureOfOtherAssetsExplanatory_zPZjeqptTUt8" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 5. &lt;span id="xdx_820_zYL7W0Gr7FRk"&gt;PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z9FYDvDSJNyd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B1_zeFC0uRP9RAd" style="display: none"&gt;Schedule of prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20221231_zLbLLnAjUTwa" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20220331_zSSOlg8LFVxk" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; March 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_pn3n3_z8Qszzkcd9Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid clinical research costs&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,286&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPzymm_z4uAeSWIsJm7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;164&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,084&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3_maCPzymm_zWNuB5Koc7ie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Research &amp;amp; development tax credits&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;169&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;169&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--TaxDeposits_iI_pn3n3_maCPzymm_zOtl5uuWIh23" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Tax deposits&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;119&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;142&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPzymm_z4IwR0DtZmHj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;33&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;45&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPzymm_z6KVymZaNuxh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;15&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;40&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPzymm_zDi4bRBk7t6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other receivables&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,786&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;1,480&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z9FYDvDSJNyd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B1_zeFC0uRP9RAd" style="display: none"&gt;Schedule of prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20221231_zLbLLnAjUTwa" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20220331_zSSOlg8LFVxk" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; March 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_pn3n3_z8Qszzkcd9Ck" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid clinical research costs&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,286&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0737"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPzymm_z4uAeSWIsJm7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;164&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,084&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3_maCPzymm_zWNuB5Koc7ie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Research &amp;amp; development tax credits&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;169&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;169&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--TaxDeposits_iI_pn3n3_maCPzymm_zOtl5uuWIh23" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Tax deposits&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;119&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;142&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPzymm_z4IwR0DtZmHj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;33&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;45&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPzymm_z6KVymZaNuxh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;15&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;40&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPzymm_zDi4bRBk7t6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other receivables&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,786&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;1,480&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock>
    <ifrs-full:CurrentReceivablesFromSaleOfProperties contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1286000</ifrs-full:CurrentReceivablesFromSaleOfProperties>
    <ifrs-full:CurrentAdvancesToSuppliers contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">164000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1084000</ifrs-full:CurrentAdvancesToSuppliers>
    <ptgef:ResearchAndDevelopmentCredit contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">169000</ptgef:ResearchAndDevelopmentCredit>
    <ptgef:ResearchAndDevelopmentCredit contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">169000</ptgef:ResearchAndDevelopmentCredit>
    <ptgef:TaxDeposits contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">119000</ptgef:TaxDeposits>
    <ptgef:TaxDeposits contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">142000</ptgef:TaxDeposits>
    <ifrs-full:CurrentPrepaidExpenses contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">33000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">45000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">15000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">40000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1786000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1480000</ifrs-full:CurrentPrepayments>
    <ptgef:InvestmentInAssociateDisclosureTextBlock contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_80C_ecustom--InvestmentInAssociateDisclosureTextBlock_z3T0Wmxqobdb" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 6. &lt;span id="xdx_82F_zNiBqGMdyEbg"&gt;INVESTMENT IN ASSOCIATE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Details of the Company&#x2019;s associate as of December 31, 2022 and March
31, 2022 are as follows:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_pn3n3_zxPQaOlhb0Y8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_8B6_zONU6GDdLls9" style="display: none"&gt;Schedule of investment associate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Name&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Principal Activity&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Place of Incorporation and &lt;br/&gt;Principal Place of Business&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Voting Rights Held as &lt;br/&gt;of December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Voting Rights Held as &lt;br/&gt;of March&#160;31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_906_eifrs-full--NameOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Name of associate"&gt;Associate: Stimunity S.A.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Principal place of business of associate"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90E_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Country of incorporation of associate"&gt;Paris, France&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_908_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zs0v3uXnDvp" title="Proportion of voting rights held in associate"&gt;44.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20210401__20220331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zICLOKswsrxa" title="Proportion of voting rights held in associate"&gt;44.0&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_ztxSSjb86aB" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following table is a roll-forward of the Company&#x2019;s investment
in Stimunity S.A. (&#x201c;Stimunity&#x201d;) as of and for the nine months ended December 31, 2022 and 2021:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_zMYY2OvtWdm6" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B9_z2HYPQOUacGg" style="display: none"&gt;Schedule of investment in Stimunity S.A.&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of and for the&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20220401__20221231_zRDqryHTVI5j" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance"&gt;1,673&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20210401__20211231_zTQ1g6GD1uJf" style="width: 12%; font-size: 10pt; text-align: right" title="Beginning balance"&gt;1,735&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Share of (loss)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20220401__20221231_zDPvdJCnrqbd" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share of (loss)"&gt;(268&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20210401__20211231_zOSJCsuv8Ma3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share of (loss)"&gt;(363&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20220401__20221231_zGJq8kXDNG3k" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending  balance"&gt;1,405&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20210401__20211231_znG1sFoL91qi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending  balance"&gt;1,372&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z4His2IdycD3" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On June 1, 2020, the Company made an additional investment of &#x20ac;&lt;span id="xdx_90B_ecustom--AdditionalInvestment_iI_pn3n3_dm_uEUR_c20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zHw1QvcpWG54" title="Additional investments"&gt;0.9&lt;/span&gt;
million ($&lt;span id="xdx_908_ecustom--AdditionalInvestment_iI_pn3n3_dm_uUSD_c20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zlqhTDDfCL25" title="Additional investments"&gt;1.0&lt;/span&gt; million) by executing its subscription for &lt;span id="xdx_905_ecustom--SubscribingClassShares_c20200529__20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pdd" title="Subscribing class A shares"&gt;2,479&lt;/span&gt; Class A shares upon the achievement of certain milestones, as provided
in the Shareholders&#x2019; Agreement, increasing its equity share in Stimunity to &lt;span id="xdx_902_eifrs-full--ProportionOfOwnershipInterestInAssociate_pid_dp_c20200529__20200601__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zYfJTbuLdkNg" title="Proportion of ownership interest in associate"&gt;44&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On July 13, 2022, &lt;span id="xdx_900_ecustom--ConvertibleNoteDescription_c20220702__20220713__ifrs-full--CounterpartiesAxis__custom--StimunityMember_zrnQmBs9a5Nc" title="Convertible Note description"&gt;the Company entered into a commitment with Stimunity
to provide &#x20ac;600,000 under a convertible note (the &#x201c;Stimunity Convertible Note&#x201d;) with a maturity date of September 1,
2023 (the &#x201c;Maturity Date&#x201d;). The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible
Note is automatically converted into Series A shares upon Stimunity completing a Series A round for at least &#x20ac;20 million. If such
subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into
Series A shares at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares
(other than Common Shares or Series A shares) for at least &#x20ac;5 million (the &#x201c;Minimum Raise&#x201d;), the Company will have the
right to convert the Stimunity Convertible Note and the historical Series A shares owned into the new category of shares. In the event
that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the
right to convert the Stimunity Convertible Note into Series A shares at &#x20ac;363.00 per share or the raise price less 15%, whichever
is lower. The Stimunity Convertible Note was funded on September 12, 2022. See Note 17, &#x201c;Commitments and Contingent Liabilities
&#x2013; Stimunity Convertible Note,&#x201d; for a further discussion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company accounts for its investment in Stimunity under the equity
method and, accordingly, records its share of Stimunity&#x2019;s earnings or loss based on its ownership percentage. The Company recorded
equity in loss in Stimunity of $&lt;span id="xdx_902_ecustom--EquityInLossIncome_c20221001__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income"&gt;152,000&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--EquityInLossIncome_c20211001__20211231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income"&gt;261,000&lt;/span&gt; for the three months ended December 31, 2022 and 2021, respectively, and $&lt;span id="xdx_901_ecustom--EquityInLossIncome_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income"&gt;268,000&lt;/span&gt;
and $&lt;span id="xdx_903_ecustom--EquityInLossIncome_c20210401__20211231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_pn3n3" title="Equity in (loss) income"&gt;363,000&lt;/span&gt; for the nine months ended December 31, 2022 and 2021, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Under the Shareholders&#x2019; Agreement, Portage has (i) a preferential
subscription right to maintain its equity interest in Stimunity in the event of a capital increase from the issuance of new securities
by Stimunity, except for issuances of new securities for stock options under a merger plan or for an acquisition, and (ii) the right to
vote against any (a) issuances of additional securities that would call for Portage to waive its preferential subscription right, or (b)
any dilutive issuance.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ptgef:InvestmentInAssociateDisclosureTextBlock>
    <ptgef:DisclosureOfInvestmentAssociatetableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_pn3n3_zxPQaOlhb0Y8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_8B6_zONU6GDdLls9" style="display: none"&gt;Schedule of investment associate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Name&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Principal Activity&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Place of Incorporation and &lt;br/&gt;Principal Place of Business&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Voting Rights Held as &lt;br/&gt;of December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Voting Rights Held as &lt;br/&gt;of March&#160;31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_906_eifrs-full--NameOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Name of associate"&gt;Associate: Stimunity S.A.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Principal place of business of associate"&gt;Biotechnology&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90E_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember" title="Country of incorporation of associate"&gt;Paris, France&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_908_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20220401__20221231__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zs0v3uXnDvp" title="Proportion of voting rights held in associate"&gt;44.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: center; width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20210401__20220331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zICLOKswsrxa" title="Proportion of voting rights held in associate"&gt;44.0&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:DisclosureOfInvestmentAssociatetableTextBlock>
    <ifrs-full:NameOfAssociate contextRef="From2022-04-012022-12-31_custom_StimunitySAMember">Associate: Stimunity S.A.</ifrs-full:NameOfAssociate>
    <ifrs-full:PrincipalPlaceOfBusinessOfAssociate contextRef="From2022-04-012022-12-31_custom_StimunitySAMember">Biotechnology</ifrs-full:PrincipalPlaceOfBusinessOfAssociate>
    <ifrs-full:CountryOfIncorporationOrResidenceOfAssociate contextRef="From2022-04-012022-12-31_custom_StimunitySAMember">Paris, France</ifrs-full:CountryOfIncorporationOrResidenceOfAssociate>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="From2022-04-012022-12-31_custom_StimunitySAMember"
      decimals="INF"
      unitRef="Pure">0.440</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="From2021-04-012022-03-31_custom_StimunitySAMember"
      decimals="INF"
      unitRef="Pure">0.440</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ptgef:ScheduleOfInvestmentInStimunitySaTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_zMYY2OvtWdm6" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B9_z2HYPQOUacGg" style="display: none"&gt;Schedule of investment in Stimunity S.A.&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;As of and for the&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Nine Months Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20220401__20221231_zRDqryHTVI5j" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance"&gt;1,673&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20210401__20211231_zTQ1g6GD1uJf" style="width: 12%; font-size: 10pt; text-align: right" title="Beginning balance"&gt;1,735&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Share of (loss)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20220401__20221231_zDPvdJCnrqbd" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share of (loss)"&gt;(268&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20210401__20211231_zOSJCsuv8Ma3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share of (loss)"&gt;(363&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20220401__20221231_zGJq8kXDNG3k" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending  balance"&gt;1,405&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20210401__20211231_znG1sFoL91qi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending  balance"&gt;1,372&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfInvestmentInStimunitySaTableTextBlock>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1673000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1735000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:UnrecognisedShareOfLossesOfAssociates
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">268000</ifrs-full:UnrecognisedShareOfLossesOfAssociates>
    <ifrs-full:UnrecognisedShareOfLossesOfAssociates
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">363000</ifrs-full:UnrecognisedShareOfLossesOfAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1405000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">1372000</ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates>
    <ptgef:AdditionalInvestment
      contextRef="AsOf2020-06-01_custom_StimunitySAMember"
      decimals="-3"
      unitRef="EUR">900000</ptgef:AdditionalInvestment>
    <ptgef:AdditionalInvestment
      contextRef="AsOf2020-06-01_custom_StimunitySAMember"
      decimals="-3"
      unitRef="USD">1000000.0</ptgef:AdditionalInvestment>
    <ptgef:SubscribingClassShares
      contextRef="From2020-05-292020-06-01_custom_StimunitySAMember"
      decimals="INF"
      unitRef="Shares">2479</ptgef:SubscribingClassShares>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="From2020-05-292020-06-01_custom_StimunitySAMember"
      decimals="INF"
      unitRef="Pure">0.44</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ptgef:ConvertibleNoteDescription contextRef="From2022-07-022022-07-13_custom_StimunityMember">the Company entered into a commitment with Stimunity
to provide &#x20ac;600,000 under a convertible note (the &#x201c;Stimunity Convertible Note&#x201d;) with a maturity date of September 1,
2023 (the &#x201c;Maturity Date&#x201d;). The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible
Note is automatically converted into Series A shares upon Stimunity completing a Series A round for at least &#x20ac;20 million. If such
subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into
Series A shares at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares
(other than Common Shares or Series A shares) for at least &#x20ac;5 million (the &#x201c;Minimum Raise&#x201d;), the Company will have the
right to convert the Stimunity Convertible Note and the historical Series A shares owned into the new category of shares. In the event
that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the
right to convert the Stimunity Convertible Note into Series A shares at &#x20ac;363.00 per share or the raise price less 15%, whichever
is lower. The Stimunity Convertible Note was funded on September 12, 2022. See Note 17, &#x201c;Commitments and Contingent Liabilities
&#x2013; Stimunity Convertible Note,&#x201d; for a further discussion.</ptgef:ConvertibleNoteDescription>
    <ptgef:EquityInLossIncome
      contextRef="From2022-10-012022-12-31_custom_StimunitySAMember"
      decimals="-3"
      unitRef="USD">152000000</ptgef:EquityInLossIncome>
    <ptgef:EquityInLossIncome
      contextRef="From2021-10-012021-12-31_custom_StimunitySAMember"
      decimals="-3"
      unitRef="USD">261000000</ptgef:EquityInLossIncome>
    <ptgef:EquityInLossIncome
      contextRef="From2022-04-012022-12-31_custom_StimunitySAMember"
      decimals="-3"
      unitRef="USD">268000000</ptgef:EquityInLossIncome>
    <ptgef:EquityInLossIncome
      contextRef="From2021-04-012021-12-31_custom_StimunitySAMember"
      decimals="-3"
      unitRef="USD">363000000</ptgef:EquityInLossIncome>
    <ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_80B_ecustom--DisclosureOfPrivateCompaniesExplanatoryTextBlock_zi7zMldnKqB2" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 7. &lt;span id="xdx_82C_zSwib493zObd"&gt;INVESTMENT IN PRIVATE COMPANY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following is a discussion of the Company&#x2019;s investment in private
company as of December 31, 2022 and March 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Intensity Therapeutics, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;In connection with the SalvaRx Acquisition in fiscal 2019, the Company
acquired a $&lt;span id="xdx_907_ecustom--PrivateInvestments_iI_pn3n3_dm_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zxnC2VC1AK8" title="Investment"&gt;4.5&lt;/span&gt; million interest in Intensity, a private clinical stage biotechnology company, of &lt;span id="xdx_904_ecustom--InvestmentOwnedShares_iI_dm_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zGyhj4jMXfph" title="Number of shares purchased"&gt;1.0&lt;/span&gt; million shares, which represented
a &lt;span id="xdx_90D_ecustom--InvestmentOwnershipPercentage_iI_pid_dp_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zuMvIcYwCtX" title="Percentage of equity held"&gt;7.5&lt;/span&gt;% equity interest in Intensity. The investment was recorded at fair value (which approximates cost) at the acquisition date. The
investment in Intensity has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through
other comprehensive income (&#x201c;OCI&#x201d;). The fair value of the asset is determined by considering other comparable equity funding
transactions by Intensity with unrelated investors.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On July 11, 2019, the Company entered into an agreement with Fast Forward
Innovations Limited (&#x201c;Fast Forward&#x201d;) to purchase Intensity Holdings Limited (&#x201c;IHL&#x201d;), a wholly-owned subsidiary
of Fast Forward. The Company paid $1.3 million for IHL through the issuance of &lt;span id="xdx_909_eifrs-full--NumberOfInstrumentsOrInterestsIssuedOrIssuable_iI_pid_uPure_c20190711__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_z534hUYPNpP2" title="Number of ordinary shares issued in acquisition"&gt;129,806&lt;/span&gt; ordinary shares. The sole asset of IHL consists
of &lt;span id="xdx_908_ecustom--NumberOfPrivateCompanyShareConsistsInSoleAsset_iI_pid_c20190711__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zsLT7iubhcA" title="Number of private company share consists in sole asset"&gt;288,458&lt;/span&gt; shares of Intensity. This transaction increased the Company&#x2019;s ownership of Intensity to 1,288,458 shares.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;There was no unrealized gain or loss recognized during the three and nine
months ended December 31, 2021.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;As of December 31, 2022 and March 31, 2022, the Company owned approximately
&lt;span id="xdx_901_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20221231__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zpGEov3B10f8" title="Percentage of voting equity interests acquired"&gt;7.00&lt;/span&gt;% and approximately &lt;span id="xdx_90D_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20220331__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zOe7ynvONFKj" title="Percentage of voting equity interests acquired"&gt;7.35&lt;/span&gt;%, respectively, of the outstanding shares of Intensity, on a fully diluted basis.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On October 28, 2021, Intensity filed a Form S-1 Registration Statement
with the SEC to register shares for an initial public offering, which was declared effective by the SEC, but subsequently withdrawn prior
to closing. Intensity is still evaluating market conditions to determine the timing of an initial public offering. As of March 31, 2022,
the Company had valued its investment in Intensity based on Intensity&#x2019;s Series C Preferred Stock Offering completed in 2020. If
the initial public offering is successful, the Company will value its investment in Intensity based upon fair value (market price) and
will record periodic changes in carrying value through OCI.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;In October and November of 2022, Intensity filed amendments to its
Form S-1 Registration Statement, which reflected a proposed offering price in the range of $&lt;span id="xdx_900_ecustom--OfferingPrice_pid_c20221001__20221031__ifrs-full--RangeAxis__srt--MinimumMember_zsjy0CxMyG23" title="Offering price"&gt;&lt;span id="xdx_907_ecustom--OfferingPrice_pid_c20221101__20221130__ifrs-full--RangeAxis__srt--MinimumMember_zv7YP90vslGe" title="Offering price"&gt;4.00&lt;/span&gt;&lt;/span&gt;
- $&lt;span id="xdx_903_ecustom--OfferingPrice_pid_c20221001__20221031__ifrs-full--RangeAxis__srt--MaximumMember_zhezDBoxcNv3" title="Offering price"&gt;&lt;span id="xdx_902_ecustom--OfferingPrice_pid_c20221101__20221130__ifrs-full--RangeAxis__srt--MaximumMember_zTDIDHta0nX2" title="Offering price"&gt;5.00&lt;/span&gt;&lt;/span&gt;
per share, which is less than the Company&#x2019;s carrying value, which indicated impairment. Accordingly, the Company
performed a fair value analysis and determined a fair value of $&lt;span id="xdx_900_eifrs-full--ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets_pn3n3_dm_c20221001__20221031_zXAbf0BvhQq9" title="Fair value"&gt;&lt;span id="xdx_90D_eifrs-full--ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets_pn3n3_dm_c20221101__20221130_zCeOGHM5yy1l" title="Fair value"&gt;3.363&lt;/span&gt;&lt;/span&gt;
million, which was $&lt;span id="xdx_908_eifrs-full--AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied_pn3n3_dm_c20221001__20221031_ztBj0DDWrGpg" title="Carrying value"&gt;&lt;span id="xdx_90C_eifrs-full--AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied_pn3n3_dm_c20221101__20221130_zNgYsCvetUVe" title="Carrying value"&gt;4.046&lt;/span&gt;&lt;/span&gt;
million less than the then carrying value. The Company recognized an unrealized loss in value in Intensity of $&lt;span id="xdx_907_ecustom--UnrealizedLoss_pn3n3_dm_c20220401__20221231_zHbzv0Tg3lvb" title="Unrealized loss"&gt;4.046&lt;/span&gt;
million through OCI in the three and nine months ended December 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















</ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock>
    <ptgef:PrivateInvestments
      contextRef="AsOf2022-12-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember"
      decimals="-3"
      unitRef="USD">4500000</ptgef:PrivateInvestments>
    <ptgef:InvestmentOwnedShares
      contextRef="AsOf2022-12-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember"
      decimals="INF"
      unitRef="Shares">1000.0</ptgef:InvestmentOwnedShares>
    <ptgef:InvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember"
      decimals="INF"
      unitRef="Pure">0.075</ptgef:InvestmentOwnershipPercentage>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="AsOf2019-07-11_custom_AcquisitionOfIntensityHoldingLimitedMember_custom_IntensityMember"
      decimals="INF"
      unitRef="Pure">129806</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ptgef:NumberOfPrivateCompanyShareConsistsInSoleAsset
      contextRef="AsOf2019-07-11_custom_AcquisitionOfIntensityHoldingLimitedMember_custom_IntensityMember"
      decimals="INF"
      unitRef="Shares">288458</ptgef:NumberOfPrivateCompanyShareConsistsInSoleAsset>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="AsOf2022-12-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember"
      decimals="INF"
      unitRef="Pure">0.0700</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="AsOf2022-03-31_custom_AcquisitionOfSalvaRxMember_custom_IntensityMember"
      decimals="INF"
      unitRef="Pure">0.0735</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ptgef:OfferingPrice
      contextRef="From2022-10-012022-10-31_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">4.00</ptgef:OfferingPrice>
    <ptgef:OfferingPrice
      contextRef="From2022-11-012022-11-30_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">4.00</ptgef:OfferingPrice>
    <ptgef:OfferingPrice
      contextRef="From2022-10-012022-10-31_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">5.00</ptgef:OfferingPrice>
    <ptgef:OfferingPrice
      contextRef="From2022-11-012022-11-30_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">5.00</ptgef:OfferingPrice>
    <ifrs-full:ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets
      contextRef="From2022-10-012022-10-31"
      decimals="-3"
      unitRef="USD">3363000</ifrs-full:ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets>
    <ifrs-full:ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets
      contextRef="From2022-11-012022-11-30"
      decimals="-3"
      unitRef="USD">3363000</ifrs-full:ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets>
    <ifrs-full:AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied
      contextRef="From2022-10-012022-10-31"
      decimals="-3"
      unitRef="USD">4046000.000</ifrs-full:AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied>
    <ifrs-full:AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied
      contextRef="From2022-11-012022-11-30"
      decimals="-3"
      unitRef="USD">4046000.000</ifrs-full:AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied>
    <ptgef:UnrealizedLoss
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">4046000.000</ptgef:UnrealizedLoss>
    <ptgef:AcquisitionsOfTarusExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_801_ecustom--AcquisitionsOfTarusExplanatory_zkabzFvg5gbb" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 8. &lt;span id="xdx_82F_z4XxMRKdSZqh"&gt;ACQUISITION OF TARUS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On July 1, 2022, the Company, its wholly-owned subsidiary, Tarus Acquisition
Inc., and Tarus Therapeutics, Inc., a Delaware corporation advancing adenosine receptor agonists for the treatment of solid tumors, entered
into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;). Under the structure of the Merger Agreement,
Tarus Therapeutics, Inc. was ultimately merged into a wholly-owned subsidiary of the Company with the surviving entity renamed Tarus Therapeutics,
LLC. The Tarus merger entitles the Company to the rights, know-how and/or ownership related to the assets developed by Tarus (the &#x201c;Adenosine
Compounds&#x201d;), including:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;1.&lt;/td&gt;&lt;td&gt;All rights and obligations related to the License Agreement between Tarus and Impetis Biosciences Limited, dated October 29, 2019,
and the Call Option under the License Agreement, which was exercised on November 5, 2020;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;2.&lt;/td&gt;&lt;td&gt;All intellectual property and related documents owned or controlled by Tarus, including issued or pending patents, patent applications
and trade secrets. Additionally, any draft submissions and/or correspondence with patent authorities;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;3.&lt;/td&gt;&lt;td&gt;All documents and supplies related to Adenosine Compounds including inventory, reagents, data, assays, reports, vendor agreements
and other information related to the preclinical development;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;4.&lt;/td&gt;&lt;td style="text-align: left"&gt;All clinical supplies, manufacturing know-how, batch records, regulatory documents pertaining to the Adenosine
Compounds, certain reservations for manufacturing campaigns and any related agreements;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;5.&lt;/td&gt;&lt;td style="text-align: left"&gt;All regulatory documents and correspondence pertaining to the Adenosine Compounds;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;6.&lt;/td&gt;&lt;td style="text-align: left"&gt;All Contract Research Organization (&#x201c;CRO&#x201d;) agreements and protocol related documents for Adenosine
Compounds;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;7.&lt;/td&gt;&lt;td style="text-align: left"&gt;All current documents related to market research, forecasting, budgets and competitive intelligence; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;8.&lt;/td&gt;&lt;td style="text-align: left"&gt;Rights to the use of Tarus Therapeutics&#x2019; name for regulatory purposes.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;As consideration for Tarus, the Company issued to Tarus
shareholders an aggregate of &lt;span id="xdx_903_ecustom--NumberOfSharesSold_c20220401__20221231_pdd" title="Number of shares sold"&gt;2,425,999&lt;/span&gt; ordinary shares of Portage, calculated on the basis of $18 million divided by the 60-day Volume
Weighted Average Price per share. The shares have not been registered with the SEC and are subject to lock-up agreements for terms ranging
from six to twelve months. Additionally, milestone payments of up to $&lt;span id="xdx_904_eifrs-full--ProceedsFromIssueOfOrdinaryShares_pn3n3_dm_c20220401__20221231_zrQSA4mhDjh2" title="Proceeds from offering"&gt;32&lt;/span&gt; million in cash or Portage ordinary shares would be triggered
upon achievement of future development and sales milestones. As a result of the transaction:&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;The Company also assumed $2 million in short-term debt held by Tarus and deferred license milestones obligations
($1 million plus interest). The short-term debt was repaid by the Company in July 2022.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;Upon enrolling the first patient in a Phase 2 clinical trial, the Company will pay an additional one-time
milestone payment of $15 million. Payment will be in the form of cash or Portage ordinary shares (at the discretion of the Company). The
remaining $&lt;span id="xdx_90F_ecustom--MilestonePayment_pn3n3_dm_c20220401__20221231_z1qt4rFfy5Ed" title="Milestone payment"&gt;17&lt;/span&gt; million milestone is based on targeted commercial sales.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;In connection with the acquisition of Tarus, the Company performed a fair
value analysis of the assets acquired and liabilities assumed. The Company based the analysis on its clinical plan and timing of development
events, and the probabilities of success determined primarily based upon empirical third party data and Company experience as well as
the relevant cost of capital. In its fair value analysis, the Company used the Multi-Period Excess Earnings Method for PORT-6 and PORT-7
and the Replacement Cost Method for PORT-8 and PORT-9, determined based upon the maturity of the assets and the availability of sufficient
data to measure fair value. The Company recorded the shares issued at $17.2 million, which represented the aggregate market value of the
shares issued on July 1, 2022. The Company followed the guidance of IAS 3 and IAS 32 and recorded a deferred purchase price payable -
Tarus of $8.538 million, which reflected the estimated acquisition date fair value of contractual milestone obligations incurred. The
principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount
rate used. The Company recorded the obligation as a non-current liability, in accordance with the provisions IAS 32 with respect to the
classification of financial assets and financial liabilities.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company will determine the fair value of the earnout shares at each
balance sheet date. Any change to the fair value will be recorded in the Company&#x2019;s statements of operations and other comprehensive
income (loss).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following table summarizes the preliminary purchase price allocation
to the fair value of assets acquired and liabilities assumed for Tarus:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_pn3n3_zcgJpov2ptab" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B6_zBnEjiGJsVLb" style="display: none"&gt;Schedule of fair value of assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zRfIBNUBk5Xj" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--AssetsAbstract_iB" style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;(In thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Identifiable intangible assets&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;28,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--Goodwill_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Goodwill&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;538&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--OtherTangibleOrIntangibleAssetsTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;28,738&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_iB" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Consideration:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Fair value of shares issued&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;17,200&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Liabilities assumed&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Deferred purchase consideration at fair value&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;8,538&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--ContingentLiabilitiesRecognisedInBusinessCombination_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;28,738&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zD9luswZEGm7" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Pro forma Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;Summary unaudited pro forma condensed
results of operations for the nine months ended December 31, 2022 and 2021, assuming the Tarus acquisition had occurred at the beginning
of the earliest period presented, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfProformaInformationTableTextBlock_pn3n3_z7CpBwzy6t86" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BA_zWRu7EqIHft5" style="display: none"&gt;Schedule of pro forma information&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;For the Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--ProfitLossFromContinuingOperations_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Loss from operations"&gt;(12,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--ProfitLossFromContinuingOperations_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Loss from operations"&gt;(13,431&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss before provision for income taxes&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ProfitLossBeforeTax_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss before provision for income taxes"&gt;(12,833&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ProfitLossBeforeTax_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss before provision for income taxes"&gt;(13,110&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ProfitLoss_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net loss and other comprehensive loss"&gt;(9,927&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ProfitLoss_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Net loss and other comprehensive loss"&gt;(12,645&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Total comprehensive loss for period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--ComprehensiveIncome_pn3n3_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zmKaplj5POOe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total comprehensive loss for period"&gt;(13,945&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--ComprehensiveIncome_pn3n3_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zaB8v3M1mJRf" style="font-size: 10pt; text-align: right" title="Total comprehensive loss for period"&gt;(12,645&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Loss per share&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--EarningLossPerShare_pid_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zJqemgtaRjoh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss per share"&gt;(0.60&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--EarningLossPerShare_pid_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zk2Ts7F4UjDc" style="font-size: 10pt; text-align: right" title="Loss per share"&gt;(0.77&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;Summary unaudited pro forma condensed
results of operations for the three months ended December 31, 2022 and 2021, assuming the Tarus acquisition had occurred at the beginning
of the earliest period presented, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;





















&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;For the Three Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022 &lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProfitLossFromContinuingOperations_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zHdfLCzdC7T3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Loss from operations"&gt;(4,759&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ProfitLossFromContinuingOperations_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Loss from operations"&gt;(4,362&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss before provision for income taxes&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--ProfitLossBeforeTax_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zRs6TI3yaLDl" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss before provision for income taxes"&gt;(5,302&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--ProfitLossBeforeTax_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss before provision for income taxes"&gt;(4,281&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--ProfitLoss_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zquh5ZicSRXe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net loss and other comprehensive loss"&gt;(7,501&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--ProfitLoss_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Net loss and other comprehensive loss"&gt;(4,398&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Total comprehensive loss for year&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--ComprehensiveIncome_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zov2r2vGJ3K7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total comprehensive loss for year"&gt;(11,518&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--ComprehensiveIncome_pn3n3_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zfzxq4miensg" style="font-size: 10pt; text-align: right" title="Total comprehensive loss for year"&gt;(4,398&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Loss per share&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--EarningLossPerShare_pid_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_z5cPInowNzre" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss per share"&gt;(0.44&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--EarningLossPerShare_pid_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zqNUVTjSNvR5" style="font-size: 10pt; text-align: right" title="Loss per share"&gt;(0.23&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;b&gt;&lt;sup id="xdx_F05_zcAeLhLmlou"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;span id="xdx_F10_zVMEtrMNyV8a" style="background-color: white"&gt;Includes the results of operations of Tarus for the period and, accordingly, there are no pro
forma adjustments for the three months ended December 31, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A5_z5JuqaAE1sId" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;These pro forma results are not
necessarily indicative of what would have occurred if the acquisition had been in effect for the period presented, and they may not be
indicative of results expected in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</ptgef:AcquisitionsOfTarusExplanatory>
    <ptgef:NumberOfSharesSold
      contextRef="From2022-04-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">2425999</ptgef:NumberOfSharesSold>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">32000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ptgef:MilestonePayment
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">17000000</ptgef:MilestonePayment>
    <ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_pn3n3_zcgJpov2ptab" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B6_zBnEjiGJsVLb" style="display: none"&gt;Schedule of fair value of assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zRfIBNUBk5Xj" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--AssetsAbstract_iB" style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;(In thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 85%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Identifiable intangible assets&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;28,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--Goodwill_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Goodwill&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;538&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--OtherTangibleOrIntangibleAssetsTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;28,738&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_iB" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Consideration:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Fair value of shares issued&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;17,200&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Liabilities assumed&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Deferred purchase consideration at fair value&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;8,538&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--ContingentLiabilitiesRecognisedInBusinessCombination_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;28,738&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">28200000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:Goodwill
      contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">538000</ifrs-full:Goodwill>
    <ifrs-full:OtherTangibleOrIntangibleAssetsTransferred
      contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">28738000</ifrs-full:OtherTangibleOrIntangibleAssetsTransferred>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">17200000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">3000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">8538000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="AsOf2022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">28738000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ptgef:ScheduleOfProformaInformationTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfProformaInformationTableTextBlock_pn3n3_z7CpBwzy6t86" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BA_zWRu7EqIHft5" style="display: none"&gt;Schedule of pro forma information&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;For the Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--ProfitLossFromContinuingOperations_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Loss from operations"&gt;(12,200&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--ProfitLossFromContinuingOperations_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Loss from operations"&gt;(13,431&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss before provision for income taxes&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ProfitLossBeforeTax_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss before provision for income taxes"&gt;(12,833&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ProfitLossBeforeTax_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss before provision for income taxes"&gt;(13,110&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ProfitLoss_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net loss and other comprehensive loss"&gt;(9,927&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ProfitLoss_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Net loss and other comprehensive loss"&gt;(12,645&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Total comprehensive loss for period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--ComprehensiveIncome_pn3n3_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zmKaplj5POOe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total comprehensive loss for period"&gt;(13,945&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--ComprehensiveIncome_pn3n3_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zaB8v3M1mJRf" style="font-size: 10pt; text-align: right" title="Total comprehensive loss for period"&gt;(12,645&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Loss per share&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--EarningLossPerShare_pid_c20220401__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zJqemgtaRjoh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss per share"&gt;(0.60&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--EarningLossPerShare_pid_c20210401__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zk2Ts7F4UjDc" style="font-size: 10pt; text-align: right" title="Loss per share"&gt;(0.77&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;Summary unaudited pro forma condensed
results of operations for the three months ended December 31, 2022 and 2021, assuming the Tarus acquisition had occurred at the beginning
of the earliest period presented, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;





















&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;For the Three Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022 &lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProfitLossFromContinuingOperations_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zHdfLCzdC7T3" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Loss from operations"&gt;(4,759&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ProfitLossFromContinuingOperations_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="width: 12%; font-size: 10pt; text-align: right" title="Loss from operations"&gt;(4,362&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss before provision for income taxes&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--ProfitLossBeforeTax_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zRs6TI3yaLDl" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss before provision for income taxes"&gt;(5,302&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--ProfitLossBeforeTax_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss before provision for income taxes"&gt;(4,281&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--ProfitLoss_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zquh5ZicSRXe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net loss and other comprehensive loss"&gt;(7,501&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--ProfitLoss_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_pn3n3" style="font-size: 10pt; text-align: right" title="Net loss and other comprehensive loss"&gt;(4,398&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Total comprehensive loss for year&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--ComprehensiveIncome_pn3n3_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_zov2r2vGJ3K7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Total comprehensive loss for year"&gt;(11,518&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--ComprehensiveIncome_pn3n3_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zfzxq4miensg" style="font-size: 10pt; text-align: right" title="Total comprehensive loss for year"&gt;(4,398&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Loss per share&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--EarningLossPerShare_pid_c20221001__20221231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_fKDEp_z5cPInowNzre" style="font-size: 10pt; font-weight: bold; text-align: right" title="Loss per share"&gt;(0.44&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--EarningLossPerShare_pid_c20211001__20211231__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zqNUVTjSNvR5" style="font-size: 10pt; text-align: right" title="Loss per share"&gt;(0.23&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;b&gt;&lt;sup id="xdx_F05_zcAeLhLmlou"&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&lt;span id="xdx_F10_zVMEtrMNyV8a" style="background-color: white"&gt;Includes the results of operations of Tarus for the period and, accordingly, there are no pro
forma adjustments for the three months ended December 31, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</ptgef:ScheduleOfProformaInformationTableTextBlock>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2022-04-012022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-12200000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2021-04-012021-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-13431000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2022-04-012022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-12833000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2021-04-012021-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-13110000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLoss
      contextRef="From2022-04-012022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-9927000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012021-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-12645000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2022-04-012022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-13945000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-012021-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-12645000</ifrs-full:ComprehensiveIncome>
    <ptgef:EarningLossPerShare
      contextRef="From2022-04-012022-12-31_custom_TarusAcquisitionMember"
      decimals="INF"
      unitRef="USDPShares">-0.60</ptgef:EarningLossPerShare>
    <ptgef:EarningLossPerShare
      contextRef="From2021-04-012021-12-31_custom_TarusAcquisitionMember"
      decimals="INF"
      unitRef="USDPShares">-0.77</ptgef:EarningLossPerShare>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2022-10-012022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      id="Fact000921"
      unitRef="USD">-4759000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossFromContinuingOperations
      contextRef="From2021-10-012021-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-4362000</ifrs-full:ProfitLossFromContinuingOperations>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2022-10-012022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      id="Fact000925"
      unitRef="USD">-5302000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2021-10-012021-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-4281000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLoss
      contextRef="From2022-10-012022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      id="Fact000929"
      unitRef="USD">-7501000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2021-10-012021-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-4398000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2022-10-012022-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      id="Fact000933"
      unitRef="USD">-11518000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-10-012021-12-31_custom_TarusAcquisitionMember"
      decimals="-3"
      unitRef="USD">-4398000</ifrs-full:ComprehensiveIncome>
    <ptgef:EarningLossPerShare
      contextRef="From2022-10-012022-12-31_custom_TarusAcquisitionMember"
      decimals="INF"
      id="Fact000937"
      unitRef="USDPShares">-0.44</ptgef:EarningLossPerShare>
    <ptgef:EarningLossPerShare
      contextRef="From2021-10-012021-12-31_custom_TarusAcquisitionMember"
      decimals="INF"
      unitRef="USDPShares">-0.23</ptgef:EarningLossPerShare>
    <ptgef:GoodwillExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_80C_ecustom--GoodwillExplanatory_zQMqwFKrF9Ed" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 9. &lt;span id="xdx_821_zZ5bdKYv259f"&gt;GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following is a roll-forward of goodwill:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_pn3n3_zLudUd1v9bSd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - GOODWILL (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B4_zbIemXnbfJ7d" style="display: none"&gt;Schedule of IPR&amp;amp;D projects&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt; &lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt;March 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--Goodwill_iS_pn3n3_c20220401__20221231_zKF2Isk5FSS7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period"&gt;43,324&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--Goodwill_iS_pn3n3_c20210401__20220331_znVRzPGwTWZi" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, beginning of period"&gt;43,324&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Tarus goodwill&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--TarusGoodwill_pn3n3_c20220401__20221231_zBDPxH24xyQ8" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Tarus goodwill"&gt;538&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--TarusGoodwill_pn3n3_c20210401__20220331_znfWoPq6WaWl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Tarus goodwill"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--Goodwill_iE_pn3n3_c20220401__20221231_zBDVkEbbyoea" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, ending of period"&gt;43,862&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--Goodwill_iE_pn3n3_c20210401__20220331_zU9JFoExOgSk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, ending of period"&gt;43,324&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company&#x2019;s goodwill arose primarily from the acquisition of SalvaRx
and its portfolio of several projects and investments.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;As a result of the acquisition of Tarus in July 2022, the Company recorded
$&lt;span id="xdx_906_eifrs-full--Goodwill_iI_pn3n3_dm_c20220731_zMGxVvItlQK" title="Goodwill"&gt;0.538&lt;/span&gt; million of goodwill, representing the difference between the consideration paid of $&lt;span id="xdx_906_eifrs-full--ConsiderationPaidReceived_pn3n3_dm_c20220701__20220731_z50dkGllOPMe" title="Consideration paid"&gt;28.738&lt;/span&gt; million and the fair value of identifiable
assets acquired of $&lt;span id="xdx_907_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iI_pn3n3_dm_c20220731_zkw0GF8wYyO9" title="Fair value of identifiable assets acquired"&gt;28.2&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Under purchase accounting as of July 1, 2022 (the acquisition date), the
assets and liabilities of Tarus Therapeutics, Inc., was recorded at their respective fair values and the excess of the acquisition consideration
is goodwill. The purchase was in the form of a merger in which Tarus Therapeutics, Inc. was merged into Tarus Therapeutics, LLC., which
is a wholly-owned subsidiary of Portage. All of the consideration for Tarus Therapeutics, LLC was paid or assumed by Portage and Portage
will control the voting rights, the board of directors and the operations of Tarus Therapeutics, LLC.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;As of December 31, 2022, the Company determined that it has only one cash-generating
unit (&#x201c;CGU&#x201d;), the consolidated Portage Biotech Inc.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Impairment Review&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&lt;span style="font-weight: normal"&gt;On an annual basis,
pursuant to IAS 36, &#x201c;Impairment of Assets,&#x201d; the Company assesses its long-lived assets with definite lives, which are not
yet available for use, for potential indicators of impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;If any such indication exists, the Company estimates the recoverable amount
of the asset or CGU and compares it to the carrying value.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company performed its annual impairment test in each of fiscal 2022
and fiscal 2021 and estimated the recoverable amount of the above-noted CGU based on its value in use, which was determined using a capitalized
cash flow methodology and categorized within level 3 of the fair market value hierarchy.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The recoverable amount of the CGU has been determined based on its value
in use. The recoverable amount considered assumptions based on probabilities of technical, regulatory and clinical acceptances and financial
support. Further, management uses risk-adjusted cash flow projections based on financial budgets. Management believes that any reasonably
possible change in the key assumptions on which the recoverable amount is based would not cause the carrying amount to exceed its recoverable
amount. The discount rate has been determined based on the Company&#x2019;s best estimate of a risk adjusted discount rate.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The key assumptions used in the calculation of the recoverable amount
include forecasts of the following:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.3in"/&gt;&lt;td style="width: 0.25in"&gt;(a)&lt;/td&gt;&lt;td&gt;revenues;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.3in"/&gt;&lt;td style="width: 0.25in"&gt;(b)&lt;/td&gt;&lt;td&gt;normalized operating expenses;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.3in"/&gt;&lt;td style="width: 0.25in"&gt;(c)&lt;/td&gt;&lt;td&gt;income taxes; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.3in"/&gt;&lt;td style="width: 0.25in"&gt;(d)&lt;/td&gt;&lt;td&gt;capital expenditures.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Discounted cash flows are determined with reference to undiscounted risk
adjusted cash flows, and the discount rate approximated &lt;span id="xdx_902_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_pid_dp_c20220331_zCwNScr0c5p8" title="Discount rate applied to cash flow projections"&gt;20.5&lt;/span&gt;% and &lt;span id="xdx_90D_eifrs-full--DescriptionOfDiscountRatesAppliedToCashFlowProjections_iI_pid_dp_c20210331_zoiBrA98PB95" title="Discount rate applied to cash flow projections"&gt;20.0&lt;/span&gt;% as of March 31, 2022 and 2021, respectively, based on the individual
characteristics of the Company&#x2019;s CGU, the risk-free rate of return and other economic and operating factors.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;As of December 31, 2022, management assessed whether any indications of
impairment existed for the Company&#x2019;s CGU. As of December 31, 2022, the Company&#x2019;s market capitalization was less than its net
assets, which is an external indicator of potential impairment. The Company evaluated this factor in conjunction with its assessment of
the overall market environment and the progress made in developing the Company&#x2019;s assets. The Company determined that a test for
impairment was not required and no impairment was recorded for the three and nine months ended December 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ptgef:GoodwillExplanatory>
    <ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory_pn3n3_zLudUd1v9bSd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - GOODWILL (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B4_zbIemXnbfJ7d" style="display: none"&gt;Schedule of IPR&amp;amp;D projects&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt; &lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt;March 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--Goodwill_iS_pn3n3_c20220401__20221231_zKF2Isk5FSS7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period"&gt;43,324&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--Goodwill_iS_pn3n3_c20210401__20220331_znVRzPGwTWZi" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, beginning of period"&gt;43,324&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Tarus goodwill&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--TarusGoodwill_pn3n3_c20220401__20221231_zBDPxH24xyQ8" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Tarus goodwill"&gt;538&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--TarusGoodwill_pn3n3_c20210401__20220331_znfWoPq6WaWl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Tarus goodwill"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--Goodwill_iE_pn3n3_c20220401__20221231_zBDVkEbbyoea" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, ending of period"&gt;43,862&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--Goodwill_iE_pn3n3_c20210401__20220331_zU9JFoExOgSk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, ending of period"&gt;43,324&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:Goodwill contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">43324000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">43324000</ifrs-full:Goodwill>
    <ptgef:TarusGoodwill
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">538000</ptgef:TarusGoodwill>
    <ifrs-full:Goodwill contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">43862000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">43324000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="AsOf2022-07-31" decimals="-3" unitRef="USD">538000</ifrs-full:Goodwill>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="From2022-07-012022-07-31"
      decimals="-3"
      unitRef="USD">28738000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="AsOf2022-07-31" decimals="-3" unitRef="USD">28200000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections contextRef="AsOf2022-03-31" decimals="INF" unitRef="Pure">0.205</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections contextRef="AsOf2021-03-31" decimals="INF" unitRef="Pure">0.200</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_80A_ecustom--InProcessResearchAndDevelopmentAndDeferredTaxLiability_z0t3q4vCUoP7" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 10. &lt;span id="xdx_82F_zmF2B0HJBA6h"&gt;IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;In-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) consists
of the following projects (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_pn3n3_zHScnRDnlYbb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BD_zbI1Fmg1K1Zd" style="display: none"&gt;Schedule of In process research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Project #&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Value as of &lt;br/&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Value as of &lt;br/&gt;March 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;iOx:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 25%; font-size: 10pt"&gt;PORT 2 (IMM60)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; font-size: 10pt; text-align: left"&gt;Melanoma &amp;amp; Lung Cancers&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_pn3n3" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;84,213&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_pn3n3" style="width: 22%; font-size: 10pt; text-align: right" title="In-process research and development"&gt;84,213&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;PORT 3 (IMM65)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Ovarian/Prostate Cancers&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;32,997&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;32,997&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;117,210&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;117,210&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Oncomer/Saugatuck&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;DNA Aptamers&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;178&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;178&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Tarus:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;PORT 6 &amp;amp; PORT 7&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Adenosine Receptors&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;27,138&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_zxIggqMDOTqb" style="font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0999"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;PORT 8&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Adenosine Receptors&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;500&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_z2UTe8vC2o1h" style="font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;PORT 9&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Adenosine Receptors&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;562&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_zc1SfRt7Efih" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;28,200&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusMember_zF69TNYjLoka" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1011"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;In-process research and development&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;145,588&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331_zXEtNRf72jZi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="In-process research and development"&gt;117,388&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Deferred tax liability&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DeferredTaxesLiability_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Deferred tax liability"&gt;28,409&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--DeferredTaxesLiability_iI_pn3n3_c20220331_zy2OYFg0dPOl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax liability"&gt;30,198&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Additionally, at the end of each reporting period, the Company is required
to assess whether there is any indication that an asset may be impaired. As indicated above, the Company identified an external indicator
of potential impairment as of December 31, 2022. Pursuant to IAS 36, the Company completed its review of underlying fundamentals, execution,
advancement of assets and value creation activities and concluded that no provision for impairment was required during the three and nine
months ended December 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Deferred tax liability represents iOx&#x2019;s estimated tax on the difference
between book and tax basis of the IPR&amp;amp;D, which is taxable in the U.K, and the effect of usable net operating loss carryforwards.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;As of December 31, 2022 and March 31, 2022, iOx had a net deferred tax
liability of approximately $&lt;span id="xdx_908_ecustom--DeferredTaxLiability_iI_pn3n3_dm_c20221231_zDJge99TLoe" title="Deferred tax liability"&gt;25.5&lt;/span&gt; million and approximately $&lt;span id="xdx_90B_ecustom--DeferredTaxLiability_iI_pn3n3_dm_c20220331_zwOLOdYSRosl" title="Deferred tax liability"&gt;28.4&lt;/span&gt; million, respectively. On January 8, 2019, the Company originally recognized
a $&lt;span id="xdx_905_ecustom--DeferredTaxLiability_iI_pn3n3_dm_c20190108_z1ULMKngf0jf" title="Deferred tax liability"&gt;19.8&lt;/span&gt; million deferred tax liability for the difference between the book and income tax basis of IPR&amp;amp;D acquired as part of the SalvaRx
Acquisition. As the iOx IPR&amp;amp;D is in the U.K., the deferred tax was recorded at 17%, the prevailing tax rate applicable in the U.K.
at the time. In fiscal 2022, the Company recorded $&lt;span id="xdx_908_ecustom--IncreaseInDeferredIncomeTaxes_pn3n3_dm_c20220401__20221231_zSnMRswCpnH8" title="Increase in deferred income taxes"&gt;7.0&lt;/span&gt; million increase in deferred income taxes to reflect a future change in the U.K.
income tax rate and recognized $0.7 million of current year losses and $0.8 million of prior year losses. The Company also recognized
a $&lt;span id="xdx_906_eifrs-full--IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_pn3n3_dm_c20210401__20220331_zdAI4qGBrvEe" title="Increase (Decrease) in deferred tax liability"&gt;1.1&lt;/span&gt; million decrease in deferred tax liability in fiscal 2022 to reflect the effect of the change in exchange rates on the liability
settleable in British pound sterling. For the nine months ended December 31, 2022, the Company recognized the reduction in deferred tax
liability of $&lt;span id="xdx_904_ecustom--ReductionInDeferredTaxLiability_pn3n3_dm_c20220401__20221231_z54kYTYHrhX7" title="Reduction in deferred tax liability"&gt;1.8&lt;/span&gt; million to reflect the effect of the change in exchange rates on the liability in the period and recognized $0.8 million
of current period losses, as well as the tax rate change effect of $&lt;span id="xdx_906_eifrs-full--TaxEffectFromChangeInTaxRate_pn3n3_dm_c20221001__20221231_zT3cMvasNGw5" title="Change in tax effect rate"&gt;0.3&lt;/span&gt; million on the current period losses.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability>
    <ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_pn3n3_zHScnRDnlYbb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BD_zbI1Fmg1K1Zd" style="display: none"&gt;Schedule of In process research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Project #&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Value as of &lt;br/&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Value as of &lt;br/&gt;March 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;iOx:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 25%; font-size: 10pt"&gt;PORT 2 (IMM60)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; font-size: 10pt; text-align: left"&gt;Melanoma &amp;amp; Lung Cancers&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_pn3n3" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;84,213&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_pn3n3" style="width: 22%; font-size: 10pt; text-align: right" title="In-process research and development"&gt;84,213&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;PORT 3 (IMM65)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Ovarian/Prostate Cancers&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;32,997&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXOvarianProstateCancersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;32,997&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;117,210&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;117,210&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Oncomer/Saugatuck&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;DNA Aptamers&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;178&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_c20220331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;178&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Tarus:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;PORT 6 &amp;amp; PORT 7&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Adenosine Receptors&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;27,138&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_zxIggqMDOTqb" style="font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0999"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;PORT 8&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Adenosine Receptors&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;500&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_z2UTe8vC2o1h" style="font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;PORT 9&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Adenosine Receptors&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;562&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_zc1SfRt7Efih" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InprocessResearchAndDevelopment_c20221231__ifrs-full--CounterpartiesAxis__custom--TarusMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;28,200&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331__ifrs-full--CounterpartiesAxis__custom--TarusMember_zF69TNYjLoka" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1011"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;In-process research and development&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--InprocessResearchAndDevelopment_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development"&gt;145,588&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_pn3n3_c20220331_zXEtNRf72jZi" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="In-process research and development"&gt;117,388&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Deferred tax liability&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DeferredTaxesLiability_c20221231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Deferred tax liability"&gt;28,409&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--DeferredTaxesLiability_iI_pn3n3_c20220331_zy2OYFg0dPOl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax liability"&gt;30,198&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-12-31_custom_IMM60IOXMelanomaLungCancersMember"
      decimals="-3"
      unitRef="USD">84213000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-03-31_custom_IMM60IOXMelanomaLungCancersMember"
      decimals="-3"
      unitRef="USD">84213000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-12-31_custom_IMM65IOXOvarianProstateCancersMember"
      decimals="-3"
      unitRef="USD">32997000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-03-31_custom_IMM65IOXOvarianProstateCancersMember"
      decimals="-3"
      unitRef="USD">32997000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-12-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">117210000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-03-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">117210000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-12-31_custom_OncomerSaugatuckDNAAptamersMember"
      decimals="-3"
      unitRef="USD">178000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-03-31_custom_OncomerSaugatuckDNAAptamersMember"
      decimals="-3"
      unitRef="USD">178000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-12-31_custom_TarusAdenosineReceptorsMember"
      decimals="-3"
      unitRef="USD">27138000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-12-31_custom_TarusAdenosineReceptors1Member"
      decimals="-3"
      unitRef="USD">500000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-12-31_custom_TarusAdenosineReceptors2Member"
      decimals="-3"
      unitRef="USD">562000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment
      contextRef="AsOf2022-12-31_custom_TarusMember"
      decimals="-3"
      unitRef="USD">28200000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">145588000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:InprocessResearchAndDevelopment contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">117388000</ptgef:InprocessResearchAndDevelopment>
    <ptgef:DeferredTaxesLiability contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">28409000</ptgef:DeferredTaxesLiability>
    <ptgef:DeferredTaxesLiability contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">30198000</ptgef:DeferredTaxesLiability>
    <ptgef:DeferredTaxLiability contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">25500000</ptgef:DeferredTaxLiability>
    <ptgef:DeferredTaxLiability contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">28400000</ptgef:DeferredTaxLiability>
    <ptgef:DeferredTaxLiability contextRef="AsOf2019-01-08" decimals="-3" unitRef="USD">19800000</ptgef:DeferredTaxLiability>
    <ptgef:IncreaseInDeferredIncomeTaxes
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">7000000.0</ptgef:IncreaseInDeferredIncomeTaxes>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">1100000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ptgef:ReductionInDeferredTaxLiability
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1800000</ptgef:ReductionInDeferredTaxLiability>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">300000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ptgef:UnsecuredNotesPayableAndWarrantsTextBlock contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_806_ecustom--UnsecuredNotesPayableAndWarrantsTextBlock_zSsTtfMNdY1i" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 11. &lt;span id="xdx_821_zPAGPseEZqk5"&gt;UNSECURED NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following is a roll-forward of current notes payable:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfNotesPayableTableTextBlock_pn3n3_zeWFs1sHNQe9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - UNSECURED NOTES PAYABLE (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zA0fi5D1dvOj" style="display: none"&gt;Schedule of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;iOx&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt"&gt;Balance, April 1, 2021&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--NotePayable_iS_pn3n3_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zestGKdqCeS9" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;150&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NotePayable_iS_pn3n3_c20210401__20220331_zfs96051DQC9" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;150&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"&gt;Exchange of notes payable and accrued interest for iOx shares&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zhbajFJGiK68" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares"&gt;(150&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20210401__20220331_z5sKKS9dM8D" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares"&gt;(150&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, March 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NotePayable_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zotCZUI590z6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--NotePayable_iE_pn3n3_c20220401__20221231_z3hA9dz5u2b5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1058"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; font-weight: bold"&gt;Exchange of notes payable and accrued interest for iOx shares&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zOU9l9CUtJ2a" style="display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares"&gt;(150)&lt;/td&gt;&lt;td style="display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20220401__20221231_z4iu4zFeibZ1" style="display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares"&gt;(150)&lt;/td&gt;&lt;td style="display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NotePayable_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zCQQK7FxQfHb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--NotePayable_iE_pn3n3_c20220401__20221231_zlxI21CXaGN8" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1066"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;iOx Unsecured Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;In connection with the SalvaRx Acquisition in January 2019, &lt;span id="xdx_90B_ecustom--DescriptionOfBusinessCombination_c20190103__20190131__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember" title="Description of business combination"&gt;the Company
assumed $2.0 million of 7% convertible notes issued by iOx, a wholly-owned subsidiary of SalvaRx (the &#x201c;Convertible Notes&#x201d;),
of which the Company holds $1.9 million. As a result of the SalvaRx Acquisition, iOx became a subsidiary of the Company during the year
ended March 31, 2019. In accordance with IFRS 3, the fair value, including interest receivable, of the Convertible Notes were effectively
settled against the note receivable upon the business combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;On September 8, 2021, &lt;span id="xdx_90B_ecustom--IssuanceOfUnsecuredNotesDescription_c20210901__20210908__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember" title="Description of business combination"&gt;the&#160;Company,
through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for
23,772 ordinary shares of iOx at a price of &#xa3;162. Simultaneously, the Company entered into an agreement with Oxford Sciences Innovation,
Plc (&#x201c;OSI&#x201d;), the holder of $0.15&#160;million notes plus accrued interest under which OSI exchanged the notes plus accrued
interest for&#160;820&#160;shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated
November 29, 2016, following the general tenets of IAS 39, &#x201c;Financial Instruments: Recognition and Measurement,&#x201d; and IFRIC
19, &#x201c;Extinguishing Financial Liabilities with Equity Instruments,&#x201d; and recorded the exchange at historical cost. Additionally,
no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased
its ownership of iOx from&#160;60.49% to&#160;78.32%.&lt;/span&gt; See Note 18, &#x201c;Related Party Transactions &#x2013; Share Exchange Agreement
&#x2013; iOx,&#x201d; for a further discussion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















</ptgef:UnsecuredNotesPayableAndWarrantsTextBlock>
    <ptgef:ScheduleOfNotesPayableTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--ScheduleOfNotesPayableTableTextBlock_pn3n3_zeWFs1sHNQe9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - UNSECURED NOTES PAYABLE (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zA0fi5D1dvOj" style="display: none"&gt;Schedule of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;iOx&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt"&gt;Balance, April 1, 2021&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--NotePayable_iS_pn3n3_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zestGKdqCeS9" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;150&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NotePayable_iS_pn3n3_c20210401__20220331_zfs96051DQC9" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;150&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"&gt;Exchange of notes payable and accrued interest for iOx shares&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zhbajFJGiK68" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares"&gt;(150&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20210401__20220331_z5sKKS9dM8D" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares"&gt;(150&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, March 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NotePayable_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zotCZUI590z6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--NotePayable_iE_pn3n3_c20220401__20221231_z3hA9dz5u2b5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1058"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; font-size: 10pt; font-weight: bold"&gt;Exchange of notes payable and accrued interest for iOx shares&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zOU9l9CUtJ2a" style="display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares"&gt;(150)&lt;/td&gt;&lt;td style="display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ExchangeOfNotesPayableAndAccruedInterestForIoxShare_pn3n3_c20220401__20221231_z4iu4zFeibZ1" style="display: none; font-size: 10pt; font-weight: bold; text-align: right" title="Exchange of notes payable and accrued interest for iOx shares"&gt;(150)&lt;/td&gt;&lt;td style="display: none; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NotePayable_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zCQQK7FxQfHb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--NotePayable_iE_pn3n3_c20220401__20221231_zlxI21CXaGN8" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1066"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:ScheduleOfNotesPayableTableTextBlock>
    <ptgef:NotePayable
      contextRef="AsOf2021-03-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">150000</ptgef:NotePayable>
    <ptgef:NotePayable contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">150000</ptgef:NotePayable>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare
      contextRef="From2021-04-012022-03-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">-150000</ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">-150000</ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare
      contextRef="From2022-04-012022-12-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">-150000</ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare>
    <ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-150000</ptgef:ExchangeOfNotesPayableAndAccruedInterestForIoxShare>
    <ptgef:DescriptionOfBusinessCombination contextRef="From2019-01-032019-01-31_custom_SalvaRxMember">the Company
assumed $2.0 million of 7% convertible notes issued by iOx, a wholly-owned subsidiary of SalvaRx (the &#x201c;Convertible Notes&#x201d;),
of which the Company holds $1.9 million. As a result of the SalvaRx Acquisition, iOx became a subsidiary of the Company during the year
ended March 31, 2019. In accordance with IFRS 3, the fair value, including interest receivable, of the Convertible Notes were effectively
settled against the note receivable upon the business combination.</ptgef:DescriptionOfBusinessCombination>
    <ptgef:IssuanceOfUnsecuredNotesDescription contextRef="From2021-09-012021-09-08_custom_IOXMember">the&#160;Company,
through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for
23,772 ordinary shares of iOx at a price of &#xa3;162. Simultaneously, the Company entered into an agreement with Oxford Sciences Innovation,
Plc (&#x201c;OSI&#x201d;), the holder of $0.15&#160;million notes plus accrued interest under which OSI exchanged the notes plus accrued
interest for&#160;820&#160;shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated
November 29, 2016, following the general tenets of IAS 39, &#x201c;Financial Instruments: Recognition and Measurement,&#x201d; and IFRIC
19, &#x201c;Extinguishing Financial Liabilities with Equity Instruments,&#x201d; and recorded the exchange at historical cost. Additionally,
no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased
its ownership of iOx from&#160;60.49% to&#160;78.32%.</ptgef:IssuanceOfUnsecuredNotesDescription>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_809_eifrs-full--DisclosureOfIncomeTaxExplanatory_z2bbpo4LmRrf" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;NOTE 12. &lt;span id="xdx_824_zYRUCl5i95jj"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company is a BVI business company. The BVI government does not, under
existing legislation, impose any income or corporate tax on corporations.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;PDS is a U.S. corporation and is subject to U.S. federal, state and local
income taxes, as applicable.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;iOx is subject to U.K. taxes.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The (expense) benefit from income taxes consists of the following:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zWnMyD12RJkk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-left: 10pt"&gt;&lt;span id="xdx_8BE_zLsQxoQ5ljE1" style="display: none"&gt;Schedule of income taxes benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20220401__20221231_zsmYLl3pLi1f" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20210401__20211231_zbPTKMiKUAMi" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;For the Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Current:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--CurrentFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1087"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--CurrentStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt"&gt;State and local&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(16&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1090"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--CurrentForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(8&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--CurrentTaxExpenseIncome_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Total current&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(24&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Deferred:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt"&gt;State and local&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1104"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1105"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,930&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;444&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--AdjustmentsForDeferredTaxExpense_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Total deferred&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,930&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;444&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_pn3n3_di_zUIk1Gkzq7kb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Benefit from income taxes&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,906&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;465&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zMmmvcaeSYsi" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following is a reconciliation of the U.S. taxes to the effective income
tax rates for the nine months ended December 31, 2022 and 2021 (U.S. Dollars in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_zvtghDqeHZw7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BD_zovpDafCwnr3" style="display: none"&gt;Schedule of reconciliation income tax rates&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Income (loss) on ordinary activities before tax&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_pn3n3_c20220401__20221231_zeTzaA6AKANg" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Income (loss) on ordinary activities before tax"&gt;(1,230&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_pn3n3_c20210401__20211231_zNKCMsniQEhf" style="width: 12%; font-size: 10pt; text-align: right" title="Income (loss) on ordinary activities before tax"&gt;(1,535&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Statutory U.S. income tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_c20220401__20221231_zz7uNLmimiCb" title="Statutory U.S. income tax rate"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_c20210401__20211231_z5NAJwlcIL14" title="Statutory U.S. income tax rate"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Income tax benefit at statutory income tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--LossAtStatutoryIncomeTaxRate_c20220401__20221231_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Income tax at statutory income tax rate"&gt;258&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--LossAtStatutoryIncomeTaxRate_pn3n3_c20210401__20211231_zoj1uUZp0jMf" style="font-size: 10pt; text-align: right" title="Income tax at statutory income tax rate"&gt;322&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Losses recognized (unrecognized)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--LossesRecognized_c20220401__20221231_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Losses recognized"&gt;(282&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--LossesRecognized_pn3n3_c20210401__20211231_zCB3y6lDVIb4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Losses recognized"&gt;(322&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--IncomeTaxBenefitExpense_pn3n3_c20220401__20221231_zGV70la4s5Wf" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Income tax benefit (expense)"&gt;(24&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncomeTaxBenefitExpense_pn3n3_c20210401__20211231_zBDa7Nvj8unf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Income tax benefit (expense)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1136"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z5GZjfAiiUh4" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;At December 31, 2022, the Company had $0.9 million of federal net operating
losses, which carryforward indefinitely but are limited to 80% of taxable income when utilized. As of December 31, 2022 and March 31,
2022, the Company had U.S. deferred tax assets of $&lt;span id="xdx_90E_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20221231_zzaA3lJq9Fe6" title="Deferred tax assets"&gt;0.2&lt;/span&gt; million and $&lt;span id="xdx_905_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20220331_z5dsWLztVdDc" title="Deferred tax assets"&gt;0.3&lt;/span&gt; million, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #1F497D"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following is a reconciliation of the U.K. taxes to the effective income
tax rates for the nine months ended December 31, 2022 and 2021 (U.S. Dollars in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfIncomeTaxExplanatory_pn3n3_zOoMLX3dTjW" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span id="xdx_8B6_zzrxDOTPC8B4" style="display: none"&gt;&#160;Schedule of effective income tax rates&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20220401__20221231_zGqL2JUpbj8l" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20210401__20211231_zc4rKzHsfoEj" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--AccountingProfit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss on ordinary activities before tax&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;4,567&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,434&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--ApplicableTaxRate_pid_dp_zeIav8WAqTy7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Statutory U.K. income tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;19.0&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;19.0&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss at statutory income tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;868&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;462&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ChangeIncreaseInDeferredIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Change (increase) in deferred income tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;274&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ForeignCurrencyEffect_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Foreign currency effect&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,788&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;444&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--TaxEffectOfRAndDCredit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Research and development credit&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;21&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--LossesUnrecognized_z2xpuyn4xRJ8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Losses (unrecognized)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(462&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--TaxEffectOfTaxLosses_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax benefit&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,930&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;465&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zGolEEKzuxLc" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;Research and development credit
receivables of $&lt;span id="xdx_90D_ecustom--ResearchAndDevelopmentCreditReceivables_iI_pn3n3_dm_c20221231_zNz1gq6jatJj" title="Research and development credit receivables"&gt;0.2&lt;/span&gt; million and $&lt;span id="xdx_90F_ecustom--ResearchAndDevelopmentCreditReceivables_iI_pn3n3_dm_c20220331_zCCqpkNUsNU1" title="Research and development credit receivables"&gt;0.2&lt;/span&gt; million were included in prepaid expenses and other receivables on the condensed consolidated interim
statements of financial position as of December 31, 2022 and March 31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following is a reconciliation of financial statement income (loss)
to tax basis income (loss) (in thousands):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock_pn3n3_z7IndVRdypqi" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BB_zrbbSQ2pe0bb" style="display: none"&gt;Schedule of reconciliation of financial statement loss to tax basis loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20221231__dei--LegalEntityAxis__custom--UnitedStateMember_zxhjDvg6vdHd" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20221231__dei--LegalEntityAxis__custom--BVIMember_zEPsYCKTKG32" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20221231__dei--LegalEntityAxis__custom--ForeignMember_zuwCe5t6y37j" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20221231_zHUbR7WxIEu8" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20211231__dei--LegalEntityAxis__custom--UnitedStateMember_z3TDGnFn1xW9" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20211231__dei--LegalEntityAxis__custom--BVIMember_zYzlxStAIMJ9" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20211231__dei--LegalEntityAxis__custom--ForeignMember_zZquenW5xqSi" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20211231_z7gJsOYoit1f" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31, 2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;United &lt;br/&gt;States&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;BVI&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;United &lt;br/&gt;Kingdom&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;United &lt;br/&gt;States&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;BVI&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Foreign&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PretaxIncomeLoss_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Pre-tax loss&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,230&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(7,320&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,567&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(13,117&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; text-align: right"&gt;(1,535&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; text-align: right"&gt;(6,802&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; text-align: right"&gt;(2,434&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; text-align: right"&gt;(10,771&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--LossForWhichNoBenefitWasTaken_pn3n3_z4kVYIP7k9b5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss for which no benefit was taken&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,622&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1194"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,622&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1197"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1198"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--LossesNotSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Losses not subject to tax&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1201"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;7,320&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1203"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;7,320&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1205"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;6,802&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1207"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;6,802&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Utilization of losses not previously benefitted&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(314&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1212"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(314&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1214"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1215"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1216"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1217"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PretaxLossSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Taxable income (loss)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;78&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,567&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,489&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(1,535&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1224"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(2,434&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(3,969&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z3eeQbUsJo25" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;As of December 31, 2022 and March
31, 2022, the Company&#x2019;s deferred tax assets and liabilities in the U.K. consisted of the effects of temporary differences attributable
to the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfDeferredTaxAssetsExplanatory_pn3n3_zE4USusoNe38" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B9_z7JyF3riiBA2" style="display: none"&gt;Schedule of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20221231_zlDcuXrMBvSk" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20220331_z48oVMtUAIPf" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzWJe_z6TrbHwZwXx7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,394&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(3,253&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetUnrecognized_i01I_pn3n3_maNDTAzWJe_zYp0TC44lH8f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Deferred tax asset (unrecognized)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--NetDeferredTaxAssets_iTI_pn3n3_mtNDTAzWJe_z3zoecpXzh76" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Deferred tax asset&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,894&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,753&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxLiabiltiesAbstract_iB" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxLiabilitiesInProcessRAndD_i01I_pn3n3_maDTLzCvC_zibvpvnpmh92" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;In-process research and development&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;28,409&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;30,198&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxLiability1_iTI_pn3n3_mtDTLzCvC_zbQ6HykEfA9f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Deferred tax liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;28,409&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;30,198&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--NetDeferredTaxLiabilities_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;25,515&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;28,445&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z8gYtpTVU167" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;iOx generated research and development cash credits of approximately $&lt;span id="xdx_90B_ecustom--ResearchAndDevelopmentExpenseCashCredits_pn3n3_dm_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zHDxojvWPDHc" title="Research and development cash credits"&gt;0.02&lt;/span&gt;
million that have been recorded for the nine months ended December 31, 2021. There were &lt;span id="xdx_90A_ecustom--ResearchAndDevelopmentExpenseCashCredits_pn3n3_do_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zUAtGiHgZ5b9" title="Research and development cash credits"&gt;no&lt;/span&gt; research and development cash credits recorded
for the nine months ended December 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;As of December 31, 2022 and March 31, 2022, iOx had a net deferred tax
liability of approximately $&lt;span id="xdx_904_eifrs-full--DeferredTaxLiabilities_iI_pn3n3_dm_c20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zZpopbcaCRui" title="Deferred tax liabilities"&gt;25.5&lt;/span&gt; million and approximately $&lt;span id="xdx_900_eifrs-full--DeferredTaxLiabilities_iI_pn3n3_dm_c20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_z5wkmarFxo56" title="Deferred tax liabilities"&gt;28.4&lt;/span&gt; million, respectively. On January 8, 2019, the Company originally recognized
a $19.8 million deferred tax liability for the difference between the book and income tax basis of IPR&amp;amp;D acquired as part of the SalvaRx
Acquisition. As the iOx IPR&amp;amp;D is in the U.K., the deferred tax was recorded at 17%, the prevailing tax rate applicable in the U.K.
at the time. In fiscal 2022, the Company recorded $&lt;span id="xdx_908_eifrs-full--DeferredTaxExpenseIncome_pn3n3_dm_c20190401__20200331_z6goouUGzaye" title="Deferred tax expense (income)"&gt;7.0&lt;/span&gt; million increase in deferred income taxes to reflect a future change in the U.K.
income tax rate and recognized $&lt;span id="xdx_902_ecustom--CurrentYearLosses_pn3n3_dm_c20210401__20220331_zcni1JRcLTs2" title="Current year losses"&gt;0.7&lt;/span&gt; million of current year losses and $0.8 million of prior year losses. The Company also recognized
a $&lt;span id="xdx_905_eifrs-full--IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_pn3n3_dm_c20210401__20220331_zhcVd587PT5i" title="Increase (Decrease) in deferred tax liability"&gt;1.1&lt;/span&gt; million decrease in deferred tax liability in fiscal 2022 to reflect the effect of the change in exchange rates on the liability
settleable in British pound sterling. For the nine months ended December 31, 2022, the Company recognized the reduction in deferred tax
liability of $1.8 million to reflect the effect of the change in exchange rates on the liability in the period and recognized $0.8 million
of current period losses, as well as the tax rate change effect of $0.3 million on the current period losses.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;There is no expiration date for accumulated tax losses in the U.K. entities&lt;span style="font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



















</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zWnMyD12RJkk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-left: 10pt"&gt;&lt;span id="xdx_8BE_zLsQxoQ5ljE1" style="display: none"&gt;Schedule of income taxes benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20220401__20221231_zsmYLl3pLi1f" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20210401__20211231_zbPTKMiKUAMi" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;For the Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Current:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--CurrentFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1087"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--CurrentStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt"&gt;State and local&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(16&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1090"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--CurrentForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(8&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--CurrentTaxExpenseIncome_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Total current&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(24&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;21&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Deferred:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt"&gt;State and local&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1104"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1105"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,930&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;444&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--AdjustmentsForDeferredTaxExpense_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Total deferred&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,930&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;444&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_pn3n3_di_zUIk1Gkzq7kb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Benefit from income taxes&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,906&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;465&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock>
    <ptgef:CurrentStateAndLocalIncomeTaxBenefit
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-16000</ptgef:CurrentStateAndLocalIncomeTaxBenefit>
    <ptgef:CurrentForeignIncomeTaxBenefit
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-8000</ptgef:CurrentForeignIncomeTaxBenefit>
    <ptgef:CurrentForeignIncomeTaxBenefit
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">21000</ptgef:CurrentForeignIncomeTaxBenefit>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-24000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">21000</ifrs-full:CurrentTaxExpenseIncome>
    <ptgef:DeferredForeignIncomeTaxBenefit
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2930000</ptgef:DeferredForeignIncomeTaxBenefit>
    <ptgef:DeferredForeignIncomeTaxBenefit
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">444000</ptgef:DeferredForeignIncomeTaxBenefit>
    <ifrs-full:AdjustmentsForDeferredTaxExpense
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2930000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">444000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-2906000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-465000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_zvtghDqeHZw7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BD_zovpDafCwnr3" style="display: none"&gt;Schedule of reconciliation income tax rates&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Income (loss) on ordinary activities before tax&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_pn3n3_c20220401__20221231_zeTzaA6AKANg" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Income (loss) on ordinary activities before tax"&gt;(1,230&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_pn3n3_c20210401__20211231_zNKCMsniQEhf" style="width: 12%; font-size: 10pt; text-align: right" title="Income (loss) on ordinary activities before tax"&gt;(1,535&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Statutory U.S. income tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_c20220401__20221231_zz7uNLmimiCb" title="Statutory U.S. income tax rate"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_c20210401__20211231_z5NAJwlcIL14" title="Statutory U.S. income tax rate"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Income tax benefit at statutory income tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--LossAtStatutoryIncomeTaxRate_c20220401__20221231_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Income tax at statutory income tax rate"&gt;258&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--LossAtStatutoryIncomeTaxRate_pn3n3_c20210401__20211231_zoj1uUZp0jMf" style="font-size: 10pt; text-align: right" title="Income tax at statutory income tax rate"&gt;322&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Losses recognized (unrecognized)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--LossesRecognized_c20220401__20221231_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Losses recognized"&gt;(282&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--LossesRecognized_pn3n3_c20210401__20211231_zCB3y6lDVIb4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Losses recognized"&gt;(322&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--IncomeTaxBenefitExpense_pn3n3_c20220401__20221231_zGV70la4s5Wf" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Income tax benefit (expense)"&gt;(24&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncomeTaxBenefitExpense_pn3n3_c20210401__20211231_zBDa7Nvj8unf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Income tax benefit (expense)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1136"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock>
    <ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-1230000</ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax>
    <ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-1535000</ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax>
    <ptgef:StatutoryU.s.IncomeTaxRate
      contextRef="From2022-04-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.210</ptgef:StatutoryU.s.IncomeTaxRate>
    <ptgef:StatutoryU.s.IncomeTaxRate
      contextRef="From2021-04-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.210</ptgef:StatutoryU.s.IncomeTaxRate>
    <ptgef:LossAtStatutoryIncomeTaxRate
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">258000</ptgef:LossAtStatutoryIncomeTaxRate>
    <ptgef:LossAtStatutoryIncomeTaxRate
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">322000</ptgef:LossAtStatutoryIncomeTaxRate>
    <ptgef:LossesRecognized
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-282000</ptgef:LossesRecognized>
    <ptgef:LossesRecognized
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-322000</ptgef:LossesRecognized>
    <ptgef:IncomeTaxBenefitExpense
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-24000</ptgef:IncomeTaxBenefitExpense>
    <ifrs-full:DeferredTaxAssets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">200000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">300000</ifrs-full:DeferredTaxAssets>
    <ptgef:ScheduleOfIncomeTaxExplanatory contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfIncomeTaxExplanatory_pn3n3_zOoMLX3dTjW" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span id="xdx_8B6_zzrxDOTPC8B4" style="display: none"&gt;&#160;Schedule of effective income tax rates&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20220401__20221231_zGqL2JUpbj8l" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20210401__20211231_zc4rKzHsfoEj" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--AccountingProfit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss on ordinary activities before tax&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;4,567&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;2,434&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--ApplicableTaxRate_pid_dp_zeIav8WAqTy7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Statutory U.K. income tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;19.0&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;19.0&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss at statutory income tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;868&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;462&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ChangeIncreaseInDeferredIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Change (increase) in deferred income tax rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;274&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ForeignCurrencyEffect_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Foreign currency effect&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,788&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;444&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--TaxEffectOfRAndDCredit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Research and development credit&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;21&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--LossesUnrecognized_z2xpuyn4xRJ8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Losses (unrecognized)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(462&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--TaxEffectOfTaxLosses_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Income tax benefit&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,930&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;465&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfIncomeTaxExplanatory>
    <ifrs-full:AccountingProfit
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">4567000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">2434000</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate
      contextRef="From2022-04-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.190</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="From2021-04-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.190</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">868000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">462000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ptgef:ChangeIncreaseInDeferredIncomeTaxRate
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">274000</ptgef:ChangeIncreaseInDeferredIncomeTaxRate>
    <ptgef:ForeignCurrencyEffect
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">1788000</ptgef:ForeignCurrencyEffect>
    <ptgef:ForeignCurrencyEffect
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">444000</ptgef:ForeignCurrencyEffect>
    <ptgef:TaxEffectOfRAndDCredit
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">21000</ptgef:TaxEffectOfRAndDCredit>
    <ptgef:LossesUnrecognized
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-462000</ptgef:LossesUnrecognized>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">2930000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">465000</ifrs-full:TaxEffectOfTaxLosses>
    <ptgef:ResearchAndDevelopmentCreditReceivables contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">200000</ptgef:ResearchAndDevelopmentCreditReceivables>
    <ptgef:ResearchAndDevelopmentCreditReceivables contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">200000</ptgef:ResearchAndDevelopmentCreditReceivables>
    <ptgef:ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock_pn3n3_z7IndVRdypqi" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BB_zrbbSQ2pe0bb" style="display: none"&gt;Schedule of reconciliation of financial statement loss to tax basis loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20221231__dei--LegalEntityAxis__custom--UnitedStateMember_zxhjDvg6vdHd" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20221231__dei--LegalEntityAxis__custom--BVIMember_zEPsYCKTKG32" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20221231__dei--LegalEntityAxis__custom--ForeignMember_zuwCe5t6y37j" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20221231_zHUbR7WxIEu8" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20211231__dei--LegalEntityAxis__custom--UnitedStateMember_z3TDGnFn1xW9" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20211231__dei--LegalEntityAxis__custom--BVIMember_zYzlxStAIMJ9" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20211231__dei--LegalEntityAxis__custom--ForeignMember_zZquenW5xqSi" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20211231_z7gJsOYoit1f" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31, 2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;United &lt;br/&gt;States&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;BVI&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;United &lt;br/&gt;Kingdom&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;United &lt;br/&gt;States&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;BVI&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Foreign&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PretaxIncomeLoss_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Pre-tax loss&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(1,230&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(7,320&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,567&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(13,117&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; text-align: right"&gt;(1,535&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; text-align: right"&gt;(6,802&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; text-align: right"&gt;(2,434&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 4%; font-size: 10pt; text-align: right"&gt;(10,771&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--LossForWhichNoBenefitWasTaken_pn3n3_z4kVYIP7k9b5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Loss for which no benefit was taken&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,622&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1194"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,622&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1197"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1198"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--LossesNotSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Losses not subject to tax&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1201"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;7,320&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1203"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;7,320&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1205"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;6,802&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1207"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;6,802&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Utilization of losses not previously benefitted&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(314&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1212"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(314&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1214"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1215"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1216"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1217"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PretaxLossSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Taxable income (loss)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;78&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,567&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,489&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(1,535&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1224"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(2,434&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(3,969&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock>
    <ptgef:PretaxIncomeLoss
      contextRef="AsOf2022-12-31_custom_UnitedStateMember"
      decimals="-3"
      unitRef="USD">-1230000</ptgef:PretaxIncomeLoss>
    <ptgef:PretaxIncomeLoss
      contextRef="AsOf2022-12-31_custom_BVIMember"
      decimals="-3"
      unitRef="USD">-7320000</ptgef:PretaxIncomeLoss>
    <ptgef:PretaxIncomeLoss
      contextRef="AsOf2022-12-31_custom_ForeignMember"
      decimals="-3"
      unitRef="USD">-4567000</ptgef:PretaxIncomeLoss>
    <ptgef:PretaxIncomeLoss contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-13117000</ptgef:PretaxIncomeLoss>
    <ptgef:PretaxIncomeLoss
      contextRef="AsOf2021-12-31_custom_UnitedStateMember"
      decimals="-3"
      unitRef="USD">-1535000</ptgef:PretaxIncomeLoss>
    <ptgef:PretaxIncomeLoss
      contextRef="AsOf2021-12-31_custom_BVIMember"
      decimals="-3"
      unitRef="USD">-6802000</ptgef:PretaxIncomeLoss>
    <ptgef:PretaxIncomeLoss
      contextRef="AsOf2021-12-31_custom_ForeignMember"
      decimals="-3"
      unitRef="USD">-2434000</ptgef:PretaxIncomeLoss>
    <ptgef:PretaxIncomeLoss contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-10771000</ptgef:PretaxIncomeLoss>
    <ptgef:LossForWhichNoBenefitWasTaken
      contextRef="AsOf2022-12-31_custom_UnitedStateMember"
      decimals="-3"
      unitRef="USD">1622000</ptgef:LossForWhichNoBenefitWasTaken>
    <ptgef:LossForWhichNoBenefitWasTaken contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1622000</ptgef:LossForWhichNoBenefitWasTaken>
    <ptgef:LossesNotSubjectToTax
      contextRef="AsOf2022-12-31_custom_BVIMember"
      decimals="-3"
      unitRef="USD">7320000</ptgef:LossesNotSubjectToTax>
    <ptgef:LossesNotSubjectToTax contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">7320000</ptgef:LossesNotSubjectToTax>
    <ptgef:LossesNotSubjectToTax
      contextRef="AsOf2021-12-31_custom_BVIMember"
      decimals="-3"
      unitRef="USD">6802000</ptgef:LossesNotSubjectToTax>
    <ptgef:LossesNotSubjectToTax contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6802000</ptgef:LossesNotSubjectToTax>
    <ptgef:UtilizationOfLossesNotPreviouslyBenefitted
      contextRef="AsOf2022-12-31_custom_UnitedStateMember"
      decimals="-3"
      unitRef="USD">-314000</ptgef:UtilizationOfLossesNotPreviouslyBenefitted>
    <ptgef:UtilizationOfLossesNotPreviouslyBenefitted contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-314000</ptgef:UtilizationOfLossesNotPreviouslyBenefitted>
    <ptgef:PretaxLossSubjectToTax
      contextRef="AsOf2022-12-31_custom_UnitedStateMember"
      decimals="-3"
      unitRef="USD">78000</ptgef:PretaxLossSubjectToTax>
    <ptgef:PretaxLossSubjectToTax
      contextRef="AsOf2022-12-31_custom_ForeignMember"
      decimals="-3"
      unitRef="USD">-4567000</ptgef:PretaxLossSubjectToTax>
    <ptgef:PretaxLossSubjectToTax contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-4489000</ptgef:PretaxLossSubjectToTax>
    <ptgef:PretaxLossSubjectToTax
      contextRef="AsOf2021-12-31_custom_UnitedStateMember"
      decimals="-3"
      unitRef="USD">-1535000</ptgef:PretaxLossSubjectToTax>
    <ptgef:PretaxLossSubjectToTax
      contextRef="AsOf2021-12-31_custom_ForeignMember"
      decimals="-3"
      unitRef="USD">-2434000</ptgef:PretaxLossSubjectToTax>
    <ptgef:PretaxLossSubjectToTax contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">-3969000</ptgef:PretaxLossSubjectToTax>
    <ptgef:DisclosureOfDeferredTaxAssetsExplanatory contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--DisclosureOfDeferredTaxAssetsExplanatory_pn3n3_zE4USusoNe38" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B9_z7JyF3riiBA2" style="display: none"&gt;Schedule of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20221231_zlDcuXrMBvSk" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20220331_z48oVMtUAIPf" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzWJe_z6TrbHwZwXx7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 70%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(4,394&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;(3,253&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetUnrecognized_i01I_pn3n3_maNDTAzWJe_zYp0TC44lH8f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Deferred tax asset (unrecognized)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--NetDeferredTaxAssets_iTI_pn3n3_mtNDTAzWJe_z3zoecpXzh76" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Deferred tax asset&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;(2,894&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(1,753&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxLiabiltiesAbstract_iB" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxLiabilitiesInProcessRAndD_i01I_pn3n3_maDTLzCvC_zibvpvnpmh92" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;In-process research and development&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;28,409&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;30,198&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxLiability1_iTI_pn3n3_mtDTLzCvC_zbQ6HykEfA9f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Deferred tax liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;28,409&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;30,198&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--NetDeferredTaxLiabilities_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;25,515&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;28,445&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:DisclosureOfDeferredTaxAssetsExplanatory>
    <ptgef:DeferredTaxAssetsNetOperatingLossCarryforward contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-4394000</ptgef:DeferredTaxAssetsNetOperatingLossCarryforward>
    <ptgef:DeferredTaxAssetsNetOperatingLossCarryforward contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">-3253000</ptgef:DeferredTaxAssetsNetOperatingLossCarryforward>
    <ptgef:DeferredTaxAssetUnrecognized contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1500000</ptgef:DeferredTaxAssetUnrecognized>
    <ptgef:DeferredTaxAssetUnrecognized contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1500000</ptgef:DeferredTaxAssetUnrecognized>
    <ifrs-full:NetDeferredTaxAssets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-2894000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">-1753000</ifrs-full:NetDeferredTaxAssets>
    <ptgef:DeferredTaxLiabilitiesInProcessRAndD contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">28409000</ptgef:DeferredTaxLiabilitiesInProcessRAndD>
    <ptgef:DeferredTaxLiabilitiesInProcessRAndD contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">30198000</ptgef:DeferredTaxLiabilitiesInProcessRAndD>
    <ptgef:DeferredTaxLiability1 contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">28409000</ptgef:DeferredTaxLiability1>
    <ptgef:DeferredTaxLiability1 contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">30198000</ptgef:DeferredTaxLiability1>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">25515000</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">28445000</ifrs-full:NetDeferredTaxLiabilities>
    <ptgef:ResearchAndDevelopmentExpenseCashCredits
      contextRef="From2021-04-012021-12-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">20000.00</ptgef:ResearchAndDevelopmentExpenseCashCredits>
    <ptgef:ResearchAndDevelopmentExpenseCashCredits
      contextRef="From2022-04-012022-12-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">0</ptgef:ResearchAndDevelopmentExpenseCashCredits>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AsOf2022-12-31_custom_IOXMember327150515"
      decimals="-3"
      unitRef="USD">25500000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AsOf2022-03-31_custom_IOXMember327152796"
      decimals="-3"
      unitRef="USD">28400000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="From2019-04-012020-03-31"
      decimals="-3"
      unitRef="USD">7000000.0</ifrs-full:DeferredTaxExpenseIncome>
    <ptgef:CurrentYearLosses
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">700000</ptgef:CurrentYearLosses>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="From2021-04-012022-03-31"
      decimals="-3"
      unitRef="USD">1100000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ptgef:WarrantLiabilitytextblock contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_80F_ecustom--WarrantLiabilitytextblock_zHX6kbOh9ngj" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 13. &lt;span id="xdx_821_z3vPvHFugKW5"&gt;WARRANT LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Below is the roll-forward of warrants issued by entity:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_pn3n3_zxcB3wcLeByb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BF_zQgm2v6c02Gc" style="display: none"&gt;Schedule of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;PBI&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;In 000&#x2019;$&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Warrants outstanding, April 1, 2022&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WarrantsOutstandingExercisePrice_iS_pid_c20220401__20221231_zQbIg6yikcg4" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at beginning"&gt;6.64&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WarrantsOutstandingShares_iS_pid_c20220401__20221231_zIoaa2z7ywMj" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at beginning"&gt;33,888&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantsOutstandingAmount_iS_pn3n3_c20220401__20221231_zaaQ4g8NQj4k" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at beginning"&gt;33&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Fair value adjustment as of December 31, 2022 (1)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--FairValueAdjustmentExercisePriceAtEnd_pid_c20220401__20221231_zAJdKDhAkp2e" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment , exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1295"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueAdjustmentShares_pid_c20220401__20221231_zgFdc2AUkvu5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, shares"&gt;(33,888&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueAdjustmentAmount_pn3n3_c20220401__20221231_zDEv3jQWO052" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, amount"&gt;(33&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrants outstanding, December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsOutstandingExercisePrice_iE_pid_c20220401__20221231_zEaPgWvmIgmh" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1301"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsOutstandingShares_iE_pid_c20220401__20221231_zMTJlKzObOkb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--WarrantsOutstandingAmount_iE_pn3n3_c20220401__20221231_zOTXaB6KFa2k" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(1)&lt;/td&gt;&lt;td&gt;The Company recognized a gain of $&lt;span id="xdx_904_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20221001__20221231_zr8knCLfZCT6" title="Gain (loss) of change in fair value of warrants"&gt;0.001&lt;/span&gt; million and $&lt;span id="xdx_906_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20220401__20221231_zPoJT2wsQ1zd" title="Gain (loss) of change in fair value of warrants"&gt;0.033&lt;/span&gt; million in the three and nine months ended December 31, 2022, respectively,
to reflect the change in fair value of the underlying warrants. The Company recognized a gain of $&lt;span id="xdx_90B_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20211001__20211231_zvqu1A8VguE3" title="Gain (loss) of change in fair value of warrants"&gt;0.342&lt;/span&gt; million and $&lt;span id="xdx_905_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20210401__20211231_zS7MXaJrKphk" title="Gain (loss) of change in fair value of warrants"&gt;0.726&lt;/span&gt; million in
the three and nine months ended December 31, 2021, respectively, to reflect the change in fair value of the underlying warrants. The warrants
expired in October 2022 unexercised.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ptgef:WarrantLiabilitytextblock>
    <ptgef:ScheduleOfWarrantLiabilityTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_pn3n3_zxcB3wcLeByb" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BF_zQgm2v6c02Gc" style="display: none"&gt;Schedule of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;PBI&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;In 000&#x2019;$&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Warrants outstanding, April 1, 2022&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WarrantsOutstandingExercisePrice_iS_pid_c20220401__20221231_zQbIg6yikcg4" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at beginning"&gt;6.64&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WarrantsOutstandingShares_iS_pid_c20220401__20221231_zIoaa2z7ywMj" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at beginning"&gt;33,888&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantsOutstandingAmount_iS_pn3n3_c20220401__20221231_zaaQ4g8NQj4k" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at beginning"&gt;33&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Fair value adjustment as of December 31, 2022 (1)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--FairValueAdjustmentExercisePriceAtEnd_pid_c20220401__20221231_zAJdKDhAkp2e" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment , exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1295"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueAdjustmentShares_pid_c20220401__20221231_zgFdc2AUkvu5" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, shares"&gt;(33,888&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueAdjustmentAmount_pn3n3_c20220401__20221231_zDEv3jQWO052" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value adjustment, amount"&gt;(33&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrants outstanding, December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsOutstandingExercisePrice_iE_pid_c20220401__20221231_zEaPgWvmIgmh" style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding exercise price at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1301"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsOutstandingShares_iE_pid_c20220401__20221231_zMTJlKzObOkb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, shares at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--WarrantsOutstandingAmount_iE_pn3n3_c20220401__20221231_zOTXaB6KFa2k" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants outstanding, amount at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(1)&lt;/td&gt;&lt;td&gt;The Company recognized a gain of $&lt;span id="xdx_904_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20221001__20221231_zr8knCLfZCT6" title="Gain (loss) of change in fair value of warrants"&gt;0.001&lt;/span&gt; million and $&lt;span id="xdx_906_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20220401__20221231_zPoJT2wsQ1zd" title="Gain (loss) of change in fair value of warrants"&gt;0.033&lt;/span&gt; million in the three and nine months ended December 31, 2022, respectively,
to reflect the change in fair value of the underlying warrants. The Company recognized a gain of $&lt;span id="xdx_90B_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20211001__20211231_zvqu1A8VguE3" title="Gain (loss) of change in fair value of warrants"&gt;0.342&lt;/span&gt; million and $&lt;span id="xdx_905_ecustom--GainLossOfChangeInFairValueOfWarrants_pn3n3_dm_c20210401__20211231_zS7MXaJrKphk" title="Gain (loss) of change in fair value of warrants"&gt;0.726&lt;/span&gt; million in
the three and nine months ended December 31, 2021, respectively, to reflect the change in fair value of the underlying warrants. The warrants
expired in October 2022 unexercised.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ptgef:ScheduleOfWarrantLiabilityTableTextBlock>
    <ptgef:WarrantsOutstandingExercisePrice
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">6.64</ptgef:WarrantsOutstandingExercisePrice>
    <ptgef:WarrantsOutstandingShares contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">33888</ptgef:WarrantsOutstandingShares>
    <ptgef:WarrantsOutstandingAmount contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">33000</ptgef:WarrantsOutstandingAmount>
    <ptgef:FairValueAdjustmentShares
      contextRef="From2022-04-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">-33888</ptgef:FairValueAdjustmentShares>
    <ptgef:FairValueAdjustmentAmount
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-33000</ptgef:FairValueAdjustmentAmount>
    <ptgef:GainLossOfChangeInFairValueOfWarrants
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">1000.000</ptgef:GainLossOfChangeInFairValueOfWarrants>
    <ptgef:GainLossOfChangeInFairValueOfWarrants
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">33000.000</ptgef:GainLossOfChangeInFairValueOfWarrants>
    <ptgef:GainLossOfChangeInFairValueOfWarrants
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">342000</ptgef:GainLossOfChangeInFairValueOfWarrants>
    <ptgef:GainLossOfChangeInFairValueOfWarrants
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">726000</ptgef:GainLossOfChangeInFairValueOfWarrants>
    <ptgef:CapitalStockTextBlock contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_804_ecustom--CapitalStockTextBlock_zr5NQqtc0LVe" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 14. &lt;span id="xdx_820_zkh6cjkWNqa5"&gt;CAPITAL STOCK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(a)&lt;/td&gt;&lt;td&gt;Authorized ordinary shares&lt;b&gt;: &lt;/b&gt;Unlimited number of Portage ordinary shares without par value.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;(b)&lt;/td&gt;&lt;td&gt;The following is a roll-forward of Portage ordinary shares for the nine months ended December 31, 2022 and 2021:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_zzVIVgdj9y0h" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span id="xdx_8BF_zrNZHUUfoUO2" style="display: none"&gt;Common shares: Unlimited number of common shares without par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Ordinary&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Ordinary &lt;br/&gt; Shares&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;In 000&#x2019;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;In 000&#x2019;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;In 000&#x2019;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;In 000&#x2019;$&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CommonStockShares_iS_pn3n3_c20220401__20221231_zfp2FkaXBDLf" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"&gt;13,349&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CommonStockValues_iS_pn3n3_c20220401__20221231_zTy7JC62NNGb" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;158,324&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--CommonStockShares_iS_pn3n3_c20210401__20211231_zHynUDgOFYFe" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, Shares"&gt;12,084&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--CommonStockValues_iS_pn3n3_c20210401__20211231_zeGlHTVH4o2b" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;130,649&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares issued in Tarus acquisition&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20220401__20221231_zo8EvsEc7O5i" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in Tarus acquisition, shares"&gt;2,426&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--AcquisitionsThroughBusinessCombinationsOtherProvisions_pn3n3_c20220401__20221231_z7EL8FH1Fvud" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in Tarus acquisition"&gt;17,200&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20210401__20211231_zpkgXx9v4htb" style="font-size: 10pt; text-align: right" title="Shares issued in Tarus acquisition, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1331"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--AcquisitionsThroughBusinessCombinationsOtherProvisions_pn3n3_c20210401__20211231_zh0xHGyYSfmi" style="font-size: 10pt; text-align: right" title="Shares issued in Tarus acquisition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares issued in iOx exchange&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharesIssuedInIoxExchangesShares_pn3n3_c20220401__20221231_zjnikFrYhKc8" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in iOx exchange, shares"&gt;1,070&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareIssuedInIoxExchange_pn3n3_c20220401__20221231_z2J5nt8zQGVe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in iOx exchange"&gt;9,737&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--SharesIssuedInIoxExchangesShares_pn3n3_c20210401__20211231_zmifDxtU3LEa" style="font-size: 10pt; text-align: right" title="Shares issued in iOx exchange, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1339"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareIssuedInIoxExchange_pn3n3_c20210401__20211231_ztcNjF12a95l" style="font-size: 10pt; text-align: right" title="Shares issued in iOx exchange"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1341"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Excess of non-controlling interest acquired over consideration &#x2013; iOx&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_pn3n3_c20220401__20221231_zG0G6GbgAnR5" style="font-size: 10pt; font-weight: bold; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_pn3n3_c20220401__20221231_ze8yb5MaaMrc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx"&gt;29,609&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_pn3n3_c20210401__20211231_zgVZygUEAuo3" style="font-size: 10pt; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_pn3n3_c20210401__20211231_zi12atFtIGC1" style="font-size: 10pt; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1349"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares issued to Lincoln for commitment fee under Committed Purchase Agreement&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharesIssuedToLincolnParksCommittedPurchaseShares_pn3n3_c20220401__20221231_zbzzld47r9Bj" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares"&gt;94&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharesIssuedToLincolnParksCommittedPurchase_pn3n3_c20220401__20221231_zjCpUMm4zLr1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase"&gt;900&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharesIssuedToLincolnParksCommittedPurchaseShares_pn3n3_c20210401__20211231_zgG4x05qRDDi" style="font-size: 10pt; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1355"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharesIssuedToLincolnParksCommittedPurchase_pn3n3_c20210401__20211231_zeJkmbAqm8Bb" style="font-size: 10pt; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1357"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares issued under public offering and ATM, net of issue costs&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_pn3n3_c20220401__20221231_zygzjapS0dw7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue costs , shares"&gt;88&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20220401__20221231_zPjY8TAPsMR7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue costs"&gt;586&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_pn3n3_c20210401__20211231_z44w1w5iidf8" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue costs , shares"&gt;1,241&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20210401__20211231_z8E33AYeVFUj" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue costs"&gt;27,216&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Purchase of shares issued under Committed Purchase Agreement, net of issue costs&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_pn3n3_c20220401__20221231_z7WYF4rX7PN6" style="font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares"&gt;30&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_pn3n3_c20220401__20221231_zKpZ3xLEhIl3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs"&gt;184&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_pn3n3_c20210401__20211231_zauzHGW2W1R6" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1371"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_pn3n3_c20210401__20211231_z3fmcpxsLElb" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1373"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares issued or accrued for services&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pn3n3_c20220401__20221231_zYSZpA8pWOO7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services"&gt;13&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20220401__20221231_zmeY5KkkdKy1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services"&gt;90&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pn3n3_c20210401__20211231_zm532sEf4CY1" style="font-size: 10pt; text-align: right" title="Shares issued or accrued for services"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20210401__20211231_zqyuD0UB4FH8" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs"&gt;90&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Warrants exercised&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsExercisedShares_pn3n3_c20220401__20221231_zup27D4RVdnc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants exercised, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1383"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_pn3n3_c20220401__20221231_zsU1T5GDBhAk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1385"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsExercisedShares1_pn3n3_c20210401__20211231_z0wiD5IFUMH9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised, shares"&gt;16&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_pn3n3_c20210401__20211231_zt2fg6EwFy1c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised"&gt;339&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--CommonStockShares_iE_pn3n3_c20220401__20221231_z75Uw8y5Gjck" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"&gt;17,070&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--CommonStockValues_iE_pn3n3_c20220401__20221231_zdRlDweUR1s2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;216,630&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CommonStockShares_iE_pn3n3_c20210401__20211231_zSwVG2ENQRsg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, Shares"&gt;13,345&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--CommonStockValues_iE_pn3n3_c20210401__20211231_z5TOiiDo2doe" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;158,294&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On June 16, 2020, the Company completed a private placement of &lt;span id="xdx_907_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_pdd" title="Shares issued in a private placement, net of issue costs, shares"&gt;698,145&lt;/span&gt;
restricted ordinary shares at a price of $&lt;span id="xdx_902_ecustom--PricePerShare_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_pdd" title="Shares price"&gt;10.00&lt;/span&gt; per share for gross proceeds of $&lt;span id="xdx_902_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--AccreditedInvestorsMember_zlFxI6kDfZdf" title="Shares issued in a private placement, net of issue costs"&gt;6.98&lt;/span&gt; million to accredited investors. Directors of the
Company subscribed for &lt;span id="xdx_900_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCostsShares_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_pdd" title="Shares issued in a private placement, net of issue costs, shares"&gt;215,000&lt;/span&gt; shares, or approximately 30.8% of the private placement, for proceeds of $&lt;span id="xdx_905_ecustom--SharesIssuedInPrivatePlacementNetOfIssueCosts_pn3n3_dm_c20200602__20200616__ifrs-full--CounterpartiesAxis__custom--DirectorsMember_zHbVlffGQNs8" title="Shares issued in a private placement, net of issue costs"&gt;2.15&lt;/span&gt; million. The Company incurred
costs of approximately $0.25 million in connection with the offering, which was treated as contra-equity on the Company&#x2019;s balance
sheet.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: center"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;During the quarter ended June 30, 2021, the Company commenced an &#x201c;at
the market&#x201d; offering, under which it sold &lt;span id="xdx_901_ecustom--NumberOfStockSold_c20210401__20210630_z0SdwjdGzYwj" title="Number of stock sold"&gt;90,888&lt;/span&gt; ordinary shares generating gross proceeds of approximately $&lt;span id="xdx_90C_ecustom--GrossProceedsFromStockSold_pn3n3_dm_c20210401__20210630_zPrRy0UiIOi4" title="Gross proceeds from stock sold"&gt;2.6&lt;/span&gt; million ($&lt;span id="xdx_904_ecustom--NetProceedsFromStockSold_pn3n3_dm_c20210401__20210630_z66gXdry42lc" title="Net proceeds from stock sold"&gt;2.5&lt;/span&gt; million,
net of commissions).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On June 24, 2021, the Company completed a firm commitment underwritten
public offering of &lt;span id="xdx_902_ecustom--NumberOfStockSold_c20210601__20210624_z1llgvOdhgL2" title="Number of stock sold"&gt;1,150,000&lt;/span&gt; ordinary shares at a public offering price of $23.00 per share for gross proceeds of approximately $&lt;span id="xdx_905_ecustom--GrossProceedsFromStockSold_pn3n3_dm_c20210601__20210624_zH5Ma8XGUELe" title="Gross proceeds from stock sold"&gt;26.5&lt;/span&gt;
million and was settled June 28, 2021. The Company incurred aggregate offering expenses for the public offering of approximately $&lt;span id="xdx_900_ecustom--OfferingExpenses_pn3n3_dm_c20210601__20210624_zj7ZP17AaDM8" title="Offering Cost"&gt;1.8&lt;/span&gt;
million, including approximately $&lt;span id="xdx_902_ecustom--ManagementUnderwritingAndSellingExpenses_pn3n3_dm_c20210601__20210624_zGUUdLmwhvLc" title="Management, underwriting and selling expenses"&gt;1.6&lt;/span&gt; million of management, underwriting and selling expenses.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company has issued &lt;span id="xdx_90C_ecustom--NumberOfSharesSold_c20220401__20221231_zib7KB7wamPl" title="Number of shares issued"&gt;2,425,999&lt;/span&gt; ordinary shares in connection with the
acquisition of Tarus Therapeutics, Inc. and in connection with the Tarus Therapeutics, Inc.&#x2019;s acquisition we may issue additional
ordinary shares. &lt;span style="background-color: white"&gt;See Note 8, &#x201c;Acquisition of Tarus,&#x201d; for a further discussion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On July 18, 2022, the Company completed the iOx Share Exchange Agreement
under which it exchanged &lt;span id="xdx_904_ecustom--NumberOfSharesExchanged_c20220701__20220718_pdd" title="Number of shares exchanged"&gt;1,070,000&lt;/span&gt; ordinary shares for the remaining minority interest of &lt;span id="xdx_901_ecustom--MinorityInterestPercentage_iI_pid_dp_c20220718_zx1LPwuwMRrj" title="Minority interest, percentage"&gt;21.68&lt;/span&gt;% of iOx. &lt;span style="background-color: white"&gt;See
Note 18, &#x201c;Related Party Transactions &#x2013; Share Exchange Agreement &#x2013; iOx,&#x201d; for a further discussion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Additionally, on August 19, 2022, the Company issued &lt;span id="xdx_909_ecustom--NumberOfSharesSold_c20220801__20220819__ifrs-full--CounterpartiesAxis__custom--LincolnMember_pdd" title="Number of shares issued"&gt;94,508&lt;/span&gt; ordinary shares
to Lincoln in consideration for entering into the $&lt;span id="xdx_90C_eifrs-full--ProceedsFromIssueOfOrdinaryShares_pn3n3_dm_c20220801__20220819__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zivIQX3tmhaj" title="Proceeds from offering"&gt;30&lt;/span&gt; million Committed Purchase Agreement. See Note 17, &#x201c;Commitments and Contingent
Liabilities &#x2013; Committed Purchase Agreement,&#x201d; for a further discussion.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;In October 2022, the Company restarted the ATM and commenced sales of
ordinary shares pursuant to the Sales Agreement. Through December 31, 2022, the Company sold &lt;span id="xdx_90C_ecustom--NumberOfSharesSold_pid_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zE6NGUFL0fXf" title="Number of shares sold"&gt;88,072&lt;/span&gt; ordinary shares under the ATM, generating
net proceeds of approximately $&lt;span id="xdx_908_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--ATMMember_zxzTdxVCSnGh" title="Net proceeds from sale"&gt;0.6&lt;/span&gt; million and sold &lt;span id="xdx_907_ecustom--NumberOfSharesSold_pid_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zNo1l4vYwCWc" title="Number of shares sold"&gt;30,000&lt;/span&gt; ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds
totaling approximately $&lt;span id="xdx_907_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20221230__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zxbYg5WF1qu7" title="Net proceeds from sale"&gt;0.2&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ptgef:CapitalStockTextBlock>
    <ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_zzVIVgdj9y0h" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span id="xdx_8BF_zrNZHUUfoUO2" style="display: none"&gt;Common shares: Unlimited number of common shares without par value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Ordinary&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Ordinary &lt;br/&gt; Shares&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;In 000&#x2019;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;In 000&#x2019;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;In 000&#x2019;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;In 000&#x2019;$&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CommonStockShares_iS_pn3n3_c20220401__20221231_zfp2FkaXBDLf" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"&gt;13,349&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CommonStockValues_iS_pn3n3_c20220401__20221231_zTy7JC62NNGb" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;158,324&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--CommonStockShares_iS_pn3n3_c20210401__20211231_zHynUDgOFYFe" style="width: 12%; font-size: 10pt; text-align: right" title="Balance, Shares"&gt;12,084&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--CommonStockValues_iS_pn3n3_c20210401__20211231_zeGlHTVH4o2b" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;130,649&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares issued in Tarus acquisition&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20220401__20221231_zo8EvsEc7O5i" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in Tarus acquisition, shares"&gt;2,426&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--AcquisitionsThroughBusinessCombinationsOtherProvisions_pn3n3_c20220401__20221231_z7EL8FH1Fvud" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in Tarus acquisition"&gt;17,200&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20210401__20211231_zpkgXx9v4htb" style="font-size: 10pt; text-align: right" title="Shares issued in Tarus acquisition, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1331"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--AcquisitionsThroughBusinessCombinationsOtherProvisions_pn3n3_c20210401__20211231_zh0xHGyYSfmi" style="font-size: 10pt; text-align: right" title="Shares issued in Tarus acquisition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares issued in iOx exchange&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharesIssuedInIoxExchangesShares_pn3n3_c20220401__20221231_zjnikFrYhKc8" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in iOx exchange, shares"&gt;1,070&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareIssuedInIoxExchange_pn3n3_c20220401__20221231_z2J5nt8zQGVe" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued in iOx exchange"&gt;9,737&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--SharesIssuedInIoxExchangesShares_pn3n3_c20210401__20211231_zmifDxtU3LEa" style="font-size: 10pt; text-align: right" title="Shares issued in iOx exchange, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1339"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareIssuedInIoxExchange_pn3n3_c20210401__20211231_ztcNjF12a95l" style="font-size: 10pt; text-align: right" title="Shares issued in iOx exchange"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1341"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Excess of non-controlling interest acquired over consideration &#x2013; iOx&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_pn3n3_c20220401__20221231_zG0G6GbgAnR5" style="font-size: 10pt; font-weight: bold; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_pn3n3_c20220401__20221231_ze8yb5MaaMrc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx"&gt;29,609&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares_pn3n3_c20210401__20211231_zgVZygUEAuo3" style="font-size: 10pt; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox_pn3n3_c20210401__20211231_zi12atFtIGC1" style="font-size: 10pt; text-align: right" title="Excess of non-controlling interest acquired over consideration iOx, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1349"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares issued to Lincoln for commitment fee under Committed Purchase Agreement&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharesIssuedToLincolnParksCommittedPurchaseShares_pn3n3_c20220401__20221231_zbzzld47r9Bj" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares"&gt;94&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharesIssuedToLincolnParksCommittedPurchase_pn3n3_c20220401__20221231_zjCpUMm4zLr1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase"&gt;900&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharesIssuedToLincolnParksCommittedPurchaseShares_pn3n3_c20210401__20211231_zgG4x05qRDDi" style="font-size: 10pt; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1355"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharesIssuedToLincolnParksCommittedPurchase_pn3n3_c20210401__20211231_zeJkmbAqm8Bb" style="font-size: 10pt; text-align: right" title="Shares issued to Lincoln Parks Committed Purchase, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1357"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares issued under public offering and ATM, net of issue costs&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_pn3n3_c20220401__20221231_zygzjapS0dw7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue costs , shares"&gt;88&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20220401__20221231_zPjY8TAPsMR7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue costs"&gt;586&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares_pn3n3_c20210401__20211231_z44w1w5iidf8" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue costs , shares"&gt;1,241&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20210401__20211231_z8E33AYeVFUj" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue costs"&gt;27,216&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Purchase of shares issued under Committed Purchase Agreement, net of issue costs&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_pn3n3_c20220401__20221231_z7WYF4rX7PN6" style="font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares"&gt;30&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_pn3n3_c20220401__20221231_zKpZ3xLEhIl3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs"&gt;184&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares_pn3n3_c20210401__20211231_zauzHGW2W1R6" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1371"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts_pn3n3_c20210401__20211231_z3fmcpxsLElb" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1373"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares issued or accrued for services&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pn3n3_c20220401__20221231_zYSZpA8pWOO7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services"&gt;13&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20220401__20221231_zmeY5KkkdKy1" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services"&gt;90&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pn3n3_c20210401__20211231_zm532sEf4CY1" style="font-size: 10pt; text-align: right" title="Shares issued or accrued for services"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20210401__20211231_zqyuD0UB4FH8" style="font-size: 10pt; text-align: right" title="Purchase of shares issued under Committed Purchase Agreement, net of issue costs"&gt;90&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Warrants exercised&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsExercisedShares_pn3n3_c20220401__20221231_zup27D4RVdnc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants exercised, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1383"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_pn3n3_c20220401__20221231_zsU1T5GDBhAk" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1385"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsExercisedShares1_pn3n3_c20210401__20211231_z0wiD5IFUMH9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised, shares"&gt;16&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_pn3n3_c20210401__20211231_zt2fg6EwFy1c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Warrants exercised"&gt;339&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--CommonStockShares_iE_pn3n3_c20220401__20221231_z75Uw8y5Gjck" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, Shares"&gt;17,070&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--CommonStockValues_iE_pn3n3_c20220401__20221231_zdRlDweUR1s2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;216,630&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--CommonStockShares_iE_pn3n3_c20210401__20211231_zSwVG2ENQRsg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, Shares"&gt;13,345&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--CommonStockValues_iE_pn3n3_c20210401__20211231_z5TOiiDo2doe" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;158,294&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock>
    <ptgef:CommonStockShares contextRef="AsOf2022-03-31" decimals="-3" unitRef="Shares">13349000</ptgef:CommonStockShares>
    <ptgef:CommonStockValues contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">158324000</ptgef:CommonStockValues>
    <ptgef:CommonStockShares contextRef="AsOf2021-03-31" decimals="-3" unitRef="Shares">12084000</ptgef:CommonStockShares>
    <ptgef:CommonStockValues contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">130649000</ptgef:CommonStockValues>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="Shares">2426000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">17200000</ifrs-full:AcquisitionsThroughBusinessCombinationsOtherProvisions>
    <ptgef:SharesIssuedInIoxExchangesShares
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="Shares">1070000</ptgef:SharesIssuedInIoxExchangesShares>
    <ptgef:ShareIssuedInIoxExchange
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">9737000</ptgef:ShareIssuedInIoxExchange>
    <ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">29609000</ptgef:ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox>
    <ptgef:SharesIssuedToLincolnParksCommittedPurchaseShares
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="Shares">94000</ptgef:SharesIssuedToLincolnParksCommittedPurchaseShares>
    <ptgef:SharesIssuedToLincolnParksCommittedPurchase
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">900000</ptgef:SharesIssuedToLincolnParksCommittedPurchase>
    <ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="Shares">88000</ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares>
    <ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">586000</ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts>
    <ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="Shares">1241000</ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares>
    <ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">27216000</ptgef:SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="Shares">30000</ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares>
    <ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">184000</ptgef:PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="Shares">13000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">90000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="Shares">4000</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">90000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ptgef:WarrantsExercisedShares1
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="Shares">16000</ptgef:WarrantsExercisedShares1>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">339000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ptgef:CommonStockShares contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">17070000</ptgef:CommonStockShares>
    <ptgef:CommonStockValues contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">216630000</ptgef:CommonStockValues>
    <ptgef:CommonStockShares contextRef="AsOf2021-12-31" decimals="-3" unitRef="Shares">13345000</ptgef:CommonStockShares>
    <ptgef:CommonStockValues contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">158294000</ptgef:CommonStockValues>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares
      contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember"
      decimals="INF"
      unitRef="Shares">698145</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares>
    <ptgef:PricePerShare
      contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember"
      decimals="INF"
      unitRef="USDPShares">10.00</ptgef:PricePerShare>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts
      contextRef="From2020-06-022020-06-16_custom_AccreditedInvestorsMember"
      decimals="-3"
      unitRef="USD">6980000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares
      contextRef="From2020-06-022020-06-16_custom_DirectorsMember"
      decimals="INF"
      unitRef="Shares">215000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCostsShares>
    <ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts
      contextRef="From2020-06-022020-06-16_custom_DirectorsMember"
      decimals="-3"
      unitRef="USD">2150000</ptgef:SharesIssuedInPrivatePlacementNetOfIssueCosts>
    <ptgef:NumberOfStockSold
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">90888</ptgef:NumberOfStockSold>
    <ptgef:GrossProceedsFromStockSold
      contextRef="From2021-04-012021-06-30"
      decimals="-3"
      unitRef="USD">2600000</ptgef:GrossProceedsFromStockSold>
    <ptgef:NetProceedsFromStockSold
      contextRef="From2021-04-012021-06-30"
      decimals="-3"
      unitRef="USD">2500000</ptgef:NetProceedsFromStockSold>
    <ptgef:NumberOfStockSold
      contextRef="From2021-06-012021-06-24"
      decimals="INF"
      unitRef="Shares">1150000</ptgef:NumberOfStockSold>
    <ptgef:GrossProceedsFromStockSold
      contextRef="From2021-06-012021-06-24"
      decimals="-3"
      unitRef="USD">26500000</ptgef:GrossProceedsFromStockSold>
    <ptgef:OfferingExpenses
      contextRef="From2021-06-012021-06-24"
      decimals="-3"
      unitRef="USD">1800000</ptgef:OfferingExpenses>
    <ptgef:ManagementUnderwritingAndSellingExpenses
      contextRef="From2021-06-012021-06-24"
      decimals="-3"
      unitRef="USD">1600000</ptgef:ManagementUnderwritingAndSellingExpenses>
    <ptgef:NumberOfSharesSold
      contextRef="From2022-04-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">2425999</ptgef:NumberOfSharesSold>
    <ptgef:NumberOfSharesExchanged
      contextRef="From2022-07-012022-07-18"
      decimals="INF"
      unitRef="Shares">1070000</ptgef:NumberOfSharesExchanged>
    <ptgef:MinorityInterestPercentage contextRef="AsOf2022-07-18" decimals="INF" unitRef="Pure">0.2168</ptgef:MinorityInterestPercentage>
    <ptgef:NumberOfSharesSold
      contextRef="From2022-08-012022-08-19_custom_LincolnMember"
      decimals="INF"
      unitRef="Shares">94508</ptgef:NumberOfSharesSold>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="From2022-08-012022-08-19_custom_LincolnMember"
      decimals="-3"
      unitRef="USD">30000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ptgef:NumberOfSharesSold
      contextRef="From2022-12-302022-12-31_custom_ATMMember"
      decimals="INF"
      unitRef="Shares">88072</ptgef:NumberOfSharesSold>
    <ifrs-full:ProceedsFromSalesOfBiologicalAssets
      contextRef="From2022-12-302022-12-31_custom_ATMMember"
      decimals="-3"
      unitRef="USD">600000</ifrs-full:ProceedsFromSalesOfBiologicalAssets>
    <ptgef:NumberOfSharesSold
      contextRef="From2022-12-302022-12-31_custom_LincolnMember"
      decimals="INF"
      unitRef="Shares">30000</ptgef:NumberOfSharesSold>
    <ifrs-full:ProceedsFromSalesOfBiologicalAssets
      contextRef="From2022-12-302022-12-31_custom_LincolnMember"
      decimals="-3"
      unitRef="USD">200000</ifrs-full:ProceedsFromSalesOfBiologicalAssets>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_801_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zwCWsz0gwXIf" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 15. &lt;span id="xdx_821_z76FFjLaAnyk"&gt;STOCK OPTION RESERVE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(a)&lt;/td&gt;&lt;td&gt;The following table provides the activity for the Company&#x2019;s stock option reserve for the nine months ended December 31, 2022
and 2021:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_zeA2xnrNPxZe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BD_zGV7nxLtU6ad" style="display: none"&gt;Disclosure Of Terms Stock Option Reserve Explanatory&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Non-Controlling Interest&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Stock Option Reserve&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Non-Controlling Interest&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Stock Option Reserve&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zVTLTJYq6Jig" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;11,659&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_ziRFOq5sbuNh" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;16,928&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zkDqJIL5TfE" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;11,468&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z9TizhLV2sM6" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;7,977&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Share-based compensation expense&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--AdjustmentsForSharebasedPayments_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pdn3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1461"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--AdjustmentsForSharebasedPayments_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;3,614&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;191&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;6,248&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Settled in iOx exchange&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--SettledInIoxExchange_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Settled in iOx exchange"&gt;(11,659&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SettledInIoxExchange_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Settled in iOx exchange"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1471"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SettledInIoxExchange_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Settled in iOx exchange"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1473"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SettledInIoxExchange_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Settled in iOx exchange"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zcPmyMmC7tAb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zZiO4J0OjKK6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;20,542&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zTyW1N75gsc5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;11,659&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zMtZAF3y94o4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;14,225&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zTtLbm6SqEwd" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On June 25, 2020, at the annual meeting of shareholders, the Company&#x2019;s
new incentive stock option plan (the &#x201c;2020 Stock Option Plan&#x201d;) was approved, which authorized the Company&#x2019;s directors
to fix the option exercise price and to issue stock options under the plan as they see fit. The Company&#x2019;s 2020 Stock Option Plan
is a 10% rolling stock option plan under which the Company&#x2019;s directors are authorized to grant up to a maximum of 10% of the issued
and outstanding ordinary shares on the date of grant.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;























&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;Effective January 13, 2021, the
Company amended and restated its 2020 Stock Option Plan to permit the grant of additional types of equity compensation securities, including
restricted stock units (&#x201c;RSUs&#x201d;) and dividend equivalent rights (the &#x201c;2021 Equity Incentive Plan&#x201d;). The aggregate
number of equity securities, which may be issued under the 2021 Equity Incentive Plan has not been changed.&#160; Pursuant to the 2021
Equity Incentive Plan, on January 13, 2021, the Company granted an aggregate of &lt;span id="xdx_90E_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_pdd" title="Option issued"&gt;868,000&lt;/span&gt; stock options exercisable at a price of $&lt;span id="xdx_90C_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_pdd" title="Exercise price"&gt;17.75&lt;/span&gt;
per share, representing the closing price of the shares on the day immediately preceding the grant date, which expire on January 13, 2031
to various directors, officers and consultants of the Company. &lt;span id="xdx_900_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember_pdd" title="Option issued"&gt;350,000&lt;/span&gt; options granted to members of the Board vest 1/3 on grant date,
1/3 on the first anniversary of the grant and 1/3 on the second anniversary of the grant. &lt;span id="xdx_907_eifrs-full--NumberOfSharesIssued_c20210113__ifrs-full--CounterpartiesAxis__custom--ConsultantsMember_pdd" title="Option issued"&gt;518,000&lt;/span&gt; options granted to consultants (one
of whom is also a director of the Company) vest 1/3 on each of the first three anniversaries of the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;Additionally, the Company granted
&lt;span id="xdx_90D_ecustom--StockGranted_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_pdd" title="Stock granted"&gt;243,000&lt;/span&gt; RSUs on January 13, 2021, with a fair value of $&lt;span id="xdx_90C_ecustom--FairValuePerShare_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_pdd" title="Fair value per share"&gt;17.75&lt;/span&gt; per share, which was the closing price on the day immediately preceding
the grant date. The RSUs vested on the date of grant, but underlying shares cannot be sold until one of four of the following conditions
are met: (1) a Change in Control (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)), (2) the participant&#x2019;s
Separation from Service (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)), (3) the participant&#x2019;s
death, or (4) the participant&#x2019;s Disability (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)).&#160;
In accordance with IFRS 2, &#x201c;Share-based Payment,&#x201d; the Company recognized compensation expense of $&lt;span id="xdx_900_eifrs-full--CommunicationExpense_pn3n3_dm_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_zyNOz5hg8wOg" title="Compensation expense"&gt;4.3&lt;/span&gt; million in the year
ended March 31, 2021, in connection with the RSU grants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Amended and Restated 2021 Equity Incentive Plan and Grants of Stock Options and Restricted
Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On January 19, 2022, the Board unanimously approved the Amended and Restated
2021 Equity Incentive Plan (the &#x201c;Amended and Restated 2021 Equity Incentive Plan&#x201d;). The Amended and Restated 2021 Equity Incentive
Plan provides for:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;An increase of aggregate number of shares available for awards to 2,001,812, which is equal to 15% of the issued and outstanding ordinary
shares of the Company as of January 19, 2022 subject to discretionary annual increases (on a cumulative basis) as may be approved by the
Board in future years by a number of shares not to exceed an additional 5% of the aggregate number of shares then outstanding;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;The authorization of incentive stock options (should shareholder approval be sought and obtained) under the Amended and Restated 2021
Equity Incentive Plan; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;The provision of dividend equivalent rights to be issued when authorized.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Pursuant to the Amended and Restated 2021 Equity Incentive Plan, on January
19, 2022, the Company granted an aggregate of &lt;span id="xdx_905_ecustom--StockGranted_c20220101__20220119__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"&gt;302,000&lt;/span&gt; stock options exercisable at a price of $&lt;span id="xdx_904_ecustom--FairValuePerShare_c20220101__20220119__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share"&gt;10.22&lt;/span&gt; per share, representing the average
price of the shares on the grant date (January 19, 2022), which expire on January 19, 2032, to various directors, officers and consultants
of the Company. A total of &lt;span id="xdx_909_ecustom--StockGranted_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--TwoMembersMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"&gt;13,800&lt;/span&gt; of the 302,000 stock options were granted to two members of the Board and vest on the first anniversary
of the grant date. The balance of &lt;span id="xdx_906_ecustom--StockGranted_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--EmployeesMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"&gt;288,200&lt;/span&gt; stock options was granted to employees (one of whom is also a director of the Company), and
a consultant, and such stock options vest ratably on each of the first four annual anniversaries of the grant date.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;Additionally, the Company granted
&lt;span id="xdx_902_ecustom--StockGranted_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"&gt;135,740&lt;/span&gt; RSUs to employees (one of whom is also a director of the Company) on January 19, 2022, with a fair value of $&lt;span id="xdx_901_ecustom--FairValuePerShare_c20220101__20220119__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share"&gt;10.22&lt;/span&gt; per share,
representing the average price of the shares on the grant date (January 19, 2022). The RSUs were &lt;/span&gt;fully vested and nonforfeitable
as of the &lt;span style="background-color: white"&gt;grant date and will expire on January 19, 2032.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On February 15, 2022, James Mellon, Linda Kozick and Mark Simon were appointed
to the Board. Mr. Mellon owned approximately 23.9% of the Company&#x2019;s outstanding shares at that date. Additionally, Mr. Mellon had
previously served as a member of the Board from 2016 to August 14, 2020. On February 15, 2022, in connection with the appointments, each
of these directors were granted &lt;span id="xdx_90C_ecustom--StockGranted_c20220201__20220215__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"&gt;13,800&lt;/span&gt; non-qualified stock options, which vest ratably monthly over a three-year period. The options have
an exercise price of $&lt;span id="xdx_90F_ecustom--FairValuePerShare_c20220201__20220215__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share"&gt;8.59&lt;/span&gt; per share, the average price of the stock on February 15, 2022, the day immediately preceding the grant date,
and will expire, if unexercised, on February 15, 2032.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On June 8, 2022, the Company granted &lt;span id="xdx_908_ecustom--StockGranted_c20220601__20220608__ifrs-full--CounterpartiesAxis__custom--ExecutiveMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"&gt;50,000&lt;/span&gt; options to purchase shares
to an executive of the Company. The options have an exercise price of $&lt;span id="xdx_909_ecustom--FairValuePerShare_c20220601__20220608__ifrs-full--CounterpartiesAxis__custom--ExecutiveMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share"&gt;11.00&lt;/span&gt;, the average price of the stock on that date, vest ratably
on each of the first four anniversaries of the grant date and will expire, if unexercised, on June 8, 2032.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following is the weighted average assumptions used in connection with
the June 8, 2022 option grant with respect to the Company&#x2019;s Amended and Restated 2021 Equity Incentive Plan:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eifrs-full--DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_pn3n3_z0PXr0XQXgy5" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_8BD_zkMLVnMurtWf" style="display: none"&gt;Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Assumption&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Unvested Options&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; font-size: 10pt; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 49%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zwlMc8xm8834" title="Risk free interest rate"&gt;3.05&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected dividend&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;Nil&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_908_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zx9aHxnRe9Zi" title="Expected volatility"&gt;111&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_907_ecustom--OptionLifeShareOptionsGranted_dtY_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z8aU8Pw0VW7i" title="Expected life"&gt;6.25&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Fair value of Portage option&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;span id="xdx_90D_ecustom--FairValueOfPortageOption_pid_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zo88QbFX6Cg3" title="Fair value of Portage option"&gt;9.36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AA_zK5eitRLRgt9" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On July 27, 2022, the Company granted &lt;span id="xdx_907_ecustom--StockGranted_c20220701__20220727__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Stock granted"&gt;15,900&lt;/span&gt; options to purchase shares
to a member of the Board. The options have an exercise price of $&lt;span id="xdx_90E_ecustom--FairValuePerShare_c20220601__20220727__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_pdd" title="Fair value per share"&gt;10.06&lt;/span&gt;, the average price of the stock on that date, vest ratably on each
of the first four anniversaries of the grant date and will expire, if unexercised, on July 27, 2032.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following is the weighted average assumptions used in connection with
the July 27, 2022 option grant with respect to the Company&#x2019;s Amended and Restated 2021 Equity Incentive Plan:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eifrs-full--ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory_zM8amTAE1ue" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8B9_z3NhZxUvbnf9" style="display: none"&gt;Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Assumption&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Unvested Options&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; font-size: 10pt; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 49%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_905_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zRXmqEnLkFh9" title="Risk free interest rate"&gt;2.83&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected dividend&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;Nil&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zyhuhdC7d8H8" title="Expected volatility"&gt;112&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_900_ecustom--OptionLifeShareOptionsGranted_dtY_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z7rEhj6JJHK" title="Expected life"&gt;5.75&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Fair value of Portage option&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;span id="xdx_90C_ecustom--FairValueOfPortageOption_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_pdd" title="Fair value of Portage option"&gt;8.38&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zmdyiiBs1uGf" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(b)&lt;/td&gt;&lt;td&gt;The movements in the number of options issued for the nine months ended December 31, 2022 and 2021 were:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_pn3n3_zpqWwIO2cFHa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BC_znNG4X0YuXGj" style="display: none"&gt;Schedule of outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;PBI Amended and Restated 2021 Equity Incentive Plan&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;iOx Option Plan&lt;br/&gt; (Subsidiary Plan)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 30,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NumberOfOutstandingShareOption_iS_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zrsA014IiTp2" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;1,151,400&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NumberOfOutstandingShareOption_iS_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zUOtQyrLwbO7" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;868,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iS_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_z3HJtOyq5itf" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;1,275&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NumberOfOutstandingShareOption_iS_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zJJGebQ4jSV8" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;1,924&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Granted&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcQwhLH0L2ge" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;65,900&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zUQPCdkUQekf" style="font-size: 10pt; text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1574"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zrhjuw4FtqRj" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1576"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zelSUFznsim9" style="font-size: 10pt; text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1578"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Expired or forfeited&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zmhHETlc5SD3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zlANHiWHq4P2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1582"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zbgbuSiqxKH2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;(1,275&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zxvSZjn3hC8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;(649&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5ceqnOjbBP2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;1,217,300&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zIEj46lAcwR7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;868,000&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfOutstandingShareOption_iE_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zKK6tNOhjOLa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1592"&gt;&#x2013;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NumberOfOutstandingShareOption_iE_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zw9b79ON8Y51" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;1,275&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Exercisable, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zevhBsJO8lFb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;419,705&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zf7yuWU9UoWf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;116,666&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zGyK7Xi8axE" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1600"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zV5kxgj5Z7Aj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;1,275&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zehUNg5QJDjb" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&#160;&lt;/p&gt;





















&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(c)&lt;/td&gt;&lt;td&gt;The following is the weighted average exercise price and the remaining contractual life for outstanding options by plan as of December
31, 2022 and 2021:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_pn3n3_zYqSDIN62r89" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B8_zy114S1FX6X6" style="display: none"&gt;Schedule of weighted average exercise price and remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;PBI Amended and Restated &lt;br/&gt;2021 Equity Incentive Plan&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;iOx Option Plan&lt;br/&gt; (Subsidiary Plan)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zsSiPYyJiDJ7" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;15.19&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcK0Lrpjxw8g" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;17.75&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zKctCx28Y2tb" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1619"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zf7SXsWg1JXa" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;162.14&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Weighted average remaining contractual life (in years)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zLsPw9gMiO62" title="Weighted average remaining contractual life (in years)"&gt;8.41&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcshMRx6Rf55" title="Weighted average remaining contractual life (in years)"&gt;9.04&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zvB5Qd59wDy1" title="Weighted average remaining contractual life (in years)"&gt;0.30&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zzLiTngfB2cb" style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The vested options can be exercised at any time in accordance with the
applicable option agreement. The exercise price was greater than the market price on the date of the grants for all options outstanding
as of December 31, 2022 and March 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company recorded approximately $&lt;span id="xdx_90A_eifrs-full--CommunicationExpense_pn3n3_dm_c20221001__20221231_z3ZMcXAubzLk" title="Compensation expense"&gt;1.2&lt;/span&gt; million and $&lt;span id="xdx_908_eifrs-full--CommunicationExpense_pn3n3_dm_c20220401__20221231_zyB5BXavfFLg" title="Compensation expense"&gt;3.6&lt;/span&gt; million of share-based
compensation expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the three and nine months ended December 31,
2022, respectively. The Company recorded approximately $&lt;span id="xdx_90E_eifrs-full--CommunicationExpense_pn3n3_dm_c20211001__20211231_zKH9xTIWRBXc" title="Compensation expense"&gt;2.0&lt;/span&gt; million and $&lt;span id="xdx_902_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20211231_zlijdNLZ5tNf" title="Compensation expense"&gt;6.2&lt;/span&gt; million of share-based compensation expense with respect
to the Amended and Restated 2021 Equity Incentive Plan in the three and nine months ended December 31, 2021, respectively. The Company
expects to record additional share-based compensation expense of approximately $&lt;span id="xdx_905_eifrs-full--CommunicationExpense_pn3n3_dm_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zVXruMFqG0jk" title="Compensation expense"&gt;2.9&lt;/span&gt; million through June 2026 with respect to the Amended
and Restated 2021 Equity Incentive Plan. Additionally, there was &lt;span id="xdx_906_ecustom--IntrinsicValueOfStockOptions_iI_pn3n3_do_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_z74DEzpR0l22" title="Intrinsic value of stock options"&gt;&lt;span id="xdx_90F_ecustom--IntrinsicValueOfStockOptions_iI_pn3n3_do_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zqYN6o8mSXM8" title="Intrinsic value of stock options"&gt;no&lt;/span&gt;&lt;/span&gt; intrinsic value with respect to the stock options granted under the
Amended and Restated 2021 Equity Incentive Plan at December 31, 2022 and was nil at December 31, 2021.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company recorded approximately $&lt;span id="xdx_902_eifrs-full--CommunicationExpense_pn3n3_dm_c20211001__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zILIVGaQUDV4" title="Compensation expense"&gt;0.03&lt;/span&gt; million and $&lt;span id="xdx_90D_eifrs-full--CommunicationExpense_pn3n3_dm_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zNqYqk2NMrC6" title="Compensation expense"&gt;0.2&lt;/span&gt; million of share-based
compensation expense related to the iOx stock option plan in the three and nine months ended December 31, 2021, respectively. As of December
31, 2021, the Company&#x2019;s iOx stock option plan was fully vested. Additionally, the intrinsic value of the iOx stock options was approximately
$&lt;span id="xdx_909_ecustom--IntrinsicValueOfStockOptions_iI_pn3n3_dm_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember_zQNuJnXdUaQg" title="Intrinsic value of stock options"&gt;0.1&lt;/span&gt; million at December 31, 2021, all of which was associated with vested exercisable options.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ptgef:DisclosureOfTermsStockOptionReserveExplanatory contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_zeA2xnrNPxZe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BD_zGV7nxLtU6ad" style="display: none"&gt;Disclosure Of Terms Stock Option Reserve Explanatory&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Non-Controlling Interest&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Stock Option Reserve&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Non-Controlling Interest&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Stock Option Reserve&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zVTLTJYq6Jig" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;11,659&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_ziRFOq5sbuNh" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;16,928&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zkDqJIL5TfE" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;11,468&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--StockOptionReserve_iS_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z9TizhLV2sM6" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;7,977&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Share-based compensation expense&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--AdjustmentsForSharebasedPayments_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pdn3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1461"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--AdjustmentsForSharebasedPayments_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"&gt;3,614&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;191&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--AdjustmentsForSharebasedPayments_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;6,248&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Settled in iOx exchange&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--SettledInIoxExchange_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Settled in iOx exchange"&gt;(11,659&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SettledInIoxExchange_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Settled in iOx exchange"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1471"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SettledInIoxExchange_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Settled in iOx exchange"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1473"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SettledInIoxExchange_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_pdn3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Settled in iOx exchange"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1475"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zcPmyMmC7tAb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20221231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zZiO4J0OjKK6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;20,542&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zTyW1N75gsc5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;11,659&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--StockOptionReserve_iE_pn3n3_c20210401__20211231__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zMtZAF3y94o4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;14,225&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:DisclosureOfTermsStockOptionReserveExplanatory>
    <ptgef:StockOptionReserve
      contextRef="AsOf2022-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">11659000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2022-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">16928000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2021-03-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">11468000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2021-03-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">7977000</ptgef:StockOptionReserve>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2022-04-012022-12-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">3614000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2021-04-012021-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">191000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2021-04-012021-12-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">6248000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ptgef:SettledInIoxExchange
      contextRef="From2022-04-012022-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">-11659000</ptgef:SettledInIoxExchange>
    <ptgef:StockOptionReserve
      contextRef="AsOf2022-12-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">20542000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2021-12-31_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      unitRef="USD">11659000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2021-12-31_custom_StockOptionReserveMember"
      decimals="-3"
      unitRef="USD">14225000</ptgef:StockOptionReserve>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">868000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="AsOf2021-01-13_custom_N2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">17.75</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2021-01-13_custom_BoardOfDirectorsMember"
      decimals="INF"
      unitRef="Shares">350000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2021-01-13_custom_ConsultantsMember"
      decimals="INF"
      unitRef="Shares">518000</ifrs-full:NumberOfSharesIssued>
    <ptgef:StockGranted
      contextRef="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember"
      decimals="INF"
      unitRef="Shares">243000</ptgef:StockGranted>
    <ptgef:FairValuePerShare
      contextRef="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember"
      decimals="INF"
      unitRef="USDPShares">17.75</ptgef:FairValuePerShare>
    <ifrs-full:CommunicationExpense
      contextRef="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember"
      decimals="-3"
      unitRef="USD">4300000</ifrs-full:CommunicationExpense>
    <ptgef:StockGranted
      contextRef="From2022-01-012022-01-19_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">302000</ptgef:StockGranted>
    <ptgef:FairValuePerShare
      contextRef="From2022-01-012022-01-19_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">10.22</ptgef:FairValuePerShare>
    <ptgef:StockGranted
      contextRef="From2022-01-012022-01-19_custom_TwoMembersMember_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">13800</ptgef:StockGranted>
    <ptgef:StockGranted
      contextRef="From2022-01-012022-01-19_custom_EmployeesMember_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">288200</ptgef:StockGranted>
    <ptgef:StockGranted
      contextRef="From2022-01-012022-01-19_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">135740</ptgef:StockGranted>
    <ptgef:FairValuePerShare
      contextRef="From2022-01-012022-01-19_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">10.22</ptgef:FairValuePerShare>
    <ptgef:StockGranted
      contextRef="From2022-02-012022-02-15_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">13800</ptgef:StockGranted>
    <ptgef:FairValuePerShare
      contextRef="From2022-02-012022-02-15_custom_DirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">8.59</ptgef:FairValuePerShare>
    <ptgef:StockGranted
      contextRef="From2022-06-012022-06-08_custom_ExecutiveMember_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">50000</ptgef:StockGranted>
    <ptgef:FairValuePerShare
      contextRef="From2022-06-012022-06-08_custom_ExecutiveMember_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">11.00</ptgef:FairValuePerShare>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eifrs-full--DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_pn3n3_z0PXr0XQXgy5" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_8BD_zkMLVnMurtWf" style="display: none"&gt;Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Assumption&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Unvested Options&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; font-size: 10pt; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 49%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zwlMc8xm8834" title="Risk free interest rate"&gt;3.05&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected dividend&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;Nil&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_908_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zx9aHxnRe9Zi" title="Expected volatility"&gt;111&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_907_ecustom--OptionLifeShareOptionsGranted_dtY_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z8aU8Pw0VW7i" title="Expected life"&gt;6.25&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Fair value of Portage option&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;span id="xdx_90D_ecustom--FairValueOfPortageOption_pid_c20190101__20190108__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zo88QbFX6Cg3" title="Fair value of Portage option"&gt;9.36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0305</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember"
      decimals="INF"
      unitRef="Pure">1.11</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ptgef:OptionLifeShareOptionsGranted contextRef="From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember">P6Y3M</ptgef:OptionLifeShareOptionsGranted>
    <ptgef:FairValueOfPortageOption
      contextRef="From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember"
      decimals="INF"
      unitRef="USDPShares">9.36</ptgef:FairValueOfPortageOption>
    <ptgef:StockGranted
      contextRef="From2022-07-012022-07-27_custom_BoardOfDirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">15900</ptgef:StockGranted>
    <ptgef:FairValuePerShare
      contextRef="From2022-06-012022-07-27_custom_BoardOfDirectorsMember_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">10.06</ptgef:FairValuePerShare>
    <ifrs-full:ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eifrs-full--ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory_zM8amTAE1ue" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8B9_z3NhZxUvbnf9" style="display: none"&gt;Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Assumption&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Unvested Options&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; font-size: 10pt; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 49%; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_905_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zRXmqEnLkFh9" title="Risk free interest rate"&gt;2.83&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected dividend&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;Nil&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_902_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zyhuhdC7d8H8" title="Expected volatility"&gt;112&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_900_ecustom--OptionLifeShareOptionsGranted_dtY_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z7rEhj6JJHK" title="Expected life"&gt;5.75&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;Fair value of Portage option&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;$&lt;span id="xdx_90C_ecustom--FairValueOfPortageOption_c20220701__20220727__ifrs-full--DefinedBenefitPlansAxis__custom--IOxOptionPlanMember__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_pdd" title="Fair value of Portage option"&gt;8.38&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2022-07-012022-07-27_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember"
      decimals="INF"
      unitRef="Pure">0.0283</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2022-07-012022-07-27_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember"
      decimals="INF"
      unitRef="Pure">1.12</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ptgef:OptionLifeShareOptionsGranted contextRef="From2022-07-012022-07-27_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember">P5Y9M</ptgef:OptionLifeShareOptionsGranted>
    <ptgef:FairValueOfPortageOption
      contextRef="From2022-07-012022-07-27_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember"
      decimals="INF"
      unitRef="USDPShares">8.38</ptgef:FairValueOfPortageOption>
    <ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_pn3n3_zpqWwIO2cFHa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BC_znNG4X0YuXGj" style="display: none"&gt;Schedule of outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;PBI Amended and Restated 2021 Equity Incentive Plan&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;iOx Option Plan&lt;br/&gt; (Subsidiary Plan)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 30,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NumberOfOutstandingShareOption_iS_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zrsA014IiTp2" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;1,151,400&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NumberOfOutstandingShareOption_iS_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zUOtQyrLwbO7" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;868,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iS_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_z3HJtOyq5itf" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;1,275&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NumberOfOutstandingShareOption_iS_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zJJGebQ4jSV8" style="width: 12%; font-size: 10pt; text-align: right" title="Balance"&gt;1,924&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Granted&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcQwhLH0L2ge" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;65,900&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zUQPCdkUQekf" style="font-size: 10pt; text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1574"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zrhjuw4FtqRj" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1576"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zelSUFznsim9" style="font-size: 10pt; text-align: right" title="Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1578"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Expired or forfeited&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zmhHETlc5SD3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zlANHiWHq4P2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1582"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zbgbuSiqxKH2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;(1,275&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zxvSZjn3hC8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;(649&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5ceqnOjbBP2" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;1,217,300&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zIEj46lAcwR7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;868,000&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NumberOfOutstandingShareOption_iE_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zKK6tNOhjOLa" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1592"&gt;&#x2013;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NumberOfOutstandingShareOption_iE_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zw9b79ON8Y51" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance"&gt;1,275&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Exercisable, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zevhBsJO8lFb" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;419,705&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zf7yuWU9UoWf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;116,666&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zGyK7Xi8axE" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1600"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_iI_pid_c20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zV5kxgj5Z7Aj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"&gt;1,275&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2022-03-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1151400</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2021-03-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">868000</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2022-03-31_custom_StockOptionsTwoMember"
      decimals="INF"
      unitRef="Shares">1275</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2021-03-31_custom_StockOptionsTwoMember"
      decimals="INF"
      unitRef="Shares">1924</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement
      contextRef="From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">65900</ptgef:NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2022-04-012022-12-31_custom_StockOptionsTwoMember"
      decimals="INF"
      unitRef="Shares">-1275</ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2021-04-012021-12-31_custom_StockOptionsTwoMember"
      decimals="INF"
      unitRef="Shares">-649</ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2022-12-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1217300</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2021-12-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">868000</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2021-12-31_custom_StockOptionsTwoMember"
      decimals="INF"
      unitRef="Shares">1275</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="AsOf2022-12-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">419705</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="AsOf2021-12-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">116666</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="AsOf2021-12-31_custom_StockOptionsTwoMember"
      decimals="INF"
      unitRef="Shares">1275</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_pn3n3_zYqSDIN62r89" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B8_zy114S1FX6X6" style="display: none"&gt;Schedule of weighted average exercise price and remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;PBI Amended and Restated &lt;br/&gt;2021 Equity Incentive Plan&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;iOx Option Plan&lt;br/&gt; (Subsidiary Plan)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zsSiPYyJiDJ7" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;15.19&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcK0Lrpjxw8g" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;17.75&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zKctCx28Y2tb" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1619"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zf7SXsWg1JXa" style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;162.14&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Weighted average remaining contractual life (in years)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20220401__20221231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zLsPw9gMiO62" title="Weighted average remaining contractual life (in years)"&gt;8.41&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zcshMRx6Rf55" title="Weighted average remaining contractual life (in years)"&gt;9.04&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_905_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20211231__ifrs-full--DefinedBenefitPlansAxis__custom--StockOptionsTwoMember_zvB5Qd59wDy1" title="Weighted average remaining contractual life (in years)"&gt;0.30&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">15.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2021-04-012021-12-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">17.75</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2021-04-012021-12-31_custom_StockOptionsTwoMember"
      decimals="INF"
      unitRef="USDPShares">162.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember">P8Y4M28D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2021-04-012021-12-31_custom_PBI2021EquityIncentivePlanMember">P9Y14D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2021-04-012021-12-31_custom_StockOptionsTwoMember">P0Y3M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:CommunicationExpense
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">1200000</ifrs-full:CommunicationExpense>
    <ifrs-full:CommunicationExpense
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">3600000</ifrs-full:CommunicationExpense>
    <ifrs-full:CommunicationExpense
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">2000000.0</ifrs-full:CommunicationExpense>
    <ifrs-full:CommunicationExpense
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">6200000</ifrs-full:CommunicationExpense>
    <ifrs-full:CommunicationExpense
      contextRef="From2022-04-012022-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="-3"
      unitRef="USD">2900000</ifrs-full:CommunicationExpense>
    <ptgef:IntrinsicValueOfStockOptions
      contextRef="AsOf2022-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="-3"
      unitRef="USD">0</ptgef:IntrinsicValueOfStockOptions>
    <ptgef:IntrinsicValueOfStockOptions
      contextRef="AsOf2021-12-31_custom_AmendedAndRestated2021EquityIncentivePlanMember"
      decimals="-3"
      unitRef="USD">0</ptgef:IntrinsicValueOfStockOptions>
    <ifrs-full:CommunicationExpense
      contextRef="From2021-10-012021-12-31_custom_IOxOptionPlanMember"
      decimals="-3"
      unitRef="USD">30000.00</ifrs-full:CommunicationExpense>
    <ifrs-full:CommunicationExpense
      contextRef="From2021-04-012021-12-31_custom_IOxOptionPlanMember"
      decimals="-3"
      unitRef="USD">200000</ifrs-full:CommunicationExpense>
    <ptgef:IntrinsicValueOfStockOptions
      contextRef="AsOf2021-12-31_custom_IOxOptionPlanMember"
      decimals="-3"
      unitRef="USD">100000</ptgef:IntrinsicValueOfStockOptions>
    <ifrs-full:EarningsPerShareExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_806_eifrs-full--EarningsPerShareExplanatory_zHfD4iyDTxq8" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 16. &lt;span id="xdx_822_zresQLOZ4ZDk"&gt;(LOSS) PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) is calculated by dividing
the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding
during the period.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Diluted EPS is calculated by dividing the net income (loss) attributable
to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period plus the weighted
average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following table reflects the loss and share data used in the basic
and diluted EPS calculations (U.S. Dollars in thousands, except per share amounts):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--EarningsPerShareTableTextBlock_pn3n3_zTcQDz7nnwD7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B2_zpIatBYYIWs7" style="display: none"&gt;Schedule of basic and diluted EPS calculations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20221001__20221231_zjglLULkusIb" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20211001__20211231_zz6OpCrbVXI3" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20220401__20221231_zeTqFzQcdnx8" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20210401__20211231_zRr5vg062j98" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;Numerator (in 000&#x2019;$)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to owners of the Company&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(7,485&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"&gt;(3,512&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(10,163&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"&gt;(9,553&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;Denominator (in 000&#x2019;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--WeightedAverageShares_i01_pid_zIoQ9lrRsQJf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Weighted average number of shares &#x2013; Basic and Diluted&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;17,039&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;13,344&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;15,719&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;12,966&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--BasicAndDilutedLossPerShare_i01_pid_zEYG7Kd8HOsi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted (loss) per share&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(0.44&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(0.65&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(0.74&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zdqeYx7Uw2w5" style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The inclusion of the Company&#x2019;s stock options, RSUs and share purchase
warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore excluded
from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the three and nine
months ended December 31, 2022 and 2021. The following table reflects the outstanding securities by year that would have an anti-dilutive
effect on loss per share and, accordingly, were excluded from the calculation.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_pn3n3_zQfmZIH8HUBj" style="width: 100%; border-collapse: collapse; font-size: 10pt" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span id="xdx_8B4_zoAsgyZtmiob" style="display: none"&gt;Schedule of anti-dilutive share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style="white-space: nowrap; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="white-space: nowrap; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: bottom; width: 67%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Stock options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; vertical-align: bottom; width: 16%; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;1,217,300&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; vertical-align: bottom; width: 11%; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;868,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 1%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Restricted stock units&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;378,740&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;243,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1697"&gt;&#x2013;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;33,888&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zd5iB02rMppd" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Inclusion of outstanding options or other common stock equivalents in
the computation of diluted loss per share would have an anti-dilutive effect on the loss per share and are therefore excluded from the
computation. Consequently, there is no difference between loss per share and diluted loss per share.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ifrs-full:EarningsPerShareExplanatory>
    <ptgef:EarningsPerShareTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--EarningsPerShareTableTextBlock_pn3n3_zTcQDz7nnwD7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B2_zpIatBYYIWs7" style="display: none"&gt;Schedule of basic and diluted EPS calculations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20221001__20221231_zjglLULkusIb" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20211001__20211231_zz6OpCrbVXI3" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20220401__20221231_zeTqFzQcdnx8" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20210401__20211231_zRr5vg062j98" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;Numerator (in 000&#x2019;$)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to owners of the Company&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(7,485&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"&gt;(3,512&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;(10,163&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 12%; font-size: 10pt; text-align: right"&gt;(9,553&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left"&gt;Denominator (in 000&#x2019;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--WeightedAverageShares_i01_pid_zIoQ9lrRsQJf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Weighted average number of shares &#x2013; Basic and Diluted&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;17,039&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;13,344&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;15,719&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;12,966&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--BasicAndDilutedLossPerShare_i01_pid_zEYG7Kd8HOsi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted (loss) per share&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(0.44&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(0.26&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;(0.65&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;(0.74&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:EarningsPerShareTableTextBlock>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">-7485000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2021-10-012021-12-31"
      decimals="-3"
      unitRef="USD">-3512000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-10163000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-9553000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares
      contextRef="From2022-10-012022-12-31"
      decimals="INF"
      unitRef="Shares">17039</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="Shares">13344</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2022-04-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">15719</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2021-04-012021-12-31"
      decimals="INF"
      unitRef="Shares">12966</ifrs-full:WeightedAverageShares>
    <ptgef:BasicAndDilutedLossPerShare
      contextRef="From2022-10-012022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.44</ptgef:BasicAndDilutedLossPerShare>
    <ptgef:BasicAndDilutedLossPerShare
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.26</ptgef:BasicAndDilutedLossPerShare>
    <ptgef:BasicAndDilutedLossPerShare
      contextRef="From2022-04-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.65</ptgef:BasicAndDilutedLossPerShare>
    <ptgef:BasicAndDilutedLossPerShare
      contextRef="From2021-04-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.74</ptgef:BasicAndDilutedLossPerShare>
    <ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_pn3n3_zQfmZIH8HUBj" style="width: 100%; border-collapse: collapse; font-size: 10pt" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span id="xdx_8B4_zoAsgyZtmiob" style="display: none"&gt;Schedule of anti-dilutive share&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
    &lt;td style="white-space: nowrap; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="white-space: nowrap; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: bottom; width: 67%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Stock options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; vertical-align: bottom; width: 16%; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;1,217,300&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_pdd" style="border-top: Black 1pt solid; border-bottom: Black 2.25pt double; vertical-align: bottom; width: 11%; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;868,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 1%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Restricted stock units&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;378,740&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;243,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1697"&gt;&#x2013;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--WarrantsMember_pdd" style="border-bottom: Black 2.25pt double; vertical-align: bottom; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="font-size: 10pt"&gt;33,888&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="From2022-04-012022-12-31_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">1217300</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="From2021-04-012021-12-31_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">868000</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="From2022-04-012022-12-31_custom_RestrictedStockUnitsMember327165015"
      decimals="INF"
      unitRef="Shares">378740</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="From2021-04-012021-12-31_custom_RestrictedStockUnitsMember"
      decimals="INF"
      unitRef="Shares">243000</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="From2021-04-012021-12-31_custom_WarrantsMember"
      decimals="INF"
      unitRef="Shares">33888</ptgef:AntidilutiveEffectOnLossPerShare>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_80B_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zwPa6iZ7H3ll" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 17. &lt;span id="xdx_822_zVV1p7v3XVG2"&gt;COMMITMENTS AND CONTINGENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Effective March 15, 2022, iOx entered into a Master Services Agreement
(the &#x201c;MSA&#x201d;) with Parexel International (IRE) Limited (&#x201c;Parexel&#x201d;) under which Parexel agrees to provide services
as CRO provided in a work order (&#x201c;Work Order&#x201d;) effective June 1, 2022 under which Parexel will operate a Phase 2 trial of
IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer (&#x201c;NSCLC&#x201d;). The MSA provides for a five-year term, and
the Work Order provides for a term to be ended upon the completion of the services required. The budget provides for service fees and
pass-through expenses and clinical sites totaling $11.5 million. During the three months ended December 31, 2022, the Company executed
two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"&gt;&lt;b&gt;&lt;i&gt;Stimunity Convertible Note&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On July 13, 2022, the Company entered into a commitment with Stimunity
to provide &#x20ac;&lt;span id="xdx_90A_ecustom--ConvertibleNote_iI_pn3n3_uEUR_c20220713_z2zJNKFzLEdi" title="Convertible note"&gt;600,000&lt;/span&gt; under the Stimunity Convertible Note. The Stimunity Convertible Note provides for simple interest at &lt;span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220713_zC10wuouL4fb" title="Interest rate"&gt;7&lt;/span&gt;% per annum.
The Convertible Note is automatically converted into Series A shares upon Stimunity completing a Series A round for at least &#x20ac;&lt;span id="xdx_908_ecustom--ConversionOfDebt_iI_pn3n3_dm_uEUR_c20220713_zhC1H9XDnyv6" title="Conversion of debt"&gt;20&lt;/span&gt;
million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible
Note into Series A shares at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category
of shares (other than Common Shares or Series A shares) for at least &#x20ac;&lt;span id="xdx_900_ecustom--ConversionOfDebtIntoShares_iI_pn3n3_dm_uEUR_c20220713_zEawQMbRT4b7" title="Conversion of debt into shares"&gt;5&lt;/span&gt; million (the &#x201c;Minimum Raise&#x201d;), the Company will
have the right to convert the Stimunity Convertible Note and the historical Series A shares owned into the new category of shares. In
the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will
have the right to convert the Stimunity Convertible Note into Series A shares at &#x20ac;&lt;span id="xdx_904_ecustom--SharePricePerShare_iI_pid_uEURPShares_c20220713_zRBZTVXYDSoj" title="Share price, per share"&gt;363.00&lt;/span&gt; per share or the raise price less 15%, whichever
is lower. The Stimunity Convertible Note was funded by the Company on September 12, 2022. In addition, the Company has eliminated 100%
of the interest earned on the Stimunity Convertible Note in reporting its condensed consolidated financial results.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Committed Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On July 6, 2022 (the &#x201c;Signing Date&#x201d;), the Company entered
into the Committed Purchase Agreement with Lincoln, pursuant to which the Company may require Lincoln to purchase ordinary shares having
an aggregate value of up to $&lt;span id="xdx_903_ecustom--AggregateValue_pn3n3_dm_c20220701__20220706__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zNQJvPblcIHc" title="Aggregate value"&gt;30&lt;/span&gt; million over a period of 36 months. Pursuant to the Committed Purchase Agreement, Lincoln will be obligated
to purchase ordinary shares in three different scenarios that are based on various market criteria and share amounts.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Upon execution of the Committed Purchase Agreement, the Company issued
to Lincoln &lt;span id="xdx_901_ecustom--NumberOfSharesSold_c20220401__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zxn8u3jTtFR" title="Number of shares issued"&gt;94,508&lt;/span&gt; ordinary shares, representing a 3% commitment fee valued at $&lt;span id="xdx_900_ecustom--CommitmentFee_pn3n3_dm_c20220401__20221231__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zwsWMj5CT36c" title="Commitment fee"&gt;0.9&lt;/span&gt; million. The Company has the right to terminate the
Committed Purchase Agreement for any reason, effective upon one business day prior written notice to Lincoln. Lincoln has no right to
terminate the Committed Purchase Agreement. The Company is accounting for the commitment fee as a deferred commitment fee on the condensed
consolidated interim statement of financial position as of December 31, 2022 and will amortize it pro-rata against equity sold under the
Committed Purchase Agreement. Any unamortized balance will be written-off to operations at the expiration of the commitment.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Committed Purchase Agreement does not impose any financial or business
covenants on the Company and there are no limitations on the use of proceeds received by the Company from Lincoln. The Company may raise
capital from other sources in its sole discretion; provided, however, that the Company shall not enter into any similar agreement for
the issuance of variable priced equity-like securities until the three-year anniversary of the Signing Date, excluding, however, an at-the-market
transaction with a registered broker-dealer.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;In connection with the Committed Purchase Agreement, the Company and Lincoln
entered into a Registration Rights Agreement, dated July 6, 2022 (the &#x201c;Registration Rights Agreement&#x201d;). Pursuant to the Registration
Rights Agreement, the Company agreed, that it will file with the SEC the prospectus supplement to the Company&#x2019;s shelf registration
statement pursuant to Rule 424(b) for the purpose of registering for resale the ordinary shares to be issued to Lincoln under the Committed
Purchase Agreement. The prospectus supplement was filed on August 19, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company is obligated under the Tarus Merger Agreement
and the iOx Share Exchange Agreement for certain third party earnouts based on the achievement of certain milestones. See Note 8, &#x201c;Acquisition
of Tarus,&#x201d; and Note 18&lt;span style="background-color: white"&gt;, &#x201c;Related Party Transactions &#x2013; Share Exchange Agreement
&#x2013; iOx,&#x201d;&lt;/span&gt; for further discussions.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ptgef:ConvertibleNote contextRef="AsOf2022-07-13" decimals="-3" unitRef="EUR">600000000</ptgef:ConvertibleNote>
    <ifrs-full:BorrowingsInterestRate contextRef="AsOf2022-07-13" decimals="INF" unitRef="Pure">0.07</ifrs-full:BorrowingsInterestRate>
    <ptgef:ConversionOfDebt contextRef="AsOf2022-07-13" decimals="-3" unitRef="EUR">20000000</ptgef:ConversionOfDebt>
    <ptgef:ConversionOfDebtIntoShares contextRef="AsOf2022-07-13" decimals="-3" unitRef="EUR">5000000</ptgef:ConversionOfDebtIntoShares>
    <ptgef:SharePricePerShare
      contextRef="AsOf2022-07-13"
      decimals="INF"
      unitRef="EURPShares">363.00</ptgef:SharePricePerShare>
    <ptgef:AggregateValue
      contextRef="From2022-07-012022-07-06_custom_LincolnMember"
      decimals="-3"
      unitRef="USD">30000000</ptgef:AggregateValue>
    <ptgef:NumberOfSharesSold
      contextRef="From2022-04-012022-12-31_custom_LincolnMember"
      decimals="INF"
      unitRef="Shares">94508</ptgef:NumberOfSharesSold>
    <ptgef:CommitmentFee
      contextRef="From2022-04-012022-12-31_custom_LincolnMember"
      decimals="-3"
      unitRef="USD">900000</ptgef:CommitmentFee>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_804_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_zzH19t1LvC16" style="margin: 0pt 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 18. &lt;span id="xdx_82C_zelntueJkh14"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company has entered into related party transactions and certain services
agreements with its investees.&#160; Key management personnel of the Company have also entered into related party transactions with investees.
Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities
of the Company. The Board, Chairman, Chief Executive Officer (the &#x201c;CEO&#x201d;) and Chief Financial Officer are key management personnel.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following subsidiaries and associates are considered related parties:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(a)&lt;/td&gt;&lt;td&gt;&lt;b&gt;Stimunity&lt;/b&gt;. The CEO of Portage is one of three members of the board of directors of Stimunity (see Note 6, &#x201c;Investment
in Associate,&#x201d; and Note 17, &#x201c;Commitments and Contingent Liabilities &#x2013; Stimunity Convertible Note&#x201d;).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(b)&lt;/td&gt;&lt;td&gt;&lt;b&gt;iOx&lt;/b&gt;. Upon the iOx Share Exchange on July 18, 2022, the non-Portage director resigned leaving two Portage insiders as directors.
The CEO of Portage is also the CEO of iOx, and the management team of Portage comprises the management team of iOx. See below for a discussion
of the Company&#x2019;s purchase of the non-controlling interest in iOx.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(c)&lt;/td&gt;&lt;td&gt;&lt;b&gt;Saugatuck&lt;/b&gt;. One of the three directorships on the board of directors of Saugatuck is controlled by Portage. Additionally, the
CEO of Portage is also the CEO of Saugatuck, and the management team of Portage comprises the management team of Saugatuck.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(d)&lt;/td&gt;&lt;td&gt;&lt;b&gt;Intensity&lt;/b&gt;. The CEO of Portage is an officer of Intensity and from time to time, he provides consulting services to Intensity. The Company also sublets a portion of Intensity&#x2019;s office space.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(e)&lt;/td&gt;&lt;td&gt;&lt;b&gt;Portage Development Services Inc&lt;/b&gt;. PDS is a 100% owned subsidiary incorporated in Delaware, which provides human resources and
other services to each operating subsidiary of Portage via a shared services agreement.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Transactions between the parent company and its subsidiaries, which are
related parties, have been eliminated in consolidation and are not disclosed in this note.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;On September 8, 2021,&lt;span id="xdx_906_ecustom--IssuanceOfUnsecuredNotesDescriptions_c20210901__20210908__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember" title="Issuance of unsecured notes, description"&gt; the&#160;Company,
through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for
23,772 ordinary shares of iOx at a price of &#xa3;162. Simultaneously, the Company entered into an agreement with OSI, the holder of
$0.15&#160;million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for&#160;820&#160;shares of iOx.
The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets
of IAS 39, &#x201c;Financial Instruments: Recognition and Measurement,&#x201d; and IFRIC 19, &#x201c;Extinguishing Financial Liabilities
with Equity Instruments,&#x201d; and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection
with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from&#160;60.49% to&#160;78.32%.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Share Exchange Agreement &#x2013; iOx&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On July 18, 2022, the Company and SalvaRx entered into a Share Exchange
Agreement (the &#x201c;Share Exchange Agreement&#x201d;) with each of the minority shareholders of iOx (the &#x201c;Sellers&#x201d;) resulting
in the acquisition of the outstanding non-controlling ownership interest (approximately 22%) of iOx, which is developing the iNKT agonist
platform. The Company followed IFRS 3, &#x201c;Business Combinations,&#x201d; and IAS 27, &#x201c;Separate Financial Statements,&#x201d; (which
substantially replaced IAS 3) to account for this transaction. The Company achieved control of iOx, as defined, on January 8, 2019 upon
the completion of the SalvaRx Acquisition. Further transactions whereby the parent entity acquires further equity interests from non-controlling
interests, or disposes of equity interests but without losing control, are accounted for as equity transactions (i.e., transactions with
owners in their capacity as owners). As such:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;the carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative interests
in the subsidiary;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;any difference between the amount by which the non-controlling interests is adjusted and the fair value of the consideration paid
or received is recognized directly in equity and attributed to the owners of the parent; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;there is no consequential adjustment to the carrying amount of goodwill, and no gain or loss is recognized in profit or loss.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company now owns the worldwide rights to its small molecule iNKT agonists,
including lead programs PORT-2 and PORT-3. Under the terms of the Share Exchange Agreement, each Seller sold to the Company, and the Company
acquired from each Seller, legal and beneficial ownership of the number of iOx shares held by each Seller, free and clear of any share
encumbrances, in exchange for the issuance in an aggregate of &lt;span id="xdx_906_ecustom--PortageOrdinaryShares_c20220401__20221231_pdd" title="Portage ordinary shares"&gt;1,070,000&lt;/span&gt; Portage ordinary shares to be allocated among the Sellers based
upon their relative ownership. As a result of the Share Exchange Agreement, the Company owns 100% of the issued and outstanding shares
of iOx.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;As additional consideration for the sale of the iOx
shares to the Company under the Share Exchange Agreement, the Sellers shall have the contingent right to receive additional shares (&#x201c;Earnout
Shares&#x201d;) from the Company having an aggregate value equal to $25 million calculated at the Per Share Earnout Price, as defined in
the Share Exchange Agreement, upon the achievement of certain milestones defined as the dosing of the first patient in a Phase 3 clinical
trial for either PORT-2 (IMM60 iNKT cell activator/agonist) or PORT-3 (PLGA-nanoparticle formulation of IMM60 combined with a NY-ESO-1
peptide vaccine). The Company shall have the option, in its sole and absolute discretion, to settle the Earnout Shares in cash. The Company
followed IFRS 3 and IAS 32, &#x201c;Financial Instruments: Presentation,&#x201d; to account for the fair value of the Earnout Shares. The
principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount
rate used. The fundamental principle of IAS 32 is that a financial instrument should be classified as either a financial liability or
an equity instrument according to the substance of the contract, not its legal form, and the definitions of financial liability and equity
instrument. A financial instrument is an equity instrument if, and only if, both conditions (a) and (b) below are met:&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(a)&lt;/td&gt;&lt;td style="text-align: left"&gt;the instrument includes no contractual obligation to deliver cash or another financial asset to another entity,
and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(b)&lt;/td&gt;&lt;td style="text-align: left"&gt;if the instrument will or may be settled in the issuer&#x2019;s own equity instruments, it is either:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 41.05pt"/&gt;&lt;td style="width: 18pt"&gt;(i)&lt;/td&gt;&lt;td style="text-align: left"&gt;a non-derivative that includes no contractual obligation for the issuer to deliver a variable number of its
own equity instruments; or&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 41.05pt"/&gt;&lt;td style="width: 18pt"&gt;(ii)&lt;/td&gt;&lt;td style="text-align: left"&gt;a derivative that will be settled only by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;When a derivative financial instrument gives one party a choice over how
it is settled (for instance, the issuer or the holder can choose settlement net in cash or by exchanging shares for cash), it is a financial
asset or a financial liability unless all of the settlement alternatives would result in it being an equity instrument. The financial
instrument includes the exclusive right of the Company to settle the obligation with cash or equity and, accordingly, accounted for the
fair value of the Earnout Shares as a non-current liability.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company recorded $5.478 million as the fair value estimate of the
Earnout Shares, which is reflected as deferred obligation - iOx milestone on the condensed consolidated balance sheet included herein.
The Company will determine the fair value of the Earnout Shares at each balance sheet date. Any change to the fair value will be recorded
in the Company&#x2019;s statements of operations and other comprehensive income (loss). The Company recorded a (loss) from the change (increase)
in fair value of the liability of $0.144 million and $0.090 million for the three and nine months ended December 31, 2022, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;PDS entered into a Services Agreement with our CEO effective December
15, 2021 (the &#x201c;CEO Services Agreement&#x201d;). The CEO Services Agreement provides that the CEO will receive a base salary of $&lt;span id="xdx_90D_ecustom--BaseSalary_pn3n3_c20211201__20211215__ifrs-full--CounterpartiesAxis__custom--ChiefExecutiveOfficersMember_zRGHwqO8kGr5" title="Base Salary"&gt;618,000&lt;/span&gt;,
plus cost-of-living increases. The CEO Services Agreement provides for annual increases based upon the review of the base salary by the
Board prior to the anniversary of the CEO Services Agreement provided that the annual increase cannot be less than the cost-of-living
increase. The CEO Services Agreement also provides that the CEO is eligible to receive an annual performance-based bonus targeted at 59%
of the applicable year&#x2019;s base salary, which bonus is earned based on the achievement of performance targets, as determined annually
by the Board and communicated to the CEO in the first quarter of the year. Any annual bonus, to the extent earned, is to be paid no later
than March 15 of the following year. The CEO Services Agreement is for an initial term of three years, after which it will automatically
renew annually unless terminated in accordance with the CEO Services Agreement.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Under the CEO Services Agreement, the CEO may terminate his employment
with PDS at any time for Good Reason (as defined in the CEO Services Agreement). PDS may terminate the CEO&#x2019;s employment immediately
upon his death, upon a period of disability or without Just Cause (as defined in the CEO Services Agreement). In the event that the CEO&#x2019;s
employment is terminated due to his death or Disability (as defined in the CEO Services Agreement), for Good Reason or without Just Cause,
he will be entitled to accrued obligations (accrued unpaid portion of base salary, accrued unused vacation time and any unpaid expenses).
Additionally, he may be entitled to Severance Benefits (as defined in the CEO Services Agreement), which include his then current base
salary and the average of his annual bonus for the prior two completed performance years, paid over 12 monthly installments. Additionally,
the CEO will be entitled to life insurance benefits and medical and dental benefits for a period of 12 months at the same rate the CEO
and PDS shared such costs during his period of employment.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Additionally, all stock options (and any other unvested equity incentive
award) held by the CEO relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as defined
in the CEO Services Agreement), and the exercise period for such stock options will be increased by a period of two years from the Termination
Date.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;If the CEO&#x2019;s employment by PDS is terminated by PDS or any successor
entity without Just Cause (not including termination by virtue of the CEO&#x2019;s death or Disability) or by the CEO for Good Reason within
12 months following the effective date of a Change in Control (as defined in the CEO Services Agreement), then, in addition to paying
or providing the CEO with the Accrued Obligations (as defined in the CEO Services Agreement), the Company will provide the following Change
in Control Severance Benefits (as defined in the CEO Services Agreement):&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(1)&lt;/td&gt;&lt;td&gt;PDS will pay the base salary continuation benefit for 18 months;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(2)&lt;/td&gt;&lt;td&gt;PDS will pay the life insurance benefit for 18 months;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(3)&lt;/td&gt;&lt;td&gt;PDS will pay an additional amount equivalent to the CEO&#x2019;s target annual bonus calculated using the bonus percentage for the
performance year in which the CEO&#x2019;s termination occurs. This bonus will be paid in 12 equal installments commencing on the first
payroll date that is more than 60 days following the date of termination of the CEO&#x2019;s employment, with the remaining installments
occurring on the first day of the month for the 11 months thereafter;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(4)&lt;/td&gt;&lt;td&gt;PDS will provide the CEO with continued medical and dental benefits, as described above, for 18 months; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(5)&lt;/td&gt;&lt;td&gt;All stock options (and any other unvested equity incentive award) held by the CEO relating to shares of the Company or its parent
will be deemed fully vested and exercisable on the Termination Date, as defined, and the exercise period for such stock options will be
increased by a period of two years from the Termination Date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;PDS entered into services agreements (individually, an &#x201c;Executive
Service Agreement,&#x201d; and collectively, the &#x201c;Executive Service Agreements&#x201d;) with each of our five other senior officers
(individually, &#x201c;Executive&#x201d; and collectively, &#x201c;Executives&#x201d;), three of which are dated as of December 1, 2021, one
of which is dated December 15, 2021 and one of which is dated June 1, 2022. Each of the Executive Services Agreements provides for an
initial term of two years that is automatically renewed for one-year periods (except two of the Executive Services Agreement, which provides
for an initial term of one year and that is automatically renewed for one-year periods). The Executive Services Agreements initially provide
for annual base salaries ranging from $175,000 to $348,000 (pro-rated for services rendered) and annual bonus targets ranging from 30%
to 40%. They also provide for long-term incentives in the form of equity awards from time to time under the Portage Biotech Inc. Amended
and Restated 2021 Equity Incentive Plan.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Executive Services Agreements can be terminated by PDS without Just
Cause, by death or Disability, or by the Executive (except one) for Good Reason (each as defined in the respective Executive Services
Agreements). In such instances, the Executive Services Agreements provide for the payment of accrued obligations (accrued unpaid portion
of base salary, accrued unused vacation time and any unpaid expenses). Additionally, the Executives (except two) are entitled to 50% of
base salary plus 50% of average annual bonus earned over the prior two performance years, as well as prevailing life insurance benefits
for a period of six months and medical and dental benefits for a period of six months at the prevailing rate PDS and the Executive were
sharing such expenses.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Additionally, all stock options (and any other unvested equity incentive
award) held by the Executives relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as
defined in the respective Executive Services Agreements), and the exercise period for such stock options will be increased by a period
of two years from the Termination Date.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;If an Executive&#x2019;s employment by PDS is terminated by the Company
or any successor entity without Just Cause (not including termination by virtue of the Executive&#x2019;s death or Disability) or by the
Executive (except one) for Good Reason within 12 months following the effective date of a Change in Control (as defined in the respective
Executive Services Agreements), then, in addition to paying or providing the Executive with the Accrued Obligations (as defined in the
respective Executive Services Agreements), the Company will provide the following Change in Control Severance Benefits (as defined in
the respective Executive Services Agreements), except in two cases in which the Executive is entitled to Item (5) and 50% of Items (1)
and (3) below:&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(1)&lt;/td&gt;&lt;td&gt;PDS will pay the Base Salary continuation benefit for 12 months;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(2)&lt;/td&gt;&lt;td&gt;PDS will pay the life insurance benefit for 12 months;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(3)&lt;/td&gt;&lt;td&gt;The Company will pay an additional amount equivalent to the Executive&#x2019;s target annual bonus calculated using the bonus percentage
for the performance year in which the Executive&#x2019;s termination occurs. This bonus will be payable in 12 equal installments commencing
on the first payroll date that is more than 60 days following the date of termination of the Executive&#x2019;s employment, with the remaining
installments occurring on the first day of the month for the 11 months thereafter;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 0.5in; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(4)&lt;/td&gt;&lt;td&gt;PDS will provide the Executive with continued medical and dental benefits, as described above, for 12 months; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;(5)&lt;/td&gt;&lt;td&gt;All stock options (and any other unvested equity incentive award) held by the Executive relating to shares of the Company or its parent
will be deemed fully vested and exercisable on the Termination Date and the exercise period for such stock options will be increased by
a period of two years from the Termination Date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Executive Services Agreements also include customary confidentiality,
as well as provisions relating to assignment of inventions. The Executive Services Agreements also includes non-competition&#160;and non-solicitation&#160;of
employees and customers provision that run during the Executive&#x2019;s employment with PDS and for a period of one year after termination
of employment.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Bonuses &amp;amp; Board Compensation Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;In December 2021, the Compensation
Committee approved performance bonuses payable to senior management totaling $0.7 million. The bonuses were paid in December 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;In addition, the Compensation Committee of the Board established director
compensation. Effective January 1, 2022, each non-executive Board member will be entitled to receive cash Board fees of $40,000 per annum,
payable quarterly in arrears. Additionally, each non-executive Board member will be entitled to an annual grant of 6,900 options to purchase
Portage ordinary shares, which would vest the first annual anniversary of the grant date. The Company incurred Board fees totaling $78,750
and $236,250 during the three and nine months ended December 31, 2022, respectively. There were no Board fees incurred during the three
and nine months ended December 31, 2021.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Non-executive Board chairpersons will be entitled to an annual cash fee
of $30,000, payable quarterly in arrears. In lieu of a non-executive chairperson, the lead director will be entitled to an annual cash
fee of $20,000 per annum paid quarterly in arrears. &lt;span id="xdx_904_ecustom--AnnualFeesdescription_c20220401__20221231" title="Annual feesDescription"&gt;Additionally, the chairperson of each of the Audit Committee, Compensation Committee
and Nomination Committee will be entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members
of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;In December 2022, the Board approved
executive performance bonuses, as recommended by the Compensation Committee, totaling $&lt;span id="xdx_909_ecustom--CompensationCommittee_pn3n3_dm_c20211201__20211231_zw5XlaKU8Fw1" title="Compensation committee"&gt;0.6&lt;/span&gt; million, which is equivalent to &lt;span id="xdx_907_ecustom--OriginalAnnualTargetsPercentage_pid_dp_c20211201__20211231_zjUl9FS3SLM4" title="Original annual targets percentage"&gt;73.5&lt;/span&gt;% of original
annual targets established by the Board in December 2021. The bonuses were approved based upon the original performance targets established.
The Board further approved a payment structure of 25% of approved bonuses, which were paid in January 2023, with the balance of amounts due
payable upon a new financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ptgef:IssuanceOfUnsecuredNotesDescriptions contextRef="From2021-09-012021-09-08_custom_IOXMember">the&#160;Company,
through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for
23,772 ordinary shares of iOx at a price of &#xa3;162. Simultaneously, the Company entered into an agreement with OSI, the holder of
$0.15&#160;million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for&#160;820&#160;shares of iOx.
The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets
of IAS 39, &#x201c;Financial Instruments: Recognition and Measurement,&#x201d; and IFRIC 19, &#x201c;Extinguishing Financial Liabilities
with Equity Instruments,&#x201d; and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection
with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from&#160;60.49% to&#160;78.32%.</ptgef:IssuanceOfUnsecuredNotesDescriptions>
    <ptgef:PortageOrdinaryShares
      contextRef="From2022-04-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">1070000</ptgef:PortageOrdinaryShares>
    <ptgef:BaseSalary
      contextRef="From2021-12-012021-12-15_custom_ChiefExecutiveOfficersMember"
      decimals="-3"
      unitRef="USD">618000000</ptgef:BaseSalary>
    <ptgef:AnnualFeesdescription contextRef="From2022-04-01to2022-12-31">Additionally, the chairperson of each of the Audit Committee, Compensation Committee
and Nomination Committee will be entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members
of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.</ptgef:AnnualFeesdescription>
    <ptgef:CompensationCommittee
      contextRef="From2021-12-012021-12-31"
      decimals="-3"
      unitRef="USD">600000</ptgef:CompensationCommittee>
    <ptgef:OriginalAnnualTargetsPercentage
      contextRef="From2021-12-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.735</ptgef:OriginalAnnualTargetsPercentage>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_80C_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zHeAhhXcGkL1" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 19. &lt;span id="xdx_825_zUoLpSqffpN3"&gt;FINANCIAL INSTRUMENTS AND RISK MANAGEMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company&#x2019;s financial instruments recognized in the Company&#x2019;s
condensed consolidated interim statements of financial position consist of the following:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Fair value estimates are made at a specific point in time, based on relevant
market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of
significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could significantly affect
these estimates.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following table summarizes the Company&#x2019;s financial instruments
as of December 31, 2022 and March 31, 2022:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory_pn3n3_zkPsGNEDvFN9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BE_zYUV3DrLCaR3" style="display: none"&gt;Schedule of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20221231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zU75MA5YgBq3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20221231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zaGOgs0d3Ou5" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zhMnrMQ8D1Xf" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20220331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z6TQFEmhz8f2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of March 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value through Other Comprehensive &lt;br/&gt;Income (&#x201c;FVTOCI&#x201d;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTOCI&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;13,104&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1806"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;23,352&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid expenses and other receivables&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,786&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1811"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,480&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1813"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ConvertibleNoteReceivableIncludingAccruedInterest_i01I_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Convertible note receivable, including accrued interest&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1815"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;642&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1817"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1818"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--CurrentInvestments_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Investments&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1820"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;4,768&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1822"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;9,082&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value through Profit or Loss (&#x201c;FVTPL&#x201d;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Accounts payable and accrued liabilities&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,422&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1831"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;750&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1833"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--WarrantLiability_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1835"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1836"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1837"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;33&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredPurchasePricePayableTarus_i01I_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred purchase price payable - Tarus&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1840"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;8,876&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1842"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1843"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredObligationIoxMilestone_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred obligation - iOx milestone&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1845"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5,568&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1847"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1848"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zHt4OUzsIO61" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;A summary of the Company&#x2019;s risk exposures as it relates to financial
instruments are reflected below.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company&#x2019;s financial assets and liabilities are comprised of
cash and cash equivalents, receivables and investments in equities and private entities, accounts payable, warrant liability and unsecured
notes payable.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company classifies the fair value of these transactions according
to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Level 1 &#x2013; Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of
the reporting date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Level 2 &#x2013; Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which
can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of
the reporting date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;Level 3 &#x2013; Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified
as Level 3 financial instrument.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Assessment of the significance of a particular input to the fair value
measurement requires judgment and may affect the placement within the fair value hierarchy.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Management has assessed that the fair values of cash and cash equivalents,
other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The following methods and assumptions were used to estimate their fair
values:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt"&gt;&lt;b&gt;Convertible Note Receivable:&lt;/b&gt; The fair
value of the Stimunity Convertible Note receivable denominated in euros at initial recognition is the transaction price for the instrument
adjusted for the effect of the currency translation rate on the reporting date (Level 3) (see Note 17, &#x201c;Commitments and Contingent
Liabilities &#x2013; Stimunity Convertible Note&#x201d;). The Company recognized an unrealized gain through OCI on the change in fair value
of the Stimunity Convertible Note receivable of $&lt;span id="xdx_906_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_pn3n3_dm_c20221001__20221231_z0tET2hILWu9" title="Convertible Note receivable"&gt;&lt;span id="xdx_901_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_pn3n3_dm_c20220401__20221231_zLV0SqenCrFi" title="Convertible Note receivable"&gt;0.29&lt;/span&gt;&lt;/span&gt; million for the three and nine months ended December 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;Investment in Intensity&lt;/b&gt;: Fair value of the asset is determined
by considering other comparable equity funding transactions by Intensity with unrelated investors (Level 3).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;Accrued Equity Issuable: &lt;/b&gt;The fair value is estimated based on the
average of the quoted market prices for the period in which the shares were earned (Level 1).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;Warrant Liability&lt;/b&gt;: The fair value is estimated using a Black-Scholes
model (Level 3) (see Note 13, &#x201c;Warrant Liability&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;Deferred Purchase Price Payable - Tarus:&lt;/b&gt; The fair value is the
estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 at acquisition
date, adjusted at each reporting date for any change in fair value (Level 3) (see Note 8, &#x201c;Acquisition of Tarus&#x201d;). The fair
value was determined using the Income Approach and was based upon the analysis on the Tarus clinical plan, the timing of development events
and the probabilities of success determined primarily based upon empirical third party data and Company experience, as well as the relevant
cost of capital. The Company recorded a (loss) from the change (increase) in fair value of the liability of $0.354 million and $0.338
million for the three and nine months ended December 31, 2022, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;Deferred Obligation - iOx Milestone:&lt;/b&gt; The fair value is the estimated
value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 as of July 18, 2022, the
date of the Share Exchange Agreement, adjusted at each reporting date for any change in fair value (Level 3) (see Note 18, &#x201c;Related
Party Transactions &#x2013; Share Exchange Agreement &#x2013; iOx&#x201d;). The fair value was determined using the Income Approach and based
on factors including the clinical plan, the timing of development events and the probabilities of success determined primarily based upon
empirical third party data and Company experience, as well as the relevant cost of capital. The Company recorded a (loss) from the change
(increase) in fair value of the liability of $0.144 million and $0.090 million for the three and nine months ended December 31, 2022,
respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;There have been no transfers between levels of the fair value hierarchy
for the nine months ended December 31, 2022 and the year ended March 31, 2022.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company&#x2019;s financial instruments are exposed to certain financial
risks: Credit Risk, Liquidity Risk and Foreign Currency Risk.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Credit risk is the risk of loss associated with a counterparty&#x2019;s
inability to fulfil its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&#x2019;s condensed consolidated interim statements of financial position.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;.&lt;/b&gt; Cash and cash equivalents comprise
cash on hand and on-demand deposits that are readily convertible to a known amount of cash with three months or less from date of acquisition
and are subject to an insignificant risk of change in value. &lt;span style="background-color: white"&gt;As of December 31, 2022 and March&#160;31,
2022, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. &lt;/span&gt;Cash
and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;





















&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Liquidity risk is the risk that the Company will encounter difficulty
in satisfying financial obligations as they become due.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company&#x2019;s approach to managing liquidity is to ensure, as far
as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without
incurring unacceptable losses or risking harm to the Company&#x2019;s reputation. The Company holds sufficient cash and cash equivalents
to satisfy obligations under accounts payable and accruals.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company monitors its liquidity position regularly to assess whether
it has the funds necessary to meet its operating needs and needs for investing in new projects. The Company believes that it has sufficient
funding to finance the committed drug development work, apart from meeting its operational needs for the foreseeable future.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;However, as a biotech company at an early stage of development and without
significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may
not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty in global
markets could have an impact on the Company&#x2019;s future ability to access capital on terms that are acceptable to the Company. There
can be no assurance that required financing will be available to the Company. See Note 2, &#x201c;Liquidity,&#x201d; and Note 14, &#x201c;Capital
Stock,&#x201d; for a discussion of the Company&#x2019;s share offering and Note 17, &#x201c;Commitments and Contingent Liabilities &#x2013;
Committed Purchase Agreement,&#x201d; for a further discussion.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;While the Company operates in various jurisdictions, substantially all
of the Company&#x2019;s transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K. settleable
in British pound sterling and the Stimunity Convertible Note receivable settleable in euros.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory_pn3n3_zkPsGNEDvFN9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BE_zYUV3DrLCaR3" style="display: none"&gt;Schedule of financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20221231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zU75MA5YgBq3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20221231__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zaGOgs0d3Ou5" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zhMnrMQ8D1Xf" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20220331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z6TQFEmhz8f2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of March 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value through Other Comprehensive &lt;br/&gt;Income (&#x201c;FVTOCI&#x201d;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTOCI&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;13,104&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1806"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;23,352&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid expenses and other receivables&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,786&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1811"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,480&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1813"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ConvertibleNoteReceivableIncludingAccruedInterest_i01I_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Convertible note receivable, including accrued interest&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1815"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;642&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1817"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1818"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--CurrentInvestments_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Investments&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1820"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;4,768&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1822"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;9,082&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value through Profit or Loss (&#x201c;FVTPL&#x201d;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Accounts payable and accrued liabilities&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;2,422&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1831"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;750&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1833"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--WarrantLiability_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1835"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1836"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1837"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;33&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredPurchasePricePayableTarus_i01I_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred purchase price payable - Tarus&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1840"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;8,876&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1842"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1843"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredObligationIoxMilestone_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Deferred obligation - iOx milestone&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1845"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;5,568&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1847"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1848"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2022-12-31_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">13104000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2022-03-31_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">23352000</ifrs-full:CashAndCashEquivalents>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2022-12-31_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">1786000</ptgef:PrepaidExpensesAndOtherReceivable>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2022-03-31_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">1480000</ptgef:PrepaidExpensesAndOtherReceivable>
    <ptgef:ConvertibleNoteReceivableIncludingAccruedInterest
      contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">642000</ptgef:ConvertibleNoteReceivableIncludingAccruedInterest>
    <ifrs-full:CurrentInvestments
      contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">4768000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">9082000</ifrs-full:CurrentInvestments>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2022-12-31_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">2422000</ptgef:AccountsPayableAndAccruedLiabilities>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2022-03-31_custom_AmortizedCostMember"
      decimals="-3"
      unitRef="USD">750000</ptgef:AccountsPayableAndAccruedLiabilities>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2022-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">33000</ifrs-full:WarrantLiability>
    <ptgef:DeferredPurchasePricePayableTarus
      contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">8876000</ptgef:DeferredPurchasePricePayableTarus>
    <ptgef:DeferredObligationIoxMilestone
      contextRef="AsOf2022-12-31_custom_FairValueToOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">5568000</ptgef:DeferredObligationIoxMilestone>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="From2022-10-012022-12-31"
      decimals="-3"
      unitRef="USD">290000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">290000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_800_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zXA5IydAGrll" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 20. &lt;span id="xdx_823_z3POdxHUjoX6"&gt;CAPITAL DISCLOSURES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company considers the items included in shareholders&#x2019; equity
as capital. The Company had accounts payable and accrued expenses of approximately $&lt;span id="xdx_901_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20221231_zTE3RNb79J38" title="Payables and accrued expenses"&gt;2.4&lt;/span&gt; million as of December 31, 2022 (approximately
$&lt;span id="xdx_901_ecustom--PayablesAndAccruedExpense_iI_pn3n3_dm_c20220331_zNdMM54oPht9" title="Payables and accrued expenses"&gt;0.8&lt;/span&gt; million as of March 31, 2022) and current assets of approximately $&lt;span id="xdx_90D_ecustom--CurrentAsset_iI_pn3n3_dm_c20221231_zcwy1LaiWpji" title="Current assets"&gt;15.5&lt;/span&gt; million as of December 31, 2022 (approximately $&lt;span id="xdx_90A_ecustom--CurrentAsset_iI_pn3n3_dm_c20220331_z7uNPnmhUs7k" title="Current assets"&gt;24.8&lt;/span&gt; million
as of March 31, 2022). The Company&#x2019;s objectives when managing capital are to safeguard the Company&#x2019;s ability to continue as
a going concern in order to pursue new business opportunities and to maintain a flexible capital structure, which optimizes the costs
of capital at an acceptable risk.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company manages the capital structure and makes adjustments to it
in light of changes in economic conditions and the risk characteristics of the underlying assets.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;As of December 31, 2022, shareholders&#x2019; equity attributable to the
owners of the company was approximately $&lt;span id="xdx_907_ecustom--ShareholdersEquityAttributableToOwners_iI_pn3n3_dm_c20221231_zP1xQNhI5ZAi" title="Shareholders' equity attributable to owners"&gt;168.9&lt;/span&gt; million (approximately $&lt;span id="xdx_906_ecustom--ShareholdersEquityAttributableToOwners_iI_pn3n3_dm_c20220331_zIi6QIux48F7" title="Shareholders' equity attributable to owners"&gt;121.2&lt;/span&gt; million as of March 31, 2022).&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;The Company is not subject to any externally imposed capital requirements
and does not presently utilize any quantitative measures to monitor its capital. There have been no changes to the Company&#x2019;s approach
to capital management during the nine months ended December 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"&gt;&#160;&lt;/p&gt;

















</ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock>
    <ptgef:PayablesAndAccruedExpense contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2400000</ptgef:PayablesAndAccruedExpense>
    <ptgef:PayablesAndAccruedExpense contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">800000</ptgef:PayablesAndAccruedExpense>
    <ptgef:CurrentAsset contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">15500000</ptgef:CurrentAsset>
    <ptgef:CurrentAsset contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">24800000</ptgef:CurrentAsset>
    <ptgef:ShareholdersEquityAttributableToOwners contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">168900000</ptgef:ShareholdersEquityAttributableToOwners>
    <ptgef:ShareholdersEquityAttributableToOwners contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">121200000</ptgef:ShareholdersEquityAttributableToOwners>
    <ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_806_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zA3wDJi97AOb" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 21. &lt;span id="xdx_82B_zUOrNJSrF3lb"&gt;NON-CONTROLLING INTEREST&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zRGrdWEf3B7h" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BF_zVq12XLVJqTb" style="display: none"&gt;Schedule of non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;iOx&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Saugatuck &lt;br/&gt;and subsidiary&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Non-controlling interest as of April 1, 2022&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zi826xxTHcmi" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning"&gt;44,701&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zcB6nOkdtrF7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning"&gt;(472&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231_zSGjEDkZJcNh" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning"&gt;44,229&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Net income (loss) attributable to non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;123&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;(171&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;(48&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Purchase of non-controlling interest pursuant to Share Exchange Agreement&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement"&gt;(44,824&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_znTeJD3WhW9b" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1911"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_c20220401__20221231_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement"&gt;(44,824&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Non-controlling interest as of December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zJYgGcTc8Sde" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1915"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zXgu9h5zKWXl" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"&gt;(643&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231_zmjnE3OGUW6c" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"&gt;(643&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;iOx&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Saugatuck&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Non-controlling interest as of April 1, 2021&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_znGz0pDUXvv5" style="width: 12%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;46,173&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zfH9IGdM7bga" style="width: 12%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;(20&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20210401__20211231_zLltgmqhsQe" style="width: 12%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;46,153&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Share-based compensation expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--StockBasedCompensationExpense_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;191&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--StockBasedCompensationExpense_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_ztUsR3nx9MW9" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1929"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--StockBasedCompensationExpense_c20210401__20211231_pn3n3" style="font-size: 10pt; text-align: right" title="Stock based compensation expense"&gt;191&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Exchange of notes payable, accrued interest and warrants for iOx shares&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="font-size: 10pt; text-align: right" title="Exchange of notes payable, accrued interest and warrants for iOx shares"&gt;184&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z2PV9oZZPGq9" style="font-size: 10pt; text-align: right" title="Exchange of notes payable, accrued interest and warrants for iOx shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1935"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares_c20210401__20211231_pn3n3" style="font-size: 10pt; text-align: right" title="Exchange of notes payable, accrued interest and warrants for iOx shares"&gt;184&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net (loss) attributable to non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zsChvEIh4Icb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;(436&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4FliM9yUwhh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;(317&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20210401__20211231_zfCSQxIM3t4d" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;(753&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Non-controlling interest as of December 31, 2021&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zXvFxENmVmv8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending"&gt;46,112&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20211231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zsXn4HSX4BB6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending"&gt;(337&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20210401__20211231_zxNbtgVdx5si" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending"&gt;45,775&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;On September 8, 2021, the Company, through SalvaRx, completed a settlement
of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price
of &#xa3;162. On July 18, 2022, the Company completed the acquisition of the remaining non-controlling interest in iOx, by issuing 1,070,000
shares of its ordinary shares and assuming certain milestone obligations. See Note 11, &#x201c;Unsecured Notes Payable &#x2013; iOx Unsecured
Notes Payable,&#x201d; and &lt;span style="background-color: white"&gt;Note 18, &#x201c;Related Party Transactions &#x2013; Share Exchange Agreement
&#x2013; iOx,&lt;/span&gt;&#x201d; for further discussions.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary,
Saugatuck Rx LLC.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory>
    <ptgef:ScheduleOfNoncontrollingInterestTableTextBlock contextRef="From2022-04-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zRGrdWEf3B7h" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BF_zVq12XLVJqTb" style="display: none"&gt;Schedule of non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;iOx&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Saugatuck &lt;br/&gt;and subsidiary&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; font-size: 10pt; font-weight: bold"&gt;Non-controlling interest as of April 1, 2022&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zi826xxTHcmi" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning"&gt;44,701&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zcB6nOkdtrF7" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning"&gt;(472&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20221231_zSGjEDkZJcNh" style="width: 12%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning"&gt;44,229&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Net income (loss) attributable to non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;123&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;(171&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_c20220401__20221231_pn3n3" style="font-size: 10pt; font-weight: bold; text-align: right" title="Net income (loss) attributable to non-controlling interest"&gt;(48&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Purchase of non-controlling interest pursuant to Share Exchange Agreement&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement"&gt;(44,824&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_znTeJD3WhW9b" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1911"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement_c20220401__20221231_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Purchase of non-controlling interest pursuant to Share Exchange Agreement"&gt;(44,824&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Non-controlling interest as of December 31, 2022&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zJYgGcTc8Sde" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1915"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zXgu9h5zKWXl" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"&gt;(643&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20221231_zmjnE3OGUW6c" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"&gt;(643&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:ScheduleOfNoncontrollingInterestTableTextBlock>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2022-03-31_custom_IOXMember327152796"
      decimals="-3"
      unitRef="USD">44701000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2022-03-31_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">-472000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">44229000</ifrs-full:NoncontrollingInterests>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2022-04-012022-12-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">123000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2022-04-012022-12-31_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">-171000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-48000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ptgef:PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement
      contextRef="From2022-04-012022-12-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">-44824000</ptgef:PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement>
    <ptgef:PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement
      contextRef="From2022-04-01to2022-12-31"
      decimals="-3"
      unitRef="USD">-44824000</ptgef:PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2022-12-31_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">-643000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-643000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-03-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">46173000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-03-31_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">-20000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">46153000</ifrs-full:NoncontrollingInterests>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2021-04-012021-12-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">191000</ptgef:StockBasedCompensationExpense>
    <ptgef:StockBasedCompensationExpense
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">191000</ptgef:StockBasedCompensationExpense>
    <ptgef:ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares
      contextRef="From2021-04-012021-12-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">184000</ptgef:ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares>
    <ptgef:ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">184000</ptgef:ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2021-04-012021-12-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">-436000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2021-04-012021-12-31_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">-317000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2021-04-012021-12-31"
      decimals="-3"
      unitRef="USD">-753000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-12-31_custom_IOXMember"
      decimals="-3"
      unitRef="USD">46112000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2021-12-31_custom_SaugatuckMember"
      decimals="-3"
      unitRef="USD">-337000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">45775000</ifrs-full:NoncontrollingInterests>
    <ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock contextRef="From2022-04-01to2022-12-31">&lt;p id="xdx_803_ecustom--DisclosureOfEventAfterBalanceSheetDateTextBlock_z9cCKRCqRHD4" style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 22. &lt;span id="xdx_82B_zNbVwecrtfSh"&gt;EVENT AFTER THE BALANCE SHEET DATE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Sale of Ordinary Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"&gt;In January and February 2023, the Company continued its share offering
pursuant to the ATM and the Committed Purchase Agreement. From January 1, 2023 through February 24, 2023, the Company sold &lt;span id="xdx_907_ecustom--NumberOfSharesSold_pid_c20230101__20230131__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zfpLAOrWMbv7" title="Number of shares sold"&gt;63,279&lt;/span&gt; ordinary
shares under the ATM and generated net proceeds of approximately $&lt;span id="xdx_90B_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20230101__20230131__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zNbxqAktnkdc" title="Net proceeds from sale"&gt;0.3&lt;/span&gt; million and sold &lt;span id="xdx_905_ecustom--NumberOfSharesSold_pid_c20230201__20230228__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zJfZCVnu0EHl" title="Number of shares sold"&gt;270,000&lt;/span&gt; ordinary shares under the Committed Purchase
Agreement for net proceeds totaling approximately $&lt;span id="xdx_90D_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20230201__20230228__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zpwzn6MaLWfd" title="Net proceeds from sale"&gt;1.3&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock>
    <ptgef:NumberOfSharesSold
      contextRef="From2023-01-012023-01-31_srt_ScenarioForecastMember"
      decimals="INF"
      unitRef="Shares">63279</ptgef:NumberOfSharesSold>
    <ifrs-full:ProceedsFromSalesOfBiologicalAssets
      contextRef="From2023-01-012023-01-31_srt_ScenarioForecastMember"
      decimals="-3"
      unitRef="USD">300000</ifrs-full:ProceedsFromSalesOfBiologicalAssets>
    <ptgef:NumberOfSharesSold
      contextRef="From2023-02-012023-02-28_srt_ScenarioForecastMember"
      decimals="INF"
      unitRef="Shares">270000</ptgef:NumberOfSharesSold>
    <ifrs-full:ProceedsFromSalesOfBiologicalAssets
      contextRef="From2023-02-012023-02-28_srt_ScenarioForecastMember"
      decimals="-3"
      unitRef="USD">1300000</ifrs-full:ProceedsFromSalesOfBiologicalAssets>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000921"
          xlink:label="Fact000921"
          xlink:type="locator"/>
        <link:footnote id="Footnote000940" xlink:label="Footnote000940" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes the results of operations of Tarus for the period and, accordingly, there are no pro
forma adjustments for the three months ended December 31, 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000921"
          xlink:to="Footnote000940"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000925"
          xlink:label="Fact000925"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000925"
          xlink:to="Footnote000940"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000929"
          xlink:label="Fact000929"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000929"
          xlink:to="Footnote000940"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000933"
          xlink:label="Fact000933"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000933"
          xlink:to="Footnote000940"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000937"
          xlink:label="Fact000937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000937"
          xlink:to="Footnote000940"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M)&81\.K%--H($%6H:FYU91'3"X2Q\[<Z*,T'I06@M!"4%D'1Q$SKQ4=R$*Z
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MH>[#25WLVL\^/Q1U76S;PPV+EZQL#/COJZ*H?YPT7Y(^?B[][O]02P,$%
M  @ UH-A5C.*V&-9"   +2D  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6RM6FUSVZ@:_2N,[\Y..[.N)9#?LHEG4G<[VYG;VTS3[GXF$HZYE847<%[^
M_3X@6]@"D=CUE\2R$3KG 9YS'M#EHY _U)(QC9Y69:6N>DNMUQ>#@<J7;$75
M.[%F%?RR$')%-5S*^X%:2T8+>].J'. D&0U6E%>]V:7][D;.+L5&E[QB-Q*I
MS6I%Y?-[5HK'JU[:VWWQE=\OM?EB,+M<TWMVR_3W]8V$JT'32\%7K%)<5$BR
MQ57O.KV89R-S@VWQ%V>/:N\S,E3NA/AA+CX55[W$(&(ER[7I@L*_!S9G96EZ
M AS_;#OM-<\T-^Y_WO7^T9(',G=4L;DH_^:%7E[U)CU4L 7=E/JK>/R3;0D-
M37^Y*)7]BQZW;9,>RC=*B]7V9D"PXE7]GSYM [%W _03O@%O;\#M&[*.&\CV
M!F*)UL@LK0]4T]FE%(](FM;0F_E@8V/O!C:\,L-XJR7\RN$^/9N+JH!!806"
M3TJ4O* :+CY5FDF^0K<:+F'4M$)B@>94+=%'&'F%WGROZ*;@T/8MZJ/OMQ_0
MFU_>HE\0K]"WI=@H6A7J<J !H7G.(-^B>5^CP1UHINBSJ/12H3\ 57%X_P"8
M-?3PCMY['.WP \O?(9+^AG""<0#/_/6WIQ$XI(DVL?V1KFB; "YL !=2K!"L
M1DDUK^[KZ<PU9^HB%+:ZVRS<K5GJ%VI-<W;5@[6LF'Q@O=FO_TE'R>\ASF?J
M[" "61.!+-;[['^0F4JA@+^02"\9@@AP480XUQT-;4<F&SW,^BD, XS#PSZ;
M8#.2C)IF!SB'#<YA=*2NB__#XJMGOH%:B:J?F]&#*;\*C]'PG&-TILX.N(\:
M[J/H&-TNJ61]DQP+E(L5*(:B-N>R)_.9A<C7/8[V1H&,TJPU5'ZC44:FX8$:
M-V#'4;"P1$&^%#.9!](WDQ)0:_J$2D[O>,GU<PCNV$/2QU.2M/ &6F59%L8[
M:?!.HGCG2UK=6[0+RB5ZH.6&F=SZ2*6DE8[#GOB "&F!#K09XX[5,&U 3T\"
MW01\O9'YTHS"6O(<_M)G>E<R4(9O5&X4 C5P;<5=R>_K"=5'_,L3R%K)0.BJ
MX,2:>G0R/&E1CH(/+Q8462=IXL0SB<;EXT$TE%DW"G&E-D#39 WS,(A'6 D3
MC]FT/0'C;0Y![RE^^O+R-GAM'H8QI4J)G(/0!V&F'@0\:@] H!$9D0Z@V '%
M\>@*"2[,I)V\GG\:5HBBM?^[!XL:Q(O]^9\.VWBC#SYAQC@#D$;5%=(5]&B"
M#1R"\(D'ORUX\2>< -YI=YK%[8L=!CMGG',Q-MW\S^F::UH&I3&-FH)CM?%<
MO1U&P3F#-"J^L^L\%QOC"V @&7\PB2[(>>@O'&\>^FW(9-BQ;IQ\IW']OI%L
M37FQD^LZ_0HP6W(/<C@G^0K=)\.VC =:I7C2(3&I$_(TKN1?+$)(1DR'P?ER
MC#UH <E.NR0[=9J=QD6[&?*=L)F(TCR7)M'O%)MWQ-07Y'0T]A9U0+;3K#.H
M3KC3N'+;H 9A^<+J^9]XF\."S&DFCFNFJ0"LD]X8?WF02EP1%$*,?3'LC\D4
MMT"'FF7#M$.-L)--G!Y5N_'J 5S+*VHW')7C8Y/?N7H[C(+39!S7Y)N=T0/_
MD L(@=3<+(A*:/9"0L0!9?9KA/CSCU<W[*09QZ5YGQK[9\/7IOH+$O$UNM]V
MX?%GG4##B31^N<(^6%^AB1JDE87&9]PF=H+X1HDYW<7QDKR] !>\HE7^F@5X
MULK\7+T=1L&).XZ+^U?0]F<S,\TT-:MN3Y2@\%C58[XMNW*8QHIW>4T<4'N<
M)&T5B ,Z8<2=(\!Q1W# M:D2]PO(HRF'_$&23-N4H[A.H.R<!HX[C1LI<L:*
M[10_K"@W50$&Z?K;9VL_YF*UXMILUNX25Y"P[RO&4R_G1C&=0-?9$QRW)R_3
ME>R>*\WLQL%BP22L]R#/G]\#V,;"]SQXFDP[[ -QMH?$;4]==1MJD+08:*<*
MNUP2L"^>S0TU2B=#W '2>1P2WQHX' [VQ&3.:T&$E9?_<-L\V]VJ,(,3'$IP
M*(B_JY F'=41<0Z&Q!U,HX]OM@+Y%JVE>. %7-P]!U4ER#+@9C F[4P2:(;'
M).OP]63O("%N5M[L]CW? @.W VJ)F>Q@/Q@7\T!+NXE=;,S2B6RWDX"K21.<
MM?=Z NTPGI"N!>)\"XG[EGDG=*K1'62!JC($8"Y&./@6!A,R;)<(H6;C<4=E
M0YQ!(?&-@2@#9FKP*'9_+R E:>(M_="VPBCI"K_S%604=5>WF_6ZM$=]M$0%
M5WDIU*;>)\QWQ@MF6'UP#.H:/J8ZP2I$SJG.U-MA1)S[(''W88?3;J28K5QN
M3D3!@ 1I_[Q=V#+V[4G:<3Y"G*4@<4OQ:2\_T/9&AMVEMKG]%=+T\S9A2],W
M);@KKSLK0::G3F!W>.=*(5B.KRX@R GF(C*MS]3;X?FK,R+9SYU96!\=/(_U
M34<ZQEZY$'_\\68R<^XEB[N7EYC9:2 J+459FE'?+6EG:^ V_N4I2-[W(M,Q
M:1?'<8 G<'>N)GOAK.28<[E^]QC[=F4R)&T+$,=R DUG>[*X[>F@>=R18N8[
MF&$V]DB>>0<GVWM%(NZ$_NLVE(\N<#/?VA"_I(\#.(&;\TA9W".]M$9S6]7:
MFG_!X*?^*^O<S+=%4Y_V"5LW4=K.767Q79L_=D>8=8;9$:_/B+6N=<O;T?FM
M.6-H4I71K5CQ%<=QA$9O.]I_KR:=M ]2!GLOGJV8O+?OXRED/4;]DE;S;?/.
MW[5]TZWU_?OT8EZ_N>>ZJ5\D_$PE6'^%2K: +I-W8T DZW?SZ@LMUO;UMCNA
MM5C9CTM&"R9- _A](2"DVPOS@.8-R=F_4$L#!!0    ( -:#85;X:ET>"P8
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M6?>D2ZE<BU*'6[O[6];^?&"\Q&H?_]*NVCN&Q:3TP>;U8;SGRE2_XJ'68>_
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M-=ZC9^+RYRBM<738__BA2ZX:F:N78(LXIJYLP- ;'S-H(1UOP/K:8CRI7]A
M^W_+^7]02P,$%     @ UH-A5K37>*JA"@  =AL  !@   !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6R=66MOVS@6_:Y?07B*00LXCA])FC0/((\6DT4[S3:=
M6>Q'6J)M(I*HDE3<S*_?<R^IA^VD+?9#:T4B[_/<<R^EL[6Q#VZEE!??B[QT
MYX.5]]6[_7V7KE0AW<A4JL23A;&%]/C3+O==997,>%.1[T_'XZ/]0NIR<''&
M]^[LQ9FI?:Y+=6>%JXM"VJ<KE9OU^6 R:&Y\T<N5IQO[%V>57*I[Y?^J[BS^
MVF^E9+I0I=.F%%8MS@>7DW=7![2>%_RMU=KUK@5Y,C?F@?ZXS<X'8S)(Y2KU
M)$'BYU%=JSPG03#C6Y0Y:%72QOYU(_T#^PY?YM*I:Y/_1V=^=3XX'HA,+62=
M^R]F_8>*_AR2O-3DCO\7Z[!V,AN(M';>%'$S+"AT&7[E]QB'WH;C\0L;IG'#
ME.T.BMC*&^GEQ9DU:V%I-:31!;O*NV&<+BDI]][BJ<8^?_'Q]M]_W=[<?OWO
MV;Z'.+JYG\:M5V'K](6M)^*3*?W*B?=EIK+-_?LPH[5EVMAR-?VAP!N5CL1L
M,A33\73Z WFSUK<9RYN]Y)O^5NM,^Z?G? M;#Y[?2J7PSE4R5><#8-TI^Z@&
M%[__-CD:G_[ L(/6L(,?2?]QT'^X]7G#_OS\];V8CD0K5UPZ818" 57%7-DV
MJ$/A5TI<FZ*2Y9-8R4RDTJV$+..%0L >9:Y*3_L36576?-? OLJ?Q"LQF8TF
MT',@)N/15+REBQDN[HSU*&"QT+G*A!1 8[Y Q2ZU\U9R\3D/&:AES[H@U54H
MR]H![7[%1MV_OTYJ ,F*]4JG*Z$]8/XD4+\Y!$KX.D2US3WNI+757M.-M;16
MDK$DM2XUKG0I3*F$L:(P%K^+A;*Z7#JQL*80'H0BO.'?8=0T5ZG$78653!$)
M[/TD+9X<<]0FXO7OOQU/I^/3+WV7[AN7^.'DE%3&=7>M?_'9FY&X+45JRC*2
M4>OV\R*'34R3E70QKOU(O4N Q>/9*8)-E-0+:.-4:AZ5=;R^"<%0:.=J6::*
MP^609S%_:K,'O-05Q>85G!X/Q^%?IZB7-%=751[2R7H@O-/T$S7(CRR;0$G/
M^] .'E0;Q]=T*RZX_/JI"6'2^-%9*HD)=5$70BZ7P!NBUWH+>W6ZX=7A+SN5
M05 F_E4#1].#@(&A0 /\92>A=3*<!(7 1:9+-+P(8Q:TA%Y'VE.E,@?7Q%:M
M38]&A^#[/"=<4,R  EL@W$6A/1O)Q;*F2H"S#(YKE )D?]#^GZ6R,L].R;A?
M<_:R7J+9B,E)0Q2-N["8G.OB.&O#2#>CQY2DR=M3M^.L7R''#9C;@MZI1?K]
MJ$MTLU+< 0WPI=)>YN(#W!R*CQ^OVR*,RQI8</R!*)F!Z1$L[#DY&!Z.CS<L
M6"MP :5,94FG:B2^4CW!/R<N : 0D$K9@IBD3Y78PX8'] *5'<[JBB2^.MP(
MRT[.=\F'Q,O"U-"(#9'TB+_2O$8_)56TY%6O&&EA1W_!,XKI/*)29<,D.!E0
M:?*,4-EW)% LW=DBCA +Q['H%FTP-?R'IHS"E)$?<ZK<#(MJ2[7@N21[M9WL
MUG8;-= :9B<T-W;T2PV('4P.7\LWKP_>D-:BSI<,S,Z6^\[SRY2#-CF9S88D
M"OQ-,\@&=73+$RSOB/BO"A7E*<=E8%T(\KLP@%R$JP)R>VOZ6=Y.U Z,NM!Q
MHK1+2N-#4OH1>VYO$VOY*'4NYP@.E2,7(O4W;+&]SK8M;2>S]TJ)/PW(<0(V
MB^&)!9;<>Y,^#)O\$&QX)5% 7/G^D4RZ7/B8ARN9,_'=\Z$!4Z=JMY.58*K:
MLH69=IA@:7P?B9NZ[1+?:FE)5D@9LRPX);)L'ZM$=@J:LE]%U5!L31 <[)/Q
M\/CX&'/+$?X=BL_E-K-OZ00Q>IYC7F1<K\JDJN>Y3D6_*;U,^4@_Z'=K1]N@
M7DUG(VP"[X3USW0(\7R'2)H.07E;HQ"<\CYO>U><7T)I-QX"M[6UY.!NSU3?
M<=ASL4=Q_>]ZN67&9'3<6#&,-<'UO;WJJ.UFD%'($OT@E-E&'V/: M'VC1F%
ME$',T7-3+(00\T$W3P1W-28W*H"NFOJL<,WI1'Z3W85M2^%N&GO$#J:(<"T-
MRDA4T[*@N6K$;><^4D<W=#\&1[OX)QBYZ\T6VP:K;WMK\3U+;LVE$8SPA129
MC,3,$&P^FHTH'!O<T/K_3*"&2>-/PS\&V0\TW/>0Y&S9$D@0<E#TW(F@T:4*
M<= F\A\!FY@)%I;BD1Z &4,=BQ3IA_4RY)\D)J$UNDWLTC3,0PF=M=FER./J
MI\X%;BHI=](15MMY'U$WX= PKQTZ$LHN0XY1GL8FL=P%J)NJM3\[-,$BHTKS
M_]@4G(M@8B,Y4HW@@B:R0CX@&%WPF]2X&O3.#+H3U#::K@9D0\@0?.H^<Q7!
MUWG_PCF-PM6#-S4C]"$:=>C8"1MX%M["NJ8V%RES&S64VNUT]PSL,7 )*JBY
M6[#>&U49IS'9/HFOED(25R8*X-0P:DAS%)$3=QV_HJ;8XN9E0&1&.0Z*+J!
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M"%->\X<W%7]9F1OO3<&7*R5Q6J %>+XP.$K'/TA!^ZGMXG]02P,$%     @
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M9LK1 ?R>6QNZ+V2@?Y%__C]02P,$%     @ UH-A5C!;TUC. @  5@8  !D
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M-DL;\/O2 ,#F@PRT_[6X^2]02P,$%     @ UH-A5BK0.G  !0  *PL  !D
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ME+\U]06NX]ECO-0H%WZA;O;V>Q&DE?.F6!L3@T+JYE\\KG78,1B^9I"L#9+
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M[F0*/8I_'EB\0CR(4J4I.C>OU,]%4[-6@?%O$*Y*;APA[=KBXUI92DB*G[A
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M3_;\.];FAU65^WXT5]:JE;O,!4=+H@5XOE#*-C]H@_:#XM6_ 5!+ P04
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M:6CD<LLUS;BHK "=KR25RGYC#1RGYOY?4$L#!!0    ( -:#859OH278C@4
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MY0WT?FJH\9L'=K#^_W'U+U!+ P04    " #6@V%6;Q-.\PL'  "#$P  &0
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M@SX6_"'W/BQBTL+0_3]*'?MC*Q2S.SH4V7+K B'U]Z62*;TWJ5/@&8_]))Q
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M^XXZX09AI'F"\++!ZF=J(6UM*"$(@I.C5A1>7AW7JFL2#&.93+F<G4,_UUS
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M=RM*EL@047?.3^-G 6 A6U=0*C?^ZB./&>KJ63JQR=VV$SQ7)93AB@M)$=F
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MX/ZL*&KWA1;P?T7DP_\!4$L#!!0    ( -:#859G;U,P5 L  #T=   9
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MH(EOK&?N>]O5)2I)>93#L0, 884BKZ4#.R8$ ->Q "6B\I']2M8'77G2Q7R
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M;L*PANS6W=M=+@Z3UZC?*KS>!&Y [W6Y!7FM(Q=9;K;1TIAAIBC-=WFP0!_
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M%LK1 3POK0W]#S(P?*R^_"]02P,$%     @ UH-A5H'%G5O' @  / 8  !D
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M3ZC>3\0P^,9K/_H=.7)""[U6"[W_K86-%,1>PY@S=QTCIV-G_9.0'MYW>%Q
M[M#SH* )EB.4*Y"F)+W#4[45:GXB[Y-0BN12E 0?#Y<ZDY6S*#;Y)^?V.PFZ
M243.G?$*<'<P=)Z9O>]QB)1240+1] 5V[L,D:=VC"*&\.WRXN(' R5$PB@?-
M>ASTNSU<=\>#0*CKPCPFS^#LS0[(CHFLP1L9^P-?2PUMG)#,4N>BW_#O7 S,
M5@OWF)&ZHG7&M)%.FU+4#@I=81V@"O&54";C>QG)FS3K0@*0TN49?LBS2ZPI
M,9/<P$F656OK:R\P5XC-K5;0C(@TK:V.4;#&:@5K5E7HXR$#,P%4<I2JWF7
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MJ/GN3=99P>3R7RH0C&HPTS5=/)<628@%ZBJ>;PI&:SATH*-V> ]WRW16=+\
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M>K65C!=8*BY*D#@]=D[\P]/$R%N![QS7ZLD83"03(>[,Y"([=CP#"'-,M;'
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M"$UCVXH%O9,HC0*=;X70QX6YH']YY_\"4$L#!!0    ( -:#859@TE#)H@,
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MH>F.RAZ@_:6DJ[I=6 ?U_X7A?U!+ P04    " #6@V%6\EG3&L4"   Y!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6RE5>]/VS 0_<Y?<0H3*A*0
M'PVT0%N),K95@H)HMWUVDVMBX=B9[5#VW^^<M*%#T'W8E^9\OO?\7N*[#E9*
M/YD<T<)+(:09>KFUY87OFR3'@ID35:*DG:72!;.TU)EO2HTLK4&%\*,@./,+
MQJ4W&M2Y!ST:J,H*+O%!@ZF*@NG?8Q1J-?1";Y-XY%EN7<(?#4J6X0SM]_)!
MT\IO65)>H#1<2="X''I7X<4X=O5UP0^.*[,5@W.R4.K)+2;IT N<(!286,?
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MP=<KA\AN6#I'B]HVZ%IH;'=K%OB^@#0!>)X+H8^.Z?G^Q4K^ E!+ P04
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M& T85P7@_B)-Y?9$*=A]\3?['U!+ P04    " #6@V%6<1%KTA,#   &#0
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M=8#:7S(F=Q-]25;_1-Y?4$L#!!0    ( -:#85;]^BS8Y (  ,4(   9
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M+(!G'PYD)Y(E^C7TG$G)(GT8$.P3K@S@_H(QN3Y1#12?;PS_ U!+ P04
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M2K+J$W^NC3@1./XK K<6N.<*O%K@G2OP:X%_KF!8"\JIV]7<2^-"+'$PY>R
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MQ0#U_9HQ^7)2O+!M_@40? 502P,$%     @ UH-A5IU@82G/!   Y!0  !D
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M6.$X$KQ&PD1K-C.PM;%H[88P\Q7OE="[1.-4_.WF9OET>76%CI>@,*'R!'U
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M"!JEPP7!4\)4@+P^HU2\3]3Q47Y<V/X?4$L#!!0    ( -:#85;=Q.F7> ,
M / -   9    >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;*U7;6^C.!#^*Q97
MK;;2M1#R1KL)4AI8;4YM-R+9O;N/+DR"M6!SMI-T__W90-BDH;31\@5L,\\S
MGL>C83S:,?Y#Q  2/:<)%6,CEC*[-4T1QI!B<<TRH.K+BO$42S7E:U-D''"4
M@]+$M"UK8*:84,,=Y6MS[H[81B:$PIPCL4E3S'_>0<)V8Z-C[!<"LHZE7C#=
M48;7L #Y+9MS-3,KEHBD0 5A%'%8C8U)Y]9WM'UN\)W 3AR,D8[DB;$?>C*+
MQH:E-P0)A%(S8/7:PA221!.I;?Q7<AJ52PT\'._9/^>QJUB>L( I2_XFD8S'
MAF.@"%9XD\B [;Y &4]?\X4L$?D3[4I;RT#A1DB6EF"U@Y30XHV?2QT. (JG
M'F"7 /N]@&X)Z+X$#%X!]$I [R6@]PJ@7P+RT,TB]EPX#TOLCCC;(:ZM%9L>
MY.KG:*47H3I/%I*KKT3AI#M[O)H'7Z?^8H$"?^%/@ND7-'GTD.=_]^^_SA_\
MQV4Y_^P'@>^AY>0?=#^;W,WN9\M_T4</)":)0(^8<ZS/_!)=H6\+#WV\N$07
MB%"TC-E&8!J)D2G5AK5;,RPW=U=LSGYE<UWTP*B,!?)I!%$-?MJ,OWD+[S7C
M.W8#@:F4KN2V]W+?V8V,'H37J-OY$]F6;=<%]'MPKQG^@'DCW&^&_X7I-;(<
M#>_<-(C1K7*OF_-U7\L]>I5Q%H(0*  !F(<QFM (>;!5]2M3U4B6\Q5P#A%:
MXF=T3_ 328C\69=.A;]>O3]=<F]%AD,8&ZJF"N!;,-P/?W0&UJ>ZHVB3S&N3
MS&^)[.C0>M6A]9K8W>HPI#J,I.DP"IY^SJ-_5UO7[O<M:V1N#U5^EY578^7T
M7EKYIU:=&^? ZBC@?A5POS'@&0W5#UB KF71/GA"0Y:"U@!JZUHCY;F)6) -
M#L(:6B<*M>G1;XGL2.]!I??@?7JK?TLQNCR2_LV\:Z0_5_LVR;S!:7YV3I*X
M)8]'V@\K[8>-V@<0;8H&[BS%&TG/57QX*I)SDNUM>O1;(CM2W*D4=QH5G\:8
MKO/:HE6&U4HUT$AU4E"GLW,B3?>DGC:Z.S=AVR3S6R(K9#8/6MX4^#J_:P@4
ML@V51?=;K5;7F4G>Q9N_S(N[D.J*UH0*E,!*0:WKH1*8%_>+8B)9EC?03TRJ
M=CP?QNI*!EP;J.\KQN1^HAU4ESSW?U!+ P04    " #6@V%61K]IPAD#  #P
M"P  &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6R]5OMOVC 0_E=.635U
MTMH\*!0ZB%0>TY#Z4FGW4+4?3'*0J(G-; /M?S_;25-80R80VR]P?GS?W6?[
M+M=>,OXH(D0)3VE"1<>*I)R=V;8((DR).&8SI&IEPGA*I!KRJ2UF'$EH0&EB
M>X[3L%,24\MOF[D;[K?97"8QQ1L.8IZFA#]W,6'+CN5:+Q.W\322>L+VVS,R
MQ1'*^]D-5R.[8 GC%*F(&06.DXYU[I[U7 ,P.[[&N!0K-F@I8\8>]6 8=BQ'
M1X0)!E)3$/6WP!XFB692<?S*2:W"IP:NVB_LGXUX)69,!/98\BT.9=2QFA:$
M."'S1-ZRY1?,!=4U7\ 287YAF>UM>!8$<R%9FH-5!&E,LW_RE!_$"D#QE .\
M'.#]"6AL -1R0,T(S2(SLOI$$K_-V1*XWJW8M&'.QJ"5FICJ:QQ)KE9CA9/^
M_=5HT+N_'?3AZOIN,(*;\Q_GW8L!'/91DC@1'^ ([D=].#SX  <04[B+V%P0
M&HJV+95_S6('N:]NYLO;X*L%EXS*2," AAB6X'O5>->K(+"5\$*]]Z*^ZU4R
M]C$XAIK[$3S'\\H"JH9?$KX)OA9.K;B,FN&K;> ;3K@822)1Y8F\4(M#90IX
MT"88^V?9J6>D)^6DN@Z<B1D)L&.I1!?(%VCY[]^Y#>=3F>(]D:WI/RGTGU2Q
M^UV2$!I@F<9*X+8:,[*Z(=-U;N&[=:=M+TI"KQ>AURM#'SP%$:%3!#8!RB0*
MF)%G,DX05*ZH8A7P.88J?R2J^"2H^@OQ]1.(B*AQF>#ZFQB/5H/,A&2;&ILV
MK2EI%$H:NUY");#\$J#L_'?@^>L;.RWDG5;*&\(U?(>'2TS'R$O3J1*_[5/;
M$]F:U&8AM?DORDESG_KW1+:FOU7H;^WZDBN!VVILO<G"C4GH.J_?9>?_%I3<
MW\9BD7^!G>JZLZYFI<MP=[V*:N065647HLUOS5[IJ5+D4]-J"@C8G,JLO2IF
MBW;VW#1Q]NOVK!=6;<(TI@(2G"BH<WRJ3I=G[64VD&QF.K0QDZK?,V:D6G+D
M>H-:GS#U /*!=E T^?YO4$L#!!0    ( -:#85:)IL_ E@4  '8/   9
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M%]#[J:;&JA[807W5/O\74$L#!!0    ( -:#85:A:44'HP,  +@3   9
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M-.L69NH=8!M^<KLC>[O/]8*$)J[=FFO7_%^F3';E7,?3*#R79YMFN'O,LW^
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M(%J_BEC?2#Y+3O,'7$H>))=3H".(X@#U_YAS^783OR#(7@AU?P!02P,$%
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M@B#<$6IO%#5SH=!U8$:81!2F&N=<=C2!J(ITU5&\*.O<A"M=-<MFIN\U($R
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M!W1!\HAF<-FEHA:N;W(U"1:8! O'K40R=HXBOZ'UI-9ZHM5ZL9-*RW?]1:8
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M*5E:/*X)5FN>-E#?EXS)EX9.4%\_3_X!4$L#!!0    ( -:#85:0PGSY3P<
M )])   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;+6<77.;1AB%_\J.
MFNFD,ZD%JR_DVIJQS9?;./'$3GN1Z05&*XD) G47V<Z_[X*PT JT%IGC7,2
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M(#^?I6GVLI,'V*[)-/D?4$L#!!0    ( -:#85;0!J'PI ,  ',/   9
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MG8:WX!&)D!!"8J];W6=RFJ%9,'1K&8X\M4M/[9.45X0*V!*V0> Q3+A0NIT
MMP6FSF+.UJ[DM=L(F]WJ\^1-_(WH-,*.5WG\)Z_%K538!,7*-AX)"[Y)55YL
MR]6RMUW8DN[^"<\;XS41*ZHK)<-80[U&6W\7(F\V^43QS-;K.5>Z^MOA6O=G
M%"9 [\><J\/$'%!V_.@W4$L#!!0    ( -:#859U6UM&]@(  /T'   9
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M\NY8>4^>MS'')3 .*DNM,#XCPHKR*GJYS/^.4Y'9+65VW[MONO5]XY-.J[9
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MX5)UR\CU ;4_9TSN)OJ"O/_N_0)02P,$%     @ UH-A5F]?GR/="@   9X
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M8UG$ U,+Y'Q$J=AVU O*OP7^7U!+ P04    " #6@V%6@;[*;X($  #O&@
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M.QO1[,"Q[Z21+R9LHBR,PJ<,Y<ST+OH\NX]"N)W=W?\%]W>SZ\7LZGY^<[V
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MH#L>!R^/!*Q:BT$,6I,K5E)L71A\\$=!#Q8L*[@A@LI"/S=ME6^VH:E4.?.
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MRZ?*+ROEA9&Y^W2PE,;(S U32G#AV@GX?"5QG5875D']?6OZ'U!+ P04
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M9Y\T@^C&61<H7MN)L.)*SQ>[+/0? (5)T.=KSM5+8(9,_T^)_P)02P,$%
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M\D7EA+T2:_CK+[#3^DW'^$A@-?YNR=\UH0\G-#GWY0XS&LE'"YDM@D@OX@O
M LS((DP2>5NW!#EN6^%FE>=UZ+H(]?KVZR8WS:P.;#OEK%K0[3+HMCEH62O#
MQ*<Q 6<1Y3+AL1 LG*4"SR("! 5) RT=D=Q79R/$<[>[14,SQVMBT2E9=(PL
M'E/F+V4Y W3>&"]8I8RG.!$9J>D2,P)NWZ15LB#@:L&(2EL=J8Z&E-M%[A8O
M8X0'IIY7\O<.3SV2! UYY^TRZ[C.%J_=26[;\]KZ#>N6 7>- 4\%]5]4!PJ
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M'=QU,^B5VD_.I=)5;!?!_9W6R_> S0P$<B$:@3WB#.-A08UA6E[:2;6X,CZ
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #6@V%6*6!D 0,&  "H-0
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M.G0"  !M,   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I-;J-
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M;KY3[V'\/)3AUO.UQNM_)]7CY=QRN_QU^;5S<E^N.-?W%</S7U!+ P04
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M;U!+ 0(4 Q0    ( -:#858'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ UH-A5C_R+3SN    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ UH-A5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #6@V%6B#XC2&T#  !4#   &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ UH-A5N1YYYU2!@  R!L  !@              ("!L L  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( -:#859*GI+Q6@<   PF   8
M              " @3@2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " #6@V%6%OO= ^4*   Z70  &               @('(&0  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ UH-A5C.*V&-9"
M+2D  !@              ("!XR0  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( -:#85;X:ET>"P8  ,,,   8              " @7(M
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #6@V%6M-=X
MJJ$*  !V&P  &               @(&S,P  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ UH-A5NJN3M2F!P  A!(  !@
M ("!BCX  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -:#
M858QEZ/:%@D  -07   8              " @69&  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " #6@V%6,%O36,X"  !6!@  &0
M        @(&R3P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( -:#85;W57E$R08  ,$0   9              " @;=2  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ UH-A5BK0.G  !0  *PL
M !D              ("!MUD  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " #6@V%6Z]K3@BP+  !<'   &0              @('N7@
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -:#85;K&U0Y
MC@<  /T1   9              " @5%J  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ UH-A5O1.X(\F!0  00L  !D
M ("!%G(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #6
M@V%6;Z$EV(X%  "+#   &0              @(%S=P  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( -:#859O$T[S"P<  (,3   9
M          " @3A]  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#
M%     @ UH-A5MR+2N3: @  /08  !D              ("!>H0  'AL+W=O
M<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #6@V%6NYQJ6F\%  "#
M#   &0              @(&+AP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM
M;%!+ 0(4 Q0    ( -:#85:?4AC"@PD  $\;   9              " @3&-
M  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ UH-A5D""
M1V8:!0  *@T  !D              ("!ZY8  'AL+W=O<FMS:&5E=',O<VAE
M970R,2YX;6Q02P$"% ,4    " #6@V%68%-$+.0&  #B#P  &0
M    @($\G   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M -:#859GWQ'0;14  %%$   9              " @5>C  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ UH-A5F=O4S!4"P  /1T  !D
M             ("!^[@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " #6@V%6'>1?Z(4#  "R!P  &0              @(&&Q   >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( -:#858FF&DKB00
M *,*   9              " @4+(  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ UH-A5E&RZMRB @  X@4  !D              ("!
M LT  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #6@V%6
M_]*CG[P(  "X%@  &0              @(';SP  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( -:#85:!Q9U;QP(  #P&   9
M      " @<[8  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ UH-A5D&*/?OL @  ^P8  !D              ("!S-L  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #6@V%6IA-3"$4$  "D"@
M&0              @('OW@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( -:#85:VXCDE: (  &(%   9              " @6OC  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ UH-A5K!Z<>%)
M P  ( <  !D              ("!"N8  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " #6@V%6EH7+3HH"  #Z!0  &0
M@(&*Z0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -:#
M859Y1)HY304  !@0   9              " @4OL  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ UH-A5ADO4#RU @  _P4  !D
M         ("!S_$  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    " #6@V%6N/QP2*8#  !G"   &0              @(&[]   >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -:#858U5G, R00  ,T.
M   9              " @9CX  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ UH-A5OXGF]M' P  A0<  !D              ("!F/T
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #6@V%68-)0
MR:(#   ["   &0              @($6 0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( -:#85;R6=,:Q0(  #D&   9
M  " @>\$ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
MUH-A5HMM@;@E @  O00  !D              ("!ZP<! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " #6@V%6E4NHN($(  #]-P  &0
M            @(%'"@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( -:#859Q$6O2$P,   8-   9              " @?\2 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ UH-A5H[^W1S\ @
M'PD  !D              ("!218! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " #6@V%6_?HLV.0"  #%"   &0              @(%\
M&0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( -:#85:"
MRN]^FP(  -8&   9              " @9<< 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ UH-A5CV]3'&:!@  RB$  !D
M     ("!:1\! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -:#858;HJ:1C (  ",'   9              "
M@1 X 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ UH-A
M5B+"L1L> P  : L  !D              ("!TSH! 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " #6@V%6+;#DS:($   Z'   &0
M        @($H/@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( -:#85;=Q.F7> ,  / -   9              " @0%# 0!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ UH-A5D:_:<(9 P  \ L
M !D              ("!L$8! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " #6@V%6B:;/P)8%  !V#P  &0              @($ 2@$
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( -:#85:A:44'
MHP,  +@3   9              " @<U/ 0!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ UH-A5KDR>4OR @  ;P@  !D
M ("!IU,! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #6
M@V%6;<P#^6P#  "M"@  &0              @('05@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( -:#85:R9XK2A00  !P:   9
M          " @7-: 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#
M%     @ UH-A5L?C1IG: @  -0D  !D              ("!+U\! 'AL+W=O
M<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #6@V%6=72VH08$  "O
M%   &0              @(% 8@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM
M;%!+ 0(4 Q0    ( -:#85;QE?[]] ,  )$5   9              " @7UF
M 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ UH-A5N=J
MH\3(!   BA8  !D              ("!J&H! 'AL+W=O<FMS:&5E=',O<VAE
M970V-BYX;6Q02P$"% ,4    " #6@V%6D,)\^4\'  "?20  &0
M    @(&G;P$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M -:#85;0!J'PI ,  ',/   9              " @2UW 0!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ UH-A5I(2BCGV @  _0<  !D
M             ("!"'L! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    " #6@V%6=5M;1O8"  #]!P  &0              @($U?@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( -:#85:OP+_#F ,
M !</   9              " @6*! 0!X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ UH-A5GMGTJ@Q P  BPL  !D              ("!
M,84! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " #6@V%6
M;U^?(]T*   !G@  &0              @(&9B $ >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    ( -:#85:?'F" 8 ,  )$+   9
M      " @:V3 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ UH-A5LXJT#L+ P  (@P  !D              ("!1)<! 'AL+W=O<FMS
M:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " #6@V%6@;[*;X($  #O&@
M&0              @(&&F@$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+
M 0(4 Q0    ( -:#858$1SYZCP8  .L:   9              " @3^? 0!X
M;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ UH-A5M2999_.
M!0  /BP  !D              ("!!:8! 'AL+W=O<FMS:&5E=',O<VAE970W
M."YX;6Q02P$"% ,4    " #6@V%66_L1!W<"  #[!0  &0
M@($*K $ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( -:#
M85:[:R=PA (  %\&   9              " @;BN 0!X;"]W;W)K<VAE971S
M+W-H965T.# N>&UL4$L! A0#%     @ UH-A5HX#POS'!   H1@  !D
M         ("!<[$! 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4
M    " #6@V%6N!?@L1<#  "@"P  &0              @(%QM@$ >&PO=V]R
M:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( -:#859-<F2+-0,  $82
M   -              "  ;^Y 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !: %H K1@  #;) 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>170</ContextCount>
  <ElementCount>352</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement -  Condensed Consolidated Interim Statements of Financial Position (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition</Role>
      <ShortName>Condensed Consolidated Interim Statements of Financial Position (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholder's Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Interim Statements of Changes in Shareholder's Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InterimStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/NatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Liquidity</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - INVESTMENT IN ASSOCIATE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInAssociate</Role>
      <ShortName>INVESTMENT IN ASSOCIATE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INVESTMENT IN PRIVATE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInPrivateCompany</Role>
      <ShortName>INVESTMENT IN PRIVATE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - ACQUISITION OF TARUS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AcquisitionOfTarus</Role>
      <ShortName>ACQUISITION OF TARUS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Goodwill</Role>
      <ShortName>GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability</Role>
      <ShortName>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - UNSECURED NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://portagebiotech.com/role/UnsecuredNotesPayable</Role>
      <ShortName>UNSECURED NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - WARRANT LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiability</Role>
      <ShortName>WARRANT LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - CAPITAL STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStock</Role>
      <ShortName>CAPITAL STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - STOCK OPTION RESERVE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserve</Role>
      <ShortName>STOCK OPTION RESERVE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShare</Role>
      <ShortName>(LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - CAPITAL DISCLOSURES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalDisclosures</Role>
      <ShortName>CAPITAL DISCLOSURES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - NON-CONTROLLING INTEREST</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterest</Role>
      <ShortName>NON-CONTROLLING INTEREST</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/EventAfterBalanceSheetDate</Role>
      <ShortName>EVENT AFTER THE BALANCE SHEET DATE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInAssociateTables</Role>
      <ShortName>INVESTMENT IN ASSOCIATE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInAssociate</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - ACQUISITION OF TARUS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AcquisitionOfTarusTables</Role>
      <ShortName>ACQUISITION OF TARUS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/AcquisitionOfTarus</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/GoodwillTables</Role>
      <ShortName>GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Goodwill</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables</Role>
      <ShortName>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://portagebiotech.com/role/UnsecuredNotesPayableTables</Role>
      <ShortName>UNSECURED NOTES PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/UnsecuredNotesPayable</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - WARRANT LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityTables</Role>
      <ShortName>WARRANT LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiability</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - CAPITAL STOCK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockTables</Role>
      <ShortName>CAPITAL STOCK (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStock</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - STOCK OPTION RESERVE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveTables</Role>
      <ShortName>STOCK OPTION RESERVE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserve</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareTables</Role>
      <ShortName>(LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterestTables</Role>
      <ShortName>NON-CONTROLLING INTEREST (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Non-controllingInterest</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - NATURE OF OPERATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/NatureOfOperations</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>LIQUIDITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Liquidity</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/BasisOfPresentation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - INVESTMENT IN ASSOCIATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInAssociateDetails</Role>
      <ShortName>INVESTMENT IN ASSOCIATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInAssociateTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - INVESTMENT IN ASSOCIATE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInAssociateDetails1</Role>
      <ShortName>INVESTMENT IN ASSOCIATE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInAssociateTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative</Role>
      <ShortName>INVESTMENT IN ASSOCIATE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInAssociateTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - INVESTMENT IN PRIVATE COMPANY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative</Role>
      <ShortName>INVESTMENT IN PRIVATE COMPANY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/InvestmentInPrivateCompany</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - ACQUISITION OF TARUS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AcquisitionOfTarusDetails</Role>
      <ShortName>ACQUISITION OF TARUS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/AcquisitionOfTarusTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - ACQUISITION OF TARUS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AcquisitionOfTarusDetails1</Role>
      <ShortName>ACQUISITION OF TARUS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/AcquisitionOfTarusTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - ACQUISITION OF TARUS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative</Role>
      <ShortName>ACQUISITION OF TARUS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/AcquisitionOfTarusTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/GoodwillDetails</Role>
      <ShortName>GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/GoodwillTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - GOODWILL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/GoodwillDetailsNarrative</Role>
      <ShortName>GOODWILL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/GoodwillTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails</Role>
      <ShortName>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative</Role>
      <ShortName>IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://portagebiotech.com/role/UnsecuredNotesPayableDetails</Role>
      <ShortName>UNSECURED NOTES PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/UnsecuredNotesPayableTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative</Role>
      <ShortName>UNSECURED NOTES PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/UnsecuredNotesPayableTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - INCOME TAXES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetails2</Role>
      <ShortName>INCOME TAXES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - INCOME TAXES (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetails3</Role>
      <ShortName>INCOME TAXES (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - INCOME TAXES (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetails4</Role>
      <ShortName>INCOME TAXES (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - WARRANT LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails</Role>
      <ShortName>WARRANT LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - CAPITAL STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockDetails</Role>
      <ShortName>CAPITAL STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStockTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - CAPITAL STOCK (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockDetailsNarrative</Role>
      <ShortName>CAPITAL STOCK (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStockTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - STOCK OPTION RESERVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails</Role>
      <ShortName>STOCK OPTION RESERVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - STOCK OPTION RESERVE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails1</Role>
      <ShortName>STOCK OPTION RESERVE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - STOCK OPTION RESERVE (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails2</Role>
      <ShortName>STOCK OPTION RESERVE (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - STOCK OPTION RESERVE (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails3</Role>
      <ShortName>STOCK OPTION RESERVE (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - STOCK OPTION RESERVE (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails4</Role>
      <ShortName>STOCK OPTION RESERVE (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - STOCK OPTION RESERVE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetailsNarrative</Role>
      <ShortName>STOCK OPTION RESERVE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareDetails</Role>
      <ShortName>(LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShareTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>00000075 - Disclosure - (LOSS) PER SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareDetails1</Role>
      <ShortName>(LOSS) PER SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShareTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>00000076 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>00000077 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>00000078 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>00000079 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>00000080 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative</Role>
      <ShortName>CAPITAL DISCLOSURES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalDisclosures</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>00000081 - Disclosure - NON-CONTROLLING INTEREST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterestDetails</Role>
      <ShortName>NON-CONTROLLING INTEREST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Non-controllingInterestTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="f6k_022823.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>00000082 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative</Role>
      <ShortName>EVENT AFTER THE BALANCE SHEET DATE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/EventAfterBalanceSheetDate</ParentRole>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="f6k_022823.htm">f6k_022823.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="exh_991.htm">exh_991.htm</File>
    <File>ptgef-20221231.xsd</File>
    <File>ptgef-20221231_cal.xml</File>
    <File>ptgef-20221231_def.xml</File>
    <File>ptgef-20221231_lab.xml</File>
    <File>ptgef-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
    <BaseTaxonomy items="390">https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "f6k_022823.htm exh_991.htm": {
   "nsprefix": "ptgef",
   "nsuri": "http://portagebiotech.com/20221231",
   "dts": {
    "inline": {
     "local": [
      "exh_991.htm",
      "f6k_022823.htm"
     ]
    },
    "schema": {
     "local": [
      "ptgef-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ptgef-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptgef-20221231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ptgef-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptgef-20221231_pre.xml"
     ]
    }
   },
   "keyStandard": 142,
   "keyCustom": 210,
   "axisStandard": 13,
   "axisCustom": 0,
   "memberStandard": 8,
   "memberCustom": 44,
   "hidden": {
    "total": 221,
    "http://portagebiotech.com/20221231": 171,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 38,
    "http://xbrl.sec.gov/dei/2022": 12
   },
   "contextCount": 170,
   "entityCount": 1,
   "segmentCount": 54,
   "elementCount": 543,
   "unitCount": 6,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 390,
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "report": {
    "R1": {
     "role": "http://portagebiotech.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f6k_022823.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f6k_022823.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition",
     "longName": "00000002 - Statement -  Condensed Consolidated Interim Statements of Financial Position (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Financial Position (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss",
     "longName": "00000003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "From2022-10-012022-12-31",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-012022-12-31",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
     "longName": "00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholder's Equity (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Changes in Shareholder's Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "AsOf2021-03-31_ifrs-full_IssuedCapitalMember",
      "name": "ifrs-full:Equity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-03-31_ifrs-full_IssuedCapitalMember",
      "name": "ifrs-full:Equity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
     "longName": "00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:ProfitLossFromDiscontinuedOperations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:ProfitLossFromDiscontinuedOperations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://portagebiotech.com/role/NatureOfOperations",
     "longName": "00000006 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:NatureOfOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:NatureOfOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://portagebiotech.com/role/Liquidity",
     "longName": "00000007 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:LiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:LiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://portagebiotech.com/role/BasisOfPresentation",
     "longName": "00000008 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfBasisOfPresentationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfBasisOfPresentationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://portagebiotech.com/role/SignificantAccountingPolicies",
     "longName": "00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables",
     "longName": "00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://portagebiotech.com/role/InvestmentInAssociate",
     "longName": "00000011 - Disclosure - INVESTMENT IN ASSOCIATE",
     "shortName": "INVESTMENT IN ASSOCIATE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:InvestmentInAssociateDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:InvestmentInAssociateDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://portagebiotech.com/role/InvestmentInPrivateCompany",
     "longName": "00000012 - Disclosure - INVESTMENT IN PRIVATE COMPANY",
     "shortName": "INVESTMENT IN PRIVATE COMPANY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://portagebiotech.com/role/AcquisitionOfTarus",
     "longName": "00000013 - Disclosure - ACQUISITION OF TARUS",
     "shortName": "ACQUISITION OF TARUS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:AcquisitionsOfTarusExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:AcquisitionsOfTarusExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://portagebiotech.com/role/Goodwill",
     "longName": "00000014 - Disclosure - GOODWILL",
     "shortName": "GOODWILL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:GoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:GoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability",
     "longName": "00000015 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY",
     "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://portagebiotech.com/role/UnsecuredNotesPayable",
     "longName": "00000016 - Disclosure - UNSECURED NOTES PAYABLE",
     "shortName": "UNSECURED NOTES PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://portagebiotech.com/role/IncomeTaxes",
     "longName": "00000017 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://portagebiotech.com/role/WarrantLiability",
     "longName": "00000018 - Disclosure - WARRANT LIABILITY",
     "shortName": "WARRANT LIABILITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:WarrantLiabilitytextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:WarrantLiabilitytextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://portagebiotech.com/role/CapitalStock",
     "longName": "00000019 - Disclosure - CAPITAL STOCK",
     "shortName": "CAPITAL STOCK",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:CapitalStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:CapitalStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://portagebiotech.com/role/StockOptionReserve",
     "longName": "00000020 - Disclosure - STOCK OPTION RESERVE",
     "shortName": "STOCK OPTION RESERVE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://portagebiotech.com/role/LossPerShare",
     "longName": "00000021 - Disclosure - (LOSS) PER SHARE",
     "shortName": "(LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities",
     "longName": "00000022 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://portagebiotech.com/role/RelatedPartyTransactions",
     "longName": "00000023 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement",
     "longName": "00000024 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://portagebiotech.com/role/CapitalDisclosures",
     "longName": "00000025 - Disclosure - CAPITAL DISCLOSURES",
     "shortName": "CAPITAL DISCLOSURES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://portagebiotech.com/role/Non-controllingInterest",
     "longName": "00000026 - Disclosure - NON-CONTROLLING INTEREST",
     "shortName": "NON-CONTROLLING INTEREST",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://portagebiotech.com/role/EventAfterBalanceSheetDate",
     "longName": "00000027 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE",
     "shortName": "EVENT AFTER THE BALANCE SHEET DATE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables",
     "longName": "00000029 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://portagebiotech.com/role/InvestmentInAssociateTables",
     "longName": "00000030 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)",
     "shortName": "INVESTMENT IN ASSOCIATE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfInvestmentAssociatetableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfInvestmentAssociatetableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://portagebiotech.com/role/AcquisitionOfTarusTables",
     "longName": "00000031 - Disclosure - ACQUISITION OF TARUS (Tables)",
     "shortName": "ACQUISITION OF TARUS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:AcquisitionsOfTarusExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:AcquisitionsOfTarusExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://portagebiotech.com/role/GoodwillTables",
     "longName": "00000032 - Disclosure - GOODWILL (Tables)",
     "shortName": "GOODWILL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:GoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:GoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables",
     "longName": "00000033 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)",
     "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://portagebiotech.com/role/UnsecuredNotesPayableTables",
     "longName": "00000034 - Disclosure - UNSECURED NOTES PAYABLE (Tables)",
     "shortName": "UNSECURED NOTES PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfNotesPayableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfNotesPayableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://portagebiotech.com/role/IncomeTaxesTables",
     "longName": "00000035 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityTables",
     "longName": "00000036 - Disclosure - WARRANT LIABILITY (Tables)",
     "shortName": "WARRANT LIABILITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:WarrantLiabilitytextblock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:WarrantLiabilitytextblock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://portagebiotech.com/role/CapitalStockTables",
     "longName": "00000037 - Disclosure - CAPITAL STOCK (Tables)",
     "shortName": "CAPITAL STOCK (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://portagebiotech.com/role/StockOptionReserveTables",
     "longName": "00000038 - Disclosure - STOCK OPTION RESERVE (Tables)",
     "shortName": "STOCK OPTION RESERVE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfTermsStockOptionReserveExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfTermsStockOptionReserveExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://portagebiotech.com/role/LossPerShareTables",
     "longName": "00000039 - Disclosure - (LOSS) PER SHARE (Tables)",
     "shortName": "(LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:EarningsPerShareTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:EarningsPerShareTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables",
     "longName": "00000040 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://portagebiotech.com/role/Non-controllingInterestTables",
     "longName": "00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)",
     "shortName": "NON-CONTROLLING INTEREST (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
     "longName": "00000042 - Disclosure - NATURE OF OPERATIONS (Details Narrative)",
     "shortName": "NATURE OF OPERATIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2018-08-13_custom_SalvaRxGroupPlcMember",
      "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:NatureOfOperationsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2018-08-13_custom_SalvaRxGroupPlcMember",
      "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:NatureOfOperationsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://portagebiotech.com/role/LiquidityDetailsNarrative",
     "longName": "00000043 - Disclosure - LIQUIDITY (Details Narrative)",
     "shortName": "LIQUIDITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ifrs-full:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:LiquidityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:NetLossIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:LiquidityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
     "longName": "00000044 - Disclosure - BASIS OF PRESENTATION (Details Narrative)",
     "shortName": "BASIS OF PRESENTATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2015-02-012015-02-10_custom_SubsidiariesOneMember",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfBasisOfPresentationExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2015-02-012015-02-10_custom_SubsidiariesOneMember",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfBasisOfPresentationExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails",
     "longName": "00000045 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ifrs-full:CurrentReceivablesFromSaleOfProperties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ifrs-full:CurrentReceivablesFromSaleOfProperties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
       "ifrs-full:DisclosureOfOtherAssetsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://portagebiotech.com/role/InvestmentInAssociateDetails",
     "longName": "00000046 - Disclosure - INVESTMENT IN ASSOCIATE (Details)",
     "shortName": "INVESTMENT IN ASSOCIATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2022-04-012022-12-31_custom_StimunitySAMember",
      "name": "ifrs-full:NameOfAssociate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfInvestmentAssociatetableTextBlock",
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-012022-12-31_custom_StimunitySAMember",
      "name": "ifrs-full:NameOfAssociate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfInvestmentAssociatetableTextBlock",
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://portagebiotech.com/role/InvestmentInAssociateDetails1",
     "longName": "00000047 - Disclosure - INVESTMENT IN ASSOCIATE (Details 1)",
     "shortName": "INVESTMENT IN ASSOCIATE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2022-03-31",
      "name": "ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-03-31",
      "name": "ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfInvestmentInStimunitySaTableTextBlock",
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative",
     "longName": "00000048 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)",
     "shortName": "INVESTMENT IN ASSOCIATE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2022-07-022022-07-13_custom_StimunityMember",
      "name": "ptgef:ConvertibleNoteDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-07-022022-07-13_custom_StimunityMember",
      "name": "ptgef:ConvertibleNoteDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ptgef:InvestmentInAssociateDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative",
     "longName": "00000049 - Disclosure - INVESTMENT IN PRIVATE COMPANY (Details Narrative)",
     "shortName": "INVESTMENT IN PRIVATE COMPANY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2022-11-012022-11-30",
      "name": "ifrs-full:ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "ifrs-full:ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets",
       "span",
       "span",
       "p",
       "ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-11-012022-11-30",
      "name": "ifrs-full:ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "ifrs-full:ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets",
       "span",
       "span",
       "p",
       "ptgef:DisclosureOfPrivateCompaniesExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://portagebiotech.com/role/AcquisitionOfTarusDetails",
     "longName": "00000050 - Disclosure - ACQUISITION OF TARUS (Details)",
     "shortName": "ACQUISITION OF TARUS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ifrs-full:Goodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_TarusAcquisitionMember",
      "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ptgef:AcquisitionsOfTarusExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://portagebiotech.com/role/AcquisitionOfTarusDetails1",
     "longName": "00000051 - Disclosure - ACQUISITION OF TARUS (Details 1)",
     "shortName": "ACQUISITION OF TARUS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2022-10-012022-12-31",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-012022-12-31_custom_TarusAcquisitionMember",
      "name": "ifrs-full:ProfitLossFromContinuingOperations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfProformaInformationTableTextBlock",
       "ptgef:AcquisitionsOfTarusExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative",
     "longName": "00000052 - Disclosure - ACQUISITION OF TARUS (Details Narrative)",
     "shortName": "ACQUISITION OF TARUS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:NumberOfSharesSold",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:AcquisitionsOfTarusExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:MilestonePayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:AcquisitionsOfTarusExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://portagebiotech.com/role/GoodwillDetails",
     "longName": "00000053 - Disclosure - GOODWILL (Details)",
     "shortName": "GOODWILL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2022-03-31",
      "name": "ifrs-full:Goodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:TarusGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory",
       "ptgef:GoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://portagebiotech.com/role/GoodwillDetailsNarrative",
     "longName": "00000054 - Disclosure - GOODWILL (Details Narrative)",
     "shortName": "GOODWILL (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2022-07-31",
      "name": "ifrs-full:Goodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:GoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-07-012022-07-31",
      "name": "ifrs-full:ConsiderationPaidReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:GoodwillExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
     "longName": "00000055 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)",
     "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ptgef:InprocessResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ptgef:DeferredTaxesLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock",
       "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative",
     "longName": "00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)",
     "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ptgef:DeferredTaxLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-03-31",
      "name": "ptgef:DeferredTaxLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
     "longName": "00000057 - Disclosure - UNSECURED NOTES PAYABLE (Details)",
     "shortName": "UNSECURED NOTES PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2021-03-31",
      "name": "ptgef:NotePayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfNotesPayableTableTextBlock",
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-03-31",
      "name": "ptgef:NotePayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfNotesPayableTableTextBlock",
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative",
     "longName": "00000058 - Disclosure - UNSECURED NOTES PAYABLE (Details Narrative)",
     "shortName": "UNSECURED NOTES PAYABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2019-01-032019-01-31_custom_SalvaRxMember",
      "name": "ptgef:DescriptionOfBusinessCombination",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2019-01-032019-01-31_custom_SalvaRxMember",
      "name": "ptgef:DescriptionOfBusinessCombination",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ptgef:UnsecuredNotesPayableAndWarrantsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetails",
     "longName": "00000059 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:CurrentStateAndLocalIncomeTaxBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:CurrentStateAndLocalIncomeTaxBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetails1",
     "longName": "00000060 - Disclosure - INCOME TAXES (Details 1)",
     "shortName": "INCOME TAXES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetails2",
     "longName": "00000061 - Disclosure - INCOME TAXES (Details 2)",
     "shortName": "INCOME TAXES (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfIncomeTaxExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfIncomeTaxExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetails3",
     "longName": "00000062 - Disclosure - INCOME TAXES (Details 3)",
     "shortName": "INCOME TAXES (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ptgef:PretaxIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ptgef:PretaxIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetails4",
     "longName": "00000063 - Disclosure - INCOME TAXES (Details 4)",
     "shortName": "INCOME TAXES (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ptgef:DeferredTaxAssetsNetOperatingLossCarryforward",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfDeferredTaxAssetsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ptgef:DeferredTaxAssetsNetOperatingLossCarryforward",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfDeferredTaxAssetsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000064 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ifrs-full:DeferredTaxAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ifrs-full:DeferredTaxAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails",
     "longName": "00000065 - Disclosure - WARRANT LIABILITY (Details)",
     "shortName": "WARRANT LIABILITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2022-03-31",
      "name": "ptgef:WarrantsOutstandingExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
       "ptgef:WarrantLiabilitytextblock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-03-31",
      "name": "ptgef:WarrantsOutstandingExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
       "ptgef:WarrantLiabilitytextblock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://portagebiotech.com/role/CapitalStockDetails",
     "longName": "00000066 - Disclosure - CAPITAL STOCK (Details)",
     "shortName": "CAPITAL STOCK (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2022-03-31",
      "name": "ptgef:CommonStockShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-03-31",
      "name": "ptgef:CommonStockShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
     "longName": "00000067 - Disclosure - CAPITAL STOCK (Details Narrative)",
     "shortName": "CAPITAL STOCK (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "From2021-06-012021-06-24",
      "name": "ptgef:NumberOfStockSold",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-06-012021-06-24",
      "name": "ptgef:OfferingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:CapitalStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails",
     "longName": "00000068 - Disclosure - STOCK OPTION RESERVE (Details)",
     "shortName": "STOCK OPTION RESERVE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ifrs-full:AdjustmentsForSharebasedPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-03-31_ifrs-full_NoncontrollingInterestsMember",
      "name": "ptgef:StockOptionReserve",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfTermsStockOptionReserveExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails1",
     "longName": "00000069 - Disclosure - STOCK OPTION RESERVE (Details 1)",
     "shortName": "STOCK OPTION RESERVE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails2",
     "longName": "00000070 - Disclosure - STOCK OPTION RESERVE (Details 2)",
     "shortName": "STOCK OPTION RESERVE (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "From2019-01-012019-01-08_custom_IOxOptionPlanMember_custom_UnvestedOptionsMember",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails3",
     "longName": "00000071 - Disclosure - STOCK OPTION RESERVE (Details 3)",
     "shortName": "STOCK OPTION RESERVE (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "AsOf2022-03-31_custom_PBI2021EquityIncentivePlanMember",
      "name": "ptgef:NumberOfOutstandingShareOption",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-03-31_custom_PBI2021EquityIncentivePlanMember",
      "name": "ptgef:NumberOfOutstandingShareOption",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails4",
     "longName": "00000072 - Disclosure - STOCK OPTION RESERVE (Details 4)",
     "shortName": "STOCK OPTION RESERVE (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-012022-12-31_custom_PBI2021EquityIncentivePlanMember",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative",
     "longName": "00000073 - Disclosure - STOCK OPTION RESERVE (Details Narrative)",
     "shortName": "STOCK OPTION RESERVE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "From2022-10-012022-12-31",
      "name": "ifrs-full:CommunicationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-012022-12-31",
      "name": "ifrs-full:CommunicationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://portagebiotech.com/role/LossPerShareDetails",
     "longName": "00000074 - Disclosure - (LOSS) PER SHARE (Details)",
     "shortName": "(LOSS) PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "From2022-10-012022-12-31",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-012022-12-31",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:EarningsPerShareTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://portagebiotech.com/role/LossPerShareDetails1",
     "longName": "00000075 - Disclosure - (LOSS) PER SHARE (Details 1)",
     "shortName": "(LOSS) PER SHARE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "From2022-04-012022-12-31_custom_StockOptionsMember",
      "name": "ptgef:AntidilutiveEffectOnLossPerShare",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-012022-12-31_custom_StockOptionsMember",
      "name": "ptgef:AntidilutiveEffectOnLossPerShare",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
     "longName": "00000076 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "AsOf2022-07-13",
      "name": "ptgef:ConvertibleNote",
      "unitRef": "EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-07-13",
      "name": "ptgef:ConvertibleNote",
      "unitRef": "EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000077 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:PortageOrdinaryShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:PortageOrdinaryShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
     "longName": "00000078 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_AmortizedCostMember",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative",
     "longName": "00000079 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "From2022-10-012022-12-31",
      "name": "ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-012022-12-31",
      "name": "ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative",
     "longName": "00000080 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)",
     "shortName": "CAPITAL DISCLOSURES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ptgef:PayablesAndAccruedExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "ptgef:PayablesAndAccruedExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://portagebiotech.com/role/Non-controllingInterestDetails",
     "longName": "00000081 - Disclosure - NON-CONTROLLING INTEREST (Details)",
     "shortName": "NON-CONTROLLING INTEREST (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "AsOf2022-03-31",
      "name": "ifrs-full:NoncontrollingInterests",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-03-31",
      "name": "ifrs-full:NoncontrollingInterests",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative",
     "longName": "00000082 - Disclosure - EVENT AFTER THE BALANCE SHEET DATE (Details Narrative)",
     "shortName": "EVENT AFTER THE BALANCE SHEET DATE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "From2022-04-01to2022-12-31",
      "name": "ptgef:NumberOfSharesSold",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:AcquisitionsOfTarusExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-012023-02-28_srt_ScenarioForecastMember",
      "name": "ptgef:NumberOfSharesSold",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfEventAfterBalanceSheetDateTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ptgef_ATMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ATMMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A T M [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccountingProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AccountingProfit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on ordinary activities before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "ptgef_AccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued liabilities",
        "label": "AccountsPayableAndAccruedLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AccreditedInvestorsMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accredited Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive (loss) income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ptgef_AcquisitionOfIntensityHoldingLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AcquisitionOfIntensityHoldingLimitedMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Of Intensity Holding Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AcquisitionOfSalvaRxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AcquisitionOfSalvaRxMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Of Salva Rx [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AcquisitionOfTarusAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AcquisitionOfTarusAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Of Tarus"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AcquisitionsOfTarusExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AcquisitionsOfTarusExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarus"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACQUISITION OF TARUS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued in Tarus acquisition",
        "label": "Acquisitions through business combinations, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in other provisions resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ptgef_AdditionalInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AdditionalInvestment",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional investments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in Tarus acquisition, shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other receivables",
        "label": "Adjustments for decrease (increase) in prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "ifrs-full_AdjustmentsForDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AdjustmentsForDeferredTaxExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total deferred"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued liabilities",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for non-cash items:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "label": "Stock based compensation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "ptgef_AggregateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AggregateValue",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AggregatedMeasurementMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r99"
     ]
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r100"
     ]
    },
    "ptgef_AmendedAndRestated2021EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AmendedAndRestated2021EquityIncentivePlanMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended And Restated 2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AmortizedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AmortizedCostMember",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized Cost [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AmountRemovedFromReserveOfCashFlowHedgesAndIncludedInInitialCostOrOtherCarryingAmountOfNonfinancialAssetLiabilityOrFirmCommitmentForWhichFairValueHedgeAccountingIsApplied",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount removed from reserve of cash flow hedges and included in the initial cost or other carrying amount of a non-financial asset (liability) or a firm commitment for which fair value hedge accounting is applied. [Refer: Reserve of cash flow hedges]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r136"
     ]
    },
    "ptgef_AnnualFeesdescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AnnualFeesdescription",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual feesDescription"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ptgef_AntidilutiveEffectOnLossPerShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "AntidilutiveEffectOnLossPerShare",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive effect on loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory U.K. income tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r99",
      "r100",
      "r101",
      "r131",
      "r133"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails",
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "verboseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ptgef_BVIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "BVIMember",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "B V I [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BaseSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "BaseSalary",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base Salary"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BasicAndDilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "BasicAndDilutedEarningsLossPerShare",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BasicAndDilutedLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "BasicAndDilutedLossPerShare",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted (loss) per share"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "BasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Presentation"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ptgef_CapitalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CapitalDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CapitalStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CapitalStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CapitalStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CapitalStockTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL STOCK"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r69",
      "r93"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r70"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r70"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r70"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CashFundDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CashFundDescription",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fund, description"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashOnHand": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CashOnHand",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash on hand"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash held by the entity. This does not include demand deposits."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ptgef_CashPaidForInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CashPaidForInterest",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CashUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CashUsedInOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone",
        "label": "ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeIncreaseInDeferredIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ChangeIncreaseInDeferredIncomeTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change (increase) in deferred income tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ChangesInFairValueOfFinancialAssetsAttributableToChangesInCreditRiskOfFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the fair value of a financial asset (or group of financial assets) designated as measured at fair value through profit or loss that is attributable to changes in the credit risk of that asset determined either: (a) as the amount of change in its fair value that is not attributable to changes in market conditions that give rise to market risk ; or (b) using an alternative method the entity believes more faithfully represents the amount of change in its fair value that is attributable to changes in the credit risk of the asset. [Refer: Credit risk [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ptgef_ChiefExecutiveOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ChiefExecutiveOfficersMember",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CommitmentAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CommitmentAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities (Note 17)"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CommitmentFee",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment fee"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CommitmentsAndContingentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CommitmentsAndContingentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingent Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares: Unlimited number of common shares without par value"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CommonStockShares",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, Shares",
        "periodEndLabel": "Balance, Shares",
        "label": "CommonStockShares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CommonStockValues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CommonStockValues",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "CommonStockValues"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommunicationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CommunicationExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from communication."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ptgef_CompensationCommittee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CompensationCommittee",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation committee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails1",
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss for period",
        "label": "Total comprehensive loss for year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r24",
      "r72",
      "r74",
      "r89",
      "r150"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss attributable to:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "label": "Comprehensive income, attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r27"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Owners of the Company",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r28"
     ]
    },
    "ifrs-full_ConsiderationPaidReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ConsiderationPaidReceived",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/GoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ptgef_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ptgef_ConversionOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ConversionOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of debt"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ConversionOfDebtIntoShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ConversionOfDebtIntoShares",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of debt into shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ConvertibleNote",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ConvertibleNoteDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ConvertibleNoteDescription",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note description"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ConvertibleNoteReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ConvertibleNoteReceivable",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ConvertibleNoteReceivableIncludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ConvertibleNoteReceivableIncludingAccruedInterest",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note receivable, including accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_CounterpartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CounterpartiesMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_CountryOfIncorporationOrResidenceOfAssociate": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CountryOfIncorporationOrResidenceOfAssociate",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country of incorporation of associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The country in which an associate of the entity is incorporated. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r52",
      "r82"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CountryRegion",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentAdvancesToSuppliers",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ptgef_CurrentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CurrentAsset",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets",
        "label": "CurrentAsset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r85",
      "r150"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CurrentFederalIncomeTaxBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CurrentFederalIncomeTaxBenefit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CurrentForeignIncomeTaxBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CurrentForeignIncomeTaxBenefit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentInvestments",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r87",
      "r150"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other receivables",
        "label": "Current prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_CurrentReceivablesFromSaleOfProperties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentReceivablesFromSaleOfProperties",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid clinical research costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current receivables from sale of properties. [Refer: Receivables from sale of properties]"
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ptgef_CurrentStateAndLocalIncomeTaxBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CurrentStateAndLocalIncomeTaxBenefit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and local"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CurrentYearLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "CurrentYearLosses",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current year losses"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredCommitmentFee",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred commitment fee"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredFederalIncomeTaxBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredFederalIncomeTaxBenefit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "DeferredFederalIncomeTaxBenefit"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredForeignIncomeTaxBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredForeignIncomeTaxBenefit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "DeferredForeignIncomeTaxBenefit"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredObligationIoxMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredObligationIoxMilestone",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred obligation - iOx milestone"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredObligationIoxMilestoneValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredObligationIoxMilestoneValue",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred obligation - iOx milestone",
        "label": "DeferredObligationIoxMilestoneValue"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredPurchasePricePayableTarus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredPurchasePricePayableTarus",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred purchase price payable - Tarus"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredStateAndLocalIncomeTaxBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredStateAndLocalIncomeTaxBenefit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State and local",
        "label": "DeferredStateAndLocalIncomeTaxBenefit"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredTaxAssetUnrecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredTaxAssetUnrecognized",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/IncomeTaxesDetails4": {
       "parentTag": "ifrs-full_NetDeferredTaxAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset (unrecognized)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r16",
      "r37"
     ]
    },
    "ptgef_DeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredTaxAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredTaxAssetsNetOperatingLossCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredTaxAssetsNetOperatingLossCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/IncomeTaxesDetails4": {
       "parentTag": "ifrs-full_NetDeferredTaxAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeAbstract",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability",
        "verboseLabel": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r16",
      "r37"
     ]
    },
    "ptgef_DeferredTaxLiabilitiesInProcessRAndD": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredTaxLiabilitiesInProcessRAndD",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/IncomeTaxesDetails4": {
       "parentTag": "ptgef_DeferredTaxLiability1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "In-process research and development",
        "label": "DeferredTaxLiabilitiesInProcessRAndD"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred purchase consideration at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ptgef_DeferredTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredTaxLiability",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liability",
        "label": "DeferredTaxLiability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredTaxLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredTaxLiability1",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/IncomeTaxesDetails4": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax liability",
        "label": "DeferredTaxLiability1"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredTaxLiabiltiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredTaxLiabiltiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DeferredTaxesLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DeferredTaxesLiability",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liability",
        "label": "DeferredTaxesLiability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DefinedBenefitPlansAxis",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetails3",
      "http://portagebiotech.com/role/StockOptionReserveDetails4",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plans [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_DefinedBenefitPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DefinedBenefitPlansMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetails3",
      "http://portagebiotech.com/role/StockOptionReserveDetails4",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ptgef_DenominatorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DenominatorAbstract",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator (in 000\u2019)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation expense",
        "label": "Depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r33",
      "r94",
      "r129",
      "r135",
      "r141"
     ]
    },
    "ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DescriptionOfBusinessCombination": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DescriptionOfBusinessCombination",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of business combination"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DescriptionOfDiscountRatesAppliedToCashFlowProjections",
     "presentation": [
      "http://portagebiotech.com/role/GoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate applied to cash flow projections"
       }
      },
      "en": {
       "role": {
        "documentation": "The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]"
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ptgef_DirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DirectorsMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureInvestmentInPrivateCompanyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureInvestmentInPrivateCompanyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment In Private Company"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOfBasisOfPresentationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfBasisOfPresentationExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsTable",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfCapitalManagementExplanatoryTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/CapitalDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL DISCLOSURES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ptgef_DisclosureOfDeferredTaxAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfDeferredTaxAssetsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetails3",
      "http://portagebiotech.com/role/StockOptionReserveDetails4",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to defined benefit plans."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOfEventAfterBalanceSheetDateTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfEventAfterBalanceSheetDateTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/EventAfterBalanceSheetDate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EVENT AFTER THE BALANCE SHEET DATE"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of financial instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ptgef_DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfGoodwillInProcessResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/GoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of IPR&amp;D projects"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfInterestsInOtherEntitiesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CONTROLLING INTEREST"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for interests in other entities."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ptgef_DisclosureOfInvestmentAssociatetableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfInvestmentAssociatetableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of investment associate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average exercise price and remaining contractual life"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfOffsettingOfFinancialAssetsTable",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of offsetting of financial assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the offsetting of financial assets."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER RECEIVABLES"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ptgef_DisclosureOfPrivateCompaniesExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfPrivateCompaniesExplanatoryTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVESTMENT IN PRIVATE COMPANY"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of outstanding stock options"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserve"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK OPTION RESERVE"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to associates."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r54",
      "r98"
     ]
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ptgef_DisclosureOfTermsStockOptionReserveExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "DisclosureOfTermsStockOptionReserveExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Terms Stock Option Reserve Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails",
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r174",
      "r175"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ptgef_EarningLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "EarningLossPerShare",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss per share",
        "label": "EarningLossPerShare"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(LOSS) PER SHARE"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ptgef_EarningsPerShareTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "EarningsPerShareTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of basic and diluted EPS calculations"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityDomain",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_EntitysTotalForAssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EntitysTotalForAssociatesMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r54",
      "r98",
      "r138",
      "r140"
     ]
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r117"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r20",
      "r71",
      "r73",
      "r99",
      "r100",
      "r101"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity attributable to owners of the Company",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParentMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ptgef_EquityInLossIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "EquityInLossIncome",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity in (loss) income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ptgef_EventAfterTheBalanceSheetDateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "EventAfterTheBalanceSheetDateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Event After Balance Sheet Date"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess of non-controlling interest acquired over consideration - iOx"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess of non-controlling interest acquired over consideration iOx, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Excess of non-controlling interest acquired over consideration iOx, shares",
        "label": "ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ExchangeOfIoxSharesForSettlementOfNotesPayableAccruedInterestAndWarrants",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of iOx shares for settlement of notes payable, accrued interest and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ExchangeOfNotesPayableAccruedInterestAndWarrantsForIoxShares",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of notes payable, accrued interest and warrants for iOx shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShare": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ExchangeOfNotesPayableAndAccruedInterestForIoxShare",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exchange of notes payable and accrued interest for iOx shares",
        "label": "ExchangeOfNotesPayableAndAccruedInterestForIoxShare"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExchangeOfNotesPayableAndAccruedInterestForIoxShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ExchangeOfNotesPayableAndAccruedInterestForIoxShares",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of notes payable and accrued interest for iOx shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExecutiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ExecutiveMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ifrs-full_ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ExplanationOfInputsAssumptionsAndEstimationTechniquesUsedToApplyImpairmentRequirementsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of fair value of these stock options on the date of grant and black-scholes option pricing model",
        "label": "Explanation of inputs, assumptions and estimation techniques used to apply impairment requirements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The explanation of the inputs, assumptions and estimation techniques used to apply the impairment requirements for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Extension",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueAdjustmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueAdjustmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueAdjustmentExercisePriceAtEnd": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueAdjustmentExercisePriceAtEnd",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment , exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueAdjustmentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueAdjustmentShares",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfDeferredObligationIoxMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueOfDeferredObligationIoxMilestone",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of deferred obligation - iOx milestone"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfDeferredPurchasePricePayabletarus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueOfDeferredPurchasePricePayabletarus",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of deferred purchase price payable-Tarus"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfPortageOption": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueOfPortageOption",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of Portage option"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueOfSharesIssuedForCommitmentFeesCommittedPurchase",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of shares issued for commitment fees - Committed Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of shares issued for non-controlling interest purchase of iOx"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfSharesIssuedForTarus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueOfSharesIssuedForTarus",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of shares issued for Tarus"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfStockIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueOfStockIssuedForServices",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of shares issued for services"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValuePerShare",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value per share"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueToOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FairValueToOtherComprehensiveIncomeMember",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value To Other Comprehensive Income [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FinancialInstrumentsAndRiskManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "FinancialInstrumentsAndRiskManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments And Risk Management"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ForeignCurrencyEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ForeignCurrencyEffect",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency effect"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ForeignExchangeLoss",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange transaction gain (loss)",
        "label": "Foreign exchange loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42"
     ]
    },
    "ptgef_ForeignMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ForeignMember",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GainLossOfChangeInFairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "GainLossOfChangeInFairValueOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) of change in fair value of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainLossOnHedgeIneffectiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "GainLossOnHedgeIneffectiveness",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of loss in associate",
        "label": "Gain (loss) on hedge ineffectiveness"
       }
      },
      "en": {
       "role": {
        "documentation": "The gain (loss) on hedge ineffectiveness. Hedge ineffectiveness is the extent to which the changes in the fair value or the cash flows of the hedging instrument are greater or less than those on the hedged item."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ptgef_GainsLossesOnChangeInFairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "GainsLossesOnChangeInFairValueOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange transaction gain",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails",
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/GoodwillDetails",
      "http://portagebiotech.com/role/GoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "periodStartLabel": "Balance, beginning of period",
        "periodEndLabel": "Balance, ending of period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r57",
      "r60",
      "r116"
     ]
    },
    "ptgef_GoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "GoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "GoodwillExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/Goodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOODWILL"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GrossProceedsFromStockSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "GrossProceedsFromStockSold",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from stock sold"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IMM60IOXMelanomaLungCancersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IMM60IOXMelanomaLungCancersMember",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "I M M 60 I O X Melanoma Lung Cancers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IMM65IOXOvarianProstateCancersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IMM65IOXOvarianProstateCancersMember",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "I M M 65 I O X Ovarian Prostate Cancers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IOXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IOXMember",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "I O X [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IOxOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IOxOptionPlanMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "I Ox Option Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails",
      "http://portagebiotech.com/role/GoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities assumed",
        "verboseLabel": "Fair value of identifiable assets acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156"
     ]
    },
    "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Identifiable intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156"
     ]
    },
    "ptgef_IfrsStatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IfrsStatementLineItems",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails",
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails1",
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails",
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative",
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative",
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://portagebiotech.com/role/StockOptionReserveDetails",
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetails3",
      "http://portagebiotech.com/role/StockOptionReserveDetails4",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails",
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IfrsStatementLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IfrsStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IfrsStatementTable",
     "presentation": [
      "http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IfrsStatementTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "InProcessResearchAndDevelopmentAndDeferredTaxLiability",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "InProcessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "In-process Research And Development And Deferred Tax Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IncomeLossOnOrdinaryActivitiesBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (loss) on ordinary activities before tax"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IncomeOnFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IncomeOnFairValueOfWarrantLiability",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of warrant liability",
        "label": "IncomeOnFairValueOfWarrantLiability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IncomeTaxBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IncomeTaxBenefitExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax benefit (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ptgef_Netloss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax (expense) benefit",
        "negatedTerseLabel": "Benefit from income taxes",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r29",
      "r34",
      "r35",
      "r36",
      "r45",
      "r97",
      "r130"
     ]
    },
    "ptgef_IncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IncomeTaxesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Decrease) increase in cash and cash equivalents during period",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in deferred tax liability",
        "label": "Increase (decrease) in deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued or accrued for services",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative",
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in deferred tax liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants exercised",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ptgef_IncreaseInAccountsPayableForStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IncreaseInAccountsPayableForStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in accounts payable for stock issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IncreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IncreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in deferred income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IncreasingDecreasingAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IncreasingDecreasingAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "IncreasingDecreasingAccountsReceivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_InprocessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "InprocessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IntensityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IntensityMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intensity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r128",
      "r135"
     ]
    },
    "ptgef_IntrinsicValueOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IntrinsicValueOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_InvestmentInAssociateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "InvestmentInAssociateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment In Associate"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_InvestmentInAssociateDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "InvestmentInAssociateDisclosureTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVESTMENT IN ASSOCIATE"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_InvestmentOwnedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "InvestmentOwnedShares",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares purchased"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_InvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "InvestmentOwnershipPercentage",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of equity held"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InvestmentProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "InvestmentProperty",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in private company"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r63",
      "r64"
     ]
    },
    "ifrs-full_InvestmentPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "InvestmentPropertyMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for investment property. It also represents the standard value for the 'Types of investment property' axis if no other member is used. [Refer: Investment property]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r153",
      "r184"
     ]
    },
    "ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "InvestmentsInSubsidiariesJointVenturesAndAssociates",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/InvestmentInAssociateDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in associate",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ptgef_IssuanceAndSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IssuanceAndSales",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and sales"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IssuanceOfUnsecuredNotesDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IssuanceOfUnsecuredNotesDescription",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Description of business combination",
        "label": "IssuanceOfUnsecuredNotesDescription"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IssuanceOfUnsecuredNotesDescriptions": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "IssuanceOfUnsecuredNotesDescriptions",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of unsecured notes, description"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r100"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r99",
      "r100",
      "r101",
      "r131",
      "r134"
     ]
    },
    "ptgef_LiabilitiesAssumedInTarusAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "LiabilitiesAssumedInTarusAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities assumed in Tarus acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LincolnMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "LincolnMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lincoln [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "LiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "LiquidityTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/Liquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LosPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "LosPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossAtStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "LossAtStatutoryIncomeTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax at statutory income tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossForWhichNoBenefitWasTaken": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "LossForWhichNoBenefitWasTaken",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss for which no benefit was taken"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossesNotSubjectToTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "LossesNotSubjectToTax",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Losses not subject to tax"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossesRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "LossesRecognized",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Losses recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossesUnrecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "LossesUnrecognized",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Losses (unrecognized)"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ManagementUnderwritingAndSellingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ManagementUnderwritingAndSellingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management, underwriting and selling expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_MaximumAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "MaximumAggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "MaximumMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r99"
     ]
    },
    "ptgef_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "MinimumMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_MinorityInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "MinorityInterestPercentage",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minority interest, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_N2021EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "N2021EquityIncentivePlanMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "N 2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NameOfAssociate": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NameOfAssociate",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The name of an associate. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r47",
      "r51",
      "r81"
     ]
    },
    "ptgef_NatureOfOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NatureOfOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NatureOfOperationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NatureOfOperationsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/NatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetChangeInWorkingCapitalComponentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NetChangeInWorkingCapitalComponentsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating working capital:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NetDeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/IncomeTaxesDetails4": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax asset",
        "label": "Net deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_NetDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NetDeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ptgef_NetLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NetLossAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) attributable to non-controlling interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetLossIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NetLossIncome",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net (loss) income"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetProceedsFromStockSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NetProceedsFromStockSold",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from stock sold"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetUnrealizedLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NetUnrealizedLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net unrealized loss on investments"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetUnrealizedLossOnInvestmentsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NetUnrealizedLossOnInvestmentsValue",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net unrealized loss on investments",
        "label": "NetUnrealizedLossOnInvestmentsValue"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_Netloss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "Netloss",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Netloss"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NonControllingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NonControllingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NoncashInvestingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NoncashInvestingItemsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest",
        "periodStartLabel": "Non-controlling interest, at beginning",
        "periodEndLabel": "Non-controlling interest, at ending"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r75",
      "r79"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r86",
      "r150"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r88",
      "r150"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NotePayable",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "NotePayable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of ordinary shares issued in acquisition"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ptgef_NumberOfOutstandingShareOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NumberOfOutstandingShareOption",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "NumberOfOutstandingShareOption"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NumberOfPrivateCompanyShareConsistsInSoleAsset",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of private company share consists in sole asset"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable as at end"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired or forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfSharesExchanged": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NumberOfSharesExchanged",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares exchanged"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ptgef_NumberOfSharesSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NumberOfSharesSold",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
      "http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares sold",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfStockSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NumberOfStockSold",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock sold"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumeratorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "NumeratorAbstract",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator (in 000\u2019$)"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OfferingAndThroughThatProcessDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "OfferingAndThroughThatProcessDescription",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering and through that process, description"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "OfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OfferingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "OfferingPrice",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OncomerSaugatuckDNAAptamersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "OncomerSaugatuckDNAAptamersMember",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oncomer Saugatuck D N A Aptamers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OptionLifeShareOptionsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "OptionLifeShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OriginalAnnualTargetsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "OriginalAnnualTargetsPercentage",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original annual targets percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets, including equipment, net"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss for period",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r23",
      "r31",
      "r92"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_OtherTangibleOrIntangibleAssetsTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "OtherTangibleOrIntangibleAssetsTransferred",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of other tangible or intangible assets (including a business or subsidiary of the acquirer) transferred as consideration in a business combination, that the entity does not separately disclose in the same note. [Refer: Intangible assets other than goodwill; Business combinations [member]; Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ptgef_PBI2021EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PBI2021EquityIncentivePlanMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails3",
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "P B I 2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PayablesAndAccruedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PayablesAndAccruedExpense",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share issuance costs",
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative",
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of acquire",
        "verboseLabel": "Percentage of voting equity interests acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ptgef_PortageOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PortageOrdinaryShares",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portage ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ptgef_PrepaidExpensesAndOtherReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PrepaidExpensesAndOtherReceivable",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other receivables",
        "label": "PrepaidExpensesAndOtherReceivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrepaidExpensesAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PrepaidExpensesAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PretaxIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PretaxIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-tax loss"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PretaxLossSubjectToTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PretaxLossSubjectToTax",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxable income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PricePerShare",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PrincipalPlaceOfBusinessOfAssociate": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "PrincipalPlaceOfBusinessOfAssociate",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal place of business of associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The principal place of business of an associate. [Refer: Principal place of business; Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r52",
      "r82"
     ]
    },
    "ptgef_PrivateInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PrivateInvestments",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ProceedsFromExerciseOfStockPurchaseWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ProceedsFromExerciseOfStockPurchaseWarrants",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock purchase warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from offering"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ifrs-full_ProceedsFromSalesOfBiologicalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProceedsFromSalesOfBiologicalAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative",
      "http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative",
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of biological assets. [Refer: Biological assets]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ProceedsFromSharesIssuedUnderAtmAndCommittedPurchase",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from shares issued under ATM and Committed Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ProceedsFromSharesIssuedUnderRegisteredOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ProceedsFromSharesIssuedUnderRegisteredOffering",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from shares issued under registered offering"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails1",
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss for period",
        "verboseLabel": "Net loss and other comprehensive loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r22",
      "r67",
      "r72",
      "r74",
      "r131",
      "r132",
      "r150",
      "r159",
      "r160"
     ]
    },
    "ifrs-full_ProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProfitLossAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r78"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails",
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Owners of the Company",
        "verboseLabel": "Net loss attributable to owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ptgef_Netloss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails1",
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before provision for income taxes",
        "label": "Loss before provision for income taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r119",
      "r141",
      "r142",
      "r157",
      "r158"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProfitLossFromContinuingOperations",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss from operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r90",
      "r131",
      "r132"
     ]
    },
    "ifrs-full_ProfitLossFromDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProfitLossFromDiscontinuedOperations",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r32",
      "r91",
      "r118"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r148",
      "r187"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r53",
      "r83"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r53",
      "r80"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "label": "Proportion of ownership interests held by non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_ProportionOfVotingPowerHeldInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ProportionOfVotingPowerHeldInAssociate",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of voting rights held in associate"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r53",
      "r83"
     ]
    },
    "srt_ProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "ProvedDevelopedAndUndevelopedOilAndGasReserveQuantitiesTable",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proved Developed and Undeveloped Oil and Gas Reserve Quantities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchaseOfConvertibleNoteReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PurchaseOfConvertibleNoteReceivable",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of convertible note receivable",
        "label": "PurchaseOfConvertibleNoteReceivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of non-controlling interest pursuant to Share Exchange Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of shares issued under Committed Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of shares issued under Committed Purchase Agreement, net of issue costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of shares issued under Committed Purchase Agreement, net of issue costs , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of shares issued under Committed Purchase Agreement , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r106",
      "r137",
      "r152",
      "r154",
      "r198"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r106",
      "r137",
      "r152",
      "r154",
      "r198"
     ]
    },
    "ptgef_ReductionInDeferredTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ReductionInDeferredTaxLiability",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction in deferred tax liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transactions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "RepaymentOfMilestoneObligationAssumedInTarusAcquisition",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of milestone obligation assumed in Tarus acquisition",
        "label": "RepaymentOfMilestoneObligationAssumedInTarusAcquisition"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "RepaymentOfNotesPayableAssumedInTarusAcquisition",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of notes payable assumed in Tarus acquisition",
        "label": "RepaymentOfNotesPayableAssumedInTarusAcquisition"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ResearchAndDevelopmentCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ResearchAndDevelopmentCredit",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; development tax credits"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ResearchAndDevelopmentCreditReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ResearchAndDevelopmentCreditReceivables",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ptgef_ResearchAndDevelopmentExpenseCashCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ResearchAndDevelopmentExpenseCashCredits",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development cash credits"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ReserveQuantitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "ReserveQuantitiesLineItems",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve Quantities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "RestrictedStockUnitsMember",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r143"
     ]
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r127",
      "r135",
      "r184"
     ]
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "SaleOrIssueOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchase of shares issued under Committed Purchase Agreement, net of issue costs",
        "label": "Sale or issue of treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "ptgef_SalvaRxGroupPlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SalvaRxGroupPlcMember",
     "presentation": [
      "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salva Rx Group Plc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SalvaRxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SalvaRxMember",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salva Rx [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SaugatuckMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SaugatuckMember",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Saugatuck [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfAntiDilutiveEffectTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive share"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of assets acquired and liabilities assumed"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfInProcessResearchAndDevelopmentTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of In process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfIncomeTaxExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of effective income tax rates"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfIncomeTaxesBenefitTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of income taxes benefit"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfInvestmentInStimunitySaTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of investment in Stimunity S.A."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfNoncontrollingInterestTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfNoncontrollingInterestTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non-controlling interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfNotesPayableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfNotesPayableTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of notes payable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfProformaInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfProformaInformationTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of pro forma information"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation income tax rates"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of financial statement loss to tax basis loss"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfWarrantLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ScheduleOfWarrantLiabilityTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12gTitle",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ptgef_SettledInIoxExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SettledInIoxExchange",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settled in iOx exchange"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ShareIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareIssuedInIoxExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ShareIssuedInIoxExchange",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued in iOx exchange",
        "label": "ShareIssuedInIoxExchange"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of loss in associate accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "ptgef_SharePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharePricePerShare",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price, per share"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareholdersEquityAttributableToOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "ShareholdersEquityAttributableToOwners",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' equity attributable to owners"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedInIoxExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedInIoxExchange",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in iOx exchange"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedInIoxExchangeShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedInIoxExchangeShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in iOx exchange , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedInIoxExchangesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedInIoxExchangesShares",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in iOx exchange, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedInPrivatePlacementNetOfIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedInPrivatePlacementNetOfIssueCosts",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in a private placement, net of issue costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedInPrivatePlacementNetOfIssueCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedInPrivatePlacementNetOfIssueCostsShares",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in a private placement, net of issue costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedInTarusAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedInTarusAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in Tarus acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedInTarusAcquisitionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedInTarusAcquisitionShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in Tarus acquisition , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedOrAccruedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedOrAccruedForServices",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued or accrued for services"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedOrAccruedForServicesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedOrAccruedForServicesShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued or accrued for services, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued to Lincoln for commitment fee under Committed Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued to Lincoln for commitment fee under Committed Purchase Agreement , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedToLincolnParksCommittedPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedToLincolnParksCommittedPurchase",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued to Lincoln Parks Committed Purchase, shares",
        "label": "Shares issued to Lincoln Park&amp;amp;#8217;s Committed Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedToLincolnParksCommittedPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedToLincolnParksCommittedPurchaseShares",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued to Lincoln Parks Committed Purchase, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderAtm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedUnderAtm",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under ATM"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderAtmShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedUnderAtmShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under ATM, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedUnderOffering",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under public offering"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedUnderOfferingShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under public offering , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under public offering and ATM, net of issue costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostsShares",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under public offering and ATM, net of issue costs , shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Associates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r54",
      "r98",
      "r138",
      "r140"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://portagebiotech.com/role/EventAfterBalanceSheetDateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StatutoryU.s.IncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "StatutoryU.s.IncomeTaxRate",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory U.S. income tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StimunityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "StimunityMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stimunity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StimunitySAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "StimunitySAMember",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails",
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stimunity S A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "StockBasedCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock based compensation expense",
        "label": "StockBasedCompensationExpense"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "StockGranted",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "StockOptionReserve",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "StockOptionReserve"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionReserveAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "StockOptionReserveAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "StockOptionReserveMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Reserve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "StockOptionsTwoMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails3",
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SubscribingClassShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SubscribingClassShares",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscribing class A shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SubsidiariesOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SubsidiariesOneMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SubsidiariesTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SubsidiariesTwoMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SupplementalCashFlowInformationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "SupplementalCashFlowInformationsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TarusAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "TarusAcquisitionMember",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails",
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tarus Acquisition [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TarusAdenosineReceptors1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "TarusAdenosineReceptors1Member",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tarus Adenosine Receptors 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TarusAdenosineReceptors2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "TarusAdenosineReceptors2Member",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tarus Adenosine Receptors 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TarusAdenosineReceptorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "TarusAdenosineReceptorsMember",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tarus Adenosine Receptors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TarusGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "TarusGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/GoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tarus goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TarusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "TarusMember",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tarus [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TaxDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "TaxDeposits",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectFromChangeInTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "TaxEffectFromChangeInTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in tax effect rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ptgef_TaxEffectOfRAndDCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "TaxEffectOfRAndDCredit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "TaxEffectOfTaxLosses",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax benefit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss at statutory income tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ptgef_TotalCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "TotalCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r19"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails",
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember",
     "presentation": [
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails",
      "http://portagebiotech.com/role/AcquisitionOfTarusDetails1"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for transactions that are recognised separately from the acquisition of assets and assumption of liabilities in business combinations. It also represents the standard value for the 'Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination' axis if no other member is used. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ptgef_TwoMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "TwoMembersMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Members [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfInvestmentPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "TypesOfInvestmentPropertyAxis",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of investment property [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ptgef_UnitedStateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "UnitedStateMember",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United State [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "UnrealizedLoss",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInPrivateCompanyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnrecognisedShareOfLossesOfAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "UnrecognisedShareOfLossesOfAssociates",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InvestmentInAssociateDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of (loss)",
        "label": "Unrecognised share of losses of associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the unrecognised share of associates' losses if the entity has stopped recognising its share of losses when applying the equity method. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ptgef_UnsecuredNotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "UnsecuredNotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UnsecuredNotesPayableAndWarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "UnsecuredNotesPayableAndWarrantsTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/UnsecuredNotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNSECURED NOTES PAYABLE"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UnvestedOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "UnvestedOptionsMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_UtilizationOfLossesNotPreviouslyBenefitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "UtilizationOfLossesNotPreviouslyBenefitted",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Utilization of losses not previously benefitted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant liability",
        "label": "Warrant liability [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ptgef_WarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WarrantLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantLiabilitytextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WarrantLiabilitytextblock",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANT LIABILITY"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsExercisedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WarrantsExercisedShares",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails",
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised , shares",
        "verboseLabel": "Warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsExercisedShares1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WarrantsExercisedShares1",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WarrantsOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, amount at beginning",
        "periodEndLabel": "Warrants outstanding, amount at ending",
        "label": "WarrantsOutstandingAmount"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsOutstandingExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WarrantsOutstandingExercisePrice",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding exercise price at beginning",
        "periodEndLabel": "Warrants outstanding exercise price at ending",
        "label": "WarrantsOutstandingExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsOutstandingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WarrantsOutstandingShares",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, shares at beginning",
        "periodEndLabel": "Warrants outstanding, shares at ending",
        "label": "WarrantsOutstandingShares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years)"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares \u2013 Basic and Diluted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WeightedAveragesSharesoutstandingBasicAndDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20221231",
     "localname": "WeightedAveragesSharesoutstandingBasicAndDiluted",
     "presentation": [
      "http://portagebiotech.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and diluted",
        "label": "WeightedAveragesSharesoutstandingBasicAndDiluted"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "54",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "82",
   "Subparagraph": "ea",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_ea&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "98",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI",
   "URIDate": "2022-03-24"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2022-03-24",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2022-03-24",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2022-03-24",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2022-03-24",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2022-03-24",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2022-03-24",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2022-03-24",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2022-03-24",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2022-03-24",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2022-03-24",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2022-03-24",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2022-03-24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2022-03-24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2022-03-24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2022-03-24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2022-03-24",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2022-03-24",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2022-03-24",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2022-03-24",
   "Paragraph": "134",
   "Subparagraph": "d",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_d_v&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2022-03-24",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_e_v&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2022-03-24",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2022-03-24",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2022-03-24",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2022-03-24",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2022-03-24",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2022-03-24",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2022-03-24",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "1",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_1&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "12",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_21_a_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_21_a_iii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "22",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_22_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2022-03-24",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2022-03-24",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2022-03-24",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2022-03-24",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2022-03-24",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2022-03-24",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2022-03-24",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2022-03-24",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2022-03-24",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2022-03-24",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B64",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_l&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2022-03-24",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2022-03-24",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "13C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_13C&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "24C",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24C_a_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "24E",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24E_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "35G",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35G&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "9",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_9_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI",
   "URIDate": "2022-03-24"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2022-03-24",
   "Paragraph": "6.5.11",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_6.5.11_d_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2023-01-01",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2022-03-24",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective on first application of IFRS 9",
   "Name": "IFRS",
   "Number": "4",
   "IssueDate": "2022-03-24",
   "Paragraph": "39M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2023-01-01",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expiry date 2023-01-01",
   "Name": "IFRS",
   "Number": "4",
   "IssueDate": "2022-03-24",
   "Paragraph": "39J",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J&doctype=Standard&book=b",
   "URIDate": "2022-03-24"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2022-03-24",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2022-03-24",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2022-03-24",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2022-03-24",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2022-03-24",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2022-03-24",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective 2023-01-01",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2022-03-24",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Note": "Effective on first application of IFRS 9",
   "Name": "IFRS",
   "Number": "4",
   "IssueDate": "2022-03-24",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2022-03-24",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2022-03-24",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2022-03-24",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2022-03-24",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2022-03-24",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001171843-23-001307-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-23-001307-xbrl.zip
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M.RZB.SRN>$[NXHN\$.7VDM@!B/4(%?3_+S5$QY<&(I AJ4U- =//X*7#(_/
MUTK%0FF7Y]:6GEL? DU!_V==J5*_TY-4$^SRJ,+2HRYT>8R?A-G9*:,O/N_R
MI,K2DQICP\ @05.6U!] ,BXUY4*R0,?^^?J>?[YYX6<W7_[]=Y=7\![ +MYQ
MA;XQ"9^BTG+UF6U@0%VQG_JEL,,S*Y7.]XOO':0%0,.KC/D*?;W+_5>=^U:G
M8</TWT<3K57_O0"JBOYC/EGZZ+\WDJ;_XJ[A!*!GJ>"_8N65^ HA7OAONW7W
M4/]P^5\P'70ZM9J WVSN\NJ+3J.]WZM[Y:<.4F.Q*A9>(2.PP\O+YYW'^XN.
MT'&6$!L*]-4NSQ []P/) $@0.F3%M!]BDN]V><X%AJ7M/*NP =)^#Z]UVF,#
M=(K+3QFA;W9Y1JES^7C7X5<A0U_M\@P>/\-%<O-1ODAV=>6%,ZT7%?Q[UD-F
M_PTG\".+>X!#=,DM>.;N]*&DY>PO<@@  _;( J/ B7N? LV1*KV\X31= ^1'
M.'V#5PI@X"6(_ 45!6AD0<)_H@MOD7X:4+;7FJEUA]>V*T,?VNMD,<\+EDX^
M"R)9QS6$-7H5@&\\[>_9^X4!?O=ZY15TWKIBG<_>$_,<RXN6;??9^W+^<RQO
M\;/K9^_SV$LI"+'BMF;JS][CRQ-XX])"</;^2V'+&Z\,2<:^I/,HXHN\05X2
M"C<LV%7!+7)'[H ,X$1"?YVM0%8W6SW7W</00.7?,Z2E(L1*R/-%Y-*--6A?
MBPP0<O#,-QI$+J1EC!$#7*A<$ +!N@ ]@+BI-/3A$%H$6[ ;2.4"99"^209R
MR:UK*'6ABK75%C<?H!RNK0%5I0V42R=DL>4!\O;;B.>@+;U@#CY(!I*)76A6
M*\<$7JNKPCX)9)KZ] 8MS::%[>I.L-4HP]882%H?-+4K"1I?)74,6KU :M:1
M1=D!)4>?A;S (WVV/WG)A5"J'C!RQ%AM0:[,4T-N'F:^N=(- /O:Y50FF%[K
MIAF1]A5Z.AD%O"#J54HQ@'<!1@:0(>$P8GM]B")2:)(_+Z<C%!A$%>0*/4&F
M &T0;:MQ2.8=F !M## 03003\DNMB,2DN%I$ 2^0>G%(I@O3-L:*<\KYK+-"
MM4+9GMX"ZU$S@*3"&5"P-K>T)G*<3.*:1+0\HD#;&X@$90";12$>-LL(3A-<
M /O?AX&AC_L#$NSAK*6"%B82,> LJ/T,;_C%.?R.+'3F+^DT37.,7$AI!"U)
MO0'#+C VL*O1\UP3QJXNHS!@K*( 1VE9 V @5QF9R0'.ZDS0RB_K0^"'<_%0
M<;X#E@0UH%Q*A@:UONF'X,&*[*VNX3L,7541?JXQ],63MIFSDRVVWC0UVRN4
M?X^A"?&E(;%!D:BE#SOWEBX_M4;XQCM@ F/B(XX%7L@B%A04K<#3#HLI8Q9.
MG0H\[76*,AH[*4V!IV<<O+!! 9/K]<>D+T*\^K([ C1418A75?9!*J264/?F
M(F&PFC1<!S'9_ Y)/,3AM15$>H$;;41VU6:1MC;'P9/H>BW&E1FFB5Y(#1?C
MRM[2Q.42K:/62]VR#-@=6R2YI[>>-6"8K5Y;PAEK/^SH104V=LA< 12"]KR7
M9[+@8]PG6)R0("G <$D0EZK13B''CB$-#2S0MI4)8AU2,0NT;6@\*&Y=FPNT
MU6_9?7C0KR'"1-6N=&.EI/:H*<#YQEJ4!NI] X#A1G&+FB(6XHQ;8\:5BDK2
M+O>D@G]8Y:1M=5-!=K<8LQAGB$90JUO#F)2S&*=R[@@[#64KQJELD?$)J3S%
M.)4G,O"[*4.)MC*XVMSJ;6"3^%)6HJTM<2)'0YVHMRHD@W!(?2O1UK=DL-M-
M(<NQK$X8,[S%HZ&;/K7&_;6M',O:% 5R&JI4CF5EV@^;D'I2CF5=V@_TW92@
M$J>+UC*05*#'*,@MO4?R#%$X&9-*4.P/HHH'#06IT,Y74\<MI+I4XO2IJ2"R
MH_+05O_MG2OQ%1*JM+,N]!#9U1!0;,>*CR<A]27A_JUHN.RF,E5Z*K/H26D;
M>@]:OMVE^VI'+,U1.\.\JR+4XFB;W(/2T=>_;#=J;;0.[B9=18I%W(2QB\S1
M(L5R:,(XA[/<1>HUTM )JTW@=S0<1>KUP3U@IR%LU"M_5/ )*4C4:WI4@-]I
MS2\68E>&5J\'# 1)3!H1:^TF"@(TU*(8NUI$1BJD;L1?7HJ,P6X*4HQ%08+3
M2/MK1CR%F2B0TU")4BPJL1\V(76!>G6) NB[*4$ISE4B=')H?Y6@7@JCA <5
M!8FSB$P%M[#J$N>*3@61W92'>BW+V>9O7DZ!(4,4/,6D+=1+65$!IZ$>U"M9
M^R,34A^H%[+VAWPW!:!>QW)W&>#N1PN8SH0 O._:UFT7(*3C37UJJW\L^2'J
MU9\8,=M5^ZD7A!+A6G0#07$N0(+XAK0AU*MAB2 7=:- ,9:I"0'Y]7UM"<4Z
MWQXP[VHE8IFPL >EH^M_E;8MWS+@QDQZPDV)XAZN!9\^(--C8C8!LS4?)',!
M<6(&H,@4?4GR^:IDRY&L]S7L;C0UF\$M(_K0F1+%S/$"H;KR:^P47)'ABFNH
M2XEZTG71PA=R6%IH4&.9C+0 %PG""('[TE:10XIHC"W^"-._H4JF"7L0*'73
M+H.CU:V.'C>!%@R[E&QB$T?=M2&9@RM5?S8Q&(]$OBE"3-LJW8&176I;6[G1
M"C4,O=4]&.X*[4V52W#/;>'"0E('GW:G"A)T&2##CR'P*O,@V=]HMHT*._7V
MYVVPWX$^-+&OIVQ-R(?87U:BZ+5M NX&NZT>\6U<&KNQ<'2@J;L-R)RT)8@3
M5%NG7X4 KLS3[AUSZ_A-#3E:^A@1SK$?.)V&Z1JZ/W8[W+1CSR4?;%F"$=0>
M(RC#:EI9H$U>?S"],RZ+A=1O7V<()&*D];:!CM8>A*<^7,$#9IKN=YEZSXD[
MXQ5Y%I37OK)(VZ+Y2_7*?DB3T@)8CF,3O9/LF.<R2/G LE3@X4JM9D#0RK[O
M(E.FV&FRY+?:TX$7(8*]P$OJPB_?\%NW3\"M4-\U343Z@ZXKSQ ?W+%5''R
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M+-8*HFE7A*M1- FS+59-PI-SEXZJO,5?7?X>(SR;FHP1GH"V*AV-K%R 'M2
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MA?);[A;9#YL/MSHF>6'YIM?N7?@7O_<7_@H,;;'.N?KV[C5BIQ=G#2 ]Y;L
M&1L$T(@(1CAN>DG@LIBNO'$9.XRU+68[R7'W?5LW+'SO.43J*@^XIB934#"<
MYX2]%_*&QES'&TLZSC4=%;^?*S8V"XV!I"%SC^P%1VSN "V<P##_[W^JHE!Y
M^^<?E[_'T'JA"^"5;I#A:[=0 ]P-NFM@<I<(9H6[ #(8=H'!%80<AWT1$F?C
M]80N!'\_OKI_Q5U@933,?V@_6Y/&"L0D)U04WG(F0,CJ2(OQT$[N#DB(Q)S-
ME1O)0$)@8UN@#(DKQDO/#&>]W*1/@><[@E#LC+2"5NC,8.O3\Z^;=O>34D86
M;CQ$<+V0"]\LA(K+<Q3D[_^DD6Z^15)!I(];D/2?'4WK&?T]'#1V"N]4H(P]
M;[]O:$8Y.1DKM E0;IXR/><[:_O>=0W+?:MGRW5]"LWE*YJF.09*0QI!2U)O
MB"'LS.2'\T_M6?'E8BR?105SN[B=&E>N0G#%S73?6[K\U!KAH.,.^<_&!+A\
ML91"31R) [D&&5_2T):Z+(^'8Q6O+2WD31@>VQ==7HUZ)?V\4>A)EQ7&*RJ\
M*NS&JSM@2<C9FS=GN8Q1BY<-_4?C_+[=8XRAPAAA-\8XWVZ9$>FRZOK\V^?&
M1/C:_:PR5B6V#BU=X3-GR.5/]U*HP]FM7-9+C#^45&FF6[U/YG?EYT2J'191
M[4QE8-Q#LV>)9GRSRY0Q%*XA\FGV4($MF;X]QLZYZ-R.27("A:UV?OIH$'-B
M#HZXNT>#%<&&L[UWSG'?CP:Y)?>7>]<UN-?OB1?,K9X:\S=N@_^'L]WAH\'=
M=2<YUY^T"<#]O4R4"]"#,K1B'JJ9(-9.,JR^>@80MSC0(MQA%H>#\'H&U$[F
M\QNI?-X>7VTG.3G*_]L!B,;"/>-<_\PN(AP)0^P9AFY)8*<M)GMX&KM7;F-*
MKWI0FHK[YH+;U.R*0?DMS_-.!>:@@8]PA@6#GD'/H&?0[PN]9P][H=R1<569
MQS.)._B3(!96IQ/;BUL'WG=F8GG\"?X>W7RHE)+K5?=< .UZ9K&XV2GBR8MS
M294T&>2X^LB JE-<%GUZ,(20#]V6>-GI43OD8&K5BQ7FV/%WJV='WZU%<QKF
MEUVD]N)OB#Q;8!GNYN;W??/Q5_GY%Y)E"UH8[7. '$ <?R#V.Q2W-V6=K1$F
M'.-VZ-E;#&WT)<EJ@UX=H6OW>1;RA:4<<<<#V4CC'.?=>RN]QL'MGY[V@+8\
M95#B-XQL_*)BBWM:<F%/]RQ5<P4QN .=2466I,(NAG?\:N$TY**<JX68$<S$
M(DMBL3 6H4OQ%$2E5F)RDJ"<!$Z-WDE0O/L :,Z/+I5R/!\\LB<>"=G(-1^Y
M<%"5C;"M"#26&U'(B:E)R4G:$:JBLK45@H)\%/&1!2QV.2CQH.*%EG+%0A:B
MDS CO)%?90#)!!? _O=A8.CC_H#$WUWTM]*67G";_8,A:::-B=F9-;OE\;0\
M?;F5HB2UXA]TXT49@E*>X$0.T$)^I42D!$SQY]2'?L?2/T]VCIQF"]9^I'N'
M4\[N,_(FD/-PFA] !0GG&PXID@BG74/EQ9JX1&9\3YSGB1\OM0,,=Q0KM6V+
M^F*#>@)IB4*N+$1<#IB81%/*(E/*!*E=8M0^:!.82O3,K&+B>EIA>GIX>KKW
M@8H94COO@+2V& EHEWWMJF%3>Y",L5F7D4TR(0:S ^WR?-:/D_*-/DT.$M3P
M/G6"'"<ML,NDKBQZ*.IAN63_&G,C17^H_T1*]4UX%.>-%,$DYC9:*Z@: 7L&
M4ACJ[+PPQ]9@(>:*(4Z^8 M#G#*1OC38B<M*3N1Y)@O)N60%7F N68+49KFZ
M)*E=8-0^J%4ER=(Y6VH25T>6I<NL.E*.\=/5+N\@O^P7/C;UZ>54)O/;]HCO
M4RPI+T><L#7E@(--)J5_$<_[9EV6&))(*#\"=XID7GVJ_0+^H?PR85.(XC=H
MDG[(-M\AD>,K;"5-UK8OB4/Z@F#W,^<JA0J3@@3]*8&%[DE2FX7N25*;A>X'
MLYXD&+6S18:6:&P]BIB>;-#O</?9+Y.X9$28QY1YH0AMG<LI6>? \OT%Z '#
M $JKBQY!FJN1]-Y %0D=B@S)N1J'7,-WT>/T.7Y<GH2F0Q?'(Q1+UD0>NT:+
M//.W$J0VB]R2I#:+W)*D-HO<DJ0VVV<0=S 4PJ7,;EA4RA4K$>=,L+ H"?'8
MN_":,<9[1VB7BPCM<BH#TVSUO%6 E*LQ-2=X^HIF0@48+E$/KCAKHXHG&B,>
MY)>P):=:8G3MUF 2T"%DR%F6<XSMP.X(U8F%<[$D=*,K5D8JB&(M5^8C3JM@
M<A+-?:PQ]S$Y:A=8DB5):K,DR_&L. G6&-DRE$S@E*#T)!9N)R\[QQAOA[;P
M:26_O(/<JG<_ZX-^#9'XJ=J5C@>*#J&%-U]? ?"(XD[G&PLH[;$A#R03U/L&
M(,=*=V9?B[=&3:S4S&'_$(N5JRVTELXY=,#ZAN=?.93@>@ @-5+L,Y]L8G N
M-;@Y.3(IYXMF9IXN\Q/I>[X^_ST8733DP=.33]_SODQ+O%%Z/WJG'PB[/=4U
M-I@DR0:XJ&*3OL#8S4]L)UNRC@>;8Y,DM:N,V@E2FZ4$CW'A2;))FZU&B6IL
MD24Z#UQC*>^^3E$!O3,CY][!,:%8W1H>7&%_-4BVP^#ZPTTFM6*1HO#)3[E<
M2"3E(#34R<>;]K0PJ?FD'.;43#IUL$J']",[-Q503;2-Y^3MNRL&Z0L L>5E
MGF6"$G6F6&B?)+59:)\DM5EH?P@+28*A.EM=DM7 $@O5,Z:!E$/O%!7*._0N
M+H(^-R7A'K*]1*1M70@_&X6N;)V/>C/E$+L0YD5IO><$E*N1Y@'W')3WY&TB
M$?^'+^.ODP\5]4-5GD?\^_ DD9:"/<B9?MSH)@X*+ T?]VH324[2EQ![1F>-
MR4>BOA_++"1);9992)+:++-P%"M-D@/8V?*3J(J66>KAT%24]E#V]#0NW$1V
M3#!)DT%#-RTSTTT!3@L B5HQQ(B)".0CE'>V5S^>S6^;\IY:5.BWE2W11.8I
M;V,KL\ P26JSP#!):K/ \ "6DEC#/K:^I*R#%1;Y94L'XYKYEHI*!9:=EX/A
MEE&790-]N-*->V!,H SV"?12+RZOMB[K!B?9Z&&F<J:#8":5P;.*',2J1 K&
M@QOK^[?ZQP^C8M^G1=R'SDDWC/M3*/T*W_QLK@)+LB;8<>0E$ND+@[,IB$E"
MDDX7.^PT26JG=2#):5*;):P.;4U)=/LW6VB25$:68<NP,E+?V9VM"N[2U+-;
M8#UJ!D /F 'E6C?-EM;4)L DV^--^^2MF=8K_J[T1EJY+F>RKNM%!808XH*+
M&:?J>*2[QL$%<D>H#ZSN&[OAKA:9X4Z0VBP>BSL)'F(%V-EO1:OM>#A6)0LM
MO=: -%*-##  F@DGH*G)^A#0+TT5<[S SA)-2C%9,'F(BIE&R9CI99)ZR>+*
MC.ME7&7DM-3,=ZKZ4L6P;>@]:&%:'6[9>/$D&T1TZ\B),TEPB6N:(V! 78DB
MA)[/WJ8E7=U0@#&__EQ%],)W<::N0H6N1M-^U_9H->AM&3!@I\FOL&M0+?#D
M7L;B0V=QX''!C,6'SN+ 1!=C<499[..^SAVR-PM_;.<(\@Y8$M2 <BD9&J)K
M#*<Q"7Q.* <W0"4H?1$"2B9XM 4OC=0%$T4FBFD>3%<,'B+,9.]H92^N3!&R
M:LBKRZ!D>::2D.9Y]:POIY?LI:$#+SNSQU[;^OBU?FX\E3/:JK"N$.*K$E:)
M<TG%NU!RW 60B1WA"D*.P^C2T#KG)3OK';F/4_0Q6FXIJ=YB"T-EA8FW8XRU
M.X6A-;9,2](P$IBO\>Y=Z$V^W$QK8%K]_6N^=^&2O!O)B,.6M4T*,5!K:T_3
MPG;XTFG5E-01#1+>M%#)\97@3J<0E,MDX)BF"OUO!"+&)'ZV7J4E:_:&.:&<
M*X<8D\@D[=@ES>YB[-Q;NOS4&N&GW &\KVR?[I(U6>-SI:+(1.VP12W0(=_)
MJJ72W53(\:7@(\J3E4,J 2$3P0@B&'\6MES*">6(Z0<F<!D0.*KREN2$R7(U
M5RN6,B9Y;,E-U=XEEG$M%R.F^YG-RX#0[2]SE Q8@<]RS+"<9\U0&UY(*[MC
M]VAD6^[9L>9U9S@N182#8<NP9=@R;!FV#-M8L?4NOHJDZ";,BVZ";_'UOC-K
MWW7O];ORJ##,P#[QI9)J?61 E;/+J4+"O%V4.Z_"ECOOE\J=JY3GJ90[E8^M
M#[^_@H>[KCHO=YZ#/M2T;17/,-))MW8IY/E"4K5+,<=7:<UA3,NJ; 1:-%BV
M)61*@#]V0%7@<^5B</*;<<>+._'7R"JY6H76SK-3XTY25:6U@32EX,S^$?)K
MGYSD)L/BK\$4JCFA$)P)C\JIH,SB$2A5DG4+7L@5V2JU-\OHI_K7>JK+.:%$
M:[[NB;&)AIH4*[ERB.QX;"$M?[$2AZ&5U0"2"2Z _>_#  6E_0$)#+KH;Z4M
MO>"-_0^&I)DVK&9G]K7:O6F!;]\O>X.,[63?I A!)4]P0:P=CI!'(1'^@RG^
M#+*<[-ACG-GAY79"[LPLBCR=&1\'2*$ "Q9%F3UW8 CSW3]"8JV&Y9P88K_/
MT;(VK/ '#A<X>0H%[LT_6@JE9QY2"3E.W&)D@=MQ1RM"+7BC'F,P;093T<UB
M(9ED@'>4<^E]/A YU[AN#3LS\5-%5G_-U.?[?OK%.M^X97YZT!@#SM4?;E*K
MWP50=..4I?6B*8W2W<UO\\&Z&K[\F!9\3EF:TXEB 6]SH/HJTCM;S=CJ>,Q:
MAF9=^DRS-UCEPK3<'BW3POKTE,9Z'B^%"J>;% E+(4H'BAX@A>(VC0G&?,Q>
MAI)UE@.A*NL');C> 5%]B_O>ZO6 07KOVH40/O[LO-HNMU\^WMZ_1&ET3*'\
MLQ8>C,9=%<J<[J"=6D@EAN")0_-MG)FS+][@ZZ?5F$P^W;6++;\C;CVIR\4?
MB:W2*GW/?MY6F1-*M,Z^.G)3[+(P?>;9UKJ<*YXRZ\+Z&2PN"Z!0D<5E011B
M<5FL!C+)X(Q9S5 2SZ(S^A)_6.(;KFB%B8$W(S5TTT)AU_#B:^/;9>GE=BJE
M7[)R(BOB^F,8$9/,P$-%63-=4NAN/<)I4[A2<[O]9O3FJC'NJ8F]\S^!-81Y
MW@$4*C'/.XA")^MYQVT=4SFL@9G, '$_6;<[%G$_.-GU]KD%[QQ\RZC+LH$^
M7.G&/3 F4,:%#^/\HR@T^+OF<_7 "A^ZP4DV0IAMG.F@E%KIHQ&>[(ETEMW>
M#6OM\:=G9=3S*6[X4##6ZH8_.=+/D[M%CD,?&Q%_-L.+B^GSS]X)S[)U@6X#
MI:/>CYA"54:A  J=;K2>I(U,L-3!#&>@T)=/-KT0O] ?C@1[1UU+[O\WR3 D
MY*]?3H$A0Q,H?KU.6V*#V=?J=:-T)2OP9R']TH@725PL.>"BF5KHQ6^A_6:W
MV29[X@W$JNUNZ<N#^ER1X#P0VR0>_:8R'U*D[Z?/F\G*I[OB[,*W]#EF#Z]*
M:/MC)OD5UD-@H540A5AH%40A%EK%8A43C*68J0P6\PH+INB)^0');&"CV.54
M'DA:'[1ZM[H%S+;T@G6UKBE.L.3.Y$!!4U.?AO#OW9#J_NIQ^-R_>#COUC)?
MZW*)P.D]1&A$!O0@0@=.TI1YV08ZI"#U&]B:.B%$=D7_Q'K60MO"\LG:PK 4
M8HYU$(688QU$H=-UK$-2J'JZ'89;?+(H#DGVYHX=_&D8A\;< V*:MT]>69FK
MW#;T'K2N=1-YTN-?5^7'_J![K8$L%B<VC\L4L/S= HM3$?S$6QX! ^I!)0N?
M!VT39,]#(-%=G*FK4-E#G?9Z\';W.^C1L=J%8Z-QZ+6V&+36,K:DP9828TL6
MV1(8(3.V4&1+X,$Z"V]@9T\W_F-V:KE2B -!XA*8X/.]F:QDHF;#I.?(I8=^
M3.TC,A4F,(<K,%2W??&Y A_<UA2S+'B?_,N'/OGWLC-K?="^?6_^./_2CS),
M/,Y:V;HTBZ]**V<#7P"9Z#=7"'<^L.\3=]80<A^GZ&.T3$51DD5#8RWLR<*7
M,?<N&C>_NF;_E_I]*,Q[%R_)NWV/%=Z7-#&=/)Q<5V,A5R@&G_$8@DP)1RR)
MB?W&67<)B<S6X_"2Z:$42L@@UH*3NDPZLB@=\1\9)J U4V3&XS#%([M'/S-Y
MH2XO^QT]G7Q.#)_26DU54G8/5 ]>2*C*2))'7XNE7*4:W _*[$JV12;VH[>1
MF%28NW*08D+#3%2$7*F<F6AFGO9Z3:PC^OSG'^]&+A!#R>A#=!]Z$,<'/%L&
M6%463Q]1>-:[[ON' <"MV\@9E+07G$.Q.[OQT%%)(\W<?4-2D; :%N[[1IZC
MB:>0XB29?=:W1O*#V*W\\P_2^PV'7 ]JDB9#=)]IH5_P^8CFJW>ON^_I@!V-
M!&>+M_\GG^>N(%"5-UQ;ZB-6WX/?8Z!A/I??<E\E=8SOX?)Y5P45.-DJ.,5%
MGM0&(F_I(_0PC('SA7M#F4!"I $AI*J.&?CWC#\C?V-Y<_]>?:6,3*8T,A%H
M[B<DHU"Q!A@__B\OA"W#+U&*X/.2W>4F+OO1A<)??B;-O:+XES>?KO++E'9I
M_)9[>!DA$.N&U(7R6^X6F0F;#[<Z)GEQ^:;7[EWX%[_W%_[RM$?K>NCJX+O7
MB)U>G#6 ])3O F2#$$ C(ACAN.DE@<MBNO+&9>PPUK:8[23'W?=MW;#PO><0
MJ:L\X%  1T'!?HU-"_9>R!L:<QUO+.DXUW14_'ZNV-@L-"1SP%VI^K-)%X@K
MW< FA[M%@0AW@^X:F-PE@DO92*F+9!.*G5NG"<'?CZ_N7W$76.$,$]E#!(X^
M-M&[S']HOTB3Q@K$-'::2C@3(,QUI+8 J2MW!R1\\(O-AAO)0%RW42_0A&3-
MMH:S4VZ5H, 7.H(@.@6 V>WU95O]]6-:X<O(EHV'"* 7<N&;A?AP>2ZBI'$+
MBOVSHZD\FY>BJ#6*[MP4NKZ8!7B+Y(MG@"T;!D]5=NQ=WKA_A^)/L=; )1QQ
M7LP123%G5O_95K]>U;K:I.@_(2+@Q=O)$,X%BX);,@WA"PI6.Q[EL-E'V'\^
M/_]Y5_W=#3=C@P:YPGBL@;KAH0)AWAY=WG?I&4"ZBOOQ_CVK;"\![ES>#BG,
MVY>KS8+X$5"ZD ZEL3$Z>@R%;3LB+E;J\GAY)*LC[BQY-/%>D=8(&)*%D*VC
M2'@"+0C,>M>T<&#<@>>=V? S%+]5/_X0^9C:*J+9:[+0]\A"WT.X<+J+!B?-
M\7B3W?T]\1GHT\+66^B+/MN L-1?0!-GF*"&IYG90H/<R@Y$*^]0:LP>OU8Z
ML\]#[:'1X\<W'W]1W"SDY0,Z7F?%(S[W0GUE/Q".?+SW!+F^K-=#=_04=WI4
MJ'2B^T0QPB-W;ZCS9[EGJYUHM]I9.OD<1[,=\NVB;9#;FQ,;U2S_)T:7B7T%
M(%%N9Z&Q<F=>[]9#B:<\+MG"NH)#>1(N7^G&'4!$D:$*%A1<K/V\@%;_V?/'
MB^;7=JL,HLQTC&WU7T*#F$)$X+R,/0)$RR%;]X\?6V]9KVV1==+LV)60S]N6
M7LB72,3%Q9H_+5W<_ 2WWPH_Q9C7_!"H$F#S!%H.%U^ 9A(SQH$I_@PRF0^*
M^*R0Y<$@;L:ZG*_-G<J5!5J[W+.;G-I!SV/A71S3"<JY8JHSPTHK!JJIR09
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ME6@$ESX#.8,7:8&F[-D3JL' Z0?[AH34+&Z>.NL$SL$S5*4!J$&R<.:.]C'
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M"Z5RN7Y_UZ[=70B-^DVM7*NV=B_B?06/,<3C(@:8A0WZ)R1D0L(^&:=Z7<4
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MV)S/TRNOE._,*T5M8CW_KEZ,\G%#^S;KF M?_Y_ZM6$:]*"$FMN_Q8M;/#P
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M/?E)_(=>"G*(3J/-\.Z@;TDJ"A)5O]9@\ZJ)YIS05*:J\NSMQ/CF)^F++$=
M,/K<3!UE.]A9=525\'_Z!&S9KF2I5N+X".2!-9%@UW"):Z66D,XE!':4'I(
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M4O4>>*I. D87=>LW8:.D$1+ [\E32?R#A4+61D?<1J ^=C#AL!9#:%D,5NB
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M<)\UT#.S9'C=WZ^MMW$Q/WYN--S"<R[TBKH;-=@68^[8V7"H]1<V.2D+?[8
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M05'F;_VC?0W^:<67IU+ESO+RZGE2+'_>B\F,?3H:6+RC;VUW)@U'$K" ,S<
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M\T+-0%%HS31"<%@0,LN"9RH6V'#]U<Z;.3WAP"8 _?\FM/:=59J8@54]=T5
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M2F]LWH.NX,^"F2(."=KC%);0I(!RE *4GU!K:6AMXK-SZ1)@*'DH3H Y;:J
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MOR"F#6#RW@2KU>Z"8+@IAZ/W4 \)K )4%%#%X-N\*,N_ %\#B>Q.,)P*4,/
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M7^]"PZ[./GLIF@>"PSUP]4VU<\>(-AR&#Y)5PP=FM=H"](.'!96,LU95?13
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MI+B&>$\$OK@5M@*O_%A\&PL$6>EC!PP_UQ^C'5O^"OE)Z$U]+)3=*S^GS24
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M4>AR#8S+MVTYWBV[B@"C@/.D?'E^JHR67%SW_3C!/;3<P&$*CP$?54 WA:V
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M@ZZTZ"V11H$BF$;1<'2^^2,*^HV9SIXB'EO?^"IO_'2:#6LA@O?<<CPD1_A
M1W1--8?$D*=T6,22<2Q:R5BX[-,UA ^ETRGM5+II:V1Y4<CR'S\F)SOH]K&#
M5=FNMJ78&)"%L%3?@0)_Z(\3EI>@#\,_H-@$Z&R23G# &$2V&@M>%!;H>F?3
M>@-UCA-RV)VA3%E6#C1BZ$"(\6A]^R_J]K_X@RA&5PR9'$;V"#HY>J 9>M('
M)]UB6$/GCP-R"$?A($*B%[=.D!&'J"__15W^1\Y(66A=L=N+@NAFTBTA QIJ
M8#*"SH!YU)S'\A09?/55/UPQC$)R-,)%>]&(XN.<Y,X."+YJ]"^$4=A"&SD
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M9--<-:*J])2NB5!5:^30A>W^3)I\JU!I[\0QII_*V2+G*9MQ* =]G#V>23%
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MSV!B?MEL%!BP)T!P!\3#\MF5#KM7A!N%T<AWF1&'7@;"?6+U&7;P"V!H4@]
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M=,N0;R2G-G778#9$:)"0%CWBW [B]Y3Y1GX+VC]LA=?!!-K8"P2'O0W2@J<
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M!":4 F.1%6%4\:-Y*%;^1<A8;]%A!'=]AS>;YSQ-5'8BL>86O&5 "\V_7;/
MU<&D$X/8964QDZ]-=DY>"A5BERE9OH09:8C'/AEH\@52\K)MACOO!]DW_/ZK
MF&C%@=*N&2ZND%:/ER=$X@WJPB**.W5MXU)S1:=:]TQU+RH^6M*(BO$3!XTQ
MKJ%'%[L^(O%[?+,";A&@\MA2 LA+&F,=MFS$Z/F.3):ARC5@6[*)(,@FF;S
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MC(NL,C_<Z27"\N)?;W;?//J@T]+A_L,CTKWZ$W9R^;1>[)LEGV=+];F!V]7
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M1$I:IL6^+%&F*=JA.VDV!%"UFV*:G-X0[D27Y%L])Z#6C8"[:2"("F [[V.
M(G#3,3HBK02P.)#-*D%L'A644N8!1-MJ+#:_/I443:0J:+HW_?C/]A_M\E!P
M&S6V.Q$$EN0JN$FT211EJW/T"XQV>HBV"9K\QG%_@*)XNF9#Z23X"N 6@"^)
M80(9FYQ-W;/@;"T!9H+''#@[Z;19\4ANP?]N[_MAS3=F\(WSN1U\BUP$4!HN
M?T1<Q&S#"@QGDOB<C\JSWV5.*B(4UI^"A9).;"E98-D1(&IQ$>X;N]O>/=B=
M-;C\A[WVSI[662R00$@I#N\;_D'])XXGB#ZT7-LZ<=TH1@?O-"O4HAB>+Z74
M$E[RJ<RM$^D5MY .XR@;#*W+T_-[.:0Q@'V6Q"SL@J1G)!O'NG.:B^!WUZD_
MRD+<W&D4$BHA^[J(@&ULP9N % G(I+UO2][1U5Q]?03UZ/ZJOYX;MM6ZQE2O
MWG@G'HL\7%,#WU,T92>BI;4I-OJ#W,EU.]-"5&@#FGW6[4R?=D1UW;KTY0R?
M_B(2L*Q!\++:<0N"<(Q*R3PEZK5V,-VWCRN.G_W.IU#;1SO59LJ\ACG4<\3
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MIT-ZNW_QQTWY:54VE*1.G+:R,7[0;(R<,.L[;LK%]C(,-&-%!VXH2O @\*V
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M=$N^'0?$73Q"TW#D\P :0L\[Y(R B+-1ATIA:@18$@%.LD&6I%;G6$T,5B@
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M(,%V6>]0^@9/XY:SR^"PMO0V%G.ON#F6[K4%7R1]*8;@:S6:WI=]E7,VRQ/
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M]?ZYIW2JKL@$[G.J0 >R'18*[2"#DS"(!Q^]H#U7V(US0Z_H*A6(P1QX0AK
M;X0-W'KW/5SE;25DP:L66?"XR()7+;+@AB"K@<OA"XIN?;]6>9( FUIN]'RK
M(P=H3QAV&4H*M59#KK?P9-FD^@TNX.*C1_(GJ: C;W "9V?_Q<X)%Y4'26K:
M4_G"Y'M&"04CGMB.(O2@E>,BY'P].8K3Z727C&58[)*-LPT @A'.N&_T?,SN
MD[N*^%JV6NPR&N9Z<70IUVL(6.<WTDIY]B64ANT=VCNT=VCOT-ZAO4-[A_8.
M[1W:.[1W>-@[[+]NRC8 9+IC@K[YI +%LA08A9-Q7L_P>1_U;^6E&OCYYO(,
MYD41?^I__?BS\CP/)0HKB+^]^_S^GYP-^L?73Q]__G]02P,$%     @ UH-A
M5LD;T_\;"@  $S@   X   !F-FM?,#(R.#(S+FAT;>T;:6_:RO9[I?Z'>:Y:
MW2?%>(&00( KUA0U+ 72YEU%0H,]X$F,36>& /GU[XS-&DP:$E+E/:4+V..S
M;W/F.,G\/1VZZ(XP3GTOJQ@Q74'$LWR;>H.L,A9]]53Y._?Q0\81  >P'L\J
MCA"CM*9-)I/8)![SV4 S4JF4-I4P2@B4GD;"F;IN:%>UB[;ED"%6J<<%]BRR
M1'*I=[N;OGRZ!.TQEVZ RI4%D[BV11J>VBN$=>"D%C[< !61H,<AJ%B 4NXG
M3./D,3E"B"7"=!>L(64&#<E5H76Q A?1\"M033#L\;[/AEB #R6E8U4W53.Y
M1D3EQ-H@!/>Q@7_W6SJG:MQ8T-ERSJ:F\G$/\Z7%;?+ W N>\  P3',I7Y]Q
MM3]VW1"<+^#E>D!>X*GO^<-9@*7J<=5,:$ND!961&)#^DN'(9P(/2(_Z@EA.
MS/*' ;)A@CI!.!-LPS>2?S*""I?D,EKX#4^'1& D*:GDUYC>996B[PGB";4S
M&X%^5GB75029"BV,>DWB:7.RF7^I*JI0XMIIU";B#-7QD*31U)Z>H6HIN.CJ
M9JE;K;3:G\V2E RIZE,1X\ENH&QW6\GN0LD]R"4* 9:>T(WGH!^;70(>!37@
M7]D#&\Z*8!R&W:IGD^DW,NOJD/5ZZC@1/]Z';FJ-;GY(/!O^BXJ+!]T^=CG9
MA]3)&JGBF#%)B'(+N_\AF)4]NX0%Z8:/+]KZI#;3[VO?L]E]6.AK+$J^-1YN
M\*C "N_NZ><-"VS2;!)&?3ND^CV^#\UX!$T9U=TD+'S;@]+)2?>J=-6%#"">
MW#QX#);WP:]TVXUN,93D^I+#%G1=(JX+'_Q6^*/K&O;\&W1![PC0<LFU>1(S
M8V#"^'6ST>KDS\O79.ITNZF4(3GS/5@G"]W+=JEK=.?%.90!EN8T>KX]0US,
M7))5^I#K:63H(X$Z=$@XJI,):OE#[!V%"T? A]%^4%5L>K? LRD?N7B61I[O
MD> AG:9E>2!,UIW@CMHV\8(J)&\!L [N8-0*"\Q4M&1!JS!_&-:]A*H;P@^N
M#3.HRQXH!ZP(34<FGI);95Y&VV!Q&*X;::GD@KQ\%4:[DE;)J7(_B!NOPG5'
M'BLY"?X'.*YEN9+['G]5CL'.EDNJWR*Y:!OA*IDRTB?@$HOP$$+N_FD>M'7
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ML+"MG!S/-)F@,'00(&B@D9402QR7BT%@6^%G@>,O4>#YX?S&7Y(./(T$FEJ
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M%F?H*A;(1B@HXOD<1=XC0484BEP.3Q0YC@K^JZN@,)VJ+,WU"MS6C:FS*3;
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MKN]9T"&EY,,Y=A=HZ9 __Q]02P,$%     @ UH-A5DK^/OKO%   F0<! !8
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MTH'%S/4%ZJNUC;@B;"HTRL0&Q?G5J6#V9"J(S1^9 ()S4K46A@2U\C(;_;%
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MV<R ;= ]BQ-06]LPSAI#9Y$V(T;V18R>.07AI8Q1X9LBJ:HFDD"%VD-G,8A
M%_!(R&'Z-DTY/\=;N:7V3*9 IC'W0A=WSRB&CYC 'EHLO4@P'WNIL%G163(:
M.]^(JZ3GWHSL89>C78++9!LE@,6$#\AU9;!:3A+& .:[1;C<,=@14D4;SWQ#
M[Z.)$8<OL'UQ\]A@Q.5PS_!815-MTS=KD&.9>;C"XIBT^8PQPP*D5MYZVXK:
MFQ.J<\3G:W]O2BQQDL93>^CB A%8<$B8(-D;LI@DB$J)YVKZ\A6% 8SF [B
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MW4;)$OAP!D%P5;"([7&?WERQ?8[+5R0"NET#G&HA:&E DR&H=BQD!\D*WS"
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MJ'Q:9 GYGZN_'M!SE J2;/7BCDFE!#UBE5 V)%JI '*\PE( 3P] 3/X!._F
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M/D?1V],O;>59A5\:?MZ6WG$#2TU&LE#>_?*6 C:_P"40#L@OJA$*=PX[<3S
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MR!E^ ?V 9YW?D!3<-+N+BL\DHM[1REAW^$T_1:5X&6"R%3_!JE43Q=&KD8E
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M/1+=R8B18#B59<Q@2A/NFQ,KR1EDG(V]:9ULU+2Y2_Z^^NL!5:_&7EEKQ^_
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M*?6H^0:@QA:(F+&VV';(@_6A( <4EKA=]44L\A%"(.IX*):"'8V\G)QW'AJ
MX_.66HF0"22*&VY0]$@*;^._3@OYA 8"B/L4#3,(_@3:(1'3#K(\#$P[G?F6
M?.,X/^ OXRYZ)=X7AQFU!^\!%J]>&BDZ7!"V:$AO?=A *ZRXT (QMXA<JX(]
MTZ6A83/&GI!L<QZ-BDA-LJIIZWB[227H^$"4!.CH+-1(*A2J:1%R!Z&86,NB
MH_>H9N00CE4+&)7P$K+_73\5^6'[U$^%[,6GRPQ[ZX,ZHCO"HEM6'MWT(7TG
MFPMHM#ZV#:JIS>UP:C/?@@[SYV4W&(@+DVBE'2[@Z"#W%FYDHMY99(:/6Z&I
MY0?#[^QW:]?3);H2*9[;#P0<+J<(@/562GJ_AC(Z2I%QOH")S+V>2U.!GO(T
MP0[KZJ\'//J*:B@(&V&JZCB)WK@QH\1ZK5X@+L,*K# !OU;^GP!2=4G="V]%
M3&ZQ$*E6FJ?XYVVS&B@)(R3"7NKP2R^Q,8?+977GV=N>0N]*]*@"CW"+,E+=
M=;Y"0U!05D7<!B%7K?0=%B>R;U;OU("Y<B >PQZQJ$0.PO([V!06&/N,3$+4
M^>)6_'Z><,R]VHA;@G\G*<[5FIU):VZO7FP+*+_%YGBC#J/@$[V 7K!\I,5
MZ'ZB9G"A=VV6Y('(V [VM6WR2;##;HUYT-H_[X'UAW NN#$':S6L0EI!>-YB
MP"0C.^GG8ZHFW1H-Q^6"==!']8-EXF%-R$R@B@L-TTLO2#:MNZ*AC4LA#JZ"
M[6K^</=\D27UPFIYG1?+_$5QQ.8X@^[X=XJ&=_0\QEH@0]T)FL"71*_'*SK,
M8:/-CL\;+J6"+D)]J4V3:]P 6KW,?5QHB9T^GFA5="@59>S*Q1P>/92"[!TT
MY&0"(944&)<<P0F"W];:S%@7V2DL9U*9F,)$'*\3&&6EC)"I%P;!;Y=P$QW2
M"M#!S=^;)R&8_N6/I8)Z_U)PPO#1>'UVUM>N>MD!OF+-BUV$Q>GZ4Y-D@:CD
M@GKI"G@RY]++Z BF-[K/4]LA0M&@^D2-4.5P0NP:;8>$V@TF+__&++MIUA<L
MW^A1%W77ZP75'19PN7F+:B^+3&;V5-]S#ZIZZ?>_#ZXG6DCBM^W[<\AD"9IJ
MR1 I+P8H(WEFG',Y:S=T%R]<XU]6>W(=!CW'4:%G19]HU8+J('.T_'$JHMGL
MF)&7!_)&'42MOK?NN\X+B+99L^)#FBCN,(%@4%VDPL>ER#-9 )MU+M([WKK@
M$NX+&".Z;DQRP'9Y42'ILKJ-7E =9 &7OX:C4V59;SUEDZ7V6?NO66-5=M9(
M**B>D6&3%G#V_\9)&L(Z>JD1DVN347; +K5VS:.J;G::CK<W=7UC 7C<85BM
MZ2MR?0VQY/I>JC;[)!V-+(,? O@<Q'@$23!>QPIZAIML3Q;P"7<K>H:,(&*V
MRZ0#>-T6(+DZ-/0P>MS7J!.3 @B"31*LM"&QD9&@.G$J=F6X_,8XP\S?!RD@
MKOT*C:61H'I^*G918;+Q]\P3()BE'&VSK3[]J=;.BPFVSL",$J'X!!9 C&Y_
M*UF>1=[=2C^ZV(L/B6PM!,"!(X'+;L4S->1O-VI0FGW5 93L2,G$@YIQZ%%J
MR\[WNLK+1W@)-[ H8+)Z3-&6SI&6^<M'E&*OD&>RNQ8,E(+YU&RP\HLI6EU?
M<\1/60&C%/V-W7>XRGJ55R2=9J 43*?98!7,.W6Z/E=C!B>@EUE#L77TTA[\
MY\YG3C(00&<>AYM?4V.ZX.NDMO(-CF! 4AL"5?32%44 7]-,(S]K."RB6V5M
M?<W51E6DPE@I@"ZUQRKH1IVNETZ[H/L;RSZNAJ-E<YB%7=K$$GS747$@!]'5
M@P3?S_,\)QAJS-P\;N(SR^.\#1 _12AC8];/,"'M8A?*XDE=!F7;C6J= (AA
M#77<R42MV1?.,_!$=+'K'RA[[;*2- K/ -H]U4N$L140J^,_KK%S*U-*LGL8
MY]L,E>2X 5O 6Q7RC>23F Z. *=KD7:S>ML1QU<@0 (5/+FK Q]6MI.6!E,5
MT#73"Z!G)\&5!'8:=7\YX\E?#O7L 1.LBV";_QV5#Q9_RI9& NC:X[%SZ>J=
M'7K\J0GCZ89K%]#O1V65 ^EX?@J#754":Z+6X85)YQL9"I@ =OAU)$#B65U%
M3)(C=(,RBO[V,*+RZ3K-O]"DMD]T1#+.WS/3#:K#+2%S03E6!QNBS]+XOCZ4
M]!SD-R$D](VK'D@+;?/#LH%2 -UHCU56NT&AZR]_H,6&0T+,INKU#F,GIW9)
MMN^>.):+-"I+M$$P691LZ<\DR_9HNP%T_2S-457VV-?&WX ],4\S#F'S@#<@
M;A\!HA([@/HA(63S"ER<,5?,=(/B@R5D<X\>0*<RAW>/H\97=H/1X'1_61YV
MI+ELY2?&Y"R1^ 9#6PL!=/"1P,?=;&O(=T>W"W;=,MZT_K8Q%&*W3\*OZ'T;
M>_Y" 8:6S$GH#CRYI1E>Y/*L0:E\ %UJ!5-0Y[:;4=', G:?/8ASKQE__*!3
M7[DP:8P5Z ;5<9:0S<?836,EA,")G_X3X#BP)/]#@LOG*#6O8R[3#JICK4$;
M;EW'I,=)R$S_ 3M#(-I4L !L@X/$V>V*-IX]XZ^:_MOC\>H7$NW346&U66;[
M0U72T8'>E$QVUZYP1+BCOZ]A_)2AOQY@23Z(=;[8[]/7Y6X?H8)XK'O2:'9A
M9-E8S0O9N=^Y'QL4Z=RUEJ]IU3Z9< _19[\AI5N:I[-Y7OM\4+4  '5:50XB
M@@&@%@0H>BC ;Q5\J<!CFL>?/=8KP5^=?/ )B@P#0**!P^=YCCTY84A8RO+7
MG]"^35C^&:;)AU?;LQU3#0;59:=HA^#,1VV3?)AY8[5+Y 9/V"YX? TFU9LK
MJT,WBU[U-^'UY(+J5@4\676@?2?K[>V3E,AF-YW.*E:;>AN>W/><DQ/#LDC<
M2#6H/K)#/.ZVOG8]F<(?6TH-U+=:UR:\+']<104I8D\:= ?9#)%?VA (!=!#
M>FQ<*,++>DV37T<OL%0D<8KE@GGU&GBR_/>AN.\.,'O]0;]\JU?O]\63=6!!
M<@/W8P '<^28^ )QK8P?'RXN1-S>:M5$@KT"Q (?;V\DF&_A&.RR$LP6MOPD
M Y;DKH,8X_R4E3 ^X*^; KZ$95R@O7B/PD IF$ZUP<JMD.EUO8X[US"!192V
M-48^P QND.!6$(U",)UEBE,V,$GTO'82K:Y-:L/EL4U7*=6"ZS SM+)N4VK[
M_<)8\K;%%R96"*[#=#BE7YA8S]\1;ECUHE)EV7*!9 #=8@A0=)O7X)"AEQKF
MTCD$@B4]'A'#LKPG)YN,ID6<5@#],P&LP;2)4PZEXU[?F4U@WX7<-3UT)E/8
M=WXJC=27KO0J-%R]P")&]=E OA]T&L',=HV!2JZ1ERJ&TE&RZXBDHB%WS0BA
M09\\:*\'<MD9BQTYCF'4&4PTY,X8(33H#*;AYW1ZOMOE&;U#3?9%<"+!O'PY
M,D$=JZ&D[Y=-SY2K7S83"?%ECY I7C:3]'?2KLLF+==/17[8/GTXE(B<Z\8@
M'Q%+1BEI.4L<RCUC66G=VFFV HBQ3M8$[LA=SQRHF#WP6!LDU4%;BV] 3BN&
M[ENC7KZ_+NV5'%/(7YH57OXSE$D&T)V& (57S@L4?.U38(K(;@:FO"(U-)Y)
M5=JL1$E39AGC%NY73#463'>>H@V"_8NI-OU]G26CZ#J_(<4FT^PN*CX3Y[1#
M5063YHB8Y(,U4PZFTZ=@%G[6)<O*I_F1M1E [/Q=M-O_B?S_?_CG]^_^Z4\E
M:.V"QG! Z=Y-U<-5@6/BJ'CMOQ[QD&QG(X!^/QJZ80)XUI:#S&MK35U(1A1O
MO?X0I7!5T$:M-FL"^-"T5-S%"H6@^M,$)_?M8AU 2A70(S6XLZI:S^#R7J??
M9ATK-NLX;6&U4G6;EJ61H'IS*G:3S[,)E&%MC'1\<WOS&WI8PU-&#IVPK?:L
M0E()BV?97?(#F6#FIPIHPBOC!Z)^4J :CS]:EEM)<C;4\L%TA"%,<0ECF9J?
M8A[# D2++*%38V4I#YU* '[.%BE_6D"CZ:6SFLI>7)Z6Y')"<ZU@NLP*++]:
MHU?V%G&HRMC*I0+H& -PD@V 7DUAO_<'U\N[O2O7!<O2O5\#>.L*4)+#,E3(
M7UCU 8=^";E, WM,V;6"!N+!O'HSE,*X2Z8EZ)S^GV[PO_"?FS_A__.(#>&_
M_/]02P,$%     @ UH-A5B2LI"SL3@  92T% !8   !P=&=E9BTR,#(R,3(S
M,5]P<F4N>&UL[7U;<^,XLN;[1NQ_T/9&;,P\5%>7JZ]S9O8$+<O5.N,2-9)<
M-;TO'30)R3A%D1J2<MGSZQ<@=2%%7!(D(8!N]4-7V06 R"^10&8B,_'7_WQ>
MAX,GE*0XCO[VS;MOO_MF@"(_#G"T^MLW]_,WSGPX'G\S2#,O"KPPCM#?OHGB
M;_[S__[/_S$@__WU?[UY,[C%* S^,KB)_3?C:!G_QV#BK=%?!A]0A!(OBY/_
M&'SRPBW]37R+0Y0,AO%Z$Z(,D7\H/OR7P0_?OOO)&[QY QCW$XJ".+F?C0_C
M/F;9)OW+V[=?OW[]-HJ?O*]Q\B7]UH_7L 'GF9=MT\-HWSU_M_NOZ/[7$$=?
M_D+_]^"E:$#PBM*_/*?X;]_0[^X^^_7]MW&R>GOUW7?OWO[SX]W<?T1K[PV.
M*&X^^F;?BX["ZO?NEU]^>9O_Z[YIK>7S0Q+NO_'^[7XZAY')OV)!^]),4OR7
M-)_>7>Q[6<YVZ6<&W!;TIS?[9F_HK]Z\NWKS_MVWSVGPS1[\',$D#M$,+0?T
M3\*]PU<W<9)Y*_2 XPSYCY1M;VF3M\.8+$LRW[SS8X*6?_MFDZW0DGSDZNK=
M5?&)_UUIE;ULR/I,,5U>WPS>MOQ\%* H10'Y2QJ'./ R%(RC#"5X35<,6J,H
M2]WE+8X(L-@+IW&**9R *;<<N4LRRQ]T-U1@R8=2)PJHD";HD4P4/Z$QV1+6
MZ"Y.4REU30?LDB@&F,-'+UJA=!S-'STRBS@,R-8S^M<69R]2DIH-IYL@+WV\
M#>.O<HY .G<YV0G93A-4YKYTBOPN74[L#A,&!1".UUIV.8UK+\6$!],$I80;
M'FC/$/3I=#? JP@OL>]%F>/[\3;*B!XP)7N4CQ% ]"&]NYPN@6/CX6#TO*'[
M*=UDW.P1)3/D(_SD/82 .<.'Z%:>GU":46$<1TZ:QF27SQ! D 6]=$UOFA <
M,D1W;R^"[)6RKEU.U/&)G!:'H[M<>,E6SG!^ERXG]B&.@Z\X#*73.6W8+1O?
M;)+81VDZ(]N&E_B/9'G?H"<4QAO*H?RG)4H2%"R\YSOL/> 0=AZV&K=+$N^)
MT/KDZ @FY!_2J?="159*@+!7MQR@:@X! ; 3,=IV.97/7I*0C1G.95Z'3I5L
M;X,S+YQGL?]%KC<S&G>K"I.!W0W=&>BZ3I[D"XG?I5.]A:C)4Y3DJJ9<=6$T
M[M8N6J]QOL$72GU^R*/C.H$H"@IC=#GU&0JIJ37UDNQE0=9VZODP]536L<M)
M'JR^,3'9D^T>I!E.OWST(M*#_D8Z8Z51-$CT#4[],$[)'@M8#=PNG5HE<?3&
M)RN-_$#ZKW*CB&@J<M-$W*_+*8Z>Z.&Y)!^X]D+JK9D_(I3=0%1#>=>SF0G=
MF MFS89%5\;#XKPF!'#>@+YZM73@/&4==6CLP*FQFUN@O8.70 >C:]?D@<0
M^FK2ZL%H<WKHU/"!<Q-WTZ7M R?'[Z)7\P=.3]91EQ4 G!Z_R]DU5N",&XQU
M!B41.'E0;[V>]AN4>3A,)U2F,PRP8.%#:/'$*\]7VE.SIUYYP@ICG%?'W<VB
M R7W9"3M6BYTYI#.YYKLNU:S?7?NZ<+7M](HY[FD:$4#;"B]YA%T@4M[GF6:
M\J4M[WJ6B<(7!'P('28HE/V<]AJG!$=0UM$"2QE^C'0QO#T$J^R+G7Y'N[L
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MG,0?Q$F $H+U?BPO\2L,JZ>![EJ\W9 S.\K>^(\X//!ZF<1K'CH[)&+.1,M
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MUU[R,L>^?-.HMX6";<2R%!-H!.V%]SP."%5YU0,*DAQT;A<H]D;,2A"Y1EA
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MZD:,Y;V+PN5:P_#^YFL6 (5<%1*+Y98L*817T?X!KK)-S!)(9G/S-0@4)$U
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M8Q'M0:8ZZ$2\09F'0UHK[5! VWF(MYET=CFJ2J=F9Y_J:1:[/D LDW-F6K)
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M]+D<*10T=F-CKA0U"%D:IXAZBZ\4IBCQ*<(KLK=\BFD=L=&_M@2!0\W,?54
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M[9WC,T)_[E[:4?6!%F,1EX=K-EX//*\M*>S70J QK#Z9]Z<X)#R@[WRU60;
MT7KE@VT.E[[X]TWAM5H"9;:(*!=WZHV?%D2\-NA+S]I-"S]@,0$>ZOSVO7'=
MRDBV/RSNZ&DN.V!_^D[- 7MU<<!>'+ 7!^S% 6N;[^[B@+TX8"UAY,4!>W'
M7ARP%P?LQ0%[<<!>'+ 7!^S% 7MQP%X<L!<'[,4!^X=VP+YG.V#?J3E@WU\<
ML!<'[,4!>W' VN:[NSA@+PY82QAIOP-V>CTFOWU7I):.(UH-"3\AN3=6WL^\
M*T/--0M%XAS99^GB:PS.4RXW-J9%-P1=2+/V.G/N-DLS+PIPM"H93SS(9;UZ
MX,L!T5$#WTA*,ZQ(8-7<'4?UI%R'OF17U(V4,;;)B'WPW;0F\DSB6)[:Z'F#
MR8ISD]LX62+<+7,;#-X;?U"G8/9J!^Y5!K:<E$ZV85WO0;)76?Y8*+5.),N+
M:UJW'K8WM=$[ M!^9^/W;&?CE9JS\?N+L_'B;+PX&R_.1MO\5!=GX\79: DC
M+\[&B[/QXFPTY6S4N&-]1GCU2(QVYPDE1/?>F0DH?\6-:4$P[?N2^7#UW;M?
M1+N=I@_VP$&J&X*^K;496GLXPM%J2$NX$K5ZZX4TUHCGN$@5EU;#\?O@=>V8
MY+[8^Q./K'EZF+'M_O=J=O]AM(O]?['_+_;_Q?ZWS72\V/\7^]\21MIO_T\:
M6?^R7GVS_6$H:+/\R3F9$2N&**3YX7D?8<%;%'D740]C%VX-P9=3KPUX9YVK
MV4X4T$G0#+M&XJ \#)!%W;]@W)!%#7'2QK<SY:A?=?\\9D,&]#-)?1AO:2XB
M023#2*J7L5I;<Y*W4<E8A%F<K5Z=KEP18[>WA7/\-2CADV[-ZSKVDH"L)IP@
MG_22'/B\UN:?0!(ME\H>)B98VUDQC*-T&V9>)-.I& W-7Z> T>62J0W8PWV-
M!-=Z.R"L/UH *X](;:B.UILP?D&"C3=O5VL&Q/0G"S#ED*@-4N 6VW1O_=D"
M2,^]J8Z>D;^E2K]DE9XV SL&+,"40Z/%^G8E@C7-GV 75L9@M^_3G;"(8HL9
M=7)WW?#B5F647EW/JL.C-RA'4K>DVJ8W:2DLTO17)9FBXIE&'IB,AKW)(.$2
M:?%6-(S7ZVV$_1Q-6CPH2H47T>SV?4CRD)"@VV4990F.4NSO"M64(]^XODMA
M'V-.9%6Q@)!N313-79RF>_'=A;P<YE@)F_G^-&SF3W?N?/[GP70T&\Q_=6;'
MD)F. V7(#/<3E$7(,)MVGG:&$MI>-A=&0Z.:I@#&T[0P-H$6;^K3)%[BC"YE
M)R.R][#-J(-Z$;M?(Y2D[G*:PR/:YJ$CF-4K^;PYW?/5$&F<XOF$DH<X15H2
M/&\061<X@L@:LZE9Q10J;@(J+1:XDX#2PAP5R1>G@UE55X2])(2V2K$V+>K:
M(VJ$$P4W.-R2CY</:^[-B:B+6;T5@+><!/OU)_;SWC_] %:@.G_:VX@*=:;H
MX@6QZ%,R2ZI=7Z/L*T+1#(4T9F-:N#R58HVAH]D0>0PX8EK1> E 5@^64%N-
MO0]''I+IKN*$T.4NJW1*HU\D/5\/<\$D6QRQ/(K(6?:2+N+,"V_CI#I[><@,
MJ+LM'(>MZ;H3'T*CKN":LHL)GDAK3_BRPOKBYM.^YN!EC1$W3:$W&,;\F:;D
M2>.;3EN9#T)N"C6;7GU1XF2: 36]\!,:+9?(S]P(8GG*^_7@JAU(B656*+WB
MP5E1HRL*:%HOCE8YF=X#?12#K"]8<NR/IT;JT/WX<;SX.)HLY@-G<D-^GBS&
MDP_DY\'=V+D>WXT7X]%<?[HL@$*9::LTA&T:6%D/=9?+%&5T]N[R%D=>Y&,O
M=%+R.S5C5SZ.#69N \X+S5\YU1?#5]TV@J[)_IN\KS+)0Y5]D&0/&PW92[+'
M6>Q1(LM^'$I2U4X:]2BU@TF>SHR.)T2F1,1P0O0^OGISTJPOVC:'/HNO/Z_C
M)(F_DLTR+3\^*-I'>#UZ%:<J)EOS^D\Q?>[O!CT(]/O3=KV)3>61>#9,"4-C
M[BT^<XKE'KV)6)63K2^RFGXFC_"6^5%8+?L0<,J=O&Y_U?Z]X#S>DNN=.FG5
MFW!2-GGG>0HCG<='$H2E\G<MC:4ZJJ+*)]/*8+BC$^06"33 2B-C*9+JNS*#
M.&M\JR4W_4OY!ACF4/WIU*$Z&]TYB]'-8.K,%K\-%C-G,G>&M/1@=TY4C9HO
M#PR![_706=[7-CW_#Q]GI, [@.?U$GAD6VQ*?[VPE\"C2^#1)?#(>.#1V/VG
MK![9/_L?9E2CTF+?Y.N\GVJ[ UY*DEUNJ>I&]2,NE3UQETOL2ZL[B?N8#^>#
M%] "$*\O.SQ-MUY$BUW<1RF90H(">O5#;.K43[ D2QS4MR^77RI(:&/'M'!]
MN$F (R]Y$5\$<!KWX29+-'_-$%][*9I[(?D@#]=RB]Y<7-7)TAB6&FV)VH90
M&AQE@^OM9S?NS465D%B-MX)K6ATDAZ-PRF9";S.K<6]NJH3$:H/83?"*[#MA
MP>"%EZQ01N.*:5%ILBOQP)9VZ\UU%A  :]S_AVBX<91FR78?ASK#Z9>/7N05
M3VL)*Z?\?'H%<#N>.)/AV+D;C"?SQ>S^&%T]&\__/OCH3)P/(_I+72550#3)
MPJD5!['-QBI;EX="5A^11W]#9^XN&T14 P:R(:2Z$?^%KGT X1>OOKK; [PP
M>^_0OT-/*$Q+%/^*44*0>WR1N;!D/5\%7\'46NS+=T2SESNY0-UM839L.=>X
M"Z)1ESO,61,5"/\;!<,XS60OP#":FO?O*ZRPD_=>N)3KKQ"ZB-WL$274'$G0
M([%(\!,:1T3_E!2;5AC ?&A]4\XHHV3SS4SI?N\DQP82/@/JW@.WIQI!/>!J
M^DCS$LD?](&H)R^DVK28D>P>YO=/%8[4N2G"09_K.D$;#P>[LK;4BLGWB1GR
M$9D#VW0KW,#RCN:WS08,@1)7XXM-P:Z5A*#CK,F&'VYI773']Y,M?>^\2$/A
MNRB5![+@!J\ASQNC9O/FNDTH9F-"65JD@ LW5D9K8^[H;C95+OTV,XU%,*Q.
M@Q@T4*$&&QW?#<C2?9GF^S10()UZ+W2+( ?$;G,H389K_('Z&LL$:0YVK$RD
M^4-49Y'?HNS0GF#6Q?6A<;VML>R3UOP7$&6>WUR)OME-9+HE)K6W>TQFMWH7
M7K+EBC.@(Y"7.E\&:R/+8&BT;;?[&;@/(5[EL(WCYX\X)*=Z''%-%%DO(%M^
ML9PM8E!Z>1$L20K[I?V-L+9"6Y>[X?!W8C$EB&P4-ZCX<_&8Q-O58SE[O&1M
ME6@4'9$M!C7JU>OFLK@UI-;L T-O@S.O=)T'RP3]^;M::3UG.EX0D;\9SX=W
M[OQ^=I8Z>K792\OF"7IT[,LKCN3TJ&SS'^@JW%S\#D9%1@YRU5LGHUM?P%_A
M7\B]$5S^5]J8#?-5!)9%GI7*>QZ$_!B'!+N4>L^S%]:S/3P.07N;C2I6Y)T:
M)-:<#I,X(KI%E)$?2*?5WM<J"A#\^=WIR3!Q)V]HH=69>W<WGGP@2N%B1$X'
M;?& $QH!6YNS](4S22_;M+H_?#8_B&L<_>V2QV]SHF-OP_XN>?R7//Y+'O\E
MC[^G>?Q\A=[;KKQLZW^1O,9RVLQ\R$E3;#D46WQ/330AAJ8N/'2X7?H4=R>A
MN[&!O$$)C@,RD2338B1/$.-!6S8Q7)-%98C>9#0W $9?/-[NCLU=LB= _ITF
MO&>+HN[JZ)FTCE;(624HIY3KZFL];F]RJKN"\ ^Q]?Y^U8^L;@@=G>R_HRC0
MXZ*DKWS1=/^@G#@M<=!+.O4F5QQ$O)6>Y?WN0#>3#!W"F:J1H$X4[-\8(RK?
M.'X65P!I-V8? O8Z(-,RO_3HB5Z$+,FDK[V0%IR9/R*4W1 @8+>75Z<^ZM$G
M&H[@W"Y&L\'BU]'@VKES)L/18/[K:+08W#B+D?[+S"-1BT=T2I?,?0WLK-%Q
MR?,QUQ>J1?YC)<SY_LF+B[C9EF7:_;OTTH><BC3)<A7P+0JSE/Z4,R%G /GA
M]\-,YCZ*/**8</RYI"VG:3^@Y\^_4V\L&/;=%.ZC=(-\O,0HN(G7'F852J)3
MYS<W##\?USK^?"):NDM;L8"H \CW!)G4I:F?MC7F>A##R86>36N_WZ@PKG^"
MGJBPS;*?)K&/4)#>$K+G7DCO0*YQ',8K[.^SGD16/JA['QQS:A0U,!9V_T+_
M]T ,4_*;_P]02P$"% ,4    " #6@V%6(I8OSDI^ 0#^^@\ "P
M    @ $     97AH7SDY,2YH=&U02P$"% ,4    " #6@V%64G7[ZRN-  "J
M-@0 "P              @ %S?@$ 97AH7SDY,BYH=&U02P$"% ,4    " #6
M@V%6R1O3_QL*   3.   #@              @ ''"P( 9C9K7S R,C@R,RYH
M=&U02P$"% ,4    " #6@V%6HGYZ[F\>  "+?@$ $@              @ $.
M%@( <'1G968M,C R,C$R,S$N>'-D4$L! A0#%     @ UH-A5DK^/OKO%
MF0<! !8              ( !K30" '!T9V5F+3(P,C(Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " #6@V%6S;L&!XPM  !!^P( %@              @ '020(
M<'1G968M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( -:#858O2LB/EV@
M %Z[!0 6              "  9!W @!P=&=E9BTR,#(R,3(S,5]L86(N>&UL
M4$L! A0#%     @ UH-A5B2LI"SL3@  92T% !8              ( !6^ "
M '!T9V5F+3(P,C(Q,C,Q7W!R92YX;6Q02P4&      @ " #^ 0  >R\#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
